2017-03-30_09-31-45 Restart Xvfb...
2017-03-30 09:31:45 start...
2017-03-30 09:31:45 reset updateRequest
2017-03-30 09:31:51  - 14968  http://www.lymphomahub.com/
2017-03-30 09:31:56  - 14968  http://www.lymphomahub.com/about
2017-03-30 09:32:03  - 14968  http://www.lymphomahub.com/terms
2017-03-30 09:32:06  - 14968  http://www.lymphomahub.com/undefined
2017-03-30 09:32:07  - 14968  http://www.lymphomahub.com/therapies
2017-03-30 09:32:14  - 14968  http://www.lymphomahub.com/newsletter
2017-03-30 09:32:18  - 14968  http://www.lymphomahub.com/cookie-policy
2017-03-30 09:32:22  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-03-30 09:32:27  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-03-30 09:32:33  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-03-30 09:32:39  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-03-30 09:32:44  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-03-30 09:32:50  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-03-30 09:32:56  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-03-30 09:33:02  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-03-30 09:33:07  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-03-30 09:33:13  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-03-30 09:33:19  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-03-30 09:33:25  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-03-30 09:33:30  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-03-30 09:33:36  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-03-30 09:33:42  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-03-30 09:33:48  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-03-30 09:33:54  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-03-30 09:33:59  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-03-30 09:34:05  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-03-30 09:34:11  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-03-30 09:34:17  - 14968  http://www.lymphomahub.com/about/secretariat
2017-03-30 09:34:21  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-03-30 09:34:27  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-03-30 09:34:33  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-03-30 09:34:39  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-03-30 09:34:45  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-03-30 09:34:51  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-03-30 09:34:57  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-03-30 09:35:03  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-03-30 09:35:09  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-03-30 09:35:14  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-30 09:35:20  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-30 09:35:26  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-03-30 09:35:32  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-03-30 09:35:37  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-03-30 09:35:43  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-30 09:35:49  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-03-30 09:35:55  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-03-30 09:36:01  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-03-30 09:36:07  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-03-30 09:36:12  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-03-30 09:36:18  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-03-30 09:36:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-30 09:36:30  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-30 09:36:36  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-03-30 09:36:42  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-03-30 09:36:47  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-03-30 09:36:53  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-03-30 09:36:59  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-03-30 09:37:04  - 14968  http://www.lymphomahub.com/medical-information
2017-03-30 09:37:08  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-03-30 09:37:14  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-03-30 09:37:20  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-30 09:37:25  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-03-30 09:37:31  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-03-30 09:37:37  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-03-30 09:37:43  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-03-30 09:37:49  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-03-30 09:37:54  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-03-30 09:38:01  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-03-30 09:38:06  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-03-30 09:38:12  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-03-30 09:38:13  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-03-30 09:38:19  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-03-30 09:38:25  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-30 09:38:30  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-30 09:38:36  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-03-30 09:38:42  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-30 09:38:47  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-03-30 09:38:53  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-03-30 09:38:59  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-03-30 09:39:05  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-03-30 09:39:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-03-30 09:39:17  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-30 09:39:23  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-30 09:39:29  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-30 09:39:34  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-30 09:39:40  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-30 09:39:46  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-30 09:39:51  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-03-30 09:39:57  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-03-30 09:40:02  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-03-30 09:40:08  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-30 09:40:14  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-30 09:40:20  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-03-30 09:40:25  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-03-30 09:40:31  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-03-30 09:40:37  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-30 09:40:43  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-30 09:40:49  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-03-30 09:40:54  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-30 09:41:00  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-30 09:41:06  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-30 09:41:07  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-30 09:41:13  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-30 09:41:18  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-30 09:41:24  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-30 09:41:30  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-30 09:41:36  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-03-30 09:41:41  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-30 09:41:47  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-30 09:41:53  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-03-30 09:41:57  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-30 09:41:58  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-30 09:42:04  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-30 09:42:10  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-30 09:42:16  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-30 09:42:22  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-30 09:42:27  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-30 09:42:28  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-30 09:42:34  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-30 09:42:40  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-30 09:42:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-30 09:42:50  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-30 09:42:56  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-30 09:43:02  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-30 09:43:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-30 09:43:12  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-30 09:43:17  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-30 09:43:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-30 09:43:28  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-30 09:43:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-30 09:43:40  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-30 09:43:46  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-30 09:43:46  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-30 09:43:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-30 09:43:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-30 09:44:04  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-30 09:44:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-30 09:44:16  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-30 09:44:22  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-30 09:44:27  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-30 09:44:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-30 09:44:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-30 09:44:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-30 09:44:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-30 09:44:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-30 09:44:59  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-30 09:45:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-30 09:45:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-30 09:45:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-30 09:45:21  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-30 09:45:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-30 09:45:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-30 09:45:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-30 09:45:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-30 09:45:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-30 09:45:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-30 09:45:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-30 09:46:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-30 09:46:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-30 09:46:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-30 09:46:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-30 09:46:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-30 09:46:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-30 09:46:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-30 09:46:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-30 09:46:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-30 09:46:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-30 09:47:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-30 09:47:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-30 09:47:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-30 09:47:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-30 09:47:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-30 09:47:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-30 09:47:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-30 09:47:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-30 09:47:48  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-30 09:47:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-30 09:47:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-30 09:48:05  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-30 09:48:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-30 09:48:16  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-30 09:48:21  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-30 09:48:27  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-30 09:48:33  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-30 09:48:39  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-30 09:48:44  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-30 09:48:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-30 09:48:55  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-30 09:49:01  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-30 09:49:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-30 09:49:13  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-30 09:49:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-30 09:49:24  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-30 09:49:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-03-30 09:49:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-30 09:49:41  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-30 09:49:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-30 09:49:52  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-30 09:49:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-03-30 09:50:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-30 09:50:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-30 09:50:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-30 09:50:22  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-30 09:50:23  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-30 09:50:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-03-30 09:50:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-30 09:50:40  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-30 09:50:47  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-30 09:50:52  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-30 09:50:58  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-30 09:51:04  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-30 09:51:10  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-30 09:51:16  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-30 09:51:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-30 09:51:28  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-30 09:51:34  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-30 09:51:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-30 09:51:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-30 09:51:52  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-30 09:51:57  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-30 09:52:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-30 09:52:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-30 09:52:15  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-30 09:52:21  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-30 09:52:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-30 09:52:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-30 09:52:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-30 09:52:45  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-30 09:52:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-30 09:52:57  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-30 09:53:03  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-30 09:53:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-30 09:53:16  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-30 09:53:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-30 09:53:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-30 09:53:34  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-03-30 09:53:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-30 09:53:46  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-30 09:53:52  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-30 09:53:58  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-30 09:54:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-30 09:54:10  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-30 09:54:16  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-30 09:54:22  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-30 09:54:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-30 09:54:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-30 09:54:35  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-30 09:54:41  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-30 09:54:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-30 09:54:53  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-30 09:54:59  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-30 09:55:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-30 09:55:11  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-30 09:55:22  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-30 09:55:28  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-30 09:55:34  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-30 09:55:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-30 09:55:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-30 09:55:53  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-30 09:55:59  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-30 09:56:05  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-30 09:56:10  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-30 09:56:17  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-30 09:56:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-30 09:56:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-30 09:56:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-30 09:56:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-30 09:56:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-30 09:56:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-30 09:56:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-30 09:56:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-30 09:57:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-30 09:57:09  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-30 09:57:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-30 09:57:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-30 09:57:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-30 09:57:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-30 09:57:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-30 09:57:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-30 09:57:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-30 09:57:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-30 09:57:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-30 09:57:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-30 09:58:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-30 09:58:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-30 09:58:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-30 09:58:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-30 09:58:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-30 09:58:22  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-30 09:58:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-30 09:58:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-30 09:58:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-30 09:58:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-30 09:58:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-30 09:58:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-30 09:58:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-30 09:59:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-30 09:59:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-30 09:59:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-30 09:59:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-30 09:59:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-30 09:59:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-30 09:59:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-30 09:59:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-30 09:59:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-30 09:59:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-30 09:59:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-30 09:59:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-30 09:59:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-30 10:00:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-30 10:00:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-30 10:00:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-30 10:00:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-30 10:00:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-30 10:00:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-30 10:00:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-30 10:00:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-30 10:00:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-30 10:00:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-30 10:00:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-30 10:00:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-30 10:00:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-30 10:01:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-30 10:01:07  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-30 10:01:13  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-30 10:01:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-30 10:01:25  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-30 10:01:26  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-30 10:01:32  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-30 10:01:38  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-30 10:01:44  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-30_10-01-45 Restart Xvfb...
2017-03-30 10:01:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-30 10:01:56  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-30 10:02:02  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-30 10:02:08  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-30 10:02:14  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-30 10:02:20  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-30 10:02:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-30 10:02:32  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-30 10:02:38  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-30 10:02:44  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-30 10:02:50  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-30 10:02:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-30 10:03:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-30 10:03:08  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-30 10:03:14  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-30 10:03:20  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-30 10:03:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-30 10:03:32  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-30 10:03:38  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-30 10:03:44  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-30 10:03:50  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-30 10:03:56  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-30 10:04:02  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-30 10:04:07  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-30 10:04:13  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-30 10:04:19  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-30 10:04:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-30 10:04:31  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-30 10:04:37  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-30 10:04:43  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-30 10:04:49  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-30 10:04:54  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-30 10:05:00  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-30 10:05:06  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-30 10:05:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-30 10:05:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-30 10:05:24  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-30 10:05:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-30 10:05:36  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-30 10:05:42  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-30 10:05:48  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-30 10:05:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-30 10:06:00  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-30 10:06:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-30 10:06:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-30 10:06:17  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-30 10:06:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-30 10:06:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-30 10:06:35  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-30 10:06:41  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-30 10:06:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-30 10:06:53  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-30 10:06:58  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-30 10:07:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-30 10:07:10  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-30 10:07:16  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-30 10:07:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-30 10:07:29  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-30 10:07:35  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-30 10:07:41  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-30 10:07:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-30 10:07:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-30 10:07:58  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-30 10:08:04  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-30 10:08:10  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-30 10:08:16  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-30 10:08:22  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-30 10:08:28  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-30 10:08:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-30 10:08:40  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-30 10:08:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-30 10:08:52  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-30 10:08:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-30 10:09:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-30 10:09:10  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-30 10:09:16  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-30 10:09:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-30 10:09:28  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-30 10:09:34  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-30 10:09:40  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-30 10:09:46  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-30 10:09:51  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-30 10:09:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-30 10:10:03  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-30 10:10:09  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-30 10:10:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-30 10:10:21  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-30 10:10:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-30 10:10:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-30 10:10:40  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-30 10:10:46  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-30 10:10:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-30 10:10:57  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-30 10:11:03  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-30 10:11:09  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-30 10:11:15  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-30 10:11:21  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-30 10:11:27  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-30 10:11:33  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-30 10:11:44  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-30 10:11:50  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-30 10:11:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-30 10:12:02  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-30 10:12:08  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-30 10:12:14  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-30 10:12:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-30 10:12:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-30 10:12:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-30 10:12:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-30 10:12:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-30 10:12:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-30 10:12:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-30 10:13:01  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-30 10:13:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-30 10:13:13  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-30 10:13:18  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-30 10:13:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-30 10:13:30  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-30 10:13:35  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-30 10:13:41  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-30 10:13:47  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-30 10:13:53  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-30 10:13:59  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-30 10:14:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-30 10:14:11  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-30 10:14:17  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-30 10:14:23  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-30 10:14:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-30 10:14:35  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-30 10:14:41  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-30 10:14:47  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-30 10:14:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-30 10:14:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-30 10:15:04  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-30 10:15:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-30 10:15:17  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-30 10:15:22  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-30 10:15:29  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-30 10:15:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-30 10:15:41  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-30 10:15:47  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-30 10:15:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-30 10:15:58  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-30 10:16:08  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-30 10:16:14  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-30 10:16:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-30 10:16:29  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-30 10:16:35  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-30 10:16:41  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-30 10:16:46  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-30 10:16:52  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-30 10:16:58  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-30 10:17:04  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-30 10:17:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-30 10:17:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-30 10:17:21  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-30 10:17:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-30 10:17:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-30 10:17:38  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-30 10:17:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-30 10:17:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-30 10:17:55  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-30 10:18:01  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-30 10:18:07  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-30 10:18:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-30 10:18:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-30 10:18:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-30 10:18:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-30 10:18:35  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-30 10:18:41  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-30 10:18:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-30 10:18:52  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-30 10:18:58  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-30 10:19:04  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-30 10:19:10  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-30 10:19:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-30 10:19:21  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-30 10:19:26  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-30 10:19:32  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-30 10:19:38  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-30 10:19:44  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-30 10:19:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-30 10:19:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-30 10:20:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-30 10:20:07  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-03-30 10:20:08  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-30 10:20:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-30 10:20:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-30 10:20:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-30 10:20:33  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-30 10:20:39  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-30 10:20:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-30 10:20:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-30 10:20:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-30 10:21:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-30 10:21:07  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-30 10:21:13  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-30 10:21:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-30 10:21:25  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-30 10:21:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-30 10:21:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-30 10:21:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-30 10:21:48  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-30 10:21:54  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-03-30 10:22:00  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-30 10:22:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-30 10:22:12  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-30 10:22:17  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-30 10:22:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-30 10:22:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-30 10:22:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-30 10:22:41  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-30 10:22:46  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-30 10:22:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-30 10:22:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-30 10:23:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-30 10:23:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-30 10:23:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-30 10:23:19  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-30 10:23:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-30 10:23:29  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-30 10:23:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-30 10:23:40  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-30 10:23:46  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-30 10:23:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-30 10:23:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-30 10:24:03  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-30 10:24:08  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-30 10:24:14  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-30 10:24:19  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-30 10:24:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-30 10:24:31  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-30 10:24:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-30 10:24:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-30 10:24:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-30 10:24:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-30 10:25:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-30 10:25:07  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-30 10:25:12  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-30 10:25:18  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-30 10:25:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-30 10:25:29  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-30 10:25:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-30 10:25:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-30 10:25:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-30 10:25:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 10:25:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 10:26:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 10:26:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 10:26:13  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-30 10:26:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 10:26:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 10:26:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-30 10:26:35  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-30 10:26:40  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-30 10:26:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-30 10:26:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-30 10:26:57  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-30 10:27:02  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-30 10:27:07  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-30 10:27:13  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-30 10:27:18  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-30 10:27:24  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-30 10:27:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-30 10:27:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-30 10:27:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-30 10:27:45  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-30 10:27:50  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-30 10:27:56  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-30 10:28:01  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-30 10:28:07  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-30 10:28:17  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-30 10:28:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 10:28:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 10:28:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 10:28:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 10:28:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 10:28:50  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-30 10:28:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 10:29:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 10:29:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 10:29:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 10:29:16  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-30 10:29:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 10:29:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 10:29:32  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 10:29:37  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-30 10:29:43  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-03-30_10-31-45 Restart Xvfb...
2017-03-30_11-01-45 Restart Xvfb...
2017-03-30_11-31-45 Restart Xvfb...
2017-03-30_12-01-45 Restart Xvfb...
2017-03-30_12-31-45 Restart Xvfb...
2017-03-30 12:31:45 reset updateRequest
2017-03-30 12:31:49  - 14968  http://www.lymphomahub.com/
2017-03-30 12:31:51  - 14968  http://www.lymphomahub.com/
2017-03-30 12:31:55  - 14968  http://www.lymphomahub.com/about
2017-03-30 12:31:56  - 14968  http://www.lymphomahub.com/about
2017-03-30 12:32:02  - 14968  http://www.lymphomahub.com/terms
2017-03-30 12:32:06  - 14968  http://www.lymphomahub.com/undefined
2017-03-30 12:32:07  - 14968  http://www.lymphomahub.com/therapies
2017-03-30 12:32:14  - 14968  http://www.lymphomahub.com/newsletter
2017-03-30 12:32:18  - 14968  http://www.lymphomahub.com/cookie-policy
2017-03-30 12:32:22  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-03-30 12:32:28  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-03-30 12:32:33  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-03-30 12:32:39  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-03-30 12:32:45  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-03-30 12:32:51  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-03-30 12:32:57  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-03-30 12:33:03  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-03-30 12:33:09  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-03-30 12:33:14  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-03-30 12:33:20  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-03-30 12:33:26  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-03-30 12:33:31  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-03-30 12:33:37  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-03-30 12:33:43  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-03-30 12:33:49  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-03-30 12:33:54  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-03-30 12:34:00  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-03-30 12:34:06  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-03-30 12:34:12  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-03-30 12:34:18  - 14968  http://www.lymphomahub.com/about/secretariat
2017-03-30 12:34:23  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-03-30 12:34:29  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-03-30 12:34:34  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-03-30 12:34:40  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-03-30 12:34:46  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-03-30 12:34:52  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-03-30 12:34:57  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-03-30 12:35:03  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-03-30 12:35:09  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-03-30 12:35:14  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-30 12:35:20  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-30 12:35:26  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-03-30 12:35:32  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-03-30 12:35:37  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-03-30 12:35:43  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-30 12:35:49  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-03-30 12:35:54  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-03-30 12:36:01  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-03-30 12:36:06  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-03-30 12:36:12  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-03-30 12:36:23  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-03-30 12:36:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-30 12:36:34  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-30 12:36:40  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-03-30 12:36:46  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-03-30 12:36:52  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-03-30 12:36:58  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-03-30 12:37:03  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-03-30 12:37:09  - 14968  http://www.lymphomahub.com/medical-information
2017-03-30 12:37:15  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-03-30 12:37:21  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-03-30 12:37:27  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-30 12:37:33  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-03-30 12:37:42  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-03-30 12:37:48  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-03-30 12:37:54  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-03-30 12:38:00  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-03-30 12:38:05  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-03-30 12:38:11  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-03-30 12:38:17  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-03-30 12:38:23  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-03-30 12:38:24  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-03-30 12:38:29  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-03-30 12:38:35  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-30 12:38:41  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-30 12:38:46  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-03-30 12:38:52  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-30 12:38:58  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-03-30 12:39:04  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-03-30 12:39:10  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-03-30 12:39:16  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-03-30 12:39:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-03-30 12:39:27  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-30 12:39:33  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-30 12:39:39  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-30 12:39:45  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-30 12:39:50  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-30 12:39:56  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-30 12:40:02  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-03-30 12:40:07  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-03-30 12:40:13  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-03-30 12:40:19  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-30 12:40:24  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-30 12:40:30  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-03-30 12:40:36  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-03-30 12:40:42  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-03-30 12:40:47  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-30 12:40:53  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-30 12:40:59  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-03-30 12:41:05  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-30 12:41:10  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-30 12:41:16  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-30 12:41:17  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-30 12:41:23  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-30 12:41:29  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-30 12:41:34  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-30 12:41:40  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-30 12:41:46  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-03-30 12:41:52  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-30 12:41:57  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-30 12:42:03  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-03-30 12:42:13  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-30 12:42:13  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-30 12:42:19  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-30 12:42:25  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-30 12:42:31  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-30 12:42:36  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-30 12:42:42  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-30 12:42:43  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-30 12:42:49  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-30 12:42:55  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-30 12:43:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-30 12:43:05  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-30 12:43:11  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-30 12:43:16  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-30 12:43:22  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-30 12:43:26  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-30 12:43:32  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-30 12:43:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-30 12:43:48  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-30 12:43:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-30 12:44:00  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-30 12:44:05  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-30 12:44:06  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-30 12:44:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-30 12:44:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-30 12:44:23  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-30 12:44:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-30 12:44:35  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-30 12:44:41  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-30 12:44:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-30 12:44:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-30 12:44:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-30 12:45:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-30 12:45:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-30 12:45:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-30 12:45:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-30 12:45:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-30 12:45:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-30 12:45:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-30 12:45:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-30 12:45:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-30 12:45:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-30 12:45:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-30 12:46:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-30 12:46:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-30 12:46:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-30 12:46:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-30 12:46:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-30 12:46:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-30 12:46:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-30 12:46:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-30 12:46:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-30 12:46:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-30 12:46:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-30 12:47:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-30 12:47:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-30 12:47:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-30 12:47:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-30 12:47:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-30 12:47:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-30 12:47:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-30 12:47:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-30 12:47:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-30 12:47:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-30 12:47:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-30 12:48:02  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-30 12:48:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-30 12:48:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-30 12:48:18  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-30 12:48:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-30 12:48:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-30 12:48:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-30 12:48:40  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-30 12:48:46  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-30 12:48:52  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-30 12:48:57  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-30 12:49:03  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-30 12:49:08  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-30 12:49:14  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-30 12:49:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-30 12:49:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-30 12:49:31  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-30 12:49:37  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-30 12:49:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-03-30 12:49:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-30 12:49:58  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-30 12:50:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-30 12:50:10  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-30 12:50:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-03-30 12:50:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-30 12:50:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-30 12:50:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-30 12:50:40  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-30 12:50:41  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-30 12:50:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-03-30 12:50:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-30 12:50:59  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-30 12:51:05  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-30 12:51:10  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-30 12:51:16  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-30 12:51:22  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-30 12:51:33  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-30 12:51:39  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-30 12:51:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-30 12:51:51  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-30 12:51:57  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-30 12:52:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-30 12:52:09  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-30 12:52:15  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-30 12:52:21  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-30 12:52:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-30 12:52:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-30 12:52:40  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-30 12:52:51  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-30 12:52:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-30 12:53:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-30 12:53:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-30 12:53:15  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-30 12:53:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-30 12:53:27  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-30 12:53:33  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-30 12:53:39  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-30 12:53:45  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-30 12:53:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-30 12:53:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-30 12:54:02  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-03-30 12:54:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-30 12:54:14  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-30 12:54:20  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-30 12:54:26  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-30 12:54:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-30 12:54:38  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-30 12:54:44  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-30 12:54:50  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-30 12:54:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-30 12:54:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-30 12:55:02  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-30 12:55:08  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-30 12:55:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-30 12:55:20  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-30 12:55:26  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-30 12:55:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-30 12:55:38  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-30 12:55:44  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-30 12:55:50  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-30 12:55:55  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-30 12:56:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-30 12:56:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-30 12:56:14  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-30 12:56:20  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-30 12:56:26  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-30 12:56:37  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-30 12:56:43  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-30 12:56:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-30 12:56:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-30 12:56:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-30 12:57:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-30 12:57:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-30 12:57:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-30 12:57:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-30 12:57:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-30 12:57:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-30 12:57:35  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-30 12:57:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-30 12:57:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-30 12:57:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-30 12:57:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-30 12:57:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-30 12:58:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-30 12:58:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-30 12:58:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-30 12:58:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-30 12:58:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-30 12:58:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-30 12:58:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-30 12:58:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-30 12:58:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-30 12:58:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-30 12:58:43  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-30 12:58:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-30 12:58:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-30 12:58:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-30 12:59:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-30 12:59:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-30 12:59:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-30 12:59:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-30 12:59:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-30 12:59:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-30 12:59:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-30 12:59:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-30 12:59:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-30 12:59:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-30 12:59:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-30 12:59:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-30 12:59:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-30 12:59:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-30 13:00:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-30 13:00:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-30 13:00:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-30 13:00:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-30 13:00:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-30 13:00:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-30 13:00:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-30 13:00:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-30 13:00:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-30 13:00:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-30 13:00:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-30 13:00:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-30 13:00:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-30 13:01:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-30 13:01:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-30 13:01:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-30 13:01:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-30 13:01:27  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-30 13:01:33  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-30 13:01:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-30_13-01-45 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors?_prerender {"code":"ECONNRESET"}
2017-03-30 13:03:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-30 13:03:50  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-30 13:03:50  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-30 13:03:57  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-30 13:04:03  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-30 13:04:09  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-30 13:04:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-30 13:04:21  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-30 13:04:27  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-30 13:04:33  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-30 13:04:39  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-30 13:04:45  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-30 13:04:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-30 13:04:57  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-30 13:05:03  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-30 13:05:09  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-30 13:05:15  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-30 13:05:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-30 13:05:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-30 13:05:33  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-30 13:05:39  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-30 13:05:45  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-30 13:05:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-30 13:05:57  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-30 13:06:03  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-30 13:06:09  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-30 13:06:15  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-30 13:06:21  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-30 13:06:27  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-30 13:06:33  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-30 13:06:39  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-30 13:06:45  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-30 13:06:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-30 13:06:56  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-30 13:07:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-30 13:07:09  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-30 13:07:14  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-30 13:07:20  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-30 13:07:26  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-30 13:07:32  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-30 13:07:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-30 13:07:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-30 13:07:50  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-30 13:07:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-30 13:08:02  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-30 13:08:08  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-30 13:08:14  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-30 13:08:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-30 13:08:26  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-30 13:08:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-30 13:08:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-30 13:08:43  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-30 13:08:54  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-30 13:09:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-30 13:09:05  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-30 13:09:11  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-30 13:09:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-30 13:09:23  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-30 13:09:29  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-30 13:09:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-30 13:09:41  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-30 13:09:48  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-30 13:09:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-30 13:10:00  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-30 13:10:06  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-30 13:10:12  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-30 13:10:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-30 13:10:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-30 13:10:30  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-30 13:10:36  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-30 13:10:42  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-30 13:10:48  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-30 13:10:54  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-30 13:10:59  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-30 13:11:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-30 13:11:12  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-30 13:11:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-30 13:11:24  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-30 13:11:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-30 13:11:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-30 13:11:42  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-30 13:11:48  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-30 13:11:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-30 13:12:00  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-30 13:12:05  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-30 13:12:11  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-30 13:12:17  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-30 13:12:23  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-30 13:12:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-30 13:12:35  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-30 13:12:40  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-30 13:12:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-30 13:12:52  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-30 13:13:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-30 13:13:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-30 13:13:11  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-30 13:13:17  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-30 13:13:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-30 13:13:29  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-30 13:13:35  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-30 13:13:41  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-30 13:13:47  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-30 13:13:53  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-30 13:13:59  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-30 13:14:05  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-30 13:14:11  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-30 13:14:17  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-30 13:14:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-30 13:14:28  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-30 13:14:34  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-30 13:14:40  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-30 13:14:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-30 13:14:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-30 13:14:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-30 13:15:04  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-30 13:15:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-30 13:15:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-30 13:15:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-30 13:15:28  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-30 13:15:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-30 13:15:41  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-30 13:15:46  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-30 13:15:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-30 13:16:03  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-30 13:16:08  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-30 13:16:15  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-30 13:16:21  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-30 13:16:27  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-30 13:16:33  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-30 13:16:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-30 13:16:45  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-30 13:16:50  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-30 13:16:56  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-30 13:17:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-30 13:17:08  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-30 13:17:14  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-30 13:17:20  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-30 13:17:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-30 13:17:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-30 13:17:38  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-30 13:17:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-30 13:17:50  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-30 13:17:56  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-30 13:18:02  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-30 13:18:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-30 13:18:14  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-30 13:18:20  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-30 13:18:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-30 13:18:32  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-30 13:18:37  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-30 13:18:43  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-30 13:18:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-30 13:18:55  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-30 13:19:00  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-30 13:19:09  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-30 13:19:15  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-30 13:19:21  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-30 13:19:27  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-30 13:19:32  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-30 13:19:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-30 13:19:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-30 13:19:50  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-30 13:19:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-30 13:20:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-30 13:20:07  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-30 13:20:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-30 13:20:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-30 13:20:25  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-30 13:20:33  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-30 13:20:38  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-30 13:20:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-30 13:20:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-30 13:21:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-30 13:21:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-30 13:21:18  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-30 13:21:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-30 13:21:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-30 13:21:35  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-30 13:21:40  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-30 13:21:47  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-30 13:21:53  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-30 13:21:58  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-30 13:22:04  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-30 13:22:09  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-30 13:22:16  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-30 13:22:21  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-30 13:22:28  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-30 13:22:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-30 13:22:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-30 13:22:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-30 13:22:51  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-03-30 13:22:52  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-30 13:22:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-30 13:23:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-30 13:23:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-30 13:23:15  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-30 13:23:21  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-30 13:23:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-30 13:23:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-30 13:23:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-30 13:23:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-30 13:23:50  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-30 13:23:55  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-30 13:24:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-30 13:24:07  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-30 13:24:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-30 13:24:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-30 13:24:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-30 13:24:33  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-30 13:24:39  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-03-30 13:24:45  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-30 13:24:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-30 13:24:57  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-30 13:25:02  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-30 13:25:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-30 13:25:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-30 13:25:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-30 13:25:26  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-30 13:25:31  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-30 13:25:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-30 13:25:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-30 13:25:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-30 13:25:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-30 13:25:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-30 13:26:04  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-30 13:26:09  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-30 13:26:14  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-30 13:26:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-30 13:26:25  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-30 13:26:31  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-30 13:26:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-30 13:26:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-30 13:26:48  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-30 13:26:53  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-30 13:26:58  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-30 13:27:04  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-30 13:27:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-30 13:27:15  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-30 13:27:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-30 13:27:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-30 13:27:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-30 13:27:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-30 13:27:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-30 13:27:49  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-30 13:27:54  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-30 13:28:00  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-30 13:28:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-30 13:28:12  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-30 13:28:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-30 13:28:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-30 13:28:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-30 13:28:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 13:28:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 13:28:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 13:28:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 13:28:55  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-30 13:29:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 13:29:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 13:29:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-30 13:29:16  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-30 13:29:22  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-30 13:29:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-30 13:29:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-30 13:29:39  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-30 13:29:44  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-30 13:29:49  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-30 13:29:55  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-30 13:30:00  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-30 13:30:05  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-30 13:30:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-30 13:30:16  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-30 13:30:22  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-30 13:30:27  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-30 13:30:32  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-30 13:30:38  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-30 13:30:43  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-30 13:30:48  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-30 13:30:56  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-30 13:31:01  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 13:31:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 13:31:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 13:31:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 13:31:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 13:31:28  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-30 13:31:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 13:31:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 13:31:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30_13-31-45 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly?_prerender {"code":"ECONNRESET"}
2017-03-30 13:33:49  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 13:33:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 13:34:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-30 13:34:05  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 13:34:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 13:34:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 13:34:21  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-30 13:34:27  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-03-30_14-01-45 Restart Xvfb...
2017-03-30_14-31-45 Restart Xvfb...
2017-03-30_15-01-45 Restart Xvfb...
2017-03-30_15-31-45 Restart Xvfb...
2017-03-30 15:31:45 reset updateRequest
2017-03-30 15:31:47  - 14968  http://www.lymphomahub.com/
2017-03-30 15:31:51  - 14968  http://www.lymphomahub.com/
2017-03-30 15:31:52  - 14968  http://www.lymphomahub.com/about
2017-03-30 15:31:55  - 14968  http://www.lymphomahub.com/about
2017-03-30 15:32:00  - 14968  http://www.lymphomahub.com/terms
2017-03-30 15:32:00  - 14968  http://www.lymphomahub.com/terms
2017-03-30 15:32:04  - 14968  http://www.lymphomahub.com/undefined
2017-03-30 15:32:05  - 14968  http://www.lymphomahub.com/undefined
2017-03-30 15:32:05  - 14968  http://www.lymphomahub.com/therapies
2017-03-30 15:32:06  - 14968  http://www.lymphomahub.com/therapies
2017-03-30 15:32:16  - 14968  http://www.lymphomahub.com/newsletter
2017-03-30 15:32:17  - 14968  http://www.lymphomahub.com/newsletter
2017-03-30 15:32:20  - 14968  http://www.lymphomahub.com/cookie-policy
2017-03-30 15:32:21  - 14968  http://www.lymphomahub.com/cookie-policy
2017-03-30 15:32:24  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-03-30 15:32:25  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-03-30 15:32:31  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-03-30 15:32:37  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-03-30 15:32:42  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-03-30 15:32:48  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-03-30 15:32:54  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-03-30 15:32:59  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-03-30 15:33:05  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-03-30 15:33:11  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-03-30 15:33:17  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-03-30 15:33:23  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-03-30 15:33:28  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-03-30 15:33:34  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-03-30 15:33:40  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-03-30 15:33:46  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-03-30 15:33:52  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-03-30 15:33:57  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-03-30 15:34:03  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-03-30 15:34:09  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-03-30 15:34:15  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-03-30 15:34:21  - 14968  http://www.lymphomahub.com/about/secretariat
2017-03-30 15:34:25  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-03-30 15:34:31  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-03-30 15:34:37  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-03-30 15:34:43  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-03-30 15:34:48  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-03-30 15:34:54  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-03-30 15:35:00  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-03-30 15:35:05  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-03-30 15:35:11  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-03-30 15:35:17  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-30 15:35:23  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-30 15:35:28  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-03-30 15:35:34  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-03-30 15:35:45  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-03-30 15:35:51  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-30 15:35:56  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-03-30 15:36:02  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-03-30 15:36:08  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-03-30 15:36:13  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-03-30 15:36:19  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-03-30 15:36:25  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-03-30 15:36:30  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-30 15:36:36  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-30 15:36:42  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-03-30 15:36:48  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-03-30 15:36:53  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-03-30 15:36:59  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-03-30 15:37:05  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-03-30 15:37:11  - 14968  http://www.lymphomahub.com/medical-information
2017-03-30 15:37:15  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-03-30 15:37:21  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-03-30 15:37:27  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-30 15:37:32  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-03-30 15:37:38  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-03-30 15:37:44  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-03-30 15:37:49  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-03-30 15:37:55  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-03-30 15:38:01  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-03-30 15:38:07  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-03-30 15:38:12  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-03-30 15:38:18  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-03-30 15:38:19  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-03-30 15:38:25  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-03-30 15:38:31  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-30 15:38:36  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-30 15:38:42  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-03-30 15:38:48  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-30 15:38:53  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-03-30 15:38:59  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-03-30 15:39:05  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-03-30 15:39:11  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-03-30 15:39:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-03-30 15:39:23  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-30 15:39:28  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-30 15:39:34  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-30 15:39:40  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-30 15:39:45  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-30 15:39:51  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-30 15:39:57  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-03-30 15:40:03  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-03-30 15:40:09  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-03-30 15:40:15  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-30 15:40:20  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-30 15:40:26  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-03-30 15:40:32  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-03-30 15:40:38  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-03-30 15:40:43  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-30 15:40:49  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-30 15:40:57  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-03-30 15:41:03  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-30 15:41:08  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-30 15:41:14  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-30 15:41:15  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-30 15:41:21  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-30 15:41:27  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-30 15:41:32  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-30 15:41:38  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-30 15:41:44  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-03-30 15:41:50  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-30 15:41:55  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-30 15:42:01  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-03-30 15:42:06  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-30 15:42:06  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-30 15:42:12  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-30 15:42:18  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-30 15:42:24  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-30 15:42:30  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-30 15:42:35  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-30 15:42:36  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-30 15:42:42  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-30 15:42:48  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-30 15:42:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-30 15:42:58  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-30 15:43:04  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-30 15:43:09  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-30 15:43:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-30 15:43:20  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-30 15:43:25  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-30 15:43:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-30 15:43:36  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-30 15:43:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-30 15:43:48  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-30 15:43:53  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-30 15:43:54  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-30 15:43:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-30 15:44:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-30 15:44:12  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-30 15:44:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-30 15:44:23  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-30 15:44:29  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-30 15:44:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-30 15:44:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-30 15:44:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-30 15:44:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-30 15:44:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-30 15:45:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-30 15:45:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-30 15:45:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-30 15:45:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-30 15:45:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-30 15:45:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-30 15:45:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-30 15:45:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-30 15:45:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-30 15:45:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-30 15:46:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-30 15:46:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-30 15:46:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-30 15:46:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-30 15:46:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-30 15:46:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-30 15:46:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-30 15:46:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-30 15:46:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-30 15:46:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-30 15:46:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-30 15:47:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-30 15:47:08  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-30 15:47:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-30 15:47:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-30 15:47:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-30 15:47:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-30 15:47:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-30 15:47:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-30 15:47:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-30 15:47:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-30 15:47:58  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-30 15:48:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-30 15:48:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-30 15:48:14  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-30 15:48:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-30 15:48:25  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-30 15:48:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-30 15:48:41  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-30 15:48:47  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-30 15:48:53  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-30 15:48:58  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-30 15:49:04  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-30 15:49:09  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-30 15:49:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-30 15:49:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-30 15:49:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-30 15:49:32  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-30 15:49:37  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-30 15:49:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-03-30 15:49:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-30 15:49:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-30 15:49:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-30 15:50:05  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-30 15:50:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-03-30 15:50:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-30 15:50:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-30 15:50:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-30 15:50:35  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-30 15:50:36  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-30 15:50:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-03-30 15:50:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-30 15:50:54  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-30 15:51:00  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-30 15:51:06  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-30 15:51:12  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-30 15:51:17  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-30 15:51:23  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-30 15:51:29  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-30 15:51:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-30 15:51:41  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-30 15:51:47  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-30 15:51:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-30 15:51:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-30 15:52:05  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-30 15:52:11  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-30 15:52:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-30 15:52:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-30 15:52:29  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-30 15:52:35  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-30 15:52:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-30 15:52:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-30 15:52:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-30 15:52:58  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-30 15:53:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-30 15:53:10  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-30 15:53:16  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-30 15:53:22  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-30 15:53:28  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-30 15:53:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-30 15:53:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-30 15:53:45  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-03-30 15:53:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-30 15:53:58  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-30 15:54:04  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-30 15:54:10  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-30 15:54:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-30 15:54:22  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-30 15:54:28  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-30 15:54:34  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-30 15:54:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-30 15:54:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-30 15:54:46  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-30 15:54:52  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-30 15:54:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-30 15:55:04  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-30 15:55:10  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-30 15:55:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-30 15:55:22  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-30 15:55:28  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-30 15:55:34  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-30 15:55:40  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-30 15:55:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-30 15:55:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-30 15:55:57  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-30 15:56:03  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-30 15:56:09  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-30 15:56:15  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-30 15:56:21  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-30 15:56:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-30 15:56:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-30 15:56:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-30 15:56:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-30 15:56:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-30 15:56:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-30 15:56:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-30 15:57:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-30 15:57:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-30 15:57:14  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-30 15:57:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-30 15:57:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-30 15:57:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-30 15:57:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-30 15:57:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-30 15:57:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-30 15:57:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-30 15:57:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-30 15:57:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-30 15:57:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-30 15:58:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-30 15:58:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-30 15:58:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-30 15:58:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-30 15:58:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-30 15:58:21  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-30 15:58:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-30 15:58:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-30 15:58:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-30 15:58:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-30 15:58:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-30 15:58:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-30 15:58:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-30 15:58:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-30 15:59:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-30 15:59:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-30 15:59:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-30 15:59:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-30 15:59:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-30 15:59:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-30 15:59:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-30 15:59:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-30 15:59:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-30 15:59:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-30 15:59:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-30 15:59:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-30 15:59:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-30 16:00:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-30 16:00:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-30 16:00:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-30 16:00:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-30 16:00:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-30 16:00:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-30 16:00:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-30 16:00:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-30 16:00:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-30 16:00:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-30 16:00:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-30 16:00:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-30 16:00:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-30 16:01:01  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-30 16:01:09  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-30 16:01:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-30 16:01:22  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-30 16:01:22  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-30 16:01:31  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-30 16:01:37  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-30 16:01:43  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-30_16-01-45 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial?_prerender {"code":"ECONNRESET"}
2017-03-30 16:03:48  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-30 16:03:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-30 16:04:05  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-30 16:04:11  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-30 16:04:17  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-30 16:04:26  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-30 16:04:34  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-30 16:04:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-30 16:04:48  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-30 16:04:53  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-30 16:04:59  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-30 16:05:05  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-30 16:05:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-30 16:05:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-30 16:05:29  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-30 16:05:35  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-30 16:05:40  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-30 16:05:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-30 16:05:52  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-30 16:05:58  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-30 16:06:04  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-30 16:06:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-30 16:06:16  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-30 16:06:22  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-30 16:06:27  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-30 16:06:38  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-30 16:06:43  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-30 16:06:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-30 16:06:56  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-30 16:07:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-30 16:07:08  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-30 16:07:14  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-30 16:07:19  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-30 16:07:25  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-30 16:07:31  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-30 16:07:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-30 16:07:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-30 16:07:49  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-30 16:07:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-30 16:08:01  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-30 16:08:07  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-30 16:08:13  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-30 16:08:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-30 16:08:25  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-30 16:08:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-30 16:08:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-30 16:08:43  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-30 16:08:54  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-30 16:09:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-30 16:09:06  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-30 16:09:12  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-30 16:09:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-30 16:09:24  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-30 16:09:30  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-30 16:09:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-30 16:09:41  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-30 16:09:47  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-30 16:09:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-30 16:09:59  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-30 16:10:05  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-30 16:10:11  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-30 16:10:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-30 16:10:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-30 16:10:29  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-30 16:10:35  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-30 16:10:41  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-30 16:10:47  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-30 16:10:52  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-30 16:10:58  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-30 16:11:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-30 16:11:10  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-30 16:11:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-30 16:11:22  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-30 16:11:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-30 16:11:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-30 16:11:39  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-30 16:11:45  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-30 16:11:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-30 16:11:57  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-30 16:12:03  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-30 16:12:09  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-30 16:12:15  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-30 16:12:20  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-30 16:12:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-30 16:12:32  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-30 16:12:38  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-30 16:12:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-30 16:12:50  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-30 16:12:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-30 16:13:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-30 16:13:08  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-30 16:13:13  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-30 16:13:20  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-30 16:13:26  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-30 16:13:31  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-30 16:13:37  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-30 16:13:51  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-30 16:13:57  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-30 16:14:03  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-30 16:14:09  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-30 16:14:15  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-30 16:14:21  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-30 16:14:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-30 16:14:33  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-30 16:14:39  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-30 16:14:44  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-30 16:14:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-30 16:14:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-30 16:15:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-30 16:15:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-30 16:15:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-30 16:15:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-30 16:15:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-30 16:15:32  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-30 16:15:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-30 16:15:44  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-30 16:15:50  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-30 16:15:56  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-30 16:16:01  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-30 16:16:07  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-30 16:16:13  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-30 16:16:19  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-30 16:16:25  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-30 16:16:31  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-30 16:16:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-30 16:16:43  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-30 16:16:49  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-30 16:16:55  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-30 16:17:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-30 16:17:07  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-30 16:17:12  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-30 16:17:19  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-30 16:17:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-30 16:17:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-30 16:17:37  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-30 16:17:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-30 16:17:48  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-30 16:17:54  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-30 16:18:00  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-30 16:18:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-30 16:18:12  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-30 16:18:19  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-30 16:18:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-30 16:18:29  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-03-30 16:18:35  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-30 16:18:40  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-30 16:18:46  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-30 16:18:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-30 16:18:58  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-30 16:19:04  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-30 16:19:10  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-30 16:19:16  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-30 16:19:21  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-30 16:19:27  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-30 16:19:32  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-30 16:19:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-30 16:19:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-30 16:19:49  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-30 16:19:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-30 16:20:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-30 16:20:12  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-30 16:20:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-30 16:20:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-30 16:20:30  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-30 16:20:36  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-30 16:20:42  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-30 16:20:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-30 16:21:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-30 16:21:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-30 16:21:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-30 16:21:18  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-30 16:21:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-30 16:21:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-30 16:21:35  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-30 16:21:40  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-30 16:21:46  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-30 16:21:52  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-30 16:21:58  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-30 16:22:03  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-30 16:22:09  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-30 16:22:17  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-30 16:22:23  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-30 16:22:29  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-30 16:22:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-30 16:22:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-30 16:22:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-30 16:22:53  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-03-30 16:22:53  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-30 16:22:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-30 16:23:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-30 16:23:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-30 16:23:17  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-30 16:23:22  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-03-30 16:23:28  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-30 16:23:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-30 16:23:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-30 16:23:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-30 16:23:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-30 16:23:57  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-30 16:24:02  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-30 16:24:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-30 16:24:14  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-30 16:24:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-30 16:24:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-30 16:24:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-30 16:24:37  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-30 16:24:43  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-03-30 16:24:49  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-30 16:24:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-30 16:25:00  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-30 16:25:06  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-30 16:25:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-30 16:25:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-30 16:25:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-30 16:25:30  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-30 16:25:35  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-30 16:25:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-30 16:25:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-30 16:25:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-30 16:25:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-30 16:26:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-30 16:26:08  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-30 16:26:13  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-30 16:26:18  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-30 16:26:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-30 16:26:29  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-30 16:26:34  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-30 16:26:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-30 16:26:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-30 16:26:51  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-30 16:26:57  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-30 16:27:02  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-30 16:27:07  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-30 16:27:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-30 16:27:18  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-30 16:27:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-30 16:27:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-30 16:27:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-30 16:27:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-30 16:27:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-30 16:27:53  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-30 16:27:58  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-30 16:28:03  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-30 16:28:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-30 16:28:15  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-30 16:28:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-30 16:28:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-30 16:28:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-30 16:28:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 16:28:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 16:28:48  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 16:28:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 16:28:58  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-30 16:29:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 16:29:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 16:29:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-30 16:29:19  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-30 16:29:25  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-30 16:29:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-30 16:29:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-30 16:29:41  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-30 16:29:47  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-30 16:29:52  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-30 16:29:57  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-30 16:30:03  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-30 16:30:08  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-30 16:30:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-30 16:30:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-30 16:30:28  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-30 16:30:34  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-30 16:30:39  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-30 16:30:44  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-30 16:30:50  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-30 16:30:55  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-30 16:31:00  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-30 16:31:05  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 16:31:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 16:31:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 16:31:24  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 16:31:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 16:31:36  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-30 16:31:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30_16-31-45 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly?_prerender {"code":"ECONNRESET"}
2017-03-30 16:33:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 16:33:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 16:34:01  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 16:34:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 16:34:17  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-30 16:34:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 16:34:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 16:34:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 16:34:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-30 16:34:43  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-03-30_17-01-45 Restart Xvfb...
2017-03-30_17-31-45 Restart Xvfb...
2017-03-30_18-01-45 Restart Xvfb...
2017-03-30_18-31-45 Restart Xvfb...
2017-03-30 18:31:45 reset updateRequest
2017-03-30 18:31:49  - 14968  http://www.lymphomahub.com/
2017-03-30 18:31:51  - 14968  http://www.lymphomahub.com/
2017-03-30 18:31:55  - 14968  http://www.lymphomahub.com/about
2017-03-30 18:31:56  - 14968  http://www.lymphomahub.com/about
2017-03-30 18:32:03  - 14968  http://www.lymphomahub.com/terms
2017-03-30 18:32:07  - 14968  http://www.lymphomahub.com/undefined
2017-03-30 18:32:08  - 14968  http://www.lymphomahub.com/therapies
2017-03-30 18:32:15  - 14968  http://www.lymphomahub.com/newsletter
2017-03-30 18:32:19  - 14968  http://www.lymphomahub.com/cookie-policy
2017-03-30 18:32:22  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-03-30 18:32:28  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-03-30 18:32:34  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-03-30 18:32:40  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-03-30 18:32:46  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-03-30 18:32:52  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-03-30 18:32:58  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-03-30 18:33:03  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-03-30 18:33:09  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-03-30 18:33:15  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-03-30 18:33:21  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-03-30 18:33:27  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-03-30 18:33:32  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-03-30 18:33:38  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-03-30 18:33:44  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-03-30 18:33:50  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-03-30 18:33:55  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-03-30 18:34:01  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-03-30 18:34:07  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-03-30 18:34:13  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-03-30 18:34:18  - 14968  http://www.lymphomahub.com/about/secretariat
2017-03-30 18:34:29  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-03-30 18:34:35  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-03-30 18:34:40  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-03-30 18:34:46  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-03-30 18:34:52  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-03-30 18:34:58  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-03-30 18:35:04  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-03-30 18:35:10  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-03-30 18:35:16  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-03-30 18:35:21  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-30 18:35:27  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-30 18:35:33  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-03-30 18:35:38  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-03-30 18:35:44  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-03-30 18:35:50  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-30 18:35:56  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-03-30 18:36:02  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-03-30 18:36:07  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-03-30 18:36:13  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-03-30 18:36:19  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-03-30 18:36:25  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-03-30 18:36:31  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-30 18:36:37  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-30 18:36:42  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-03-30 18:36:48  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-03-30 18:36:54  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-03-30 18:37:00  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-03-30 18:37:06  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-03-30 18:37:11  - 14968  http://www.lymphomahub.com/medical-information
2017-03-30 18:37:17  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-03-30 18:37:23  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-03-30 18:37:28  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-30 18:37:34  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-03-30 18:37:40  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-03-30 18:37:46  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-03-30 18:37:52  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-03-30 18:37:58  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-03-30 18:38:03  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-03-30 18:38:09  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-03-30 18:38:15  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-03-30 18:38:21  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-03-30 18:38:21  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-03-30 18:38:27  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-03-30 18:38:33  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-30 18:38:44  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-30 18:38:49  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-03-30 18:38:55  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-30 18:39:01  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-03-30 18:39:06  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-03-30 18:39:12  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-03-30 18:39:18  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-03-30 18:39:24  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-03-30 18:39:29  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-30 18:39:35  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-30 18:39:41  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-30 18:39:46  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-30 18:39:52  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-30 18:39:58  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-30 18:40:04  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-03-30 18:40:10  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-03-30 18:40:15  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-03-30 18:40:21  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-30 18:40:27  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-30 18:40:33  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-03-30 18:40:38  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-03-30 18:40:45  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-03-30 18:40:50  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-30 18:40:56  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-30 18:41:02  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-03-30 18:41:07  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-30 18:41:13  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-30 18:41:19  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-30 18:41:20  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-30 18:41:25  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-30 18:41:31  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-30 18:41:37  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-30 18:41:43  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-30 18:41:49  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-03-30 18:41:54  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-30 18:42:00  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-30 18:42:06  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-03-30 18:42:11  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-30 18:42:11  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-30 18:42:17  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-30 18:42:23  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-30 18:42:28  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-30 18:42:34  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-30 18:42:40  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-30 18:42:41  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-30 18:42:47  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-30 18:42:53  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-30 18:43:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-30 18:43:06  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-30 18:43:12  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-30 18:43:17  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-30 18:43:22  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-30 18:43:27  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-30 18:43:33  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-30 18:43:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-30 18:43:44  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-30 18:43:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-30 18:43:56  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-30 18:44:01  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-30 18:44:02  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-30 18:44:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-30 18:44:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-30 18:44:20  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-30 18:44:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-30 18:44:31  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-30 18:44:37  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-30 18:44:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-30 18:44:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-30 18:44:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-30 18:44:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-30 18:45:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-30 18:45:10  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-30 18:45:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-30 18:45:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-30 18:45:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-30 18:45:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-30 18:45:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-30 18:45:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-30 18:45:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-30 18:45:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-30 18:45:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-30 18:46:03  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-30 18:46:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-30 18:46:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-30 18:46:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-30 18:46:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-30 18:46:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-30 18:46:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-30 18:46:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-30 18:46:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-30 18:46:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-30 18:46:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-30 18:47:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-30 18:47:08  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-30 18:47:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-30 18:47:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-30 18:47:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-30 18:47:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-30 18:47:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-30 18:47:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-30 18:47:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-30 18:47:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-30 18:48:01  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-30 18:48:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-03-30 18:48:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-30 18:48:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-30 18:48:22  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-30 18:48:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-30 18:48:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-30 18:48:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-30 18:48:43  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-30 18:48:49  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-30 18:48:55  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-30 18:49:00  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-30 18:49:06  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-30 18:49:12  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-30 18:49:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-30 18:49:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-30 18:49:29  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-30 18:49:34  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-30 18:49:39  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-30 18:49:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-03-30 18:49:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-30 18:49:57  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-30 18:50:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-30 18:50:08  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-30 18:50:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-03-30 18:50:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-30 18:50:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-30 18:50:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-30 18:50:37  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-30 18:50:38  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-30 18:50:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-03-30 18:50:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-30 18:50:56  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-30 18:51:07  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-30 18:51:12  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-30 18:51:18  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-30 18:51:24  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-30 18:51:30  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-30 18:51:36  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-30 18:51:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-30 18:51:48  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-30 18:51:54  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-30 18:52:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-30 18:52:06  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-30 18:52:12  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-30 18:52:18  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-30 18:52:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-30 18:52:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-30 18:52:35  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-30 18:52:41  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-30 18:52:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-30 18:52:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-30 18:52:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-30 18:53:06  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-30 18:53:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-30 18:53:18  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-30 18:53:24  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-30 18:53:30  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-30 18:53:36  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-30 18:53:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-30 18:53:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-30 18:53:53  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-03-30 18:53:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-30 18:54:05  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-30 18:54:11  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-30 18:54:17  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-30 18:54:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-30 18:54:29  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-30 18:54:35  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-30 18:54:41  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-30 18:54:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-30 18:54:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-30 18:54:53  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-30 18:54:59  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-30 18:55:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-30 18:55:11  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-30 18:55:16  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-30 18:55:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-30 18:55:28  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-30 18:55:34  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-30 18:55:40  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-30 18:55:46  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-30 18:55:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-30 18:55:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-30 18:56:04  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-30 18:56:10  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-30 18:56:16  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-30 18:56:22  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-30 18:56:27  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-30 18:56:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-30 18:56:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-30 18:56:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-30 18:56:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-30 18:56:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-30 18:57:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-30 18:57:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-30 18:57:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-30 18:57:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-30 18:57:20  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-30 18:57:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-30 18:57:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-30 18:57:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-30 18:57:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-30 18:57:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-30 18:57:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-30 18:57:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-30 18:57:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-30 18:57:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-30 18:58:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-30 18:58:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-30 18:58:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-30 18:58:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-30 18:58:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-30 18:58:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-30 18:58:27  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-30 18:58:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-30 18:58:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-30 18:58:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-30 18:58:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-30 18:58:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-30 18:58:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-30 18:59:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-30 18:59:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-30 18:59:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-30 18:59:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-30 18:59:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-30 18:59:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-30 18:59:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-30 18:59:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-30 18:59:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-30 18:59:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-30 18:59:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-30 18:59:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-30 18:59:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-30 18:59:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-30 19:00:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-30 19:00:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-30 19:00:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-30 19:00:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-30 19:00:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-30 19:00:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-30 19:00:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-30 19:00:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-30 19:00:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-30 19:00:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-30 19:00:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-30 19:00:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-30 19:01:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-30 19:01:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-30 19:01:13  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-30 19:01:20  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-30 19:01:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-30 19:01:32  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-30 19:01:33  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-30 19:01:39  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-30 19:01:45  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-30_19-01-45 Restart Xvfb...
2017-03-30 19:01:51  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-30 19:01:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-30 19:02:04  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-30 19:02:10  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-30 19:02:16  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-30 19:02:22  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-30 19:02:28  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-30 19:02:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-30 19:02:40  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-30 19:02:46  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-30 19:02:52  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-30 19:02:58  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-30 19:03:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-30 19:03:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-30 19:03:16  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-30 19:03:21  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-30 19:03:27  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-30 19:03:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-30 19:03:39  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-30 19:03:45  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-30 19:03:50  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-30 19:03:56  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-30 19:04:02  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-30 19:04:08  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-30 19:04:14  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-30 19:04:20  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-30 19:04:26  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-30 19:04:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-30 19:04:37  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-30 19:04:43  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-30 19:04:49  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-30 19:04:55  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-30 19:05:01  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-30 19:05:07  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-30 19:05:12  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-30 19:05:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-30 19:05:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-30 19:05:30  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-30 19:05:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-30 19:05:42  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-30 19:05:48  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-30 19:05:54  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-30 19:06:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-30 19:06:06  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-30 19:06:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-30 19:06:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-30 19:06:23  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-30 19:06:29  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-30 19:06:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-30 19:06:41  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-30 19:06:47  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-30 19:06:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-30 19:06:59  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-30 19:07:05  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-30 19:07:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-30 19:07:16  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-30 19:07:27  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-30 19:07:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-30 19:07:39  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-30 19:07:45  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-30 19:07:51  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-30 19:07:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-30 19:08:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-30 19:08:10  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-30 19:08:16  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-30 19:08:22  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-30 19:08:28  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-30 19:08:34  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-30 19:08:40  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-30 19:08:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-30 19:08:52  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-30 19:08:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-30 19:09:04  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-30 19:09:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-30 19:09:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-30 19:09:22  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-30 19:09:28  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-30 19:09:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-30 19:09:39  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-30 19:09:45  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-30 19:09:51  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-30 19:09:57  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-30 19:10:02  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-30 19:10:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-30 19:10:14  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-30 19:10:20  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-30 19:10:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-30 19:10:32  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-30 19:10:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-30 19:10:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-30 19:10:50  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-30 19:11:00  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-30 19:11:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-30 19:11:12  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-30 19:11:18  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-30 19:11:24  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-30 19:11:30  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-30 19:11:36  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-30 19:11:41  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-30 19:11:47  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-30 19:11:54  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-30 19:11:59  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-30 19:12:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-30 19:12:11  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-30 19:12:17  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-30 19:12:23  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-30 19:12:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-30 19:12:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-30 19:12:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-30 19:12:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-30 19:12:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-30 19:12:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-30 19:13:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-30 19:13:10  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-30 19:13:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-30 19:13:22  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-30 19:13:28  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-30 19:13:34  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-30 19:13:39  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-30 19:13:45  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-30 19:13:51  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-30 19:13:57  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-30 19:14:02  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-30 19:14:08  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-30 19:14:14  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-30 19:14:20  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-30 19:14:26  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-30 19:14:32  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-30 19:14:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-30 19:14:44  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-30 19:14:50  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-30 19:14:56  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-30 19:15:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-30 19:15:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-30 19:15:14  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-30 19:15:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-30 19:15:26  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-30 19:15:32  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-30 19:15:38  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-30 19:15:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-30 19:15:50  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-30 19:15:55  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-30 19:16:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-30 19:16:09  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-03-30 19:16:15  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-30 19:16:20  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-30 19:16:27  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-30 19:16:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-30 19:16:39  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-30 19:16:44  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-30 19:16:50  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-30 19:16:56  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-30 19:17:02  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-30 19:17:08  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-30 19:17:13  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-30 19:17:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-30 19:17:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-30 19:17:30  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-30 19:17:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-30 19:17:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-30 19:17:47  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-30 19:17:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-30 19:17:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-30 19:18:05  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-30 19:18:10  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-30 19:18:16  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-30 19:18:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-30 19:18:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-30 19:18:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-30 19:18:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-30 19:18:49  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-30 19:18:55  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-30 19:19:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-30 19:19:06  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-30 19:19:12  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-30 19:19:18  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-30 19:19:23  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-30 19:19:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-30 19:19:34  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-30 19:19:40  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-30 19:19:46  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-30 19:19:51  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-30 19:20:00  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-30 19:20:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-30 19:20:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-30 19:20:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-30 19:20:24  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-03-30 19:20:25  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-30 19:20:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-30 19:20:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-30 19:20:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-30 19:20:48  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-30 19:20:54  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-03-30 19:21:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-30 19:21:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-30 19:21:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-30 19:21:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-30 19:21:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-30 19:21:28  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-30 19:21:34  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-30 19:21:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-30 19:21:45  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-30 19:21:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-30 19:21:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-30 19:22:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-30 19:22:09  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-30 19:22:15  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-03-30 19:22:21  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-30 19:22:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-30 19:22:32  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-30 19:22:37  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-30 19:22:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-30 19:22:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-30 19:22:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-30 19:23:01  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-30 19:23:06  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-30 19:23:12  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-30 19:23:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-30 19:23:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-30 19:23:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-30 19:23:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-30 19:23:39  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-30 19:23:45  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-30 19:23:50  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-30 19:23:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-30 19:24:01  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-30 19:24:06  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-30 19:24:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-30 19:24:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-30 19:24:23  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-30 19:24:28  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-30 19:24:34  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-30 19:24:39  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-30 19:24:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-30 19:24:50  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-30 19:24:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-30 19:25:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-30 19:25:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-30 19:25:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-30 19:25:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-30 19:25:24  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-30 19:25:30  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-30 19:25:35  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-30 19:25:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-30 19:25:46  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-30 19:25:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-30 19:25:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-30 19:26:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-30 19:26:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 19:26:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 19:26:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 19:26:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 19:26:30  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-30 19:26:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 19:26:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 19:26:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-30 19:26:51  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-30 19:26:56  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-30 19:27:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-30 19:27:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-30 19:27:13  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-30 19:27:18  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-30 19:27:24  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-30 19:27:29  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-30 19:27:35  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-30 19:27:40  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-30 19:27:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-30 19:27:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-30 19:27:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-30 19:28:02  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-30 19:28:07  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-30 19:28:13  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-30 19:28:18  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-30 19:28:24  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-30 19:28:29  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-30 19:28:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 19:28:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 19:28:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 19:28:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 19:28:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 19:29:01  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-30 19:29:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 19:29:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 19:29:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 19:29:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 19:29:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-30 19:29:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 19:29:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 19:29:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 19:29:49  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-30 19:29:54  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-03-30_19-31-45 Restart Xvfb...
2017-03-30_20-01-45 Restart Xvfb...
2017-03-30_20-31-45 Restart Xvfb...
2017-03-30_21-01-45 Restart Xvfb...
2017-03-30_21-31-45 Restart Xvfb...
2017-03-30 21:31:45 reset updateRequest
2017-03-30 21:31:50  - 14968  http://www.lymphomahub.com/
2017-03-30 21:31:51  - 14968  http://www.lymphomahub.com/
2017-03-30 21:31:56  - 14968  http://www.lymphomahub.com/about
2017-03-30 21:32:02  - 14968  http://www.lymphomahub.com/terms
2017-03-30 21:32:06  - 14968  http://www.lymphomahub.com/undefined
2017-03-30 21:32:07  - 14968  http://www.lymphomahub.com/therapies
2017-03-30 21:32:14  - 14968  http://www.lymphomahub.com/newsletter
2017-03-30 21:32:18  - 14968  http://www.lymphomahub.com/cookie-policy
2017-03-30 21:32:21  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-03-30 21:32:27  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-03-30 21:32:33  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-03-30 21:32:39  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-03-30 21:32:44  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-03-30 21:32:50  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-03-30 21:32:56  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-03-30 21:33:02  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-03-30 21:33:08  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-03-30 21:33:13  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-03-30 21:33:19  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-03-30 21:33:25  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-03-30 21:33:30  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-03-30 21:33:36  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-03-30 21:33:42  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-03-30 21:33:47  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-03-30 21:33:53  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-03-30 21:33:59  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-03-30 21:34:05  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-03-30 21:34:10  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-03-30 21:34:16  - 14968  http://www.lymphomahub.com/about/secretariat
2017-03-30 21:34:21  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-03-30 21:34:27  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-03-30 21:34:32  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-03-30 21:34:38  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-03-30 21:34:44  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-03-30 21:34:50  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-03-30 21:34:56  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-03-30 21:35:01  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-03-30 21:35:10  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-03-30 21:35:16  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-30 21:35:21  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-30 21:35:32  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-03-30 21:35:38  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-03-30 21:35:44  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-03-30 21:35:49  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-30 21:35:55  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-03-30 21:36:01  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-03-30 21:36:06  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-03-30 21:36:12  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-03-30 21:36:18  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-03-30 21:36:24  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-03-30 21:36:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-30 21:36:35  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-30 21:36:41  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-03-30 21:36:46  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-03-30 21:36:52  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-03-30 21:36:58  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-03-30 21:37:04  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-03-30 21:37:09  - 14968  http://www.lymphomahub.com/medical-information
2017-03-30 21:37:15  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-03-30 21:37:21  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-03-30 21:37:26  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-30 21:37:32  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-03-30 21:37:38  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-03-30 21:37:43  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-03-30 21:37:49  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-03-30 21:37:55  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-03-30 21:38:01  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-03-30 21:38:07  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-03-30 21:38:12  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-03-30 21:38:18  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-03-30 21:38:19  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-03-30 21:38:25  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-03-30 21:38:30  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-30 21:38:36  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-30 21:38:42  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-03-30 21:38:48  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-30 21:38:54  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-03-30 21:38:59  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-03-30 21:39:05  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-03-30 21:39:11  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-03-30 21:39:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-03-30 21:39:23  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-30 21:39:28  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-30 21:39:34  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-30 21:39:40  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-30 21:39:45  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-30 21:39:51  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-30 21:39:57  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-03-30 21:40:03  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-03-30 21:40:09  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-03-30 21:40:15  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-30 21:40:20  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-30 21:40:26  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-03-30 21:40:32  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-03-30 21:40:37  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-03-30 21:40:43  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-30 21:40:49  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-30 21:40:54  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-03-30 21:41:00  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-30 21:41:06  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-30 21:41:11  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-30 21:41:12  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-30 21:41:18  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-30 21:41:25  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-30 21:41:31  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-30 21:41:36  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-30 21:41:42  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-03-30 21:41:48  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-30 21:41:53  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-30 21:41:59  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-03-30 21:42:04  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-30 21:42:05  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-30 21:42:10  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-30 21:42:16  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-30 21:42:21  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-30 21:42:27  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-30 21:42:33  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-30 21:42:34  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-30 21:42:40  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-30 21:42:46  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-30 21:42:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-30 21:42:56  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-30 21:43:01  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-30 21:43:08  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-30 21:43:13  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-30 21:43:18  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-30 21:43:23  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-30 21:43:30  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-30 21:43:35  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-30 21:43:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-30 21:43:47  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-30 21:43:52  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-30 21:43:52  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-30 21:43:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-30 21:44:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-30 21:44:10  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-30 21:44:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-30 21:44:21  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-30 21:44:27  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-30 21:44:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-30 21:44:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-30 21:44:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-30 21:44:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-30 21:44:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-30 21:44:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-30 21:45:04  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-30 21:45:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-30 21:45:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-30 21:45:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-30 21:45:26  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-30 21:45:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-30 21:45:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-30 21:45:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-30 21:45:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-30 21:45:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-30 21:45:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-30 21:46:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-30 21:46:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-30 21:46:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-30 21:46:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-30 21:46:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-30 21:46:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-30 21:46:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-30 21:46:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-30 21:46:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-30 21:46:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-30 21:46:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-30 21:47:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-30 21:47:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-30 21:47:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-30 21:47:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-30 21:47:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-30 21:47:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-30 21:47:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-30 21:47:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-30 21:47:48  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-30 21:47:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-03-30 21:47:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-30 21:48:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-30 21:48:08  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-30 21:48:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-30 21:48:19  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-30 21:48:24  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-30 21:48:29  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-30 21:48:35  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-30 21:48:41  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-30 21:48:47  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-30 21:48:52  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-30 21:48:58  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-30 21:49:04  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-30 21:49:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-30 21:49:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-30 21:49:21  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-30 21:49:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-30 21:49:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-03-30 21:49:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-30 21:49:43  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-30 21:49:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-30 21:49:55  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-30 21:50:01  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-03-30 21:50:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-30 21:50:12  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-30 21:50:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-30 21:50:24  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-30 21:50:25  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-30 21:50:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-03-30 21:50:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-30 21:50:42  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-30 21:50:48  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-30 21:50:54  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-30 21:51:00  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-30 21:51:06  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-30 21:51:12  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-30 21:51:18  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-30 21:51:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-30 21:51:29  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-30 21:51:35  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-30 21:51:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-30 21:51:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-30 21:51:53  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-30 21:51:59  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-30 21:52:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-30 21:52:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-30 21:52:16  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-30 21:52:22  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-30 21:52:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-30 21:52:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-30 21:52:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-30 21:52:45  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-30 21:52:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-30 21:52:57  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-30 21:53:03  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-30 21:53:09  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-30 21:53:15  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-30 21:53:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-30 21:53:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-30 21:53:33  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-03-30 21:53:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-30 21:53:45  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-30 21:53:50  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-30 21:53:56  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-30 21:54:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-30 21:54:08  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-30 21:54:14  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-30 21:54:20  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-30 21:54:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-30 21:54:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-30 21:54:33  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-30 21:54:39  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-30 21:54:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-30 21:54:51  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-30 21:54:57  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-30 21:55:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-30 21:55:08  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-30 21:55:14  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-30 21:55:20  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-30 21:55:26  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-30 21:55:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-30 21:55:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-30 21:55:44  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-30 21:55:50  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-30 21:55:56  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-30 21:56:02  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-30 21:56:08  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-30 21:56:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-30 21:56:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-30 21:56:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-30 21:56:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-30 21:56:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-30 21:56:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-30 21:56:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-30 21:56:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-30 21:56:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-30 21:57:00  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-30 21:57:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-30 21:57:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-30 21:57:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-30 21:57:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-30 21:57:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-30 21:57:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-30 21:57:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-30 21:57:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-30 21:57:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-30 21:57:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-30 21:57:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-30 21:57:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-30 21:57:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-30 21:57:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-30 21:58:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-30 21:58:07  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-30 21:58:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-30 21:58:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-30 21:58:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-30 21:58:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-30 21:58:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-30 21:58:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-30 21:58:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-30 21:58:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-30 21:58:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-30 21:58:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-30 21:58:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-30 21:59:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-30 21:59:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-30 21:59:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-30 21:59:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-30 21:59:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-30 21:59:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-30 21:59:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-30 21:59:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-30 21:59:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-30 21:59:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-30 21:59:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-30 21:59:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-30 21:59:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-30 21:59:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-30 22:00:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-30 22:00:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-30 22:00:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-30 22:00:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-30 22:00:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-30 22:00:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-30 22:00:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-30 22:00:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-30 22:00:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-30 22:00:41  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-30 22:00:47  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-30 22:00:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-30 22:00:59  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-30 22:01:00  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-30 22:01:06  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-30 22:01:11  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-30 22:01:17  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-30 22:01:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-30 22:01:29  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-30 22:01:35  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-30 22:01:41  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-30_22-01-45 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis?_prerender {"code":"ECONNRESET"}
2017-03-30 22:03:46  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-30 22:03:51  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-30 22:03:57  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-30 22:04:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-30 22:04:10  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-30 22:04:16  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-30 22:04:22  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-30 22:04:28  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-30 22:04:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-30 22:04:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-30 22:04:46  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-30 22:04:52  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-30 22:04:57  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-30 22:05:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-30 22:05:10  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-30 22:05:21  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-30 22:05:26  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-30 22:05:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-30 22:05:38  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-30 22:05:44  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-30 22:05:50  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-30 22:05:56  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-30 22:06:01  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-30 22:06:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-30 22:06:13  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-30 22:06:19  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-30 22:06:25  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-30 22:06:31  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-30 22:06:37  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-30 22:06:42  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-30 22:06:48  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-30 22:06:54  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-30 22:07:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-30 22:07:06  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-30 22:07:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-30 22:07:18  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-30 22:07:24  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-30 22:07:29  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-30 22:07:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-30 22:07:41  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-30 22:07:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-30 22:07:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-30 22:07:58  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-30 22:08:04  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-30 22:08:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-30 22:08:16  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-30 22:08:22  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-30 22:08:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-30 22:08:34  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-30 22:08:40  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-30 22:08:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-30 22:08:51  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-30 22:08:57  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-30 22:09:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-30 22:09:09  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-30 22:09:15  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-30 22:09:23  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-30 22:09:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-30 22:09:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-30 22:09:42  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-30 22:09:47  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-30 22:09:53  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-30 22:09:59  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-30 22:10:05  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-30 22:10:11  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-30 22:10:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-30 22:10:23  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-30 22:10:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-30 22:10:35  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-30 22:10:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-30 22:10:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-30 22:10:53  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-30 22:11:04  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-30 22:11:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-30 22:11:15  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-30 22:11:21  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-30 22:11:27  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-30 22:11:33  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-30 22:11:38  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-30 22:11:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-30 22:11:50  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-30 22:11:56  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-30 22:12:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-30 22:12:07  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-30 22:12:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-30 22:12:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-30 22:12:25  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-30 22:12:31  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-30 22:12:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-30 22:12:42  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-30 22:12:48  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-30 22:12:54  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-30 22:13:00  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-30 22:13:06  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-30 22:13:11  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-30 22:13:18  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-30 22:13:23  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-30 22:13:29  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-30 22:13:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-30 22:13:41  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-30 22:13:46  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-30 22:13:52  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-30 22:13:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-30 22:14:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-30 22:14:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-30 22:14:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-30 22:14:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-30 22:14:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-30 22:14:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-30 22:14:40  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-30 22:14:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-30 22:14:52  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-30 22:14:58  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-30 22:15:04  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-30 22:15:09  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-30 22:15:15  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-30 22:15:21  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-30 22:15:26  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-30 22:15:33  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-30 22:15:39  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-30 22:15:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-30 22:15:51  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-30 22:15:57  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-30 22:16:03  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-30 22:16:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-30 22:16:15  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-30 22:16:21  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-30 22:16:27  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-30 22:16:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-30 22:16:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-30 22:16:44  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-30 22:16:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-30 22:16:56  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-30 22:17:02  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-30 22:17:08  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-30 22:17:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-30 22:17:20  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-30 22:17:25  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-30 22:17:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-30 22:17:40  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-03-30 22:17:45  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-30 22:17:50  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-30 22:17:56  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-30 22:18:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-30 22:18:08  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-30 22:18:13  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-30 22:18:19  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-30 22:18:25  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-30 22:18:31  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-30 22:18:37  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-30 22:18:42  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-30 22:18:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-30 22:18:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-30 22:18:58  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-30 22:19:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-30 22:19:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-30 22:19:15  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-30 22:19:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-30 22:19:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-30 22:19:32  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-30 22:19:38  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-30 22:19:43  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-30 22:19:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-30 22:19:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-30 22:20:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-30 22:20:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-30 22:20:12  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-30 22:20:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-30 22:20:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-30 22:20:30  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-30 22:20:35  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-30 22:20:41  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-30 22:20:47  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-30 22:20:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-30 22:20:58  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-30 22:21:03  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-30 22:21:09  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-30 22:21:15  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-30 22:21:21  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-30 22:21:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-30 22:21:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-30 22:21:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-30 22:21:45  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-03-30 22:21:46  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-30 22:21:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-30 22:22:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-30 22:22:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-30 22:22:21  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-30 22:22:26  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-03-30 22:22:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-30 22:22:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-30 22:22:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-30 22:22:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-30 22:22:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-30 22:23:00  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-30 22:23:05  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-30 22:23:11  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-30 22:23:16  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-30 22:23:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-30 22:23:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-30 22:23:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-30 22:23:39  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-30 22:23:47  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-03-30 22:23:53  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-30 22:23:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-30 22:24:04  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-30 22:24:09  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-30 22:24:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-30 22:24:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-30 22:24:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-30 22:24:32  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-30 22:24:38  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-30 22:24:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-30 22:24:48  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-30 22:24:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-30 22:24:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-30 22:25:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-30 22:25:10  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-30 22:25:15  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-30 22:25:21  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-30 22:25:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-30 22:25:31  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-30 22:25:36  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-30 22:25:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-30 22:25:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-30 22:25:53  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-30 22:25:59  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-30 22:26:04  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-30 22:26:09  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-30 22:26:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-30 22:26:20  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-30 22:26:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-30 22:26:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-30 22:26:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-30 22:26:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-30 22:26:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-30 22:26:55  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-30 22:27:00  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-30 22:27:06  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-30 22:27:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-30 22:27:17  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-30 22:27:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-30 22:27:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-30 22:27:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-30 22:27:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 22:27:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 22:27:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 22:27:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 22:28:00  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-30 22:28:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 22:28:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-30 22:28:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-30 22:28:21  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-30 22:28:26  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-30 22:28:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-30 22:28:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-30 22:28:48  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-30 22:28:53  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-30 22:28:58  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-30 22:29:03  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-30 22:29:09  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-30 22:29:14  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-30 22:29:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-30 22:29:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-30 22:29:31  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-30 22:29:36  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-30 22:29:41  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-30 22:29:46  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-30 22:29:52  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-30 22:29:57  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-30 22:30:03  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-30 22:30:08  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 22:30:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 22:30:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 22:30:24  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 22:30:29  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-30 22:30:34  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-30 22:30:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 22:30:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 22:30:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 22:30:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 22:31:01  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-30 22:31:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 22:31:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 22:31:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-30 22:31:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-30 22:31:32  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-03-30_22-31-45 Restart Xvfb...
2017-03-30_23-01-45 Restart Xvfb...
2017-03-30_23-31-45 Restart Xvfb...
2017-03-31_00-01-45 Restart Xvfb...
2017-03-31_00-31-45 Restart Xvfb...
2017-03-31 00:31:45 reset updateRequest
2017-03-31 00:31:48  - 14968  http://www.lymphomahub.com/
2017-03-31 00:31:51  - 14968  http://www.lymphomahub.com/
2017-03-31 00:31:53  - 14968  http://www.lymphomahub.com/about
2017-03-31 00:31:55  - 14968  http://www.lymphomahub.com/about
2017-03-31 00:32:00  - 14968  http://www.lymphomahub.com/terms
2017-03-31 00:32:00  - 14968  http://www.lymphomahub.com/terms
2017-03-31 00:32:04  - 14968  http://www.lymphomahub.com/undefined
2017-03-31 00:32:05  - 14968  http://www.lymphomahub.com/therapies
2017-03-31 00:32:05  - 14968  http://www.lymphomahub.com/therapies
2017-03-31 00:32:15  - 14968  http://www.lymphomahub.com/newsletter
2017-03-31 00:32:19  - 14968  http://www.lymphomahub.com/cookie-policy
2017-03-31 00:32:23  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-03-31 00:32:29  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-03-31 00:32:34  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-03-31 00:32:40  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-03-31 00:32:46  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-03-31 00:32:52  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-03-31 00:32:57  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-03-31 00:33:03  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-03-31 00:33:09  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-03-31 00:33:15  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-03-31 00:33:21  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-03-31 00:33:26  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-03-31 00:33:32  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-03-31 00:33:38  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-03-31 00:33:44  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-03-31 00:33:50  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-03-31 00:33:55  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-03-31 00:34:01  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-03-31 00:34:07  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-03-31 00:34:12  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-03-31 00:34:18  - 14968  http://www.lymphomahub.com/about/secretariat
2017-03-31 00:34:23  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-03-31 00:34:29  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-03-31 00:34:34  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-03-31 00:34:40  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-03-31 00:34:46  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-03-31 00:34:51  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-03-31 00:34:57  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-03-31 00:35:03  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-03-31 00:35:09  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-03-31 00:35:14  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-31 00:35:20  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-31 00:35:26  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-03-31 00:35:32  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-03-31 00:35:37  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-03-31 00:35:43  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-31 00:35:52  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-03-31 00:35:58  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-03-31 00:36:03  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-03-31 00:36:09  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-03-31 00:36:15  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-03-31 00:36:20  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-03-31 00:36:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-31 00:36:32  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-31 00:36:37  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-03-31 00:36:43  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-03-31 00:36:49  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-03-31 00:36:55  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-03-31 00:37:01  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-03-31 00:37:06  - 14968  http://www.lymphomahub.com/medical-information
2017-03-31 00:37:17  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-03-31 00:37:23  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-03-31 00:37:29  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-31 00:37:34  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-03-31 00:37:40  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-03-31 00:37:45  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-03-31 00:37:51  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-03-31 00:37:57  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-03-31 00:38:02  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-03-31 00:38:08  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-03-31 00:38:14  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-03-31 00:38:20  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-03-31 00:38:21  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-03-31 00:38:27  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-03-31 00:38:32  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-31 00:38:38  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-31 00:38:44  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-03-31 00:38:49  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-31 00:38:55  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-03-31 00:39:01  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-03-31 00:39:07  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-03-31 00:39:12  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-03-31 00:39:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-03-31 00:39:24  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-31 00:39:30  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-31 00:39:35  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-31 00:39:41  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-31 00:39:47  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-31 00:39:52  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-31 00:39:58  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-03-31 00:40:04  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-03-31 00:40:10  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-03-31 00:40:15  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-31 00:40:21  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-31 00:40:27  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-03-31 00:40:32  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-03-31 00:40:38  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-03-31 00:40:44  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-31 00:40:50  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-31 00:40:55  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-03-31 00:41:01  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-31 00:41:07  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-31 00:41:12  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-31 00:41:13  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-31 00:41:19  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-31 00:41:25  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-31 00:41:30  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-31 00:41:36  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-31 00:41:42  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-03-31 00:41:48  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-31 00:41:53  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-31 00:42:05  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-03-31 00:42:09  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-31 00:42:10  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-31 00:42:16  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-31 00:42:21  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-31 00:42:27  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-31 00:42:32  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-31 00:42:38  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-31 00:42:39  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-31 00:42:45  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-31 00:42:50  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-31 00:42:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-31 00:43:01  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-31 00:43:07  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-31 00:43:12  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-31 00:43:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-31 00:43:22  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-31 00:43:27  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-31 00:43:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-31 00:43:39  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-31 00:43:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-31 00:43:50  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-31 00:43:55  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-31 00:43:56  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-31 00:44:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-31 00:44:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-31 00:44:13  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-31 00:44:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-31 00:44:25  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-31 00:44:31  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-31 00:44:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-31 00:44:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-31 00:44:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-31 00:44:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-31 00:44:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-31 00:45:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-31 00:45:08  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-31 00:45:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-31 00:45:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-31 00:45:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-31 00:45:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-31 00:45:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-31 00:45:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-31 00:45:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-31 00:45:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-31 00:45:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-31 00:46:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-31 00:46:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-31 00:46:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-31 00:46:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-31 00:46:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-31 00:46:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-31 00:46:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-31 00:46:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-31 00:46:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-31 00:46:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-31 00:46:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-31 00:47:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-31 00:47:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-31 00:47:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-31 00:47:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-31 00:47:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-31 00:47:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-31 00:47:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-31 00:47:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-31 00:47:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-31 00:47:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-31 00:47:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-03-31 00:48:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-31 00:48:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-31 00:48:11  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-31 00:48:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-31 00:48:21  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-31 00:48:27  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-31 00:48:32  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-31 00:48:38  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-31 00:48:44  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-31 00:48:49  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-31 00:48:55  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-31 00:49:00  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-31 00:49:06  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-31 00:49:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-31 00:49:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-31 00:49:23  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-31 00:49:28  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-31 00:49:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-03-31 00:49:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-31 00:49:45  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-31 00:49:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-31 00:49:56  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-31 00:50:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-03-31 00:50:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-31 00:50:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-31 00:50:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-31 00:50:26  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-31 00:50:26  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-31 00:50:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-03-31 00:50:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-31 00:50:44  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-31 00:50:50  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-31 00:50:56  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-31 00:51:02  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 00:51:07  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 00:51:13  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-31 00:51:19  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 00:51:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-31 00:51:31  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-31 00:51:37  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-31 00:51:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-31 00:51:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-31 00:51:54  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-31 00:52:00  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-31 00:52:06  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-31 00:52:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-31 00:52:18  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-31 00:52:24  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 00:52:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-31 00:52:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-31 00:52:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-31 00:52:47  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-31 00:52:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-31 00:52:59  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-31 00:53:05  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-31 00:53:11  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-31 00:53:17  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-31 00:53:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-31 00:53:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-31 00:53:34  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-03-31 00:53:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-31 00:53:46  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-31 00:53:51  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-31 00:53:57  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-31 00:54:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-31 00:54:09  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-31 00:54:15  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-31 00:54:21  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-31 00:54:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-31 00:54:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-31 00:54:33  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-31 00:54:39  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-31 00:54:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-31 00:54:51  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-31 00:54:57  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-31 00:55:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-31 00:55:09  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-31 00:55:15  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-31 00:55:20  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-31 00:55:26  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-31 00:55:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-31 00:55:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-31 00:55:44  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-31 00:55:50  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-31 00:55:55  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-31 00:56:01  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-31 00:56:07  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-31 00:56:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-31 00:56:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-31 00:56:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-31 00:56:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-31 00:56:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-31 00:56:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-31 00:56:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-31 00:56:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-31 00:56:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-31 00:56:59  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-31 00:56:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-31 00:57:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-31 00:57:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-31 00:57:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-31 00:57:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-31 00:57:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-31 00:57:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-31 00:57:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-31 00:57:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-31 00:57:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-31 00:57:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-31 00:57:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-31 00:57:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-31 00:57:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-31 00:58:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-31 00:58:06  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-31 00:58:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-31 00:58:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-31 00:58:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-31 00:58:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-31 00:58:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-31 00:58:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-31 00:58:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-31 00:58:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-31 00:58:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-31 00:58:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-31 00:58:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-31 00:59:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-31 00:59:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-31 00:59:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-31 00:59:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-31 00:59:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-31 00:59:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-31 00:59:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-31 00:59:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-31 00:59:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-31 00:59:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-31 00:59:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-31 00:59:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-31 00:59:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-31 00:59:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-31 01:00:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-31 01:00:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-31 01:00:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-31 01:00:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-31 01:00:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-31 01:00:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-31 01:00:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-31 01:00:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-31 01:00:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-31 01:00:43  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-31 01:00:49  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-31 01:00:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-31 01:01:04  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-31 01:01:05  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-31 01:01:11  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-31 01:01:17  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-31 01:01:23  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-31 01:01:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-31 01:01:35  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-31 01:01:41  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-31_01-01-45 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll?_prerender {"code":"ECONNRESET"}
2017-03-31 01:03:46  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-31 01:03:52  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-31 01:03:57  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-31 01:04:03  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-31 01:04:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-31 01:04:15  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-31 01:04:21  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-31 01:04:27  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-31 01:04:33  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-31 01:04:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-31 01:04:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-31 01:04:52  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-31 01:04:58  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-31 01:05:04  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-31 01:05:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-31 01:05:15  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-31 01:05:21  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-31 01:05:27  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-31 01:05:33  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-31 01:05:39  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-31 01:05:45  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-31 01:05:50  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-31 01:05:56  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-31 01:06:07  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-31 01:06:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-31 01:06:19  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-31 01:06:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-31 01:06:31  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-31 01:06:37  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-31 01:06:42  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-31 01:06:48  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-31 01:06:54  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-31 01:07:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-31 01:07:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-31 01:07:12  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-31 01:07:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-31 01:07:24  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-31 01:07:30  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-31 01:07:35  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-31 01:07:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-31 01:07:47  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-31 01:07:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-31 01:07:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-31 01:08:04  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-31 01:08:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-31 01:08:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-31 01:08:22  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-31 01:08:28  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-31 01:08:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-31 01:08:40  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-31 01:08:46  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-31 01:08:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-31 01:08:57  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-31 01:09:03  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-31 01:09:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-31 01:09:15  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-31 01:09:21  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-31 01:09:27  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-31 01:09:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-31 01:09:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-31 01:09:45  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-31 01:09:51  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-31 01:09:57  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-31 01:10:03  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-31 01:10:09  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-31 01:10:15  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-31 01:10:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-31 01:10:26  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-31 01:10:32  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-31 01:10:38  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-31 01:10:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-31 01:10:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-31 01:10:56  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-31 01:11:02  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-31 01:11:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-31 01:11:13  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-31 01:11:19  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-31 01:11:25  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-31 01:11:32  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-31 01:11:42  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-31 01:11:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-31 01:11:54  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-31 01:12:00  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-31 01:12:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-31 01:12:12  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-31 01:12:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-31 01:12:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-31 01:12:29  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-31 01:12:35  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-31 01:12:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-31 01:12:46  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-31 01:12:52  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-31 01:12:58  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-31 01:13:04  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-31 01:13:10  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-31 01:13:16  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-31 01:13:22  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-31 01:13:27  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-31 01:13:33  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-31 01:13:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-31 01:13:45  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-31 01:13:51  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-31 01:13:57  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-31 01:14:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-31 01:14:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-31 01:14:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-31 01:14:20  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-31 01:14:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-31 01:14:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-31 01:14:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-31 01:14:44  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-31 01:14:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-31 01:14:55  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-31 01:15:01  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-31 01:15:07  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-31 01:15:12  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-31 01:15:18  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-31 01:15:24  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-31 01:15:30  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-31 01:15:36  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-31 01:15:41  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-31 01:15:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-31 01:15:53  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-31 01:15:59  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-31 01:16:05  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-31 01:16:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-31 01:16:17  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-31 01:16:23  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-31 01:16:29  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-31 01:16:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-31 01:16:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-31 01:16:47  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-31 01:16:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-31 01:16:59  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-31 01:17:05  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-31 01:17:10  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-31 01:17:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-31 01:17:22  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-31 01:17:27  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-31 01:17:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-31 01:17:39  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-03-31 01:17:45  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-31 01:17:50  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-31 01:17:56  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-31 01:18:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-31 01:18:08  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-31 01:18:13  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-31 01:18:19  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-31 01:18:25  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-31 01:18:31  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-31 01:18:37  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-31 01:18:42  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-31 01:18:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-31 01:18:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-31 01:18:59  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-31 01:19:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-31 01:19:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-31 01:19:15  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-31 01:19:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-31 01:19:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-31 01:19:32  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-31 01:19:38  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-31 01:19:43  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-31 01:19:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-31 01:19:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-31 01:20:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-31 01:20:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-31 01:20:12  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-31 01:20:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-31 01:20:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-31 01:20:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-31 01:20:34  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-31 01:20:43  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-31 01:20:49  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-31 01:20:54  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-31 01:21:00  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-31 01:21:05  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-31 01:21:11  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-31 01:21:17  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-31 01:21:23  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-31 01:21:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-31 01:21:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-31 01:21:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-31 01:21:47  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-03-31 01:21:47  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-31 01:21:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-31 01:21:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-31 01:22:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-31 01:22:10  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-31 01:22:16  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-03-31 01:22:22  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-31 01:22:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-31 01:22:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-31 01:22:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-31 01:22:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-31 01:22:51  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-31 01:22:56  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-31 01:23:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-31 01:23:08  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-31 01:23:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-31 01:23:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-31 01:23:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-31 01:23:29  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-31 01:23:35  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-03-31 01:23:41  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-31 01:23:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-31 01:23:52  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-31 01:23:57  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-31 01:24:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-31 01:24:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-31 01:24:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-31 01:24:21  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-31 01:24:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-31 01:24:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-31 01:24:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-31 01:24:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-31 01:24:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-31 01:24:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-31 01:24:59  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-31 01:25:05  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-31 01:25:10  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-31 01:25:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-31 01:25:21  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-31 01:25:26  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-31 01:25:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-31 01:25:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-31 01:25:43  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-31 01:25:48  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-31 01:25:54  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-31 01:25:59  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-31 01:26:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-31 01:26:10  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-31 01:26:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-31 01:26:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-31 01:26:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-31 01:26:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-31 01:26:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-31 01:26:50  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-31 01:26:55  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-31 01:27:00  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-31 01:27:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-31 01:27:11  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-31 01:27:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-31 01:27:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-31 01:27:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-31 01:27:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 01:27:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 01:27:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 01:27:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 01:27:55  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-31 01:28:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 01:28:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 01:28:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-31 01:28:16  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-31 01:28:22  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-31 01:28:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-31 01:28:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-31 01:28:38  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-31 01:28:43  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-31 01:28:49  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-31 01:28:54  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-31 01:28:59  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-31 01:29:05  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-31 01:29:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-31 01:29:16  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-31 01:29:22  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-31 01:29:27  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-31 01:29:32  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-31 01:29:38  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-31 01:29:43  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-31 01:29:48  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-31 01:29:53  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-31 01:29:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 01:30:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 01:30:10  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 01:30:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 01:30:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 01:30:26  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-31 01:30:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 01:30:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 01:30:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 01:30:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 01:30:52  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-31 01:30:57  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 01:31:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 01:31:08  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 01:31:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-31 01:31:18  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-03-31_01-31-45 Restart Xvfb...
2017-03-31_02-01-45 Restart Xvfb...
2017-03-31_02-31-45 Restart Xvfb...
2017-03-31_03-01-46 Restart Xvfb...
2017-03-31 03:31:45 reset updateRequest
2017-03-31_03-31-46 Restart Xvfb...
2017-03-31 03:31:49  - 14968  http://www.lymphomahub.com/
2017-03-31 03:31:51  - 14968  http://www.lymphomahub.com/
2017-03-31 03:31:55  - 14968  http://www.lymphomahub.com/about
2017-03-31 03:31:56  - 14968  http://www.lymphomahub.com/about
2017-03-31 03:32:03  - 14968  http://www.lymphomahub.com/terms
2017-03-31 03:32:06  - 14968  http://www.lymphomahub.com/undefined
2017-03-31 03:32:07  - 14968  http://www.lymphomahub.com/therapies
2017-03-31 03:32:14  - 14968  http://www.lymphomahub.com/newsletter
2017-03-31 03:32:17  - 14968  http://www.lymphomahub.com/cookie-policy
2017-03-31 03:32:21  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-03-31 03:32:27  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-03-31 03:32:33  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-03-31 03:32:39  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-03-31 03:32:44  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-03-31 03:32:50  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-03-31 03:32:56  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-03-31 03:33:02  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-03-31 03:33:07  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-03-31 03:33:13  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-03-31 03:33:19  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-03-31 03:33:25  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-03-31 03:33:31  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-03-31 03:33:37  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-03-31 03:33:42  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-03-31 03:33:48  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-03-31 03:33:54  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-03-31 03:34:00  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-03-31 03:34:06  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-03-31 03:34:12  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-03-31 03:34:17  - 14968  http://www.lymphomahub.com/about/secretariat
2017-03-31 03:34:22  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-03-31 03:34:28  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-03-31 03:34:33  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-03-31 03:34:39  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-03-31 03:34:45  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-03-31 03:34:50  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-03-31 03:34:56  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-03-31 03:35:05  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-03-31 03:35:13  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-03-31 03:35:19  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-31 03:35:24  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-31 03:35:30  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-03-31 03:35:36  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-03-31 03:35:41  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-03-31 03:35:47  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-31 03:35:53  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-03-31 03:35:58  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-03-31 03:36:04  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-03-31 03:36:13  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-03-31 03:36:18  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-03-31 03:36:24  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-03-31 03:36:30  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-31 03:36:36  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-31 03:36:42  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-03-31 03:36:47  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-03-31 03:36:53  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-03-31 03:36:59  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-03-31 03:37:06  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-03-31 03:37:11  - 14968  http://www.lymphomahub.com/medical-information
2017-03-31 03:37:15  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-03-31 03:37:21  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-03-31 03:37:27  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-31 03:37:33  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-03-31 03:37:39  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-03-31 03:37:44  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-03-31 03:37:50  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-03-31 03:37:56  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-03-31 03:38:01  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-03-31 03:38:07  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-03-31 03:38:13  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-03-31 03:38:18  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-03-31 03:38:19  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-03-31 03:38:25  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-03-31 03:38:31  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-31 03:38:37  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-31 03:38:42  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-03-31 03:38:48  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-31 03:38:53  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-03-31 03:38:59  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-03-31 03:39:05  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-03-31 03:39:11  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-03-31 03:39:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-03-31 03:39:22  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-31 03:39:28  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-31 03:39:33  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-31 03:39:39  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-31 03:39:44  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-31 03:39:50  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-31 03:39:56  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-03-31 03:40:01  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-03-31 03:40:07  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-03-31 03:40:13  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-31 03:40:19  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-31 03:40:25  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-03-31 03:40:31  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-03-31 03:40:37  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-03-31 03:40:42  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-31 03:40:48  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-31 03:40:54  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-03-31 03:40:59  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-31 03:41:05  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-31 03:41:11  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-31 03:41:12  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-31 03:41:18  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-31 03:41:24  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-31 03:41:29  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-31 03:41:35  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-31 03:41:41  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-03-31 03:41:52  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-31 03:41:57  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-31 03:42:03  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-03-31 03:42:08  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-31 03:42:09  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-31 03:42:14  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-31 03:42:20  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-31 03:42:26  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-31 03:42:31  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-31 03:42:37  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-31 03:42:38  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-31 03:42:44  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-31 03:42:50  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-31 03:42:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-31 03:43:00  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-31 03:43:05  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-31 03:43:11  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-31 03:43:21  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-31 03:43:26  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-31 03:43:31  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-31 03:43:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-31 03:43:43  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-31 03:43:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-31 03:43:54  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-31 03:43:59  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-31 03:44:00  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-31 03:44:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-31 03:44:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-31 03:44:17  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-31 03:44:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-31 03:44:29  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-31 03:44:35  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-31 03:44:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-31 03:44:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-31 03:44:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-31 03:44:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-31 03:45:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-31 03:45:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-31 03:45:12  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-31 03:45:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-31 03:45:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-31 03:45:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-31 03:45:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-31 03:45:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-31 03:45:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-31 03:45:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-31 03:45:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-31 03:46:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-31 03:46:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-31 03:46:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-31 03:46:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-31 03:46:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-31 03:46:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-31 03:46:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-31 03:46:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-31 03:46:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-31 03:46:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-31 03:47:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-31 03:47:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-31 03:47:10  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-31 03:47:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-31 03:47:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-31 03:47:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-31 03:47:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-31 03:47:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-31 03:47:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-31 03:47:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-31 03:47:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-31 03:48:00  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-31 03:48:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-03-31 03:48:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-31 03:48:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-31 03:48:21  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-31 03:48:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-31 03:48:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-31 03:48:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-31 03:48:42  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-31 03:48:48  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-31 03:48:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-31 03:48:59  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-31 03:49:05  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-31 03:49:11  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-31 03:49:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-31 03:49:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-31 03:49:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-31 03:49:39  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-31 03:49:44  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-31 03:49:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-03-31 03:49:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-31 03:50:01  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-31 03:50:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-31 03:50:12  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-31 03:50:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-03-31 03:50:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-31 03:50:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-31 03:50:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-31 03:50:46  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-31 03:50:47  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-31 03:50:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-03-31 03:50:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-31 03:51:04  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-31 03:51:10  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-31 03:51:16  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-31 03:51:22  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 03:51:28  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 03:51:33  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-31 03:51:39  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 03:51:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-31 03:51:51  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-31 03:51:57  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-31 03:52:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-31 03:52:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-31 03:52:19  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-31 03:52:25  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-31 03:52:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-31 03:52:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-31 03:52:43  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-31 03:52:49  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 03:52:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-31 03:53:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-31 03:53:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-31 03:53:13  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-31 03:53:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-31 03:53:25  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-31 03:53:31  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-31 03:53:36  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-31 03:53:42  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-31 03:53:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-31 03:53:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-31 03:54:00  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-03-31 03:54:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-31 03:54:16  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-31 03:54:22  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-31 03:54:27  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-31 03:54:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-31 03:54:40  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-31 03:54:45  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-31 03:54:51  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-31 03:54:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-31 03:54:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-31 03:55:04  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-31 03:55:10  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-31 03:55:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-31 03:55:22  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-31 03:55:28  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-31 03:55:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-31 03:55:39  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-31 03:55:45  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-31 03:55:51  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-31 03:55:57  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-31 03:56:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-31 03:56:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-31 03:56:17  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-31 03:56:23  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-31 03:56:28  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-31 03:56:34  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-31 03:56:40  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-31 03:56:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-31 03:56:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-31 03:56:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-31 03:57:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-31 03:57:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-31 03:57:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-31 03:57:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-31 03:57:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-31 03:57:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-31 03:57:32  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-31 03:57:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-31 03:57:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-31 03:57:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-31 03:57:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-31 03:57:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-31 03:57:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-31 03:58:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-31 03:58:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-31 03:58:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-31 03:58:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-31 03:58:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-31 03:58:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-31 03:58:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-31 03:58:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-31 03:58:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-31 03:58:40  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-31 03:58:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-31 03:58:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-31 03:58:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-31 03:58:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-31 03:59:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-31 03:59:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-31 03:59:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-31 03:59:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-31 03:59:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-31 03:59:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-31 03:59:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-31 03:59:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-31 03:59:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-31 03:59:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-31 03:59:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-31 03:59:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-31 03:59:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-31 03:59:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-31 04:00:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-31 04:00:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-31 04:00:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-31 04:00:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-31 04:00:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-31 04:00:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-31 04:00:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-31 04:00:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-31 04:00:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-31 04:00:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-31 04:00:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-31 04:00:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-31 04:01:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-31 04:01:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-31 04:01:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-31 04:01:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-31 04:01:26  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-31 04:01:32  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-31 04:01:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-31 04:01:44  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-31 04:01:44  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-31_04-01-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl?_prerender {"code":"ECONNRESET"}
2017-03-31 04:03:49  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-31 04:03:56  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-31 04:04:02  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-31 04:04:08  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-31 04:04:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-31 04:04:20  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-31 04:04:26  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-31 04:04:32  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-31 04:04:38  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-31 04:04:43  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-31 04:04:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-31 04:04:56  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-31 04:05:02  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-31 04:05:08  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-31 04:05:14  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-31 04:05:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-31 04:05:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-31 04:05:32  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-31 04:05:38  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-31 04:05:44  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-31 04:05:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-31 04:05:55  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-31 04:06:01  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-31 04:06:07  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-31 04:06:13  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-31 04:06:19  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-31 04:06:25  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-31 04:06:31  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-31 04:06:37  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-31 04:06:43  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-31 04:06:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-31 04:06:55  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-31 04:07:00  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-31 04:07:06  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-31 04:07:12  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-31 04:07:18  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-31 04:07:23  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-31 04:07:29  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-31 04:07:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-31 04:07:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-31 04:07:47  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-31 04:07:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-31 04:07:59  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-31 04:08:05  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-31 04:08:11  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-31 04:08:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-31 04:08:23  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-31 04:08:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-31 04:08:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-31 04:08:40  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-31 04:08:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-31 04:08:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-31 04:08:58  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-31 04:09:04  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-31 04:09:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-31 04:09:16  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-31 04:09:22  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-31 04:09:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-31 04:09:33  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-31 04:09:39  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-31 04:09:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-31 04:09:51  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-31 04:09:57  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-31 04:10:08  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-31 04:10:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-31 04:10:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-31 04:10:26  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-31 04:10:32  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-31 04:10:38  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-31 04:10:44  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-31 04:10:50  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-31 04:10:56  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-31 04:11:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-31 04:11:07  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-31 04:11:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-31 04:11:19  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-31 04:11:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-31 04:11:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-31 04:11:42  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-31 04:11:48  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-31 04:11:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-31 04:11:59  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-31 04:12:06  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-31 04:12:11  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-31 04:12:17  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-31 04:12:23  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-31 04:12:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-31 04:12:34  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-31 04:12:40  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-31 04:12:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-31 04:12:52  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-31 04:12:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-31 04:13:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-31 04:13:09  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-31 04:13:15  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-31 04:13:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-31 04:13:27  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-31 04:13:33  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-31 04:13:39  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-31 04:13:45  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-31 04:13:51  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-31 04:13:56  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-31 04:14:03  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-31 04:14:13  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-31 04:14:19  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-31 04:14:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-31 04:14:31  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-31 04:14:36  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-31 04:14:42  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-31 04:14:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-31 04:14:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-31 04:15:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-31 04:15:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-31 04:15:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-31 04:15:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-31 04:15:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-31 04:15:29  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-31 04:15:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-31 04:15:41  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-31 04:15:47  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-31 04:15:53  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-31 04:15:58  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-31 04:16:04  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-31 04:16:10  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-31 04:16:16  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-31 04:16:22  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-31 04:16:28  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-31 04:16:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-31 04:16:39  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-31 04:16:45  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-31 04:16:51  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-31 04:16:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-31 04:17:03  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-31 04:17:09  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-31 04:17:15  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-31 04:17:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-31 04:17:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-31 04:17:33  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-31 04:17:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-31 04:17:45  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-31 04:17:51  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-31 04:17:57  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-31 04:18:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-31 04:18:09  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-31 04:18:14  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-31 04:18:20  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-31 04:18:26  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-03-31 04:18:31  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-31 04:18:37  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-31 04:18:42  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-31 04:18:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-31 04:18:54  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-31 04:19:00  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-31 04:19:06  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-31 04:19:11  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-31 04:19:17  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-31 04:19:23  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-31 04:19:28  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-31 04:19:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-31 04:19:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-31 04:19:46  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-31 04:19:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-31 04:19:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-31 04:20:03  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-31 04:20:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-31 04:20:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-31 04:20:25  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-31 04:20:31  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-31 04:20:36  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-31 04:20:42  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-31 04:20:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-31 04:20:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-31 04:20:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-31 04:21:06  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-31 04:21:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-31 04:21:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-31 04:21:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-31 04:21:28  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-31 04:21:34  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-31 04:21:39  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-31 04:21:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-31 04:21:50  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-31 04:21:56  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-31 04:22:02  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-31 04:22:08  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-31 04:22:14  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-31 04:22:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-31 04:22:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-31 04:22:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-31 04:22:38  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-03-31 04:22:38  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-31 04:22:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-31 04:22:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-31 04:22:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-31 04:23:02  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-31 04:23:07  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-03-31 04:23:13  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-31 04:23:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-31 04:23:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-31 04:23:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-31 04:23:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-31 04:23:42  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-31 04:23:47  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-31 04:23:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-31 04:23:59  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-31 04:24:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-31 04:24:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-31 04:24:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-31 04:24:22  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-31 04:24:28  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-03-31 04:24:34  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-31 04:24:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-31 04:24:45  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-31 04:24:50  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-31 04:24:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-31 04:25:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-31 04:25:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-31 04:25:14  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-31 04:25:19  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-31 04:25:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-31 04:25:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-31 04:25:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-31 04:25:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-31 04:25:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-31 04:25:52  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-31 04:25:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-31 04:26:03  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-31 04:26:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-31 04:26:13  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-31 04:26:20  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-31 04:26:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-31 04:26:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-31 04:26:37  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-31 04:26:42  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-31 04:26:47  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-31 04:26:53  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-31 04:26:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-31 04:27:04  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-31 04:27:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-31 04:27:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-31 04:27:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-31 04:27:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-31 04:27:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-31 04:27:39  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-31 04:27:44  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-31 04:27:49  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-31 04:27:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-31 04:28:01  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-31 04:28:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-31 04:28:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-31 04:28:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-31 04:28:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 04:28:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 04:28:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 04:28:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 04:28:44  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-31 04:28:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 04:28:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 04:29:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-31 04:29:05  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-31 04:29:10  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-31 04:29:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-31 04:29:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-31 04:29:31  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-31 04:29:37  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-31 04:29:42  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-31 04:29:47  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-31 04:29:52  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-31 04:29:58  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-31 04:30:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-31 04:30:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-31 04:30:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-31 04:30:19  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-31 04:30:25  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-31 04:30:30  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-31 04:30:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-31 04:30:45  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-31 04:30:51  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-31 04:30:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 04:31:01  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 04:31:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 04:31:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 04:31:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 04:31:22  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-31 04:31:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 04:31:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 04:31:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 04:31:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31_04-31-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly?_prerender {"code":"ECONNRESET"}
2017-03-31 04:33:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 04:33:54  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-31 04:33:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 04:34:05  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 04:34:10  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 04:34:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-31 04:34:20  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-03-31_05-01-46 Restart Xvfb...
2017-03-31_05-31-46 Restart Xvfb...
2017-03-31_06-01-46 Restart Xvfb...
2017-03-31 06:31:45 reset updateRequest
2017-03-31_06-31-46 Restart Xvfb...
2017-03-31 06:31:50  - 14968  http://www.lymphomahub.com/
2017-03-31 06:31:51  - 14968  http://www.lymphomahub.com/
2017-03-31 06:31:56  - 14968  http://www.lymphomahub.com/about
2017-03-31 06:31:57  - 14968  http://www.lymphomahub.com/about
2017-03-31 06:32:03  - 14968  http://www.lymphomahub.com/terms
2017-03-31 06:32:04  - 14968  http://www.lymphomahub.com/terms
2017-03-31 06:32:08  - 14968  http://www.lymphomahub.com/undefined
2017-03-31 06:32:08  - 14968  http://www.lymphomahub.com/undefined
2017-03-31 06:32:09  - 14968  http://www.lymphomahub.com/therapies
2017-03-31 06:32:09  - 14968  http://www.lymphomahub.com/therapies
2017-03-31 06:32:19  - 14968  http://www.lymphomahub.com/newsletter
2017-03-31 06:32:19  - 14968  http://www.lymphomahub.com/newsletter
2017-03-31 06:32:23  - 14968  http://www.lymphomahub.com/cookie-policy
2017-03-31 06:32:24  - 14968  http://www.lymphomahub.com/cookie-policy
2017-03-31 06:32:27  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-03-31 06:32:28  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-03-31 06:32:34  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-03-31 06:32:34  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-03-31 06:32:40  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-03-31 06:32:40  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-03-31 06:32:47  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-03-31 06:32:52  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-03-31 06:32:58  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-03-31 06:33:04  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-03-31 06:33:10  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-03-31 06:33:16  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-03-31 06:33:21  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-03-31 06:33:27  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-03-31 06:33:33  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-03-31 06:33:39  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-03-31 06:33:44  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-03-31 06:33:50  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-03-31 06:33:56  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-03-31 06:34:02  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-03-31 06:34:07  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-03-31 06:34:13  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-03-31 06:34:19  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-03-31 06:34:25  - 14968  http://www.lymphomahub.com/about/secretariat
2017-03-31 06:34:30  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-03-31 06:34:36  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-03-31 06:34:41  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-03-31 06:34:47  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-03-31 06:34:53  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-03-31 06:34:59  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-03-31 06:35:04  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-03-31 06:35:10  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-03-31 06:35:16  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-03-31 06:35:22  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-31 06:35:27  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-31 06:35:33  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-03-31 06:35:39  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-03-31 06:35:44  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-03-31 06:35:51  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-31 06:35:57  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-03-31 06:36:02  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-03-31 06:36:08  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-03-31 06:36:17  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-03-31 06:36:22  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-03-31 06:36:28  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-03-31 06:36:34  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-31 06:36:40  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-31 06:36:46  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-03-31 06:36:51  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-03-31 06:36:57  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-03-31 06:37:03  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-03-31 06:37:09  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-03-31 06:37:14  - 14968  http://www.lymphomahub.com/medical-information
2017-03-31 06:37:20  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-03-31 06:37:26  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-03-31 06:37:32  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-31 06:37:37  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-03-31 06:37:43  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-03-31 06:37:49  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-03-31 06:37:54  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-03-31 06:38:00  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-03-31 06:38:06  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-03-31 06:38:11  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-03-31 06:38:17  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-03-31 06:38:23  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-03-31 06:38:24  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-03-31 06:38:30  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-03-31 06:38:35  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-31 06:38:41  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-31 06:38:46  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-03-31 06:38:52  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-31 06:38:58  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-03-31 06:39:04  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-03-31 06:39:09  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-03-31 06:39:15  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-03-31 06:39:21  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-03-31 06:39:27  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-31 06:39:32  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-31 06:39:38  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-31 06:39:43  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-31 06:39:49  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-31 06:39:55  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-31 06:40:00  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-03-31 06:40:06  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-03-31 06:40:12  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-03-31 06:40:18  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-31 06:40:24  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-31 06:40:30  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-03-31 06:40:35  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-03-31 06:40:41  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-03-31 06:40:46  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-31 06:40:52  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-31 06:40:58  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-03-31 06:41:04  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-31 06:41:10  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-31 06:41:16  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-31 06:41:17  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-31 06:41:22  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-31 06:41:28  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-31 06:41:34  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-31 06:41:40  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-31 06:41:45  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-03-31 06:41:51  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-31 06:42:00  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-31 06:42:05  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-03-31 06:42:10  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-31 06:42:10  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-31 06:42:16  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-31 06:42:21  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-31 06:42:27  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-31 06:42:33  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-31 06:42:39  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-31 06:42:40  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-31 06:42:46  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-31 06:42:51  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-31 06:42:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-31 06:43:02  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-31 06:43:08  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-31 06:43:13  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-31 06:43:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-31 06:43:23  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-31 06:43:28  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-31 06:43:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-31 06:43:40  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-31 06:43:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-31 06:43:51  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-31 06:43:56  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-31 06:43:57  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-31 06:44:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-31 06:44:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-31 06:44:14  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-31 06:44:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-31 06:44:26  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-31 06:44:32  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-31 06:44:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-31 06:44:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-31 06:44:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-31 06:44:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-31 06:44:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-31 06:45:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-31 06:45:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-31 06:45:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-31 06:45:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-31 06:45:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-31 06:45:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-31 06:45:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-31 06:45:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-31 06:45:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-31 06:45:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-31 06:45:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-31 06:46:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-31 06:46:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-31 06:46:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-31 06:46:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-31 06:46:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-31 06:46:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-31 06:46:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-31 06:46:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-31 06:46:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-31 06:46:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-31 06:46:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-31 06:47:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-31 06:47:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-31 06:47:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-31 06:47:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-31 06:47:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-31 06:47:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-31 06:47:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-31 06:47:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-31 06:47:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-31 06:47:51  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-31 06:47:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-03-31 06:48:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-31 06:48:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-31 06:48:11  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-31 06:48:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-31 06:48:22  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-31 06:48:27  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-31 06:48:33  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-31 06:48:39  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-31 06:48:45  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-31 06:48:50  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-31 06:48:56  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-31 06:49:01  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-31 06:49:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-31 06:49:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-31 06:49:19  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-31 06:49:24  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-31 06:49:29  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-31 06:49:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-03-31 06:49:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-31 06:49:46  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-31 06:49:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-31 06:49:58  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-31 06:50:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-03-31 06:50:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-31 06:50:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-31 06:50:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-31 06:50:27  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-31 06:50:28  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-31 06:50:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-03-31 06:50:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-31 06:50:46  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-31 06:50:51  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-31 06:50:57  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-31 06:51:08  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 06:51:14  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 06:51:25  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-31 06:51:31  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 06:51:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-31 06:51:42  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-31 06:51:48  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-31 06:51:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-31 06:52:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-31 06:52:06  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-31 06:52:12  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-31 06:52:18  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-31 06:52:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-31 06:52:34  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-31 06:52:40  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 06:52:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-31 06:53:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-31 06:53:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-31 06:53:12  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-31 06:53:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-31 06:53:23  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-31 06:53:29  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-31 06:53:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-31 06:53:41  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-31 06:53:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-31 06:53:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-31 06:53:58  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-03-31 06:54:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-31 06:54:10  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-31 06:54:16  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-31 06:54:22  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-31 06:54:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-31 06:54:34  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-31 06:54:40  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-31 06:54:45  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-31 06:54:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-31 06:54:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-31 06:54:58  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-31 06:55:04  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-31 06:55:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-31 06:55:16  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-31 06:55:22  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-31 06:55:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-31 06:55:34  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-31 06:55:39  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-31 06:55:46  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-31 06:55:51  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-31 06:55:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-31 06:56:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-31 06:56:09  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-31 06:56:15  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-31 06:56:21  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-31 06:56:26  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-31 06:56:32  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-31 06:56:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-31 06:56:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-31 06:56:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-31 06:57:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-31 06:57:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-31 06:57:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-31 06:57:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-31 06:57:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-31 06:57:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-31 06:57:28  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-31 06:57:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-31 06:57:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-31 06:57:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-31 06:57:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-31 06:57:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-31 06:57:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-31 06:57:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-31 06:58:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-31 06:58:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-31 06:58:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-31 06:58:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-31 06:58:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-31 06:58:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-31 06:58:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-31 06:58:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-31 06:58:36  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-31 06:58:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-31 06:58:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-31 06:58:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-31 06:58:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-31 06:58:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-31 06:59:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-31 06:59:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-31 06:59:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-31 06:59:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-31 06:59:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-31 06:59:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-31 06:59:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-31 06:59:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-31 06:59:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-31 06:59:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-31 06:59:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-31 06:59:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-31 06:59:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-31 06:59:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-31 07:00:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-31 07:00:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-31 07:00:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-31 07:00:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-31 07:00:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-31 07:00:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-31 07:00:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-31 07:00:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-31 07:00:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-31 07:00:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-31 07:00:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-31 07:00:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-31 07:01:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-31 07:01:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-31 07:01:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-31 07:01:14  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-31 07:01:20  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-31 07:01:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-31 07:01:32  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-31 07:01:33  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-31 07:01:42  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-31_07-01-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm?_prerender {"code":"ECONNRESET"}
2017-03-31 07:03:47  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-31 07:03:52  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-31 07:03:58  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-31 07:04:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-31 07:04:10  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-31 07:04:16  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-31 07:04:22  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-31 07:04:28  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-31 07:04:34  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-31 07:04:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-31 07:04:46  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-31 07:04:52  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-31 07:04:58  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-31 07:05:04  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-31 07:05:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-31 07:05:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-31 07:05:21  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-31 07:05:27  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-31 07:05:33  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-31 07:05:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-31 07:05:45  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-31 07:05:51  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-31 07:05:56  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-31 07:06:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-31 07:06:11  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-31 07:06:17  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-31 07:06:23  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-31 07:06:28  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-31 07:06:34  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-31 07:06:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-31 07:06:46  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-31 07:06:52  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-31 07:07:01  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-31 07:07:07  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-31 07:07:12  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-31 07:07:18  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-31 07:07:24  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-31 07:07:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-31 07:07:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-31 07:07:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-31 07:07:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-31 07:07:53  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-31 07:07:59  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-31 07:08:05  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-31 07:08:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-31 07:08:17  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-31 07:08:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-31 07:08:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-31 07:08:34  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-31 07:08:39  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-31 07:08:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-31 07:08:56  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-31 07:09:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-31 07:09:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-31 07:09:14  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-31 07:09:20  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-31 07:09:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-31 07:09:31  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-31 07:09:37  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-31 07:09:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-31 07:09:49  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-31 07:09:55  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-31 07:10:01  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-31 07:10:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-31 07:10:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-31 07:10:25  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-31 07:10:31  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-31 07:10:36  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-31 07:10:42  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-31 07:10:48  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-31 07:10:54  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-31 07:11:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-31 07:11:06  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-31 07:11:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-31 07:11:18  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-31 07:11:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-31 07:11:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-31 07:11:36  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-31 07:11:42  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-31 07:11:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-31 07:11:53  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-31 07:11:59  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-31 07:12:05  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-31 07:12:11  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-31 07:12:16  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-31 07:12:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-31 07:12:28  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-31 07:12:34  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-31 07:12:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-31 07:12:45  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-31 07:12:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-31 07:12:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-31 07:13:03  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-31 07:13:09  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-31 07:13:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-31 07:13:21  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-31 07:13:26  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-31 07:13:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-31 07:13:38  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-31 07:13:44  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-31 07:13:51  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-31 07:13:56  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-31 07:14:02  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-31 07:14:08  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-31 07:14:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-31 07:14:20  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-31 07:14:26  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-31 07:14:32  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-31 07:14:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-31 07:14:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-31 07:14:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-31 07:14:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-31 07:15:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-31 07:15:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-31 07:15:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-31 07:15:19  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-31 07:15:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-31 07:15:31  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-31 07:15:37  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-31 07:15:43  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-31 07:15:48  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-31 07:15:54  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-31 07:16:00  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-31 07:16:06  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-31 07:16:12  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-31 07:16:18  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-31 07:16:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-31 07:16:29  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-31 07:16:35  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-31 07:16:41  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-31 07:16:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-31 07:16:56  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-31 07:17:02  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-31 07:17:07  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-31 07:17:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-31 07:17:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-31 07:17:25  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-31 07:17:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-31 07:17:37  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-31 07:17:43  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-31 07:17:49  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-31 07:17:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-31 07:18:01  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-31 07:18:07  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-31 07:18:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-31 07:18:18  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-03-31 07:18:24  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-31 07:18:29  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-31 07:18:35  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-31 07:18:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-31 07:18:47  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-31 07:18:53  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-31 07:18:59  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-31 07:19:05  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-31 07:19:11  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-31 07:19:17  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-31 07:19:22  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-31 07:19:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-31 07:19:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-31 07:19:39  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-31 07:19:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-31 07:19:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-31 07:19:56  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-31 07:20:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-31 07:20:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-31 07:20:13  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-31 07:20:19  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-31 07:20:24  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-31 07:20:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-31 07:20:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-31 07:20:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-31 07:20:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-31 07:20:53  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-31 07:20:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-31 07:21:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-31 07:21:11  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-31 07:21:16  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-31 07:21:22  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-31 07:21:28  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-31 07:21:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-31 07:21:39  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-31 07:21:44  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-31 07:21:51  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-31 07:21:57  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-31 07:22:03  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-31 07:22:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-31 07:22:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-31 07:22:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-31 07:22:26  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-03-31 07:22:27  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-31 07:22:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-31 07:22:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-31 07:22:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-31 07:22:50  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-31 07:22:56  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-03-31 07:23:07  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-31 07:23:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-31 07:23:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-31 07:23:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-31 07:23:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-31 07:23:35  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-31 07:23:40  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-31 07:23:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-31 07:23:52  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-31 07:23:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-31 07:24:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-31 07:24:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-31 07:24:15  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-31 07:24:21  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-03-31 07:24:27  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-31 07:24:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-31 07:24:38  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-31 07:24:44  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-31 07:24:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-31 07:24:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-31 07:25:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-31 07:25:07  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-31 07:25:12  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-31 07:25:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-31 07:25:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-31 07:25:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-31 07:25:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-31 07:25:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-31 07:25:45  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-31 07:25:50  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-31 07:25:56  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-31 07:26:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-31 07:26:06  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-31 07:26:11  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-31 07:26:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-31 07:26:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-31 07:26:29  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-31 07:26:39  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-31 07:26:45  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-31 07:26:50  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-31 07:26:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-31 07:27:01  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-31 07:27:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-31 07:27:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-31 07:27:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-31 07:27:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-31 07:27:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-31 07:27:36  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-31 07:27:41  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-31 07:27:46  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-31 07:27:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-31 07:27:57  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-31 07:28:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-31 07:28:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-31 07:28:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-31 07:28:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 07:28:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 07:28:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 07:28:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 07:28:41  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-31 07:28:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 07:28:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 07:28:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-31 07:29:02  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-31 07:29:07  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-31 07:29:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-31 07:29:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-31 07:29:24  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-31 07:29:29  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-31 07:29:35  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-31 07:29:40  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-31 07:29:45  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-31 07:29:51  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-31 07:29:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-31 07:30:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-31 07:30:07  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-31 07:30:12  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-31 07:30:17  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-31 07:30:23  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-31 07:30:28  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-31 07:30:34  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-31 07:30:39  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-31 07:30:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 07:30:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 07:30:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 07:31:01  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 07:31:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 07:31:12  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-31 07:31:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 07:31:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 07:31:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 07:31:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 07:31:38  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-31_07-31-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established?_prerender {"code":"ECONNRESET"}
2017-03-31 07:33:43  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-31 07:33:49  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 07:33:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 07:34:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 07:34:05  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-31 07:34:10  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-03-31_08-01-46 Restart Xvfb...
2017-03-31_08-31-46 Restart Xvfb...
2017-03-31_09-01-46 Restart Xvfb...
2017-03-31 09:31:45 reset updateRequest
2017-03-31_09-31-46 Restart Xvfb...
2017-03-31 09:31:50  - 14968  http://www.lymphomahub.com/
2017-03-31 09:31:51  - 14968  http://www.lymphomahub.com/
2017-03-31 09:31:56  - 14968  http://www.lymphomahub.com/about
2017-03-31 09:31:57  - 14968  http://www.lymphomahub.com/about
2017-03-31 09:32:03  - 14968  http://www.lymphomahub.com/terms
2017-03-31 09:32:03  - 14968  http://www.lymphomahub.com/terms
2017-03-31 09:32:08  - 14968  http://www.lymphomahub.com/undefined
2017-03-31 09:32:08  - 14968  http://www.lymphomahub.com/undefined
2017-03-31 09:32:09  - 14968  http://www.lymphomahub.com/therapies
2017-03-31 09:32:09  - 14968  http://www.lymphomahub.com/therapies
2017-03-31 09:32:19  - 14968  http://www.lymphomahub.com/newsletter
2017-03-31 09:32:19  - 14968  http://www.lymphomahub.com/newsletter
2017-03-31 09:32:24  - 14968  http://www.lymphomahub.com/cookie-policy
2017-03-31 09:32:24  - 14968  http://www.lymphomahub.com/cookie-policy
2017-03-31 09:32:28  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-03-31 09:32:29  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-03-31 09:32:35  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-03-31 09:32:41  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-03-31 09:32:47  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-03-31 09:32:52  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-03-31 09:32:58  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-03-31 09:33:04  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-03-31 09:33:10  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-03-31 09:33:15  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-03-31 09:33:21  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-03-31 09:33:27  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-03-31 09:33:33  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-03-31 09:33:38  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-03-31 09:33:44  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-03-31 09:33:50  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-03-31 09:33:56  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-03-31 09:34:01  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-03-31 09:34:07  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-03-31 09:34:13  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-03-31 09:34:19  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-03-31 09:34:24  - 14968  http://www.lymphomahub.com/about/secretariat
2017-03-31 09:34:29  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-03-31 09:34:35  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-03-31 09:34:40  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-03-31 09:34:46  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-03-31 09:34:52  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-03-31 09:34:58  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-03-31 09:35:04  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-03-31 09:35:09  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-03-31 09:35:15  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-03-31 09:35:21  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-31 09:35:26  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-31 09:35:32  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-03-31 09:35:38  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-03-31 09:35:43  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-03-31 09:35:49  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-31 09:35:55  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-03-31 09:36:01  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-03-31 09:36:06  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-03-31 09:36:12  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-03-31 09:36:18  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-03-31 09:36:23  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-03-31 09:36:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-31 09:36:35  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-31 09:36:41  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-03-31 09:36:46  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-03-31 09:36:52  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-03-31 09:36:58  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-03-31 09:37:04  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-03-31 09:37:10  - 14968  http://www.lymphomahub.com/medical-information
2017-03-31 09:37:15  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-03-31 09:37:21  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-03-31 09:37:27  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-31 09:37:33  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-03-31 09:37:39  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-03-31 09:37:44  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-03-31 09:37:50  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-03-31 09:37:56  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-03-31 09:38:02  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-03-31 09:38:07  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-03-31 09:38:13  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-03-31 09:38:18  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-03-31 09:38:19  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-03-31 09:38:25  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-03-31 09:38:31  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-31 09:38:36  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-31 09:38:42  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-03-31 09:38:48  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-31 09:38:53  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-03-31 09:38:59  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-03-31 09:39:05  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-03-31 09:39:10  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-03-31 09:39:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-03-31 09:39:22  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-31 09:39:28  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-31 09:39:34  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-31 09:39:39  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-31 09:39:45  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-31 09:39:50  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-31 09:39:56  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-03-31 09:40:02  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-03-31 09:40:07  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-03-31 09:40:15  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-31 09:40:21  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-31 09:40:27  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-03-31 09:40:32  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-03-31 09:40:38  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-03-31 09:40:44  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-31 09:40:50  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-31 09:40:56  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-03-31 09:41:03  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-31 09:41:08  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-31 09:41:14  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-31 09:41:15  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-31 09:41:21  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-31 09:41:27  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-31 09:41:32  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-31 09:41:38  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-31 09:41:45  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-03-31 09:41:51  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-31 09:41:56  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-31 09:42:02  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-03-31 09:42:07  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-31 09:42:07  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-31 09:42:13  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-31 09:42:18  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-31 09:42:24  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-31 09:42:30  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-31 09:42:36  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-31 09:42:37  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-31 09:42:43  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-31 09:42:48  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-31 09:42:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-31 09:42:59  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-31 09:43:05  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-31 09:43:10  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-31 09:43:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-31 09:43:20  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-31 09:43:25  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-31 09:43:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-31 09:43:37  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-31 09:43:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-31 09:43:48  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-31 09:43:54  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-31 09:43:55  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-31 09:44:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-31 09:44:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-31 09:44:12  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-31 09:44:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-31 09:44:23  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-31 09:44:29  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-31 09:44:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-31 09:44:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-31 09:44:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-31 09:44:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-31 09:44:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-31 09:45:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-31 09:45:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-31 09:45:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-31 09:45:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-31 09:45:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-31 09:45:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-31 09:45:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-31 09:45:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-31 09:45:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-31 09:45:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-31 09:45:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-31 09:46:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-31 09:46:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-31 09:46:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-31 09:46:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-31 09:46:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-31 09:46:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-31 09:46:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-31 09:46:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-31 09:46:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-31 09:46:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-31 09:47:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-31 09:47:05  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-31 09:47:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-31 09:47:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-31 09:47:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-31 09:47:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-31 09:47:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-31 09:47:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-31 09:47:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-31 09:47:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-31 09:47:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-31 09:48:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-03-31 09:48:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-31 09:48:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-31 09:48:15  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-31 09:48:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-31 09:48:25  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-31 09:48:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-31 09:48:36  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-31 09:48:42  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-31 09:48:48  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-31 09:48:53  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-31 09:49:00  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-31 09:49:05  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-31 09:49:11  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-31 09:49:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-31 09:49:22  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-31 09:49:28  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-31 09:49:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-31 09:49:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-03-31 09:49:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-31 09:49:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-31 09:49:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-31 09:50:01  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-31 09:50:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-03-31 09:50:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-31 09:50:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-31 09:50:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-31 09:50:31  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-31 09:50:32  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-31 09:50:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-03-31 09:50:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-31 09:50:55  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-31 09:51:01  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-31 09:51:07  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-31 09:51:13  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 09:51:18  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 09:51:24  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-31 09:51:30  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 09:51:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-31 09:51:42  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-31 09:51:47  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-31 09:51:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-31 09:51:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-31 09:52:05  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-31 09:52:11  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-31 09:52:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-31 09:52:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-31 09:52:39  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-31 09:52:45  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 09:52:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-31 09:52:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-31 09:53:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-31 09:53:08  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-31 09:53:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-31 09:53:20  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-31 09:53:26  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-31 09:53:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-31 09:53:38  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-31 09:53:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-31 09:53:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-31 09:53:56  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-03-31 09:54:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-31 09:54:07  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-31 09:54:14  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-31 09:54:20  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-31 09:54:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-31 09:54:32  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-31 09:54:38  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-31 09:54:44  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-31 09:54:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-31 09:54:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-31 09:54:56  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-31 09:55:02  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-31 09:55:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-31 09:55:13  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-31 09:55:19  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-31 09:55:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-31 09:55:31  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-31 09:55:37  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-31 09:55:43  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-31 09:55:49  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-31 09:55:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-31 09:56:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-31 09:56:06  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-31 09:56:12  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-31 09:56:18  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-31 09:56:24  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-31 09:56:30  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-31 09:56:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-31 09:56:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-31 09:56:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-31 09:56:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-31 09:56:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-31 09:57:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-31 09:57:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-31 09:57:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-31 09:57:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-31 09:57:22  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-31 09:57:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-31 09:57:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-31 09:57:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-31 09:57:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-31 09:57:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-31 09:57:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-31 09:57:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-31 09:57:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-31 09:58:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-31 09:58:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-31 09:58:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-31 09:58:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-31 09:58:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-31 09:58:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-31 09:58:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-31 09:58:32  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-31 09:58:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-31 09:58:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-31 09:58:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-31 09:58:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-31 09:58:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-31 09:58:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-31 09:59:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-31 09:59:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-31 09:59:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-31 09:59:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-31 09:59:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-31 09:59:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-31 09:59:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-31 09:59:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-31 09:59:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-31 09:59:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-31 09:59:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-31 09:59:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-31 09:59:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-31 10:00:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-31 10:00:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-31 10:00:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-31 10:00:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-31 10:00:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-31 10:00:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-31 10:00:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-31 10:00:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-31 10:00:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-31 10:00:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-31 10:00:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-31 10:00:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-31 10:00:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-31 10:01:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-31 10:01:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-31 10:01:14  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-31 10:01:20  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-31 10:01:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-31 10:01:32  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-31 10:01:33  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-31 10:01:39  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-31 10:01:45  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-31_10-01-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab?_prerender {"code":"ECONNRESET"}
2017-03-31 10:03:50  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-31 10:03:56  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-31 10:04:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-31 10:04:09  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-31 10:04:14  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-31 10:04:20  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-31 10:04:26  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-31 10:04:35  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-31 10:04:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-31 10:04:47  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-31 10:04:53  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-31 10:04:59  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-31 10:05:05  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-31 10:05:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-31 10:05:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-31 10:05:23  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-31 10:05:29  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-31 10:05:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-31 10:05:41  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-31 10:05:47  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-31 10:05:53  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-31 10:05:58  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-31 10:06:04  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-31 10:06:10  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-31 10:06:16  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-31 10:06:22  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-31 10:06:28  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-31 10:06:34  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-31 10:06:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-31 10:06:46  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-31 10:06:52  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-31 10:06:58  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-31 10:07:04  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-31 10:07:10  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-31 10:07:15  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-31 10:07:21  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-31 10:07:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-31 10:07:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-31 10:07:40  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-31 10:07:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-31 10:07:52  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-31 10:07:58  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-31 10:08:04  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-31 10:08:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-31 10:08:15  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-31 10:08:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-31 10:08:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-31 10:08:32  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-31 10:08:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-31 10:08:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-31 10:08:50  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-31 10:08:56  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-31 10:09:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-31 10:09:08  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-31 10:09:14  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-31 10:09:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-31 10:09:26  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-31 10:09:36  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-31 10:09:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-31 10:09:48  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-31 10:09:54  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-31 10:10:00  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-31 10:10:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-31 10:10:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-31 10:10:19  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-31 10:10:25  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-31 10:10:30  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-31 10:10:36  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-31 10:10:42  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-31 10:10:47  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-31 10:10:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-31 10:10:59  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-31 10:11:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-31 10:11:11  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-31 10:11:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-31 10:11:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-31 10:11:28  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-31 10:11:35  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-31 10:11:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-31 10:11:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-31 10:11:52  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-31 10:11:58  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-31 10:12:04  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-31 10:12:09  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-31 10:12:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-31 10:12:21  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-31 10:12:27  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-31 10:12:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-31 10:12:38  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-31 10:12:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-31 10:12:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-31 10:12:56  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-31 10:13:02  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-31 10:13:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-31 10:13:14  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-31 10:13:21  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-31 10:13:27  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-31 10:13:33  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-31 10:13:39  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-31 10:13:45  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-31 10:13:50  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-31 10:13:56  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-31 10:14:02  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-31 10:14:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-31 10:14:13  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-31 10:14:19  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-31 10:14:25  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-31 10:14:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-31 10:14:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-31 10:14:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-31 10:14:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-31 10:14:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-31 10:15:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-31 10:15:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-31 10:15:13  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-31 10:15:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-31 10:15:26  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-31 10:15:32  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-31 10:15:38  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-31 10:15:43  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-31 10:15:49  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-31 10:15:55  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-31 10:16:00  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-31 10:16:06  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-31 10:16:13  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-31 10:16:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-31 10:16:25  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-31 10:16:31  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-31 10:16:37  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-31 10:16:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-31 10:16:48  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-31 10:16:54  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-31 10:17:00  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-31 10:17:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-31 10:17:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-31 10:17:18  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-31 10:17:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-31 10:17:30  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-31 10:17:35  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-31 10:17:41  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-31 10:17:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-31 10:17:53  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-31 10:17:59  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-31 10:18:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-31 10:18:10  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-03-31 10:18:16  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-31 10:18:22  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-31 10:18:27  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-31 10:18:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-31 10:18:39  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-31 10:18:45  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-31 10:18:51  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-31 10:18:56  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-31 10:19:02  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-31 10:19:08  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-31 10:19:14  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-31 10:19:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-31 10:19:25  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-31 10:19:31  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-31 10:19:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-31 10:19:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-31 10:19:47  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-31 10:19:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-31 10:19:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-31 10:20:04  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-31 10:20:10  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-31 10:20:18  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-31 10:20:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-31 10:20:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-31 10:20:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-31 10:20:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-31 10:20:48  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-31 10:20:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-31 10:20:58  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-31 10:21:04  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-31 10:21:10  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-31 10:21:16  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-31 10:21:22  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-31 10:21:27  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-31 10:21:33  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-31 10:21:38  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-31 10:21:44  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-31 10:21:50  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-31 10:21:56  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-31 10:22:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-31 10:22:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-31 10:22:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-31 10:22:25  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-03-31 10:22:26  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-31 10:22:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-31 10:22:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-31 10:22:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-31 10:22:49  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-31 10:23:00  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-03-31 10:23:06  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-31 10:23:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-31 10:23:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-31 10:23:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-31 10:23:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-31 10:23:34  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-31 10:23:39  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-31 10:23:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-31 10:23:51  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-31 10:23:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-31 10:24:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-31 10:24:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-31 10:24:14  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-31 10:24:20  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-03-31 10:24:26  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-31 10:24:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-31 10:24:38  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-31 10:24:43  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-31 10:24:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-31 10:24:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-31 10:25:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-31 10:25:13  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-31 10:25:18  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-31 10:25:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-31 10:25:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-31 10:25:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-31 10:25:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-31 10:25:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-31 10:25:55  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-31 10:26:01  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-31 10:26:06  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-31 10:26:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-31 10:26:17  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-31 10:26:23  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-31 10:26:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-31 10:26:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-31 10:26:40  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-31 10:26:45  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-31 10:26:51  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-31 10:26:56  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-31 10:27:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-31 10:27:08  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-31 10:27:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-31 10:27:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-31 10:27:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-31 10:27:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-31 10:27:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-31 10:27:43  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-31 10:27:48  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-31 10:27:53  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-31 10:27:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-31 10:28:05  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-31 10:28:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-31 10:28:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-31 10:28:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-31 10:28:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 10:28:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 10:28:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 10:28:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 10:28:48  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-31 10:28:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 10:28:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 10:29:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-31 10:29:09  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-31 10:29:15  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-31 10:29:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-31 10:29:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-31 10:29:31  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-31 10:29:36  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-31 10:29:42  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-31 10:29:47  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-31 10:29:52  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-31 10:29:57  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-31 10:30:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-31 10:30:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-31 10:30:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-31 10:30:20  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-31 10:30:28  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-31 10:30:34  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-31 10:30:39  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-31 10:30:44  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-31 10:30:49  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-31 10:30:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 10:31:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 10:31:05  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 10:31:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 10:31:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 10:31:21  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-31 10:31:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 10:31:32  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 10:31:37  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 10:31:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31_10-31-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly?_prerender {"code":"ECONNRESET"}
2017-03-31 10:33:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 10:33:52  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-31 10:33:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 10:34:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 10:34:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 10:34:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-31 10:34:19  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-03-31_11-01-46 Restart Xvfb...
2017-03-31_11-31-46 Restart Xvfb...
2017-03-31_12-01-46 Restart Xvfb...
2017-03-31 12:31:45 reset updateRequest
2017-03-31_12-31-46 Restart Xvfb...
2017-03-31 12:31:50  - 14968  http://www.lymphomahub.com/
2017-03-31 12:31:51  - 14968  http://www.lymphomahub.com/
2017-03-31 12:31:56  - 14968  http://www.lymphomahub.com/about
2017-03-31 12:31:57  - 14968  http://www.lymphomahub.com/about
2017-03-31 12:32:03  - 14968  http://www.lymphomahub.com/terms
2017-03-31 12:32:03  - 14968  http://www.lymphomahub.com/terms
2017-03-31 12:32:08  - 14968  http://www.lymphomahub.com/undefined
2017-03-31 12:32:09  - 14968  http://www.lymphomahub.com/undefined
2017-03-31 12:32:09  - 14968  http://www.lymphomahub.com/therapies
2017-03-31 12:32:10  - 14968  http://www.lymphomahub.com/therapies
2017-03-31 12:32:20  - 14968  http://www.lymphomahub.com/newsletter
2017-03-31 12:32:20  - 14968  http://www.lymphomahub.com/newsletter
2017-03-31 12:32:24  - 14968  http://www.lymphomahub.com/cookie-policy
2017-03-31 12:32:24  - 14968  http://www.lymphomahub.com/cookie-policy
2017-03-31 12:32:28  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-03-31 12:32:29  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-03-31 12:32:34  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-03-31 12:32:34  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-03-31 12:32:40  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-03-31 12:32:46  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-03-31 12:32:52  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-03-31 12:32:58  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-03-31 12:33:03  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-03-31 12:33:09  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-03-31 12:33:15  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-03-31 12:33:20  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-03-31 12:33:26  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-03-31 12:33:32  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-03-31 12:33:38  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-03-31 12:33:43  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-03-31 12:33:49  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-03-31 12:33:55  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-03-31 12:34:01  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-03-31 12:34:07  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-03-31 12:34:13  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-03-31 12:34:18  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-03-31 12:34:24  - 14968  http://www.lymphomahub.com/about/secretariat
2017-03-31 12:34:28  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-03-31 12:34:34  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-03-31 12:34:40  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-03-31 12:34:46  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-03-31 12:34:51  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-03-31 12:34:57  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-03-31 12:35:03  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-03-31 12:35:09  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-03-31 12:35:15  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-03-31 12:35:21  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-31 12:35:26  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-31 12:35:32  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-03-31 12:35:38  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-03-31 12:35:44  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-03-31 12:35:50  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-31 12:35:55  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-03-31 12:36:01  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-03-31 12:36:07  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-03-31 12:36:13  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-03-31 12:36:18  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-03-31 12:36:24  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-03-31 12:36:30  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-31 12:36:35  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-31 12:36:41  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-03-31 12:36:47  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-03-31 12:36:53  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-03-31 12:36:58  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-03-31 12:37:04  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-03-31 12:37:10  - 14968  http://www.lymphomahub.com/medical-information
2017-03-31 12:37:14  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-03-31 12:37:19  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-03-31 12:37:25  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-31 12:37:31  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-03-31 12:37:37  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-03-31 12:37:43  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-03-31 12:37:49  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-03-31 12:37:55  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-03-31 12:38:00  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-03-31 12:38:06  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-03-31 12:38:12  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-03-31 12:38:17  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-03-31 12:38:18  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-03-31 12:38:24  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-03-31 12:38:30  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-31 12:38:36  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-31 12:38:41  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-03-31 12:38:47  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-31 12:38:52  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-03-31 12:38:58  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-03-31 12:39:04  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-03-31 12:39:10  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-03-31 12:39:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-03-31 12:39:21  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-31 12:39:27  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-31 12:39:33  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-31 12:39:39  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-31 12:39:45  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-31 12:39:50  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-31 12:39:56  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-03-31 12:40:02  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-03-31 12:40:07  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-03-31 12:40:16  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-31 12:40:22  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-31 12:40:28  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-03-31 12:40:37  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-03-31 12:40:42  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-03-31 12:40:49  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-31 12:40:55  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-31 12:41:03  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-03-31 12:41:09  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-31 12:41:15  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-31 12:41:23  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-31 12:41:24  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-31 12:41:30  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-31 12:41:36  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-31 12:41:41  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-31 12:41:47  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-31 12:41:53  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-03-31 12:41:59  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-31 12:42:04  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-31 12:42:10  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-03-31 12:42:15  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-31 12:42:15  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-31 12:42:21  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-31 12:42:27  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-31 12:42:33  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-31 12:42:38  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-31 12:42:44  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-31 12:42:46  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-31 12:42:52  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-31 12:42:58  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-31 12:43:03  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-31 12:43:08  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-31 12:43:14  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-31 12:43:19  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-31 12:43:25  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-31 12:43:29  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-31 12:43:35  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-31 12:43:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-31 12:43:46  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-31 12:43:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-31 12:43:58  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-31 12:44:04  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-31 12:44:04  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-31 12:44:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-31 12:44:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-31 12:44:22  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-31 12:44:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-31 12:44:34  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-31 12:44:39  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-31 12:44:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-31 12:44:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-31 12:44:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-31 12:45:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-31 12:45:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-31 12:45:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-31 12:45:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-31 12:45:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-31 12:45:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-31 12:45:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-31 12:45:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-31 12:45:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-31 12:45:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-31 12:45:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-31 12:46:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-31 12:46:05  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-31 12:46:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-31 12:46:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-31 12:46:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-31 12:46:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-31 12:46:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-31 12:46:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-31 12:46:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-31 12:46:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-31 12:46:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-31 12:47:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-31 12:47:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-31 12:47:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-31 12:47:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-31 12:47:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-31 12:47:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-31 12:47:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-31 12:47:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-31 12:47:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-31 12:47:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-31 12:47:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-31 12:48:05  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-31 12:48:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-03-31 12:48:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-31 12:48:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-31 12:48:26  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-31 12:48:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-31 12:48:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-31 12:48:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-31 12:48:48  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-31 12:48:54  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-31 12:49:00  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-31 12:49:05  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-31 12:49:11  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-31 12:49:17  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-31 12:49:23  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-31 12:49:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-31 12:49:34  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-31 12:49:39  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-31 12:49:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-31 12:49:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-03-31 12:50:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-31 12:50:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-31 12:50:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-31 12:50:18  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-31 12:50:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-03-31 12:50:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-31 12:50:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-31 12:50:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-31 12:50:50  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-31 12:50:51  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-31 12:50:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-03-31 12:51:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-31 12:51:08  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-31 12:51:14  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-31 12:51:20  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-31 12:51:26  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 12:51:32  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 12:51:38  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-31 12:51:44  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 12:51:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-31 12:51:55  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-31 12:52:01  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-31 12:52:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-31 12:52:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-31 12:52:19  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-31 12:52:25  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-31 12:52:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-31 12:52:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-31 12:52:43  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-31 12:52:49  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 12:52:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-31 12:53:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-31 12:53:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-31 12:53:12  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-31 12:53:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-31 12:53:24  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-31 12:53:31  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-31 12:53:36  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-31 12:53:43  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-31 12:53:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-31 12:53:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-31 12:54:00  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-03-31 12:54:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-31 12:54:12  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-31 12:54:18  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-31 12:54:24  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-31 12:54:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-31 12:54:36  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-31 12:54:42  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-31 12:54:48  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-31 12:54:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-31 12:54:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-31 12:55:00  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-31 12:55:06  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-31 12:55:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-31 12:55:18  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-31 12:55:24  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-31 12:55:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-31 12:55:36  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-31 12:55:42  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-31 12:55:48  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-31 12:55:54  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-31 12:56:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-31 12:56:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-31 12:56:11  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-31 12:56:16  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-31 12:56:22  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-31 12:56:28  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-31 12:56:34  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-31 12:56:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-31 12:56:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-31 12:56:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-31 12:56:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-31 12:57:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-31 12:57:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-31 12:57:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-31 12:57:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-31 12:57:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-31 12:57:26  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-31 12:57:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-31 12:57:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-31 12:57:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-31 12:57:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-31 12:57:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-31 12:57:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-31 12:57:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-31 12:57:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-31 12:58:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-31 12:58:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-31 12:58:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-31 12:58:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-31 12:58:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-31 12:58:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-31 12:58:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-31 12:58:35  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-31 12:58:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-31 12:58:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-31 12:58:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-31 12:58:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-31 12:58:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-31 12:59:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-31 12:59:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-31 12:59:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-31 12:59:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-31 12:59:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-31 12:59:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-31 12:59:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-31 12:59:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-31 12:59:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-31 12:59:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-31 12:59:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-31 12:59:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-31 12:59:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-31 12:59:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-31 13:00:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-31 13:00:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-31 13:00:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-31 13:00:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-31 13:00:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-31 13:00:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-31 13:00:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-31 13:00:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-31 13:00:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-31 13:00:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-31 13:00:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-31 13:00:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-31 13:01:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-31 13:01:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-31 13:01:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-31 13:01:16  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-31 13:01:22  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-31 13:01:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-31 13:01:35  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-31 13:01:39  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-31 13:01:45  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-31_13-01-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm?_prerender {"code":"ECONNRESET"}
2017-03-31 13:03:50  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-31 13:03:56  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-31 13:04:03  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-31 13:04:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-31 13:04:15  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-31 13:04:21  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-31 13:04:27  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-31 13:04:33  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-31 13:04:39  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-31 13:04:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-31 13:04:51  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-31 13:04:57  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-31 13:05:03  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-31 13:05:09  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-31 13:05:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-31 13:05:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-31 13:05:27  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-31 13:05:33  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-31 13:05:39  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-31 13:05:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-31 13:05:51  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-31 13:05:56  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-31 13:06:02  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-31 13:06:08  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-31 13:06:14  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-31 13:06:20  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-31 13:06:26  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-31 13:06:32  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-31 13:06:38  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-31 13:06:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-31 13:06:49  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-31 13:06:55  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-31 13:07:01  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-31 13:07:07  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-31 13:07:13  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-31 13:07:19  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-31 13:07:25  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-31 13:07:31  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-31 13:07:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-31 13:07:43  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-31 13:07:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-31 13:07:55  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-31 13:08:01  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-31 13:08:07  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-31 13:08:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-31 13:08:19  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-31 13:08:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-31 13:08:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-31 13:08:36  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-31 13:08:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-31 13:08:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-31 13:08:53  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-31 13:08:59  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-31 13:09:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-31 13:09:12  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-31 13:09:18  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-31 13:09:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-31 13:09:30  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-31 13:09:35  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-31 13:09:41  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-31 13:09:47  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-31 13:09:53  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-31 13:09:59  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-31 13:10:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-31 13:10:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-31 13:10:17  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-31 13:10:23  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-31 13:10:29  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-31 13:10:35  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-31 13:10:41  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-31 13:10:47  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-31 13:10:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-31 13:10:59  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-31 13:11:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-31 13:11:11  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-31 13:11:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-31 13:11:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-31 13:11:29  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-31 13:11:35  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-31 13:11:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-31 13:11:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-31 13:11:52  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-31 13:11:58  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-31 13:12:04  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-31 13:12:09  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-31 13:12:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-31 13:12:21  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-31 13:12:27  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-31 13:12:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-31 13:12:38  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-31 13:12:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-31 13:12:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-31 13:12:56  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-31 13:13:02  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-31 13:13:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-31 13:13:14  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-31 13:13:20  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-31 13:13:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-31 13:13:31  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-31 13:13:37  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-31 13:13:43  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-31 13:13:49  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-31 13:13:55  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-31 13:14:01  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-31 13:14:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-31 13:14:12  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-31 13:14:18  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-31 13:14:24  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-31 13:14:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-31 13:14:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-31 13:14:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-31 13:14:48  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-31 13:14:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-31 13:15:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-31 13:15:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-31 13:15:12  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-31 13:15:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-31 13:15:24  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-31 13:15:30  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-31 13:15:36  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-31 13:15:41  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-31 13:15:47  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-31 13:15:53  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-31 13:15:59  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-31 13:16:04  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-31 13:16:10  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-31 13:16:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-31 13:16:22  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-31 13:16:28  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-31 13:16:34  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-31 13:16:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-31 13:16:45  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-31 13:16:51  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-31 13:16:57  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-31 13:17:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-31 13:17:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-31 13:17:15  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-31 13:17:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-31 13:17:27  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-31 13:17:33  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-31 13:17:39  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-31 13:17:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-31 13:17:51  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-31 13:17:57  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-31 13:18:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-31 13:18:08  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-03-31 13:18:14  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-31 13:18:19  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-31 13:18:25  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-31 13:18:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-31 13:18:37  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-31 13:18:42  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-31 13:18:48  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-31 13:18:54  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-31 13:19:00  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-31 13:19:05  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-31 13:19:11  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-31 13:19:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-31 13:19:22  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-31 13:19:28  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-31 13:19:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-31 13:19:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-31 13:19:44  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-31 13:19:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-31 13:19:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-31 13:20:02  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-31 13:20:09  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-31 13:20:15  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-31 13:20:22  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-31 13:20:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-31 13:20:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-31 13:20:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-31 13:20:46  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-31 13:20:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-31 13:20:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-31 13:21:03  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-31 13:21:08  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-31 13:21:14  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-31 13:21:20  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-31 13:21:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-31 13:21:31  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-31 13:21:37  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-31 13:21:42  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-31 13:21:48  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-31 13:21:54  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-31 13:22:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-31 13:22:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-31 13:22:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-31 13:22:17  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-03-31 13:22:18  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-31 13:22:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-31 13:22:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-31 13:22:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-31 13:22:42  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-31 13:22:48  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-03-31 13:22:54  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-31 13:22:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-31 13:23:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-31 13:23:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-31 13:23:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-31 13:23:22  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-31 13:23:27  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-31 13:23:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-31 13:23:39  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-31 13:23:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-31 13:23:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-31 13:23:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-31 13:24:02  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-31 13:24:08  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-03-31 13:24:13  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-31 13:24:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-31 13:24:24  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-31 13:24:30  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-31 13:24:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-31 13:24:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-31 13:24:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-31 13:24:53  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-31 13:24:59  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-31 13:25:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-31 13:25:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-31 13:25:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-31 13:25:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-31 13:25:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-31 13:25:37  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-31 13:25:42  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-31 13:25:47  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-31 13:25:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-31 13:25:58  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-31 13:26:03  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-31 13:26:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-31 13:26:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-31 13:26:20  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-31 13:26:26  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-31 13:26:31  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-31 13:26:36  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-31 13:26:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-31 13:26:47  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-31 13:26:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-31 13:26:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-31 13:27:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-31 13:27:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-31 13:27:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-31 13:27:22  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-31 13:27:27  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-31 13:27:32  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-31 13:27:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-31 13:27:43  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-31 13:27:48  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-31 13:27:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-31 13:28:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-31 13:28:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 13:28:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 13:28:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 13:28:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 13:28:26  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-31 13:28:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 13:28:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 13:28:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-31 13:28:47  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-31 13:28:52  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-31 13:28:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-31 13:29:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-31 13:29:09  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-31 13:29:14  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-31 13:29:19  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-31 13:29:25  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-31 13:29:30  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-31 13:29:36  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-31 13:29:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-31 13:29:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-31 13:29:52  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-31 13:29:57  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-31 13:30:03  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-31 13:30:11  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-31 13:30:16  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-31 13:30:22  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-31 13:30:27  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-31 13:30:32  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 13:30:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 13:30:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 13:30:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 13:30:57  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 13:31:00  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-31 13:31:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 13:31:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 13:31:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 13:31:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 13:31:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-31 13:31:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 13:31:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31_13-31-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly?_prerender {"code":"ECONNRESET"}
2017-03-31 13:33:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 13:33:53  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 13:33:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-31 13:34:03  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-03-31_14-01-46 Restart Xvfb...
2017-03-31_14-31-46 Restart Xvfb...
2017-03-31_15-01-46 Restart Xvfb...
2017-03-31 15:31:45 reset updateRequest
2017-03-31_15-31-46 Restart Xvfb...
2017-03-31 15:31:49  - 14968  http://www.lymphomahub.com/
2017-03-31 15:31:51  - 14968  http://www.lymphomahub.com/
2017-03-31 15:31:55  - 14968  http://www.lymphomahub.com/about
2017-03-31 15:31:56  - 14968  http://www.lymphomahub.com/about
2017-03-31 15:32:02  - 14968  http://www.lymphomahub.com/terms
2017-03-31 15:32:06  - 14968  http://www.lymphomahub.com/undefined
2017-03-31 15:32:07  - 14968  http://www.lymphomahub.com/therapies
2017-03-31 15:32:14  - 14968  http://www.lymphomahub.com/newsletter
2017-03-31 15:32:17  - 14968  http://www.lymphomahub.com/cookie-policy
2017-03-31 15:32:21  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-03-31 15:32:27  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-03-31 15:32:33  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-03-31 15:32:39  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-03-31 15:32:45  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-03-31 15:32:50  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-03-31 15:32:56  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-03-31 15:33:02  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-03-31 15:33:07  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-03-31 15:33:13  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-03-31 15:33:19  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-03-31 15:33:24  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-03-31 15:33:30  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-03-31 15:33:36  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-03-31 15:33:42  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-03-31 15:33:48  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-03-31 15:33:53  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-03-31 15:33:59  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-03-31 15:34:05  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-03-31 15:34:11  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-03-31 15:34:16  - 14968  http://www.lymphomahub.com/about/secretariat
2017-03-31 15:34:21  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-03-31 15:34:27  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-03-31 15:34:33  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-03-31 15:34:38  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-03-31 15:34:44  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-03-31 15:34:50  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-03-31 15:34:55  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-03-31 15:35:01  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-03-31 15:35:07  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-03-31 15:35:13  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-31 15:35:19  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-31 15:35:24  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-03-31 15:35:30  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-03-31 15:35:35  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-03-31 15:35:41  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-31 15:35:47  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-03-31 15:35:53  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-03-31 15:35:58  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-03-31 15:36:05  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-03-31 15:36:10  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-03-31 15:36:16  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-03-31 15:36:21  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-31 15:36:28  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-31 15:36:33  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-03-31 15:36:39  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-03-31 15:36:48  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-03-31 15:36:54  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-03-31 15:37:01  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-03-31 15:37:07  - 14968  http://www.lymphomahub.com/medical-information
2017-03-31 15:37:12  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-03-31 15:37:18  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-03-31 15:37:24  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-31 15:37:30  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-03-31 15:37:35  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-03-31 15:37:41  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-03-31 15:37:47  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-03-31 15:37:53  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-03-31 15:37:58  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-03-31 15:38:04  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-03-31 15:38:10  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-03-31 15:38:16  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-03-31 15:38:17  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-03-31 15:38:22  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-03-31 15:38:28  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-31 15:38:33  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-31 15:38:39  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-03-31 15:38:45  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-31 15:38:50  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-03-31 15:38:56  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-03-31 15:39:02  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-03-31 15:39:07  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-03-31 15:39:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-03-31 15:39:19  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-31 15:39:25  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-31 15:39:31  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-31 15:39:36  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-31 15:39:42  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-31 15:39:48  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-31 15:39:53  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-03-31 15:39:59  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-03-31 15:40:05  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-03-31 15:40:10  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-31 15:40:16  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-31 15:40:22  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-03-31 15:40:27  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-03-31 15:40:33  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-03-31 15:40:42  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-31 15:40:47  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-31 15:40:53  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-03-31 15:40:59  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-31 15:41:05  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-31 15:41:10  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-31 15:41:11  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-31 15:41:17  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-31 15:41:23  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-31 15:41:28  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-31 15:41:34  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-31 15:41:40  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-03-31 15:41:46  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-31 15:41:52  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-31 15:41:57  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-03-31 15:42:02  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-31 15:42:03  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-31 15:42:09  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-31 15:42:15  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-31 15:42:21  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-31 15:42:27  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-31 15:42:33  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-31 15:42:34  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-31 15:42:39  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-31 15:42:45  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-31 15:42:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-31 15:42:55  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-31 15:43:01  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-31 15:43:06  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-31 15:43:12  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-31 15:43:17  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-31 15:43:22  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-31 15:43:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-31 15:43:34  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-31 15:43:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-31 15:43:45  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-31 15:43:50  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-31 15:43:51  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-31 15:43:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-31 15:44:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-31 15:44:09  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-31 15:44:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-31 15:44:21  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-31 15:44:26  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-31 15:44:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-31 15:44:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-31 15:44:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-31 15:44:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-31 15:44:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-31 15:44:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-31 15:45:04  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-31 15:45:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-31 15:45:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-31 15:45:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-31 15:45:30  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-31 15:45:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-31 15:45:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-31 15:45:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-31 15:45:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-31 15:45:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-31 15:46:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-31 15:46:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-31 15:46:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-31 15:46:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-31 15:46:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-31 15:46:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-31 15:46:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-31 15:46:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-31 15:46:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-31 15:46:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-31 15:46:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-31 15:47:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-31 15:47:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-31 15:47:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-31 15:47:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-31 15:47:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-31 15:47:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-31 15:47:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-31 15:47:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-31 15:47:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-31 15:47:51  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-31 15:47:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-03-31 15:48:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-31 15:48:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-31 15:48:11  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-31 15:48:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-31 15:48:22  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-31 15:48:27  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-31 15:48:33  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-31 15:48:39  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-31 15:48:45  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-31 15:48:50  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-31 15:48:56  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-31 15:49:02  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-31 15:49:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-31 15:49:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-31 15:49:19  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-31 15:49:24  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-31 15:49:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-31 15:49:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-03-31 15:49:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-31 15:49:46  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-31 15:49:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-31 15:49:57  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-31 15:50:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-03-31 15:50:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-31 15:50:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-31 15:50:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-31 15:50:28  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-31 15:50:29  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-31 15:50:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-03-31 15:50:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-31 15:50:47  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-31 15:50:58  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-31 15:51:03  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-31 15:51:09  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 15:51:15  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 15:51:21  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-31 15:51:27  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 15:51:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-31 15:51:39  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-31 15:51:44  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-31 15:51:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-31 15:51:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-31 15:52:02  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-31 15:52:08  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-31 15:52:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-31 15:52:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-31 15:52:31  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-31 15:52:37  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 15:52:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-31 15:52:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-31 15:52:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-31 15:53:01  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-31 15:53:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-31 15:53:13  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-31 15:53:19  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-31 15:53:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-31 15:53:31  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-31 15:53:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-31 15:53:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-31 15:53:48  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-03-31 15:53:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-31 15:54:00  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-31 15:54:06  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-31 15:54:12  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-31 15:54:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-31 15:54:24  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-31 15:54:30  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-31 15:54:36  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-31 15:54:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-31 15:54:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-31 15:54:47  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-31 15:54:53  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-31 15:54:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-31 15:55:05  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-31 15:55:11  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-31 15:55:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-31 15:55:23  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-31 15:55:29  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-31 15:55:35  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-31 15:55:41  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-31 15:55:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-31 15:55:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-31 15:55:58  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-31 15:56:05  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-31 15:56:11  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-31 15:56:17  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-31 15:56:23  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-31 15:56:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-31 15:56:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-31 15:56:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-31 15:56:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-31 15:56:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-31 15:56:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-31 15:56:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-31 15:57:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-31 15:57:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-31 15:57:19  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-31 15:57:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-31 15:57:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-31 15:57:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-31 15:57:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-31 15:57:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-31 15:57:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-31 15:57:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-31 15:57:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-31 15:57:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-31 15:58:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-31 15:58:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-31 15:58:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-31 15:58:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-31 15:58:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-31 15:58:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-31 15:58:26  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-31 15:58:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-31 15:58:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-31 15:58:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-31 15:58:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-31 15:58:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-31 15:58:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-31 15:58:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-31 15:59:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-31 15:59:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-31 15:59:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-31 15:59:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-31 15:59:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-31 15:59:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-31 15:59:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-31 15:59:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-31 15:59:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-31 15:59:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-31 15:59:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-31 15:59:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-31 15:59:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-31 15:59:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-31 16:00:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-31 16:00:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-31 16:00:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-31 16:00:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-31 16:00:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-31 16:00:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-31 16:00:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-31 16:00:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-31 16:00:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-31 16:00:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-31 16:00:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-31 16:00:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-31 16:00:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-31 16:01:01  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-31 16:01:07  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-31 16:01:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-31 16:01:19  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-31 16:01:20  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-31 16:01:26  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-31 16:01:32  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-31 16:01:43  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-31_16-01-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial?_prerender {"code":"ECONNRESET"}
2017-03-31 16:03:48  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-31 16:03:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-31 16:04:01  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-31 16:04:07  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-31 16:04:12  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-31 16:04:18  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-31 16:04:25  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-31 16:04:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-31 16:04:36  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-31 16:04:42  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-31 16:04:48  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-31 16:04:54  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-31 16:05:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-31 16:05:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-31 16:05:12  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-31 16:05:18  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-31 16:05:24  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-31 16:05:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-31 16:05:36  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-31 16:05:42  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-31 16:05:47  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-31 16:05:53  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-31 16:05:59  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-31 16:06:05  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-31 16:06:11  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-31 16:06:17  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-31 16:06:22  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-31 16:06:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-31 16:06:34  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-31 16:06:40  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-31 16:06:46  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-31 16:06:52  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-31 16:06:58  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-31 16:07:03  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-31 16:07:09  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-31 16:07:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-31 16:07:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-31 16:07:27  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-31 16:07:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-31 16:07:39  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-31 16:07:45  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-31 16:07:50  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-31 16:07:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-31 16:08:02  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-31 16:08:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-31 16:08:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-31 16:08:19  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-31 16:08:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-31 16:08:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-31 16:08:37  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-31 16:08:43  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-31 16:08:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-31 16:08:55  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-31 16:09:01  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-31 16:09:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-31 16:09:12  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-31 16:09:18  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-31 16:09:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-31 16:09:35  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-31 16:09:41  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-31 16:09:48  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-31 16:09:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-31 16:09:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-31 16:10:05  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-31 16:10:11  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-31 16:10:17  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-31 16:10:23  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-31 16:10:28  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-31 16:10:34  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-31 16:10:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-31 16:10:46  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-31 16:10:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-31 16:10:58  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-31 16:11:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-31 16:11:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-31 16:11:16  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-31 16:11:22  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-31 16:11:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-31 16:11:34  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-31 16:11:40  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-31 16:11:46  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-31 16:11:51  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-31 16:11:57  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-31 16:12:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-31 16:12:09  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-31 16:12:14  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-31 16:12:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-31 16:12:26  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-31 16:12:32  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-31 16:12:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-31 16:12:43  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-31 16:12:49  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-31 16:12:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-31 16:13:00  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-31 16:13:06  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-31 16:13:12  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-31 16:13:23  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-31 16:13:29  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-31 16:13:35  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-31 16:13:41  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-31 16:13:46  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-31 16:13:52  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-31 16:13:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-31 16:14:04  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-31 16:14:10  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-31 16:14:16  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-31 16:14:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-31 16:14:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-31 16:14:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-31 16:14:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-31 16:14:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-31 16:14:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-31 16:14:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-31 16:15:03  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-31 16:15:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-31 16:15:15  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-31 16:15:21  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-31 16:15:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-31 16:15:32  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-31 16:15:38  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-31 16:15:44  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-31 16:15:50  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-31 16:15:56  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-31 16:16:01  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-31 16:16:07  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-31 16:16:13  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-31 16:16:20  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-31 16:16:26  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-31 16:16:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-31 16:16:38  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-31 16:16:44  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-31 16:16:49  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-31 16:16:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-31 16:17:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-31 16:17:07  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-31 16:17:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-31 16:17:19  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-31 16:17:25  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-31 16:17:31  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-31 16:17:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-31 16:17:43  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-31 16:17:49  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-31 16:17:54  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-31 16:18:00  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-03-31 16:18:06  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-31 16:18:16  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-31 16:18:22  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-31 16:18:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-31 16:18:34  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-31 16:18:40  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-31 16:18:45  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-31 16:18:51  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-31 16:18:57  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-31 16:19:03  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-31 16:19:08  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-31 16:19:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-31 16:19:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-31 16:19:25  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-31 16:19:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-31 16:19:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-31 16:19:41  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-31 16:19:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-31 16:19:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-31 16:19:59  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-31 16:20:05  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-31 16:20:11  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-31 16:20:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-31 16:20:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-31 16:20:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-31 16:20:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-31 16:20:39  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-31 16:20:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-31 16:20:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-31 16:20:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-31 16:21:02  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-31 16:21:08  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-31 16:21:14  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-31 16:21:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-31 16:21:25  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-31 16:21:30  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-31 16:21:36  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-31 16:21:42  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-31 16:21:48  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-31 16:21:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-31 16:22:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-31 16:22:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-31 16:22:12  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-03-31 16:22:13  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-31 16:22:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-31 16:22:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-31 16:22:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-31 16:22:37  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-31 16:22:43  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-03-31 16:22:48  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-31 16:22:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-31 16:22:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-31 16:23:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-31 16:23:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-31 16:23:16  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-31 16:23:22  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-31 16:23:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-31 16:23:34  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-31 16:23:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-31 16:23:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-31 16:23:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-31 16:23:57  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-31 16:24:03  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-03-31 16:24:09  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-31 16:24:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-31 16:24:25  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-31 16:24:30  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-31 16:24:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-31 16:24:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-31 16:24:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-31 16:24:54  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-31 16:25:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-31 16:25:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-31 16:25:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-31 16:25:16  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-31 16:25:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-31 16:25:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-31 16:25:33  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-31 16:25:38  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-31 16:25:44  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-31 16:25:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-31 16:25:54  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-31 16:25:59  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-31 16:26:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-31 16:26:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-31 16:26:16  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-31 16:26:22  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-31 16:26:27  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-31 16:26:33  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-31 16:26:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-31 16:26:44  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-31 16:26:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-31 16:26:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-31 16:27:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-31 16:27:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-31 16:27:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-31 16:27:19  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-31 16:27:24  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-31 16:27:30  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-31 16:27:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-31 16:27:41  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-31 16:27:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-31 16:27:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-31 16:27:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-31 16:28:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 16:28:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 16:28:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 16:28:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 16:28:24  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-31 16:28:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 16:28:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 16:28:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-31 16:28:45  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-31 16:28:51  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-31 16:29:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-31 16:29:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-31 16:29:12  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-31 16:29:17  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-31 16:29:22  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-31 16:29:28  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-31 16:29:33  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-31 16:29:39  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-31 16:29:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-31 16:29:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-31 16:29:55  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-31 16:30:01  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-31 16:30:06  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-31 16:30:12  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-31 16:30:22  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-31 16:30:27  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-31 16:30:35  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-31 16:30:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 16:30:46  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 16:30:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 16:30:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 16:31:02  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 16:31:07  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-31 16:31:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 16:31:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 16:31:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 16:31:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 16:31:34  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-31 16:31:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 16:31:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31_16-31-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly?_prerender {"code":"ECONNRESET"}
2017-03-31 16:33:49  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 16:33:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 16:34:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-31 16:34:05  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-03-31_17-01-46 Restart Xvfb...
2017-03-31_17-31-46 Restart Xvfb...
2017-03-31_18-01-46 Restart Xvfb...
2017-03-31 18:31:45 reset updateRequest
2017-03-31_18-31-46 Restart Xvfb...
2017-03-31 18:31:50  - 14968  http://www.lymphomahub.com/
2017-03-31 18:31:51  - 14968  http://www.lymphomahub.com/
2017-03-31 18:31:56  - 14968  http://www.lymphomahub.com/about
2017-03-31 18:31:57  - 14968  http://www.lymphomahub.com/about
2017-03-31 18:32:02  - 14968  http://www.lymphomahub.com/terms
2017-03-31 18:32:04  - 14968  http://www.lymphomahub.com/terms
2017-03-31 18:32:07  - 14968  http://www.lymphomahub.com/undefined
2017-03-31 18:32:08  - 14968  http://www.lymphomahub.com/therapies
2017-03-31 18:32:09  - 14968  http://www.lymphomahub.com/therapies
2017-03-31 18:32:18  - 14968  http://www.lymphomahub.com/newsletter
2017-03-31 18:32:20  - 14968  http://www.lymphomahub.com/newsletter
2017-03-31 18:32:23  - 14968  http://www.lymphomahub.com/cookie-policy
2017-03-31 18:32:24  - 14968  http://www.lymphomahub.com/cookie-policy
2017-03-31 18:32:27  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-03-31 18:32:29  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-03-31 18:32:34  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-03-31 18:32:34  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-03-31 18:32:40  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-03-31 18:32:46  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-03-31 18:32:52  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-03-31 18:32:58  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-03-31 18:33:04  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-03-31 18:33:10  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-03-31 18:33:16  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-03-31 18:33:21  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-03-31 18:33:27  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-03-31 18:33:33  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-03-31 18:33:39  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-03-31 18:33:44  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-03-31 18:33:50  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-03-31 18:33:56  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-03-31 18:34:01  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-03-31 18:34:07  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-03-31 18:34:13  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-03-31 18:34:19  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-03-31 18:34:24  - 14968  http://www.lymphomahub.com/about/secretariat
2017-03-31 18:34:29  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-03-31 18:34:35  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-03-31 18:34:40  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-03-31 18:34:46  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-03-31 18:34:52  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-03-31 18:34:58  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-03-31 18:35:04  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-03-31 18:35:09  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-03-31 18:35:15  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-03-31 18:35:21  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-31 18:35:27  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-31 18:35:32  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-03-31 18:35:38  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-03-31 18:35:49  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-03-31 18:35:55  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-31 18:36:01  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-03-31 18:36:06  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-03-31 18:36:12  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-03-31 18:36:18  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-03-31 18:36:23  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-03-31 18:36:29  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-03-31 18:36:35  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-31 18:36:40  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-31 18:36:46  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-03-31 18:36:52  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-03-31 18:36:58  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-03-31 18:37:03  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-03-31 18:37:09  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-03-31 18:37:15  - 14968  http://www.lymphomahub.com/medical-information
2017-03-31 18:37:20  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-03-31 18:37:26  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-03-31 18:37:32  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-31 18:37:37  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-03-31 18:37:43  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-03-31 18:37:49  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-03-31 18:37:54  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-03-31 18:38:00  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-03-31 18:38:06  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-03-31 18:38:12  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-03-31 18:38:17  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-03-31 18:38:23  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-03-31 18:38:24  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-03-31 18:38:30  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-03-31 18:38:36  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-31 18:38:42  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-31 18:38:47  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-03-31 18:38:53  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-31 18:38:59  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-03-31 18:39:04  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-03-31 18:39:10  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-03-31 18:39:16  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-03-31 18:39:21  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-03-31 18:39:27  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-31 18:39:33  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-31 18:39:39  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-31 18:39:44  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-31 18:39:50  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-31 18:39:56  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-31 18:40:02  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-03-31 18:40:07  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-03-31 18:40:13  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-03-31 18:40:19  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-31 18:40:25  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-31 18:40:31  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-03-31 18:40:36  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-03-31 18:40:47  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-03-31 18:40:52  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-31 18:40:58  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-31 18:41:03  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-03-31 18:41:09  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-31 18:41:15  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-31 18:41:20  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-31 18:41:21  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-31 18:41:27  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-31 18:41:33  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-31 18:41:38  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-31 18:41:44  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-31 18:41:50  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-03-31 18:41:55  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-31 18:42:01  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-31 18:42:07  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-03-31 18:42:11  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-31 18:42:12  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-31 18:42:18  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-31 18:42:24  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-31 18:42:30  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-31 18:42:35  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-31 18:42:41  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-31 18:42:42  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-31 18:42:48  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-31 18:42:53  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-31 18:42:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-31 18:43:04  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-31 18:43:10  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-31 18:43:15  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-31 18:43:20  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-31 18:43:25  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-31 18:43:31  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-31 18:43:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-31 18:43:42  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-31 18:43:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-31 18:43:53  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-31 18:43:59  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-31 18:43:59  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-31 18:44:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-31 18:44:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-31 18:44:17  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-31 18:44:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-31 18:44:28  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-31 18:44:34  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-31 18:44:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-31 18:44:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-31 18:44:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-31 18:44:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-31 18:45:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-31 18:45:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-31 18:45:12  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-31 18:45:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-31 18:45:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-31 18:45:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-31 18:45:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-31 18:45:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-31 18:45:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-31 18:45:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-31 18:45:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-31 18:45:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-31 18:46:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-31 18:46:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-31 18:46:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-31 18:46:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-31 18:46:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-31 18:46:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-31 18:46:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-31 18:46:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-31 18:46:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-31 18:46:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-31 18:47:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-31 18:47:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-31 18:47:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-31 18:47:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-31 18:47:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-31 18:47:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-31 18:47:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-31 18:47:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-31 18:47:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-31 18:47:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-31 18:47:55  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-31 18:48:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-03-31 18:48:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-31 18:48:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-31 18:48:16  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-31 18:48:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-31 18:48:26  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-31 18:48:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-31 18:48:37  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-31 18:48:44  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-31 18:48:49  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-31 18:48:55  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-31 18:49:00  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-31 18:49:06  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-31 18:49:11  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-31 18:49:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-31 18:49:23  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-31 18:49:28  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-31 18:49:34  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-31 18:49:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-03-31 18:49:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-31 18:49:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-31 18:49:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-31 18:50:02  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-31 18:50:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-03-31 18:50:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-31 18:50:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-31 18:50:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-31 18:50:39  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-31 18:50:40  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-31 18:50:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-03-31 18:50:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-31 18:50:58  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-31 18:51:04  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-31 18:51:10  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-31 18:51:16  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 18:51:21  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 18:51:27  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-31 18:51:33  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 18:51:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-31 18:51:45  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-31 18:51:51  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-31 18:51:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-31 18:52:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-31 18:52:09  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-31 18:52:15  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-31 18:52:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-31 18:52:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-31 18:52:33  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-31 18:52:39  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 18:52:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-31 18:52:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-31 18:52:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-31 18:53:03  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-31 18:53:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-31 18:53:14  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-31 18:53:20  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-31 18:53:26  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-31 18:53:32  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-31 18:53:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-31 18:53:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-31 18:53:50  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-03-31 18:53:55  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-31 18:54:01  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-31 18:54:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-31 18:54:13  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-31 18:54:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-31 18:54:25  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-31 18:54:31  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-31 18:54:37  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-31 18:54:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-31 18:54:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-31 18:54:49  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-31 18:54:55  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-31 18:55:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-31 18:55:08  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-31 18:55:19  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-31 18:55:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-31 18:55:30  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-31 18:55:36  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-31 18:55:42  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-31 18:55:48  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-31 18:55:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-31 18:56:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-31 18:56:06  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-31 18:56:12  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-31 18:56:18  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-31 18:56:24  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-31 18:56:30  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-31 18:56:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-31 18:56:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-31 18:56:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-31 18:56:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-31 18:56:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-31 18:57:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-31 18:57:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-31 18:57:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-31 18:57:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-31 18:57:21  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-31 18:57:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-31 18:57:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-31 18:57:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-31 18:57:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-31 18:57:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-31 18:57:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-31 18:57:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-31 18:57:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-31 18:58:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-31 18:58:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-31 18:58:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-31 18:58:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-31 18:58:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-31 18:58:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-31 18:58:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-31 18:58:33  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-31 18:58:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-31 18:58:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-31 18:58:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-31 18:58:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-31 18:58:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-31 18:59:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-31 18:59:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-31 18:59:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-31 18:59:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-31 18:59:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-31 18:59:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-31 18:59:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-31 18:59:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-31 18:59:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-31 18:59:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-31 18:59:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-31 18:59:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-31 18:59:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-31 18:59:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-31 19:00:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-31 19:00:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-31 19:00:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-31 19:00:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-31 19:00:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-31 19:00:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-31 19:00:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-31 19:00:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-31 19:00:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-31 19:00:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-31 19:00:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-31 19:00:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-31 19:00:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-31 19:00:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-31 19:01:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-31 19:01:08  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-31 19:01:14  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-31 19:01:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-31 19:01:26  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-31 19:01:27  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-31 19:01:32  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-31 19:01:38  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-31 19:01:45  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-31_19-01-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial?_prerender {"code":"ECONNRESET"}
2017-03-31 19:03:50  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-31 19:03:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-31 19:04:02  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-31 19:04:08  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-31 19:04:14  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-31 19:04:20  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-31 19:04:26  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-31 19:04:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-31 19:04:39  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-31 19:04:45  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-31 19:04:51  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-31 19:04:57  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-31 19:05:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-31 19:05:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-31 19:05:16  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-31 19:05:22  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-31 19:05:28  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-31 19:05:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-31 19:05:40  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-31 19:05:46  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-31 19:05:52  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-31 19:05:57  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-31 19:06:03  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-31 19:06:10  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-31 19:06:15  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-31 19:06:22  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-31 19:06:28  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-31 19:06:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-31 19:06:39  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-31 19:06:45  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-31 19:06:51  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-31 19:06:57  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-31 19:07:03  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-31 19:07:09  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-31 19:07:15  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-31 19:07:20  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-31 19:07:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-31 19:07:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-31 19:07:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-31 19:07:44  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-31 19:07:50  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-31 19:07:56  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-31 19:08:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-31 19:08:08  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-31 19:08:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-31 19:08:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-31 19:08:25  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-31 19:08:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-31 19:08:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-31 19:08:42  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-31 19:08:48  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-31 19:08:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-31 19:09:00  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-31 19:09:06  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-31 19:09:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-31 19:09:18  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-31 19:09:24  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-31 19:09:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-31 19:09:36  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-31 19:09:42  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-31 19:09:47  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-31 19:09:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-31 19:09:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-31 19:10:05  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-31 19:10:11  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-31 19:10:17  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-31 19:10:23  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-31 19:10:29  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-31 19:10:35  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-31 19:10:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-31 19:10:46  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-31 19:10:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-31 19:10:58  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-31 19:11:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-31 19:11:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-31 19:11:16  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-31 19:11:22  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-31 19:11:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-31 19:11:34  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-31 19:11:39  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-31 19:11:45  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-31 19:11:51  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-31 19:11:57  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-31 19:12:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-31 19:12:08  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-31 19:12:14  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-31 19:12:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-31 19:12:26  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-31 19:12:32  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-31 19:12:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-31 19:12:44  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-31 19:12:50  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-31 19:12:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-31 19:13:02  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-31 19:13:07  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-31 19:13:13  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-31 19:13:19  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-31 19:13:25  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-31 19:13:31  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-31 19:13:37  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-31 19:13:42  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-31 19:13:48  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-31 19:13:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-31 19:14:00  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-31 19:14:06  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-31 19:14:12  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-31 19:14:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-31 19:14:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-31 19:14:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-31 19:14:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-31 19:14:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-31 19:14:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-31 19:14:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-31 19:14:59  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-31 19:15:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-31 19:15:11  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-31 19:15:17  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-31 19:15:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-31 19:15:28  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-31 19:15:34  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-31 19:15:40  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-31 19:15:46  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-31 19:15:52  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-31 19:15:58  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-31 19:16:04  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-31 19:16:10  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-31 19:16:16  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-31 19:16:22  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-31 19:16:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-31 19:16:34  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-31 19:16:40  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-31 19:16:46  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-31 19:16:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-31 19:16:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-31 19:17:03  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-31 19:17:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-31 19:17:14  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-31 19:17:20  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-31 19:17:26  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-31 19:17:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-31 19:17:38  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-31 19:17:44  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-31 19:17:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-31 19:17:55  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-03-31 19:18:01  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-31 19:18:06  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-31 19:18:12  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-31 19:18:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-31 19:18:24  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-31 19:18:29  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-31 19:18:35  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-31 19:18:41  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-31 19:18:47  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-31 19:18:52  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-31 19:18:58  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-31 19:19:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-31 19:19:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-31 19:19:15  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-31 19:19:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-31 19:19:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-31 19:19:32  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-31 19:19:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-31 19:19:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-31 19:19:50  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-31 19:19:55  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-31 19:20:00  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-31 19:20:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-31 19:20:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-31 19:20:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-31 19:20:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-31 19:20:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-31 19:20:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-31 19:20:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-31 19:20:46  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-31 19:20:51  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-31 19:20:57  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-31 19:21:03  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-31 19:21:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-31 19:21:14  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-31 19:21:19  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-31 19:21:25  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-31 19:21:32  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-31 19:21:38  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-31 19:21:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-31 19:21:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-31 19:21:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-31 19:22:01  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-03-31 19:22:02  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-31 19:22:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-31 19:22:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-31 19:22:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-31 19:22:26  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-31 19:22:34  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-03-31 19:22:43  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-31 19:22:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-31 19:22:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-31 19:23:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-31 19:23:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-31 19:23:11  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-31 19:23:16  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-31 19:23:22  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-31 19:23:28  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-31 19:23:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-31 19:23:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-31 19:23:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-31 19:23:51  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-31 19:23:57  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-03-31 19:24:03  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-31 19:24:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-31 19:24:14  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-31 19:24:20  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-31 19:24:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-31 19:24:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-31 19:24:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-31 19:24:44  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-31 19:24:49  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-31 19:24:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-31 19:25:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-31 19:25:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-31 19:25:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-31 19:25:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-31 19:25:22  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-31 19:25:28  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-31 19:25:33  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-31 19:25:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-31 19:25:43  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-31 19:25:49  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-31 19:25:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-31 19:26:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-31 19:26:05  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-31 19:26:10  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-31 19:26:16  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-31 19:26:21  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-31 19:26:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-31 19:26:32  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-31 19:26:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-31 19:26:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-31 19:26:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-31 19:26:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-31 19:27:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-31 19:27:07  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-31 19:27:12  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-31 19:27:17  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-31 19:27:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-31 19:27:28  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-31 19:27:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-31 19:27:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-31 19:27:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-31 19:27:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 19:27:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 19:28:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 19:28:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 19:28:11  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-31 19:28:16  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 19:28:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 19:28:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-31 19:28:32  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-31 19:28:37  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-31 19:28:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-31 19:28:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-31 19:28:54  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-31 19:28:59  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-31 19:29:04  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-31 19:29:09  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-31 19:29:15  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-31 19:29:20  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-31 19:29:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-31 19:29:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-31 19:29:36  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-31 19:29:42  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-31 19:29:47  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-31 19:29:52  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-31 19:29:58  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-31 19:30:03  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-31 19:30:08  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-31 19:30:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 19:30:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 19:30:24  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 19:30:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 19:30:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 19:30:44  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-31 19:30:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 19:31:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 19:31:05  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 19:31:10  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 19:31:16  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-31 19:31:21  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 19:31:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 19:31:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 19:31:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-31 19:31:41  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-03-31_19-31-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-?_prerender {"code":"ECONNRESET"}
2017-03-31 19:33:47  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-03-31_20-01-46 Restart Xvfb...
2017-03-31_20-31-46 Restart Xvfb...
2017-03-31_21-01-46 Restart Xvfb...
2017-03-31 21:31:45 reset updateRequest
2017-03-31 21:31:46  - 14968  http://www.lymphomahub.com/
2017-03-31_21-31-46 Restart Xvfb...
2017-03-31 21:31:51  - 14968  http://www.lymphomahub.com/
2017-03-31 21:31:52  - 14968  http://www.lymphomahub.com/about
2017-03-31 21:31:55  - 14968  http://www.lymphomahub.com/about
2017-03-31 21:31:59  - 14968  http://www.lymphomahub.com/terms
2017-03-31 21:32:00  - 14968  http://www.lymphomahub.com/terms
2017-03-31 21:32:04  - 14968  http://www.lymphomahub.com/undefined
2017-03-31 21:32:04  - 14968  http://www.lymphomahub.com/therapies
2017-03-31 21:32:05  - 14968  http://www.lymphomahub.com/therapies
2017-03-31 21:32:14  - 14968  http://www.lymphomahub.com/newsletter
2017-03-31 21:32:15  - 14968  http://www.lymphomahub.com/newsletter
2017-03-31 21:32:19  - 14968  http://www.lymphomahub.com/cookie-policy
2017-03-31 21:32:20  - 14968  http://www.lymphomahub.com/cookie-policy
2017-03-31 21:32:23  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-03-31 21:32:24  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-03-31 21:32:30  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-03-31 21:32:30  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-03-31 21:32:37  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-03-31 21:32:37  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-03-31 21:32:43  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-03-31 21:32:49  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-03-31 21:32:54  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-03-31 21:33:00  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-03-31 21:33:06  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-03-31 21:33:12  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-03-31 21:33:18  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-03-31 21:33:24  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-03-31 21:33:30  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-03-31 21:33:36  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-03-31 21:33:41  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-03-31 21:33:47  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-03-31 21:33:53  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-03-31 21:33:58  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-03-31 21:34:04  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-03-31 21:34:10  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-03-31 21:34:16  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-03-31 21:34:21  - 14968  http://www.lymphomahub.com/about/secretariat
2017-03-31 21:34:26  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-03-31 21:34:32  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-03-31 21:34:37  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-03-31 21:34:43  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-03-31 21:34:49  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-03-31 21:34:55  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-03-31 21:35:05  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-03-31 21:35:11  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-03-31 21:35:17  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-03-31 21:35:23  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-03-31 21:35:28  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-03-31 21:35:34  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-03-31 21:35:40  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-03-31 21:35:45  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-03-31 21:35:51  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-03-31 21:35:57  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-03-31 21:36:02  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-03-31 21:36:08  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-03-31 21:36:14  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-03-31 21:36:20  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-03-31 21:36:25  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-03-31 21:36:31  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-03-31 21:36:37  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-03-31 21:36:42  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-03-31 21:36:48  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-03-31 21:36:54  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-03-31 21:37:00  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-03-31 21:37:06  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-03-31 21:37:11  - 14968  http://www.lymphomahub.com/medical-information
2017-03-31 21:37:17  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-03-31 21:37:23  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-03-31 21:37:28  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-03-31 21:37:34  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-03-31 21:37:40  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-03-31 21:37:45  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-03-31 21:37:51  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-03-31 21:37:57  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-03-31 21:38:02  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-03-31 21:38:08  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-03-31 21:38:14  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-03-31 21:38:20  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-03-31 21:38:21  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-03-31 21:38:26  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-03-31 21:38:32  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-03-31 21:38:38  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-03-31 21:38:43  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-03-31 21:38:49  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-03-31 21:38:55  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-03-31 21:39:00  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-03-31 21:39:06  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-03-31 21:39:12  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-03-31 21:39:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-03-31 21:39:23  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-03-31 21:39:29  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-03-31 21:39:35  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-03-31 21:39:40  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-03-31 21:39:46  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-03-31 21:39:52  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-03-31 21:39:57  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-03-31 21:40:03  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-03-31 21:40:09  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-03-31 21:40:14  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-03-31 21:40:20  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-03-31 21:40:26  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-03-31 21:40:31  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-03-31 21:40:37  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-03-31 21:40:43  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-03-31 21:40:48  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-03-31 21:40:54  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-03-31 21:41:00  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-03-31 21:41:06  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-03-31 21:41:11  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-03-31 21:41:13  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-03-31 21:41:18  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-03-31 21:41:24  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-03-31 21:41:30  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-03-31 21:41:36  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-03-31 21:41:42  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-03-31 21:41:47  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-03-31 21:41:53  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-03-31 21:41:59  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-03-31 21:42:03  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-03-31 21:42:04  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-03-31 21:42:10  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-03-31 21:42:16  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-03-31 21:42:21  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-03-31 21:42:27  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-03-31 21:42:33  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-03-31 21:42:34  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-03-31 21:42:40  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-03-31 21:42:46  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-03-31 21:42:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-03-31 21:42:56  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-03-31 21:43:02  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-03-31 21:43:07  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-03-31 21:43:12  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-03-31 21:43:17  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-03-31 21:43:23  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-03-31 21:43:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-03-31 21:43:34  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-03-31 21:43:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-03-31 21:43:46  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-03-31 21:43:51  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-03-31 21:43:52  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-03-31 21:43:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-03-31 21:44:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-03-31 21:44:09  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-03-31 21:44:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-03-31 21:44:21  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-03-31 21:44:26  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-03-31 21:44:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-03-31 21:44:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-03-31 21:44:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-03-31 21:44:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-03-31 21:44:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-03-31 21:44:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-03-31 21:45:04  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-03-31 21:45:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-03-31 21:45:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-03-31 21:45:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-03-31 21:45:26  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-03-31 21:45:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-03-31 21:45:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-03-31 21:45:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-03-31 21:45:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-03-31 21:45:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-03-31 21:45:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-03-31 21:46:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-03-31 21:46:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-03-31 21:46:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-03-31 21:46:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-03-31 21:46:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-03-31 21:46:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-03-31 21:46:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-03-31 21:46:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-03-31 21:46:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-03-31 21:46:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-03-31 21:46:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-03-31 21:47:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-03-31 21:47:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-03-31 21:47:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-03-31 21:47:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-03-31 21:47:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-03-31 21:47:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-03-31 21:47:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-03-31 21:47:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-03-31 21:47:46  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-03-31 21:47:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-03-31 21:47:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-03-31 21:48:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-03-31 21:48:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-03-31 21:48:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-03-31 21:48:17  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-03-31 21:48:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-03-31 21:48:28  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-03-31 21:48:34  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-03-31 21:48:40  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-03-31 21:48:46  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-03-31 21:48:51  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-03-31 21:48:57  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-03-31 21:49:03  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-03-31 21:49:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-03-31 21:49:14  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-03-31 21:49:19  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-03-31 21:49:25  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-03-31 21:49:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-03-31 21:49:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-03-31 21:49:42  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-03-31 21:49:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-03-31 21:49:53  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-03-31 21:49:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-03-31 21:50:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-03-31 21:50:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-03-31 21:50:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-03-31 21:50:23  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-31 21:50:24  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-03-31 21:50:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-03-31 21:50:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-03-31 21:50:42  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-03-31 21:50:48  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-03-31 21:50:53  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-03-31 21:50:59  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 21:51:05  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 21:51:11  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-03-31 21:51:17  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 21:51:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-03-31 21:51:29  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-03-31 21:51:35  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-03-31 21:51:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-03-31 21:51:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-03-31 21:51:52  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-03-31 21:51:58  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-03-31 21:52:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-03-31 21:52:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-03-31 21:52:15  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-03-31 21:52:21  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-03-31 21:52:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-03-31 21:52:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-03-31 21:52:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-03-31 21:52:45  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-03-31 21:52:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-03-31 21:52:57  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-03-31 21:53:03  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-03-31 21:53:09  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-03-31 21:53:15  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-03-31 21:53:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-03-31 21:53:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-03-31 21:53:32  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-03-31 21:53:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-03-31 21:53:45  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-03-31 21:53:51  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-03-31 21:53:57  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-03-31 21:54:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-03-31 21:54:09  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-03-31 21:54:15  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-03-31 21:54:21  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-03-31 21:54:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-03-31 21:54:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-03-31 21:54:33  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-03-31 21:54:39  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-03-31 21:54:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-03-31 21:54:51  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-03-31 21:54:57  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-03-31 21:55:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-03-31 21:55:08  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-03-31 21:55:15  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-03-31 21:55:21  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-03-31 21:55:26  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-03-31 21:55:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-03-31 21:55:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-03-31 21:55:44  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-03-31 21:55:50  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-03-31 21:55:56  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-03-31 21:56:02  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-03-31 21:56:08  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-03-31 21:56:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-03-31 21:56:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-03-31 21:56:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-03-31 21:56:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-03-31 21:56:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-03-31 21:56:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-03-31 21:56:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-03-31 21:56:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-03-31 21:56:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-03-31 21:56:59  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-03-31 21:57:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-03-31 21:57:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-03-31 21:57:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-03-31 21:57:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-03-31 21:57:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-03-31 21:57:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-03-31 21:57:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-03-31 21:57:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-03-31 21:57:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-03-31 21:57:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-03-31 21:57:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-03-31 21:57:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-03-31 21:57:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-03-31 21:57:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-03-31 21:58:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-03-31 21:58:07  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-03-31 21:58:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-03-31 21:58:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-03-31 21:58:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-03-31 21:58:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-03-31 21:58:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-03-31 21:58:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-03-31 21:58:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-03-31 21:58:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-03-31 21:58:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-03-31 21:58:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-03-31 21:58:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-03-31 21:59:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-03-31 21:59:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-03-31 21:59:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-03-31 21:59:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-03-31 21:59:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-03-31 21:59:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-03-31 21:59:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-03-31 21:59:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-03-31 21:59:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-03-31 21:59:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-03-31 21:59:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-03-31 21:59:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-03-31 21:59:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-03-31 21:59:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-03-31 22:00:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-03-31 22:00:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-03-31 22:00:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-03-31 22:00:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-03-31 22:00:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-03-31 22:00:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-03-31 22:00:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-03-31 22:00:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-03-31 22:00:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-03-31 22:00:43  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-03-31 22:00:49  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-03-31 22:00:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-03-31 22:01:01  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-03-31 22:01:02  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-03-31 22:01:08  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-03-31 22:01:14  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-03-31 22:01:20  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-03-31 22:01:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-03-31 22:01:37  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-03-31 22:01:43  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-31_22-01-46 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll?_prerender {"code":"ECONNRESET"}
2017-03-31 22:03:48  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-03-31 22:03:53  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-03-31 22:03:59  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-03-31 22:04:05  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-03-31 22:04:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-03-31 22:04:17  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-03-31 22:04:23  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-03-31 22:04:30  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-03-31 22:04:35  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-03-31 22:04:41  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-03-31 22:04:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-03-31 22:04:56  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-03-31 22:05:02  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-03-31 22:05:08  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-03-31 22:05:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-03-31 22:05:20  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-31 22:05:26  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-03-31 22:05:31  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-03-31 22:05:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-03-31 22:05:43  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-03-31 22:05:49  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-03-31 22:05:55  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-03-31 22:06:01  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-03-31 22:06:07  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-03-31 22:06:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-03-31 22:06:18  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-03-31 22:06:24  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-03-31 22:06:34  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-03-31 22:06:40  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-03-31 22:06:46  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-03-31 22:06:52  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-03-31 22:06:58  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-03-31 22:07:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-03-31 22:07:14  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-03-31 22:07:20  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-03-31 22:07:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-03-31 22:07:34  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-03-31 22:07:40  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-03-31 22:07:46  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-03-31 22:07:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-03-31 22:07:58  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-03-31 22:08:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-03-31 22:08:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-03-31 22:08:15  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-03-31 22:08:20  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-03-31 22:08:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-03-31 22:08:32  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-03-31 22:08:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-03-31 22:08:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-03-31 22:08:50  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-03-31 22:08:57  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-03-31 22:09:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-03-31 22:09:08  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-03-31 22:09:14  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-03-31 22:09:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-03-31 22:09:26  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-03-31 22:09:31  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-03-31 22:09:37  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-03-31 22:09:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-03-31 22:09:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-03-31 22:09:55  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-03-31 22:10:01  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-03-31 22:10:07  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-03-31 22:10:13  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-03-31 22:10:19  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-03-31 22:10:25  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-03-31 22:10:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-03-31 22:10:37  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-03-31 22:10:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-03-31 22:10:48  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-03-31 22:10:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-03-31 22:11:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-03-31 22:11:06  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-03-31 22:11:12  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-03-31 22:11:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-03-31 22:11:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-03-31 22:11:29  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-03-31 22:11:35  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-03-31 22:11:41  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-03-31 22:11:46  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-03-31 22:11:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-03-31 22:11:58  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-03-31 22:12:04  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-03-31 22:12:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-03-31 22:12:16  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-03-31 22:12:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-03-31 22:12:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-03-31 22:12:34  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-03-31 22:12:39  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-03-31 22:12:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-03-31 22:12:52  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-03-31 22:12:57  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-03-31 22:13:03  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-03-31 22:13:09  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-03-31 22:13:15  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-03-31 22:13:21  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-03-31 22:13:27  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-03-31 22:13:33  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-03-31 22:13:39  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-03-31 22:13:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-03-31 22:13:56  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-03-31 22:14:02  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-03-31 22:14:08  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-03-31 22:14:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-03-31 22:14:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-03-31 22:14:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-03-31 22:14:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-03-31 22:14:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-03-31 22:14:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-03-31 22:14:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-03-31 22:14:55  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-03-31 22:15:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-03-31 22:15:07  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-03-31 22:15:13  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-03-31 22:15:19  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-03-31 22:15:24  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-03-31 22:15:30  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-03-31 22:15:36  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-03-31 22:15:42  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-03-31 22:15:48  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-03-31 22:15:54  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-03-31 22:16:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-03-31 22:16:06  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-03-31 22:16:12  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-03-31 22:16:18  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-03-31 22:16:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-03-31 22:16:30  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-03-31 22:16:36  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-03-31 22:16:41  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-03-31 22:16:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-03-31 22:16:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-03-31 22:16:59  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-03-31 22:17:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-03-31 22:17:16  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-03-31 22:17:22  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-03-31 22:17:28  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-03-31 22:17:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-03-31 22:17:39  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-03-31 22:17:46  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-03-31 22:17:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-03-31 22:18:02  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-03-31 22:18:07  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-03-31 22:18:13  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-03-31 22:18:18  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-03-31 22:18:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-03-31 22:18:30  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-03-31 22:18:36  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-03-31 22:18:42  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-03-31 22:18:48  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-03-31 22:18:53  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-03-31 22:18:59  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-03-31 22:19:05  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-03-31 22:19:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-03-31 22:19:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-03-31 22:19:21  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-03-31 22:19:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-03-31 22:19:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-03-31 22:19:43  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-03-31 22:19:48  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-03-31 22:19:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-03-31 22:20:00  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-03-31 22:20:06  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-03-31 22:20:12  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-03-31 22:20:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-03-31 22:20:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-03-31 22:20:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-03-31 22:20:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-03-31 22:20:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-03-31 22:20:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-03-31 22:20:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-03-31 22:20:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-03-31 22:21:03  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-03-31 22:21:08  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-03-31 22:21:14  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-03-31 22:21:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-03-31 22:21:25  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-03-31 22:21:30  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-03-31 22:21:36  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-03-31 22:21:42  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-03-31 22:21:48  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-03-31 22:21:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-03-31 22:21:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-03-31 22:22:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-03-31 22:22:11  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-03-31 22:22:12  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-03-31 22:22:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-03-31 22:22:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-03-31 22:22:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-03-31 22:22:35  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-03-31 22:22:41  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-03-31 22:22:47  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-03-31 22:22:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-03-31 22:22:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-03-31 22:23:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-03-31 22:23:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-03-31 22:23:15  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-03-31 22:23:21  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-03-31 22:23:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-03-31 22:23:32  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-03-31 22:23:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-03-31 22:23:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-03-31 22:23:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-03-31 22:23:55  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-03-31 22:24:01  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-03-31 22:24:07  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-03-31 22:24:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-03-31 22:24:19  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-03-31 22:24:24  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-03-31 22:24:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-03-31 22:24:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-03-31 22:24:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-03-31 22:24:48  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-03-31 22:24:53  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-03-31 22:24:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-03-31 22:25:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-03-31 22:25:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-03-31 22:25:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-03-31 22:25:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-03-31 22:25:31  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-31 22:25:36  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-31 22:25:41  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-03-31 22:25:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-31 22:25:52  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-03-31 22:25:57  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-03-31 22:26:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-03-31 22:26:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-03-31 22:26:14  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-03-31 22:26:19  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-03-31 22:26:25  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-03-31 22:26:31  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-03-31 22:26:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-03-31 22:26:42  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-03-31 22:26:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-03-31 22:26:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-03-31 22:26:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-03-31 22:27:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-03-31 22:27:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-03-31 22:27:17  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-03-31 22:27:22  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-03-31 22:27:27  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-03-31 22:27:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-03-31 22:27:39  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-03-31 22:27:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-03-31 22:27:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-03-31 22:27:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-03-31 22:28:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 22:28:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 22:28:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 22:28:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 22:28:22  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-03-31 22:28:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 22:28:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-03-31 22:28:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-03-31 22:28:43  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-03-31 22:28:49  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-03-31 22:28:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-03-31 22:28:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-03-31 22:29:05  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-03-31 22:29:11  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-03-31 22:29:16  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-03-31 22:29:21  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-03-31 22:29:27  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-03-31 22:29:32  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-03-31 22:29:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-03-31 22:29:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-03-31 22:29:49  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-03-31 22:29:54  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-03-31 22:29:59  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-03-31 22:30:05  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-03-31 22:30:10  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-03-31 22:30:16  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-03-31 22:30:21  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-03-31 22:30:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 22:30:32  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 22:30:37  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 22:30:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 22:30:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-03-31 22:30:53  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-03-31 22:30:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 22:31:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 22:31:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 22:31:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 22:31:20  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-03-31 22:31:25  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 22:31:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 22:31:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-03-31 22:31:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-03-31 22:31:46  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-03-31_22-31-46 Restart Xvfb...
2017-03-31_23-01-46 Restart Xvfb...
2017-03-31_23-31-47 Restart Xvfb...
2017-04-01_00-01-47 Restart Xvfb...
2017-04-01 00:31:45 reset updateRequest
2017-04-01_00-31-47 Restart Xvfb...
2017-04-01 00:31:47  - 14968  http://www.lymphomahub.com/
2017-04-01 00:31:51  - 14968  http://www.lymphomahub.com/
2017-04-01 00:31:52  - 14968  http://www.lymphomahub.com/about
2017-04-01 00:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-01 00:32:00  - 14968  http://www.lymphomahub.com/terms
2017-04-01 00:32:00  - 14968  http://www.lymphomahub.com/terms
2017-04-01 00:32:04  - 14968  http://www.lymphomahub.com/undefined
2017-04-01 00:32:05  - 14968  http://www.lymphomahub.com/undefined
2017-04-01 00:32:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-01 00:32:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-01 00:32:16  - 14968  http://www.lymphomahub.com/newsletter
2017-04-01 00:32:17  - 14968  http://www.lymphomahub.com/newsletter
2017-04-01 00:32:21  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-01 00:32:22  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-01 00:32:25  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-01 00:32:26  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-01 00:32:31  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-01 00:32:31  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-01 00:32:38  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-01 00:32:38  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-01 00:32:45  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-01 00:32:50  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-01 00:32:56  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-01 00:33:02  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-01 00:33:07  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-01 00:33:13  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-01 00:33:19  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-01 00:33:24  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-01 00:33:30  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-01 00:33:36  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-01 00:33:42  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-01 00:33:48  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-01 00:33:53  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-01 00:33:59  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-01 00:34:05  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-01 00:34:11  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-01 00:34:16  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-01 00:34:22  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-01 00:34:27  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-01 00:34:32  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-01 00:34:38  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-01 00:34:44  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-01 00:34:50  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-01 00:34:55  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-01 00:35:01  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-01 00:35:07  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-01 00:35:13  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-01 00:35:19  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-01 00:35:25  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-01 00:35:31  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-01 00:35:36  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-01 00:35:42  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-01 00:35:48  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-01 00:35:53  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-01 00:35:59  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-01 00:36:05  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-01 00:36:10  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-01 00:36:16  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-01 00:36:22  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-01 00:36:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-01 00:36:33  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-01 00:36:39  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-01 00:36:45  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-01 00:36:52  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-01 00:36:58  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-01 00:37:03  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-01 00:37:09  - 14968  http://www.lymphomahub.com/medical-information
2017-04-01 00:37:14  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-01 00:37:20  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-01 00:37:26  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-01 00:37:32  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-01 00:37:37  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-01 00:37:43  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-01 00:37:49  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-01 00:37:55  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-01 00:38:00  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-01 00:38:06  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-01 00:38:11  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-01 00:38:17  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-01 00:38:18  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-01 00:38:24  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-01 00:38:30  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-01 00:38:35  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-01 00:38:41  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-01 00:38:47  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-01 00:38:52  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-01 00:38:58  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-01 00:39:05  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-01 00:39:10  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-01 00:39:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-01 00:39:22  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-01 00:39:27  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-01 00:39:33  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-01 00:39:38  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-01 00:39:44  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-01 00:39:50  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-01 00:39:56  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-01 00:40:01  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-01 00:40:07  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-01 00:40:13  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-01 00:40:18  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-01 00:40:24  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-01 00:40:30  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-01 00:40:36  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-01 00:40:41  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-01 00:40:47  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-01 00:40:53  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-01 00:40:58  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-01 00:41:04  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-01 00:41:10  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-01 00:41:11  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-01 00:41:17  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-01 00:41:23  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-01 00:41:28  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-01 00:41:34  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-01 00:41:40  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-01 00:41:45  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-01 00:41:52  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-01 00:41:57  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-01 00:42:02  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-01 00:42:03  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-01 00:42:08  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-01 00:42:14  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-01 00:42:20  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-01 00:42:25  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-01 00:42:31  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-01 00:42:32  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-01 00:42:38  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-01 00:42:44  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-01 00:42:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-01 00:42:57  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-01 00:43:02  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-01 00:43:08  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-01 00:43:13  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-01 00:43:18  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-01 00:43:23  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-01 00:43:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-01 00:43:34  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-01 00:43:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-01 00:43:51  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-01 00:43:56  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-01 00:43:57  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-01 00:44:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-01 00:44:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-01 00:44:15  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-01 00:44:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-01 00:44:26  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-01 00:44:32  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-01 00:44:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-01 00:44:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-01 00:44:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-01 00:44:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-01 00:44:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-01 00:45:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-01 00:45:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-01 00:45:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-01 00:45:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-01 00:45:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-01 00:45:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-01 00:45:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-01 00:45:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-01 00:45:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-01 00:45:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-01 00:45:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-01 00:46:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-01 00:46:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-01 00:46:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-01 00:46:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-01 00:46:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-01 00:46:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-01 00:46:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-01 00:46:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-01 00:46:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-01 00:46:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-01 00:47:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-01 00:47:05  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-01 00:47:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-01 00:47:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-01 00:47:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-01 00:47:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-01 00:47:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-01 00:47:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-01 00:47:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-01 00:47:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-01 00:47:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-01 00:47:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-01 00:48:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-01 00:48:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-01 00:48:15  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-01 00:48:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-01 00:48:25  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-01 00:48:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-01 00:48:36  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-01 00:48:42  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-01 00:48:48  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-01 00:48:53  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-01 00:48:59  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-01 00:49:04  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-01 00:49:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-01 00:49:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-01 00:49:21  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-01 00:49:27  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-01 00:49:32  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-01 00:49:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-01 00:49:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-01 00:49:49  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-01 00:49:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-01 00:50:00  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-01 00:50:06  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-01 00:50:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-01 00:50:18  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-01 00:50:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-01 00:50:30  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-01 00:50:31  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-01 00:50:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-01 00:50:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-01 00:50:48  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-01 00:50:54  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-01 00:51:00  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-01 00:51:05  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 00:51:11  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 00:51:17  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-01 00:51:23  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 00:51:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-01 00:51:34  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-01 00:51:40  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-01 00:51:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-01 00:51:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-01 00:51:58  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-01 00:52:04  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-01 00:52:09  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-01 00:52:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-01 00:52:21  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-01 00:52:27  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 00:52:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-01 00:52:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-01 00:52:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-01 00:52:51  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-01 00:52:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-01 00:53:03  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-01 00:53:09  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-01 00:53:15  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-01 00:53:20  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-01 00:53:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-01 00:53:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-01 00:53:38  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-01 00:53:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-01 00:53:50  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-01 00:53:55  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-01 00:54:01  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-01 00:54:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-01 00:54:13  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-01 00:54:19  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-01 00:54:25  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-01 00:54:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-01 00:54:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-01 00:54:37  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-01 00:54:44  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-01 00:54:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-01 00:54:55  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-01 00:55:01  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-01 00:55:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-01 00:55:13  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-01 00:55:19  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-01 00:55:24  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-01 00:55:30  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-01 00:55:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-01 00:55:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-01 00:55:48  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-01 00:55:53  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-01 00:55:59  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-01 00:56:05  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-01 00:56:11  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-01 00:56:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-01 00:56:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-01 00:56:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-01 00:56:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-01 00:56:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-01 00:56:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-01 00:56:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-01 00:56:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-01 00:57:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-01 00:57:08  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-01 00:57:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-01 00:57:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-01 00:57:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-01 00:57:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-01 00:57:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-01 00:57:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-01 00:57:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-01 00:57:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-01 00:57:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-01 00:57:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-01 00:57:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-01 00:57:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-01 00:58:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-01 00:58:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-01 00:58:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-01 00:58:15  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-01 00:58:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-01 00:58:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-01 00:58:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-01 00:58:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-01 00:58:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-01 00:58:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-01 00:58:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-01 00:58:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-01 00:58:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-01 00:59:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-01 00:59:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-01 00:59:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-01 00:59:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-01 00:59:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-01 00:59:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-01 00:59:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-01 00:59:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-01 00:59:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-01 00:59:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-01 00:59:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-01 00:59:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-01 00:59:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-01 00:59:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-01 01:00:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-01 01:00:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-01 01:00:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-01 01:00:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-01 01:00:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-01 01:00:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-01 01:00:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-01 01:00:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-01 01:00:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-01 01:00:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-01 01:00:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-01 01:00:50  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-01 01:00:56  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-01 01:01:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-01 01:01:08  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-01 01:01:09  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-01 01:01:15  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-01 01:01:21  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-01 01:01:27  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-01 01:01:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-01 01:01:38  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-01 01:01:44  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-01_01-01-47 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll?_prerender {"code":"ECONNRESET"}
2017-04-01 01:03:49  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-01 01:03:55  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-01 01:04:02  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-01 01:04:08  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-01 01:04:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-01 01:04:20  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-01 01:04:26  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-01 01:04:32  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-01 01:04:38  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-01 01:04:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-01 01:04:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-01 01:04:55  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-01 01:05:01  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-01 01:05:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-01 01:05:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-01 01:05:19  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-01 01:05:25  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-01 01:05:31  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-01 01:05:37  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-01 01:05:42  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-01 01:05:48  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-01 01:05:54  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-01 01:06:00  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-01 01:06:06  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-01 01:06:12  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-01 01:06:18  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-01 01:06:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-01 01:06:29  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-01 01:06:35  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-01 01:06:41  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-01 01:06:47  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-01 01:06:53  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-01 01:06:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-01 01:07:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-01 01:07:11  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-01 01:07:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-01 01:07:23  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-01 01:07:29  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-01 01:07:35  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-01 01:07:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-01 01:07:47  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-01 01:07:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-01 01:07:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-01 01:08:04  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-01 01:08:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-01 01:08:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-01 01:08:21  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-01 01:08:27  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-01 01:08:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-01 01:08:39  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-01 01:08:45  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-01 01:08:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-01 01:08:56  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-01 01:09:02  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-01 01:09:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-01 01:09:14  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-01 01:09:20  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-01 01:09:26  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-01 01:09:32  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-01 01:09:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-01 01:09:43  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-01 01:09:49  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-01 01:09:55  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-01 01:10:00  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-01 01:10:06  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-01 01:10:12  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-01 01:10:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-01 01:10:24  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-01 01:10:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-01 01:10:36  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-01 01:10:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-01 01:10:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-01 01:10:59  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-01 01:11:04  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-01 01:11:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-01 01:11:16  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-01 01:11:22  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-01 01:11:28  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-01 01:11:33  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-01 01:11:39  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-01 01:11:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-01 01:11:50  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-01 01:11:56  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-01 01:12:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-01 01:12:08  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-01 01:12:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-01 01:12:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-01 01:12:26  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-01 01:12:32  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-01 01:12:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-01 01:12:44  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-01 01:12:50  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-01 01:13:01  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-01 01:13:06  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-01 01:13:12  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-01 01:13:18  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-01 01:13:24  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-01 01:13:30  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-01 01:13:36  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-01 01:13:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-01 01:13:48  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-01 01:13:54  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-01 01:14:00  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-01 01:14:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-01 01:14:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-01 01:14:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-01 01:14:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-01 01:14:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-01 01:14:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-01 01:14:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-01 01:14:48  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-01 01:14:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-01 01:14:59  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-01 01:15:06  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-01 01:15:12  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-01 01:15:17  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-01 01:15:23  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-01 01:15:30  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-01 01:15:35  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-01 01:15:41  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-01 01:15:47  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-01 01:15:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-01 01:15:58  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-01 01:16:04  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-01 01:16:10  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-01 01:16:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-01 01:16:22  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-01 01:16:28  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-01 01:16:34  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-01 01:16:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-01 01:16:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-01 01:16:51  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-01 01:16:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-01 01:17:03  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-01 01:17:09  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-01 01:17:15  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-01 01:17:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-01 01:17:26  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-01 01:17:32  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-01 01:17:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-01 01:17:43  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-01 01:17:49  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-01 01:17:55  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-01 01:18:01  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-01 01:18:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-01 01:18:12  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-01 01:18:23  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-01 01:18:29  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-01 01:18:35  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-01 01:18:41  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-01 01:18:47  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-01 01:18:52  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-01 01:18:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-01 01:19:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-01 01:19:09  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-01 01:19:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-01 01:19:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-01 01:19:26  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-01 01:19:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-01 01:19:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-01 01:19:44  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-01 01:19:49  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-01 01:19:55  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-01 01:20:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-01 01:20:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-01 01:20:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-01 01:20:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-01 01:20:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-01 01:20:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-01 01:20:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-01 01:20:41  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-01 01:20:46  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-01 01:20:52  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-01 01:20:58  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-01 01:21:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-01 01:21:09  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-01 01:21:14  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-01 01:21:20  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-01 01:21:26  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-01 01:21:32  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-01 01:21:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-01 01:21:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-01 01:21:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-01 01:21:55  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-01 01:21:56  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-01 01:22:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-01 01:22:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-01 01:22:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-01 01:22:19  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-01 01:22:25  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-01 01:22:30  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-01 01:22:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-01 01:22:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-01 01:22:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-01 01:22:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-01 01:22:59  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-01 01:23:04  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-01 01:23:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-01 01:23:16  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-01 01:23:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-01 01:23:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-01 01:23:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-01 01:23:39  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-01 01:23:45  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-01 01:23:50  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-01 01:23:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-01 01:24:01  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-01 01:24:06  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-01 01:24:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-01 01:24:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-01 01:24:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-01 01:24:30  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-01 01:24:35  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-01 01:24:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-01 01:24:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-01 01:24:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-01 01:24:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-01 01:25:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-01 01:25:09  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-01 01:25:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-01 01:25:19  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-01 01:25:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-01 01:25:30  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-01 01:25:35  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-01 01:25:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-01 01:25:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-01 01:25:52  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-01 01:25:57  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-01 01:26:03  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-01 01:26:08  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-01 01:26:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-01 01:26:19  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-01 01:26:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-01 01:26:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-01 01:26:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-01 01:26:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-01 01:26:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-01 01:26:54  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-01 01:26:59  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-01 01:27:05  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-01 01:27:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-01 01:27:16  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-01 01:27:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-01 01:27:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-01 01:27:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-01 01:27:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 01:27:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 01:27:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 01:27:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 01:27:59  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-01 01:28:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 01:28:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 01:28:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-01 01:28:21  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-01 01:28:27  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-01 01:28:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-01 01:28:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-01 01:28:43  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-01 01:28:49  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-01 01:28:54  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-01 01:28:59  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-01 01:29:04  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-01 01:29:10  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-01 01:29:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-01 01:29:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-01 01:29:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-01 01:29:32  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-01 01:29:37  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-01 01:29:42  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-01 01:29:47  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-01 01:29:53  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-01 01:29:58  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-01 01:30:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 01:30:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 01:30:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 01:30:21  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 01:30:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 01:30:31  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-01 01:30:37  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 01:30:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 01:30:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 01:30:53  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 01:30:58  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-01 01:31:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 01:31:08  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 01:31:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 01:31:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-01 01:31:24  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-01_01-31-47 Restart Xvfb...
2017-04-01_02-01-47 Restart Xvfb...
2017-04-01_02-31-47 Restart Xvfb...
2017-04-01_03-01-47 Restart Xvfb...
2017-04-01 03:31:45 reset updateRequest
2017-04-01_03-31-47 Restart Xvfb...
2017-04-01 03:31:50  - 14968  http://www.lymphomahub.com/
2017-04-01 03:31:51  - 14968  http://www.lymphomahub.com/
2017-04-01 03:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-01 03:31:57  - 14968  http://www.lymphomahub.com/about
2017-04-01 03:32:03  - 14968  http://www.lymphomahub.com/terms
2017-04-01 03:32:07  - 14968  http://www.lymphomahub.com/undefined
2017-04-01 03:32:08  - 14968  http://www.lymphomahub.com/therapies
2017-04-01 03:32:15  - 14968  http://www.lymphomahub.com/newsletter
2017-04-01 03:32:18  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-01 03:32:22  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-01 03:32:28  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-01 03:32:34  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-01 03:32:40  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-01 03:32:45  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-01 03:32:51  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-01 03:32:57  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-01 03:33:03  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-01 03:33:08  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-01 03:33:14  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-01 03:33:20  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-01 03:33:26  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-01 03:33:31  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-01 03:33:37  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-01 03:33:43  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-01 03:33:49  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-01 03:33:54  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-01 03:34:00  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-01 03:34:06  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-01 03:34:12  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-01 03:34:18  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-01 03:34:22  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-01 03:34:28  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-01 03:34:34  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-01 03:34:40  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-01 03:34:46  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-01 03:34:52  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-01 03:34:58  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-01 03:35:04  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-01 03:35:09  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-01 03:35:15  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-01 03:35:21  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-01 03:35:26  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-01 03:35:32  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-01 03:35:38  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-01 03:35:44  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-01 03:35:49  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-01 03:35:55  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-01 03:36:01  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-01 03:36:07  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-01 03:36:12  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-01 03:36:18  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-01 03:36:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-01 03:36:30  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-01 03:36:36  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-01 03:36:41  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-01 03:36:47  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-01 03:36:53  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-01 03:36:58  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-01 03:37:04  - 14968  http://www.lymphomahub.com/medical-information
2017-04-01 03:37:09  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-01 03:37:16  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-01 03:37:21  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-01 03:37:27  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-01 03:37:33  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-01 03:37:38  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-01 03:37:44  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-01 03:37:50  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-01 03:37:56  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-01 03:38:01  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-01 03:38:07  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-01 03:38:13  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-01 03:38:14  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-01 03:38:19  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-01 03:38:25  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-01 03:38:31  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-01 03:38:37  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-01 03:38:42  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-01 03:38:48  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-01 03:38:54  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-01 03:38:59  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-01 03:39:05  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-01 03:39:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-01 03:39:17  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-01 03:39:22  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-01 03:39:28  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-01 03:39:34  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-01 03:39:40  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-01 03:39:46  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-01 03:39:51  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-01 03:39:57  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-01 03:40:03  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-01 03:40:08  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-01 03:40:14  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-01 03:40:20  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-01 03:40:26  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-01 03:40:32  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-01 03:40:37  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-01 03:40:43  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-01 03:40:49  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-01 03:40:54  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-01 03:41:00  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-01 03:41:06  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-01 03:41:07  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-01 03:41:12  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-01 03:41:18  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-01 03:41:24  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-01 03:41:29  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-01 03:41:35  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-01 03:41:41  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-01 03:41:47  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-01 03:41:53  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-01 03:41:57  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-01 03:41:58  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-01 03:42:04  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-01 03:42:10  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-01 03:42:15  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-01 03:42:21  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-01 03:42:27  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-01 03:42:28  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-01 03:42:34  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-01 03:42:39  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-01 03:42:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-01 03:42:50  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-01 03:42:56  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-01 03:43:01  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-01 03:43:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-01 03:43:12  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-01 03:43:17  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-01 03:43:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-01 03:43:29  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-01 03:43:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-01 03:43:40  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-01 03:43:45  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-01 03:43:46  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-01 03:43:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-01 03:43:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-01 03:44:06  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-01 03:44:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-01 03:44:17  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-01 03:44:23  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-01 03:44:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-01 03:44:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-01 03:44:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-01 03:44:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-01 03:44:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-01 03:44:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-01 03:45:02  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-01 03:45:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-01 03:45:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-01 03:45:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-01 03:45:24  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-01 03:45:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-01 03:45:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-01 03:45:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-01 03:45:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-01 03:45:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-01 03:45:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-01 03:46:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-01 03:46:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-01 03:46:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-01 03:46:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-01 03:46:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-01 03:46:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-01 03:46:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-01 03:46:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-01 03:46:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-01 03:46:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-01 03:46:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-01 03:47:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-01 03:47:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-01 03:47:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-01 03:47:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-01 03:47:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-01 03:47:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-01 03:47:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-01 03:47:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-01 03:47:44  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-01 03:47:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-01 03:47:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-01 03:48:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-01 03:48:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-01 03:48:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-01 03:48:17  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-01 03:48:22  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-01 03:48:27  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-01 03:48:33  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-01 03:48:39  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-01 03:48:44  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-01 03:48:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-01 03:48:58  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-01 03:49:04  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-01 03:49:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-01 03:49:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-01 03:49:21  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-01 03:49:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-01 03:49:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-01 03:49:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-01 03:49:43  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-01 03:49:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-01 03:49:54  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-01 03:50:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-01 03:50:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-01 03:50:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-01 03:50:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-01 03:50:27  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-01 03:50:27  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-01 03:50:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-01 03:50:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-01 03:50:45  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-01 03:50:51  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-01 03:51:00  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-01 03:51:06  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 03:51:12  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 03:51:17  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-01 03:51:23  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 03:51:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-01 03:51:35  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-01 03:51:41  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-01 03:51:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-01 03:51:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-01 03:51:59  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-01 03:52:05  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-01 03:52:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-01 03:52:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-01 03:52:23  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-01 03:52:29  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 03:52:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-01 03:52:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-01 03:52:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-01 03:52:53  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-01 03:52:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-01 03:53:05  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-01 03:53:11  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-01 03:53:17  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-01 03:53:23  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-01 03:53:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-01 03:53:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-01 03:53:40  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-01 03:53:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-01 03:53:52  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-01 03:53:58  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-01 03:54:04  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-01 03:54:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-01 03:54:15  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-01 03:54:21  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-01 03:54:27  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-01 03:54:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-01 03:54:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-01 03:54:40  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-01 03:54:46  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-01 03:54:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-01 03:54:58  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-01 03:55:04  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-01 03:55:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-01 03:55:16  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-01 03:55:27  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-01 03:55:32  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-01 03:55:38  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-01 03:55:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-01 03:55:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-01 03:55:57  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-01 03:56:03  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-01 03:56:09  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-01 03:56:15  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-01 03:56:21  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-01 03:56:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-01 03:56:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-01 03:56:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-01 03:56:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-01 03:56:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-01 03:56:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-01 03:56:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-01 03:57:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-01 03:57:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-01 03:57:16  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-01 03:57:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-01 03:57:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-01 03:57:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-01 03:57:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-01 03:57:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-01 03:57:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-01 03:57:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-01 03:57:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-01 03:57:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-01 03:57:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-01 03:58:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-01 03:58:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-01 03:58:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-01 03:58:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-01 03:58:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-01 03:58:24  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-01 03:58:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-01 03:58:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-01 03:58:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-01 03:58:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-01 03:58:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-01 03:58:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-01 03:58:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-01 03:59:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-01 03:59:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-01 03:59:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-01 03:59:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-01 03:59:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-01 03:59:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-01 03:59:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-01 03:59:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-01 03:59:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-01 03:59:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-01 03:59:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-01 03:59:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-01 03:59:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-01 03:59:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-01 04:00:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-01 04:00:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-01 04:00:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-01 04:00:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-01 04:00:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-01 04:00:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-01 04:00:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-01 04:00:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-01 04:00:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-01 04:00:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-01 04:00:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-01 04:00:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-01 04:00:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-01 04:00:58  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-01 04:01:04  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-01 04:01:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-01 04:01:17  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-01 04:01:17  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-01 04:01:23  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-01 04:01:29  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-01 04:01:35  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-01 04:01:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-01 04:01:46  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-01_04-01-47 Restart Xvfb...
2017-04-01 04:01:52  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-01 04:01:58  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-01 04:02:04  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-01 04:02:10  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-01 04:02:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-01 04:02:22  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-01 04:02:28  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-01 04:02:34  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-01 04:02:40  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-01 04:02:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-01 04:02:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-01 04:02:58  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-01 04:03:04  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-01 04:03:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-01 04:03:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-01 04:03:21  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-01 04:03:27  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-01 04:03:33  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-01 04:03:39  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-01 04:03:50  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-01 04:03:56  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-01 04:04:02  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-01 04:04:08  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-01 04:04:14  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-01 04:04:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-01 04:04:25  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-01 04:04:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-01 04:04:37  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-01 04:04:43  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-01 04:04:49  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-01 04:04:55  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-01 04:05:00  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-01 04:05:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-01 04:05:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-01 04:05:18  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-01 04:05:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-01 04:05:29  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-01 04:05:35  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-01 04:05:41  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-01 04:05:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-01 04:05:52  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-01 04:05:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-01 04:06:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-01 04:06:10  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-01 04:06:16  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-01 04:06:22  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-01 04:06:27  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-01 04:06:33  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-01 04:06:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-01 04:06:45  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-01 04:06:51  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-01 04:06:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-01 04:07:03  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-01 04:07:09  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-01 04:07:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-01 04:07:20  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-01 04:07:27  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-01 04:07:32  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-01 04:07:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-01 04:07:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-01 04:07:50  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-01 04:07:56  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-01 04:08:02  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-01 04:08:08  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-01 04:08:14  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-01 04:08:20  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-01 04:08:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-01 04:08:32  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-01 04:08:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-01 04:08:46  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-01 04:08:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-01 04:08:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-01 04:09:04  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-01 04:09:10  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-01 04:09:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-01 04:09:22  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-01 04:09:28  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-01 04:09:34  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-01 04:09:39  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-01 04:09:45  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-01 04:09:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-01 04:09:56  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-01 04:10:02  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-01 04:10:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-01 04:10:14  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-01 04:10:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-01 04:10:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-01 04:10:32  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-01 04:10:38  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-01 04:10:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-01 04:10:49  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-01 04:10:55  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-01 04:11:01  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-01 04:11:07  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-01 04:11:13  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-01 04:11:19  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-01 04:11:25  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-01 04:11:31  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-01 04:11:37  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-01 04:11:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-01 04:11:48  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-01 04:11:54  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-01 04:12:00  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-01 04:12:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-01 04:12:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-01 04:12:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-01 04:12:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-01 04:12:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-01 04:12:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-01 04:12:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-01 04:12:47  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-01 04:12:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-01 04:12:59  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-01 04:13:05  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-01 04:13:11  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-01 04:13:16  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-01 04:13:22  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-01 04:13:28  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-01 04:13:34  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-01 04:13:40  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-01 04:13:45  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-01 04:13:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-01 04:13:57  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-01 04:14:03  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-01 04:14:09  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-01 04:14:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-01 04:14:21  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-01 04:14:26  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-01 04:14:32  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-01 04:14:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-01 04:14:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-01 04:14:50  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-01 04:14:55  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-01 04:15:01  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-01 04:15:08  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-01 04:15:14  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-01 04:15:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-01 04:15:25  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-01 04:15:31  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-01 04:15:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-01 04:15:42  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-01 04:15:48  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-01 04:15:54  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-01 04:16:00  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-01 04:16:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-01 04:16:12  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-01 04:16:17  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-01 04:16:23  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-01 04:16:29  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-01 04:16:35  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-01 04:16:41  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-01 04:16:46  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-01 04:16:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-01 04:17:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-01 04:17:08  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-01 04:17:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-01 04:17:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-01 04:17:25  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-01 04:17:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-01 04:17:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-01 04:17:42  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-01 04:17:48  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-01 04:17:53  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-01 04:17:58  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-01 04:18:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-01 04:18:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-01 04:18:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-01 04:18:25  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-01 04:18:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-01 04:18:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-01 04:18:42  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-01 04:18:47  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-01 04:18:53  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-01 04:18:59  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-01 04:19:04  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-01 04:19:10  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-01 04:19:15  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-01 04:19:21  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-01 04:19:27  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-01 04:19:33  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-01 04:19:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-01 04:19:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-01 04:19:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-01 04:19:57  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-01 04:19:57  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-01 04:20:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-01 04:20:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-01 04:20:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-01 04:20:21  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-01 04:20:27  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-01 04:20:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-01 04:20:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-01 04:20:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-01 04:20:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-01 04:20:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-01 04:21:01  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-01 04:21:06  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-01 04:21:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-01 04:21:23  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-01 04:21:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-01 04:21:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-01 04:21:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-01 04:21:50  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-01 04:21:56  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-01 04:22:02  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-01 04:22:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-01 04:22:14  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-01 04:22:19  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-01 04:22:25  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-01 04:22:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-01 04:22:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-01 04:22:42  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-01 04:22:48  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-01 04:22:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-01 04:22:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-01 04:23:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-01 04:23:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-01 04:23:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-01 04:23:21  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-01 04:23:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-01 04:23:31  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-01 04:23:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-01 04:23:42  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-01 04:23:47  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-01 04:23:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-01 04:23:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-01 04:24:04  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-01 04:24:09  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-01 04:24:15  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-01 04:24:20  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-01 04:24:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-01 04:24:31  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-01 04:24:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-01 04:24:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-01 04:24:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-01 04:24:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-01 04:25:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-01 04:25:06  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-01 04:25:11  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-01 04:25:17  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-01 04:25:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-01 04:25:28  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-01 04:25:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-01 04:25:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-01 04:25:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-01 04:25:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 04:25:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 04:26:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 04:26:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 04:26:11  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-01 04:26:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 04:26:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 04:26:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-01 04:26:35  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-01 04:26:40  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-01 04:26:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-01 04:26:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-01 04:26:57  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-01 04:27:02  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-01 04:27:07  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-01 04:27:13  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-01 04:27:18  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-01 04:27:23  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-01 04:27:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-01 04:27:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-01 04:27:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-01 04:27:45  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-01 04:27:50  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-01 04:27:56  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-01 04:28:01  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-01 04:28:07  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-01 04:28:12  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-01 04:28:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 04:28:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 04:28:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 04:28:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 04:28:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 04:28:43  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-01 04:28:49  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 04:28:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 04:28:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 04:29:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 04:29:10  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-01 04:29:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 04:29:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 04:29:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 04:29:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-01 04:29:36  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-01_04-31-47 Restart Xvfb...
2017-04-01_05-01-47 Restart Xvfb...
2017-04-01_05-31-47 Restart Xvfb...
2017-04-01_06-01-47 Restart Xvfb...
2017-04-01 06:31:45 reset updateRequest
2017-04-01_06-31-47 Restart Xvfb...
2017-04-01 06:31:47  - 14968  http://www.lymphomahub.com/
2017-04-01 06:31:51  - 14968  http://www.lymphomahub.com/
2017-04-01 06:31:53  - 14968  http://www.lymphomahub.com/about
2017-04-01 06:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-01 06:32:00  - 14968  http://www.lymphomahub.com/terms
2017-04-01 06:32:04  - 14968  http://www.lymphomahub.com/undefined
2017-04-01 06:32:05  - 14968  http://www.lymphomahub.com/therapies
2017-04-01 06:32:11  - 14968  http://www.lymphomahub.com/newsletter
2017-04-01 06:32:15  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-01 06:32:19  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-01 06:32:25  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-01 06:32:31  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-01 06:32:36  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-01 06:32:42  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-01 06:32:48  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-01 06:32:54  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-01 06:33:00  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-01 06:33:05  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-01 06:33:11  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-01 06:33:17  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-01 06:33:23  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-01 06:33:28  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-01 06:33:34  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-01 06:33:39  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-01 06:33:48  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-01 06:33:54  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-01 06:34:00  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-01 06:34:06  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-01 06:34:12  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-01 06:34:17  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-01 06:34:22  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-01 06:34:28  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-01 06:34:33  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-01 06:34:39  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-01 06:34:45  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-01 06:34:51  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-01 06:34:56  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-01 06:35:02  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-01 06:35:08  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-01 06:35:14  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-01 06:35:20  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-01 06:35:25  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-01 06:35:31  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-01 06:35:37  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-01 06:35:43  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-01 06:35:48  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-01 06:35:54  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-01 06:36:00  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-01 06:36:05  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-01 06:36:11  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-01 06:36:17  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-01 06:36:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-01 06:36:28  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-01 06:36:34  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-01 06:36:40  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-01 06:36:45  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-01 06:36:51  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-01 06:36:57  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-01 06:37:03  - 14968  http://www.lymphomahub.com/medical-information
2017-04-01 06:37:08  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-01 06:37:14  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-01 06:37:20  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-01 06:37:26  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-01 06:37:31  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-01 06:37:37  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-01 06:37:43  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-01 06:37:49  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-01 06:37:55  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-01 06:38:06  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-01 06:38:11  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-01 06:38:17  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-01 06:38:18  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-01 06:38:24  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-01 06:38:29  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-01 06:38:35  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-01 06:38:40  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-01 06:38:46  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-01 06:38:52  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-01 06:38:58  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-01 06:39:04  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-01 06:39:10  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-01 06:39:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-01 06:39:21  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-01 06:39:27  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-01 06:39:32  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-01 06:39:38  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-01 06:39:44  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-01 06:39:50  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-01 06:39:56  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-01 06:40:01  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-01 06:40:07  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-01 06:40:13  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-01 06:40:18  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-01 06:40:24  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-01 06:40:30  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-01 06:40:36  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-01 06:40:41  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-01 06:40:47  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-01 06:40:53  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-01 06:41:01  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-01 06:41:07  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-01 06:41:13  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-01 06:41:14  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-01 06:41:19  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-01 06:41:25  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-01 06:41:31  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-01 06:41:36  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-01 06:41:42  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-01 06:41:48  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-01 06:41:53  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-01 06:41:59  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-01 06:42:04  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-01 06:42:05  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-01 06:42:10  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-01 06:42:16  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-01 06:42:22  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-01 06:42:28  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-01 06:42:34  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-01 06:42:35  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-01 06:42:40  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-01 06:42:46  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-01 06:42:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-01 06:42:57  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-01 06:43:02  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-01 06:43:08  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-01 06:43:13  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-01 06:43:18  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-01 06:43:23  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-01 06:43:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-01 06:43:34  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-01 06:43:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-01 06:43:46  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-01 06:43:51  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-01 06:43:52  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-01 06:43:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-01 06:44:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-01 06:44:09  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-01 06:44:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-01 06:44:20  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-01 06:44:26  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-01 06:44:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-01 06:44:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-01 06:44:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-01 06:44:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-01 06:44:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-01 06:45:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-01 06:45:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-01 06:45:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-01 06:45:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-01 06:45:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-01 06:45:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-01 06:45:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-01 06:45:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-01 06:45:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-01 06:45:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-01 06:45:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-01 06:46:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-01 06:46:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-01 06:46:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-01 06:46:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-01 06:46:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-01 06:46:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-01 06:46:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-01 06:46:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-01 06:46:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-01 06:46:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-01 06:46:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-01 06:47:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-01 06:47:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-01 06:47:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-01 06:47:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-01 06:47:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-01 06:47:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-01 06:47:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-01 06:47:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-01 06:47:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-01 06:47:56  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-01 06:48:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-01 06:48:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-01 06:48:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-01 06:48:17  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-01 06:48:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-01 06:48:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-01 06:48:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-01 06:48:38  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-01 06:48:44  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-01 06:48:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-01 06:48:56  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-01 06:49:01  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-01 06:49:07  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-01 06:49:13  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-01 06:49:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-01 06:49:24  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-01 06:49:29  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-01 06:49:34  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-01 06:49:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-01 06:49:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-01 06:49:51  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-01 06:49:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-01 06:50:02  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-01 06:50:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-01 06:50:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-01 06:50:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-01 06:50:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-01 06:50:32  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-01 06:50:33  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-01 06:50:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-01 06:50:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-01 06:50:51  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-01 06:50:57  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-01 06:51:03  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-01 06:51:09  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 06:51:14  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 06:51:20  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-01 06:51:26  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 06:51:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-01 06:51:38  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-01 06:51:44  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-01 06:51:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-01 06:51:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-01 06:52:01  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-01 06:52:07  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-01 06:52:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-01 06:52:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-01 06:52:25  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-01 06:52:31  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 06:52:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-01 06:52:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-01 06:52:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-01 06:52:55  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-01 06:53:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-01 06:53:07  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-01 06:53:13  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-01 06:53:19  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-01 06:53:25  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-01 06:53:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-01 06:53:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-01 06:53:42  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-01 06:53:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-01 06:53:54  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-01 06:54:00  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-01 06:54:06  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-01 06:54:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-01 06:54:18  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-01 06:54:24  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-01 06:54:30  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-01 06:54:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-01 06:54:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-01 06:54:42  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-01 06:54:48  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-01 06:54:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-01 06:55:00  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-01 06:55:06  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-01 06:55:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-01 06:55:17  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-01 06:55:23  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-01 06:55:30  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-01 06:55:35  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-01 06:55:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-01 06:55:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-01 06:55:53  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-01 06:55:59  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-01 06:56:05  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-01 06:56:11  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-01 06:56:17  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-01 06:56:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-01 06:56:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-01 06:56:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-01 06:56:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-01 06:56:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-01 06:56:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-01 06:56:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-01 06:56:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-01 06:57:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-01 06:57:09  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-01 06:57:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-01 06:57:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-01 06:57:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-01 06:57:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-01 06:57:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-01 06:57:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-01 06:57:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-01 06:57:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-01 06:57:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-01 06:57:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-01 06:57:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-01 06:57:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-01 06:58:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-01 06:58:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-01 06:58:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-01 06:58:22  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-01 06:58:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-01 06:58:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-01 06:58:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-01 06:58:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-01 06:58:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-01 06:58:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-01 06:58:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-01 06:58:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-01 06:59:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-01 06:59:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-01 06:59:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-01 06:59:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-01 06:59:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-01 06:59:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-01 06:59:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-01 06:59:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-01 06:59:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-01 06:59:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-01 06:59:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-01 06:59:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-01 06:59:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-01 06:59:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-01 07:00:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-01 07:00:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-01 07:00:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-01 07:00:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-01 07:00:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-01 07:00:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-01 07:00:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-01 07:00:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-01 07:00:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-01 07:00:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-01 07:00:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-01 07:01:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-01 07:01:06  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-01 07:01:12  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-01 07:01:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-01 07:01:23  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-01 07:01:24  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-01 07:01:30  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-01 07:01:36  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-01 07:01:42  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-01_07-01-47 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial?_prerender {"code":"ECONNRESET"}
2017-04-01 07:03:47  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-01 07:03:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-01 07:03:58  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-01 07:04:04  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-01 07:04:11  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-01 07:04:17  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-01 07:04:23  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-01 07:04:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-01 07:04:35  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-01 07:04:41  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-01 07:04:47  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-01 07:04:53  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-01 07:04:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-01 07:05:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-01 07:05:11  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-01 07:05:17  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-01 07:05:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-01 07:05:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-01 07:05:35  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-01 07:05:41  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-01 07:05:52  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-01 07:05:58  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-01 07:06:04  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-01 07:06:15  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-01 07:06:21  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-01 07:06:27  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-01 07:06:33  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-01 07:06:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-01 07:06:50  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-01 07:06:56  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-01 07:07:02  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-01 07:07:08  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-01 07:07:14  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-01 07:07:20  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-01 07:07:26  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-01 07:07:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-01 07:07:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-01 07:07:44  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-01 07:07:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-01 07:07:55  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-01 07:08:01  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-01 07:08:07  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-01 07:08:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-01 07:08:19  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-01 07:08:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-01 07:08:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-01 07:08:36  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-01 07:08:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-01 07:08:48  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-01 07:08:54  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-01 07:09:00  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-01 07:09:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-01 07:09:15  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-01 07:09:21  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-01 07:09:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-01 07:09:33  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-01 07:09:39  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-01 07:09:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-01 07:09:50  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-01 07:09:56  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-01 07:10:03  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-01 07:10:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-01 07:10:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-01 07:10:21  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-01 07:10:27  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-01 07:10:33  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-01 07:10:38  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-01 07:10:44  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-01 07:10:55  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-01 07:11:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-01 07:11:07  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-01 07:11:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-01 07:11:19  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-01 07:11:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-01 07:11:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-01 07:11:36  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-01 07:11:42  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-01 07:11:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-01 07:11:54  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-01 07:12:00  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-01 07:12:06  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-01 07:12:12  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-01 07:12:17  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-01 07:12:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-01 07:12:28  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-01 07:12:34  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-01 07:12:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-01 07:12:46  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-01 07:12:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-01 07:12:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-01 07:13:03  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-01 07:13:09  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-01 07:13:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-01 07:13:21  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-01 07:13:27  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-01 07:13:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-01 07:13:38  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-01 07:13:44  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-01 07:13:50  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-01 07:13:56  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-01 07:14:02  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-01 07:14:07  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-01 07:14:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-01 07:14:19  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-01 07:14:25  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-01 07:14:31  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-01 07:14:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-01 07:14:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-01 07:14:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-01 07:14:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-01 07:15:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-01 07:15:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-01 07:15:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-01 07:15:18  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-01 07:15:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-01 07:15:30  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-01 07:15:36  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-01 07:15:41  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-01 07:15:47  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-01 07:15:53  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-01 07:15:58  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-01 07:16:04  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-01 07:16:10  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-01 07:16:16  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-01 07:16:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-01 07:16:27  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-01 07:16:33  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-01 07:16:39  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-01 07:16:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-01 07:16:51  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-01 07:16:57  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-01 07:17:03  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-01 07:17:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-01 07:17:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-01 07:17:20  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-01 07:17:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-01 07:17:32  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-01 07:17:38  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-01 07:17:44  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-01 07:17:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-01 07:17:56  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-01 07:18:01  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-01 07:18:07  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-01 07:18:12  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-01 07:18:18  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-01 07:18:24  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-01 07:18:30  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-01 07:18:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-01 07:18:41  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-01 07:18:47  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-01 07:18:52  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-01 07:18:58  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-01 07:19:04  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-01 07:19:10  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-01 07:19:16  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-01 07:19:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-01 07:19:27  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-01 07:19:33  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-01 07:19:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-01 07:19:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-01 07:19:49  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-01 07:19:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-01 07:20:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-01 07:20:07  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-01 07:20:14  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-01 07:20:19  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-01 07:20:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-01 07:20:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-01 07:20:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-01 07:20:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-01 07:20:50  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-01 07:20:55  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-01 07:21:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-01 07:21:07  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-01 07:21:12  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-01 07:21:18  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-01 07:21:24  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-01 07:21:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-01 07:21:35  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-01 07:21:40  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-01 07:21:46  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-01 07:21:52  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-01 07:21:58  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-01 07:22:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-01 07:22:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-01 07:22:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-01 07:22:21  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-01 07:22:22  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-01 07:22:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-01 07:22:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-01 07:22:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-01 07:22:44  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-01 07:22:50  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-01 07:22:56  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-01 07:23:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-01 07:23:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-01 07:23:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-01 07:23:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-01 07:23:25  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-01 07:23:30  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-01 07:23:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-01 07:23:42  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-01 07:23:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-01 07:23:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-01 07:23:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-01 07:24:05  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-01 07:24:11  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-01 07:24:17  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-01 07:24:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-01 07:24:28  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-01 07:24:34  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-01 07:24:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-01 07:24:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-01 07:24:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-01 07:24:57  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-01 07:25:03  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-01 07:25:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-01 07:25:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-01 07:25:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-01 07:25:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-01 07:25:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-01 07:25:36  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-01 07:25:41  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-01 07:25:46  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-01 07:25:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-01 07:25:57  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-01 07:26:02  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-01 07:26:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-01 07:26:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-01 07:26:19  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-01 07:26:24  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-01 07:26:29  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-01 07:26:35  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-01 07:26:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-01 07:26:46  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-01 07:26:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-01 07:26:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-01 07:27:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-01 07:27:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-01 07:27:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-01 07:27:21  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-01 07:27:26  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-01 07:27:31  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-01 07:27:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-01 07:27:42  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-01 07:27:48  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-01 07:27:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-01 07:27:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-01 07:28:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 07:28:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 07:28:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 07:28:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 07:28:25  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-01 07:28:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 07:28:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 07:28:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-01 07:28:46  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-01 07:28:52  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-01 07:28:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-01 07:29:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-01 07:29:08  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-01 07:29:13  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-01 07:29:19  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-01 07:29:24  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-01 07:29:29  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-01 07:29:35  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-01 07:29:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-01 07:29:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-01 07:29:51  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-01 07:29:57  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-01 07:30:02  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-01 07:30:07  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-01 07:30:13  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-01 07:30:18  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-01 07:30:24  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-01 07:30:29  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 07:30:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 07:30:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 07:30:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 07:30:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 07:30:56  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-01 07:31:01  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 07:31:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 07:31:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 07:31:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 07:31:25  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-01 07:31:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 07:31:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 07:31:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 07:31:46  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-01_07-31-47 Restart Xvfb...
2017-04-01 07:31:52  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-01_08-01-47 Restart Xvfb...
2017-04-01_08-31-47 Restart Xvfb...
2017-04-01_09-01-47 Restart Xvfb...
2017-04-01 09:31:45 reset updateRequest
2017-04-01_09-31-47 Restart Xvfb...
2017-04-01 09:31:48  - 14968  http://www.lymphomahub.com/
2017-04-01 09:31:51  - 14968  http://www.lymphomahub.com/
2017-04-01 09:31:53  - 14968  http://www.lymphomahub.com/about
2017-04-01 09:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-01 09:32:00  - 14968  http://www.lymphomahub.com/terms
2017-04-01 09:32:04  - 14968  http://www.lymphomahub.com/undefined
2017-04-01 09:32:05  - 14968  http://www.lymphomahub.com/therapies
2017-04-01 09:32:11  - 14968  http://www.lymphomahub.com/newsletter
2017-04-01 09:32:15  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-01 09:32:24  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-01 09:32:30  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-01 09:32:36  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-01 09:32:42  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-01 09:32:48  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-01 09:32:54  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-01 09:33:00  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-01 09:33:06  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-01 09:33:12  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-01 09:33:17  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-01 09:33:23  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-01 09:33:29  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-01 09:33:35  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-01 09:33:40  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-01 09:33:46  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-01 09:33:52  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-01 09:33:57  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-01 09:34:03  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-01 09:34:09  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-01 09:34:15  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-01 09:34:21  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-01 09:34:25  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-01 09:34:31  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-01 09:34:37  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-01 09:34:42  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-01 09:34:48  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-01 09:34:54  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-01 09:35:00  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-01 09:35:05  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-01 09:35:11  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-01 09:35:17  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-01 09:35:23  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-01 09:35:28  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-01 09:35:34  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-01 09:35:40  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-01 09:35:46  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-01 09:35:51  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-01 09:35:57  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-01 09:36:03  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-01 09:36:09  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-01 09:36:14  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-01 09:36:20  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-01 09:36:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-01 09:36:32  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-01 09:36:38  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-01 09:36:43  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-01 09:36:49  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-01 09:36:55  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-01 09:37:01  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-01 09:37:07  - 14968  http://www.lymphomahub.com/medical-information
2017-04-01 09:37:12  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-01 09:37:18  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-01 09:37:24  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-01 09:37:29  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-01 09:37:35  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-01 09:37:41  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-01 09:37:47  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-01 09:37:52  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-01 09:37:58  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-01 09:38:04  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-01 09:38:10  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-01 09:38:15  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-01 09:38:16  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-01 09:38:22  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-01 09:38:28  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-01 09:38:34  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-01 09:38:39  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-01 09:38:45  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-01 09:38:51  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-01 09:38:56  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-01 09:39:02  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-01 09:39:08  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-01 09:39:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-01 09:39:19  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-01 09:39:25  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-01 09:39:31  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-01 09:39:37  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-01 09:39:42  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-01 09:39:48  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-01 09:39:54  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-01 09:40:00  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-01 09:40:06  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-01 09:40:11  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-01 09:40:17  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-01 09:40:23  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-01 09:40:29  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-01 09:40:35  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-01 09:40:41  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-01 09:40:46  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-01 09:40:52  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-01 09:40:58  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-01 09:41:03  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-01 09:41:09  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-01 09:41:10  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-01 09:41:16  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-01 09:41:22  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-01 09:41:27  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-01 09:41:33  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-01 09:41:39  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-01 09:41:44  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-01 09:41:50  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-01 09:41:56  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-01 09:42:01  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-01 09:42:02  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-01 09:42:13  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-01 09:42:18  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-01 09:42:24  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-01 09:42:30  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-01 09:42:36  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-01 09:42:37  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-01 09:42:43  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-01 09:42:48  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-01 09:42:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-01 09:42:59  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-01 09:43:05  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-01 09:43:10  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-01 09:43:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-01 09:43:20  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-01 09:43:25  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-01 09:43:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-01 09:43:37  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-01 09:43:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-01 09:43:51  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-01 09:43:57  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-01 09:43:57  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-01 09:44:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-01 09:44:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-01 09:44:15  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-01 09:44:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-01 09:44:26  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-01 09:44:32  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-01 09:44:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-01 09:44:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-01 09:44:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-01 09:44:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-01 09:44:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-01 09:45:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-01 09:45:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-01 09:45:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-01 09:45:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-01 09:45:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-01 09:45:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-01 09:45:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-01 09:45:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-01 09:45:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-01 09:45:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-01 09:45:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-01 09:46:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-01 09:46:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-01 09:46:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-01 09:46:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-01 09:46:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-01 09:46:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-01 09:46:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-01 09:46:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-01 09:46:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-01 09:46:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-01 09:46:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-01 09:47:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-01 09:47:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-01 09:47:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-01 09:47:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-01 09:47:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-01 09:47:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-01 09:47:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-01 09:47:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-01 09:47:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-01 09:47:51  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-01 09:47:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-01 09:48:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-01 09:48:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-01 09:48:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-01 09:48:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-01 09:48:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-01 09:48:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-01 09:48:41  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-01 09:48:48  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-01 09:48:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-01 09:48:59  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-01 09:49:05  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-01 09:49:10  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-01 09:49:16  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-01 09:49:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-01 09:49:27  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-01 09:49:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-01 09:49:38  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-01 09:49:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-01 09:49:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-01 09:49:55  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-01 09:50:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-01 09:50:06  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-01 09:50:12  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-01 09:50:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-01 09:50:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-01 09:50:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-01 09:50:36  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-01 09:50:37  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-01 09:50:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-01 09:50:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-01 09:50:54  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-01 09:51:00  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-01 09:51:06  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-01 09:51:12  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 09:51:18  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 09:51:24  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-01 09:51:29  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 09:51:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-01 09:51:41  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-01 09:51:47  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-01 09:51:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-01 09:51:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-01 09:52:05  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-01 09:52:11  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-01 09:52:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-01 09:52:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-01 09:52:34  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-01 09:52:40  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 09:52:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-01 09:52:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-01 09:52:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-01 09:53:03  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-01 09:53:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-01 09:53:16  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-01 09:53:22  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-01 09:53:28  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-01 09:53:34  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-01 09:53:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-01 09:53:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-01 09:53:51  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-01 09:53:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-01 09:54:03  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-01 09:54:09  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-01 09:54:15  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-01 09:54:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-01 09:54:27  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-01 09:54:33  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-01 09:54:38  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-01 09:54:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-01 09:54:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-01 09:54:51  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-01 09:54:57  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-01 09:55:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-01 09:55:09  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-01 09:55:15  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-01 09:55:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-01 09:55:27  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-01 09:55:33  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-01 09:55:38  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-01 09:55:44  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-01 09:55:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-01 09:55:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-01 09:56:02  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-01 09:56:08  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-01 09:56:14  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-01 09:56:20  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-01 09:56:26  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-01 09:56:32  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-01 09:56:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-01 09:56:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-01 09:56:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-01 09:56:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-01 09:56:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-01 09:57:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-01 09:57:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-01 09:57:12  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-01 09:57:18  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-01 09:57:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-01 09:57:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-01 09:57:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-01 09:57:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-01 09:57:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-01 09:57:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-01 09:57:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-01 09:57:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-01 09:57:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-01 09:58:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-01 09:58:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-01 09:58:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-01 09:58:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-01 09:58:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-01 09:58:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-01 09:58:27  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-01 09:58:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-01 09:58:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-01 09:58:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-01 09:58:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-01 09:58:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-01 09:58:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-01 09:58:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-01 09:59:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-01 09:59:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-01 09:59:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-01 09:59:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-01 09:59:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-01 09:59:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-01 09:59:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-01 09:59:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-01 09:59:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-01 09:59:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-01 09:59:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-01 09:59:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-01 09:59:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-01 10:00:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-01 10:00:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-01 10:00:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-01 10:00:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-01 10:00:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-01 10:00:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-01 10:00:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-01 10:00:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-01 10:00:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-01 10:00:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-01 10:00:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-01 10:00:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-01 10:00:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-01 10:01:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-01 10:01:06  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-01 10:01:11  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-01 10:01:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-01 10:01:24  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-01 10:01:25  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-01 10:01:31  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-01 10:01:37  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-01 10:01:43  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-01_10-01-47 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial?_prerender {"code":"ECONNRESET"}
2017-04-01 10:03:48  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-01 10:03:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-01 10:03:59  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-01 10:04:05  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-01 10:04:11  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-01 10:04:17  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-01 10:04:23  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-01 10:04:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-01 10:04:35  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-01 10:04:40  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-01 10:04:46  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-01 10:04:52  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-01 10:04:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-01 10:05:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-01 10:05:10  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-01 10:05:16  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-01 10:05:22  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-01 10:05:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-01 10:05:34  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-01 10:05:39  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-01 10:05:45  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-01 10:05:51  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-01 10:05:58  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-01 10:06:04  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-01 10:06:10  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-01 10:06:15  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-01 10:06:21  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-01 10:06:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-01 10:06:33  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-01 10:06:39  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-01 10:06:44  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-01 10:06:50  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-01 10:06:56  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-01 10:07:06  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-01 10:07:12  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-01 10:07:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-01 10:07:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-01 10:07:30  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-01 10:07:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-01 10:07:41  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-01 10:07:47  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-01 10:07:53  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-01 10:07:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-01 10:08:10  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-01 10:08:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-01 10:08:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-01 10:08:27  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-01 10:08:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-01 10:08:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-01 10:08:44  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-01 10:08:50  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-01 10:08:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-01 10:09:02  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-01 10:09:08  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-01 10:09:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-01 10:09:19  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-01 10:09:25  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-01 10:09:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-01 10:09:37  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-01 10:09:43  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-01 10:09:49  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-01 10:09:55  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-01 10:10:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-01 10:10:07  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-01 10:10:13  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-01 10:10:19  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-01 10:10:24  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-01 10:10:30  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-01 10:10:36  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-01 10:10:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-01 10:10:48  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-01 10:10:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-01 10:11:00  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-01 10:11:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-01 10:11:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-01 10:11:18  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-01 10:11:23  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-01 10:11:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-01 10:11:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-01 10:11:41  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-01 10:11:46  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-01 10:11:52  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-01 10:11:58  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-01 10:12:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-01 10:12:10  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-01 10:12:15  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-01 10:12:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-01 10:12:27  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-01 10:12:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-01 10:12:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-01 10:12:45  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-01 10:12:51  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-01 10:12:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-01 10:13:03  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-01 10:13:09  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-01 10:13:14  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-01 10:13:20  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-01 10:13:26  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-01 10:13:32  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-01 10:13:38  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-01 10:13:44  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-01 10:13:50  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-01 10:13:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-01 10:14:01  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-01 10:14:07  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-01 10:14:13  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-01 10:14:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-01 10:14:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-01 10:14:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-01 10:14:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-01 10:14:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-01 10:14:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-01 10:14:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-01 10:15:01  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-01 10:15:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-01 10:15:13  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-01 10:15:18  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-01 10:15:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-01 10:15:29  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-01 10:15:37  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-01 10:15:43  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-01 10:15:49  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-01 10:15:54  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-01 10:16:00  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-01 10:16:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-01 10:16:12  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-01 10:16:18  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-01 10:16:25  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-01 10:16:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-01 10:16:37  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-01 10:16:43  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-01 10:16:49  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-01 10:16:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-01 10:17:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-01 10:17:07  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-01 10:17:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-01 10:17:19  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-01 10:17:25  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-01 10:17:31  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-01 10:17:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-01 10:17:43  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-01 10:17:49  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-01 10:17:54  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-01 10:18:00  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-01 10:18:06  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-01 10:18:11  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-01 10:18:17  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-01 10:18:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-01 10:18:29  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-01 10:18:34  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-01 10:18:40  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-01 10:18:46  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-01 10:18:52  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-01 10:18:58  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-01 10:19:03  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-01 10:19:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-01 10:19:14  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-01 10:19:20  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-01 10:19:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-01 10:19:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-01 10:19:37  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-01 10:19:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-01 10:19:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-01 10:19:54  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-01 10:20:00  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-01 10:20:06  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-01 10:20:11  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-01 10:20:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-01 10:20:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-01 10:20:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-01 10:20:35  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-01 10:20:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-01 10:20:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-01 10:20:52  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-01 10:20:57  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-01 10:21:03  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-01 10:21:09  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-01 10:21:14  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-01 10:21:20  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-01 10:21:25  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-01 10:21:31  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-01 10:21:42  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-01 10:21:48  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-01 10:21:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-01 10:22:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-01 10:22:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-01 10:22:12  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-01 10:22:13  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-01 10:22:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-01 10:22:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-01 10:22:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-01 10:22:36  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-01 10:22:42  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-01 10:22:48  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-01 10:22:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-01 10:22:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-01 10:23:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-01 10:23:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-01 10:23:17  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-01 10:23:22  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-01 10:23:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-01 10:23:34  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-01 10:23:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-01 10:23:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-01 10:23:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-01 10:23:57  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-01 10:24:03  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-01 10:24:09  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-01 10:24:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-01 10:24:20  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-01 10:24:26  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-01 10:24:31  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-01 10:24:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-01 10:24:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-01 10:24:54  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-01 10:24:59  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-01 10:25:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-01 10:25:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-01 10:25:16  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-01 10:25:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-01 10:25:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-01 10:25:36  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-01 10:25:41  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-01 10:25:47  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-01 10:25:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-01 10:25:58  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-01 10:26:03  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-01 10:26:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-01 10:26:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-01 10:26:20  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-01 10:26:25  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-01 10:26:31  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-01 10:26:36  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-01 10:26:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-01 10:26:47  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-01 10:26:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-01 10:26:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-01 10:27:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-01 10:27:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-01 10:27:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-01 10:27:27  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-01 10:27:33  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-01 10:27:38  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-01 10:27:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-01 10:27:49  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-01 10:27:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-01 10:27:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-01 10:28:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-01 10:28:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 10:28:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 10:28:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 10:28:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 10:28:32  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-01 10:28:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 10:28:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 10:28:48  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-01 10:28:53  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-01 10:28:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-01 10:29:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-01 10:29:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-01 10:29:15  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-01 10:29:20  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-01 10:29:26  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-01 10:29:31  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-01 10:29:36  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-01 10:29:42  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-01 10:29:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-01 10:29:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-01 10:29:59  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-01 10:30:05  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-01 10:30:10  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-01 10:30:16  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-01 10:30:22  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-01 10:30:27  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-01 10:30:32  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-01 10:30:37  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 10:30:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 10:30:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 10:30:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 10:31:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 10:31:09  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-01 10:31:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 10:31:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 10:31:25  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 10:31:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 10:31:41  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-01 10:31:46  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01_10-31-47 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly?_prerender {"code":"ECONNRESET"}
2017-04-01 10:33:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 10:33:57  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 10:34:02  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 10:34:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-01 10:34:13  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-01_11-01-47 Restart Xvfb...
2017-04-01_11-31-47 Restart Xvfb...
2017-04-01_12-01-47 Restart Xvfb...
2017-04-01 12:31:45 reset updateRequest
2017-04-01_12-31-47 Restart Xvfb...
2017-04-01 12:31:48  - 14968  http://www.lymphomahub.com/
2017-04-01 12:31:51  - 14968  http://www.lymphomahub.com/
2017-04-01 12:31:52  - 14968  http://www.lymphomahub.com/about
2017-04-01 12:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-01 12:32:00  - 14968  http://www.lymphomahub.com/terms
2017-04-01 12:32:02  - 14968  http://www.lymphomahub.com/terms
2017-04-01 12:32:05  - 14968  http://www.lymphomahub.com/undefined
2017-04-01 12:32:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-01 12:32:12  - 14968  http://www.lymphomahub.com/newsletter
2017-04-01 12:32:16  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-01 12:32:19  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-01 12:32:25  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-01 12:32:31  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-01 12:32:37  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-01 12:32:43  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-01 12:32:49  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-01 12:32:55  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-01 12:33:00  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-01 12:33:06  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-01 12:33:12  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-01 12:33:18  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-01 12:33:24  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-01 12:33:29  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-01 12:33:35  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-01 12:33:40  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-01 12:33:46  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-01 12:33:52  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-01 12:33:57  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-01 12:34:03  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-01 12:34:09  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-01 12:34:15  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-01 12:34:19  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-01 12:34:25  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-01 12:34:31  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-01 12:34:37  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-01 12:34:42  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-01 12:34:48  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-01 12:34:54  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-01 12:34:59  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-01 12:35:05  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-01 12:35:11  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-01 12:35:17  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-01 12:35:23  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-01 12:35:28  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-01 12:35:34  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-01 12:35:40  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-01 12:35:45  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-01 12:35:51  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-01 12:35:56  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-01 12:36:02  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-01 12:36:08  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-01 12:36:14  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-01 12:36:19  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-01 12:36:25  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-01 12:36:31  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-01 12:36:37  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-01 12:36:42  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-01 12:36:48  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-01 12:36:54  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-01 12:36:59  - 14968  http://www.lymphomahub.com/medical-information
2017-04-01 12:37:03  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-01 12:37:09  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-01 12:37:20  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-01 12:37:26  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-01 12:37:37  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-01 12:37:42  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-01 12:37:48  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-01 12:37:54  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-01 12:38:00  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-01 12:38:05  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-01 12:38:11  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-01 12:38:17  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-01 12:38:18  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-01 12:38:23  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-01 12:38:29  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-01 12:38:36  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-01 12:38:42  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-01 12:38:48  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-01 12:38:53  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-01 12:38:59  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-01 12:39:05  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-01 12:39:10  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-01 12:39:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-01 12:39:22  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-01 12:39:28  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-01 12:39:34  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-01 12:39:39  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-01 12:39:45  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-01 12:39:51  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-01 12:39:57  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-01 12:40:03  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-01 12:40:09  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-01 12:40:15  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-01 12:40:21  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-01 12:40:26  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-01 12:40:32  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-01 12:40:38  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-01 12:40:44  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-01 12:40:49  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-01 12:40:55  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-01 12:41:00  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-01 12:41:06  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-01 12:41:12  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-01 12:41:13  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-01 12:41:18  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-01 12:41:24  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-01 12:41:30  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-01 12:41:35  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-01 12:41:41  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-01 12:41:47  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-01 12:41:52  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-01 12:41:58  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-01 12:42:03  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-01 12:42:03  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-01 12:42:09  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-01 12:42:15  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-01 12:42:21  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-01 12:42:26  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-01 12:42:32  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-01 12:42:33  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-01 12:42:39  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-01 12:42:44  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-01 12:42:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-01 12:42:55  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-01 12:43:01  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-01 12:43:06  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-01 12:43:11  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-01 12:43:16  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-01 12:43:22  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-01 12:43:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-01 12:43:33  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-01 12:43:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-01 12:43:44  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-01 12:43:50  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-01 12:43:50  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-01 12:43:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-01 12:44:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-01 12:44:13  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-01 12:44:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-01 12:44:24  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-01 12:44:30  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-01 12:44:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-01 12:44:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-01 12:44:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-01 12:44:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-01 12:44:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-01 12:45:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-01 12:45:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-01 12:45:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-01 12:45:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-01 12:45:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-01 12:45:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-01 12:45:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-01 12:45:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-01 12:45:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-01 12:45:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-01 12:45:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-01 12:46:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-01 12:46:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-01 12:46:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-01 12:46:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-01 12:46:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-01 12:46:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-01 12:46:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-01 12:46:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-01 12:46:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-01 12:46:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-01 12:47:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-01 12:47:05  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-01 12:47:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-01 12:47:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-01 12:47:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-01 12:47:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-01 12:47:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-01 12:47:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-01 12:47:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-01 12:47:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-01 12:47:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-01 12:47:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-01 12:48:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-01 12:48:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-01 12:48:15  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-01 12:48:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-01 12:48:26  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-01 12:48:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-01 12:48:36  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-01 12:48:42  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-01 12:48:48  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-01 12:48:53  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-01 12:48:59  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-01 12:49:05  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-01 12:49:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-01 12:49:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-01 12:49:24  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-01 12:49:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-01 12:49:35  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-01 12:49:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-01 12:49:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-01 12:49:52  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-01 12:49:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-01 12:50:04  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-01 12:50:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-01 12:50:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-01 12:50:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-01 12:50:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-01 12:50:34  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-01 12:50:34  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-01 12:50:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-01 12:50:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-01 12:50:52  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-01 12:50:58  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-01 12:51:03  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-01 12:51:12  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 12:51:18  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 12:51:24  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-01 12:51:30  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 12:51:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-01 12:51:42  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-01 12:51:48  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-01 12:51:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-01 12:52:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-01 12:52:06  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-01 12:52:11  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-01 12:52:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-01 12:52:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-01 12:52:30  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-01 12:52:36  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 12:52:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-01 12:52:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-01 12:52:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-01 12:53:00  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-01 12:53:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-01 12:53:12  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-01 12:53:18  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-01 12:53:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-01 12:53:29  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-01 12:53:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-01 12:53:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-01 12:53:47  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-01 12:53:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-01 12:53:59  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-01 12:54:05  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-01 12:54:11  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-01 12:54:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-01 12:54:22  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-01 12:54:28  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-01 12:54:34  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-01 12:54:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-01 12:54:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-01 12:54:46  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-01 12:54:52  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-01 12:54:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-01 12:55:04  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-01 12:55:10  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-01 12:55:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-01 12:55:22  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-01 12:55:28  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-01 12:55:34  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-01 12:55:40  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-01 12:55:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-01 12:55:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-01 12:55:58  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-01 12:56:04  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-01 12:56:10  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-01 12:56:16  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-01 12:56:22  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-01 12:56:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-01 12:56:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-01 12:56:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-01 12:56:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-01 12:56:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-01 12:56:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-01 12:56:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-01 12:57:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-01 12:57:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-01 12:57:14  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-01 12:57:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-01 12:57:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-01 12:57:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-01 12:57:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-01 12:57:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-01 12:57:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-01 12:57:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-01 12:57:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-01 12:57:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-01 12:57:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-01 12:57:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-01 12:58:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-01 12:58:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-01 12:58:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-01 12:58:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-01 12:58:21  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-01 12:58:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-01 12:58:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-01 12:58:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-01 12:58:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-01 12:58:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-01 12:58:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-01 12:58:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-01 12:58:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-01 12:59:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-01 12:59:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-01 12:59:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-01 12:59:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-01 12:59:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-01 12:59:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-01 12:59:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-01 12:59:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-01 12:59:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-01 12:59:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-01 12:59:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-01 12:59:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-01 12:59:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-01 13:00:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-01 13:00:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-01 13:00:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-01 13:00:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-01 13:00:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-01 13:00:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-01 13:00:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-01 13:00:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-01 13:00:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-01 13:00:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-01 13:00:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-01 13:00:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-01 13:00:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-01 13:01:00  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-01 13:01:06  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-01 13:01:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-01 13:01:18  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-01 13:01:19  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-01 13:01:25  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-01 13:01:31  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-01 13:01:36  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-01 13:01:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-01_13-01-47 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185?_prerender {"code":"ECONNRESET"}
2017-04-01 13:03:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-01 13:03:53  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-01 13:03:59  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-01 13:04:05  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-01 13:04:11  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-01 13:04:17  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-01 13:04:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-01 13:04:29  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-01 13:04:35  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-01 13:04:41  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-01 13:04:47  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-01 13:04:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-01 13:04:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-01 13:05:05  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-01 13:05:11  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-01 13:05:16  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-01 13:05:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-01 13:05:28  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-01 13:05:34  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-01 13:05:40  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-01 13:05:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-01 13:05:52  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-01 13:05:57  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-01 13:06:04  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-01 13:06:09  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-01 13:06:15  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-01 13:06:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-01 13:06:27  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-01 13:06:33  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-01 13:06:39  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-01 13:06:45  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-01 13:06:56  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-01 13:07:01  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-01 13:07:07  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-01 13:07:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-01 13:07:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-01 13:07:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-01 13:07:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-01 13:07:36  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-01 13:07:42  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-01 13:07:48  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-01 13:07:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-01 13:08:00  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-01 13:08:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-01 13:08:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-01 13:08:17  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-01 13:08:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-01 13:08:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-01 13:08:35  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-01 13:08:41  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-01 13:08:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-01 13:08:53  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-01 13:08:59  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-01 13:09:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-01 13:09:10  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-01 13:09:16  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-01 13:09:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-01 13:09:28  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-01 13:09:34  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-01 13:09:40  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-01 13:09:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-01 13:09:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-01 13:09:58  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-01 13:10:04  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-01 13:10:10  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-01 13:10:16  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-01 13:10:22  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-01 13:10:28  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-01 13:10:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-01 13:10:39  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-01 13:10:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-01 13:10:51  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-01 13:10:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-01 13:11:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-01 13:11:09  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-01 13:11:14  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-01 13:11:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-01 13:11:26  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-01 13:11:32  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-01 13:11:38  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-01 13:11:44  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-01 13:11:50  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-01 13:11:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-01 13:12:01  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-01 13:12:07  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-01 13:12:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-01 13:12:19  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-01 13:12:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-01 13:12:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-01 13:12:37  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-01 13:12:48  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-01 13:12:54  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-01 13:12:59  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-01 13:13:05  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-01 13:13:11  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-01 13:13:17  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-01 13:13:23  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-01 13:13:29  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-01 13:13:35  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-01 13:13:41  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-01 13:13:47  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-01 13:13:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-01 13:13:58  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-01 13:14:04  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-01 13:14:10  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-01 13:14:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-01 13:14:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-01 13:14:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-01 13:14:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-01 13:14:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-01 13:14:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-01 13:14:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-01 13:14:57  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-01 13:15:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-01 13:15:09  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-01 13:15:15  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-01 13:15:21  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-01 13:15:26  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-01 13:15:32  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-01 13:15:38  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-01 13:15:44  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-01 13:15:50  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-01 13:15:56  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-01 13:16:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-01 13:16:07  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-01 13:16:13  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-01 13:16:19  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-01 13:16:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-01 13:16:31  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-01 13:16:37  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-01 13:16:43  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-01 13:16:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-01 13:16:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-01 13:17:00  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-01 13:17:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-01 13:17:12  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-01 13:17:18  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-01 13:17:24  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-01 13:17:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-01 13:17:36  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-01 13:17:42  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-01 13:17:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-01 13:17:53  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-01 13:17:58  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-01 13:18:04  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-01 13:18:10  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-01 13:18:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-01 13:18:22  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-01 13:18:27  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-01 13:18:33  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-01 13:18:39  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-01 13:18:44  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-01 13:18:50  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-01 13:18:55  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-01 13:19:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-01 13:19:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-01 13:19:12  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-01 13:19:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-01 13:19:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-01 13:19:29  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-01 13:19:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-01 13:19:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-01 13:19:46  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-01 13:19:52  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-01 13:19:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-01 13:20:04  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-01 13:20:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-01 13:20:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-01 13:20:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-01 13:20:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-01 13:20:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-01 13:20:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-01 13:20:44  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-01 13:20:50  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-01 13:20:55  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-01 13:21:01  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-01 13:21:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-01 13:21:12  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-01 13:21:17  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-01 13:21:23  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-01 13:21:29  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-01 13:21:35  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-01 13:21:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-01 13:21:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-01 13:21:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-01 13:21:59  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-01 13:22:00  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-01 13:22:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-01 13:22:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-01 13:22:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-01 13:22:23  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-01 13:22:29  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-01 13:22:35  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-01 13:22:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-01 13:22:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-01 13:22:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-01 13:22:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-01 13:23:04  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-01 13:23:09  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-01 13:23:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-01 13:23:20  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-01 13:23:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-01 13:23:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-01 13:23:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-01 13:23:44  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-01 13:23:50  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-01 13:23:56  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-01 13:24:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-01 13:24:07  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-01 13:24:12  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-01 13:24:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-01 13:24:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-01 13:24:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-01 13:24:36  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-01 13:24:41  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-01 13:24:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-01 13:24:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-01 13:24:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-01 13:25:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-01 13:25:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-01 13:25:12  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-01 13:25:17  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-01 13:25:23  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-01 13:25:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-01 13:25:33  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-01 13:25:38  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-01 13:25:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-01 13:25:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-01 13:25:55  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-01 13:26:00  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-01 13:26:05  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-01 13:26:11  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-01 13:26:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-01 13:26:22  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-01 13:26:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-01 13:26:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-01 13:26:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-01 13:26:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-01 13:26:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-01 13:26:57  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-01 13:27:02  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-01 13:27:08  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-01 13:27:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-01 13:27:18  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-01 13:27:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-01 13:27:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-01 13:27:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-01 13:27:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 13:27:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 13:27:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 13:27:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 13:28:02  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-01 13:28:07  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 13:28:12  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 13:28:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-01 13:28:23  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-01 13:28:28  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-01 13:28:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-01 13:28:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-01 13:28:50  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-01 13:28:55  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-01 13:29:00  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-01 13:29:05  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-01 13:29:11  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-01 13:29:21  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-01 13:29:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-01 13:29:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-01 13:29:38  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-01 13:29:43  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-01 13:29:48  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-01 13:29:53  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-01 13:29:59  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-01 13:30:05  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-01 13:30:10  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-01 13:30:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 13:30:21  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 13:30:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 13:30:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 13:30:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 13:30:42  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-01 13:30:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 13:30:57  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 13:31:02  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 13:31:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 13:31:12  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-01 13:31:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 13:31:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 13:31:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 13:31:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-01 13:31:44  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-01_13-31-47 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-?_prerender {"code":"ECONNRESET"}
2017-04-01 13:33:49  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-01_14-01-47 Restart Xvfb...
2017-04-01_14-31-47 Restart Xvfb...
2017-04-01_15-01-47 Restart Xvfb...
2017-04-01 15:31:46 reset updateRequest
2017-04-01_15-31-47 Restart Xvfb...
2017-04-01 15:31:49  - 14968  http://www.lymphomahub.com/
2017-04-01 15:31:51  - 14968  http://www.lymphomahub.com/
2017-04-01 15:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-01 15:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-01 15:32:02  - 14968  http://www.lymphomahub.com/terms
2017-04-01 15:32:05  - 14968  http://www.lymphomahub.com/terms
2017-04-01 15:32:06  - 14968  http://www.lymphomahub.com/undefined
2017-04-01 15:32:07  - 14968  http://www.lymphomahub.com/therapies
2017-04-01 15:32:09  - 14968  http://www.lymphomahub.com/therapies
2017-04-01 15:32:17  - 14968  http://www.lymphomahub.com/newsletter
2017-04-01 15:32:18  - 14968  http://www.lymphomahub.com/newsletter
2017-04-01 15:32:22  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-01 15:32:23  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-01 15:32:26  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-01 15:32:27  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-01 15:32:32  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-01 15:32:32  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-01 15:32:39  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-01 15:32:45  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-01 15:32:51  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-01 15:32:56  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-01 15:33:02  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-01 15:33:08  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-01 15:33:14  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-01 15:33:20  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-01 15:33:25  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-01 15:33:31  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-01 15:33:37  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-01 15:33:42  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-01 15:33:48  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-01 15:33:54  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-01 15:34:00  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-01 15:34:06  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-01 15:34:12  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-01 15:34:17  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-01 15:34:23  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-01 15:34:28  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-01 15:34:34  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-01 15:34:40  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-01 15:34:45  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-01 15:34:51  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-01 15:34:57  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-01 15:35:03  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-01 15:35:08  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-01 15:35:14  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-01 15:35:20  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-01 15:35:25  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-01 15:35:31  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-01 15:35:37  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-01 15:35:43  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-01 15:35:49  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-01 15:35:55  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-01 15:36:00  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-01 15:36:06  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-01 15:36:12  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-01 15:36:17  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-01 15:36:23  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-01 15:36:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-01 15:36:35  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-01 15:36:40  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-01 15:36:46  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-01 15:36:52  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-01 15:36:58  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-01 15:37:04  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-01 15:37:09  - 14968  http://www.lymphomahub.com/medical-information
2017-04-01 15:37:15  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-01 15:37:20  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-01 15:37:26  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-01 15:37:32  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-01 15:37:37  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-01 15:37:43  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-01 15:37:49  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-01 15:37:58  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-01 15:38:03  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-01 15:38:09  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-01 15:38:15  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-01 15:38:21  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-01 15:38:22  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-01 15:38:28  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-01 15:38:34  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-01 15:38:39  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-01 15:38:45  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-01 15:38:51  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-01 15:38:57  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-01 15:39:02  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-01 15:39:09  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-01 15:39:15  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-01 15:39:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-01 15:39:26  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-01 15:39:32  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-01 15:39:38  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-01 15:39:47  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-01 15:39:53  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-01 15:39:59  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-01 15:40:05  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-01 15:40:11  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-01 15:40:17  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-01 15:40:22  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-01 15:40:28  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-01 15:40:34  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-01 15:40:39  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-01 15:40:45  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-01 15:40:51  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-01 15:40:57  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-01 15:41:02  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-01 15:41:08  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-01 15:41:14  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-01 15:41:20  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-01 15:41:21  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-01 15:41:27  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-01 15:41:33  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-01 15:41:38  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-01 15:41:44  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-01 15:41:50  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-01 15:41:56  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-01 15:42:01  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-01 15:42:07  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-01 15:42:12  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-01 15:42:13  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-01 15:42:19  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-01 15:42:24  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-01 15:42:30  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-01 15:42:36  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-01 15:42:42  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-01 15:42:43  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-01 15:42:48  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-01 15:42:54  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-01 15:42:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-01 15:43:04  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-01 15:43:10  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-01 15:43:15  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-01 15:43:21  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-01 15:43:26  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-01 15:43:31  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-01 15:43:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-01 15:43:43  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-01 15:43:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-01 15:43:54  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-01 15:44:00  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-01 15:44:00  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-01 15:44:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-01 15:44:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-01 15:44:18  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-01 15:44:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-01 15:44:29  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-01 15:44:35  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-01 15:44:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-01 15:44:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-01 15:44:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-01 15:44:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-01 15:45:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-01 15:45:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-01 15:45:13  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-01 15:45:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-01 15:45:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-01 15:45:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-01 15:45:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-01 15:45:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-01 15:45:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-01 15:45:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-01 15:45:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-01 15:46:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-01 15:46:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-01 15:46:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-01 15:46:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-01 15:46:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-01 15:46:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-01 15:46:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-01 15:46:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-01 15:46:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-01 15:46:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-01 15:46:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-01 15:47:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-01 15:47:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-01 15:47:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-01 15:47:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-01 15:47:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-01 15:47:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-01 15:47:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-01 15:47:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-01 15:47:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-01 15:47:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-01 15:47:55  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-01 15:48:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-01 15:48:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-01 15:48:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-01 15:48:17  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-01 15:48:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-01 15:48:27  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-01 15:48:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-01 15:48:38  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-01 15:48:44  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-01 15:48:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-01 15:48:55  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-01 15:49:06  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-01 15:49:11  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-01 15:49:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-01 15:49:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-01 15:49:31  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-01 15:49:36  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-01 15:49:42  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-01 15:49:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-01 15:49:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-01 15:49:59  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-01 15:50:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-01 15:50:10  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-01 15:50:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-01 15:50:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-01 15:50:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-01 15:50:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-01 15:50:40  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-01 15:50:41  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-01 15:50:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-01 15:50:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-01 15:50:58  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-01 15:51:04  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-01 15:51:10  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-01 15:51:16  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 15:51:22  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 15:51:28  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-01 15:51:34  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 15:51:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-01 15:51:46  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-01 15:51:52  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-01 15:51:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-01 15:52:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-01 15:52:10  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-01 15:52:15  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-01 15:52:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-01 15:52:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-01 15:52:33  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-01 15:52:39  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 15:52:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-01 15:52:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-01 15:52:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-01 15:53:04  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-01 15:53:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-01 15:53:17  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-01 15:53:22  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-01 15:53:28  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-01 15:53:34  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-01 15:53:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-01 15:53:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-01 15:53:52  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-01 15:53:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-01 15:54:04  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-01 15:54:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-01 15:54:16  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-01 15:54:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-01 15:54:28  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-01 15:54:34  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-01 15:54:40  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-01 15:54:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-01 15:54:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-01 15:54:53  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-01 15:54:59  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-01 15:55:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-01 15:55:11  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-01 15:55:17  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-01 15:55:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-01 15:55:29  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-01 15:55:35  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-01 15:55:41  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-01 15:55:47  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-01 15:55:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-01 15:55:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-01 15:56:05  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-01 15:56:11  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-01 15:56:17  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-01 15:56:22  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-01 15:56:28  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-01 15:56:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-01 15:56:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-01 15:56:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-01 15:56:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-01 15:56:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-01 15:57:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-01 15:57:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-01 15:57:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-01 15:57:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-01 15:57:20  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-01 15:57:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-01 15:57:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-01 15:57:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-01 15:57:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-01 15:57:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-01 15:57:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-01 15:57:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-01 15:57:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-01 15:58:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-01 15:58:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-01 15:58:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-01 15:58:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-01 15:58:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-01 15:58:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-01 15:58:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-01 15:58:33  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-01 15:58:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-01 15:58:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-01 15:58:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-01 15:58:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-01 15:58:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-01 15:59:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-01 15:59:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-01 15:59:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-01 15:59:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-01 15:59:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-01 15:59:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-01 15:59:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-01 15:59:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-01 15:59:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-01 15:59:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-01 15:59:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-01 15:59:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-01 15:59:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-01 15:59:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-01 16:00:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-01 16:00:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-01 16:00:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-01 16:00:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-01 16:00:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-01 16:00:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-01 16:00:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-01 16:00:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-01 16:00:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-01 16:00:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-01 16:00:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-01 16:00:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-01 16:00:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-01 16:01:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-01 16:01:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-01 16:01:10  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-01 16:01:16  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-01 16:01:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-01 16:01:28  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-01 16:01:29  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-01 16:01:35  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-01 16:01:41  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-01 16:01:47  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-01_16-01-47 Restart Xvfb...
2017-04-01 16:01:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-01 16:01:59  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-01 16:02:05  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-01 16:02:11  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-01 16:02:17  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-01 16:02:28  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-01 16:02:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-01 16:02:40  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-01 16:02:46  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-01 16:02:52  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-01 16:02:57  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-01 16:03:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-01 16:03:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-01 16:03:16  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-01 16:03:21  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-01 16:03:28  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-01 16:03:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-01 16:03:39  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-01 16:03:45  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-01 16:03:51  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-01 16:03:57  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-01 16:04:04  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-01 16:04:10  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-01 16:04:15  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-01 16:04:21  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-01 16:04:27  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-01 16:04:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-01 16:04:39  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-01 16:04:44  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-01 16:04:50  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-01 16:04:57  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-01 16:05:03  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-01 16:05:08  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-01 16:05:14  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-01 16:05:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-01 16:05:27  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-01 16:05:33  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-01 16:05:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-01 16:05:45  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-01 16:05:51  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-01 16:05:57  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-01 16:06:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-01 16:06:08  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-01 16:06:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-01 16:06:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-01 16:06:26  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-01 16:06:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-01 16:06:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-01 16:06:43  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-01 16:06:49  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-01 16:06:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-01 16:07:01  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-01 16:07:07  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-01 16:07:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-01 16:07:19  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-01 16:07:25  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-01 16:07:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-01 16:07:36  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-01 16:07:43  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-01 16:07:48  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-01 16:08:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-01 16:08:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-01 16:08:11  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-01 16:08:17  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-01 16:08:23  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-01 16:08:29  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-01 16:08:35  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-01 16:08:41  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-01 16:08:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-01 16:08:52  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-01 16:08:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-01 16:09:05  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-01 16:09:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-01 16:09:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-01 16:09:23  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-01 16:09:29  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-01 16:09:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-01 16:09:45  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-01 16:09:51  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-01 16:09:57  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-01 16:10:03  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-01 16:10:08  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-01 16:10:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-01 16:10:20  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-01 16:10:26  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-01 16:10:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-01 16:10:38  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-01 16:10:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-01 16:10:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-01 16:10:55  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-01 16:11:01  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-01 16:11:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-01 16:11:18  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-01 16:11:24  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-01 16:11:30  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-01 16:11:36  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-01 16:11:41  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-01 16:11:47  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-01 16:11:53  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-01 16:11:59  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-01 16:12:05  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-01 16:12:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-01 16:12:17  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-01 16:12:23  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-01 16:12:28  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-01 16:12:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-01 16:12:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-01 16:12:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-01 16:12:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-01 16:12:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-01 16:13:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-01 16:13:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-01 16:13:16  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-01 16:13:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-01 16:13:28  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-01 16:13:34  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-01 16:13:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-01 16:13:45  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-01 16:13:52  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-01 16:13:58  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-01 16:14:04  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-01 16:14:09  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-01 16:14:15  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-01 16:14:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-01 16:14:27  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-01 16:14:33  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-01 16:14:39  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-01 16:14:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-01 16:14:51  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-01 16:14:56  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-01 16:15:02  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-01 16:15:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-01 16:15:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-01 16:15:21  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-01 16:15:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-01 16:15:32  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-01 16:15:39  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-01 16:15:45  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-01 16:15:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-01 16:15:57  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-01 16:16:03  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-01 16:16:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-01 16:16:14  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-01 16:16:19  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-01 16:16:25  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-01 16:16:30  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-01 16:16:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-01 16:16:42  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-01 16:16:48  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-01 16:16:54  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-01 16:17:00  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-01 16:17:06  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-01 16:17:12  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-01 16:17:17  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-01 16:17:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-01 16:17:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-01 16:17:34  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-01 16:17:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-01 16:17:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-01 16:17:51  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-01 16:17:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-01 16:18:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-01 16:18:09  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-01 16:18:15  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-01 16:18:20  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-01 16:18:25  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-01 16:18:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-01 16:18:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-01 16:18:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-01 16:18:48  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-01 16:18:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-01 16:18:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-01 16:19:05  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-01 16:19:11  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-01 16:19:16  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-01 16:19:23  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-01 16:19:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-01 16:19:33  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-01 16:19:39  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-01 16:19:44  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-01 16:19:50  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-01 16:19:56  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-01 16:20:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-01 16:20:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-01 16:20:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-01 16:20:20  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-01 16:20:21  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-01 16:20:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-01 16:20:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-01 16:20:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-01 16:20:44  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-01 16:20:50  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-01 16:20:56  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-01 16:21:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-01 16:21:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-01 16:21:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-01 16:21:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-01 16:21:25  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-01 16:21:30  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-01 16:21:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-01 16:21:42  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-01 16:21:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-01 16:21:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-01 16:21:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-01 16:22:05  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-01 16:22:11  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-01 16:22:17  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-01 16:22:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-01 16:22:31  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-01 16:22:36  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-01 16:22:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-01 16:22:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-01 16:22:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-01 16:23:02  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-01 16:23:07  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-01 16:23:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-01 16:23:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-01 16:23:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-01 16:23:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-01 16:23:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-01 16:23:41  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-01 16:23:46  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-01 16:23:52  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-01 16:23:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-01 16:24:04  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-01 16:24:09  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-01 16:24:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-01 16:24:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-01 16:24:27  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-01 16:24:32  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-01 16:24:38  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-01 16:24:43  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-01 16:24:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-01 16:24:54  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-01 16:25:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-01 16:25:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-01 16:25:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-01 16:25:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-01 16:25:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-01 16:25:32  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-01 16:25:37  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-01 16:25:42  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-01 16:25:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-01 16:25:53  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-01 16:25:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-01 16:26:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-01 16:26:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-01 16:26:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 16:26:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 16:26:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 16:26:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 16:26:36  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-01 16:26:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 16:26:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 16:26:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-01 16:26:57  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-01 16:27:02  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-01 16:27:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-01 16:27:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-01 16:27:19  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-01 16:27:24  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-01 16:27:30  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-01 16:27:35  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-01 16:27:41  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-01 16:27:46  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-01 16:27:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-01 16:27:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-01 16:28:03  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-01 16:28:08  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-01 16:28:14  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-01 16:28:19  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-01 16:28:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-01 16:28:30  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-01 16:28:35  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-01 16:28:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 16:28:46  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 16:28:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 16:28:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 16:29:02  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 16:29:07  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-01 16:29:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 16:29:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 16:29:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 16:29:29  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 16:29:34  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-01 16:29:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 16:29:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 16:29:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 16:29:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-01 16:30:01  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-01_16-31-47 Restart Xvfb...
2017-04-01_17-01-47 Restart Xvfb...
2017-04-01_17-31-47 Restart Xvfb...
2017-04-01_18-01-47 Restart Xvfb...
2017-04-01 18:31:46 reset updateRequest
2017-04-01 18:31:47  - 14968  http://www.lymphomahub.com/
2017-04-01_18-31-47 Restart Xvfb...
2017-04-01 18:31:51  - 14968  http://www.lymphomahub.com/
2017-04-01 18:31:53  - 14968  http://www.lymphomahub.com/about
2017-04-01 18:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-01 18:31:59  - 14968  http://www.lymphomahub.com/terms
2017-04-01 18:32:04  - 14968  http://www.lymphomahub.com/undefined
2017-04-01 18:32:04  - 14968  http://www.lymphomahub.com/undefined
2017-04-01 18:32:04  - 14968  http://www.lymphomahub.com/therapies
2017-04-01 18:32:05  - 14968  http://www.lymphomahub.com/therapies
2017-04-01 18:32:14  - 14968  http://www.lymphomahub.com/newsletter
2017-04-01 18:32:14  - 14968  http://www.lymphomahub.com/newsletter
2017-04-01 18:32:19  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-01 18:32:20  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-01 18:32:24  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-01 18:32:25  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-01 18:32:30  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-01 18:32:30  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-01 18:32:36  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-01 18:32:42  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-01 18:32:47  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-01 18:32:53  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-01 18:32:59  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-01 18:33:05  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-01 18:33:10  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-01 18:33:16  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-01 18:33:22  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-01 18:33:27  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-01 18:33:33  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-01 18:33:39  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-01 18:33:45  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-01 18:33:50  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-01 18:33:56  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-01 18:34:02  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-01 18:34:08  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-01 18:34:14  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-01 18:34:19  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-01 18:34:24  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-01 18:34:29  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-01 18:34:35  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-01 18:34:46  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-01 18:34:52  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-01 18:34:58  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-01 18:35:04  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-01 18:35:10  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-01 18:35:15  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-01 18:35:21  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-01 18:35:27  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-01 18:35:33  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-01 18:35:39  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-01 18:35:44  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-01 18:35:50  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-01 18:35:56  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-01 18:36:01  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-01 18:36:07  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-01 18:36:13  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-01 18:36:19  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-01 18:36:24  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-01 18:36:30  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-01 18:36:36  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-01 18:36:41  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-01 18:36:47  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-01 18:36:53  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-01 18:36:59  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-01 18:37:05  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-01 18:37:10  - 14968  http://www.lymphomahub.com/medical-information
2017-04-01 18:37:16  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-01 18:37:22  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-01 18:37:27  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-01 18:37:33  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-01 18:37:39  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-01 18:37:44  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-01 18:37:50  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-01 18:37:56  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-01 18:38:03  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-01 18:38:09  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-01 18:38:20  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-01 18:38:25  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-01 18:38:26  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-01 18:38:32  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-01 18:38:38  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-01 18:38:44  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-01 18:38:50  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-01 18:38:56  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-01 18:39:02  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-01 18:39:07  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-01 18:39:13  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-01 18:39:19  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-01 18:39:24  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-01 18:39:30  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-01 18:39:36  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-01 18:39:42  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-01 18:39:48  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-01 18:39:53  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-01 18:39:59  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-01 18:40:05  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-01 18:40:11  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-01 18:40:17  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-01 18:40:22  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-01 18:40:28  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-01 18:40:34  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-01 18:40:39  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-01 18:40:45  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-01 18:40:51  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-01 18:40:57  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-01 18:41:02  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-01 18:41:08  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-01 18:41:14  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-01 18:41:19  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-01 18:41:20  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-01 18:41:26  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-01 18:41:32  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-01 18:41:38  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-01 18:41:43  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-01 18:41:49  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-01 18:41:55  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-01 18:42:00  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-01 18:42:06  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-01 18:42:11  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-01 18:42:11  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-01 18:42:17  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-01 18:42:23  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-01 18:42:28  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-01 18:42:34  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-01 18:42:40  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-01 18:42:41  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-01 18:42:47  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-01 18:42:52  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-01 18:42:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-01 18:43:03  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-01 18:43:09  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-01 18:43:14  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-01 18:43:20  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-01 18:43:25  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-01 18:43:30  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-01 18:43:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-01 18:43:41  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-01 18:43:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-01 18:43:52  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-01 18:43:57  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-01 18:43:58  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-01 18:44:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-01 18:44:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-01 18:44:15  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-01 18:44:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-01 18:44:26  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-01 18:44:32  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-01 18:44:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-01 18:44:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-01 18:44:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-01 18:44:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-01 18:45:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-01 18:45:09  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-01 18:45:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-01 18:45:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-01 18:45:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-01 18:45:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-01 18:45:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-01 18:45:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-01 18:45:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-01 18:45:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-01 18:45:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-01 18:46:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-01 18:46:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-01 18:46:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-01 18:46:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-01 18:46:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-01 18:46:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-01 18:46:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-01 18:46:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-01 18:46:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-01 18:46:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-01 18:46:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-01 18:47:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-01 18:47:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-01 18:47:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-01 18:47:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-01 18:47:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-01 18:47:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-01 18:47:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-01 18:47:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-01 18:47:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-01 18:47:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-01 18:48:02  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-01 18:48:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-01 18:48:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-01 18:48:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-01 18:48:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-01 18:48:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-01 18:48:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-01 18:48:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-01 18:48:44  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-01 18:48:50  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-01 18:48:56  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-01 18:49:02  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-01 18:49:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-01 18:49:13  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-01 18:49:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-01 18:49:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-01 18:49:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-01 18:49:35  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-01 18:49:41  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-01 18:49:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-01 18:49:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-01 18:49:58  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-01 18:50:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-01 18:50:09  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-01 18:50:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-01 18:50:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-01 18:50:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-01 18:50:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-01 18:50:39  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-01 18:50:40  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-01 18:50:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-01 18:50:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-01 18:50:58  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-01 18:51:04  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-01 18:51:10  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-01 18:51:16  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 18:51:22  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 18:51:27  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-01 18:51:33  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 18:51:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-01 18:51:45  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-01 18:51:52  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-01 18:51:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-01 18:52:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-01 18:52:09  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-01 18:52:14  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-01 18:52:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-01 18:52:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-01 18:52:32  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-01 18:52:38  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 18:52:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-01 18:52:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-01 18:52:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-01 18:53:01  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-01 18:53:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-01 18:53:13  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-01 18:53:19  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-01 18:53:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-01 18:53:31  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-01 18:53:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-01 18:53:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-01 18:53:49  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-01 18:53:55  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-01 18:54:01  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-01 18:54:06  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-01 18:54:12  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-01 18:54:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-01 18:54:25  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-01 18:54:30  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-01 18:54:36  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-01 18:54:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-01 18:54:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-01 18:54:48  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-01 18:54:54  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-01 18:55:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-01 18:55:06  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-01 18:55:12  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-01 18:55:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-01 18:55:23  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-01 18:55:29  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-01 18:55:35  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-01 18:55:41  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-01 18:55:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-01 18:55:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-01 18:55:59  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-01 18:56:04  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-01 18:56:10  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-01 18:56:16  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-01 18:56:22  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-01 18:56:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-01 18:56:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-01 18:56:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-01 18:56:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-01 18:56:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-01 18:56:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-01 18:56:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-01 18:57:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-01 18:57:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-01 18:57:14  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-01 18:57:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-01 18:57:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-01 18:57:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-01 18:57:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-01 18:57:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-01 18:57:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-01 18:57:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-01 18:57:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-01 18:57:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-01 18:58:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-01 18:58:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-01 18:58:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-01 18:58:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-01 18:58:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-01 18:58:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-01 18:58:28  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-01 18:58:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-01 18:58:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-01 18:58:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-01 18:58:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-01 18:58:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-01 18:58:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-01 18:59:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-01 18:59:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-01 18:59:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-01 18:59:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-01 18:59:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-01 18:59:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-01 18:59:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-01 18:59:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-01 18:59:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-01 18:59:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-01 18:59:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-01 18:59:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-01 18:59:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-01 18:59:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-01 19:00:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-01 19:00:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-01 19:00:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-01 19:00:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-01 19:00:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-01 19:00:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-01 19:00:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-01 19:00:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-01 19:00:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-01 19:00:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-01 19:00:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-01 19:00:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-01 19:00:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-01 19:00:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-01 19:01:02  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-01 19:01:08  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-01 19:01:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-01 19:01:20  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-01 19:01:21  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-01 19:01:27  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-01 19:01:33  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-01 19:01:39  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-01 19:01:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-01_19-01-47 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185?_prerender {"code":"ECONNRESET"}
2017-04-01 19:03:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-01 19:03:56  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-01 19:04:02  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-01 19:04:08  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-01 19:04:14  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-01 19:04:20  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-01 19:04:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-01 19:04:32  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-01 19:04:38  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-01 19:04:44  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-01 19:04:50  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-01 19:04:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-01 19:05:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-01 19:05:09  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-01 19:05:15  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-01 19:05:21  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-01 19:05:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-01 19:05:33  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-01 19:05:38  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-01 19:05:44  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-01 19:05:50  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-01 19:05:56  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-01 19:06:02  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-01 19:06:08  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-01 19:06:14  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-01 19:06:20  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-01 19:06:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-01 19:06:32  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-01 19:06:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-01 19:06:44  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-01 19:06:50  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-01 19:06:56  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-01 19:07:02  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-01 19:07:08  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-01 19:07:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-01 19:07:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-01 19:07:26  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-01 19:07:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-01 19:07:38  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-01 19:07:43  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-01 19:07:49  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-01 19:07:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-01 19:08:01  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-01 19:08:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-01 19:08:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-01 19:08:19  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-01 19:08:24  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-01 19:08:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-01 19:08:36  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-01 19:08:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-01 19:08:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-01 19:08:54  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-01 19:09:00  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-01 19:09:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-01 19:09:12  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-01 19:09:18  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-01 19:09:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-01 19:09:29  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-01 19:09:35  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-01 19:09:41  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-01 19:09:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-01 19:09:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-01 19:09:59  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-01 19:10:05  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-01 19:10:11  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-01 19:10:17  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-01 19:10:24  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-01 19:10:30  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-01 19:10:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-01 19:10:42  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-01 19:10:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-01 19:10:53  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-01 19:10:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-01 19:11:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-01 19:11:12  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-01 19:11:17  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-01 19:11:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-01 19:11:29  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-01 19:11:35  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-01 19:11:41  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-01 19:11:46  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-01 19:11:52  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-01 19:11:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-01 19:12:03  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-01 19:12:09  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-01 19:12:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-01 19:12:22  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-01 19:12:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-01 19:12:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-01 19:12:39  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-01 19:12:45  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-01 19:12:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-01 19:12:57  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-01 19:13:03  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-01 19:13:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-01 19:13:16  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-01 19:13:22  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-01 19:13:28  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-01 19:13:34  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-01 19:13:39  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-01 19:13:45  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-01 19:13:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-01 19:13:57  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-01 19:14:03  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-01 19:14:08  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-01 19:14:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-01 19:14:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-01 19:14:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-01 19:14:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-01 19:14:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-01 19:14:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-01 19:14:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-01 19:14:56  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-01 19:15:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-01 19:15:08  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-01 19:15:14  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-01 19:15:19  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-01 19:15:24  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-01 19:15:30  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-01 19:15:36  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-01 19:15:42  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-01 19:15:48  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-01 19:15:53  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-01 19:15:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-01 19:16:05  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-01 19:16:11  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-01 19:16:17  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-01 19:16:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-01 19:16:29  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-01 19:16:35  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-01 19:16:41  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-01 19:16:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-01 19:16:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-01 19:16:59  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-01 19:17:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-01 19:17:10  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-01 19:17:16  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-01 19:17:22  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-01 19:17:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-01 19:17:34  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-01 19:17:40  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-01 19:17:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-01 19:17:51  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-01 19:17:57  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-01 19:18:02  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-01 19:18:08  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-01 19:18:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-01 19:18:20  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-01 19:18:25  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-01 19:18:31  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-01 19:18:37  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-01 19:18:43  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-01 19:18:49  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-01 19:18:54  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-01 19:18:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-01 19:19:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-01 19:19:12  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-01 19:19:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-01 19:19:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-01 19:19:28  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-01 19:19:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-01 19:19:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-01 19:19:46  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-01 19:19:52  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-01 19:19:57  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-01 19:20:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-01 19:20:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-01 19:20:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-01 19:20:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-01 19:20:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-01 19:20:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-01 19:20:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-01 19:20:43  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-01 19:20:48  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-01 19:20:54  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-01 19:21:00  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-01 19:21:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-01 19:21:12  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-01 19:21:17  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-01 19:21:23  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-01 19:21:29  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-01 19:21:35  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-01 19:21:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-01 19:21:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-01 19:21:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-01 19:21:58  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-01 19:21:59  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-01 19:22:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-01 19:22:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-01 19:22:16  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-01 19:22:27  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-01 19:22:33  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-01 19:22:39  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-01 19:22:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-01 19:22:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-01 19:22:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-01 19:23:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-01 19:23:08  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-01 19:23:13  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-01 19:23:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-01 19:23:25  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-01 19:23:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-01 19:23:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-01 19:23:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-01 19:23:48  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-01 19:23:53  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-01 19:24:00  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-01 19:24:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-01 19:24:11  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-01 19:24:17  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-01 19:24:22  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-01 19:24:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-01 19:24:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-01 19:24:40  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-01 19:24:45  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-01 19:24:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-01 19:24:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-01 19:25:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-01 19:25:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-01 19:25:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-01 19:25:18  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-01 19:25:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-01 19:25:29  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-01 19:25:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-01 19:25:40  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-01 19:25:45  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-01 19:25:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-01 19:25:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-01 19:26:02  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-01 19:26:07  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-01 19:26:12  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-01 19:26:18  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-01 19:26:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-01 19:26:29  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-01 19:26:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-01 19:26:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-01 19:26:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-01 19:26:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-01 19:26:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-01 19:27:04  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-01 19:27:09  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-01 19:27:14  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-01 19:27:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-01 19:27:26  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-01 19:27:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-01 19:27:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-01 19:27:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-01 19:27:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 19:27:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 19:27:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 19:28:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 19:28:09  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-01 19:28:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 19:28:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 19:28:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-01 19:28:30  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-01 19:28:36  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-01 19:28:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-01 19:28:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-01 19:28:53  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-01 19:28:58  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-01 19:29:04  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-01 19:29:09  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-01 19:29:15  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-01 19:29:20  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-01 19:29:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-01 19:29:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-01 19:29:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-01 19:29:45  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-01 19:29:50  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-01 19:29:55  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-01 19:30:01  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-01 19:30:06  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-01 19:30:12  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-01 19:30:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 19:30:24  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 19:30:29  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 19:30:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 19:30:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 19:30:45  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-01 19:30:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 19:30:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 19:31:01  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 19:31:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 19:31:12  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-01 19:31:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 19:31:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 19:31:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 19:31:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-01 19:31:38  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-01_19-31-47 Restart Xvfb...
2017-04-01_20-01-47 Restart Xvfb...
2017-04-01_20-31-47 Restart Xvfb...
2017-04-01_21-01-47 Restart Xvfb...
2017-04-01 21:31:46 reset updateRequest
2017-04-01_21-31-47 Restart Xvfb...
2017-04-01 21:31:49  - 14968  http://www.lymphomahub.com/
2017-04-01 21:31:51  - 14968  http://www.lymphomahub.com/
2017-04-01 21:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-01 21:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-01 21:32:03  - 14968  http://www.lymphomahub.com/terms
2017-04-01 21:32:03  - 14968  http://www.lymphomahub.com/terms
2017-04-01 21:32:07  - 14968  http://www.lymphomahub.com/undefined
2017-04-01 21:32:07  - 14968  http://www.lymphomahub.com/undefined
2017-04-01 21:32:08  - 14968  http://www.lymphomahub.com/therapies
2017-04-01 21:32:08  - 14968  http://www.lymphomahub.com/therapies
2017-04-01 21:32:17  - 14968  http://www.lymphomahub.com/newsletter
2017-04-01 21:32:18  - 14968  http://www.lymphomahub.com/newsletter
2017-04-01 21:32:22  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-01 21:32:22  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-01 21:32:26  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-01 21:32:26  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-01 21:32:32  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-01 21:32:38  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-01 21:32:44  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-01 21:32:49  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-01 21:32:55  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-01 21:33:01  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-01 21:33:07  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-01 21:33:13  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-01 21:33:19  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-01 21:33:25  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-01 21:33:30  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-01 21:33:36  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-01 21:33:42  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-01 21:33:47  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-01 21:33:53  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-01 21:33:58  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-01 21:34:04  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-01 21:34:10  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-01 21:34:16  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-01 21:34:22  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-01 21:34:27  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-01 21:34:32  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-01 21:34:38  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-01 21:34:43  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-01 21:34:49  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-01 21:34:55  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-01 21:35:06  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-01 21:35:12  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-01 21:35:18  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-01 21:35:23  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-01 21:35:29  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-01 21:35:35  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-01 21:35:40  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-01 21:35:46  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-01 21:35:52  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-01 21:36:03  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-01 21:36:08  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-01 21:36:14  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-01 21:36:20  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-01 21:36:26  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-01 21:36:32  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-01 21:36:37  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-01 21:36:43  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-01 21:36:49  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-01 21:36:55  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-01 21:37:01  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-01 21:37:06  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-01 21:37:12  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-01 21:37:18  - 14968  http://www.lymphomahub.com/medical-information
2017-04-01 21:37:23  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-01 21:37:29  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-01 21:37:35  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-01 21:37:40  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-01 21:37:46  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-01 21:37:52  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-01 21:37:58  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-01 21:38:03  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-01 21:38:09  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-01 21:38:15  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-01 21:38:20  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-01 21:38:26  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-01 21:38:27  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-01 21:38:33  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-01 21:38:39  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-01 21:38:44  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-01 21:38:53  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-01 21:38:58  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-01 21:39:04  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-01 21:39:10  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-01 21:39:16  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-01 21:39:22  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-01 21:39:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-01 21:39:33  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-01 21:39:39  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-01 21:39:45  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-01 21:39:51  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-01 21:39:56  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-01 21:40:02  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-01 21:40:08  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-01 21:40:13  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-01 21:40:19  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-01 21:40:25  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-01 21:40:31  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-01 21:40:37  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-01 21:40:42  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-01 21:40:48  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-01 21:40:54  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-01 21:41:00  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-01 21:41:05  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-01 21:41:11  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-01 21:41:17  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-01 21:41:22  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-01 21:41:24  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-01 21:41:29  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-01 21:41:35  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-01 21:41:41  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-01 21:41:47  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-01 21:41:52  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-01 21:41:58  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-01 21:42:04  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-01 21:42:10  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-01 21:42:15  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-01 21:42:15  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-01 21:42:21  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-01 21:42:26  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-01 21:42:32  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-01 21:42:38  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-01 21:42:44  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-01 21:42:45  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-01 21:42:51  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-01 21:42:56  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-01 21:43:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-01 21:43:07  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-01 21:43:13  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-01 21:43:18  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-01 21:43:23  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-01 21:43:28  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-01 21:43:34  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-01 21:43:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-01 21:43:45  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-01 21:43:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-01 21:43:56  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-01 21:44:02  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-01 21:44:03  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-01 21:44:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-01 21:44:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-01 21:44:20  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-01 21:44:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-01 21:44:32  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-01 21:44:38  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-01 21:44:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-01 21:44:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-01 21:44:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-01 21:44:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-01 21:45:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-01 21:45:10  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-01 21:45:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-01 21:45:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-01 21:45:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-01 21:45:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-01 21:45:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-01 21:45:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-01 21:45:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-01 21:45:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-01 21:46:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-01 21:46:09  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-01 21:46:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-01 21:46:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-01 21:46:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-01 21:46:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-01 21:46:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-01 21:46:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-01 21:46:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-01 21:46:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-01 21:46:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-01 21:47:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-01 21:47:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-01 21:47:14  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-01 21:47:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-01 21:47:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-01 21:47:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-01 21:47:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-01 21:47:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-01 21:47:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-01 21:47:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-01 21:48:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-01 21:48:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-01 21:48:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-01 21:48:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-01 21:48:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-01 21:48:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-01 21:48:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-01 21:48:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-01 21:48:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-01 21:48:57  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-01 21:49:03  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-01 21:49:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-01 21:49:15  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-01 21:49:21  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-01 21:49:26  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-01 21:49:32  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-01 21:49:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-01 21:49:48  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-01 21:49:53  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-01 21:49:59  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-01 21:50:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-01 21:50:10  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-01 21:50:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-01 21:50:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-01 21:50:27  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-01 21:50:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-01 21:50:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-01 21:50:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-01 21:50:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-01 21:50:56  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-01 21:50:57  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-01 21:51:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-01 21:51:09  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-01 21:51:15  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-01 21:51:21  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-01 21:51:26  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-01 21:51:32  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 21:51:38  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 21:51:44  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-01 21:51:49  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 21:51:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-01 21:52:02  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-01 21:52:07  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-01 21:52:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-01 21:52:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-01 21:52:25  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-01 21:52:31  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-01 21:52:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-01 21:52:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-01 21:52:49  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-01 21:52:55  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-01 21:53:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-01 21:53:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-01 21:53:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-01 21:53:18  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-01 21:53:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-01 21:53:30  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-01 21:53:36  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-01 21:53:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-01 21:53:48  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-01 21:53:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-01 21:54:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-01 21:54:11  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-01 21:54:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-01 21:54:28  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-01 21:54:34  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-01 21:54:40  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-01 21:54:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-01 21:54:52  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-01 21:54:58  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-01 21:55:04  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-01 21:55:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-01 21:55:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-01 21:55:17  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-01 21:55:23  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-01 21:55:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-01 21:55:35  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-01 21:55:40  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-01 21:55:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-01 21:55:52  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-01 21:55:58  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-01 21:56:04  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-01 21:56:10  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-01 21:56:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-01 21:56:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-01 21:56:28  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-01 21:56:34  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-01 21:56:40  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-01 21:56:46  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-01 21:56:52  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-01 21:56:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-01 21:57:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-01 21:57:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-01 21:57:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-01 21:57:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-01 21:57:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-01 21:57:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-01 21:57:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-01 21:57:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-01 21:57:44  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-01 21:57:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-01 21:57:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-01 21:58:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-01 21:58:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-01 21:58:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-01 21:58:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-01 21:58:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-01 21:58:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-01 21:58:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-01 21:58:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-01 21:58:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-01 21:58:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-01 21:58:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-01 21:58:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-01 21:58:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-01 21:59:00  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-01 21:59:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-01 21:59:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-01 21:59:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-01 21:59:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-01 21:59:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-01 21:59:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-01 21:59:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-01 21:59:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-01 21:59:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-01 21:59:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-01 21:59:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-01 21:59:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-01 21:59:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-01 22:00:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-01 22:00:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-01 22:00:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-01 22:00:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-01 22:00:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-01 22:00:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-01 22:00:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-01 22:00:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-01 22:00:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-01 22:00:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-01 22:00:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-01 22:00:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-01 22:00:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-01 22:01:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-01 22:01:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-01 22:01:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-01 22:01:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-01 22:01:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-01 22:01:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-01 22:01:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-01 22:01:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-01 22:01:40  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-01 22:01:46  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-01_22-01-48 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance?_prerender {"code":"ECONNRESET"}
2017-04-01 22:03:51  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-01 22:04:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-01 22:04:06  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-01 22:04:07  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-01 22:04:13  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-01 22:04:19  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-01 22:04:26  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-01 22:04:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-01 22:04:38  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-01 22:04:44  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-01 22:04:50  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-01 22:04:56  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-01 22:05:02  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-01 22:05:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-01 22:05:14  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-01 22:05:20  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-01 22:05:26  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-01 22:05:32  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-01 22:05:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-01 22:05:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-01 22:05:50  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-01 22:05:56  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-01 22:06:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-01 22:06:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-01 22:06:14  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-01 22:06:20  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-01 22:06:26  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-01 22:06:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-01 22:06:37  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-01 22:06:43  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-01 22:06:49  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-01 22:06:55  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-01 22:07:01  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-01 22:07:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-01 22:07:13  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-01 22:07:19  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-01 22:07:25  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-01 22:07:31  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-01 22:07:36  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-01 22:07:42  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-01 22:07:48  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-01 22:07:54  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-01 22:08:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-01 22:08:06  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-01 22:08:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-01 22:08:17  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-01 22:08:24  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-01 22:08:29  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-01 22:08:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-01 22:08:47  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-01 22:08:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-01 22:08:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-01 22:09:04  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-01 22:09:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-01 22:09:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-01 22:09:21  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-01 22:09:27  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-01 22:09:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-01 22:09:39  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-01 22:09:45  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-01 22:09:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-01 22:09:57  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-01 22:10:03  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-01 22:10:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-01 22:10:15  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-01 22:10:21  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-01 22:10:26  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-01 22:10:32  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-01 22:10:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-01 22:10:44  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-01 22:10:50  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-01 22:10:55  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-01 22:11:01  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-01 22:11:07  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-01 22:11:13  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-01 22:11:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-01 22:11:25  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-01 22:11:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-01 22:11:37  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-01 22:11:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-01 22:11:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-01 22:11:54  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-01 22:12:00  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-01 22:12:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-01 22:12:12  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-01 22:12:18  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-01 22:12:24  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-01 22:12:30  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-01 22:12:36  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-01 22:12:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-01 22:12:47  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-01 22:12:53  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-01 22:13:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-01 22:13:05  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-01 22:13:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-01 22:13:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-01 22:13:23  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-01 22:13:29  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-01 22:13:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-01 22:13:41  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-01 22:13:47  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-01 22:13:53  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-01 22:13:59  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-01 22:14:05  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-01 22:14:10  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-01 22:14:16  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-01 22:14:25  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-01 22:14:31  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-01 22:14:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-01 22:14:43  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-01 22:14:49  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-01 22:14:55  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-01 22:15:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-01 22:15:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-01 22:15:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-01 22:15:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-01 22:15:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-01 22:15:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-01 22:15:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-01 22:15:42  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-01 22:15:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-01 22:15:57  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-01 22:16:03  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-01 22:16:09  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-01 22:16:14  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-01 22:16:20  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-01 22:16:26  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-01 22:16:32  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-01 22:16:43  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-01 22:16:48  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-01 22:16:54  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-01 22:17:00  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-01 22:17:06  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-01 22:17:12  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-01 22:17:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-01 22:17:24  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-01 22:17:30  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-01 22:17:36  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-01 22:17:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-01 22:17:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-01 22:17:54  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-01 22:17:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-01 22:18:05  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-01 22:18:11  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-01 22:18:17  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-01 22:18:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-01 22:18:29  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-01 22:18:35  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-01 22:18:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-01 22:18:46  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-01 22:18:52  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-01 22:18:57  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-01 22:19:03  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-01 22:19:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-01 22:19:15  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-01 22:19:20  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-01 22:19:26  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-01 22:19:32  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-01 22:19:38  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-01 22:19:44  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-01 22:19:49  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-01 22:19:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-01 22:20:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-01 22:20:06  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-01 22:20:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-01 22:20:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-01 22:20:23  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-01 22:20:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-01 22:20:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-01 22:20:45  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-01 22:20:51  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-01 22:20:57  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-01 22:21:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-01 22:21:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-01 22:21:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-01 22:21:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-01 22:21:25  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-01 22:21:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-01 22:21:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-01 22:21:42  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-01 22:21:48  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-01 22:21:54  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-01 22:22:00  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-01 22:22:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-01 22:22:11  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-01 22:22:16  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-01 22:22:22  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-01 22:22:28  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-01 22:22:34  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-01 22:22:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-01 22:22:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-01 22:22:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-01 22:23:02  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-01 22:23:03  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-01 22:23:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-01 22:23:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-01 22:23:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-01 22:23:27  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-01 22:23:33  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-01 22:23:39  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-01 22:23:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-01 22:23:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-01 22:23:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-01 22:24:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-01 22:24:07  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-01 22:24:12  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-01 22:24:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-01 22:24:23  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-01 22:24:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-01 22:24:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-01 22:24:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-01 22:24:46  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-01 22:24:52  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-01 22:24:58  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-01 22:25:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-01 22:25:10  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-01 22:25:15  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-01 22:25:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-01 22:25:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-01 22:25:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-01 22:25:39  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-01 22:25:44  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-01 22:25:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-01 22:25:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-01 22:26:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-01 22:26:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-01 22:26:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-01 22:26:17  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-01 22:26:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-01 22:26:28  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-01 22:26:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-01 22:26:39  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-01 22:26:44  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-01 22:26:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-01 22:26:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-01 22:27:01  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-01 22:27:07  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-01 22:27:12  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-01 22:27:17  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-01 22:27:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-01 22:27:28  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-01 22:27:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-01 22:27:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-01 22:27:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-01 22:27:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-01 22:27:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-01 22:28:03  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-01 22:28:08  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-01 22:28:13  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-01 22:28:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-01 22:28:24  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-01 22:28:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-01 22:28:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-01 22:28:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-01 22:28:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 22:28:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 22:28:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 22:29:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 22:29:07  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-01 22:29:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 22:29:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-01 22:29:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-01 22:29:28  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-01 22:29:34  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-01 22:29:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-01 22:29:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-01 22:29:50  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-01 22:29:56  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-01 22:30:01  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-01 22:30:07  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-01 22:30:12  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-01 22:30:18  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-01 22:30:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-01 22:30:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-01 22:30:35  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-01 22:30:40  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-01 22:30:46  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-01 22:30:51  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-01 22:30:56  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-01 22:31:01  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-01 22:31:07  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-01 22:31:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 22:31:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 22:31:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 22:31:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 22:31:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-01 22:31:39  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-01 22:31:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01_22-31-48 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly?_prerender {"code":"ECONNRESET"}
2017-04-01 22:33:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 22:33:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 22:34:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 22:34:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 22:34:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-01 22:34:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 22:34:25  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 22:34:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-01 22:34:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-01 22:34:41  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-01_23-01-48 Restart Xvfb...
2017-04-01_23-31-48 Restart Xvfb...
2017-04-02_00-01-48 Restart Xvfb...
2017-04-02 00:31:46 reset updateRequest
2017-04-02 00:31:46  - 14968  http://www.lymphomahub.com/
2017-04-02_00-31-48 Restart Xvfb...
2017-04-02 00:31:51  - 14968  http://www.lymphomahub.com/
2017-04-02 00:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-02 00:32:03  - 14968  http://www.lymphomahub.com/terms
2017-04-02 00:32:07  - 14968  http://www.lymphomahub.com/undefined
2017-04-02 00:32:07  - 14968  http://www.lymphomahub.com/therapies
2017-04-02 00:32:14  - 14968  http://www.lymphomahub.com/newsletter
2017-04-02 00:32:18  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-02 00:32:22  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-02 00:32:28  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-02 00:32:33  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-02 00:32:39  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-02 00:32:45  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-02 00:32:51  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-02 00:32:56  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-02 00:33:02  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-02 00:33:08  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-02 00:33:13  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-02 00:33:19  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-02 00:33:25  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-02 00:33:31  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-02 00:33:36  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-02 00:33:42  - 14968  http://www.lymphomahub.com/therapies/imgn529
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-02 00:33:48  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-02 00:33:51  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-02 00:33:53  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-02 00:33:56  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-02 00:34:00  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-02 00:34:02  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-02 00:34:06  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-02 00:34:09  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-02 00:34:12  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-02 00:34:14  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-02 00:34:19  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-02 00:34:23  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-02 00:34:24  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-02 00:34:31  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-02 00:34:31  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-02 00:34:36  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-02 00:34:37  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-02 00:34:43  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-02 00:34:54  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-02 00:35:00  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-02 00:35:06  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-02 00:35:11  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-02 00:35:17  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-02 00:35:23  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-02 00:35:29  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-02 00:35:34  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-02 00:35:40  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-02 00:35:46  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-02 00:35:51  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-02 00:35:57  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-02 00:36:03  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-02 00:36:08  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-02 00:36:14  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-02 00:36:20  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-02 00:36:25  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-02 00:36:31  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-02 00:36:37  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-02 00:36:42  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-02 00:36:53  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-02 00:36:59  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-02 00:37:05  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-02 00:37:10  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-02 00:37:16  - 14968  http://www.lymphomahub.com/medical-information
2017-04-02 00:37:21  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-02 00:37:27  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-02 00:37:33  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-02 00:37:38  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-02 00:37:44  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-02 00:37:50  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-02 00:37:55  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-02 00:38:01  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-02 00:38:07  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-02 00:38:12  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-02 00:38:18  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-02 00:38:23  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-02 00:38:24  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-02 00:38:30  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-02 00:38:36  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-02 00:38:42  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-02 00:38:47  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-02 00:38:53  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-02 00:38:59  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-02 00:39:05  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-02 00:39:10  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-02 00:39:17  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-02 00:39:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-02 00:39:28  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-02 00:39:34  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-02 00:39:45  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-02 00:39:50  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-02 00:39:56  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-02 00:40:01  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-02 00:40:07  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-02 00:40:13  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-02 00:40:19  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-02 00:40:24  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-02 00:40:30  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-02 00:40:36  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-02 00:40:41  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-02 00:40:47  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-02 00:40:53  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-02 00:40:58  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-02 00:41:04  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-02 00:41:10  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-02 00:41:16  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-02 00:41:22  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-02 00:41:23  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-02 00:41:28  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-02 00:41:34  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-02 00:41:39  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-02 00:41:45  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-02 00:41:51  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-02 00:41:57  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-02 00:42:03  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-02 00:42:09  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-02 00:42:13  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-02 00:42:14  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-02 00:42:20  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-02 00:42:25  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-02 00:42:31  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-02 00:42:37  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-02 00:42:42  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-02 00:42:43  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-02 00:42:49  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-02 00:42:55  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-02 00:43:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-02 00:43:05  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-02 00:43:11  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-02 00:43:16  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-02 00:43:22  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-02 00:43:26  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-02 00:43:32  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-02 00:43:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-02 00:43:43  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-02 00:43:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-02 00:43:54  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-02 00:43:59  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-02 00:44:00  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-02 00:44:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-02 00:44:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-02 00:44:18  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-02 00:44:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-02 00:44:29  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-02 00:44:35  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-02 00:44:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-02 00:44:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-02 00:44:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-02 00:44:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-02 00:45:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-02 00:45:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-02 00:45:12  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-02 00:45:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-02 00:45:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-02 00:45:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-02 00:45:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-02 00:45:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-02 00:45:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-02 00:45:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-02 00:45:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-02 00:46:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-02 00:46:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-02 00:46:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-02 00:46:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-02 00:46:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-02 00:46:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-02 00:46:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-02 00:46:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-02 00:46:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-02 00:46:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-02 00:46:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-02 00:47:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-02 00:47:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-02 00:47:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-02 00:47:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-02 00:47:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-02 00:47:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-02 00:47:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-02 00:47:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-02 00:47:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-02 00:47:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-02 00:48:00  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-02 00:48:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-02 00:48:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-02 00:48:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-02 00:48:21  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-02 00:48:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-02 00:48:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-02 00:48:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-02 00:48:42  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-02 00:48:48  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-02 00:48:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-02 00:48:59  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-02 00:49:05  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-02 00:49:10  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-02 00:49:16  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-02 00:49:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-02 00:49:27  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-02 00:49:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-02 00:49:38  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-02 00:49:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-02 00:49:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-02 00:49:55  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-02 00:50:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-02 00:50:06  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-02 00:50:12  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-02 00:50:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-02 00:50:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-02 00:50:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-02 00:50:36  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-02 00:50:37  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-02 00:50:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-02 00:50:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-02 00:50:54  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-02 00:51:00  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-02 00:51:06  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-02 00:51:12  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 00:51:17  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 00:51:23  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-02 00:51:29  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 00:51:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-02 00:51:40  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-02 00:51:46  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-02 00:51:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-02 00:51:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-02 00:52:04  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-02 00:52:09  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-02 00:52:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-02 00:52:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-02 00:52:27  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-02 00:52:33  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 00:52:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-02 00:52:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-02 00:52:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-02 00:53:02  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-02 00:53:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-02 00:53:13  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-02 00:53:19  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-02 00:53:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-02 00:53:31  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-02 00:53:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-02 00:53:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-02 00:53:48  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-02 00:53:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-02 00:54:00  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-02 00:54:06  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-02 00:54:12  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-02 00:54:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-02 00:54:23  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-02 00:54:29  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-02 00:54:35  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-02 00:54:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-02 00:54:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-02 00:54:47  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-02 00:54:53  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-02 00:54:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-02 00:55:05  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-02 00:55:11  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-02 00:55:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-02 00:55:23  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-02 00:55:29  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-02 00:55:35  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-02 00:55:41  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-02 00:55:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-02 00:55:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-02 00:55:58  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-02 00:56:04  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-02 00:56:10  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-02 00:56:15  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-02 00:56:21  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-02 00:56:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-02 00:56:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-02 00:56:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-02 00:56:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-02 00:56:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-02 00:56:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-02 00:56:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-02 00:57:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-02 00:57:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-02 00:57:13  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-02 00:57:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-02 00:57:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-02 00:57:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-02 00:57:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-02 00:57:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-02 00:57:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-02 00:57:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-02 00:57:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-02 00:57:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-02 00:57:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-02 00:57:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-02 00:58:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-02 00:58:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-02 00:58:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-02 00:58:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-02 00:58:21  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-02 00:58:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-02 00:58:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-02 00:58:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-02 00:58:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-02 00:58:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-02 00:58:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-02 00:58:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-02 00:58:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-02 00:59:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-02 00:59:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-02 00:59:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-02 00:59:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-02 00:59:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-02 00:59:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-02 00:59:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-02 00:59:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-02 00:59:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-02 00:59:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-02 00:59:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-02 00:59:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-02 00:59:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-02 00:59:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-02 01:00:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-02 01:00:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-02 01:00:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-02 01:00:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-02 01:00:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-02 01:00:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-02 01:00:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-02 01:00:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-02 01:00:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-02 01:00:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-02 01:00:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-02 01:00:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-02 01:00:56  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-02 01:01:03  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-02 01:01:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-02 01:01:15  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-02 01:01:16  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-02 01:01:22  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-02 01:01:27  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-02 01:01:33  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-02 01:01:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-02 01:01:45  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-02_01-01-48 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl?_prerender {"code":"ECONNRESET"}
2017-04-02 01:03:50  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-02 01:03:57  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-02 01:04:03  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-02 01:04:08  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-02 01:04:14  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-02 01:04:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-02 01:04:26  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-02 01:04:33  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-02 01:04:39  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-02 01:04:44  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-02 01:04:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-02 01:04:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-02 01:05:03  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-02 01:05:09  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-02 01:05:16  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-02 01:05:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-02 01:05:27  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-02 01:05:33  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-02 01:05:39  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-02 01:05:45  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-02 01:05:51  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-02 01:05:57  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-02 01:06:03  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-02 01:06:09  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-02 01:06:15  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-02 01:06:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-02 01:06:27  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-02 01:06:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-02 01:06:38  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-02 01:06:44  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-02 01:06:50  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-02 01:06:56  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-02 01:07:02  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-02 01:07:07  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-02 01:07:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-02 01:07:19  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-02 01:07:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-02 01:07:31  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-02 01:07:37  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-02 01:07:42  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-02 01:07:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-02 01:07:54  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-02 01:08:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-02 01:08:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-02 01:08:11  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-02 01:08:17  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-02 01:08:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-02 01:08:29  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-02 01:08:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-02 01:08:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-02 01:08:46  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-02 01:08:52  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-02 01:08:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-02 01:09:04  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-02 01:09:10  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-02 01:09:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-02 01:09:22  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-02 01:09:28  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-02 01:09:34  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-02 01:09:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-02 01:09:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-02 01:09:52  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-02 01:09:58  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-02 01:10:04  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-02 01:10:10  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-02 01:10:15  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-02 01:10:21  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-02 01:10:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-02 01:10:33  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-02 01:10:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-02 01:10:45  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-02 01:10:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-02 01:10:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-02 01:11:03  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-02 01:11:09  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-02 01:11:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-02 01:11:20  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-02 01:11:26  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-02 01:11:32  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-02 01:11:38  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-02 01:11:43  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-02 01:11:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-02 01:11:54  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-02 01:12:00  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-02 01:12:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-02 01:12:12  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-02 01:12:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-02 01:12:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-02 01:12:30  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-02 01:12:36  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-02 01:12:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-02 01:12:47  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-02 01:12:53  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-02 01:12:59  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-02 01:13:05  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-02 01:13:11  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-02 01:13:17  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-02 01:13:23  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-02 01:13:28  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-02 01:13:34  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-02 01:13:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-02 01:13:46  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-02 01:13:52  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-02 01:13:57  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-02 01:14:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-02 01:14:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-02 01:14:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-02 01:14:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-02 01:14:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-02 01:14:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-02 01:14:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-02 01:14:48  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-02 01:14:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-02 01:14:59  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-02 01:15:05  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-02 01:15:12  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-02 01:15:17  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-02 01:15:23  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-02 01:15:28  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-02 01:15:34  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-02 01:15:40  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-02 01:15:46  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-02 01:15:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-02 01:15:58  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-02 01:16:04  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-02 01:16:09  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-02 01:16:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-02 01:16:21  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-02 01:16:27  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-02 01:16:32  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-02 01:16:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-02 01:16:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-02 01:16:50  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-02 01:16:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-02 01:17:02  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-02 01:17:08  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-02 01:17:14  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-02 01:17:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-02 01:17:25  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-02 01:17:31  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-02 01:17:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-02 01:17:42  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-02 01:17:48  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-02 01:17:53  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-02 01:17:59  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-02 01:18:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-02 01:18:10  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-02 01:18:16  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-02 01:18:21  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-02 01:18:27  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-02 01:18:33  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-02 01:18:39  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-02 01:18:45  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-02 01:18:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-02 01:18:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-02 01:19:02  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-02 01:19:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-02 01:19:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-02 01:19:19  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-02 01:19:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-02 01:19:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-02 01:19:36  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-02 01:19:42  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-02 01:19:47  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-02 01:19:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-02 01:19:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-02 01:20:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-02 01:20:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-02 01:20:16  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-02 01:20:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-02 01:20:27  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-02 01:20:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-02 01:20:38  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-02 01:20:44  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-02 01:20:49  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-02 01:20:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-02 01:21:01  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-02 01:21:06  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-02 01:21:14  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-02 01:21:20  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-02 01:21:26  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-02 01:21:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-02 01:21:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-02 01:21:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-02 01:21:49  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-02 01:21:50  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-02 01:21:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-02 01:22:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-02 01:22:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-02 01:22:13  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-02 01:22:19  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-02 01:22:25  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-02 01:22:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-02 01:22:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-02 01:22:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-02 01:22:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-02 01:22:53  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-02 01:22:58  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-02 01:23:04  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-02 01:23:10  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-02 01:23:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-02 01:23:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-02 01:23:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-02 01:23:33  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-02 01:23:39  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-02 01:23:45  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-02 01:23:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-02 01:23:56  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-02 01:24:01  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-02 01:24:07  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-02 01:24:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-02 01:24:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-02 01:24:25  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-02 01:24:30  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-02 01:24:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-02 01:24:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-02 01:24:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-02 01:24:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-02 01:24:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-02 01:25:03  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-02 01:25:09  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-02 01:25:14  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-02 01:25:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-02 01:25:27  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-02 01:25:33  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-02 01:25:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-02 01:25:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-02 01:25:50  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-02 01:25:55  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-02 01:26:00  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-02 01:26:06  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-02 01:26:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-02 01:26:17  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-02 01:26:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-02 01:26:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-02 01:26:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-02 01:26:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-02 01:26:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-02 01:26:51  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-02 01:26:57  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-02 01:27:02  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-02 01:27:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-02 01:27:13  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-02 01:27:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-02 01:27:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-02 01:27:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-02 01:27:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 01:27:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 01:27:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 01:27:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 01:27:56  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-02 01:28:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 01:28:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 01:28:16  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-02 01:28:22  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-02 01:28:27  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-02 01:28:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-02 01:28:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-02 01:28:43  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-02 01:28:49  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-02 01:28:54  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-02 01:28:59  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-02 01:29:05  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-02 01:29:10  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-02 01:29:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-02 01:29:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-02 01:29:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-02 01:29:32  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-02 01:29:37  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-02 01:29:42  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-02 01:29:48  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-02 01:29:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-02 01:30:04  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-02 01:30:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 01:30:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 01:30:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 01:30:25  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 01:30:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 01:30:36  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-02 01:30:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 01:30:46  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 01:30:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 01:30:57  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 01:31:02  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-02 01:31:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 01:31:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 01:31:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 01:31:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-02 01:31:29  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-02_01-31-48 Restart Xvfb...
2017-04-02_02-01-48 Restart Xvfb...
2017-04-02_02-31-48 Restart Xvfb...
2017-04-02_03-01-48 Restart Xvfb...
2017-04-02 03:31:46 reset updateRequest
2017-04-02_03-31-48 Restart Xvfb...
2017-04-02 03:31:49  - 14968  http://www.lymphomahub.com/
2017-04-02 03:31:51  - 14968  http://www.lymphomahub.com/
2017-04-02 03:31:54  - 14968  http://www.lymphomahub.com/about
2017-04-02 03:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-02 03:32:01  - 14968  http://www.lymphomahub.com/terms
2017-04-02 03:32:05  - 14968  http://www.lymphomahub.com/undefined
2017-04-02 03:32:05  - 14968  http://www.lymphomahub.com/therapies
2017-04-02 03:32:11  - 14968  http://www.lymphomahub.com/newsletter
2017-04-02 03:32:15  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-02 03:32:18  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-02 03:32:22  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-02 03:32:27  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-02 03:32:31  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-02 03:32:41  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-02 03:32:45  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-02 03:32:50  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-02 03:32:54  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-02 03:32:59  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-02 03:33:03  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-02 03:33:07  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-02 03:33:12  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-02 03:33:16  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-02 03:33:20  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-02 03:33:25  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-02 03:33:29  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-02 03:33:33  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-02 03:33:38  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-02 03:33:42  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-02 03:33:47  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-02 03:33:57  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-02 03:34:00  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-02 03:34:05  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-02 03:34:09  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-02 03:34:13  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-02 03:34:18  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-02 03:34:23  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-02 03:34:27  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-02 03:34:31  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-02 03:34:36  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-02 03:34:40  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-02 03:34:44  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-02 03:34:49  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-02 03:34:53  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-02 03:34:57  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-02 03:35:02  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-02 03:35:11  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-02 03:35:16  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-02 03:35:21  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-02 03:35:25  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-02 03:35:29  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-02 03:35:34  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-02 03:35:38  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-02 03:35:42  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-02 03:35:47  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-02 03:35:51  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-02 03:35:55  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-02 03:36:00  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-02 03:36:04  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-02 03:36:09  - 14968  http://www.lymphomahub.com/medical-information
2017-04-02 03:36:13  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-02 03:36:18  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-02 03:36:23  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-02 03:36:27  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-02 03:36:32  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-02 03:36:36  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-02 03:36:40  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-02 03:36:45  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-02 03:36:50  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-02 03:36:54  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-02 03:36:58  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-02 03:37:03  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-02 03:37:03  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-02 03:37:08  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-02 03:37:12  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-02 03:37:16  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-02 03:37:21  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-02 03:37:25  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-02 03:37:35  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-02 03:37:39  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-02 03:37:43  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-02 03:37:48  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-02 03:37:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-02 03:37:57  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-02 03:38:01  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-02 03:38:05  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-02 03:38:10  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-02 03:38:14  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-02 03:38:18  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-02 03:38:23  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-02 03:38:27  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-02 03:38:31  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-02 03:38:36  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-02 03:38:40  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-02 03:38:44  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-02 03:38:49  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-02 03:38:53  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-02 03:38:58  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-02 03:39:02  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-02 03:39:06  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-02 03:39:11  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-02 03:39:15  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-02 03:39:19  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-02 03:39:20  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-02 03:39:24  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-02 03:39:29  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-02 03:39:33  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-02 03:39:38  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-02 03:39:42  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-02 03:39:46  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-02 03:39:51  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-02 03:39:55  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-02 03:39:59  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-02 03:39:59  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-02 03:40:04  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-02 03:40:08  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-02 03:40:13  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-02 03:40:17  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-02 03:40:21  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-02 03:40:22  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-02 03:40:27  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-02 03:40:36  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-02 03:40:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-02 03:40:44  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-02 03:40:48  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-02 03:40:52  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-02 03:40:56  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-02 03:40:59  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-02 03:41:03  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-02 03:41:08  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-02 03:41:12  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-02 03:41:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-02 03:41:20  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-02 03:41:24  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-02 03:41:24  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-02 03:41:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-02 03:41:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-02 03:41:37  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-02 03:41:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-02 03:41:46  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-02 03:41:50  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-02 03:41:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-02 03:41:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-02 03:42:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-02 03:42:05  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-02 03:42:09  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-02 03:42:13  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-02 03:42:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-02 03:42:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-02 03:42:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-02 03:42:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-02 03:42:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-02 03:42:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-02 03:42:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-02 03:42:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-02 03:42:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-02 03:42:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-02 03:42:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-02 03:43:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-02 03:43:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-02 03:43:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-02 03:43:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-02 03:43:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-02 03:43:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-02 03:43:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-02 03:43:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-02 03:43:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-02 03:43:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-02 03:43:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-02 03:43:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-02 03:43:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-02 03:44:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-02 03:44:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-02 03:44:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-02 03:44:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-02 03:44:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-02 03:44:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-02 03:44:28  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-02 03:44:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-02 03:44:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-02 03:44:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-02 03:44:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-02 03:44:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-02 03:44:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-02 03:44:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-02 03:45:00  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-02 03:45:05  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-02 03:45:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-02 03:45:13  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-02 03:45:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-02 03:45:21  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-02 03:45:25  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-02 03:45:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-02 03:45:34  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-02 03:45:37  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-02 03:45:41  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-02 03:45:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-02 03:45:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-02 03:45:53  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-02 03:45:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-02 03:46:02  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-02 03:46:06  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-02 03:46:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-02 03:46:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-02 03:46:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-02 03:46:30  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-02 03:46:31  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-02 03:46:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-02 03:46:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-02 03:46:44  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-02 03:46:49  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-02 03:46:53  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-02 03:46:58  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 03:47:02  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 03:47:07  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-02 03:47:11  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 03:47:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-02 03:47:20  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-02 03:47:25  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-02 03:47:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-02 03:47:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-02 03:47:38  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-02 03:47:48  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-02 03:47:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-02 03:47:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-02 03:48:02  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-02 03:48:06  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 03:48:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-02 03:48:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-02 03:48:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-02 03:48:25  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-02 03:48:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-02 03:48:34  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-02 03:48:38  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-02 03:48:43  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-02 03:48:47  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-02 03:48:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-02 03:48:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-02 03:49:01  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-02 03:49:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-02 03:49:10  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-02 03:49:15  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-02 03:49:20  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-02 03:49:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-02 03:49:29  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-02 03:49:33  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-02 03:49:38  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-02 03:49:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-02 03:49:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-02 03:49:47  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-02 03:49:52  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-02 03:49:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-02 03:50:01  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-02 03:50:06  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-02 03:50:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-02 03:50:15  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-02 03:50:19  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-02 03:50:24  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-02 03:50:28  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-02 03:50:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-02 03:50:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-02 03:50:42  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-02 03:50:47  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-02 03:50:51  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-02 03:50:56  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-02 03:51:01  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-02 03:51:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-02 03:51:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-02 03:51:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-02 03:51:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-02 03:51:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-02 03:51:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-02 03:51:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-02 03:51:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-02 03:51:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-02 03:51:43  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-02 03:51:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-02 03:51:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-02 03:51:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-02 03:51:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-02 03:52:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-02 03:52:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-02 03:52:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-02 03:52:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-02 03:52:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-02 03:52:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-02 03:52:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-02 03:52:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-02 03:52:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-02 03:52:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-02 03:52:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-02 03:52:47  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-02 03:52:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-02 03:52:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-02 03:53:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-02 03:53:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-02 03:53:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-02 03:53:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-02 03:53:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-02 03:53:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-02 03:53:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-02 03:53:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-02 03:53:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-02 03:53:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-02 03:53:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-02 03:53:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-02 03:53:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-02 03:53:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-02 03:53:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-02 03:53:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-02 03:53:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-02 03:54:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-02 03:54:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-02 03:54:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-02 03:54:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-02 03:54:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-02 03:54:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-02 03:54:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-02 03:54:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-02 03:54:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-02 03:54:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-02 03:54:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-02 03:54:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-02 03:54:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-02 03:54:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-02 03:54:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-02 03:54:59  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-02 03:55:04  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-02 03:55:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-02 03:55:13  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-02 03:55:14  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-02 03:55:18  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-02 03:55:23  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-02 03:55:27  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-02 03:55:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-02 03:55:36  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-02 03:55:41  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-02 03:55:46  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-02 03:55:50  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-02 03:55:54  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-02 03:55:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-02 03:56:04  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-02 03:56:08  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-02 03:56:13  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-02 03:56:17  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-02 03:56:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-02 03:56:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-02 03:56:31  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-02 03:56:35  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-02 03:56:40  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-02 03:56:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-02 03:56:49  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-02 03:56:53  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-02 03:56:58  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-02 03:57:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-02 03:57:07  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-02 03:57:11  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-02 03:57:16  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-02 03:57:25  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-02 03:57:30  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-02 03:57:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-02 03:57:39  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-02 03:57:43  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-02 03:57:48  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-02 03:57:52  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-02 03:57:57  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-02 03:58:01  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-02 03:58:06  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-02 03:58:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-02 03:58:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-02 03:58:20  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-02 03:58:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-02 03:58:29  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-02 03:58:34  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-02 03:58:38  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-02 03:58:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-02 03:58:47  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-02 03:58:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-02 03:58:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-02 03:59:00  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-02 03:59:05  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-02 03:59:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-02 03:59:14  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-02 03:59:18  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-02 03:59:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-02 03:59:27  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-02 03:59:32  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-02 03:59:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-02 03:59:41  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-02 03:59:46  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-02 03:59:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-02 03:59:55  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-02 04:00:00  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-02 04:00:04  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-02 04:00:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-02 04:00:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-02 04:00:18  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-02 04:00:23  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-02 04:00:27  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-02 04:00:32  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-02 04:00:37  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-02 04:00:41  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-02 04:00:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-02 04:00:50  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-02 04:00:55  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-02 04:01:03  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-02 04:01:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-02 04:01:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-02 04:01:16  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-02 04:01:21  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-02 04:01:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-02 04:01:33  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-02 04:01:38  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-02 04:01:42  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-02 04:01:47  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-02_04-01-48 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma?_prerender {"code":"ECONNRESET"}
2017-04-02 04:03:52  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-02 04:03:56  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-02 04:04:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-02 04:04:05  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-02 04:04:10  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-02 04:04:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-02 04:04:19  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-02 04:04:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-02 04:04:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-02 04:04:33  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-02 04:04:37  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-02 04:04:42  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-02 04:04:46  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-02 04:04:51  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-02 04:04:55  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-02 04:05:00  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-02 04:05:05  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-02 04:05:09  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-02 04:05:14  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-02 04:05:19  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-02 04:05:24  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-02 04:05:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-02 04:05:36  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-02 04:05:41  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-02 04:05:45  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-02 04:05:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-02 04:05:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-02 04:05:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-02 04:06:04  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-02 04:06:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-02 04:06:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-02 04:06:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-02 04:06:22  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-02 04:06:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-02 04:06:32  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-02 04:06:36  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-02 04:06:41  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-02 04:06:45  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-02 04:06:50  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-02 04:06:54  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-02 04:06:59  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-02 04:07:03  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-02 04:07:08  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-02 04:07:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-02 04:07:17  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-02 04:07:22  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-02 04:07:26  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-02 04:07:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-02 04:07:35  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-02 04:07:40  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-02 04:07:44  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-02 04:07:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-02 04:07:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-02 04:07:58  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-02 04:08:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-02 04:08:07  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-02 04:08:11  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-02 04:08:16  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-02 04:08:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-02 04:08:25  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-02 04:08:33  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-02 04:08:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-02 04:08:41  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-02 04:08:46  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-02 04:08:50  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-02 04:08:54  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-02 04:08:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-02 04:09:04  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-02 04:09:08  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-02 04:09:12  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-02 04:09:17  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-02 04:09:21  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-02 04:09:26  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-02 04:09:30  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-02 04:09:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-02 04:09:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-02 04:09:43  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-02 04:09:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-02 04:09:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-02 04:09:56  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-02 04:10:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-02 04:10:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-02 04:10:10  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-02 04:10:14  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-02 04:10:18  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-02 04:10:22  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-02 04:10:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-02 04:10:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-02 04:10:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-02 04:10:44  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-02 04:10:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-02 04:10:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-02 04:10:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-02 04:11:01  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-02 04:11:05  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-02 04:11:10  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-02 04:11:14  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-02 04:11:18  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-02 04:11:22  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-02 04:11:27  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-02 04:11:31  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-02 04:11:36  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-02 04:11:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-02 04:11:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-02 04:11:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-02 04:11:54  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-02 04:11:54  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-02 04:11:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-02 04:12:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-02 04:12:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-02 04:12:13  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-02 04:12:17  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-02 04:12:22  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-02 04:12:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-02 04:12:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-02 04:12:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-02 04:12:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-02 04:12:43  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-02 04:12:47  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-02 04:12:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-02 04:12:56  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-02 04:13:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-02 04:13:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-02 04:13:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-02 04:13:14  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-02 04:13:19  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-02 04:13:23  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-02 04:13:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-02 04:13:35  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-02 04:13:39  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-02 04:13:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-02 04:13:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-02 04:13:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-02 04:13:57  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-02 04:14:01  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-02 04:14:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-02 04:14:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-02 04:14:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-02 04:14:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-02 04:14:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-02 04:14:30  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-02 04:14:34  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-02 04:14:38  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-02 04:14:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-02 04:14:46  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-02 04:14:51  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-02 04:14:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-02 04:14:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-02 04:15:04  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-02 04:15:08  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-02 04:15:12  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-02 04:15:16  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-02 04:15:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-02 04:15:25  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-02 04:15:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-02 04:15:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-02 04:15:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-02 04:15:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-02 04:15:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-02 04:15:56  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-02 04:16:00  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-02 04:16:04  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-02 04:16:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-02 04:16:13  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-02 04:16:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-02 04:16:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-02 04:16:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-02 04:16:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 04:16:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 04:16:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 04:16:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 04:16:45  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-02 04:16:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 04:16:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 04:16:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-02 04:17:02  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-02 04:17:06  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-02 04:17:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-02 04:17:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-02 04:17:18  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-02 04:17:22  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-02 04:17:26  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-02 04:17:30  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-02 04:17:34  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-02 04:17:38  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-02 04:17:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-02 04:17:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-02 04:17:51  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-02 04:17:55  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-02 04:17:59  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-02 04:18:03  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-02 04:18:07  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-02 04:18:10  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-02 04:18:14  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-02 04:18:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 04:18:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 04:18:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 04:18:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 04:18:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 04:18:44  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-02 04:18:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 04:18:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 04:18:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 04:19:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 04:19:05  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-02 04:19:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 04:19:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 04:19:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 04:19:21  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-02 04:19:25  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-02_04-31-48 Restart Xvfb...
2017-04-02_05-01-48 Restart Xvfb...
2017-04-02_05-31-48 Restart Xvfb...
2017-04-02_06-01-48 Restart Xvfb...
2017-04-02 06:31:46 reset updateRequest
2017-04-02_06-31-48 Restart Xvfb...
2017-04-02 06:31:50  - 14968  http://www.lymphomahub.com/
2017-04-02 06:31:51  - 14968  http://www.lymphomahub.com/
2017-04-02 06:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-02 06:31:57  - 14968  http://www.lymphomahub.com/about
2017-04-02 06:32:04  - 14968  http://www.lymphomahub.com/terms
2017-04-02 06:32:07  - 14968  http://www.lymphomahub.com/undefined
2017-04-02 06:32:08  - 14968  http://www.lymphomahub.com/therapies
2017-04-02 06:32:14  - 14968  http://www.lymphomahub.com/newsletter
2017-04-02 06:32:17  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-02 06:32:20  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-02 06:32:25  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-02 06:32:29  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-02 06:32:34  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-02 06:32:38  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-02 06:32:42  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-02 06:32:47  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-02 06:32:51  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-02 06:32:56  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-02 06:33:00  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-02 06:33:05  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-02 06:33:09  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-02 06:33:13  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-02 06:33:18  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-02 06:33:22  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-02 06:33:27  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-02 06:33:32  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-02 06:33:36  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-02 06:33:41  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-02 06:33:45  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-02 06:33:50  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-02 06:33:53  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-02 06:33:57  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-02 06:34:02  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-02 06:34:06  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-02 06:34:10  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-02 06:34:15  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-02 06:34:19  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-02 06:34:24  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-02 06:34:28  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-02 06:34:32  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-02 06:34:37  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-02 06:34:41  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-02 06:34:45  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-02 06:34:50  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-02 06:34:54  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-02 06:34:58  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-02 06:35:03  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-02 06:35:07  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-02 06:35:12  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-02 06:35:16  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-02 06:35:20  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-02 06:35:25  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-02 06:35:29  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-02 06:35:34  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-02 06:35:38  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-02 06:35:42  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-02 06:35:47  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-02 06:35:51  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-02 06:35:55  - 14968  http://www.lymphomahub.com/medical-information
2017-04-02 06:35:59  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-02 06:36:04  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-02 06:36:08  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-02 06:36:12  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-02 06:36:17  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-02 06:36:21  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-02 06:36:26  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-02 06:36:30  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-02 06:36:35  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-02 06:36:39  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-02 06:36:43  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-02 06:36:48  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-02 06:36:48  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-02 06:36:53  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-02 06:36:57  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-02 06:37:01  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-02 06:37:06  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-02 06:37:10  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-02 06:37:14  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-02 06:37:19  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-02 06:37:23  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-02 06:37:28  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-02 06:37:32  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-02 06:37:37  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-02 06:37:41  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-02 06:37:45  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-02 06:37:50  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-02 06:37:54  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-02 06:37:58  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-02 06:38:03  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-02 06:38:07  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-02 06:38:11  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-02 06:38:16  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-02 06:38:20  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-02 06:38:25  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-02 06:38:29  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-02 06:38:33  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-02 06:38:38  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-02 06:38:42  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-02 06:38:46  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-02 06:38:51  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-02 06:38:55  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-02 06:38:59  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-02 06:39:00  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-02 06:39:04  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-02 06:39:09  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-02 06:39:13  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-02 06:39:17  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-02 06:39:22  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-02 06:39:26  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-02 06:39:31  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-02 06:39:35  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-02 06:39:39  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-02 06:39:39  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-02 06:39:43  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-02 06:39:48  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-02 06:39:57  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-02 06:40:02  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-02 06:40:06  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-02 06:40:07  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-02 06:40:11  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-02 06:40:16  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-02 06:40:19  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-02 06:40:24  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-02 06:40:28  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-02 06:40:32  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-02 06:40:35  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-02 06:40:39  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-02 06:40:43  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-02 06:40:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-02 06:40:52  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-02 06:40:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-02 06:41:00  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-02 06:41:04  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-02 06:41:04  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-02 06:41:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-02 06:41:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-02 06:41:17  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-02 06:41:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-02 06:41:26  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-02 06:41:31  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-02 06:41:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-02 06:41:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-02 06:41:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-02 06:41:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-02 06:41:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-02 06:41:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-02 06:41:57  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-02 06:42:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-02 06:42:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-02 06:42:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-02 06:42:14  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-02 06:42:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-02 06:42:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-02 06:42:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-02 06:42:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-02 06:42:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-02 06:42:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-02 06:42:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-02 06:42:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-02 06:42:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-02 06:42:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-02 06:43:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-02 06:43:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-02 06:43:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-02 06:43:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-02 06:43:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-02 06:43:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-02 06:43:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-02 06:43:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-02 06:43:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-02 06:43:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-02 06:43:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-02 06:44:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-02 06:44:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-02 06:44:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-02 06:44:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-02 06:44:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-02 06:44:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-02 06:44:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-02 06:44:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-02 06:44:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-02 06:44:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-02 06:44:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-02 06:44:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-02 06:44:51  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-02 06:44:55  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-02 06:45:00  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-02 06:45:04  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-02 06:45:08  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-02 06:45:12  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-02 06:45:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-02 06:45:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-02 06:45:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-02 06:45:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-02 06:45:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-02 06:45:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-02 06:45:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-02 06:45:46  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-02 06:45:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-02 06:45:54  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-02 06:45:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-02 06:46:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-02 06:46:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-02 06:46:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-02 06:46:17  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-02 06:46:18  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-02 06:46:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-02 06:46:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-02 06:46:31  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-02 06:46:37  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-02 06:46:41  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-02 06:46:46  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 06:46:50  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 06:46:55  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-02 06:46:59  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 06:47:06  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-02 06:47:11  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-02 06:47:15  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-02 06:47:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-02 06:47:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-02 06:47:29  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-02 06:47:34  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-02 06:47:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-02 06:47:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-02 06:47:47  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-02 06:47:52  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 06:47:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-02 06:48:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-02 06:48:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-02 06:48:11  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-02 06:48:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-02 06:48:19  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-02 06:48:24  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-02 06:48:33  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-02 06:48:38  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-02 06:48:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-02 06:48:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-02 06:48:51  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-02 06:48:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-02 06:49:00  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-02 06:49:05  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-02 06:49:09  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-02 06:49:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-02 06:49:19  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-02 06:49:23  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-02 06:49:28  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-02 06:49:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-02 06:49:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-02 06:49:38  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-02 06:49:43  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-02 06:49:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-02 06:49:52  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-02 06:49:56  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-02 06:50:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-02 06:50:05  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-02 06:50:10  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-02 06:50:15  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-02 06:50:19  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-02 06:50:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-02 06:50:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-02 06:50:33  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-02 06:50:37  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-02 06:50:42  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-02 06:50:46  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-02 06:50:51  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-02 06:50:55  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-02 06:51:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-02 06:51:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-02 06:51:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-02 06:51:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-02 06:51:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-02 06:51:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-02 06:51:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-02 06:51:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-02 06:51:38  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-02 06:51:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-02 06:51:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-02 06:51:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-02 06:51:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-02 06:51:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-02 06:51:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-02 06:52:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-02 06:52:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-02 06:52:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-02 06:52:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-02 06:52:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-02 06:52:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-02 06:52:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-02 06:52:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-02 06:52:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-02 06:52:39  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-02 06:52:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-02 06:52:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-02 06:52:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-02 06:52:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-02 06:52:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-02 06:53:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-02 06:53:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-02 06:53:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-02 06:53:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-02 06:53:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-02 06:53:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-02 06:53:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-02 06:53:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-02 06:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-02 06:53:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-02 06:53:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-02 06:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-02 06:53:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-02 06:53:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-02 06:53:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-02 06:54:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-02 06:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-02 06:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-02 06:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-02 06:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-02 06:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-02 06:54:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-02 06:54:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-02 06:54:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-02 06:54:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-02 06:54:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-02 06:54:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-02 06:54:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-02 06:54:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-02 06:54:53  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-02 06:54:57  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-02 06:55:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-02 06:55:07  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-02 06:55:07  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-02 06:55:12  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-02 06:55:17  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-02 06:55:21  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-02 06:55:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-02 06:55:30  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-02 06:55:35  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-02 06:55:40  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-02 06:55:44  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-02 06:55:49  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-02 06:55:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-02 06:55:58  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-02 06:56:02  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-02 06:56:07  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-02 06:56:11  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-02 06:56:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-02 06:56:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-02 06:56:25  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-02 06:56:30  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-02 06:56:34  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-02 06:56:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-02 06:56:43  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-02 06:56:48  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-02 06:56:52  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-02 06:56:57  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-02 06:57:01  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-02 06:57:06  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-02 06:57:11  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-02 06:57:15  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-02 06:57:20  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-02 06:57:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-02 06:57:34  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-02 06:57:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-02 06:57:43  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-02 06:57:47  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-02 06:57:52  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-02 06:57:56  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-02 06:58:01  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-02 06:58:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-02 06:58:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-02 06:58:14  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-02 06:58:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-02 06:58:24  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-02 06:58:28  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-02 06:58:33  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-02 06:58:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-02 06:58:42  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-02 06:58:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-02 06:58:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-02 06:58:55  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-02 06:59:00  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-02 06:59:04  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-02 06:59:08  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-02 06:59:13  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-02 06:59:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-02 06:59:22  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-02 06:59:27  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-02 06:59:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-02 06:59:36  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-02 06:59:40  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-02 06:59:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-02 06:59:49  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-02 06:59:53  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-02 06:59:58  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-02 07:00:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-02 07:00:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-02 07:00:12  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-02 07:00:17  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-02 07:00:21  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-02 07:00:29  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-02 07:00:33  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-02 07:00:38  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-02 07:00:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-02 07:00:47  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-02 07:00:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-02 07:00:56  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-02 07:01:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-02 07:01:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-02 07:01:09  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-02 07:01:14  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-02 07:01:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-02 07:01:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-02 07:01:27  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-02 07:01:32  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-02 07:01:36  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-02 07:01:40  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-02 07:01:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-02_07-01-48 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl?_prerender {"code":"ECONNRESET"}
2017-04-02 07:03:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-02 07:03:54  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-02 07:03:59  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-02 07:04:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-02 07:04:08  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-02 07:04:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-02 07:04:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-02 07:04:26  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-02 07:04:31  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-02 07:04:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-02 07:04:40  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-02 07:04:45  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-02 07:04:49  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-02 07:04:54  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-02 07:04:58  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-02 07:05:03  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-02 07:05:08  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-02 07:05:12  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-02 07:05:17  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-02 07:05:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-02 07:05:26  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-02 07:05:30  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-02 07:05:35  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-02 07:05:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-02 07:05:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-02 07:05:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-02 07:05:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-02 07:06:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-02 07:06:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-02 07:06:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-02 07:06:17  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-02 07:06:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-02 07:06:26  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-02 07:06:30  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-02 07:06:35  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-02 07:06:39  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-02 07:06:43  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-02 07:06:48  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-02 07:06:52  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-02 07:06:57  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-02 07:07:02  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-02 07:07:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-02 07:07:10  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-02 07:07:15  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-02 07:07:19  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-02 07:07:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-02 07:07:29  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-02 07:07:33  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-02 07:07:38  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-02 07:07:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-02 07:07:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-02 07:07:52  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-02 07:07:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-02 07:08:01  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-02 07:08:06  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-02 07:08:10  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-02 07:08:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-02 07:08:19  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-02 07:08:24  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-02 07:08:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-02 07:08:32  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-02 07:08:37  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-02 07:08:41  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-02 07:08:45  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-02 07:08:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-02 07:08:54  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-02 07:08:58  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-02 07:09:03  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-02 07:09:08  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-02 07:09:12  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-02 07:09:16  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-02 07:09:21  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-02 07:09:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-02 07:09:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-02 07:09:34  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-02 07:09:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-02 07:09:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-02 07:09:46  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-02 07:09:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-02 07:09:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-02 07:10:00  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-02 07:10:05  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-02 07:10:09  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-02 07:10:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-02 07:10:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-02 07:10:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-02 07:10:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-02 07:10:31  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-02 07:10:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-02 07:10:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-02 07:10:44  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-02 07:10:48  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-02 07:10:53  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-02 07:10:57  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-02 07:11:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-02 07:11:05  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-02 07:11:13  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-02 07:11:17  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-02 07:11:22  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-02 07:11:26  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-02 07:11:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-02 07:11:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-02 07:11:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-02 07:11:45  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-02 07:11:46  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-02 07:11:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-02 07:11:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-02 07:11:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-02 07:12:03  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-02 07:12:08  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-02 07:12:13  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-02 07:12:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-02 07:12:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-02 07:12:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-02 07:12:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-02 07:12:34  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-02 07:12:38  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-02 07:12:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-02 07:12:47  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-02 07:12:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-02 07:12:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-02 07:13:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-02 07:13:05  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-02 07:13:10  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-02 07:13:14  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-02 07:13:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-02 07:13:23  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-02 07:13:27  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-02 07:13:31  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-02 07:13:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-02 07:13:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-02 07:13:45  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-02 07:13:49  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-02 07:13:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-02 07:13:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-02 07:14:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-02 07:14:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-02 07:14:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-02 07:14:19  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-02 07:14:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-02 07:14:27  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-02 07:14:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-02 07:14:35  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-02 07:14:39  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-02 07:14:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-02 07:14:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-02 07:14:52  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-02 07:14:56  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-02 07:15:00  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-02 07:15:04  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-02 07:15:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-02 07:15:13  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-02 07:15:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-02 07:15:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-02 07:15:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-02 07:15:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-02 07:15:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-02 07:15:40  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-02 07:15:44  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-02 07:15:47  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-02 07:15:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-02 07:15:56  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-02 07:16:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-02 07:16:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-02 07:16:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-02 07:16:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 07:16:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 07:16:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 07:16:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 07:16:29  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-02 07:16:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 07:16:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 07:16:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-02 07:16:45  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-02 07:16:49  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-02 07:16:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-02 07:16:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-02 07:17:02  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-02 07:17:06  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-02 07:17:10  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-02 07:17:14  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-02 07:17:18  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-02 07:17:22  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-02 07:17:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-02 07:17:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-02 07:17:34  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-02 07:17:39  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-02 07:17:43  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-02 07:17:47  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-02 07:17:56  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-02 07:18:00  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-02 07:18:04  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-02 07:18:08  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 07:18:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 07:18:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 07:18:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 07:18:24  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 07:18:28  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-02 07:18:32  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 07:18:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 07:18:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 07:18:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 07:18:48  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-02 07:18:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 07:18:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 07:19:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 07:19:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-02 07:19:08  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-02_07-31-48 Restart Xvfb...
2017-04-02_08-01-48 Restart Xvfb...
2017-04-02_08-31-48 Restart Xvfb...
2017-04-02_09-01-48 Restart Xvfb...
2017-04-02 09:31:46 reset updateRequest
2017-04-02_09-31-48 Restart Xvfb...
2017-04-02 09:31:49  - 14968  http://www.lymphomahub.com/
2017-04-02 09:31:51  - 14968  http://www.lymphomahub.com/
2017-04-02 09:31:53  - 14968  http://www.lymphomahub.com/about
2017-04-02 09:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-02 09:31:57  - 14968  http://www.lymphomahub.com/terms
2017-04-02 09:31:59  - 14968  http://www.lymphomahub.com/terms
2017-04-02 09:32:01  - 14968  http://www.lymphomahub.com/undefined
2017-04-02 09:32:01  - 14968  http://www.lymphomahub.com/therapies
2017-04-02 09:32:02  - 14968  http://www.lymphomahub.com/therapies
2017-04-02 09:32:11  - 14968  http://www.lymphomahub.com/newsletter
2017-04-02 09:32:11  - 14968  http://www.lymphomahub.com/newsletter
2017-04-02 09:32:15  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-02 09:32:16  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-02 09:32:19  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-02 09:32:20  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-02 09:32:24  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-02 09:32:24  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-02 09:32:29  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-02 09:32:29  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-02 09:32:34  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-02 09:32:39  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-02 09:32:43  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-02 09:32:48  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-02 09:32:52  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-02 09:32:56  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-02 09:33:01  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-02 09:33:05  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-02 09:33:10  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-02 09:33:14  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-02 09:33:18  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-02 09:33:23  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-02 09:33:27  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-02 09:33:32  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-02 09:33:36  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-02 09:33:41  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-02 09:33:45  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-02 09:33:49  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-02 09:33:53  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-02 09:33:57  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-02 09:34:02  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-02 09:34:06  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-02 09:34:11  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-02 09:34:15  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-02 09:34:20  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-02 09:34:24  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-02 09:34:28  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-02 09:34:33  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-02 09:34:37  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-02 09:34:41  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-02 09:34:46  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-02 09:34:50  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-02 09:34:55  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-02 09:34:59  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-02 09:35:03  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-02 09:35:08  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-02 09:35:12  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-02 09:35:16  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-02 09:35:21  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-02 09:35:25  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-02 09:35:29  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-02 09:35:34  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-02 09:35:38  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-02 09:35:42  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-02 09:35:47  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-02 09:35:51  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-02 09:35:56  - 14968  http://www.lymphomahub.com/medical-information
2017-04-02 09:35:59  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-02 09:36:04  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-02 09:36:08  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-02 09:36:18  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-02 09:36:22  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-02 09:36:27  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-02 09:36:31  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-02 09:36:35  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-02 09:36:39  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-02 09:36:44  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-02 09:36:48  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-02 09:36:52  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-02 09:36:53  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-02 09:36:57  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-02 09:37:02  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-02 09:37:06  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-02 09:37:11  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-02 09:37:15  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-02 09:37:19  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-02 09:37:24  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-02 09:37:28  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-02 09:37:32  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-02 09:37:37  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-02 09:37:41  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-02 09:37:45  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-02 09:37:50  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-02 09:37:54  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-02 09:37:59  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-02 09:38:03  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-02 09:38:07  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-02 09:38:11  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-02 09:38:19  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-02 09:38:24  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-02 09:38:28  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-02 09:38:32  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-02 09:38:37  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-02 09:38:41  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-02 09:38:45  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-02 09:38:50  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-02 09:38:54  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-02 09:38:58  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-02 09:39:03  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-02 09:39:07  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-02 09:39:08  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-02 09:39:12  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-02 09:39:16  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-02 09:39:21  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-02 09:39:25  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-02 09:39:30  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-02 09:39:35  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-02 09:39:39  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-02 09:39:44  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-02 09:39:47  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-02 09:39:48  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-02 09:39:52  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-02 09:39:57  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-02 09:40:01  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-02 09:40:05  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-02 09:40:10  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-02 09:40:10  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-02 09:40:15  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-02 09:40:19  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-02 09:40:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-02 09:40:27  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-02 09:40:31  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-02 09:40:35  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-02 09:40:38  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-02 09:40:42  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-02 09:40:46  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-02 09:40:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-02 09:40:55  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-02 09:40:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-02 09:41:04  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-02 09:41:07  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-02 09:41:08  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-02 09:41:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-02 09:41:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-02 09:41:21  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-02 09:41:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-02 09:41:29  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-02 09:41:34  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-02 09:41:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-02 09:41:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-02 09:41:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-02 09:41:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-02 09:41:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-02 09:41:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-02 09:42:00  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-02 09:42:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-02 09:42:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-02 09:42:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-02 09:42:17  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-02 09:42:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-02 09:42:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-02 09:42:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-02 09:42:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-02 09:42:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-02 09:42:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-02 09:42:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-02 09:42:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-02 09:42:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-02 09:43:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-02 09:43:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-02 09:43:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-02 09:43:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-02 09:43:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-02 09:43:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-02 09:43:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-02 09:43:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-02 09:43:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-02 09:43:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-02 09:43:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-02 09:43:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-02 09:43:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-02 09:43:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-02 09:44:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-02 09:44:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-02 09:44:16  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-02 09:44:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-02 09:44:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-02 09:44:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-02 09:44:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-02 09:44:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-02 09:44:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-02 09:44:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-02 09:44:48  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-02 09:44:57  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-02 09:45:02  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-02 09:45:05  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-02 09:45:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-02 09:45:14  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-02 09:45:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-02 09:45:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-02 09:45:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-02 09:45:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-02 09:45:34  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-02 09:45:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-02 09:45:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-02 09:45:46  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-02 09:45:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-02 09:45:55  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-02 09:46:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-02 09:46:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-02 09:46:09  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-02 09:46:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-02 09:46:18  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-02 09:46:18  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-02 09:46:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-02 09:46:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-02 09:46:31  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-02 09:46:36  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-02 09:46:40  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-02 09:46:45  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 09:46:49  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 09:46:54  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-02 09:46:58  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 09:47:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-02 09:47:07  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-02 09:47:12  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-02 09:47:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-02 09:47:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-02 09:47:26  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-02 09:47:31  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-02 09:47:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-02 09:47:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-02 09:47:49  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-02 09:47:54  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 09:48:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-02 09:48:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-02 09:48:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-02 09:48:16  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-02 09:48:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-02 09:48:25  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-02 09:48:30  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-02 09:48:34  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-02 09:48:38  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-02 09:48:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-02 09:48:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-02 09:48:52  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-02 09:48:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-02 09:49:01  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-02 09:49:06  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-02 09:49:10  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-02 09:49:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-02 09:49:19  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-02 09:49:24  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-02 09:49:29  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-02 09:49:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-02 09:49:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-02 09:49:38  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-02 09:49:42  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-02 09:49:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-02 09:49:52  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-02 09:49:56  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-02 09:50:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-02 09:50:06  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-02 09:50:15  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-02 09:50:19  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-02 09:50:24  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-02 09:50:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-02 09:50:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-02 09:50:41  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-02 09:50:45  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-02 09:50:50  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-02 09:50:54  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-02 09:50:59  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-02 09:51:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-02 09:51:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-02 09:51:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-02 09:51:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-02 09:51:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-02 09:51:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-02 09:51:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-02 09:51:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-02 09:51:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-02 09:51:41  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-02 09:51:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-02 09:51:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-02 09:51:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-02 09:51:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-02 09:51:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-02 09:52:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-02 09:52:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-02 09:52:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-02 09:52:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-02 09:52:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-02 09:52:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-02 09:52:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-02 09:52:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-02 09:52:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-02 09:52:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-02 09:52:38  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-02 09:52:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-02 09:52:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-02 09:52:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-02 09:52:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-02 09:52:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-02 09:53:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-02 09:53:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-02 09:53:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-02 09:53:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-02 09:53:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-02 09:53:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-02 09:53:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-02 09:53:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-02 09:53:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-02 09:53:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-02 09:53:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-02 09:53:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-02 09:53:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-02 09:53:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-02 09:53:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-02 09:53:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-02 09:53:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-02 09:54:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-02 09:54:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-02 09:54:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-02 09:54:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-02 09:54:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-02 09:54:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-02 09:54:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-02 09:54:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-02 09:54:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-02 09:54:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-02 09:54:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-02 09:54:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-02 09:54:47  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-02 09:54:52  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-02 09:54:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-02 09:55:01  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-02 09:55:02  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-02 09:55:06  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-02 09:55:11  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-02 09:55:16  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-02 09:55:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-02 09:55:25  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-02 09:55:29  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-02 09:55:33  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-02 09:55:38  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-02 09:55:42  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-02 09:55:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-02 09:55:51  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-02 09:55:56  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-02 09:56:01  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-02 09:56:05  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-02 09:56:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-02 09:56:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-02 09:56:19  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-02 09:56:23  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-02 09:56:27  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-02 09:56:32  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-02 09:56:36  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-02 09:56:41  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-02 09:56:45  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-02 09:56:50  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-02 09:56:54  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-02 09:56:59  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-02 09:57:03  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-02 09:57:08  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-02 09:57:12  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-02 09:57:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-02 09:57:22  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-02 09:57:26  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-02 09:57:30  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-02 09:57:35  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-02 09:57:40  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-02 09:57:44  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-02 09:57:48  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-02 09:57:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-02 09:57:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-02 09:58:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-02 09:58:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-02 09:58:11  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-02 09:58:15  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-02 09:58:20  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-02 09:58:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-02 09:58:29  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-02 09:58:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-02 09:58:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-02 09:58:41  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-02 09:58:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-02 09:58:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-02 09:58:55  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-02 09:58:59  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-02 09:59:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-02 09:59:08  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-02 09:59:13  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-02 09:59:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-02 09:59:22  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-02 09:59:26  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-02 09:59:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-02 09:59:35  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-02 09:59:39  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-02 09:59:44  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-02 09:59:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-02 09:59:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-02 09:59:57  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-02 10:00:02  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-02 10:00:06  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-02 10:00:10  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-02 10:00:15  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-02 10:00:19  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-02 10:00:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-02 10:00:28  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-02 10:00:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-02 10:00:37  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-02 10:00:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-02 10:00:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-02 10:00:51  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-02 10:00:55  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-02 10:01:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-02 10:01:04  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-02 10:01:09  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-02 10:01:13  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-02 10:01:18  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-02 10:01:22  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-02 10:01:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-02 10:01:30  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-02 10:01:35  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-02 10:01:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-02 10:01:44  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-02 10:01:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-02_10-01-48 Restart Xvfb...
2017-04-02 10:01:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-02 10:01:57  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-02 10:02:02  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-02 10:02:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-02 10:02:11  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-02 10:02:16  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-02 10:02:20  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-02 10:02:25  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-02 10:02:29  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-02 10:02:34  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-02 10:02:38  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-02 10:02:48  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-02 10:02:53  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-02 10:02:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-02 10:03:01  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-02 10:03:06  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-02 10:03:11  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-02 10:03:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-02 10:03:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-02 10:03:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-02 10:03:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-02 10:03:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-02 10:03:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-02 10:03:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-02 10:03:47  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-02 10:03:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-02 10:03:56  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-02 10:04:01  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-02 10:04:05  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-02 10:04:09  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-02 10:04:14  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-02 10:04:18  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-02 10:04:23  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-02 10:04:27  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-02 10:04:32  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-02 10:04:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-02 10:04:41  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-02 10:04:45  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-02 10:04:50  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-02 10:04:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-02 10:04:59  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-02 10:05:05  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-02 10:05:09  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-02 10:05:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-02 10:05:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-02 10:05:23  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-02 10:05:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-02 10:05:32  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-02 10:05:36  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-02 10:05:41  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-02 10:05:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-02 10:05:50  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-02 10:05:54  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-02 10:05:58  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-02 10:06:03  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-02 10:06:07  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-02 10:06:11  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-02 10:06:16  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-02 10:06:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-02 10:06:25  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-02 10:06:29  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-02 10:06:33  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-02 10:06:38  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-02 10:06:42  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-02 10:06:47  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-02 10:06:51  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-02 10:06:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-02 10:07:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-02 10:07:04  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-02 10:07:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-02 10:07:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-02 10:07:17  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-02 10:07:22  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-02 10:07:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-02 10:07:31  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-02 10:07:36  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-02 10:07:39  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-02 10:07:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-02 10:07:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-02 10:07:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-02 10:07:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-02 10:08:01  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-02 10:08:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-02 10:08:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-02 10:08:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-02 10:08:18  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-02 10:08:23  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-02 10:08:32  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-02 10:08:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-02 10:08:45  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-02 10:08:49  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-02 10:08:54  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-02 10:08:58  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-02 10:09:03  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-02 10:09:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-02 10:09:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-02 10:09:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-02 10:09:21  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-02 10:09:22  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-02 10:09:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-02 10:09:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-02 10:09:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-02 10:09:39  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-02 10:09:44  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-02 10:09:48  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-02 10:09:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-02 10:09:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-02 10:10:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-02 10:10:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-02 10:10:11  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-02 10:10:15  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-02 10:10:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-02 10:10:23  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-02 10:10:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-02 10:10:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-02 10:10:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-02 10:10:41  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-02 10:10:45  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-02 10:10:50  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-02 10:10:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-02 10:11:03  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-02 10:11:11  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-02 10:11:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-02 10:11:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-02 10:11:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-02 10:11:29  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-02 10:11:33  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-02 10:11:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-02 10:11:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-02 10:11:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-02 10:11:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-02 10:11:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-02 10:11:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-02 10:12:01  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-02 10:12:05  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-02 10:12:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-02 10:12:13  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-02 10:12:17  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-02 10:12:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-02 10:12:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-02 10:12:30  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-02 10:12:34  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-02 10:12:38  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-02 10:12:42  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-02 10:12:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-02 10:12:51  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-02 10:12:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-02 10:12:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-02 10:13:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-02 10:13:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-02 10:13:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-02 10:13:17  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-02 10:13:21  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-02 10:13:25  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-02 10:13:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-02 10:13:33  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-02 10:13:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-02 10:13:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-02 10:13:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-02 10:13:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 10:13:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 10:13:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 10:14:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 10:14:06  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-02 10:14:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 10:14:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 10:14:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-02 10:14:22  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-02 10:14:26  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-02 10:14:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-02 10:14:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-02 10:14:39  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-02 10:14:43  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-02 10:14:47  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-02 10:14:51  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-02 10:14:55  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-02 10:14:59  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-02 10:15:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-02 10:15:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-02 10:15:12  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-02 10:15:16  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-02 10:15:20  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-02 10:15:24  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-02 10:15:28  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-02 10:15:32  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-02 10:15:36  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-02 10:15:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 10:15:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 10:15:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 10:15:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 10:15:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 10:16:00  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-02 10:16:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 10:16:08  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 10:16:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 10:16:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 10:16:21  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-02 10:16:25  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 10:16:29  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 10:16:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 10:16:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-02 10:16:41  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-02_10-31-48 Restart Xvfb...
2017-04-02_11-01-48 Restart Xvfb...
2017-04-02_11-31-48 Restart Xvfb...
2017-04-02_12-01-48 Restart Xvfb...
2017-04-02 12:31:46 reset updateRequest
2017-04-02 12:31:47  - 14968  http://www.lymphomahub.com/
2017-04-02_12-31-48 Restart Xvfb...
2017-04-02 12:31:51  - 14968  http://www.lymphomahub.com/
2017-04-02 12:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-02 12:32:01  - 14968  http://www.lymphomahub.com/terms
2017-04-02 12:32:04  - 14968  http://www.lymphomahub.com/undefined
2017-04-02 12:32:05  - 14968  http://www.lymphomahub.com/therapies
2017-04-02 12:32:12  - 14968  http://www.lymphomahub.com/newsletter
2017-04-02 12:32:16  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-02 12:32:19  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-02 12:32:23  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-02 12:32:28  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-02 12:32:32  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-02 12:32:37  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-02 12:32:41  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-02 12:32:45  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-02 12:32:50  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-02 12:32:54  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-02 12:32:59  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-02 12:33:03  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-02 12:33:07  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-02 12:33:12  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-02 12:33:16  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-02 12:33:20  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-02 12:33:25  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-02 12:33:31  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-02 12:33:35  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-02 12:33:40  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-02 12:33:44  - 14968  http://www.lymphomahub.com/therapies/kte-c19
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-02 12:33:48  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-02 12:33:52  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-02 12:33:56  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-02 12:34:00  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-02 12:34:05  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-02 12:34:09  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-02 12:34:14  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-02 12:34:18  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-02 12:34:22  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-02 12:34:27  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-02 12:34:32  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-02 12:34:37  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-02 12:34:41  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-02 12:34:46  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-02 12:34:51  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-02 12:34:55  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-02 12:35:00  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-02 12:35:04  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-02 12:35:09  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-02 12:35:13  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-02 12:35:22  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-02 12:35:27  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-02 12:35:31  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-02 12:35:36  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-02 12:35:40  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-02 12:35:44  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-02 12:35:49  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-02 12:35:53  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-02 12:35:58  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-02 12:36:02  - 14968  http://www.lymphomahub.com/medical-information
2017-04-02 12:36:07  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-02 12:36:11  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-02 12:36:16  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-02 12:36:20  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-02 12:36:24  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-02 12:36:29  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-02 12:36:33  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-02 12:36:37  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-02 12:36:42  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-02 12:36:47  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-02 12:36:52  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-02 12:36:56  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-02 12:36:57  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-02 12:37:01  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-02 12:37:05  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-02 12:37:10  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-02 12:37:14  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-02 12:37:19  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-02 12:37:23  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-02 12:37:27  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-02 12:37:32  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-02 12:37:36  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-02 12:37:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-02 12:37:45  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-02 12:37:49  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-02 12:37:53  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-02 12:37:57  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-02 12:38:02  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-02 12:38:06  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-02 12:38:11  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-02 12:38:15  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-02 12:38:19  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-02 12:38:23  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-02 12:38:27  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-02 12:38:32  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-02 12:38:36  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-02 12:38:41  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-02 12:38:45  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-02 12:38:49  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-02 12:38:54  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-02 12:38:58  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-02 12:39:03  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-02 12:39:07  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-02 12:39:08  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-02 12:39:12  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-02 12:39:17  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-02 12:39:21  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-02 12:39:25  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-02 12:39:30  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-02 12:39:34  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-02 12:39:38  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-02 12:39:43  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-02 12:39:47  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-02 12:39:47  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-02 12:39:51  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-02 12:39:56  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-02 12:40:00  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-02 12:40:05  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-02 12:40:09  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-02 12:40:10  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-02 12:40:15  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-02 12:40:19  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-02 12:40:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-02 12:40:27  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-02 12:40:31  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-02 12:40:35  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-02 12:40:39  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-02 12:40:42  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-02 12:40:46  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-02 12:40:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-02 12:40:55  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-02 12:40:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-02 12:41:04  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-02 12:41:07  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-02 12:41:08  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-02 12:41:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-02 12:41:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-02 12:41:20  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-02 12:41:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-02 12:41:29  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-02 12:41:33  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-02 12:41:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-02 12:41:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-02 12:41:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-02 12:41:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-02 12:41:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-02 12:41:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-02 12:41:59  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-02 12:42:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-02 12:42:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-02 12:42:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-02 12:42:16  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-02 12:42:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-02 12:42:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-02 12:42:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-02 12:42:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-02 12:42:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-02 12:42:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-02 12:42:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-02 12:42:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-02 12:42:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-02 12:42:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-02 12:43:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-02 12:43:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-02 12:43:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-02 12:43:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-02 12:43:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-02 12:43:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-02 12:43:30  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-02 12:43:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-02 12:43:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-02 12:43:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-02 12:43:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-02 12:43:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-02 12:43:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-02 12:44:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-02 12:44:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-02 12:44:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-02 12:44:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-02 12:44:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-02 12:44:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-02 12:44:25  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-02 12:44:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-02 12:44:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-02 12:44:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-02 12:44:41  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-02 12:44:46  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-02 12:44:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-02 12:44:54  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-02 12:44:59  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-02 12:45:02  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-02 12:45:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-02 12:45:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-02 12:45:20  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-02 12:45:24  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-02 12:45:27  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-02 12:45:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-02 12:45:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-02 12:45:40  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-02 12:45:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-02 12:45:48  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-02 12:45:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-02 12:45:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-02 12:46:01  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-02 12:46:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-02 12:46:10  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-02 12:46:11  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-02 12:46:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-02 12:46:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-02 12:46:24  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-02 12:46:29  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-02 12:46:33  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-02 12:46:38  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 12:46:42  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 12:46:47  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-02 12:46:52  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 12:46:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-02 12:47:00  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-02 12:47:05  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-02 12:47:09  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-02 12:47:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-02 12:47:18  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-02 12:47:23  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-02 12:47:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-02 12:47:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-02 12:47:36  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-02 12:47:40  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 12:47:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-02 12:47:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-02 12:47:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-02 12:47:59  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-02 12:48:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-02 12:48:08  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-02 12:48:12  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-02 12:48:16  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-02 12:48:24  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-02 12:48:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-02 12:48:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-02 12:48:38  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-02 12:48:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-02 12:48:47  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-02 12:48:52  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-02 12:48:56  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-02 12:49:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-02 12:49:05  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-02 12:49:10  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-02 12:49:15  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-02 12:49:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-02 12:49:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-02 12:49:24  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-02 12:49:29  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-02 12:49:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-02 12:49:38  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-02 12:49:42  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-02 12:49:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-02 12:49:51  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-02 12:49:56  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-02 12:50:00  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-02 12:50:05  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-02 12:50:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-02 12:50:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-02 12:50:18  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-02 12:50:23  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-02 12:50:28  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-02 12:50:32  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-02 12:50:37  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-02 12:50:41  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-02 12:50:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-02 12:50:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-02 12:50:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-02 12:50:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-02 12:51:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-02 12:51:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-02 12:51:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-02 12:51:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-02 12:51:20  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-02 12:51:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-02 12:51:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-02 12:51:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-02 12:51:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-02 12:51:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-02 12:51:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-02 12:51:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-02 12:51:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-02 12:51:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-02 12:51:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-02 12:51:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-02 12:52:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-02 12:52:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-02 12:52:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-02 12:52:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-02 12:52:18  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-02 12:52:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-02 12:52:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-02 12:52:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-02 12:52:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-02 12:52:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-02 12:52:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-02 12:52:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-02 12:52:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-02 12:52:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-02 12:52:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-02 12:52:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-02 12:53:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-02 12:53:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-02 12:53:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-02 12:53:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-02 12:53:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-02 12:53:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-02 12:53:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-02 12:53:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-02 12:53:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-02 12:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-02 12:53:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-02 12:53:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-02 12:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-02 12:53:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-02 12:53:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-02 12:53:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-02 12:54:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-02 12:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-02 12:54:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-02 12:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-02 12:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-02 12:54:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-02 12:54:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-02 12:54:27  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-02 12:54:31  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-02 12:54:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-02 12:54:40  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-02 12:54:41  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-02 12:54:45  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-02 12:54:50  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-02 12:54:54  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-02 12:54:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-02 12:55:04  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-02 12:55:08  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-02 12:55:13  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-02 12:55:17  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-02 12:55:21  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-02 12:55:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-02 12:55:31  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-02 12:55:35  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-02 12:55:40  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-02 12:55:44  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-02 12:55:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-02 12:55:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-02 12:55:58  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-02 12:56:02  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-02 12:56:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-02 12:56:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-02 12:56:21  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-02 12:56:25  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-02 12:56:29  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-02 12:56:34  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-02 12:56:38  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-02 12:56:43  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-02 12:56:47  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-02 12:56:52  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-02 12:56:56  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-02 12:57:01  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-02 12:57:05  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-02 12:57:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-02 12:57:14  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-02 12:57:19  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-02 12:57:23  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-02 12:57:28  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-02 12:57:32  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-02 12:57:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-02 12:57:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-02 12:57:45  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-02 12:57:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-02 12:57:55  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-02 12:57:59  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-02 12:58:04  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-02 12:58:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-02 12:58:13  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-02 12:58:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-02 12:58:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-02 12:58:30  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-02 12:58:34  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-02 12:58:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-02 12:58:43  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-02 12:58:48  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-02 12:58:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-02 12:58:57  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-02 12:59:01  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-02 12:59:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-02 12:59:10  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-02 12:59:15  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-02 12:59:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-02 12:59:24  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-02 12:59:28  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-02 12:59:33  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-02 12:59:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-02 12:59:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-02 12:59:46  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-02 12:59:51  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-02 12:59:55  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-02 13:00:00  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-02 13:00:04  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-02 13:00:09  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-02 13:00:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-02 13:00:18  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-02 13:00:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-02 13:00:27  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-02 13:00:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-02 13:00:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-02 13:00:40  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-02 13:00:45  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-02 13:00:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-02 13:00:54  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-02 13:00:58  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-02 13:01:03  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-02 13:01:07  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-02 13:01:12  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-02 13:01:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-02 13:01:21  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-02 13:01:25  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-02 13:01:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-02 13:01:34  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-02 13:01:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-02 13:01:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-02 13:01:47  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-02_13-01-48 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients?_prerender {"code":"ECONNRESET"}
2017-04-02 13:03:52  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-02 13:03:57  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-02 13:04:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-02 13:04:07  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-02 13:04:11  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-02 13:04:16  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-02 13:04:20  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-02 13:04:25  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-02 13:04:30  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-02 13:04:34  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-02 13:04:38  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-02 13:04:43  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-02 13:04:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-02 13:04:52  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-02 13:04:56  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-02 13:05:01  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-02 13:05:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-02 13:05:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-02 13:05:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-02 13:05:20  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-02 13:05:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-02 13:05:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-02 13:05:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-02 13:05:38  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-02 13:05:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-02 13:05:48  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-02 13:05:52  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-02 13:05:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-02 13:06:00  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-02 13:06:05  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-02 13:06:10  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-02 13:06:14  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-02 13:06:18  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-02 13:06:23  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-02 13:06:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-02 13:06:32  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-02 13:06:37  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-02 13:06:41  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-02 13:06:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-02 13:06:50  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-02 13:06:55  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-02 13:07:00  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-02 13:07:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-02 13:07:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-02 13:07:13  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-02 13:07:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-02 13:07:22  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-02 13:07:27  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-02 13:07:31  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-02 13:07:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-02 13:07:40  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-02 13:07:45  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-02 13:07:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-02 13:07:54  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-02 13:08:04  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-02 13:08:13  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-02 13:08:17  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-02 13:08:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-02 13:08:27  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-02 13:08:31  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-02 13:08:35  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-02 13:08:40  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-02 13:08:44  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-02 13:08:49  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-02 13:08:53  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-02 13:08:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-02 13:09:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-02 13:09:06  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-02 13:09:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-02 13:09:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-02 13:09:19  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-02 13:09:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-02 13:09:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-02 13:09:32  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-02 13:09:37  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-02 13:09:41  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-02 13:09:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-02 13:09:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-02 13:09:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-02 13:09:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-02 13:10:03  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-02 13:10:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-02 13:10:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-02 13:10:16  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-02 13:10:24  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-02 13:10:29  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-02 13:10:33  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-02 13:10:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-02 13:10:42  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-02 13:10:46  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-02 13:10:50  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-02 13:10:55  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-02 13:10:59  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-02 13:11:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-02 13:11:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-02 13:11:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-02 13:11:17  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-02 13:11:18  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-02 13:11:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-02 13:11:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-02 13:11:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-02 13:11:36  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-02 13:11:40  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-02 13:11:45  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-02 13:11:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-02 13:11:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-02 13:11:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-02 13:12:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-02 13:12:06  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-02 13:12:11  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-02 13:12:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-02 13:12:21  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-02 13:12:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-02 13:12:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-02 13:12:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-02 13:12:38  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-02 13:12:43  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-02 13:12:47  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-02 13:12:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-02 13:12:56  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-02 13:13:00  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-02 13:13:04  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-02 13:13:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-02 13:13:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-02 13:13:22  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-02 13:13:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-02 13:13:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-02 13:13:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-02 13:13:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-02 13:13:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-02 13:13:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-02 13:13:56  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-02 13:14:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-02 13:14:04  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-02 13:14:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-02 13:14:12  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-02 13:14:16  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-02 13:14:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-02 13:14:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-02 13:14:29  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-02 13:14:33  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-02 13:14:37  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-02 13:14:41  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-02 13:14:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-02 13:14:50  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-02 13:14:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-02 13:14:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-02 13:15:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-02 13:15:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-02 13:15:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-02 13:15:16  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-02 13:15:20  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-02 13:15:24  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-02 13:15:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-02 13:15:33  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-02 13:15:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-02 13:15:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-02 13:15:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-02 13:15:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 13:15:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 13:15:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 13:16:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 13:16:05  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-02 13:16:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 13:16:12  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 13:16:16  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-02 13:16:20  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-02 13:16:24  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-02 13:16:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-02 13:16:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-02 13:16:37  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-02 13:16:41  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-02 13:16:45  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-02 13:16:49  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-02 13:16:54  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-02 13:16:57  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-02 13:17:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-02 13:17:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-02 13:17:13  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-02 13:17:17  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-02 13:17:22  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-02 13:17:29  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-02 13:17:33  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-02 13:17:37  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-02 13:17:41  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-02 13:17:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 13:17:49  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 13:17:53  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 13:17:57  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 13:18:01  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 13:18:05  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-02 13:18:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 13:18:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 13:18:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 13:18:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 13:18:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-02 13:18:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 13:18:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 13:18:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 13:18:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-02 13:18:45  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-02_13-31-48 Restart Xvfb...
2017-04-02_14-01-48 Restart Xvfb...
2017-04-02_14-31-48 Restart Xvfb...
2017-04-02_15-01-48 Restart Xvfb...
2017-04-02 15:31:46 reset updateRequest
2017-04-02 15:31:46  - 14968  http://www.lymphomahub.com/
2017-04-02_15-31-48 Restart Xvfb...
2017-04-02 15:31:51  - 14968  http://www.lymphomahub.com/
2017-04-02 15:31:54  - 14968  http://www.lymphomahub.com/about
2017-04-02 15:31:59  - 14968  http://www.lymphomahub.com/terms
2017-04-02 15:32:02  - 14968  http://www.lymphomahub.com/undefined
2017-04-02 15:32:03  - 14968  http://www.lymphomahub.com/therapies
2017-04-02 15:32:09  - 14968  http://www.lymphomahub.com/newsletter
2017-04-02 15:32:13  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-02 15:32:16  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-02 15:32:21  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-02 15:32:25  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-02 15:32:29  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-02 15:32:34  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-02 15:32:38  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-02 15:32:42  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-02 15:32:47  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-02 15:32:51  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-02 15:32:56  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-02 15:33:00  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-02 15:33:05  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-02 15:33:09  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-02 15:33:14  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-02 15:33:18  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-02 15:33:23  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-02 15:33:27  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-02 15:33:32  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-02 15:33:37  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-02 15:33:41  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-02 15:33:45  - 14968  http://www.lymphomahub.com/about/secretariat
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-02 15:33:49  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-02 15:33:51  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-02 15:33:53  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-02 15:33:56  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-02 15:33:58  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-02 15:34:00  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-02 15:34:03  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-02 15:34:04  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-02 15:34:07  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-02 15:34:09  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-02 15:34:12  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-02 15:34:13  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-02 15:34:18  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-02 15:34:18  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-02 15:34:23  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-02 15:34:23  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-02 15:34:28  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-02 15:34:32  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-02 15:34:42  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-02 15:34:46  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-02 15:34:50  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-02 15:34:55  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-02 15:34:59  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-02 15:35:04  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-02 15:35:08  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-02 15:35:12  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-02 15:35:17  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-02 15:35:21  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-02 15:35:26  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-02 15:35:30  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-02 15:35:34  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-02 15:35:38  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-02 15:35:43  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-02 15:35:47  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-02 15:35:51  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-02 15:35:56  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-02 15:36:00  - 14968  http://www.lymphomahub.com/medical-information
2017-04-02 15:36:05  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-02 15:36:09  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-02 15:36:14  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-02 15:36:18  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-02 15:36:23  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-02 15:36:27  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-02 15:36:32  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-02 15:36:36  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-02 15:36:40  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-02 15:36:45  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-02 15:36:49  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-02 15:36:54  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-02 15:36:55  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-02 15:36:59  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-02 15:37:03  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-02 15:37:08  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-02 15:37:12  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-02 15:37:16  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-02 15:37:21  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-02 15:37:25  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-02 15:37:30  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-02 15:37:34  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-02 15:37:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-02 15:37:42  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-02 15:37:47  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-02 15:37:51  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-02 15:37:56  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-02 15:38:00  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-02 15:38:04  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-02 15:38:09  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-02 15:38:13  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-02 15:38:17  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-02 15:38:22  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-02 15:38:26  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-02 15:38:30  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-02 15:38:35  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-02 15:38:39  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-02 15:38:43  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-02 15:38:48  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-02 15:38:52  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-02 15:38:57  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-02 15:39:01  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-02 15:39:05  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-02 15:39:06  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-02 15:39:10  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-02 15:39:15  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-02 15:39:19  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-02 15:39:24  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-02 15:39:28  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-02 15:39:32  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-02 15:39:37  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-02 15:39:41  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-02 15:39:45  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-02 15:39:46  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-02 15:39:50  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-02 15:39:54  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-02 15:39:58  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-02 15:40:03  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-02 15:40:07  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-02 15:40:08  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-02 15:40:13  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-02 15:40:17  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-02 15:40:21  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-02 15:40:25  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-02 15:40:29  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-02 15:40:33  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-02 15:40:36  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-02 15:40:40  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-02 15:40:44  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-02 15:40:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-02 15:40:52  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-02 15:40:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-02 15:41:01  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-02 15:41:05  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-02 15:41:05  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-02 15:41:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-02 15:41:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-02 15:41:18  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-02 15:41:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-02 15:41:27  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-02 15:41:31  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-02 15:41:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-02 15:41:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-02 15:41:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-02 15:41:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-02 15:41:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-02 15:41:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-02 15:41:57  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-02 15:42:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-02 15:42:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-02 15:42:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-02 15:42:15  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-02 15:42:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-02 15:42:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-02 15:42:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-02 15:42:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-02 15:42:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-02 15:42:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-02 15:42:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-02 15:42:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-02 15:42:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-02 15:42:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-02 15:43:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-02 15:43:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-02 15:43:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-02 15:43:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-02 15:43:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-02 15:43:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-02 15:43:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-02 15:43:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-02 15:43:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-02 15:43:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-02 15:43:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-02 15:43:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-02 15:43:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-02 15:43:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-02 15:44:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-02 15:44:08  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-02 15:44:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-02 15:44:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-02 15:44:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-02 15:44:24  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-02 15:44:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-02 15:44:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-02 15:44:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-02 15:44:41  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-02 15:44:45  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-02 15:44:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-02 15:44:53  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-02 15:44:58  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-02 15:45:02  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-02 15:45:06  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-02 15:45:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-02 15:45:14  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-02 15:45:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-02 15:45:22  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-02 15:45:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-02 15:45:30  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-02 15:45:34  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-02 15:45:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-02 15:45:42  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-02 15:45:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-02 15:45:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-02 15:45:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-02 15:46:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-02 15:46:05  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-02 15:46:06  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-02 15:46:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-02 15:46:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-02 15:46:19  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-02 15:46:23  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-02 15:46:28  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-02 15:46:32  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 15:46:37  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 15:46:42  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-02 15:46:46  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 15:46:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-02 15:46:55  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-02 15:47:00  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-02 15:47:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-02 15:47:09  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-02 15:47:13  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-02 15:47:18  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-02 15:47:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-02 15:47:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-02 15:47:31  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-02 15:47:36  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 15:47:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-02 15:47:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-02 15:47:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-02 15:47:54  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-02 15:47:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-02 15:48:03  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-02 15:48:08  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-02 15:48:12  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-02 15:48:17  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-02 15:48:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-02 15:48:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-02 15:48:30  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-02 15:48:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-02 15:48:39  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-02 15:48:44  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-02 15:48:48  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-02 15:48:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-02 15:48:57  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-02 15:49:02  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-02 15:49:06  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-02 15:49:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-02 15:49:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-02 15:49:16  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-02 15:49:20  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-02 15:49:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-02 15:49:29  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-02 15:49:34  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-02 15:49:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-02 15:49:43  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-02 15:49:47  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-02 15:49:52  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-02 15:49:56  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-02 15:50:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-02 15:50:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-02 15:50:10  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-02 15:50:15  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-02 15:50:19  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-02 15:50:23  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-02 15:50:28  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-02 15:50:32  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-02 15:50:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-02 15:50:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-02 15:50:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-02 15:50:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-02 15:50:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-02 15:50:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-02 15:51:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-02 15:51:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-02 15:51:10  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-02 15:51:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-02 15:51:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-02 15:51:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-02 15:51:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-02 15:51:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-02 15:51:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-02 15:51:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-02 15:51:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-02 15:51:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-02 15:51:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-02 15:51:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-02 15:51:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-02 15:51:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-02 15:51:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-02 15:52:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-02 15:52:07  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-02 15:52:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-02 15:52:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-02 15:52:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-02 15:52:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-02 15:52:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-02 15:52:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-02 15:52:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-02 15:52:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-02 15:52:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-02 15:52:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-02 15:52:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-02 15:52:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-02 15:52:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-02 15:52:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-02 15:53:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-02 15:53:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-02 15:53:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-02 15:53:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-02 15:53:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-02 15:53:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-02 15:53:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-02 15:53:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-02 15:53:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-02 15:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-02 15:53:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-02 15:53:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-02 15:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-02 15:53:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-02 15:53:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-02 15:53:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-02 15:54:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-02 15:54:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-02 15:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-02 15:54:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-02 15:54:21  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-02 15:54:25  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-02 15:54:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-02 15:54:35  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-02 15:54:36  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-02 15:54:40  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-02 15:54:45  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-02 15:54:49  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-02 15:54:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-02 15:54:58  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-02 15:55:03  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-02 15:55:07  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-02 15:55:11  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-02 15:55:16  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-02 15:55:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-02 15:55:25  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-02 15:55:29  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-02 15:55:34  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-02 15:55:38  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-02 15:55:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-02 15:55:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-02 15:55:52  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-02 15:55:57  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-02 15:56:01  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-02 15:56:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-02 15:56:10  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-02 15:56:14  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-02 15:56:19  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-02 15:56:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-02 15:56:28  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-02 15:56:32  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-02 15:56:37  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-02 15:56:41  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-02 15:56:46  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-02 15:56:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-02 15:56:54  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-02 15:56:59  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-02 15:57:04  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-02 15:57:08  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-02 15:57:12  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-02 15:57:17  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-02 15:57:21  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-02 15:57:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-02 15:57:31  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-02 15:57:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-02 15:57:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-02 15:57:44  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-02 15:57:48  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-02 15:57:53  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-02 15:57:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-02 15:58:02  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-02 15:58:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-02 15:58:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-02 15:58:15  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-02 15:58:19  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-02 15:58:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-02 15:58:29  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-02 15:58:33  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-02 15:58:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-02 15:58:42  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-02 15:58:47  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-02 15:58:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-02 15:58:56  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-02 15:59:01  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-02 15:59:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-02 15:59:10  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-02 15:59:14  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-02 15:59:18  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-02 15:59:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-02 15:59:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-02 15:59:32  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-02 15:59:36  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-02 15:59:40  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-02 15:59:45  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-02 15:59:49  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-02 15:59:54  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-02 15:59:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-02 16:00:03  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-02 16:00:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-02 16:00:14  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-02 16:00:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-02 16:00:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-02 16:00:28  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-02 16:00:32  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-02 16:00:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-02 16:00:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-02 16:00:46  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-02 16:00:51  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-02 16:00:55  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-02 16:00:59  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-02 16:01:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-02 16:01:08  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-02 16:01:12  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-02 16:01:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-02 16:01:21  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-02 16:01:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-02 16:01:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-02 16:01:35  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-02 16:01:45  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-02_16-01-48 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections?_prerender {"code":"ECONNRESET"}
2017-04-02 16:03:50  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-02 16:03:54  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-02 16:03:59  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-02 16:04:04  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-02 16:04:08  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-02 16:04:13  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-02 16:04:17  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-02 16:04:22  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-02 16:04:27  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-02 16:04:31  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-02 16:04:36  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-02 16:04:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-02 16:04:44  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-02 16:04:49  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-02 16:04:53  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-02 16:04:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-02 16:05:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-02 16:05:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-02 16:05:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-02 16:05:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-02 16:05:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-02 16:05:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-02 16:05:30  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-02 16:05:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-02 16:05:39  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-02 16:05:44  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-02 16:05:48  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-02 16:05:52  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-02 16:05:57  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-02 16:06:01  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-02 16:06:06  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-02 16:06:10  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-02 16:06:15  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-02 16:06:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-02 16:06:24  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-02 16:06:28  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-02 16:06:33  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-02 16:06:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-02 16:06:42  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-02 16:06:47  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-02 16:06:51  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-02 16:06:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-02 16:07:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-02 16:07:04  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-02 16:07:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-02 16:07:13  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-02 16:07:18  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-02 16:07:22  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-02 16:07:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-02 16:07:31  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-02 16:07:36  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-02 16:07:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-02 16:07:44  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-02 16:07:49  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-02 16:07:53  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-02 16:07:57  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-02 16:08:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-02 16:08:06  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-02 16:08:10  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-02 16:08:15  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-02 16:08:19  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-02 16:08:24  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-02 16:08:28  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-02 16:08:32  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-02 16:08:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-02 16:08:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-02 16:08:44  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-02 16:08:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-02 16:08:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-02 16:08:57  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-02 16:09:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-02 16:09:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-02 16:09:11  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-02 16:09:15  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-02 16:09:19  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-02 16:09:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-02 16:09:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-02 16:09:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-02 16:09:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-02 16:09:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-02 16:09:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-02 16:09:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-02 16:09:53  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-02 16:10:02  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-02 16:10:07  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-02 16:10:11  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-02 16:10:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-02 16:10:20  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-02 16:10:24  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-02 16:10:28  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-02 16:10:33  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-02 16:10:37  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-02 16:10:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-02 16:10:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-02 16:10:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-02 16:10:55  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-02 16:10:55  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-02 16:11:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-02 16:11:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-02 16:11:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-02 16:11:13  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-02 16:11:17  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-02 16:11:22  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-02 16:11:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-02 16:11:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-02 16:11:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-02 16:11:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-02 16:11:43  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-02 16:11:47  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-02 16:11:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-02 16:11:56  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-02 16:12:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-02 16:12:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-02 16:12:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-02 16:12:19  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-02 16:12:23  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-02 16:12:28  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-02 16:12:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-02 16:12:36  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-02 16:12:40  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-02 16:12:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-02 16:12:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-02 16:12:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-02 16:12:58  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-02 16:13:02  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-02 16:13:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-02 16:13:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-02 16:13:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-02 16:13:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-02 16:13:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-02 16:13:27  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-02 16:13:31  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-02 16:13:35  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-02 16:13:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-02 16:13:43  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-02 16:13:47  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-02 16:13:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-02 16:13:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-02 16:14:00  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-02 16:14:04  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-02 16:14:08  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-02 16:14:12  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-02 16:14:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-02 16:14:20  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-02 16:14:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-02 16:14:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-02 16:14:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-02 16:14:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-02 16:14:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-02 16:14:47  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-02 16:14:51  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-02 16:14:55  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-02 16:14:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-02 16:15:03  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-02 16:15:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-02 16:15:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-02 16:15:16  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-02 16:15:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 16:15:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 16:15:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 16:15:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 16:15:41  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-02 16:15:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 16:15:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 16:15:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-02 16:15:57  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-02 16:16:01  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-02 16:16:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-02 16:16:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-02 16:16:14  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-02 16:16:18  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-02 16:16:21  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-02 16:16:25  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-02 16:16:29  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-02 16:16:33  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-02 16:16:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-02 16:16:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-02 16:16:46  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-02 16:16:50  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-02 16:16:54  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-02 16:16:58  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-02 16:17:02  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-02 16:17:06  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-02 16:17:10  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-02 16:17:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 16:17:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 16:17:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 16:17:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 16:17:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 16:17:34  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-02 16:17:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 16:17:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 16:17:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 16:17:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 16:17:58  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-02 16:18:02  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 16:18:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 16:18:10  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 16:18:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-02 16:18:18  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-02_16-31-48 Restart Xvfb...
2017-04-02_17-01-48 Restart Xvfb...
2017-04-02_17-31-48 Restart Xvfb...
2017-04-02_18-01-49 Restart Xvfb...
2017-04-02 18:31:46 reset updateRequest
2017-04-02_18-31-49 Restart Xvfb...
2017-04-02 18:31:49  - 14968  http://www.lymphomahub.com/
2017-04-02 18:31:51  - 14968  http://www.lymphomahub.com/
2017-04-02 18:31:53  - 14968  http://www.lymphomahub.com/about
2017-04-02 18:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-02 18:32:00  - 14968  http://www.lymphomahub.com/terms
2017-04-02 18:32:00  - 14968  http://www.lymphomahub.com/terms
2017-04-02 18:32:04  - 14968  http://www.lymphomahub.com/undefined
2017-04-02 18:32:04  - 14968  http://www.lymphomahub.com/therapies
2017-04-02 18:32:04  - 14968  http://www.lymphomahub.com/therapies
2017-04-02 18:32:13  - 14968  http://www.lymphomahub.com/newsletter
2017-04-02 18:32:14  - 14968  http://www.lymphomahub.com/newsletter
2017-04-02 18:32:18  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-02 18:32:18  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-02 18:32:22  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-02 18:32:22  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-02 18:32:27  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-02 18:32:27  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-02 18:32:32  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-02 18:32:37  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-02 18:32:42  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-02 18:32:47  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-02 18:32:51  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-02 18:32:55  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-02 18:33:00  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-02 18:33:04  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-02 18:33:09  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-02 18:33:13  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-02 18:33:17  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-02 18:33:22  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-02 18:33:26  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-02 18:33:30  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-02 18:33:35  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-02 18:33:44  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-02 18:33:48  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-02 18:33:52  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-02 18:33:57  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-02 18:34:00  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-02 18:34:05  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-02 18:34:09  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-02 18:34:13  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-02 18:34:18  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-02 18:34:22  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-02 18:34:27  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-02 18:34:31  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-02 18:34:35  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-02 18:34:40  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-02 18:34:44  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-02 18:34:48  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-02 18:34:53  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-02 18:34:57  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-02 18:35:01  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-02 18:35:06  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-02 18:35:10  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-02 18:35:14  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-02 18:35:19  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-02 18:35:23  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-02 18:35:27  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-02 18:35:31  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-02 18:35:36  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-02 18:35:40  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-02 18:35:44  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-02 18:35:49  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-02 18:35:53  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-02 18:35:58  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-02 18:36:02  - 14968  http://www.lymphomahub.com/medical-information
2017-04-02 18:36:07  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-02 18:36:11  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-02 18:36:15  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-02 18:36:19  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-02 18:36:24  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-02 18:36:28  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-02 18:36:32  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-02 18:36:37  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-02 18:36:41  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-02 18:36:46  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-02 18:36:50  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-02 18:36:54  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-02 18:36:55  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-02 18:36:59  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-02 18:37:04  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-02 18:37:08  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-02 18:37:12  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-02 18:37:17  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-02 18:37:21  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-02 18:37:25  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-02 18:37:30  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-02 18:37:34  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-02 18:37:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-02 18:37:42  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-02 18:37:47  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-02 18:37:51  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-02 18:37:55  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-02 18:38:00  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-02 18:38:04  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-02 18:38:08  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-02 18:38:13  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-02 18:38:17  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-02 18:38:21  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-02 18:38:26  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-02 18:38:30  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-02 18:38:35  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-02 18:38:39  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-02 18:38:44  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-02 18:38:48  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-02 18:38:52  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-02 18:38:57  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-02 18:39:01  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-02 18:39:05  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-02 18:39:06  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-02 18:39:11  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-02 18:39:15  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-02 18:39:19  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-02 18:39:24  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-02 18:39:28  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-02 18:39:32  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-02 18:39:42  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-02 18:39:46  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-02 18:39:49  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-02 18:39:50  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-02 18:39:54  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-02 18:39:58  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-02 18:40:03  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-02 18:40:07  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-02 18:40:12  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-02 18:40:12  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-02 18:40:17  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-02 18:40:21  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-02 18:40:24  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-02 18:40:28  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-02 18:40:33  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-02 18:40:36  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-02 18:40:40  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-02 18:40:44  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-02 18:40:48  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-02 18:40:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-02 18:40:56  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-02 18:41:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-02 18:41:04  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-02 18:41:08  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-02 18:41:08  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-02 18:41:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-02 18:41:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-02 18:41:21  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-02 18:41:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-02 18:41:29  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-02 18:41:33  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-02 18:41:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-02 18:41:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-02 18:41:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-02 18:41:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-02 18:41:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-02 18:41:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-02 18:42:00  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-02 18:42:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-02 18:42:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-02 18:42:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-02 18:42:17  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-02 18:42:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-02 18:42:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-02 18:42:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-02 18:42:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-02 18:42:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-02 18:42:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-02 18:42:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-02 18:42:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-02 18:42:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-02 18:42:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-02 18:43:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-02 18:43:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-02 18:43:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-02 18:43:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-02 18:43:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-02 18:43:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-02 18:43:30  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-02 18:43:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-02 18:43:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-02 18:43:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-02 18:43:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-02 18:43:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-02 18:43:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-02 18:44:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-02 18:44:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-02 18:44:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-02 18:44:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-02 18:44:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-02 18:44:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-02 18:44:25  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-02 18:44:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-02 18:44:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-02 18:44:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-02 18:44:40  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-02 18:44:45  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-02 18:44:49  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-02 18:44:53  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-02 18:44:57  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-02 18:45:01  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-02 18:45:06  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-02 18:45:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-02 18:45:14  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-02 18:45:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-02 18:45:21  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-02 18:45:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-02 18:45:30  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-02 18:45:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-02 18:45:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-02 18:45:42  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-02 18:45:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-02 18:45:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-02 18:45:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-02 18:46:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-02 18:46:05  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-02 18:46:05  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-02 18:46:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-02 18:46:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-02 18:46:18  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-02 18:46:23  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-02 18:46:27  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-02 18:46:32  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 18:46:36  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 18:46:41  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-02 18:46:45  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 18:46:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-02 18:46:54  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-02 18:46:58  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-02 18:47:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-02 18:47:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-02 18:47:12  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-02 18:47:16  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-02 18:47:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-02 18:47:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-02 18:47:30  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-02 18:47:34  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 18:47:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-02 18:47:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-02 18:47:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-02 18:47:53  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-02 18:47:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-02 18:48:02  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-02 18:48:06  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-02 18:48:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-02 18:48:15  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-02 18:48:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-02 18:48:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-02 18:48:33  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-02 18:48:41  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-02 18:48:46  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-02 18:48:50  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-02 18:48:54  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-02 18:48:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-02 18:49:03  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-02 18:49:08  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-02 18:49:12  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-02 18:49:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-02 18:49:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-02 18:49:22  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-02 18:49:26  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-02 18:49:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-02 18:49:35  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-02 18:49:39  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-02 18:49:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-02 18:49:48  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-02 18:49:53  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-02 18:49:57  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-02 18:50:02  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-02 18:50:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-02 18:50:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-02 18:50:15  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-02 18:50:20  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-02 18:50:24  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-02 18:50:28  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-02 18:50:33  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-02 18:50:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-02 18:50:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-02 18:50:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-02 18:50:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-02 18:50:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-02 18:50:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-02 18:51:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-02 18:51:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-02 18:51:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-02 18:51:16  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-02 18:51:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-02 18:51:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-02 18:51:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-02 18:51:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-02 18:51:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-02 18:51:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-02 18:51:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-02 18:51:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-02 18:51:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-02 18:51:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-02 18:51:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-02 18:51:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-02 18:52:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-02 18:52:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-02 18:52:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-02 18:52:13  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-02 18:52:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-02 18:52:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-02 18:52:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-02 18:52:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-02 18:52:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-02 18:52:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-02 18:52:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-02 18:52:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-02 18:52:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-02 18:52:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-02 18:52:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-02 18:52:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-02 18:53:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-02 18:53:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-02 18:53:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-02 18:53:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-02 18:53:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-02 18:53:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-02 18:53:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-02 18:53:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-02 18:53:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-02 18:53:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-02 18:53:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-02 18:53:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-02 18:53:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-02 18:53:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-02 18:53:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-02 18:53:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-02 18:53:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-02 18:54:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-02 18:54:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-02 18:54:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-02 18:54:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-02 18:54:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-02 18:54:21  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-02 18:54:26  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-02 18:54:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-02 18:54:35  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-02 18:54:36  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-02 18:54:40  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-02 18:54:45  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-02 18:54:50  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-02 18:54:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-02 18:54:59  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-02 18:55:03  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-02 18:55:08  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-02 18:55:12  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-02 18:55:17  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-02 18:55:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-02 18:55:31  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-02 18:55:36  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-02 18:55:40  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-02 18:55:45  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-02 18:55:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-02 18:55:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-02 18:55:58  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-02 18:56:03  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-02 18:56:08  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-02 18:56:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-02 18:56:16  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-02 18:56:21  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-02 18:56:25  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-02 18:56:30  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-02 18:56:34  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-02 18:56:38  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-02 18:56:43  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-02 18:56:47  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-02 18:56:52  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-02 18:56:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-02 18:57:01  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-02 18:57:05  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-02 18:57:10  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-02 18:57:14  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-02 18:57:18  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-02 18:57:23  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-02 18:57:27  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-02 18:57:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-02 18:57:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-02 18:57:41  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-02 18:57:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-02 18:57:50  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-02 18:57:54  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-02 18:57:59  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-02 18:58:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-02 18:58:08  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-02 18:58:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-02 18:58:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-02 18:58:20  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-02 18:58:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-02 18:58:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-02 18:58:34  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-02 18:58:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-02 18:58:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-02 18:58:48  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-02 18:58:52  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-02 18:58:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-02 18:59:01  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-02 18:59:05  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-02 18:59:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-02 18:59:14  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-02 18:59:18  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-02 18:59:23  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-02 18:59:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-02 18:59:32  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-02 18:59:36  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-02 18:59:40  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-02 18:59:45  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-02 18:59:49  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-02 18:59:53  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-02 18:59:58  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-02 19:00:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-02 19:00:07  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-02 19:00:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-02 19:00:15  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-02 19:00:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-02 19:00:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-02 19:00:29  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-02 19:00:33  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-02 19:00:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-02 19:00:43  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-02 19:00:47  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-02 19:00:52  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-02 19:00:56  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-02 19:01:00  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-02 19:01:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-02 19:01:09  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-02 19:01:14  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-02 19:01:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-02 19:01:23  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-02 19:01:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-02 19:01:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-02 19:01:36  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-02 19:01:41  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-02 19:01:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-02_19-01-49 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies?_prerender {"code":"ECONNRESET"}
2017-04-02 19:03:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-02 19:03:54  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-02 19:03:59  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-02 19:04:04  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-02 19:04:08  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-02 19:04:13  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-02 19:04:17  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-02 19:04:22  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-02 19:04:27  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-02 19:04:31  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-02 19:04:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-02 19:04:45  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-02 19:04:50  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-02 19:04:55  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-02 19:04:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-02 19:05:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-02 19:05:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-02 19:05:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-02 19:05:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-02 19:05:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-02 19:05:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-02 19:05:31  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-02 19:05:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-02 19:05:40  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-02 19:05:44  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-02 19:05:48  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-02 19:05:52  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-02 19:05:57  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-02 19:06:01  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-02 19:06:06  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-02 19:06:10  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-02 19:06:15  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-02 19:06:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-02 19:06:24  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-02 19:06:28  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-02 19:06:33  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-02 19:06:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-02 19:06:42  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-02 19:06:47  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-02 19:06:51  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-02 19:06:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-02 19:07:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-02 19:07:05  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-02 19:07:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-02 19:07:14  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-02 19:07:19  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-02 19:07:23  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-02 19:07:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-02 19:07:32  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-02 19:07:36  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-02 19:07:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-02 19:07:45  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-02 19:07:49  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-02 19:07:53  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-02 19:07:57  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-02 19:08:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-02 19:08:06  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-02 19:08:10  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-02 19:08:15  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-02 19:08:19  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-02 19:08:24  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-02 19:08:28  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-02 19:08:32  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-02 19:08:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-02 19:08:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-02 19:08:45  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-02 19:08:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-02 19:08:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-02 19:08:58  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-02 19:09:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-02 19:09:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-02 19:09:11  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-02 19:09:16  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-02 19:09:20  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-02 19:09:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-02 19:09:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-02 19:09:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-02 19:09:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-02 19:09:46  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-02 19:09:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-02 19:09:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-02 19:09:59  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-02 19:10:03  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-02 19:10:08  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-02 19:10:12  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-02 19:10:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-02 19:10:21  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-02 19:10:24  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-02 19:10:29  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-02 19:10:34  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-02 19:10:38  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-02 19:10:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-02 19:10:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-02 19:10:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-02 19:10:56  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-02 19:10:56  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-02 19:11:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-02 19:11:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-02 19:11:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-02 19:11:14  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-02 19:11:18  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-02 19:11:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-02 19:11:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-02 19:11:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-02 19:11:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-02 19:11:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-02 19:11:44  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-02 19:11:48  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-02 19:11:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-02 19:11:58  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-02 19:12:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-02 19:12:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-02 19:12:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-02 19:12:15  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-02 19:12:20  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-02 19:12:24  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-02 19:12:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-02 19:12:33  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-02 19:12:37  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-02 19:12:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-02 19:12:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-02 19:12:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-02 19:12:54  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-02 19:12:58  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-02 19:13:07  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-02 19:13:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-02 19:13:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-02 19:13:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-02 19:13:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-02 19:13:28  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-02 19:13:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-02 19:13:37  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-02 19:13:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-02 19:13:44  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-02 19:13:48  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-02 19:13:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-02 19:13:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-02 19:14:02  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-02 19:14:06  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-02 19:14:10  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-02 19:14:14  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-02 19:14:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-02 19:14:22  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-02 19:14:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-02 19:14:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-02 19:14:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-02 19:14:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-02 19:14:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-02 19:14:48  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-02 19:14:52  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-02 19:14:56  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-02 19:15:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-02 19:15:04  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-02 19:15:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-02 19:15:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-02 19:15:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-02 19:15:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 19:15:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 19:15:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 19:15:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 19:15:37  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-02 19:15:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 19:15:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 19:15:48  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-02 19:15:52  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-02 19:15:56  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-02 19:16:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-02 19:16:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-02 19:16:09  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-02 19:16:13  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-02 19:16:17  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-02 19:16:21  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-02 19:16:25  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-02 19:16:29  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-02 19:16:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-02 19:16:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-02 19:16:41  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-02 19:16:45  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-02 19:16:49  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-02 19:16:53  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-02 19:16:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-02 19:17:01  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-02 19:17:05  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-02 19:17:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 19:17:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 19:17:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 19:17:24  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 19:17:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 19:17:32  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-02 19:17:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 19:17:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 19:17:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 19:17:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 19:17:52  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-02 19:17:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 19:18:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 19:18:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 19:18:08  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-02 19:18:12  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-02_19-31-49 Restart Xvfb...
2017-04-02_20-01-49 Restart Xvfb...
2017-04-02_20-31-49 Restart Xvfb...
2017-04-02_21-01-49 Restart Xvfb...
2017-04-02 21:31:46 reset updateRequest
2017-04-02 21:31:48  - 14968  http://www.lymphomahub.com/
2017-04-02_21-31-49 Restart Xvfb...
2017-04-02 21:31:51  - 14968  http://www.lymphomahub.com/
2017-04-02 21:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-02 21:32:00  - 14968  http://www.lymphomahub.com/terms
2017-04-02 21:32:04  - 14968  http://www.lymphomahub.com/undefined
2017-04-02 21:32:04  - 14968  http://www.lymphomahub.com/therapies
2017-04-02 21:32:10  - 14968  http://www.lymphomahub.com/newsletter
2017-04-02 21:32:13  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-02 21:32:16  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-02 21:32:21  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-02 21:32:25  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-02 21:32:30  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-02 21:32:34  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-02 21:32:38  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-02 21:32:46  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-02 21:32:51  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-02 21:32:55  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-02 21:32:59  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-02 21:33:04  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-02 21:33:08  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-02 21:33:13  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-02 21:33:17  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-02 21:33:21  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-02 21:33:26  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-02 21:33:30  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-02 21:33:35  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-02 21:33:39  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-02 21:33:44  - 14968  http://www.lymphomahub.com/therapies/kte-c19
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-02 21:33:48  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-02 21:33:52  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-02 21:33:53  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-02 21:33:57  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-02 21:33:57  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-02 21:34:02  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-02 21:34:02  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-02 21:34:08  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-02 21:34:08  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-02 21:34:13  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-02 21:34:18  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-02 21:34:22  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-02 21:34:26  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-02 21:34:31  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-02 21:34:35  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-02 21:34:39  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-02 21:34:43  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-02 21:34:48  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-02 21:34:52  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-02 21:34:57  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-02 21:35:01  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-02 21:35:06  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-02 21:35:10  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-02 21:35:14  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-02 21:35:18  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-02 21:35:23  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-02 21:35:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-02 21:35:32  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-02 21:35:36  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-02 21:35:41  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-02 21:35:45  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-02 21:35:50  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-02 21:35:54  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-02 21:35:58  - 14968  http://www.lymphomahub.com/medical-information
2017-04-02 21:36:02  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-02 21:36:06  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-02 21:36:11  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-02 21:36:15  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-02 21:36:19  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-02 21:36:24  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-02 21:36:28  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-02 21:36:32  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-02 21:36:37  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-02 21:36:41  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-02 21:36:45  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-02 21:36:49  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-02 21:36:50  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-02 21:36:55  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-02 21:36:59  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-02 21:37:03  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-02 21:37:07  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-02 21:37:12  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-02 21:37:16  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-02 21:37:20  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-02 21:37:25  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-02 21:37:29  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-02 21:37:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-02 21:37:38  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-02 21:37:42  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-02 21:37:46  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-02 21:37:51  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-02 21:37:55  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-02 21:37:59  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-02 21:38:03  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-02 21:38:08  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-02 21:38:12  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-02 21:38:16  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-02 21:38:21  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-02 21:38:25  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-02 21:38:29  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-02 21:38:34  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-02 21:38:38  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-02 21:38:42  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-02 21:38:47  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-02 21:38:51  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-02 21:38:55  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-02 21:39:00  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-02 21:39:00  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-02 21:39:05  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-02 21:39:09  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-02 21:39:13  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-02 21:39:18  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-02 21:39:22  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-02 21:39:26  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-02 21:39:31  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-02 21:39:35  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-02 21:39:39  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-02 21:39:39  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-02 21:39:44  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-02 21:39:48  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-02 21:39:52  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-02 21:39:56  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-02 21:40:01  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-02 21:40:01  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-02 21:40:06  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-02 21:40:14  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-02 21:40:18  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-02 21:40:22  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-02 21:40:26  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-02 21:40:30  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-02 21:40:34  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-02 21:40:37  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-02 21:40:41  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-02 21:40:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-02 21:40:50  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-02 21:40:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-02 21:40:58  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-02 21:41:02  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-02 21:41:02  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-02 21:41:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-02 21:41:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-02 21:41:15  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-02 21:41:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-02 21:41:23  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-02 21:41:27  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-02 21:41:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-02 21:41:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-02 21:41:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-02 21:41:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-02 21:41:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-02 21:41:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-02 21:41:53  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-02 21:41:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-02 21:42:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-02 21:42:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-02 21:42:10  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-02 21:42:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-02 21:42:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-02 21:42:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-02 21:42:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-02 21:42:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-02 21:42:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-02 21:42:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-02 21:42:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-02 21:42:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-02 21:42:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-02 21:43:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-02 21:43:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-02 21:43:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-02 21:43:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-02 21:43:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-02 21:43:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-02 21:43:27  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-02 21:43:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-02 21:43:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-02 21:43:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-02 21:43:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-02 21:43:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-02 21:43:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-02 21:43:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-02 21:44:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-02 21:44:06  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-02 21:44:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-02 21:44:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-02 21:44:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-02 21:44:22  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-02 21:44:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-02 21:44:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-02 21:44:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-02 21:44:38  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-02 21:44:43  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-02 21:44:47  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-02 21:44:51  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-02 21:44:55  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-02 21:44:59  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-02 21:45:03  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-02 21:45:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-02 21:45:12  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-02 21:45:16  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-02 21:45:19  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-02 21:45:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-02 21:45:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-02 21:45:31  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-02 21:45:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-02 21:45:39  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-02 21:45:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-02 21:45:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-02 21:45:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-02 21:45:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-02 21:46:01  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-02 21:46:01  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-02 21:46:06  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-02 21:46:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-02 21:46:15  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-02 21:46:19  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-02 21:46:23  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-02 21:46:28  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 21:46:32  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 21:46:37  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-02 21:46:41  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 21:46:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-02 21:46:50  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-02 21:46:54  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-02 21:46:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-02 21:47:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-02 21:47:07  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-02 21:47:12  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-02 21:47:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-02 21:47:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-02 21:47:26  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-02 21:47:31  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-02 21:47:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-02 21:47:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-02 21:47:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-02 21:47:59  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-02 21:48:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-02 21:48:08  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-02 21:48:12  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-02 21:48:16  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-02 21:48:21  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-02 21:48:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-02 21:48:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-02 21:48:34  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-02 21:48:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-02 21:48:43  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-02 21:48:47  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-02 21:48:52  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-02 21:48:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-02 21:49:01  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-02 21:49:05  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-02 21:49:10  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-02 21:49:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-02 21:49:18  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-02 21:49:28  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-02 21:49:32  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-02 21:49:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-02 21:49:41  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-02 21:49:46  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-02 21:49:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-02 21:49:55  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-02 21:49:59  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-02 21:50:04  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-02 21:50:08  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-02 21:50:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-02 21:50:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-02 21:50:22  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-02 21:50:26  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-02 21:50:31  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-02 21:50:35  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-02 21:50:40  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-02 21:50:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-02 21:50:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-02 21:50:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-02 21:51:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-02 21:51:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-02 21:51:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-02 21:51:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-02 21:51:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-02 21:51:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-02 21:51:24  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-02 21:51:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-02 21:51:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-02 21:51:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-02 21:51:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-02 21:51:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-02 21:51:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-02 21:51:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-02 21:51:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-02 21:51:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-02 21:51:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-02 21:52:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-02 21:52:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-02 21:52:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-02 21:52:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-02 21:52:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-02 21:52:24  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-02 21:52:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-02 21:52:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-02 21:52:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-02 21:52:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-02 21:52:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-02 21:52:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-02 21:52:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-02 21:52:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-02 21:52:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-02 21:53:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-02 21:53:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-02 21:53:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-02 21:53:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-02 21:53:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-02 21:53:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-02 21:53:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-02 21:53:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-02 21:53:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-02 21:53:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-02 21:53:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-02 21:53:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-02 21:53:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-02 21:53:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-02 21:53:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-02 21:54:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-02 21:54:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-02 21:54:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-02 21:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-02 21:54:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-02 21:54:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-02 21:54:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-02 21:54:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-02 21:54:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-02 21:54:32  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-02 21:54:37  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-02 21:54:41  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-02 21:54:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-02 21:54:51  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-02 21:54:51  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-02 21:54:56  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-02 21:55:01  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-02 21:55:05  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-02 21:55:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-02 21:55:14  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-02 21:55:18  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-02 21:55:23  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-02 21:55:27  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-02 21:55:32  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-02 21:55:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-02 21:55:41  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-02 21:55:45  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-02 21:55:50  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-02 21:55:54  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-02 21:55:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-02 21:56:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-02 21:56:07  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-02 21:56:12  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-02 21:56:16  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-02 21:56:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-02 21:56:25  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-02 21:56:30  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-02 21:56:39  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-02 21:56:44  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-02 21:56:48  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-02 21:56:52  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-02 21:56:57  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-02 21:57:01  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-02 21:57:09  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-02 21:57:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-02 21:57:18  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-02 21:57:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-02 21:57:28  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-02 21:57:32  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-02 21:57:36  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-02 21:57:41  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-02 21:57:45  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-02 21:57:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-02 21:57:54  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-02 21:57:59  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-02 21:58:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-02 21:58:08  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-02 21:58:16  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-02 21:58:20  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-02 21:58:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-02 21:58:29  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-02 21:58:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-02 21:58:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-02 21:58:42  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-02 21:58:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-02 21:58:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-02 21:58:55  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-02 21:58:59  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-02 21:59:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-02 21:59:09  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-02 21:59:13  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-02 21:59:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-02 21:59:22  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-02 21:59:26  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-02 21:59:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-02 21:59:35  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-02 21:59:40  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-02 21:59:44  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-02 21:59:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-02 21:59:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-02 21:59:58  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-02 22:00:02  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-02 22:00:10  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-02 22:00:14  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-02 22:00:19  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-02 22:00:23  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-02 22:00:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-02 22:00:32  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-02 22:00:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-02 22:00:41  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-02 22:00:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-02 22:00:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-02 22:01:00  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-02 22:01:04  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-02 22:01:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-02 22:01:14  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-02 22:01:18  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-02 22:01:23  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-02 22:01:27  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-02 22:01:31  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-02 22:01:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-02 22:01:40  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-02 22:01:44  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-02 22:01:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-02_22-01-49 Restart Xvfb...
2017-04-02 22:01:53  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-02 22:01:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-02 22:02:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-02 22:02:07  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-02 22:02:11  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-02 22:02:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-02 22:02:20  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-02 22:02:25  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-02 22:02:29  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-02 22:02:34  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-02 22:02:38  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-02 22:02:43  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-02 22:02:47  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-02 22:02:52  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-02 22:02:56  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-02 22:03:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-02 22:03:06  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-02 22:03:10  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-02 22:03:15  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-02 22:03:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-02 22:03:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-02 22:03:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-02 22:03:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-02 22:03:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-02 22:03:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-02 22:03:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-02 22:03:51  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-02 22:03:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-02 22:04:00  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-02 22:04:05  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-02 22:04:09  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-02 22:04:13  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-02 22:04:18  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-02 22:04:22  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-02 22:04:26  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-02 22:04:31  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-02 22:04:39  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-02 22:04:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-02 22:04:48  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-02 22:04:52  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-02 22:04:57  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-02 22:05:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-02 22:05:06  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-02 22:05:10  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-02 22:05:15  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-02 22:05:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-02 22:05:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-02 22:05:28  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-02 22:05:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-02 22:05:37  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-02 22:05:42  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-02 22:05:46  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-02 22:05:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-02 22:05:55  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-02 22:06:00  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-02 22:06:04  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-02 22:06:08  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-02 22:06:12  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-02 22:06:16  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-02 22:06:21  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-02 22:06:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-02 22:06:30  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-02 22:06:34  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-02 22:06:38  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-02 22:06:43  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-02 22:06:47  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-02 22:06:52  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-02 22:06:56  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-02 22:06:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-02 22:07:04  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-02 22:07:09  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-02 22:07:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-02 22:07:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-02 22:07:21  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-02 22:07:25  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-02 22:07:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-02 22:07:35  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-02 22:07:39  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-02 22:07:43  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-02 22:07:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-02 22:07:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-02 22:07:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-02 22:08:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-02 22:08:04  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-02 22:08:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-02 22:08:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-02 22:08:17  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-02 22:08:21  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-02 22:08:25  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-02 22:08:30  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-02 22:08:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-02 22:08:38  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-02 22:08:47  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-02 22:08:52  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-02 22:08:56  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-02 22:09:01  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-02 22:09:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-02 22:09:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-02 22:09:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-02 22:09:19  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-02 22:09:19  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-02 22:09:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-02 22:09:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-02 22:09:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-02 22:09:37  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-02 22:09:41  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-02 22:09:46  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-02 22:09:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-02 22:09:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-02 22:09:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-02 22:10:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-02 22:10:07  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-02 22:10:11  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-02 22:10:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-02 22:10:20  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-02 22:10:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-02 22:10:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-02 22:10:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-02 22:10:37  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-02 22:10:41  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-02 22:10:46  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-02 22:10:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-02 22:10:54  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-02 22:11:04  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-02 22:11:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-02 22:11:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-02 22:11:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-02 22:11:22  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-02 22:11:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-02 22:11:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-02 22:11:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-02 22:11:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-02 22:11:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-02 22:11:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-02 22:11:50  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-02 22:11:58  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-02 22:12:02  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-02 22:12:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-02 22:12:10  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-02 22:12:14  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-02 22:12:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-02 22:12:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-02 22:12:27  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-02 22:12:31  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-02 22:12:35  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-02 22:12:39  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-02 22:12:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-02 22:12:51  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-02 22:12:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-02 22:12:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-02 22:13:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-02 22:13:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-02 22:13:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-02 22:13:17  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-02 22:13:21  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-02 22:13:25  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-02 22:13:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-02 22:13:33  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-02 22:13:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-02 22:13:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-02 22:13:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-02 22:13:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 22:13:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 22:13:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 22:14:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 22:14:05  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-02 22:14:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 22:14:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-02 22:14:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-02 22:14:21  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-02 22:14:25  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-02 22:14:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-02 22:14:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-02 22:14:38  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-02 22:14:42  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-02 22:14:46  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-02 22:14:50  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-02 22:14:54  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-02 22:14:58  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-02 22:15:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-02 22:15:07  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-02 22:15:11  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-02 22:15:15  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-02 22:15:19  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-02 22:15:22  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-02 22:15:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-02 22:15:30  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-02 22:15:34  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-02 22:15:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 22:15:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 22:15:46  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 22:15:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 22:15:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-02 22:15:58  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-02 22:16:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 22:16:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 22:16:10  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 22:16:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 22:16:18  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-02 22:16:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 22:16:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 22:16:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-02 22:16:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-02 22:16:38  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-02_22-31-49 Restart Xvfb...
2017-04-02_23-01-49 Restart Xvfb...
2017-04-02_23-31-49 Restart Xvfb...
2017-04-03_00-01-49 Restart Xvfb...
2017-04-03 00:31:46 reset updateRequest
2017-04-03_00-31-49 Restart Xvfb...
2017-04-03 00:31:50  - 14968  http://www.lymphomahub.com/
2017-04-03 00:31:51  - 14968  http://www.lymphomahub.com/
2017-04-03 00:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-03 00:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-03 00:32:01  - 14968  http://www.lymphomahub.com/terms
2017-04-03 00:32:01  - 14968  http://www.lymphomahub.com/terms
2017-04-03 00:32:05  - 14968  http://www.lymphomahub.com/undefined
2017-04-03 00:32:05  - 14968  http://www.lymphomahub.com/undefined
2017-04-03 00:32:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-03 00:32:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-03 00:32:16  - 14968  http://www.lymphomahub.com/newsletter
2017-04-03 00:32:16  - 14968  http://www.lymphomahub.com/newsletter
2017-04-03 00:32:20  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-03 00:32:21  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-03 00:32:24  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-03 00:32:25  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-03 00:32:30  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-03 00:32:30  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-03 00:32:35  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-03 00:32:40  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-03 00:32:44  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-03 00:32:48  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-03 00:32:52  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-03 00:32:57  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-03 00:33:01  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-03 00:33:05  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-03 00:33:10  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-03 00:33:14  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-03 00:33:18  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-03 00:33:23  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-03 00:33:27  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-03 00:33:31  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-03 00:33:36  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-03 00:33:40  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-03 00:33:44  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-03 00:33:49  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-03 00:33:53  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-03 00:33:57  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-03 00:34:01  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-03 00:34:05  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-03 00:34:10  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-03 00:34:14  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-03 00:34:18  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-03 00:34:23  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-03 00:34:27  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-03 00:34:32  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-03 00:34:41  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-03 00:34:45  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-03 00:34:50  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-03 00:34:54  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-03 00:34:58  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-03 00:35:03  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-03 00:35:07  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-03 00:35:12  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-03 00:35:16  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-03 00:35:21  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-03 00:35:25  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-03 00:35:29  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-03 00:35:34  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-03 00:35:38  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-03 00:35:42  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-03 00:35:47  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-03 00:35:51  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-03 00:35:55  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-03 00:35:59  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-03 00:36:04  - 14968  http://www.lymphomahub.com/medical-information
2017-04-03 00:36:07  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-03 00:36:12  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-03 00:36:16  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-03 00:36:21  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-03 00:36:25  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-03 00:36:29  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-03 00:36:33  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-03 00:36:38  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-03 00:36:42  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-03 00:36:46  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-03 00:36:51  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-03 00:36:55  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-03 00:36:56  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-03 00:37:00  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-03 00:37:05  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-03 00:37:09  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-03 00:37:13  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-03 00:37:17  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-03 00:37:22  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-03 00:37:26  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-03 00:37:30  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-03 00:37:35  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-03 00:37:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-03 00:37:44  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-03 00:37:48  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-03 00:37:52  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-03 00:37:56  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-03 00:38:01  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-03 00:38:05  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-03 00:38:09  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-03 00:38:13  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-03 00:38:18  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-03 00:38:23  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-03 00:38:27  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-03 00:38:31  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-03 00:38:36  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-03 00:38:40  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-03 00:38:44  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-03 00:38:49  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-03 00:38:53  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-03 00:38:57  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-03 00:39:01  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-03 00:39:06  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-03 00:39:06  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-03 00:39:11  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-03 00:39:15  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-03 00:39:19  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-03 00:39:24  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-03 00:39:32  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-03 00:39:36  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-03 00:39:40  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-03 00:39:45  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-03 00:39:48  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-03 00:39:49  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-03 00:39:53  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-03 00:39:58  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-03 00:40:02  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-03 00:40:06  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-03 00:40:11  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-03 00:40:11  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-03 00:40:16  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-03 00:40:20  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-03 00:40:24  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-03 00:40:28  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-03 00:40:32  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-03 00:40:36  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-03 00:40:40  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-03 00:40:43  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-03 00:40:47  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-03 00:40:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-03 00:40:55  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-03 00:40:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-03 00:41:04  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-03 00:41:08  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-03 00:41:08  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-03 00:41:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-03 00:41:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-03 00:41:21  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-03 00:41:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-03 00:41:29  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-03 00:41:34  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-03 00:41:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-03 00:41:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-03 00:41:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-03 00:41:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-03 00:41:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-03 00:41:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-03 00:42:00  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-03 00:42:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-03 00:42:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-03 00:42:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-03 00:42:17  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-03 00:42:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-03 00:42:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-03 00:42:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-03 00:42:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-03 00:42:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-03 00:42:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-03 00:42:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-03 00:42:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-03 00:42:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-03 00:43:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-03 00:43:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-03 00:43:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-03 00:43:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-03 00:43:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-03 00:43:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-03 00:43:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-03 00:43:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-03 00:43:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-03 00:43:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-03 00:43:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-03 00:43:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-03 00:43:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-03 00:44:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-03 00:44:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-03 00:44:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-03 00:44:13  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-03 00:44:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-03 00:44:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-03 00:44:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-03 00:44:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-03 00:44:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-03 00:44:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-03 00:44:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-03 00:44:45  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-03 00:44:49  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-03 00:44:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-03 00:44:58  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-03 00:45:02  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-03 00:45:06  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-03 00:45:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-03 00:45:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-03 00:45:19  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-03 00:45:22  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-03 00:45:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-03 00:45:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-03 00:45:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-03 00:45:38  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-03 00:45:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-03 00:45:46  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-03 00:45:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-03 00:45:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-03 00:46:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-03 00:46:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-03 00:46:09  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-03 00:46:09  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-03 00:46:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-03 00:46:18  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-03 00:46:23  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-03 00:46:27  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-03 00:46:32  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-03 00:46:36  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 00:46:40  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 00:46:45  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-03 00:46:49  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 00:46:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-03 00:46:58  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-03 00:47:03  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-03 00:47:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-03 00:47:12  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-03 00:47:16  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-03 00:47:21  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-03 00:47:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-03 00:47:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-03 00:47:34  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-03 00:47:39  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 00:47:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-03 00:47:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-03 00:47:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-03 00:47:57  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-03 00:48:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-03 00:48:06  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-03 00:48:10  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-03 00:48:15  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-03 00:48:19  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-03 00:48:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-03 00:48:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-03 00:48:32  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-03 00:48:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-03 00:48:41  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-03 00:48:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-03 00:48:50  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-03 00:48:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-03 00:48:59  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-03 00:49:04  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-03 00:49:08  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-03 00:49:09  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-03 00:49:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-03 00:49:17  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-03 00:49:22  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-03 00:49:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-03 00:49:31  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-03 00:49:36  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-03 00:49:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-03 00:49:45  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-03 00:49:49  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-03 00:49:54  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-03 00:49:58  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-03 00:50:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-03 00:50:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-03 00:50:12  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-03 00:50:16  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-03 00:50:21  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-03 00:50:25  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-03 00:50:30  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-03 00:50:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-03 00:50:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-03 00:50:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-03 00:50:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-03 00:50:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-03 00:50:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-03 00:51:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-03 00:51:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-03 00:51:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-03 00:51:12  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-03 00:51:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-03 00:51:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-03 00:51:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-03 00:51:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-03 00:51:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-03 00:51:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-03 00:51:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-03 00:51:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-03 00:51:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-03 00:51:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-03 00:51:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-03 00:51:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-03 00:51:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-03 00:52:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-03 00:52:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-03 00:52:09  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-03 00:52:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-03 00:52:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-03 00:52:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-03 00:52:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-03 00:52:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-03 00:52:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-03 00:52:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-03 00:52:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-03 00:52:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-03 00:52:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-03 00:52:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-03 00:52:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-03 00:52:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-03 00:53:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-03 00:53:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-03 00:53:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-03 00:53:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-03 00:53:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-03 00:53:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-03 00:53:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-03 00:53:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-03 00:53:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-03 00:53:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-03 00:53:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-03 00:53:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-03 00:53:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-03 00:53:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-03 00:53:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-03 00:53:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-03 00:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-03 00:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-03 00:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-03 00:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-03 00:54:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-03 00:54:23  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-03 00:54:28  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-03 00:54:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-03 00:54:37  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-03 00:54:38  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-03 00:54:42  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-03 00:54:47  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-03 00:54:51  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-03 00:54:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-03 00:55:00  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-03 00:55:05  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-03 00:55:09  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-03 00:55:13  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-03 00:55:18  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-03 00:55:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-03 00:55:27  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-03 00:55:32  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-03 00:55:37  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-03 00:55:41  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-03 00:55:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-03 00:55:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-03 00:55:54  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-03 00:55:59  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-03 00:56:03  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-03 00:56:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-03 00:56:12  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-03 00:56:16  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-03 00:56:21  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-03 00:56:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-03 00:56:30  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-03 00:56:34  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-03 00:56:39  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-03 00:56:43  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-03 00:56:48  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-03 00:56:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-03 00:56:57  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-03 00:57:01  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-03 00:57:05  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-03 00:57:10  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-03 00:57:14  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-03 00:57:19  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-03 00:57:23  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-03 00:57:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-03 00:57:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-03 00:57:37  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-03 00:57:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-03 00:57:46  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-03 00:57:50  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-03 00:57:55  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-03 00:57:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-03 00:58:04  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-03 00:58:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-03 00:58:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-03 00:58:17  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-03 00:58:21  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-03 00:58:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-03 00:58:30  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-03 00:58:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-03 00:58:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-03 00:58:43  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-03 00:58:47  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-03 00:58:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-03 00:58:56  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-03 00:59:01  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-03 00:59:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-03 00:59:10  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-03 00:59:15  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-03 00:59:19  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-03 00:59:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-03 00:59:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-03 00:59:33  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-03 00:59:37  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-03 00:59:41  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-03 00:59:46  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-03 00:59:50  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-03 00:59:55  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-03 01:00:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-03 01:00:04  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-03 01:00:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-03 01:00:14  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-03 01:00:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-03 01:00:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-03 01:00:28  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-03 01:00:33  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-03 01:00:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-03 01:00:41  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-03 01:00:46  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-03 01:00:50  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-03 01:00:55  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-03 01:00:59  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-03 01:01:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-03 01:01:08  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-03 01:01:12  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-03 01:01:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-03 01:01:21  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-03 01:01:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-03 01:01:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-03 01:01:34  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-03 01:01:39  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-03 01:01:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-03 01:01:48  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-03_01-01-49 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients?_prerender {"code":"ECONNRESET"}
2017-04-03 01:03:53  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-03 01:03:57  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-03 01:04:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-03 01:04:07  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-03 01:04:11  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-03 01:04:16  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-03 01:04:20  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-03 01:04:25  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-03 01:04:29  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-03 01:04:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-03 01:04:38  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-03 01:04:43  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-03 01:04:47  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-03 01:04:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-03 01:04:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-03 01:05:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-03 01:05:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-03 01:05:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-03 01:05:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-03 01:05:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-03 01:05:23  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-03 01:05:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-03 01:05:32  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-03 01:05:37  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-03 01:05:41  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-03 01:05:45  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-03 01:05:49  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-03 01:05:54  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-03 01:05:58  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-03 01:06:03  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-03 01:06:07  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-03 01:06:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-03 01:06:16  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-03 01:06:21  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-03 01:06:25  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-03 01:06:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-03 01:06:34  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-03 01:06:39  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-03 01:06:43  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-03 01:06:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-03 01:06:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-03 01:06:57  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-03 01:07:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-03 01:07:06  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-03 01:07:11  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-03 01:07:15  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-03 01:07:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-03 01:07:24  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-03 01:07:29  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-03 01:07:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-03 01:07:37  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-03 01:07:42  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-03 01:07:46  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-03 01:07:50  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-03 01:07:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-03 01:07:59  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-03 01:08:03  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-03 01:08:08  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-03 01:08:12  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-03 01:08:17  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-03 01:08:21  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-03 01:08:25  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-03 01:08:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-03 01:08:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-03 01:08:38  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-03 01:08:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-03 01:08:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-03 01:08:51  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-03 01:08:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-03 01:08:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-03 01:09:04  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-03 01:09:08  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-03 01:09:12  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-03 01:09:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-03 01:09:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-03 01:09:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-03 01:09:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-03 01:09:34  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-03 01:09:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-03 01:09:42  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-03 01:09:47  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-03 01:09:51  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-03 01:09:55  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-03 01:10:00  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-03 01:10:04  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-03 01:10:08  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-03 01:10:12  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-03 01:10:17  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-03 01:10:21  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-03 01:10:26  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-03 01:10:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-03 01:10:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-03 01:10:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-03 01:10:44  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-03 01:10:44  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-03 01:10:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-03 01:10:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-03 01:10:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-03 01:11:02  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-03 01:11:06  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-03 01:11:11  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-03 01:11:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-03 01:11:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-03 01:11:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-03 01:11:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-03 01:11:32  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-03 01:11:36  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-03 01:11:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-03 01:11:45  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-03 01:11:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-03 01:11:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-03 01:11:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-03 01:12:03  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-03 01:12:08  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-03 01:12:12  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-03 01:12:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-03 01:12:26  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-03 01:12:30  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-03 01:12:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-03 01:12:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-03 01:12:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-03 01:12:48  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-03 01:12:52  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-03 01:12:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-03 01:13:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-03 01:13:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-03 01:13:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-03 01:13:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-03 01:13:18  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-03 01:13:22  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-03 01:13:26  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-03 01:13:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-03 01:13:34  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-03 01:13:38  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-03 01:13:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-03 01:13:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-03 01:13:51  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-03 01:13:55  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-03 01:13:59  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-03 01:14:03  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-03 01:14:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-03 01:14:11  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-03 01:14:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-03 01:14:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-03 01:14:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-03 01:14:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-03 01:14:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-03 01:14:38  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-03 01:14:42  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-03 01:14:46  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-03 01:14:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-03 01:14:54  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-03 01:14:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-03 01:15:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-03 01:15:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-03 01:15:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 01:15:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 01:15:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 01:15:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 01:15:26  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-03 01:15:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 01:15:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 01:15:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-03 01:15:42  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-03 01:15:46  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-03 01:15:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-03 01:15:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-03 01:15:59  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-03 01:16:03  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-03 01:16:07  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-03 01:16:11  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-03 01:16:15  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-03 01:16:19  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-03 01:16:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-03 01:16:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-03 01:16:31  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-03 01:16:35  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-03 01:16:39  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-03 01:16:43  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-03 01:16:47  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-03 01:16:51  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-03 01:16:55  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-03 01:16:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 01:17:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 01:17:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 01:17:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 01:17:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 01:17:19  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-03 01:17:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 01:17:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 01:17:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 01:17:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 01:17:39  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-03 01:17:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 01:17:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 01:17:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 01:17:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-03 01:17:59  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-03_01-31-49 Restart Xvfb...
2017-04-03_02-01-49 Restart Xvfb...
2017-04-03_02-31-49 Restart Xvfb...
2017-04-03_03-01-49 Restart Xvfb...
2017-04-03 03:31:46 reset updateRequest
2017-04-03_03-31-49 Restart Xvfb...
2017-04-03 03:31:49  - 14968  http://www.lymphomahub.com/
2017-04-03 03:31:51  - 14968  http://www.lymphomahub.com/
2017-04-03 03:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-03 03:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-03 03:32:02  - 14968  http://www.lymphomahub.com/terms
2017-04-03 03:32:05  - 14968  http://www.lymphomahub.com/undefined
2017-04-03 03:32:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-03 03:32:12  - 14968  http://www.lymphomahub.com/newsletter
2017-04-03 03:32:15  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-03 03:32:18  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-03 03:32:23  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-03 03:32:28  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-03 03:32:32  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-03 03:32:36  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-03 03:32:40  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-03 03:32:44  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-03 03:32:49  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-03 03:32:53  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-03 03:32:58  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-03 03:33:02  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-03 03:33:07  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-03 03:33:11  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-03 03:33:15  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-03 03:33:19  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-03 03:33:24  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-03 03:33:28  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-03 03:33:33  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-03 03:33:37  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-03 03:33:41  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-03 03:33:46  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-03 03:33:49  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-03 03:33:54  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-03 03:33:58  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-03 03:34:03  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-03 03:34:07  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-03 03:34:11  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-03 03:34:16  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-03 03:34:20  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-03 03:34:24  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-03 03:34:29  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-03 03:34:33  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-03 03:34:37  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-03 03:34:42  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-03 03:34:46  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-03 03:34:55  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-03 03:35:00  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-03 03:35:04  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-03 03:35:08  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-03 03:35:13  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-03 03:35:17  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-03 03:35:22  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-03 03:35:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-03 03:35:31  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-03 03:35:35  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-03 03:35:39  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-03 03:35:43  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-03 03:35:48  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-03 03:35:52  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-03 03:35:56  - 14968  http://www.lymphomahub.com/medical-information
2017-04-03 03:36:00  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-03 03:36:05  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-03 03:36:09  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-03 03:36:14  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-03 03:36:18  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-03 03:36:22  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-03 03:36:27  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-03 03:36:31  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-03 03:36:35  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-03 03:36:40  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-03 03:36:48  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-03 03:36:53  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-03 03:36:53  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-03 03:36:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-03 03:37:02  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-03 03:37:06  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-03 03:37:11  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-03 03:37:15  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-03 03:37:19  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-03 03:37:23  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-03 03:37:28  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-03 03:37:32  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-03 03:37:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-03 03:37:41  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-03 03:37:45  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-03 03:37:50  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-03 03:37:54  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-03 03:38:04  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-03 03:38:08  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-03 03:38:12  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-03 03:38:16  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-03 03:38:21  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-03 03:38:25  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-03 03:38:29  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-03 03:38:34  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-03 03:38:38  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-03 03:38:42  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-03 03:38:46  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-03 03:38:51  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-03 03:38:55  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-03 03:38:59  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-03 03:39:04  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-03 03:39:08  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-03 03:39:09  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-03 03:39:13  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-03 03:39:18  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-03 03:39:22  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-03 03:39:27  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-03 03:39:31  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-03 03:39:35  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-03 03:39:39  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-03 03:39:44  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-03 03:39:47  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-03 03:39:48  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-03 03:39:52  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-03 03:39:56  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-03 03:40:01  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-03 03:40:05  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-03 03:40:10  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-03 03:40:10  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-03 03:40:15  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-03 03:40:19  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-03 03:40:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-03 03:40:27  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-03 03:40:31  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-03 03:40:35  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-03 03:40:39  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-03 03:40:42  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-03 03:40:46  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-03 03:40:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-03 03:40:54  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-03 03:40:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-03 03:41:03  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-03 03:41:07  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-03 03:41:07  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-03 03:41:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-03 03:41:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-03 03:41:20  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-03 03:41:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-03 03:41:33  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-03 03:41:38  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-03 03:41:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-03 03:41:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-03 03:41:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-03 03:41:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-03 03:41:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-03 03:42:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-03 03:42:05  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-03 03:42:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-03 03:42:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-03 03:42:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-03 03:42:21  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-03 03:42:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-03 03:42:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-03 03:42:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-03 03:42:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-03 03:42:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-03 03:42:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-03 03:42:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-03 03:42:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-03 03:42:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-03 03:43:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-03 03:43:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-03 03:43:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-03 03:43:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-03 03:43:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-03 03:43:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-03 03:43:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-03 03:43:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-03 03:43:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-03 03:43:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-03 03:43:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-03 03:43:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-03 03:43:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-03 03:44:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-03 03:44:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-03 03:44:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-03 03:44:16  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-03 03:44:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-03 03:44:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-03 03:44:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-03 03:44:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-03 03:44:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-03 03:44:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-03 03:44:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-03 03:44:53  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-03 03:44:57  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-03 03:45:02  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-03 03:45:05  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-03 03:45:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-03 03:45:14  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-03 03:45:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-03 03:45:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-03 03:45:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-03 03:45:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-03 03:45:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-03 03:45:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-03 03:45:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-03 03:45:45  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-03 03:45:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-03 03:45:53  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-03 03:45:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-03 03:46:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-03 03:46:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-03 03:46:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-03 03:46:24  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-03 03:46:25  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-03 03:46:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-03 03:46:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-03 03:46:38  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-03 03:46:43  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-03 03:46:47  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-03 03:46:52  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 03:46:56  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 03:47:01  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-03 03:47:05  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 03:47:09  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-03 03:47:14  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-03 03:47:18  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-03 03:47:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-03 03:47:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-03 03:47:32  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-03 03:47:36  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-03 03:47:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-03 03:47:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-03 03:47:50  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-03 03:47:54  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 03:47:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-03 03:48:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-03 03:48:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-03 03:48:12  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-03 03:48:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-03 03:48:22  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-03 03:48:27  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-03 03:48:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-03 03:48:36  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-03 03:48:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-03 03:48:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-03 03:48:50  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-03 03:48:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-03 03:48:59  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-03 03:49:03  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-03 03:49:08  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-03 03:49:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-03 03:49:17  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-03 03:49:21  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-03 03:49:27  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-03 03:49:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-03 03:49:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-03 03:49:37  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-03 03:49:42  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-03 03:49:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-03 03:49:51  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-03 03:49:56  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-03 03:50:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-03 03:50:04  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-03 03:50:09  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-03 03:50:13  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-03 03:50:18  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-03 03:50:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-03 03:50:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-03 03:50:31  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-03 03:50:35  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-03 03:50:40  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-03 03:50:44  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-03 03:50:49  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-03 03:50:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-03 03:50:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-03 03:51:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-03 03:51:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-03 03:51:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-03 03:51:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-03 03:51:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-03 03:51:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-03 03:51:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-03 03:51:35  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-03 03:51:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-03 03:51:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-03 03:51:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-03 03:51:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-03 03:51:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-03 03:51:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-03 03:52:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-03 03:52:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-03 03:52:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-03 03:52:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-03 03:52:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-03 03:52:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-03 03:52:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-03 03:52:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-03 03:52:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-03 03:52:32  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-03 03:52:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-03 03:52:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-03 03:52:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-03 03:52:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-03 03:52:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-03 03:52:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-03 03:52:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-03 03:53:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-03 03:53:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-03 03:53:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-03 03:53:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-03 03:53:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-03 03:53:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-03 03:53:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-03 03:53:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-03 03:53:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-03 03:53:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-03 03:53:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-03 03:53:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-03 03:53:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-03 03:53:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-03 03:53:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-03 03:53:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-03 03:54:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-03 03:54:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-03 03:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-03 03:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-03 03:54:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-03 03:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-03 03:54:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-03 03:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-03 03:54:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-03 03:54:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-03 03:54:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-03 03:54:42  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-03 03:54:46  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-03 03:54:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-03 03:54:55  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-03 03:54:56  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-03 03:55:00  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-03 03:55:05  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-03 03:55:10  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-03 03:55:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-03 03:55:18  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-03 03:55:23  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-03 03:55:27  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-03 03:55:32  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-03 03:55:36  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-03 03:55:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-03 03:55:45  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-03 03:55:50  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-03 03:55:54  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-03 03:55:59  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-03 03:56:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-03 03:56:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-03 03:56:12  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-03 03:56:17  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-03 03:56:21  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-03 03:56:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-03 03:56:30  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-03 03:56:34  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-03 03:56:39  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-03 03:56:43  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-03 03:56:48  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-03 03:56:53  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-03 03:56:57  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-03 03:57:01  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-03 03:57:06  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-03 03:57:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-03 03:57:20  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-03 03:57:24  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-03 03:57:29  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-03 03:57:33  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-03 03:57:38  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-03 03:57:42  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-03 03:57:47  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-03 03:57:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-03 03:57:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-03 03:58:05  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-03 03:58:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-03 03:58:15  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-03 03:58:19  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-03 03:58:23  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-03 03:58:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-03 03:58:32  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-03 03:58:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-03 03:58:41  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-03 03:58:46  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-03 03:58:50  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-03 03:58:54  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-03 03:58:59  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-03 03:59:03  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-03 03:59:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-03 03:59:13  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-03 03:59:17  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-03 03:59:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-03 03:59:26  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-03 03:59:31  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-03 03:59:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-03 03:59:40  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-03 03:59:44  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-03 03:59:49  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-03 03:59:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-03 03:59:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-03 04:00:02  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-03 04:00:07  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-03 04:00:11  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-03 04:00:16  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-03 04:00:20  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-03 04:00:25  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-03 04:00:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-03 04:00:34  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-03 04:00:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-03 04:00:43  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-03 04:00:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-03 04:00:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-03 04:00:56  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-03 04:01:01  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-03 04:01:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-03 04:01:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-03 04:01:15  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-03 04:01:19  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-03 04:01:23  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-03 04:01:27  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-03 04:01:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-03 04:01:36  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-03 04:01:41  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-03 04:01:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-03_04-01-49 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet?_prerender {"code":"ECONNRESET"}
2017-04-03 04:03:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-03 04:03:55  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-03 04:03:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-03 04:04:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-03 04:04:09  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-03 04:04:13  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-03 04:04:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-03 04:04:23  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-03 04:04:27  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-03 04:04:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-03 04:04:36  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-03 04:04:41  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-03 04:04:45  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-03 04:04:50  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-03 04:04:54  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-03 04:04:59  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-03 04:05:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-03 04:05:08  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-03 04:05:12  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-03 04:05:17  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-03 04:05:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-03 04:05:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-03 04:05:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-03 04:05:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-03 04:05:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-03 04:05:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-03 04:05:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-03 04:05:53  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-03 04:05:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-03 04:06:02  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-03 04:06:06  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-03 04:06:10  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-03 04:06:14  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-03 04:06:19  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-03 04:06:23  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-03 04:06:28  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-03 04:06:32  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-03 04:06:37  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-03 04:06:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-03 04:06:46  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-03 04:06:50  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-03 04:06:55  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-03 04:06:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-03 04:07:04  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-03 04:07:08  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-03 04:07:13  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-03 04:07:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-03 04:07:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-03 04:07:26  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-03 04:07:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-03 04:07:35  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-03 04:07:39  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-03 04:07:44  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-03 04:07:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-03 04:07:53  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-03 04:07:57  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-03 04:08:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-03 04:08:06  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-03 04:08:10  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-03 04:08:14  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-03 04:08:18  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-03 04:08:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-03 04:08:27  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-03 04:08:31  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-03 04:08:36  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-03 04:08:40  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-03 04:08:45  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-03 04:08:49  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-03 04:08:53  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-03 04:08:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-03 04:09:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-03 04:09:06  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-03 04:09:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-03 04:09:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-03 04:09:19  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-03 04:09:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-03 04:09:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-03 04:09:32  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-03 04:09:36  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-03 04:09:40  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-03 04:09:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-03 04:09:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-03 04:09:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-03 04:09:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-03 04:10:02  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-03 04:10:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-03 04:10:11  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-03 04:10:15  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-03 04:10:19  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-03 04:10:24  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-03 04:10:28  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-03 04:10:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-03 04:10:37  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-03 04:10:41  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-03 04:10:45  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-03 04:10:49  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-03 04:10:54  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-03 04:10:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-03 04:11:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-03 04:11:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-03 04:11:12  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-03 04:11:12  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-03 04:11:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-03 04:11:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-03 04:11:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-03 04:11:30  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-03 04:11:34  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-03 04:11:39  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-03 04:11:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-03 04:11:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-03 04:11:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-03 04:11:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-03 04:12:04  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-03 04:12:08  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-03 04:12:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-03 04:12:17  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-03 04:12:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-03 04:12:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-03 04:12:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-03 04:12:34  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-03 04:12:39  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-03 04:12:43  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-03 04:12:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-03 04:12:51  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-03 04:12:55  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-03 04:13:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-03 04:13:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-03 04:13:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-03 04:13:13  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-03 04:13:17  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-03 04:13:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-03 04:13:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-03 04:13:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-03 04:13:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-03 04:13:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-03 04:13:42  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-03 04:13:46  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-03 04:13:50  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-03 04:13:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-03 04:13:58  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-03 04:14:02  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-03 04:14:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-03 04:14:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-03 04:14:15  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-03 04:14:18  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-03 04:14:22  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-03 04:14:26  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-03 04:14:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-03 04:14:35  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-03 04:14:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-03 04:14:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-03 04:14:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-03 04:14:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-03 04:14:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-03 04:15:02  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-03 04:15:06  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-03 04:15:10  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-03 04:15:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-03 04:15:18  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-03 04:15:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-03 04:15:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-03 04:15:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-03 04:15:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 04:15:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 04:15:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 04:15:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 04:15:50  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-03 04:15:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 04:15:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 04:16:07  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-03 04:16:11  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-03 04:16:15  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-03 04:16:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-03 04:16:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-03 04:16:28  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-03 04:16:32  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-03 04:16:35  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-03 04:16:39  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-03 04:16:43  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-03 04:16:48  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-03 04:16:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-03 04:16:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-03 04:17:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-03 04:17:04  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-03 04:17:08  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-03 04:17:12  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-03 04:17:16  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-03 04:17:20  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-03 04:17:24  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-03 04:17:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 04:17:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 04:17:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 04:17:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 04:17:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 04:17:47  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-03 04:17:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 04:17:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 04:17:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 04:18:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 04:18:07  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-03 04:18:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 04:18:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 04:18:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 04:18:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-03 04:18:27  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-03_04-31-49 Restart Xvfb...
2017-04-03_05-01-49 Restart Xvfb...
2017-04-03_05-31-49 Restart Xvfb...
2017-04-03_06-01-49 Restart Xvfb...
2017-04-03 06:31:46 reset updateRequest
2017-04-03 06:31:49  - 14968  http://www.lymphomahub.com/
2017-04-03_06-31-49 Restart Xvfb...
2017-04-03 06:31:51  - 14968  http://www.lymphomahub.com/
2017-04-03 06:31:53  - 14968  http://www.lymphomahub.com/about
2017-04-03 06:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-03 06:32:00  - 14968  http://www.lymphomahub.com/terms
2017-04-03 06:32:03  - 14968  http://www.lymphomahub.com/undefined
2017-04-03 06:32:04  - 14968  http://www.lymphomahub.com/therapies
2017-04-03 06:32:10  - 14968  http://www.lymphomahub.com/newsletter
2017-04-03 06:32:13  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-03 06:32:16  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-03 06:32:21  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-03 06:32:25  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-03 06:32:29  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-03 06:32:34  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-03 06:32:38  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-03 06:32:43  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-03 06:32:47  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-03 06:32:52  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-03 06:33:00  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-03 06:33:04  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-03 06:33:08  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-03 06:33:13  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-03 06:33:17  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-03 06:33:21  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-03 06:33:26  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-03 06:33:30  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-03 06:33:34  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-03 06:33:39  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-03 06:33:43  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-03 06:33:48  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-03 06:33:52  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-03 06:33:56  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-03 06:34:00  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-03 06:34:05  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-03 06:34:09  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-03 06:34:14  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-03 06:34:18  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-03 06:34:23  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-03 06:34:27  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-03 06:34:32  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-03 06:34:36  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-03 06:34:40  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-03 06:34:45  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-03 06:34:49  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-03 06:34:53  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-03 06:34:58  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-03 06:35:02  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-03 06:35:06  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-03 06:35:11  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-03 06:35:15  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-03 06:35:20  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-03 06:35:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-03 06:35:28  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-03 06:35:33  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-03 06:35:37  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-03 06:35:41  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-03 06:35:45  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-03 06:35:53  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-03 06:35:57  - 14968  http://www.lymphomahub.com/medical-information
2017-04-03 06:36:01  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-03 06:36:06  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-03 06:36:11  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-03 06:36:15  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-03 06:36:19  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-03 06:36:24  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-03 06:36:28  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-03 06:36:33  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-03 06:36:37  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-03 06:36:41  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-03 06:36:45  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-03 06:36:50  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-03 06:36:50  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-03 06:36:55  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-03 06:36:59  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-03 06:37:03  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-03 06:37:08  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-03 06:37:12  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-03 06:37:16  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-03 06:37:21  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-03 06:37:25  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-03 06:37:29  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-03 06:37:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-03 06:37:38  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-03 06:37:43  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-03 06:37:52  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-03 06:37:56  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-03 06:38:00  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-03 06:38:05  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-03 06:38:09  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-03 06:38:13  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-03 06:38:17  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-03 06:38:22  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-03 06:38:26  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-03 06:38:30  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-03 06:38:34  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-03 06:38:39  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-03 06:38:44  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-03 06:38:49  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-03 06:38:53  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-03 06:38:57  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-03 06:39:01  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-03 06:39:06  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-03 06:39:06  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-03 06:39:11  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-03 06:39:15  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-03 06:39:19  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-03 06:39:23  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-03 06:39:28  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-03 06:39:32  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-03 06:39:36  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-03 06:39:41  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-03 06:39:44  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-03 06:39:45  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-03 06:39:49  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-03 06:39:53  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-03 06:39:57  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-03 06:40:02  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-03 06:40:06  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-03 06:40:07  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-03 06:40:11  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-03 06:40:16  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-03 06:40:19  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-03 06:40:24  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-03 06:40:28  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-03 06:40:31  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-03 06:40:35  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-03 06:40:39  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-03 06:40:43  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-03 06:40:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-03 06:40:51  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-03 06:40:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-03 06:40:59  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-03 06:41:03  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-03 06:41:04  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-03 06:41:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-03 06:41:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-03 06:41:17  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-03 06:41:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-03 06:41:25  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-03 06:41:30  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-03 06:41:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-03 06:41:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-03 06:41:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-03 06:41:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-03 06:41:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-03 06:41:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-03 06:41:56  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-03 06:42:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-03 06:42:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-03 06:42:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-03 06:42:13  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-03 06:42:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-03 06:42:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-03 06:42:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-03 06:42:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-03 06:42:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-03 06:42:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-03 06:42:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-03 06:42:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-03 06:42:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-03 06:43:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-03 06:43:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-03 06:43:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-03 06:43:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-03 06:43:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-03 06:43:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-03 06:43:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-03 06:43:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-03 06:43:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-03 06:43:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-03 06:43:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-03 06:43:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-03 06:43:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-03 06:43:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-03 06:44:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-03 06:44:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-03 06:44:11  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-03 06:44:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-03 06:44:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-03 06:44:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-03 06:44:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-03 06:44:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-03 06:44:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-03 06:44:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-03 06:44:47  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-03 06:44:52  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-03 06:44:57  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-03 06:45:01  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-03 06:45:05  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-03 06:45:09  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-03 06:45:13  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-03 06:45:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-03 06:45:27  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-03 06:45:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-03 06:45:34  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-03 06:45:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-03 06:45:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-03 06:45:46  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-03 06:45:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-03 06:45:55  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-03 06:45:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-03 06:46:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-03 06:46:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-03 06:46:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-03 06:46:17  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-03 06:46:18  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-03 06:46:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-03 06:46:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-03 06:46:31  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-03 06:46:35  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-03 06:46:40  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-03 06:46:44  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 06:46:49  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 06:46:53  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-03 06:46:58  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 06:47:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-03 06:47:07  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-03 06:47:11  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-03 06:47:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-03 06:47:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-03 06:47:25  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-03 06:47:29  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-03 06:47:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-03 06:47:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-03 06:47:43  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-03 06:47:48  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 06:47:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-03 06:47:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-03 06:48:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-03 06:48:07  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-03 06:48:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-03 06:48:15  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-03 06:48:20  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-03 06:48:24  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-03 06:48:29  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-03 06:48:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-03 06:48:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-03 06:48:42  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-03 06:48:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-03 06:48:52  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-03 06:48:56  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-03 06:49:01  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-03 06:49:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-03 06:49:10  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-03 06:49:14  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-03 06:49:19  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-03 06:49:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-03 06:49:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-03 06:49:28  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-03 06:49:33  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-03 06:49:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-03 06:49:42  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-03 06:49:46  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-03 06:49:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-03 06:49:55  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-03 06:50:05  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-03 06:50:10  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-03 06:50:14  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-03 06:50:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-03 06:50:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-03 06:50:28  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-03 06:50:33  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-03 06:50:37  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-03 06:50:42  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-03 06:50:46  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-03 06:50:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-03 06:50:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-03 06:50:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-03 06:51:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-03 06:51:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-03 06:51:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-03 06:51:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-03 06:51:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-03 06:51:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-03 06:51:30  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-03 06:51:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-03 06:51:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-03 06:51:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-03 06:51:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-03 06:51:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-03 06:51:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-03 06:51:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-03 06:51:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-03 06:52:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-03 06:52:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-03 06:52:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-03 06:52:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-03 06:52:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-03 06:52:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-03 06:52:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-03 06:52:27  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-03 06:52:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-03 06:52:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-03 06:52:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-03 06:52:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-03 06:52:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-03 06:52:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-03 06:52:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-03 06:52:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-03 06:53:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-03 06:53:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-03 06:53:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-03 06:53:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-03 06:53:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-03 06:53:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-03 06:53:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-03 06:53:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-03 06:53:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-03 06:53:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-03 06:53:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-03 06:53:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-03 06:53:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-03 06:53:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-03 06:53:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-03 06:53:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-03 06:54:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-03 06:54:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-03 06:54:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-03 06:54:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-03 06:54:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-03 06:54:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-03 06:54:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-03 06:54:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-03 06:54:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-03 06:54:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-03 06:54:40  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-03 06:54:45  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-03 06:54:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-03 06:54:54  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-03 06:54:55  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-03 06:54:59  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-03 06:55:04  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-03 06:55:09  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-03 06:55:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-03 06:55:18  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-03 06:55:22  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-03 06:55:27  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-03 06:55:31  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-03 06:55:36  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-03 06:55:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-03 06:55:45  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-03 06:55:49  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-03 06:55:54  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-03 06:55:59  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-03 06:56:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-03 06:56:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-03 06:56:12  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-03 06:56:17  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-03 06:56:21  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-03 06:56:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-03 06:56:30  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-03 06:56:35  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-03 06:56:39  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-03 06:56:43  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-03 06:56:48  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-03 06:56:52  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-03 06:56:57  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-03 06:57:01  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-03 06:57:06  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-03 06:57:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-03 06:57:15  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-03 06:57:19  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-03 06:57:24  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-03 06:57:29  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-03 06:57:33  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-03 06:57:37  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-03 06:57:42  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-03 06:57:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-03 06:57:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-03 06:57:55  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-03 06:58:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-03 06:58:04  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-03 06:58:09  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-03 06:58:14  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-03 06:58:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-03 06:58:23  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-03 06:58:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-03 06:58:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-03 06:58:36  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-03 06:58:40  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-03 06:58:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-03 06:58:50  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-03 06:58:55  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-03 06:58:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-03 06:59:04  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-03 06:59:08  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-03 06:59:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-03 06:59:17  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-03 06:59:22  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-03 06:59:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-03 06:59:31  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-03 06:59:35  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-03 06:59:40  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-03 06:59:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-03 06:59:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-03 06:59:53  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-03 06:59:58  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-03 07:00:02  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-03 07:00:07  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-03 07:00:15  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-03 07:00:19  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-03 07:00:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-03 07:00:29  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-03 07:00:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-03 07:00:38  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-03 07:00:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-03 07:00:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-03 07:00:52  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-03 07:00:56  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-03 07:01:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-03 07:01:06  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-03 07:01:10  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-03 07:01:15  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-03 07:01:19  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-03 07:01:23  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-03 07:01:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-03 07:01:32  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-03 07:01:36  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-03 07:01:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-03 07:01:45  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-03_07-01-49 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet?_prerender {"code":"ECONNRESET"}
2017-04-03 07:03:50  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-03 07:03:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-03 07:03:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-03 07:04:04  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-03 07:04:08  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-03 07:04:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-03 07:04:17  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-03 07:04:22  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-03 07:04:26  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-03 07:04:32  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-03 07:04:37  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-03 07:04:41  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-03 07:04:46  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-03 07:04:50  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-03 07:04:55  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-03 07:04:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-03 07:05:09  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-03 07:05:13  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-03 07:05:18  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-03 07:05:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-03 07:05:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-03 07:05:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-03 07:05:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-03 07:05:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-03 07:05:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-03 07:05:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-03 07:05:54  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-03 07:05:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-03 07:06:03  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-03 07:06:08  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-03 07:06:13  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-03 07:06:17  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-03 07:06:22  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-03 07:06:26  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-03 07:06:31  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-03 07:06:35  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-03 07:06:39  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-03 07:06:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-03 07:06:48  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-03 07:06:53  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-03 07:06:57  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-03 07:07:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-03 07:07:06  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-03 07:07:11  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-03 07:07:16  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-03 07:07:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-03 07:07:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-03 07:07:29  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-03 07:07:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-03 07:07:38  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-03 07:07:43  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-03 07:07:47  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-03 07:07:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-03 07:07:56  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-03 07:08:01  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-03 07:08:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-03 07:08:09  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-03 07:08:13  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-03 07:08:17  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-03 07:08:22  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-03 07:08:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-03 07:08:35  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-03 07:08:39  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-03 07:08:43  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-03 07:08:48  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-03 07:08:52  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-03 07:08:57  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-03 07:09:01  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-03 07:09:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-03 07:09:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-03 07:09:14  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-03 07:09:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-03 07:09:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-03 07:09:27  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-03 07:09:31  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-03 07:09:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-03 07:09:40  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-03 07:09:45  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-03 07:09:49  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-03 07:09:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-03 07:09:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-03 07:10:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-03 07:10:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-03 07:10:11  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-03 07:10:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-03 07:10:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-03 07:10:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-03 07:10:33  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-03 07:10:38  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-03 07:10:42  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-03 07:10:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-03 07:10:51  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-03 07:10:55  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-03 07:10:59  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-03 07:11:04  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-03 07:11:08  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-03 07:11:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-03 07:11:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-03 07:11:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-03 07:11:26  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-03 07:11:27  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-03 07:11:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-03 07:11:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-03 07:11:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-03 07:11:44  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-03 07:11:49  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-03 07:11:53  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-03 07:11:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-03 07:12:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-03 07:12:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-03 07:12:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-03 07:12:14  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-03 07:12:18  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-03 07:12:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-03 07:12:27  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-03 07:12:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-03 07:12:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-03 07:12:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-03 07:12:44  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-03 07:12:48  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-03 07:12:53  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-03 07:12:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-03 07:13:01  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-03 07:13:05  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-03 07:13:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-03 07:13:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-03 07:13:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-03 07:13:23  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-03 07:13:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-03 07:13:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-03 07:13:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-03 07:13:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-03 07:13:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-03 07:13:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-03 07:13:57  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-03 07:14:01  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-03 07:14:05  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-03 07:14:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-03 07:14:13  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-03 07:14:17  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-03 07:14:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-03 07:14:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-03 07:14:30  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-03 07:14:34  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-03 07:14:38  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-03 07:14:42  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-03 07:14:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-03 07:14:50  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-03 07:14:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-03 07:14:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-03 07:15:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-03 07:15:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-03 07:15:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-03 07:15:17  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-03 07:15:21  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-03 07:15:25  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-03 07:15:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-03 07:15:34  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-03 07:15:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-03 07:15:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-03 07:15:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-03 07:15:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 07:15:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 07:15:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 07:16:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 07:16:06  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-03 07:16:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 07:16:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 07:16:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-03 07:16:27  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-03 07:16:31  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-03 07:16:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-03 07:16:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-03 07:16:43  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-03 07:16:47  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-03 07:16:51  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-03 07:16:56  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-03 07:17:00  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-03 07:17:04  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-03 07:17:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-03 07:17:12  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-03 07:17:16  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-03 07:17:20  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-03 07:17:24  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-03 07:17:28  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-03 07:17:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-03 07:17:36  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-03 07:17:40  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-03 07:17:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 07:17:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 07:17:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 07:17:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 07:18:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 07:18:04  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-03 07:18:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 07:18:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 07:18:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 07:18:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 07:18:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-03 07:18:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 07:18:32  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 07:18:37  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 07:18:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-03 07:18:45  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-03_07-31-49 Restart Xvfb...
2017-04-03_08-01-49 Restart Xvfb...
2017-04-03_08-31-49 Restart Xvfb...
2017-04-03_09-01-49 Restart Xvfb...
2017-04-03 09:31:46 reset updateRequest
2017-04-03_09-31-49 Restart Xvfb...
2017-04-03 09:31:50  - 14968  http://www.lymphomahub.com/
2017-04-03 09:31:51  - 14968  http://www.lymphomahub.com/
2017-04-03 09:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-03 09:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-03 09:32:01  - 14968  http://www.lymphomahub.com/terms
2017-04-03 09:32:04  - 14968  http://www.lymphomahub.com/undefined
2017-04-03 09:32:05  - 14968  http://www.lymphomahub.com/therapies
2017-04-03 09:32:10  - 14968  http://www.lymphomahub.com/newsletter
2017-04-03 09:32:14  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-03 09:32:17  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-03 09:32:21  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-03 09:32:26  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-03 09:32:30  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-03 09:32:34  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-03 09:32:39  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-03 09:32:43  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-03 09:32:48  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-03 09:32:53  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-03 09:32:57  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-03 09:33:01  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-03 09:33:06  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-03 09:33:10  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-03 09:33:18  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-03 09:33:23  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-03 09:33:27  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-03 09:33:32  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-03 09:33:37  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-03 09:33:41  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-03 09:33:46  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-03 09:33:50  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-03 09:33:54  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-03 09:33:58  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-03 09:34:02  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-03 09:34:07  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-03 09:34:11  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-03 09:34:15  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-03 09:34:20  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-03 09:34:25  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-03 09:34:29  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-03 09:34:33  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-03 09:34:38  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-03 09:34:42  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-03 09:34:46  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-03 09:34:51  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-03 09:34:55  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-03 09:35:00  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-03 09:35:04  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-03 09:35:09  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-03 09:35:13  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-03 09:35:17  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-03 09:35:22  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-03 09:35:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-03 09:35:30  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-03 09:35:35  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-03 09:35:39  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-03 09:35:43  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-03 09:35:48  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-03 09:35:52  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-03 09:35:56  - 14968  http://www.lymphomahub.com/medical-information
2017-04-03 09:36:00  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-03 09:36:05  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-03 09:36:09  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-03 09:36:13  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-03 09:36:18  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-03 09:36:22  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-03 09:36:26  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-03 09:36:31  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-03 09:36:35  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-03 09:36:39  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-03 09:36:44  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-03 09:36:48  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-03 09:36:48  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-03 09:36:53  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-03 09:36:57  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-03 09:37:01  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-03 09:37:06  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-03 09:37:10  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-03 09:37:14  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-03 09:37:18  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-03 09:37:23  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-03 09:37:27  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-03 09:37:32  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-03 09:37:36  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-03 09:37:40  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-03 09:37:45  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-03 09:37:49  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-03 09:37:53  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-03 09:37:58  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-03 09:38:02  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-03 09:38:06  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-03 09:38:11  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-03 09:38:15  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-03 09:38:19  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-03 09:38:24  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-03 09:38:28  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-03 09:38:32  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-03 09:38:37  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-03 09:38:41  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-03 09:38:45  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-03 09:38:49  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-03 09:38:54  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-03 09:38:59  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-03 09:38:59  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-03 09:39:04  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-03 09:39:08  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-03 09:39:13  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-03 09:39:17  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-03 09:39:21  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-03 09:39:26  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-03 09:39:30  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-03 09:39:34  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-03 09:39:38  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-03 09:39:38  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-03 09:39:43  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-03 09:39:47  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-03 09:39:51  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-03 09:39:56  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-03 09:40:00  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-03 09:40:01  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-03 09:40:06  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-03 09:40:10  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-03 09:40:14  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-03 09:40:18  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-03 09:40:23  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-03 09:40:26  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-03 09:40:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-03 09:40:34  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-03 09:40:38  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-03 09:40:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-03 09:40:46  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-03 09:40:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-03 09:40:55  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-03 09:40:59  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-03 09:40:59  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-03 09:41:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-03 09:41:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-03 09:41:12  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-03 09:41:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-03 09:41:21  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-03 09:41:26  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-03 09:41:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-03 09:41:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-03 09:41:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-03 09:41:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-03 09:41:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-03 09:41:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-03 09:41:52  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-03 09:41:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-03 09:42:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-03 09:42:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-03 09:42:09  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-03 09:42:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-03 09:42:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-03 09:42:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-03 09:42:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-03 09:42:30  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-03 09:42:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-03 09:42:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-03 09:42:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-03 09:42:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-03 09:42:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-03 09:42:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-03 09:43:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-03 09:43:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-03 09:43:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-03 09:43:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-03 09:43:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-03 09:43:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-03 09:43:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-03 09:43:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-03 09:43:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-03 09:43:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-03 09:43:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-03 09:43:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-03 09:43:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-03 09:43:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-03 09:44:02  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-03 09:44:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-03 09:44:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-03 09:44:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-03 09:44:19  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-03 09:44:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-03 09:44:27  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-03 09:44:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-03 09:44:34  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-03 09:44:39  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-03 09:44:43  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-03 09:44:47  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-03 09:44:52  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-03 09:44:56  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-03 09:45:00  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-03 09:45:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-03 09:45:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-03 09:45:13  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-03 09:45:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-03 09:45:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-03 09:45:26  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-03 09:45:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-03 09:45:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-03 09:45:38  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-03 09:45:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-03 09:45:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-03 09:45:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-03 09:45:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-03 09:46:00  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-03 09:46:01  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-03 09:46:06  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-03 09:46:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-03 09:46:15  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-03 09:46:19  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-03 09:46:24  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-03 09:46:28  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 09:46:32  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 09:46:37  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-03 09:46:41  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 09:46:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-03 09:46:50  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-03 09:46:54  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-03 09:46:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-03 09:47:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-03 09:47:08  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-03 09:47:13  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-03 09:47:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-03 09:47:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-03 09:47:31  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-03 09:47:36  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 09:47:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-03 09:47:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-03 09:47:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-03 09:47:54  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-03 09:48:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-03 09:48:08  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-03 09:48:13  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-03 09:48:17  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-03 09:48:22  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-03 09:48:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-03 09:48:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-03 09:48:35  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-03 09:48:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-03 09:48:44  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-03 09:48:48  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-03 09:48:53  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-03 09:48:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-03 09:49:02  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-03 09:49:07  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-03 09:49:12  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-03 09:49:12  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-03 09:49:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-03 09:49:21  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-03 09:49:26  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-03 09:49:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-03 09:49:35  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-03 09:49:39  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-03 09:49:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-03 09:49:48  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-03 09:49:53  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-03 09:49:57  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-03 09:50:02  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-03 09:50:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-03 09:50:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-03 09:50:16  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-03 09:50:20  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-03 09:50:30  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-03 09:50:34  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-03 09:50:39  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-03 09:50:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-03 09:50:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-03 09:50:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-03 09:50:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-03 09:51:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-03 09:51:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-03 09:51:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-03 09:51:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-03 09:51:18  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-03 09:51:23  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-03 09:51:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-03 09:51:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-03 09:51:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-03 09:51:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-03 09:51:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-03 09:51:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-03 09:51:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-03 09:51:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-03 09:51:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-03 09:51:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-03 09:52:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-03 09:52:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-03 09:52:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-03 09:52:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-03 09:52:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-03 09:52:19  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-03 09:52:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-03 09:52:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-03 09:52:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-03 09:52:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-03 09:52:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-03 09:52:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-03 09:52:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-03 09:52:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-03 09:52:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-03 09:52:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-03 09:53:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-03 09:53:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-03 09:53:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-03 09:53:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-03 09:53:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-03 09:53:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-03 09:53:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-03 09:53:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-03 09:53:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-03 09:53:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-03 09:53:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-03 09:53:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-03 09:53:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-03 09:53:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-03 09:53:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-03 09:53:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-03 09:53:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-03 09:54:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-03 09:54:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-03 09:54:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-03 09:54:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-03 09:54:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-03 09:54:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-03 09:54:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-03 09:54:29  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-03 09:54:39  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-03 09:54:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-03 09:54:48  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-03 09:54:49  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-03 09:54:53  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-03 09:54:58  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-03 09:55:02  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-03 09:55:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-03 09:55:11  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-03 09:55:15  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-03 09:55:20  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-03 09:55:24  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-03 09:55:29  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-03 09:55:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-03 09:55:38  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-03 09:55:42  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-03 09:55:47  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-03 09:55:51  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-03 09:55:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-03 09:56:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-03 09:56:05  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-03 09:56:09  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-03 09:56:13  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-03 09:56:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-03 09:56:22  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-03 09:56:27  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-03 09:56:31  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-03 09:56:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-03 09:56:40  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-03 09:56:44  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-03 09:56:49  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-03 09:56:54  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-03 09:56:58  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-03 09:57:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-03 09:57:07  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-03 09:57:11  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-03 09:57:16  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-03 09:57:20  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-03 09:57:25  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-03 09:57:29  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-03 09:57:34  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-03 09:57:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-03 09:57:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-03 09:57:47  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-03 09:57:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-03 09:57:56  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-03 09:58:01  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-03 09:58:05  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-03 09:58:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-03 09:58:14  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-03 09:58:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-03 09:58:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-03 09:58:28  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-03 09:58:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-03 09:58:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-03 09:58:41  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-03 09:58:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-03 09:58:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-03 09:58:55  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-03 09:59:04  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-03 09:59:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-03 09:59:13  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-03 09:59:18  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-03 09:59:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-03 09:59:27  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-03 09:59:31  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-03 09:59:36  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-03 09:59:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-03 09:59:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-03 09:59:49  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-03 09:59:53  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-03 09:59:58  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-03 10:00:02  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-03 10:00:07  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-03 10:00:11  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-03 10:00:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-03 10:00:20  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-03 10:00:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-03 10:00:29  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-03 10:00:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-03 10:00:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-03 10:00:42  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-03 10:00:47  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-03 10:00:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-03 10:00:56  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-03 10:01:00  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-03 10:01:05  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-03 10:01:09  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-03 10:01:13  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-03 10:01:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-03 10:01:22  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-03 10:01:27  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-03 10:01:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-03 10:01:36  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-03 10:01:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-03 10:01:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-03_10-01-49 Restart Xvfb...
2017-04-03 10:01:50  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-03 10:01:54  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-03 10:01:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-03 10:02:03  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-03 10:02:08  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-03 10:02:12  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-03 10:02:17  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-03 10:02:21  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-03 10:02:26  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-03 10:02:30  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-03 10:02:35  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-03 10:02:40  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-03 10:02:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-03 10:02:50  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-03 10:02:54  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-03 10:02:59  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-03 10:03:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-03 10:03:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-03 10:03:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-03 10:03:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-03 10:03:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-03 10:03:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-03 10:03:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-03 10:03:40  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-03 10:03:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-03 10:03:49  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-03 10:03:54  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-03 10:03:58  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-03 10:04:03  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-03 10:04:07  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-03 10:04:12  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-03 10:04:16  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-03 10:04:21  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-03 10:04:26  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-03 10:04:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-03 10:04:35  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-03 10:04:39  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-03 10:04:44  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-03 10:04:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-03 10:04:53  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-03 10:04:57  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-03 10:05:02  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-03 10:05:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-03 10:05:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-03 10:05:15  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-03 10:05:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-03 10:05:24  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-03 10:05:29  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-03 10:05:34  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-03 10:05:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-03 10:05:42  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-03 10:05:47  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-03 10:05:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-03 10:05:55  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-03 10:06:00  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-03 10:06:04  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-03 10:06:09  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-03 10:06:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-03 10:06:17  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-03 10:06:21  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-03 10:06:26  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-03 10:06:30  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-03 10:06:35  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-03 10:06:39  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-03 10:06:43  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-03 10:06:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-03 10:06:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-03 10:06:56  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-03 10:07:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-03 10:07:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-03 10:07:09  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-03 10:07:14  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-03 10:07:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-03 10:07:23  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-03 10:07:27  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-03 10:07:32  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-03 10:07:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-03 10:07:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-03 10:07:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-03 10:07:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-03 10:07:58  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-03 10:08:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-03 10:08:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-03 10:08:17  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-03 10:08:20  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-03 10:08:25  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-03 10:08:29  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-03 10:08:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-03 10:08:38  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-03 10:08:42  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-03 10:08:46  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-03 10:08:51  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-03 10:08:56  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-03 10:09:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-03 10:09:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-03 10:09:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-03 10:09:13  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-03 10:09:14  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-03 10:09:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-03 10:09:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-03 10:09:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-03 10:09:31  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-03 10:09:36  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-03 10:09:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-03 10:09:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-03 10:09:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-03 10:09:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-03 10:09:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-03 10:10:02  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-03 10:10:06  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-03 10:10:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-03 10:10:15  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-03 10:10:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-03 10:10:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-03 10:10:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-03 10:10:32  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-03 10:10:36  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-03 10:10:41  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-03 10:10:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-03 10:10:49  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-03 10:10:53  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-03 10:10:58  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-03 10:11:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-03 10:11:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-03 10:11:11  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-03 10:11:15  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-03 10:11:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-03 10:11:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-03 10:11:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-03 10:11:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-03 10:11:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-03 10:11:40  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-03 10:11:44  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-03 10:11:48  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-03 10:11:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-03 10:11:56  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-03 10:11:59  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-03 10:12:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-03 10:12:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-03 10:12:13  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-03 10:12:17  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-03 10:12:21  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-03 10:12:25  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-03 10:12:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-03 10:12:34  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-03 10:12:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-03 10:12:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-03 10:12:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-03 10:12:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-03 10:13:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-03 10:13:05  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-03 10:13:09  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-03 10:13:13  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-03 10:13:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-03 10:13:21  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-03 10:13:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-03 10:13:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-03 10:13:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-03 10:13:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 10:13:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 10:13:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 10:13:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 10:13:55  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-03 10:13:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 10:14:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 10:14:07  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-03 10:14:11  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-03 10:14:15  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-03 10:14:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-03 10:14:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-03 10:14:28  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-03 10:14:32  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-03 10:14:35  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-03 10:14:40  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-03 10:14:44  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-03 10:14:48  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-03 10:14:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-03 10:14:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-03 10:15:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-03 10:15:04  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-03 10:15:08  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-03 10:15:12  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-03 10:15:16  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-03 10:15:20  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-03 10:15:24  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-03 10:15:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 10:15:32  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 10:15:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 10:15:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 10:15:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 10:15:48  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-03 10:15:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 10:15:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 10:16:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 10:16:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 10:16:08  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-03 10:16:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 10:16:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 10:16:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 10:16:24  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-03 10:16:28  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-03_10-31-49 Restart Xvfb...
2017-04-03_11-01-49 Restart Xvfb...
2017-04-03_11-31-49 Restart Xvfb...
2017-04-03_12-01-49 Restart Xvfb...
2017-04-03 12:31:46 reset updateRequest
2017-04-03 12:31:49  - 14968  http://www.lymphomahub.com/
2017-04-03_12-31-49 Restart Xvfb...
2017-04-03 12:31:51  - 14968  http://www.lymphomahub.com/
2017-04-03 12:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-03 12:32:00  - 14968  http://www.lymphomahub.com/terms
2017-04-03 12:32:04  - 14968  http://www.lymphomahub.com/undefined
2017-04-03 12:32:04  - 14968  http://www.lymphomahub.com/therapies
2017-04-03 12:32:11  - 14968  http://www.lymphomahub.com/newsletter
2017-04-03 12:32:14  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-03 12:32:17  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-03 12:32:21  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-03 12:32:26  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-03 12:32:31  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-03 12:32:36  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-03 12:32:40  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-03 12:32:44  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-03 12:32:49  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-03 12:32:53  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-03 12:32:57  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-03 12:33:02  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-03 12:33:06  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-03 12:33:11  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-03 12:33:21  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-03 12:33:25  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-03 12:33:29  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-03 12:33:34  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-03 12:33:38  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-03 12:33:43  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-03 12:33:47  - 14968  http://www.lymphomahub.com/therapies/kte-c19
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-03 12:33:52  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-03 12:33:54  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-03 12:33:55  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-03 12:33:58  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-03 12:34:00  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-03 12:34:02  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-03 12:34:05  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-03 12:34:06  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-03 12:34:10  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-03 12:34:11  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-03 12:34:15  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-03 12:34:16  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-03 12:34:20  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-03 12:34:21  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-03 12:34:26  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-03 12:34:30  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-03 12:34:34  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-03 12:34:38  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-03 12:34:43  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-03 12:34:47  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-03 12:34:51  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-03 12:34:55  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-03 12:35:00  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-03 12:35:04  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-03 12:35:09  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-03 12:35:13  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-03 12:35:17  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-03 12:35:22  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-03 12:35:26  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-03 12:35:30  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-03 12:35:35  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-03 12:35:39  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-03 12:35:44  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-03 12:35:48  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-03 12:35:52  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-03 12:35:57  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-03 12:36:01  - 14968  http://www.lymphomahub.com/medical-information
2017-04-03 12:36:04  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-03 12:36:09  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-03 12:36:13  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-03 12:36:18  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-03 12:36:22  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-03 12:36:27  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-03 12:36:31  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-03 12:36:36  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-03 12:36:40  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-03 12:36:44  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-03 12:36:48  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-03 12:36:53  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-03 12:36:53  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-03 12:36:57  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-03 12:37:02  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-03 12:37:07  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-03 12:37:11  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-03 12:37:15  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-03 12:37:20  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-03 12:37:24  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-03 12:37:28  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-03 12:37:33  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-03 12:37:37  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-03 12:37:41  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-03 12:37:46  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-03 12:37:50  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-03 12:37:54  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-03 12:37:58  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-03 12:38:03  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-03 12:38:07  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-03 12:38:12  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-03 12:38:16  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-03 12:38:20  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-03 12:38:24  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-03 12:38:29  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-03 12:38:33  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-03 12:38:37  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-03 12:38:42  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-03 12:38:46  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-03 12:38:51  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-03 12:38:55  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-03 12:38:59  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-03 12:39:04  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-03 12:39:05  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-03 12:39:09  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-03 12:39:14  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-03 12:39:18  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-03 12:39:23  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-03 12:39:27  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-03 12:39:32  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-03 12:39:36  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-03 12:39:41  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-03 12:39:45  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-03 12:39:45  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-03 12:39:50  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-03 12:39:54  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-03 12:39:58  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-03 12:40:03  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-03 12:40:08  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-03 12:40:08  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-03 12:40:13  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-03 12:40:17  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-03 12:40:21  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-03 12:40:25  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-03 12:40:29  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-03 12:40:33  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-03 12:40:37  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-03 12:40:41  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-03 12:40:44  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-03 12:40:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-03 12:40:53  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-03 12:40:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-03 12:41:02  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-03 12:41:05  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-03 12:41:06  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-03 12:41:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-03 12:41:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-03 12:41:19  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-03 12:41:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-03 12:41:28  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-03 12:41:32  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-03 12:41:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-03 12:41:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-03 12:41:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-03 12:41:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-03 12:41:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-03 12:41:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-03 12:41:58  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-03 12:42:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-03 12:42:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-03 12:42:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-03 12:42:16  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-03 12:42:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-03 12:42:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-03 12:42:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-03 12:42:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-03 12:42:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-03 12:42:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-03 12:42:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-03 12:42:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-03 12:42:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-03 12:42:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-03 12:43:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-03 12:43:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-03 12:43:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-03 12:43:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-03 12:43:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-03 12:43:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-03 12:43:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-03 12:43:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-03 12:43:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-03 12:43:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-03 12:43:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-03 12:43:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-03 12:43:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-03 12:43:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-03 12:44:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-03 12:44:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-03 12:44:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-03 12:44:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-03 12:44:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-03 12:44:25  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-03 12:44:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-03 12:44:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-03 12:44:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-03 12:44:41  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-03 12:44:46  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-03 12:44:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-03 12:44:54  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-03 12:44:58  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-03 12:45:02  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-03 12:45:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-03 12:45:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-03 12:45:16  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-03 12:45:20  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-03 12:45:24  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-03 12:45:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-03 12:45:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-03 12:45:36  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-03 12:45:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-03 12:45:44  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-03 12:45:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-03 12:45:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-03 12:45:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-03 12:46:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-03 12:46:06  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-03 12:46:07  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-03 12:46:12  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-03 12:46:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-03 12:46:20  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-03 12:46:25  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-03 12:46:29  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-03 12:46:34  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 12:46:39  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 12:46:43  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-03 12:46:47  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 12:46:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-03 12:46:56  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-03 12:47:01  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-03 12:47:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-03 12:47:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-03 12:47:14  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-03 12:47:19  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-03 12:47:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-03 12:47:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-03 12:47:33  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-03 12:47:38  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 12:47:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-03 12:47:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-03 12:47:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-03 12:47:59  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-03 12:48:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-03 12:48:09  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-03 12:48:13  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-03 12:48:18  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-03 12:48:22  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-03 12:48:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-03 12:48:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-03 12:48:36  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-03 12:48:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-03 12:48:50  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-03 12:48:55  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-03 12:48:59  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-03 12:49:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-03 12:49:09  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-03 12:49:13  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-03 12:49:18  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-03 12:49:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-03 12:49:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-03 12:49:28  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-03 12:49:33  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-03 12:49:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-03 12:49:42  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-03 12:49:46  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-03 12:49:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-03 12:49:56  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-03 12:50:00  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-03 12:50:05  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-03 12:50:09  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-03 12:50:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-03 12:50:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-03 12:50:24  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-03 12:50:29  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-03 12:50:33  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-03 12:50:38  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-03 12:50:42  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-03 12:50:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-03 12:50:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-03 12:50:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-03 12:51:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-03 12:51:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-03 12:51:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-03 12:51:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-03 12:51:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-03 12:51:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-03 12:51:25  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-03 12:51:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-03 12:51:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-03 12:51:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-03 12:51:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-03 12:51:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-03 12:51:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-03 12:51:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-03 12:51:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-03 12:51:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-03 12:52:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-03 12:52:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-03 12:52:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-03 12:52:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-03 12:52:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-03 12:52:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-03 12:52:22  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-03 12:52:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-03 12:52:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-03 12:52:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-03 12:52:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-03 12:52:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-03 12:52:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-03 12:52:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-03 12:52:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-03 12:52:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-03 12:52:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-03 12:53:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-03 12:53:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-03 12:53:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-03 12:53:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-03 12:53:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-03 12:53:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-03 12:53:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-03 12:53:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-03 12:53:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-03 12:53:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-03 12:53:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-03 12:53:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-03 12:53:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-03 12:53:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-03 12:53:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-03 12:53:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-03 12:54:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-03 12:54:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-03 12:54:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-03 12:54:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-03 12:54:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-03 12:54:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-03 12:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-03 12:54:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-03 12:54:36  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-03 12:54:40  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-03 12:54:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-03 12:54:50  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-03 12:54:50  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-03 12:54:55  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-03 12:55:00  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-03 12:55:05  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-03 12:55:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-03 12:55:15  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-03 12:55:19  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-03 12:55:24  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-03 12:55:29  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-03 12:55:33  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-03 12:55:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-03 12:55:43  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-03 12:55:47  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-03 12:55:52  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-03 12:55:56  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-03 12:56:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-03 12:56:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-03 12:56:09  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-03 12:56:14  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-03 12:56:18  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-03 12:56:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-03 12:56:27  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-03 12:56:32  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-03 12:56:36  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-03 12:56:41  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-03 12:56:45  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-03 12:56:50  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-03 12:56:54  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-03 12:56:59  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-03 12:57:03  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-03 12:57:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-03 12:57:12  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-03 12:57:17  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-03 12:57:21  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-03 12:57:26  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-03 12:57:30  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-03 12:57:34  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-03 12:57:39  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-03 12:57:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-03 12:57:48  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-03 12:57:52  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-03 12:57:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-03 12:58:02  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-03 12:58:06  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-03 12:58:10  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-03 12:58:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-03 12:58:19  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-03 12:58:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-03 12:58:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-03 12:58:33  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-03 12:58:37  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-03 12:58:42  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-03 12:58:46  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-03 12:58:51  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-03 12:58:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-03 12:59:00  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-03 12:59:04  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-03 12:59:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-03 12:59:13  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-03 12:59:18  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-03 12:59:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-03 12:59:32  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-03 12:59:36  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-03 12:59:40  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-03 12:59:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-03 12:59:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-03 12:59:55  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-03 13:00:00  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-03 13:00:04  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-03 13:00:09  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-03 13:00:14  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-03 13:00:20  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-03 13:00:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-03 13:00:29  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-03 13:00:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-03 13:00:43  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-03 13:00:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-03 13:00:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-03 13:00:57  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-03 13:01:01  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-03 13:01:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-03 13:01:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-03 13:01:15  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-03 13:01:19  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-03 13:01:23  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-03 13:01:27  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-03 13:01:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-03 13:01:36  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-03 13:01:41  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-03 13:01:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-03_13-01-49 Restart Xvfb...
2017-04-03 13:01:49  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-03 13:01:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-03 13:01:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-03 13:02:03  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-03 13:02:08  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-03 13:02:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-03 13:02:16  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-03 13:02:21  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-03 13:02:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-03 13:02:30  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-03 13:02:35  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-03 13:02:39  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-03 13:02:44  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-03 13:02:48  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-03 13:02:53  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-03 13:02:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-03 13:03:02  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-03 13:03:06  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-03 13:03:10  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-03 13:03:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-03 13:03:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-03 13:03:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-03 13:03:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-03 13:03:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-03 13:03:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-03 13:03:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-03 13:03:47  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-03 13:03:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-03 13:03:57  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-03 13:04:02  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-03 13:04:07  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-03 13:04:11  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-03 13:04:15  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-03 13:04:20  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-03 13:04:24  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-03 13:04:28  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-03 13:04:33  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-03 13:04:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-03 13:04:42  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-03 13:04:46  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-03 13:04:51  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-03 13:04:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-03 13:05:00  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-03 13:05:05  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-03 13:05:09  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-03 13:05:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-03 13:05:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-03 13:05:23  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-03 13:05:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-03 13:05:32  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-03 13:05:37  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-03 13:05:42  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-03 13:05:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-03 13:05:53  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-03 13:05:57  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-03 13:06:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-03 13:06:05  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-03 13:06:10  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-03 13:06:14  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-03 13:06:18  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-03 13:06:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-03 13:06:28  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-03 13:06:33  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-03 13:06:37  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-03 13:06:41  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-03 13:06:46  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-03 13:06:51  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-03 13:06:54  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-03 13:06:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-03 13:07:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-03 13:07:08  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-03 13:07:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-03 13:07:16  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-03 13:07:21  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-03 13:07:25  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-03 13:07:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-03 13:07:34  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-03 13:07:39  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-03 13:07:43  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-03 13:07:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-03 13:07:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-03 13:07:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-03 13:08:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-03 13:08:05  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-03 13:08:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-03 13:08:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-03 13:08:18  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-03 13:08:22  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-03 13:08:27  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-03 13:08:31  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-03 13:08:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-03 13:08:39  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-03 13:08:43  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-03 13:08:48  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-03 13:08:53  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-03 13:08:57  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-03 13:09:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-03 13:09:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-03 13:09:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-03 13:09:16  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-03 13:09:16  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-03 13:09:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-03 13:09:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-03 13:09:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-03 13:09:34  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-03 13:09:38  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-03 13:09:43  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-03 13:09:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-03 13:09:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-03 13:09:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-03 13:10:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-03 13:10:04  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-03 13:10:08  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-03 13:10:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-03 13:10:17  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-03 13:10:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-03 13:10:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-03 13:10:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-03 13:10:35  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-03 13:10:39  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-03 13:10:43  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-03 13:10:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-03 13:10:52  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-03 13:10:56  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-03 13:11:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-03 13:11:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-03 13:11:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-03 13:11:14  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-03 13:11:18  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-03 13:11:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-03 13:11:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-03 13:11:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-03 13:11:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-03 13:11:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-03 13:11:43  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-03 13:11:47  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-03 13:11:51  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-03 13:11:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-03 13:11:59  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-03 13:12:03  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-03 13:12:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-03 13:12:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-03 13:12:16  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-03 13:12:20  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-03 13:12:24  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-03 13:12:28  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-03 13:12:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-03 13:12:36  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-03 13:12:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-03 13:12:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-03 13:12:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-03 13:12:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-03 13:12:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-03 13:13:03  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-03 13:13:07  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-03 13:13:11  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-03 13:13:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-03 13:13:20  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-03 13:13:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-03 13:13:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-03 13:13:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-03 13:13:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 13:13:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 13:13:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 13:13:48  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 13:13:52  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-03 13:13:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 13:14:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 13:14:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-03 13:14:09  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-03 13:14:13  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-03 13:14:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-03 13:14:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-03 13:14:25  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-03 13:14:29  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-03 13:14:33  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-03 13:14:37  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-03 13:14:41  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-03 13:14:45  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-03 13:14:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-03 13:14:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-03 13:14:58  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-03 13:15:02  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-03 13:15:06  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-03 13:15:12  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-03 13:15:17  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-03 13:15:21  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-03 13:15:25  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-03 13:15:29  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 13:15:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 13:15:37  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 13:15:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 13:15:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 13:15:50  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-03 13:15:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 13:15:57  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 13:16:01  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 13:16:05  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 13:16:09  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-03 13:16:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 13:16:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 13:16:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 13:16:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-03 13:16:30  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-03_13-31-49 Restart Xvfb...
2017-04-03_14-01-49 Restart Xvfb...
2017-04-03_14-31-49 Restart Xvfb...
2017-04-03_15-01-49 Restart Xvfb...
2017-04-03 15:31:46 reset updateRequest
2017-04-03 15:31:46  - 14968  http://www.lymphomahub.com/
2017-04-03_15-31-50 Restart Xvfb...
2017-04-03 15:31:51  - 14968  http://www.lymphomahub.com/
2017-04-03 15:31:54  - 14968  http://www.lymphomahub.com/about
2017-04-03 15:32:00  - 14968  http://www.lymphomahub.com/terms
2017-04-03 15:32:03  - 14968  http://www.lymphomahub.com/undefined
2017-04-03 15:32:04  - 14968  http://www.lymphomahub.com/therapies
2017-04-03 15:32:10  - 14968  http://www.lymphomahub.com/newsletter
2017-04-03 15:32:13  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-03 15:32:17  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-03 15:32:21  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-03 15:32:26  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-03 15:32:30  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-03 15:32:35  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-03 15:32:40  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-03 15:32:46  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-03 15:32:52  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-03 15:32:57  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-03 15:33:03  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-03 15:33:12  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-03 15:33:17  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-03 15:33:21  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-03 15:33:26  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-03 15:33:30  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-03 15:33:34  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-03 15:33:38  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-03 15:33:43  - 14968  http://www.lymphomahub.com/therapies/actr087
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-03 15:33:48  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-03 15:33:51  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-03 15:33:52  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-03 15:33:56  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-03 15:33:58  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-03 15:34:01  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-03 15:34:03  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-03 15:34:05  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-03 15:34:08  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-03 15:34:10  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-03 15:34:13  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-03 15:34:14  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-03 15:34:19  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-03 15:34:23  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-03 15:34:29  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-03 15:34:33  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-03 15:34:37  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-03 15:34:42  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-03 15:34:46  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-03 15:34:50  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-03 15:34:54  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-03 15:34:59  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-03 15:35:03  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-03 15:35:08  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-03 15:35:12  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-03 15:35:16  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-03 15:35:21  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-03 15:35:26  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-03 15:35:30  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-03 15:35:34  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-03 15:35:39  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-03 15:35:43  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-03 15:35:48  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-03 15:35:52  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-03 15:35:57  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-03 15:36:01  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-03 15:36:05  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-03 15:36:10  - 14968  http://www.lymphomahub.com/medical-information
2017-04-03 15:36:13  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-03 15:36:18  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-03 15:36:22  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-03 15:36:26  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-03 15:36:31  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-03 15:36:35  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-03 15:36:39  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-03 15:36:44  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-03 15:36:48  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-03 15:36:52  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-03 15:36:57  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-03 15:37:01  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-03 15:37:02  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-03 15:37:07  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-03 15:37:11  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-03 15:37:16  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-03 15:37:20  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-03 15:37:24  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-03 15:37:29  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-03 15:37:33  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-03 15:37:41  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-03 15:37:45  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-03 15:37:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-03 15:37:55  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-03 15:37:59  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-03 15:38:03  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-03 15:38:08  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-03 15:38:12  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-03 15:38:17  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-03 15:38:21  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-03 15:38:26  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-03 15:38:30  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-03 15:38:34  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-03 15:38:38  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-03 15:38:43  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-03 15:38:47  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-03 15:38:51  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-03 15:38:56  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-03 15:39:00  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-03 15:39:05  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-03 15:39:09  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-03 15:39:13  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-03 15:39:18  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-03 15:39:19  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-03 15:39:23  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-03 15:39:27  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-03 15:39:32  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-03 15:39:36  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-03 15:39:41  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-03 15:39:45  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-03 15:39:49  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-03 15:39:54  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-03 15:39:58  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-03 15:39:58  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-03 15:40:03  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-03 15:40:07  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-03 15:40:12  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-03 15:40:21  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-03 15:40:26  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-03 15:40:26  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-03 15:40:31  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-03 15:40:35  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-03 15:40:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-03 15:40:43  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-03 15:40:47  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-03 15:40:51  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-03 15:40:55  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-03 15:40:59  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-03 15:41:02  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-03 15:41:08  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-03 15:41:11  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-03 15:41:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-03 15:41:20  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-03 15:41:25  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-03 15:41:25  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-03 15:41:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-03 15:41:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-03 15:41:38  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-03 15:41:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-03 15:41:46  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-03 15:41:51  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-03 15:41:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-03 15:41:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-03 15:42:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-03 15:42:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-03 15:42:10  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-03 15:42:13  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-03 15:42:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-03 15:42:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-03 15:42:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-03 15:42:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-03 15:42:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-03 15:42:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-03 15:42:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-03 15:42:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-03 15:42:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-03 15:42:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-03 15:42:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-03 15:43:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-03 15:43:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-03 15:43:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-03 15:43:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-03 15:43:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-03 15:43:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-03 15:43:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-03 15:43:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-03 15:43:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-03 15:43:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-03 15:43:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-03 15:43:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-03 15:44:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-03 15:44:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-03 15:44:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-03 15:44:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-03 15:44:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-03 15:44:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-03 15:44:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-03 15:44:41  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-03 15:44:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-03 15:44:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-03 15:44:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-03 15:44:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-03 15:45:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-03 15:45:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-03 15:45:10  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-03 15:45:13  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-03 15:45:18  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-03 15:45:23  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-03 15:45:26  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-03 15:45:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-03 15:45:34  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-03 15:45:39  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-03 15:45:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-03 15:45:47  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-03 15:45:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-03 15:45:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-03 15:45:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-03 15:46:03  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-03 15:46:06  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-03 15:46:11  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-03 15:46:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-03 15:46:19  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-03 15:46:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-03 15:46:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-03 15:46:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-03 15:46:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-03 15:46:42  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-03 15:46:43  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-03 15:46:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-03 15:46:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-03 15:46:56  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-03 15:47:01  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-03 15:47:05  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-03 15:47:10  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 15:47:14  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 15:47:19  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-03 15:47:23  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 15:47:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-03 15:47:32  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-03 15:47:37  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-03 15:47:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-03 15:47:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-03 15:47:50  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-03 15:47:54  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-03 15:47:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-03 15:48:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-03 15:48:09  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-03 15:48:14  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 15:48:18  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-03 15:48:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-03 15:48:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-03 15:48:32  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-03 15:48:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-03 15:48:42  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-03 15:48:46  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-03 15:48:51  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-03 15:48:55  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-03 15:48:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-03 15:49:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-03 15:49:09  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-03 15:49:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-03 15:49:17  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-03 15:49:22  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-03 15:49:27  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-03 15:49:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-03 15:49:36  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-03 15:49:44  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-03 15:49:49  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-03 15:49:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-03 15:49:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-03 15:49:58  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-03 15:50:03  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-03 15:50:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-03 15:50:12  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-03 15:50:17  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-03 15:50:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-03 15:50:26  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-03 15:50:31  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-03 15:50:36  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-03 15:50:40  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-03 15:50:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-03 15:50:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-03 15:50:54  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-03 15:50:59  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-03 15:51:03  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-03 15:51:08  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-03 15:51:12  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-03 15:51:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-03 15:51:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-03 15:51:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-03 15:51:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-03 15:51:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-03 15:51:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-03 15:51:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-03 15:51:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-03 15:51:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-03 15:52:05  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-03 15:52:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-03 15:52:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-03 15:52:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-03 15:52:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-03 15:52:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-03 15:52:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-03 15:52:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-03 15:52:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-03 15:52:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-03 15:52:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-03 15:52:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-03 15:52:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-03 15:52:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-03 15:52:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-03 15:52:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-03 15:53:01  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-03 15:53:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-03 15:53:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-03 15:53:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-03 15:53:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-03 15:53:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-03 15:53:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-03 15:53:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-03 15:53:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-03 15:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-03 15:53:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-03 15:53:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-03 15:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-03 15:53:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-03 15:53:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-03 15:53:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-03 15:54:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-03 15:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-03 15:54:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-03 15:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-03 15:54:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-03 15:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-03 15:54:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-03 15:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-03 15:54:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-03 15:54:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-03 15:54:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-03 15:54:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-03 15:54:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-03 15:54:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-03 15:54:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-03 15:55:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-03 15:55:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-03 15:55:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-03 15:55:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-03 15:55:16  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-03 15:55:20  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-03 15:55:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-03 15:55:30  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-03 15:55:30  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-03 15:55:35  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-03 15:55:39  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-03 15:55:44  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-03 15:55:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-03 15:55:53  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-03 15:55:57  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-03 15:56:02  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-03 15:56:07  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-03 15:56:11  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-03 15:56:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-03 15:56:20  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-03 15:56:25  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-03 15:56:33  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-03 15:56:37  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-03 15:56:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-03 15:56:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-03 15:56:51  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-03 15:56:55  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-03 15:57:00  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-03 15:57:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-03 15:57:09  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-03 15:57:14  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-03 15:57:18  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-03 15:57:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-03 15:57:27  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-03 15:57:32  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-03 15:57:36  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-03 15:57:41  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-03 15:57:45  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-03 15:57:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-03 15:57:55  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-03 15:57:59  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-03 15:58:03  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-03 15:58:08  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-03 15:58:13  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-03 15:58:17  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-03 15:58:21  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-03 15:58:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-03 15:58:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-03 15:58:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-03 15:58:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-03 15:58:44  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-03 15:58:48  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-03 15:58:52  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-03 15:58:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-03 15:59:01  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-03 15:59:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-03 15:59:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-03 15:59:14  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-03 15:59:19  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-03 15:59:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-03 15:59:28  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-03 15:59:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-03 15:59:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-03 15:59:41  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-03 15:59:46  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-03 15:59:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-03 15:59:55  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-03 15:59:59  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-03 16:00:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-03 16:00:09  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-03 16:00:14  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-03 16:00:18  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-03 16:00:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-03 16:00:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-03 16:00:32  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-03 16:00:36  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-03 16:00:41  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-03 16:00:45  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-03 16:00:50  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-03 16:00:54  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-03 16:00:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-03 16:01:04  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-03 16:01:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-03 16:01:13  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-03 16:01:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-03 16:01:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-03 16:01:26  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-03 16:01:31  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-03 16:01:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-03 16:01:39  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-03 16:01:44  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-03 16:01:48  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-03_16-01-50 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll?_prerender {"code":"ECONNRESET"}
2017-04-03 16:03:53  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-03 16:03:58  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-03 16:04:03  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-03 16:04:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-03 16:04:12  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-03 16:04:16  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-03 16:04:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-03 16:04:25  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-03 16:04:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-03 16:04:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-03 16:04:39  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-03 16:04:44  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-03 16:04:48  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-03 16:04:53  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-03 16:04:57  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-03 16:05:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-03 16:05:07  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-03 16:05:11  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-03 16:05:16  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-03 16:05:20  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-03 16:05:24  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-03 16:05:29  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-03 16:05:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-03 16:05:43  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-03 16:05:47  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-03 16:05:52  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-03 16:05:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-03 16:06:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-03 16:06:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-03 16:06:11  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-03 16:06:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-03 16:06:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-03 16:06:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-03 16:06:29  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-03 16:06:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-03 16:06:38  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-03 16:06:43  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-03 16:06:47  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-03 16:06:51  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-03 16:06:56  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-03 16:07:00  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-03 16:07:05  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-03 16:07:09  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-03 16:07:14  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-03 16:07:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-03 16:07:23  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-03 16:07:27  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-03 16:07:32  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-03 16:07:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-03 16:07:41  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-03 16:07:46  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-03 16:07:51  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-03 16:07:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-03 16:08:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-03 16:08:04  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-03 16:08:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-03 16:08:14  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-03 16:08:19  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-03 16:08:23  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-03 16:08:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-03 16:08:33  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-03 16:08:37  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-03 16:08:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-03 16:08:46  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-03 16:08:50  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-03 16:08:55  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-03 16:08:59  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-03 16:09:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-03 16:09:08  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-03 16:09:12  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-03 16:09:17  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-03 16:09:22  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-03 16:09:26  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-03 16:09:31  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-03 16:09:35  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-03 16:09:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-03 16:09:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-03 16:09:47  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-03 16:09:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-03 16:09:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-03 16:10:00  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-03 16:10:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-03 16:10:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-03 16:10:15  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-03 16:10:19  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-03 16:10:23  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-03 16:10:27  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-03 16:10:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-03 16:10:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-03 16:10:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-03 16:10:49  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-03 16:10:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-03 16:10:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-03 16:11:02  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-03 16:11:06  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-03 16:11:11  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-03 16:11:15  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-03 16:11:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-03 16:11:24  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-03 16:11:28  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-03 16:11:33  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-03 16:11:37  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-03 16:11:42  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-03 16:11:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-03 16:11:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-03 16:11:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-03 16:12:00  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-03 16:12:00  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-03 16:12:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-03 16:12:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-03 16:12:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-03 16:12:18  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-03 16:12:23  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-03 16:12:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-03 16:12:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-03 16:12:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-03 16:12:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-03 16:12:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-03 16:12:49  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-03 16:12:53  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-03 16:12:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-03 16:13:02  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-03 16:13:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-03 16:13:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-03 16:13:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-03 16:13:20  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-03 16:13:24  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-03 16:13:29  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-03 16:13:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-03 16:13:38  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-03 16:13:42  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-03 16:13:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-03 16:13:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-03 16:13:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-03 16:14:05  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-03 16:14:09  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-03 16:14:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-03 16:14:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-03 16:14:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-03 16:14:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-03 16:14:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-03 16:14:34  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-03 16:14:38  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-03 16:14:42  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-03 16:14:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-03 16:14:55  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-03 16:15:00  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-03 16:15:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-03 16:15:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-03 16:15:13  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-03 16:15:17  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-03 16:15:21  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-03 16:15:25  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-03 16:15:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-03 16:15:34  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-03 16:15:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-03 16:15:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-03 16:15:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-03 16:15:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-03 16:15:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-03 16:16:00  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-03 16:16:04  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-03 16:16:08  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-03 16:16:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-03 16:16:20  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-03 16:16:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-03 16:16:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-03 16:16:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-03 16:16:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 16:16:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 16:16:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 16:16:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 16:16:53  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-03 16:16:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 16:17:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 16:17:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-03 16:17:09  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-03 16:17:13  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-03 16:17:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-03 16:17:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-03 16:17:25  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-03 16:17:30  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-03 16:17:34  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-03 16:17:38  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-03 16:17:42  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-03 16:17:46  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-03 16:17:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-03 16:17:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-03 16:17:59  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-03 16:18:03  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-03 16:18:07  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-03 16:18:11  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-03 16:18:15  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-03 16:18:19  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-03 16:18:23  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-03 16:18:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 16:18:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 16:18:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 16:18:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 16:18:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 16:18:47  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-03 16:18:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 16:18:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 16:18:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 16:19:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 16:19:07  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-03 16:19:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 16:19:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 16:19:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 16:19:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-03 16:19:27  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-03_16-31-50 Restart Xvfb...
2017-04-03_17-01-50 Restart Xvfb...
2017-04-03_17-31-50 Restart Xvfb...
2017-04-03_18-01-50 Restart Xvfb...
2017-04-03 18:31:46 reset updateRequest
2017-04-03 18:31:48  - 14968  http://www.lymphomahub.com/
2017-04-03_18-31-50 Restart Xvfb...
2017-04-03 18:31:51  - 14968  http://www.lymphomahub.com/
2017-04-03 18:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-03 18:32:00  - 14968  http://www.lymphomahub.com/terms
2017-04-03 18:32:03  - 14968  http://www.lymphomahub.com/undefined
2017-04-03 18:32:04  - 14968  http://www.lymphomahub.com/therapies
2017-04-03 18:32:10  - 14968  http://www.lymphomahub.com/newsletter
2017-04-03 18:32:13  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-03 18:32:16  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-03 18:32:21  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-03 18:32:25  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-03 18:32:30  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-03 18:32:34  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-03 18:32:39  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-03 18:32:43  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-03 18:32:48  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-03 18:32:52  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-03 18:32:57  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-03 18:33:01  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-03 18:33:05  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-03 18:33:10  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-03 18:33:14  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-03 18:33:19  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-03 18:33:23  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-03 18:33:27  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-03 18:33:31  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-03 18:33:36  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-03 18:33:40  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-03 18:33:45  - 14968  http://www.lymphomahub.com/about/secretariat
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-03 18:33:49  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-03 18:33:53  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-03 18:33:53  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-03 18:33:59  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-03 18:33:59  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-03 18:34:04  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-03 18:34:04  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-03 18:34:09  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-03 18:34:09  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-03 18:34:14  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-03 18:34:14  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-03 18:34:20  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-03 18:34:24  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-03 18:34:28  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-03 18:34:33  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-03 18:34:37  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-03 18:34:41  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-03 18:34:46  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-03 18:34:50  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-03 18:34:54  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-03 18:34:59  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-03 18:35:03  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-03 18:35:08  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-03 18:35:12  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-03 18:35:16  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-03 18:35:20  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-03 18:35:25  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-03 18:35:29  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-03 18:35:34  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-03 18:35:38  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-03 18:35:43  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-03 18:35:47  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-03 18:35:51  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-03 18:35:56  - 14968  http://www.lymphomahub.com/medical-information
2017-04-03 18:36:00  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-03 18:36:05  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-03 18:36:09  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-03 18:36:13  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-03 18:36:18  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-03 18:36:22  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-03 18:36:27  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-03 18:36:31  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-03 18:36:35  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-03 18:36:40  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-03 18:36:44  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-03 18:36:49  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-03 18:36:49  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-03 18:36:54  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-03 18:36:58  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-03 18:37:03  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-03 18:37:07  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-03 18:37:11  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-03 18:37:15  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-03 18:37:20  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-03 18:37:25  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-03 18:37:30  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-03 18:37:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-03 18:37:38  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-03 18:37:42  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-03 18:37:47  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-03 18:37:51  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-03 18:37:55  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-03 18:37:59  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-03 18:38:04  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-03 18:38:08  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-03 18:38:12  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-03 18:38:17  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-03 18:38:21  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-03 18:38:26  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-03 18:38:31  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-03 18:38:35  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-03 18:38:39  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-03 18:38:44  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-03 18:38:48  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-03 18:38:53  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-03 18:38:57  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-03 18:39:02  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-03 18:39:02  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-03 18:39:07  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-03 18:39:11  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-03 18:39:16  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-03 18:39:20  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-03 18:39:24  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-03 18:39:29  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-03 18:39:33  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-03 18:39:38  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-03 18:39:41  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-03 18:39:42  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-03 18:39:46  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-03 18:39:50  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-03 18:39:55  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-03 18:39:59  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-03 18:40:04  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-03 18:40:06  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-03 18:40:10  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-03 18:40:15  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-03 18:40:18  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-03 18:40:23  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-03 18:40:27  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-03 18:40:31  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-03 18:40:35  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-03 18:40:38  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-03 18:40:42  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-03 18:40:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-03 18:40:51  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-03 18:40:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-03 18:40:59  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-03 18:41:03  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-03 18:41:03  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-03 18:41:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-03 18:41:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-03 18:41:16  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-03 18:41:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-03 18:41:25  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-03 18:41:29  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-03 18:41:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-03 18:41:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-03 18:41:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-03 18:41:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-03 18:41:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-03 18:41:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-03 18:41:55  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-03 18:41:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-03 18:42:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-03 18:42:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-03 18:42:13  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-03 18:42:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-03 18:42:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-03 18:42:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-03 18:42:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-03 18:42:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-03 18:42:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-03 18:42:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-03 18:42:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-03 18:42:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-03 18:42:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-03 18:43:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-03 18:43:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-03 18:43:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-03 18:43:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-03 18:43:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-03 18:43:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-03 18:43:27  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-03 18:43:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-03 18:43:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-03 18:43:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-03 18:43:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-03 18:43:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-03 18:43:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-03 18:43:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-03 18:44:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-03 18:44:06  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-03 18:44:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-03 18:44:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-03 18:44:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-03 18:44:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-03 18:44:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-03 18:44:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-03 18:44:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-03 18:44:39  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-03 18:44:43  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-03 18:44:48  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-03 18:44:52  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-03 18:44:56  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-03 18:45:00  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-03 18:45:05  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-03 18:45:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-03 18:45:13  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-03 18:45:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-03 18:45:21  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-03 18:45:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-03 18:45:30  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-03 18:45:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-03 18:45:38  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-03 18:45:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-03 18:45:46  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-03 18:45:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-03 18:45:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-03 18:46:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-03 18:46:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-03 18:46:08  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-03 18:46:09  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-03 18:46:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-03 18:46:18  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-03 18:46:22  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-03 18:46:26  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-03 18:46:31  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-03 18:46:35  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 18:46:39  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 18:46:44  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-03 18:46:49  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 18:46:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-03 18:46:57  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-03 18:47:02  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-03 18:47:06  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-03 18:47:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-03 18:47:15  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-03 18:47:20  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-03 18:47:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-03 18:47:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-03 18:47:33  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-03 18:47:38  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 18:47:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-03 18:47:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-03 18:47:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-03 18:47:57  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-03 18:48:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-03 18:48:06  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-03 18:48:10  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-03 18:48:15  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-03 18:48:19  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-03 18:48:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-03 18:48:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-03 18:48:33  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-03 18:48:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-03 18:48:42  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-03 18:48:47  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-03 18:48:51  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-03 18:48:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-03 18:49:01  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-03 18:49:05  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-03 18:49:10  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-03 18:49:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-03 18:49:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-03 18:49:19  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-03 18:49:24  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-03 18:49:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-03 18:49:33  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-03 18:49:37  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-03 18:49:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-03 18:49:46  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-03 18:49:51  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-03 18:49:55  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-03 18:50:00  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-03 18:50:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-03 18:50:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-03 18:50:13  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-03 18:50:17  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-03 18:50:22  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-03 18:50:26  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-03 18:50:31  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-03 18:50:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-03 18:50:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-03 18:50:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-03 18:50:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-03 18:50:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-03 18:50:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-03 18:51:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-03 18:51:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-03 18:51:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-03 18:51:12  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-03 18:51:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-03 18:51:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-03 18:51:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-03 18:51:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-03 18:51:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-03 18:51:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-03 18:51:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-03 18:51:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-03 18:51:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-03 18:51:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-03 18:51:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-03 18:51:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-03 18:51:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-03 18:52:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-03 18:52:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-03 18:52:11  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-03 18:52:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-03 18:52:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-03 18:52:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-03 18:52:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-03 18:52:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-03 18:52:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-03 18:52:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-03 18:52:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-03 18:52:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-03 18:52:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-03 18:52:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-03 18:52:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-03 18:52:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-03 18:53:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-03 18:53:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-03 18:53:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-03 18:53:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-03 18:53:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-03 18:53:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-03 18:53:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-03 18:53:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-03 18:53:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-03 18:53:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-03 18:53:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-03 18:53:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-03 18:53:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-03 18:53:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-03 18:53:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-03 18:53:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-03 18:54:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-03 18:54:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-03 18:54:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-03 18:54:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-03 18:54:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-03 18:54:22  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-03 18:54:26  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-03 18:54:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-03 18:54:35  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-03 18:54:36  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-03 18:54:40  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-03 18:54:45  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-03 18:54:49  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-03 18:54:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-03 18:54:58  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-03 18:55:03  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-03 18:55:07  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-03 18:55:12  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-03 18:55:16  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-03 18:55:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-03 18:55:25  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-03 18:55:29  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-03 18:55:34  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-03 18:55:38  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-03 18:55:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-03 18:55:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-03 18:55:52  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-03 18:55:56  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-03 18:56:00  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-03 18:56:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-03 18:56:09  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-03 18:56:14  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-03 18:56:18  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-03 18:56:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-03 18:56:27  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-03 18:56:31  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-03 18:56:36  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-03 18:56:40  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-03 18:56:45  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-03 18:56:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-03 18:56:54  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-03 18:56:58  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-03 18:57:02  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-03 18:57:07  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-03 18:57:11  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-03 18:57:16  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-03 18:57:20  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-03 18:57:25  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-03 18:57:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-03 18:57:34  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-03 18:57:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-03 18:57:43  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-03 18:57:47  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-03 18:57:52  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-03 18:57:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-03 18:58:00  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-03 18:58:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-03 18:58:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-03 18:58:14  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-03 18:58:18  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-03 18:58:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-03 18:58:28  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-03 18:58:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-03 18:58:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-03 18:58:41  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-03 18:58:45  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-03 18:58:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-03 18:58:54  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-03 18:58:59  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-03 18:59:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-03 18:59:08  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-03 18:59:13  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-03 18:59:17  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-03 18:59:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-03 18:59:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-03 18:59:30  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-03 18:59:35  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-03 18:59:39  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-03 18:59:43  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-03 18:59:48  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-03 18:59:52  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-03 18:59:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-03 19:00:01  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-03 19:00:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-03 19:00:10  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-03 19:00:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-03 19:00:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-03 19:00:24  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-03 19:00:28  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-03 19:00:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-03 19:00:37  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-03 19:00:42  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-03 19:00:46  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-03 19:00:51  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-03 19:00:55  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-03 19:00:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-03 19:01:07  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-03 19:01:12  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-03 19:01:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-03 19:01:21  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-03 19:01:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-03 19:01:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-03 19:01:34  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-03 19:01:39  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-03 19:01:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-03 19:01:47  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-03_19-01-50 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients?_prerender {"code":"ECONNRESET"}
2017-04-03 19:03:52  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-03 19:03:57  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-03 19:04:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-03 19:04:07  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-03 19:04:11  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-03 19:04:16  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-03 19:04:21  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-03 19:04:25  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-03 19:04:30  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-03 19:04:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-03 19:04:39  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-03 19:04:44  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-03 19:04:48  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-03 19:04:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-03 19:04:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-03 19:05:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-03 19:05:07  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-03 19:05:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-03 19:05:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-03 19:05:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-03 19:05:26  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-03 19:05:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-03 19:05:35  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-03 19:05:39  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-03 19:05:44  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-03 19:05:48  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-03 19:05:52  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-03 19:05:57  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-03 19:06:01  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-03 19:06:06  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-03 19:06:11  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-03 19:06:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-03 19:06:20  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-03 19:06:25  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-03 19:06:30  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-03 19:06:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-03 19:06:39  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-03 19:06:43  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-03 19:06:48  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-03 19:06:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-03 19:06:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-03 19:07:02  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-03 19:07:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-03 19:07:11  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-03 19:07:16  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-03 19:07:20  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-03 19:07:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-03 19:07:29  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-03 19:07:34  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-03 19:07:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-03 19:07:42  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-03 19:07:47  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-03 19:07:51  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-03 19:07:55  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-03 19:08:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-03 19:08:05  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-03 19:08:09  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-03 19:08:13  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-03 19:08:18  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-03 19:08:22  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-03 19:08:27  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-03 19:08:31  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-03 19:08:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-03 19:08:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-03 19:08:44  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-03 19:08:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-03 19:08:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-03 19:08:56  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-03 19:09:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-03 19:09:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-03 19:09:09  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-03 19:09:14  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-03 19:09:18  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-03 19:09:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-03 19:09:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-03 19:09:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-03 19:09:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-03 19:09:39  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-03 19:09:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-03 19:09:48  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-03 19:09:53  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-03 19:09:57  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-03 19:10:02  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-03 19:10:06  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-03 19:10:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-03 19:10:15  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-03 19:10:19  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-03 19:10:23  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-03 19:10:28  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-03 19:10:32  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-03 19:10:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-03 19:10:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-03 19:10:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-03 19:10:50  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-03 19:10:50  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-03 19:10:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-03 19:10:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-03 19:11:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-03 19:11:07  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-03 19:11:12  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-03 19:11:17  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-03 19:11:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-03 19:11:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-03 19:11:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-03 19:11:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-03 19:11:38  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-03 19:11:42  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-03 19:11:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-03 19:11:51  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-03 19:11:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-03 19:12:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-03 19:12:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-03 19:12:10  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-03 19:12:14  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-03 19:12:19  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-03 19:12:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-03 19:12:27  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-03 19:12:31  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-03 19:12:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-03 19:12:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-03 19:12:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-03 19:12:49  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-03 19:12:53  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-03 19:12:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-03 19:13:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-03 19:13:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-03 19:13:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-03 19:13:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-03 19:13:19  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-03 19:13:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-03 19:13:27  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-03 19:13:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-03 19:13:34  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-03 19:13:38  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-03 19:13:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-03 19:13:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-03 19:13:52  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-03 19:13:56  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-03 19:14:00  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-03 19:14:04  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-03 19:14:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-03 19:14:13  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-03 19:14:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-03 19:14:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-03 19:14:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-03 19:14:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-03 19:14:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-03 19:14:40  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-03 19:14:44  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-03 19:14:48  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-03 19:14:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-03 19:14:57  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-03 19:15:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-03 19:15:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-03 19:15:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-03 19:15:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 19:15:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 19:15:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 19:15:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 19:15:31  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-03 19:15:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 19:15:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 19:15:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-03 19:15:47  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-03 19:15:52  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-03 19:15:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-03 19:16:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-03 19:16:05  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-03 19:16:09  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-03 19:16:13  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-03 19:16:17  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-03 19:16:21  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-03 19:16:25  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-03 19:16:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-03 19:16:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-03 19:16:38  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-03 19:16:42  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-03 19:16:47  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-03 19:16:51  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-03 19:16:55  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-03 19:16:59  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-03 19:17:03  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-03 19:17:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 19:17:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 19:17:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 19:17:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 19:17:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 19:17:27  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-03 19:17:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 19:17:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 19:17:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 19:17:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 19:17:48  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-03 19:17:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 19:17:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 19:18:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 19:18:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-03 19:18:08  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-03_19-31-50 Restart Xvfb...
2017-04-03_20-01-50 Restart Xvfb...
2017-04-03_20-31-50 Restart Xvfb...
2017-04-03_21-01-50 Restart Xvfb...
2017-04-03 21:31:46 reset updateRequest
2017-04-03 21:31:49  - 14968  http://www.lymphomahub.com/
2017-04-03_21-31-50 Restart Xvfb...
2017-04-03 21:31:51  - 14968  http://www.lymphomahub.com/
2017-04-03 21:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-03 21:32:01  - 14968  http://www.lymphomahub.com/terms
2017-04-03 21:32:04  - 14968  http://www.lymphomahub.com/undefined
2017-04-03 21:32:05  - 14968  http://www.lymphomahub.com/therapies
2017-04-03 21:32:11  - 14968  http://www.lymphomahub.com/newsletter
2017-04-03 21:32:14  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-03 21:32:17  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-03 21:32:22  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-03 21:32:26  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-03 21:32:30  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-03 21:32:34  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-03 21:32:39  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-03 21:32:44  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-03 21:32:49  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-03 21:32:53  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-03 21:32:58  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-03 21:33:02  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-03 21:33:07  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-03 21:33:11  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-03 21:33:15  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-03 21:33:20  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-03 21:33:24  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-03 21:33:29  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-03 21:33:33  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-03 21:33:38  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-03 21:33:42  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-03 21:33:47  - 14968  http://www.lymphomahub.com/about/secretariat
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-03 21:33:50  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-03 21:33:54  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-03 21:33:55  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-03 21:33:59  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-03 21:34:00  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-03 21:34:05  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-03 21:34:09  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-03 21:34:14  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-03 21:34:19  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-03 21:34:23  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-03 21:34:27  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-03 21:34:32  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-03 21:34:36  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-03 21:34:40  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-03 21:34:45  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-03 21:34:49  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-03 21:34:54  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-03 21:34:58  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-03 21:35:03  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-03 21:35:07  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-03 21:35:12  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-03 21:35:16  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-03 21:35:20  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-03 21:35:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-03 21:35:29  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-03 21:35:33  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-03 21:35:38  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-03 21:35:42  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-03 21:35:46  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-03 21:35:50  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-03 21:35:55  - 14968  http://www.lymphomahub.com/medical-information
2017-04-03 21:35:59  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-03 21:36:04  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-03 21:36:08  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-03 21:36:12  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-03 21:36:17  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-03 21:36:21  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-03 21:36:25  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-03 21:36:30  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-03 21:36:34  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-03 21:36:39  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-03 21:36:43  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-03 21:36:47  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-03 21:36:48  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-03 21:36:52  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-03 21:36:56  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-03 21:37:01  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-03 21:37:05  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-03 21:37:09  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-03 21:37:14  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-03 21:37:18  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-03 21:37:22  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-03 21:37:27  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-03 21:37:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-03 21:37:36  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-03 21:37:40  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-03 21:37:44  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-03 21:37:48  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-03 21:37:53  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-03 21:37:57  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-03 21:38:01  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-03 21:38:06  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-03 21:38:10  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-03 21:38:15  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-03 21:38:19  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-03 21:38:23  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-03 21:38:28  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-03 21:38:32  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-03 21:38:37  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-03 21:38:41  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-03 21:38:45  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-03 21:38:49  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-03 21:38:54  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-03 21:38:58  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-03 21:38:59  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-03 21:39:03  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-03 21:39:08  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-03 21:39:12  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-03 21:39:16  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-03 21:39:20  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-03 21:39:25  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-03 21:39:29  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-03 21:39:34  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-03 21:39:37  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-03 21:39:38  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-03 21:39:42  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-03 21:39:46  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-03 21:39:50  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-03 21:39:55  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-03 21:39:59  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-03 21:39:59  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-03 21:40:04  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-03 21:40:09  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-03 21:40:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-03 21:40:16  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-03 21:40:21  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-03 21:40:25  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-03 21:40:29  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-03 21:40:33  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-03 21:40:36  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-03 21:40:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-03 21:40:45  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-03 21:40:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-03 21:40:54  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-03 21:40:57  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-03 21:40:58  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-03 21:41:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-03 21:41:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-03 21:41:11  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-03 21:41:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-03 21:41:19  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-03 21:41:24  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-03 21:41:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-03 21:41:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-03 21:41:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-03 21:41:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-03 21:41:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-03 21:41:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-03 21:41:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-03 21:41:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-03 21:41:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-03 21:42:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-03 21:42:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-03 21:42:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-03 21:42:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-03 21:42:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-03 21:42:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-03 21:42:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-03 21:42:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-03 21:42:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-03 21:42:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-03 21:42:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-03 21:42:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-03 21:42:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-03 21:42:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-03 21:43:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-03 21:43:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-03 21:43:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-03 21:43:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-03 21:43:20  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-03 21:43:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-03 21:43:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-03 21:43:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-03 21:43:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-03 21:43:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-03 21:43:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-03 21:43:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-03 21:43:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-03 21:43:59  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-03 21:44:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-03 21:44:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-03 21:44:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-03 21:44:15  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-03 21:44:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-03 21:44:24  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-03 21:44:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-03 21:44:31  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-03 21:44:36  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-03 21:44:40  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-03 21:44:44  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-03 21:44:49  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-03 21:44:52  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-03 21:44:57  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-03 21:45:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-03 21:45:05  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-03 21:45:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-03 21:45:12  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-03 21:45:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-03 21:45:21  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-03 21:45:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-03 21:45:29  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-03 21:45:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-03 21:45:38  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-03 21:45:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-03 21:45:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-03 21:45:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-03 21:45:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-03 21:46:00  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-03 21:46:00  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-03 21:46:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-03 21:46:09  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-03 21:46:14  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-03 21:46:18  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-03 21:46:23  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-03 21:46:27  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 21:46:32  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 21:46:36  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-03 21:46:40  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 21:46:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-03 21:46:49  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-03 21:46:54  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-03 21:46:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-03 21:47:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-03 21:47:07  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-03 21:47:12  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-03 21:47:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-03 21:47:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-03 21:47:25  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-03 21:47:30  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-03 21:47:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-03 21:47:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-03 21:47:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-03 21:47:49  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-03 21:47:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-03 21:47:57  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-03 21:48:02  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-03 21:48:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-03 21:48:11  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-03 21:48:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-03 21:48:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-03 21:48:25  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-03 21:48:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-03 21:48:34  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-03 21:48:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-03 21:48:43  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-03 21:48:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-03 21:48:52  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-03 21:48:57  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-03 21:49:01  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-03 21:49:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-03 21:49:06  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-03 21:49:11  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-03 21:49:16  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-03 21:49:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-03 21:49:25  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-03 21:49:29  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-03 21:49:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-03 21:49:38  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-03 21:49:43  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-03 21:49:47  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-03 21:49:52  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-03 21:49:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-03 21:50:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-03 21:50:06  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-03 21:50:11  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-03 21:50:15  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-03 21:50:20  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-03 21:50:24  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-03 21:50:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-03 21:50:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-03 21:50:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-03 21:50:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-03 21:50:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-03 21:50:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-03 21:50:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-03 21:50:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-03 21:51:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-03 21:51:06  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-03 21:51:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-03 21:51:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-03 21:51:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-03 21:51:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-03 21:51:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-03 21:51:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-03 21:51:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-03 21:51:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-03 21:51:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-03 21:51:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-03 21:51:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-03 21:51:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-03 21:51:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-03 21:51:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-03 21:51:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-03 21:52:02  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-03 21:52:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-03 21:52:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-03 21:52:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-03 21:52:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-03 21:52:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-03 21:52:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-03 21:52:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-03 21:52:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-03 21:52:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-03 21:52:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-03 21:52:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-03 21:52:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-03 21:52:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-03 21:52:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-03 21:52:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-03 21:53:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-03 21:53:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-03 21:53:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-03 21:53:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-03 21:53:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-03 21:53:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-03 21:53:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-03 21:53:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-03 21:53:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-03 21:53:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-03 21:53:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-03 21:53:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-03 21:53:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-03 21:53:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-03 21:53:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-03 21:53:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-03 21:54:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-03 21:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-03 21:54:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-03 21:54:12  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-03 21:54:17  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-03 21:54:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-03 21:54:26  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-03 21:54:26  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-03 21:54:31  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-03 21:54:35  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-03 21:54:40  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-03 21:54:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-03 21:54:49  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-03 21:54:54  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-03 21:54:58  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-03 21:55:03  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-03 21:55:08  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-03 21:55:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-03 21:55:16  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-03 21:55:21  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-03 21:55:25  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-03 21:55:30  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-03 21:55:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-03 21:55:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-03 21:55:43  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-03 21:55:47  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-03 21:55:52  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-03 21:55:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-03 21:56:01  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-03 21:56:05  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-03 21:56:10  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-03 21:56:15  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-03 21:56:19  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-03 21:56:24  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-03 21:56:28  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-03 21:56:33  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-03 21:56:37  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-03 21:56:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-03 21:56:46  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-03 21:56:50  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-03 21:56:55  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-03 21:56:59  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-03 21:57:03  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-03 21:57:08  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-03 21:57:12  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-03 21:57:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-03 21:57:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-03 21:57:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-03 21:57:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-03 21:57:34  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-03 21:57:39  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-03 21:57:43  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-03 21:57:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-03 21:57:52  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-03 21:57:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-03 21:58:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-03 21:58:05  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-03 21:58:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-03 21:58:14  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-03 21:58:19  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-03 21:58:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-03 21:58:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-03 21:58:33  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-03 21:58:37  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-03 21:58:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-03 21:58:46  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-03 21:58:51  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-03 21:58:55  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-03 21:58:59  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-03 21:59:04  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-03 21:59:09  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-03 21:59:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-03 21:59:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-03 21:59:22  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-03 21:59:27  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-03 21:59:31  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-03 21:59:35  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-03 21:59:40  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-03 21:59:44  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-03 21:59:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-03 21:59:53  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-03 21:59:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-03 22:00:02  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-03 22:00:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-03 22:00:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-03 22:00:16  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-03 22:00:20  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-03 22:00:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-03 22:00:30  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-03 22:00:34  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-03 22:00:39  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-03 22:00:43  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-03 22:00:47  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-03 22:00:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-03 22:00:56  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-03 22:01:00  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-03 22:01:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-03 22:01:09  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-03 22:01:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-03 22:01:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-03 22:01:23  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-03 22:01:27  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-03 22:01:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-03 22:01:36  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-03 22:01:41  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-03 22:01:45  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-03 22:01:50  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-03_22-01-50 Restart Xvfb...
2017-04-03 22:01:54  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-03 22:01:59  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-03 22:02:03  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-03 22:02:08  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-03 22:02:13  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-03 22:02:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-03 22:02:22  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-03 22:02:26  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-03 22:02:31  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-03 22:02:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-03 22:02:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-03 22:02:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-03 22:02:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-03 22:02:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-03 22:02:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-03 22:03:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-03 22:03:08  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-03 22:03:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-03 22:03:17  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-03 22:03:22  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-03 22:03:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-03 22:03:30  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-03 22:03:34  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-03 22:03:39  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-03 22:03:43  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-03 22:03:48  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-03 22:03:52  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-03 22:03:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-03 22:04:01  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-03 22:04:06  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-03 22:04:11  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-03 22:04:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-03 22:04:20  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-03 22:04:24  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-03 22:04:29  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-03 22:04:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-03 22:04:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-03 22:04:42  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-03 22:04:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-03 22:04:51  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-03 22:04:56  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-03 22:05:00  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-03 22:05:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-03 22:05:09  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-03 22:05:14  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-03 22:05:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-03 22:05:23  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-03 22:05:27  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-03 22:05:31  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-03 22:05:36  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-03 22:05:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-03 22:05:45  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-03 22:05:49  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-03 22:05:54  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-03 22:05:58  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-03 22:06:02  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-03 22:06:07  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-03 22:06:11  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-03 22:06:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-03 22:06:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-03 22:06:24  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-03 22:06:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-03 22:06:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-03 22:06:36  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-03 22:06:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-03 22:06:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-03 22:06:50  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-03 22:06:54  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-03 22:06:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-03 22:07:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-03 22:07:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-03 22:07:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-03 22:07:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-03 22:07:20  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-03 22:07:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-03 22:07:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-03 22:07:33  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-03 22:07:37  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-03 22:07:41  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-03 22:07:46  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-03 22:07:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-03 22:07:55  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-03 22:07:58  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-03 22:08:03  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-03 22:08:08  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-03 22:08:12  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-03 22:08:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-03 22:08:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-03 22:08:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-03 22:08:30  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-03 22:08:31  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-03 22:08:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-03 22:08:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-03 22:08:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-03 22:08:48  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-03 22:08:52  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-03 22:08:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-03 22:09:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-03 22:09:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-03 22:09:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-03 22:09:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-03 22:09:19  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-03 22:09:23  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-03 22:09:27  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-03 22:09:32  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-03 22:09:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-03 22:09:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-03 22:09:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-03 22:09:49  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-03 22:09:54  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-03 22:09:59  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-03 22:10:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-03 22:10:08  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-03 22:10:12  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-03 22:10:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-03 22:10:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-03 22:10:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-03 22:10:30  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-03 22:10:34  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-03 22:10:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-03 22:10:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-03 22:10:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-03 22:10:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-03 22:10:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-03 22:10:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-03 22:11:02  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-03 22:11:06  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-03 22:11:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-03 22:11:14  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-03 22:11:18  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-03 22:11:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-03 22:11:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-03 22:11:31  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-03 22:11:35  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-03 22:11:39  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-03 22:11:43  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-03 22:11:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-03 22:11:51  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-03 22:11:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-03 22:12:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-03 22:12:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-03 22:12:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-03 22:12:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-03 22:12:17  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-03 22:12:21  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-03 22:12:25  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-03 22:12:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-03 22:12:34  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-03 22:12:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-03 22:12:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-03 22:12:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-03 22:12:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 22:12:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 22:12:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 22:13:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 22:13:05  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-03 22:13:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 22:13:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-03 22:13:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-03 22:13:21  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-03 22:13:25  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-03 22:13:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-03 22:13:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-03 22:13:38  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-03 22:13:42  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-03 22:13:46  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-03 22:13:50  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-03 22:13:54  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-03 22:13:58  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-03 22:14:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-03 22:14:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-03 22:14:10  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-03 22:14:14  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-03 22:14:18  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-03 22:14:22  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-03 22:14:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-03 22:14:30  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-03 22:14:34  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-03 22:14:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 22:14:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 22:14:46  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 22:14:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 22:14:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-03 22:14:58  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-03 22:15:02  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 22:15:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 22:15:10  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 22:15:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 22:15:18  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-03 22:15:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 22:15:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 22:15:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-03 22:15:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-03 22:15:37  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-03_22-31-50 Restart Xvfb...
2017-04-03_23-01-50 Restart Xvfb...
2017-04-03_23-31-50 Restart Xvfb...
2017-04-04_00-01-50 Restart Xvfb...
2017-04-04 00:31:46 reset updateRequest
2017-04-04 00:31:49  - 14968  http://www.lymphomahub.com/
2017-04-04_00-31-50 Restart Xvfb...
2017-04-04 00:31:51  - 14968  http://www.lymphomahub.com/
2017-04-04 00:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-04 00:32:00  - 14968  http://www.lymphomahub.com/terms
2017-04-04 00:32:03  - 14968  http://www.lymphomahub.com/undefined
2017-04-04 00:32:04  - 14968  http://www.lymphomahub.com/therapies
2017-04-04 00:32:09  - 14968  http://www.lymphomahub.com/newsletter
2017-04-04 00:32:13  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-04 00:32:16  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-04 00:32:20  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-04 00:32:24  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-04 00:32:29  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-04 00:32:34  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-04 00:32:38  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-04 00:32:42  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-04 00:32:46  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-04 00:32:51  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-04 00:32:55  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-04 00:33:00  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-04 00:33:04  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-04 00:33:08  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-04 00:33:12  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-04 00:33:17  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-04 00:33:21  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-04 00:33:26  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-04 00:33:30  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-04 00:33:35  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-04 00:33:39  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-04 00:33:43  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-04 00:33:47  - 14968  http://www.lymphomahub.com/therapies/alt-803
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-04 00:33:51  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-04 00:33:54  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-04 00:33:56  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-04 00:33:58  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-04 00:34:01  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-04 00:34:02  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-04 00:34:05  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-04 00:34:07  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-04 00:34:10  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-04 00:34:11  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-04 00:34:15  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-04 00:34:16  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-04 00:34:21  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-04 00:34:21  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-04 00:34:26  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-04 00:34:30  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-04 00:34:35  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-04 00:34:39  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-04 00:34:44  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-04 00:34:48  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-04 00:34:52  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-04 00:34:58  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-04 00:35:02  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-04 00:35:06  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-04 00:35:11  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-04 00:35:15  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-04 00:35:19  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-04 00:35:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-04 00:35:28  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-04 00:35:32  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-04 00:35:37  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-04 00:35:41  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-04 00:35:45  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-04 00:35:50  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-04 00:35:54  - 14968  http://www.lymphomahub.com/medical-information
2017-04-04 00:35:58  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-04 00:36:03  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-04 00:36:07  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-04 00:36:11  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-04 00:36:16  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-04 00:36:20  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-04 00:36:24  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-04 00:36:29  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-04 00:36:33  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-04 00:36:37  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-04 00:36:41  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-04 00:36:46  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-04 00:36:46  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-04 00:36:51  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-04 00:36:55  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-04 00:37:00  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-04 00:37:04  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-04 00:37:08  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-04 00:37:12  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-04 00:37:17  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-04 00:37:21  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-04 00:37:25  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-04 00:37:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-04 00:37:34  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-04 00:37:38  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-04 00:37:42  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-04 00:37:47  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-04 00:37:51  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-04 00:37:56  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-04 00:38:00  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-04 00:38:04  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-04 00:38:09  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-04 00:38:13  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-04 00:38:18  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-04 00:38:22  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-04 00:38:26  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-04 00:38:31  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-04 00:38:35  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-04 00:38:39  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-04 00:38:44  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-04 00:38:48  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-04 00:38:52  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-04 00:38:57  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-04 00:38:57  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-04 00:39:01  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-04 00:39:06  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-04 00:39:10  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-04 00:39:15  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-04 00:39:19  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-04 00:39:23  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-04 00:39:28  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-04 00:39:32  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-04 00:39:36  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-04 00:39:36  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-04 00:39:40  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-04 00:39:45  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-04 00:39:49  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-04 00:39:53  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-04 00:39:58  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-04 00:39:58  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-04 00:40:03  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-04 00:40:07  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-04 00:40:11  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-04 00:40:15  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-04 00:40:19  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-04 00:40:23  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-04 00:40:27  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-04 00:40:30  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-04 00:40:34  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-04 00:40:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-04 00:40:42  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-04 00:40:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-04 00:40:51  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-04 00:40:55  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-04 00:40:55  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-04 00:40:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-04 00:41:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-04 00:41:08  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-04 00:41:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-04 00:41:16  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-04 00:41:21  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-04 00:41:25  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-04 00:41:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-04 00:41:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-04 00:41:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-04 00:41:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-04 00:41:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-04 00:41:47  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-04 00:41:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-04 00:41:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-04 00:41:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-04 00:42:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-04 00:42:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-04 00:42:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-04 00:42:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-04 00:42:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-04 00:42:25  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-04 00:42:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-04 00:42:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-04 00:42:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-04 00:42:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-04 00:42:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-04 00:42:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-04 00:42:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-04 00:43:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-04 00:43:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-04 00:43:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-04 00:43:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-04 00:43:18  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-04 00:43:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-04 00:43:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-04 00:43:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-04 00:43:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-04 00:43:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-04 00:43:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-04 00:43:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-04 00:43:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-04 00:43:57  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-04 00:44:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-04 00:44:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-04 00:44:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-04 00:44:13  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-04 00:44:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-04 00:44:21  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-04 00:44:25  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-04 00:44:28  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-04 00:44:33  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-04 00:44:37  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-04 00:44:41  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-04 00:44:45  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-04 00:44:49  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-04 00:44:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-04 00:44:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-04 00:45:02  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-04 00:45:06  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-04 00:45:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-04 00:45:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-04 00:45:18  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-04 00:45:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-04 00:45:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-04 00:45:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-04 00:45:34  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-04 00:45:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-04 00:45:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-04 00:45:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-04 00:45:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-04 00:45:57  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-04 00:45:57  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-04 00:46:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-04 00:46:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-04 00:46:11  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-04 00:46:15  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-04 00:46:20  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-04 00:46:24  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 00:46:29  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 00:46:33  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-04 00:46:38  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 00:46:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-04 00:46:47  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-04 00:46:51  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-04 00:46:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-04 00:47:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-04 00:47:05  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-04 00:47:09  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-04 00:47:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-04 00:47:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-04 00:47:23  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-04 00:47:28  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 00:47:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-04 00:47:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-04 00:47:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-04 00:47:46  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-04 00:47:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-04 00:47:55  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-04 00:47:59  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-04 00:48:04  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-04 00:48:08  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-04 00:48:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-04 00:48:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-04 00:48:22  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-04 00:48:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-04 00:48:30  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-04 00:48:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-04 00:48:39  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-04 00:48:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-04 00:48:48  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-04 00:48:53  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-04 00:48:58  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-04 00:48:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-04 00:49:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-04 00:49:07  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-04 00:49:12  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-04 00:49:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-04 00:49:21  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-04 00:49:25  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-04 00:49:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-04 00:49:34  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-04 00:49:38  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-04 00:49:43  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-04 00:49:47  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-04 00:49:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-04 00:49:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-04 00:50:01  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-04 00:50:05  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-04 00:50:10  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-04 00:50:14  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-04 00:50:19  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-04 00:50:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-04 00:50:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-04 00:50:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-04 00:50:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-04 00:50:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-04 00:50:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-04 00:50:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-04 00:50:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-04 00:50:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-04 00:51:01  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-04 00:51:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-04 00:51:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-04 00:51:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-04 00:51:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-04 00:51:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-04 00:51:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-04 00:51:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-04 00:51:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-04 00:51:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-04 00:51:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-04 00:51:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-04 00:51:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-04 00:51:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-04 00:51:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-04 00:51:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-04 00:51:58  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-04 00:52:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-04 00:52:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-04 00:52:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-04 00:52:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-04 00:52:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-04 00:52:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-04 00:52:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-04 00:52:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-04 00:52:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-04 00:52:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-04 00:52:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-04 00:52:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-04 00:52:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-04 00:52:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-04 00:52:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-04 00:52:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-04 00:53:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-04 00:53:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-04 00:53:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-04 00:53:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-04 00:53:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-04 00:53:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-04 00:53:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-04 00:53:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-04 00:53:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-04 00:53:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-04 00:53:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-04 00:53:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-04 00:53:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-04 00:53:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-04 00:53:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-04 00:53:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-04 00:53:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-04 00:54:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-04 00:54:07  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-04 00:54:11  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-04 00:54:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-04 00:54:20  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-04 00:54:21  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-04 00:54:26  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-04 00:54:30  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-04 00:54:34  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-04 00:54:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-04 00:54:44  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-04 00:54:48  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-04 00:54:53  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-04 00:54:57  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-04 00:55:01  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-04 00:55:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-04 00:55:10  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-04 00:55:15  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-04 00:55:19  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-04 00:55:24  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-04 00:55:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-04 00:55:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-04 00:55:37  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-04 00:55:41  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-04 00:55:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-04 00:55:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-04 00:55:55  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-04 00:55:59  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-04 00:56:04  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-04 00:56:08  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-04 00:56:13  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-04 00:56:17  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-04 00:56:21  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-04 00:56:26  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-04 00:56:30  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-04 00:56:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-04 00:56:39  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-04 00:56:44  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-04 00:56:48  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-04 00:56:53  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-04 00:56:57  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-04 00:57:01  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-04 00:57:06  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-04 00:57:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-04 00:57:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-04 00:57:19  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-04 00:57:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-04 00:57:28  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-04 00:57:33  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-04 00:57:37  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-04 00:57:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-04 00:57:46  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-04 00:57:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-04 00:57:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-04 00:57:59  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-04 00:58:03  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-04 00:58:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-04 00:58:12  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-04 00:58:16  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-04 00:58:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-04 00:58:25  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-04 00:58:30  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-04 00:58:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-04 00:58:39  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-04 00:58:43  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-04 00:58:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-04 00:58:52  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-04 00:58:56  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-04 00:59:01  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-04 00:59:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-04 00:59:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-04 00:59:15  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-04 00:59:19  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-04 00:59:23  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-04 00:59:28  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-04 00:59:32  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-04 00:59:37  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-04 00:59:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-04 00:59:46  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-04 00:59:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-04 00:59:55  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-04 00:59:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-04 01:00:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-04 01:00:09  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-04 01:00:13  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-04 01:00:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-04 01:00:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-04 01:00:27  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-04 01:00:31  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-04 01:00:36  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-04 01:00:40  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-04 01:00:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-04 01:00:48  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-04 01:00:53  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-04 01:00:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-04 01:01:02  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-04 01:01:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-04 01:01:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-04 01:01:16  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-04 01:01:20  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-04 01:01:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-04 01:01:29  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-04 01:01:33  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-04 01:01:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-04 01:01:42  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-04 01:01:47  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-04_01-01-50 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate?_prerender {"code":"ECONNRESET"}
2017-04-04 01:03:52  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-04 01:03:56  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-04 01:04:00  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-04 01:04:05  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-04 01:04:09  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-04 01:04:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-04 01:04:19  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-04 01:04:23  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-04 01:04:28  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-04 01:04:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-04 01:04:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-04 01:04:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-04 01:04:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-04 01:04:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-04 01:04:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-04 01:04:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-04 01:05:04  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-04 01:05:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-04 01:05:13  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-04 01:05:18  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-04 01:05:22  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-04 01:05:26  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-04 01:05:30  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-04 01:05:35  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-04 01:05:39  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-04 01:05:44  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-04 01:05:48  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-04 01:05:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-04 01:05:57  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-04 01:06:02  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-04 01:06:07  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-04 01:06:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-04 01:06:16  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-04 01:06:20  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-04 01:06:25  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-04 01:06:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-04 01:06:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-04 01:06:38  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-04 01:06:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-04 01:06:47  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-04 01:06:52  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-04 01:06:57  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-04 01:07:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-04 01:07:06  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-04 01:07:10  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-04 01:07:14  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-04 01:07:19  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-04 01:07:23  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-04 01:07:27  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-04 01:07:32  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-04 01:07:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-04 01:07:41  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-04 01:07:45  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-04 01:07:49  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-04 01:07:54  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-04 01:07:58  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-04 01:08:03  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-04 01:08:07  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-04 01:08:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-04 01:08:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-04 01:08:20  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-04 01:08:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-04 01:08:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-04 01:08:32  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-04 01:08:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-04 01:08:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-04 01:08:46  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-04 01:08:50  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-04 01:08:54  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-04 01:08:58  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-04 01:09:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-04 01:09:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-04 01:09:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-04 01:09:16  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-04 01:09:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-04 01:09:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-04 01:09:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-04 01:09:33  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-04 01:09:38  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-04 01:09:42  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-04 01:09:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-04 01:09:51  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-04 01:09:55  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-04 01:09:59  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-04 01:10:04  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-04 01:10:08  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-04 01:10:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-04 01:10:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-04 01:10:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-04 01:10:26  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-04 01:10:27  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-04 01:10:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-04 01:10:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-04 01:10:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-04 01:10:44  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-04 01:10:49  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-04 01:10:53  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-04 01:10:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-04 01:11:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-04 01:11:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-04 01:11:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-04 01:11:15  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-04 01:11:19  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-04 01:11:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-04 01:11:27  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-04 01:11:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-04 01:11:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-04 01:11:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-04 01:11:45  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-04 01:11:49  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-04 01:11:55  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-04 01:11:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-04 01:12:03  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-04 01:12:07  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-04 01:12:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-04 01:12:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-04 01:12:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-04 01:12:25  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-04 01:12:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-04 01:12:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-04 01:12:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-04 01:12:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-04 01:12:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-04 01:12:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-04 01:12:54  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-04 01:12:58  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-04 01:13:02  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-04 01:13:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-04 01:13:10  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-04 01:13:13  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-04 01:13:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-04 01:13:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-04 01:13:26  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-04 01:13:30  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-04 01:13:34  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-04 01:13:38  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-04 01:13:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-04 01:13:47  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-04 01:13:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-04 01:13:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-04 01:14:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-04 01:14:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-04 01:14:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-04 01:14:14  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-04 01:14:18  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-04 01:14:22  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-04 01:14:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-04 01:14:30  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-04 01:14:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-04 01:14:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-04 01:14:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-04 01:14:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 01:14:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 01:14:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 01:14:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 01:15:02  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-04 01:15:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 01:15:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 01:15:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-04 01:15:18  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-04 01:15:22  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-04 01:15:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-04 01:15:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-04 01:15:35  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-04 01:15:39  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-04 01:15:43  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-04 01:15:47  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-04 01:15:51  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-04 01:15:55  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-04 01:15:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-04 01:16:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-04 01:16:07  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-04 01:16:11  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-04 01:16:15  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-04 01:16:19  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-04 01:16:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-04 01:16:27  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-04 01:16:31  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-04 01:16:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 01:16:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 01:16:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 01:16:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 01:16:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 01:16:55  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-04 01:16:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 01:17:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 01:17:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 01:17:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 01:17:15  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-04 01:17:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 01:17:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 01:17:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 01:17:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-04 01:17:35  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-04_01-31-50 Restart Xvfb...
2017-04-04_02-01-50 Restart Xvfb...
2017-04-04_02-31-50 Restart Xvfb...
2017-04-04_03-01-50 Restart Xvfb...
2017-04-04 03:31:46 reset updateRequest
2017-04-04 03:31:46  - 14968  http://www.lymphomahub.com/
2017-04-04_03-31-50 Restart Xvfb...
2017-04-04 03:31:51  - 14968  http://www.lymphomahub.com/
2017-04-04 03:31:54  - 14968  http://www.lymphomahub.com/about
2017-04-04 03:31:59  - 14968  http://www.lymphomahub.com/terms
2017-04-04 03:32:03  - 14968  http://www.lymphomahub.com/undefined
2017-04-04 03:32:03  - 14968  http://www.lymphomahub.com/therapies
2017-04-04 03:32:09  - 14968  http://www.lymphomahub.com/newsletter
2017-04-04 03:32:12  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-04 03:32:16  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-04 03:32:20  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-04 03:32:25  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-04 03:32:29  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-04 03:32:33  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-04 03:32:38  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-04 03:32:43  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-04 03:32:47  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-04 03:32:52  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-04 03:32:56  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-04 03:33:00  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-04 03:33:05  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-04 03:33:09  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-04 03:33:14  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-04 03:33:19  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-04 03:33:23  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-04 03:33:27  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-04 03:33:32  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-04 03:33:36  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-04 03:33:41  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-04 03:33:45  - 14968  http://www.lymphomahub.com/about/secretariat
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-04 03:33:49  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-04 03:33:51  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-04 03:33:54  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-04 03:33:56  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-04 03:33:59  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-04 03:34:00  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-04 03:34:03  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-04 03:34:05  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-04 03:34:08  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-04 03:34:09  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-04 03:34:14  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-04 03:34:15  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-04 03:34:19  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-04 03:34:20  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-04 03:34:25  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-04 03:34:29  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-04 03:34:34  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-04 03:34:38  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-04 03:34:43  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-04 03:34:47  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-04 03:34:52  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-04 03:34:56  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-04 03:35:01  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-04 03:35:05  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-04 03:35:10  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-04 03:35:14  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-04 03:35:19  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-04 03:35:23  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-04 03:35:28  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-04 03:35:32  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-04 03:35:37  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-04 03:35:41  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-04 03:35:46  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-04 03:35:50  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-04 03:35:54  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-04 03:35:59  - 14968  http://www.lymphomahub.com/medical-information
2017-04-04 03:36:03  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-04 03:36:08  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-04 03:36:13  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-04 03:36:17  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-04 03:36:22  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-04 03:36:26  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-04 03:36:31  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-04 03:36:36  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-04 03:36:40  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-04 03:36:44  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-04 03:36:49  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-04 03:36:53  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-04 03:36:54  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-04 03:36:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-04 03:37:03  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-04 03:37:07  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-04 03:37:12  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-04 03:37:16  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-04 03:37:20  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-04 03:37:25  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-04 03:37:29  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-04 03:37:33  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-04 03:37:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-04 03:37:42  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-04 03:37:47  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-04 03:37:51  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-04 03:37:55  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-04 03:38:00  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-04 03:38:04  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-04 03:38:09  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-04 03:38:13  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-04 03:38:17  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-04 03:38:22  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-04 03:38:26  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-04 03:38:31  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-04 03:38:35  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-04 03:38:39  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-04 03:38:44  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-04 03:38:49  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-04 03:38:53  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-04 03:38:58  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-04 03:39:02  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-04 03:39:06  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-04 03:39:07  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-04 03:39:11  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-04 03:39:16  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-04 03:39:20  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-04 03:39:25  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-04 03:39:29  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-04 03:39:34  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-04 03:39:38  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-04 03:39:43  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-04 03:39:46  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-04 03:39:47  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-04 03:39:51  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-04 03:39:56  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-04 03:40:00  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-04 03:40:05  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-04 03:40:09  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-04 03:40:10  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-04 03:40:15  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-04 03:40:19  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-04 03:40:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-04 03:40:27  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-04 03:40:32  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-04 03:40:35  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-04 03:40:39  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-04 03:40:43  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-04 03:40:47  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-04 03:40:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-04 03:40:56  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-04 03:41:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-04 03:41:04  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-04 03:41:08  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-04 03:41:08  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-04 03:41:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-04 03:41:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-04 03:41:22  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-04 03:41:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-04 03:41:30  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-04 03:41:35  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-04 03:41:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-04 03:41:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-04 03:41:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-04 03:41:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-04 03:41:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-04 03:41:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-04 03:42:01  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-04 03:42:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-04 03:42:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-04 03:42:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-04 03:42:19  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-04 03:42:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-04 03:42:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-04 03:42:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-04 03:42:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-04 03:42:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-04 03:42:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-04 03:42:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-04 03:42:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-04 03:42:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-04 03:43:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-04 03:43:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-04 03:43:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-04 03:43:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-04 03:43:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-04 03:43:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-04 03:43:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-04 03:43:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-04 03:43:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-04 03:43:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-04 03:43:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-04 03:43:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-04 03:43:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-04 03:43:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-04 03:44:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-04 03:44:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-04 03:44:11  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-04 03:44:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-04 03:44:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-04 03:44:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-04 03:44:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-04 03:44:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-04 03:44:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-04 03:44:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-04 03:44:45  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-04 03:44:49  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-04 03:44:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-04 03:44:58  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-04 03:45:03  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-04 03:45:07  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-04 03:45:11  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-04 03:45:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-04 03:45:19  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-04 03:45:23  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-04 03:45:27  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-04 03:45:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-04 03:45:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-04 03:45:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-04 03:45:44  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-04 03:45:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-04 03:45:53  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-04 03:45:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-04 03:46:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-04 03:46:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-04 03:46:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-04 03:46:16  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-04 03:46:17  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-04 03:46:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-04 03:46:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-04 03:46:30  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-04 03:46:35  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-04 03:46:39  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-04 03:46:44  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 03:46:48  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 03:46:53  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-04 03:46:57  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 03:47:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-04 03:47:07  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-04 03:47:11  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-04 03:47:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-04 03:47:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-04 03:47:25  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-04 03:47:29  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-04 03:47:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-04 03:47:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-04 03:47:43  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-04 03:47:48  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 03:47:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-04 03:47:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-04 03:48:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-04 03:48:06  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-04 03:48:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-04 03:48:16  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-04 03:48:20  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-04 03:48:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-04 03:48:30  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-04 03:48:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-04 03:48:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-04 03:48:44  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-04 03:48:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-04 03:48:53  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-04 03:48:58  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-04 03:49:02  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-04 03:49:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-04 03:49:12  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-04 03:49:16  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-04 03:49:21  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-04 03:49:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-04 03:49:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-04 03:49:30  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-04 03:49:35  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-04 03:49:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-04 03:49:44  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-04 03:49:48  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-04 03:49:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-04 03:49:57  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-04 03:50:02  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-04 03:50:07  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-04 03:50:11  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-04 03:50:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-04 03:50:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-04 03:50:25  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-04 03:50:30  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-04 03:50:34  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-04 03:50:39  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-04 03:50:44  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-04 03:50:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-04 03:50:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-04 03:50:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-04 03:51:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-04 03:51:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-04 03:51:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-04 03:51:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-04 03:51:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-04 03:51:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-04 03:51:26  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-04 03:51:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-04 03:51:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-04 03:51:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-04 03:51:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-04 03:51:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-04 03:51:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-04 03:51:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-04 03:51:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-04 03:51:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-04 03:52:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-04 03:52:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-04 03:52:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-04 03:52:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-04 03:52:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-04 03:52:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-04 03:52:24  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-04 03:52:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-04 03:52:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-04 03:52:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-04 03:52:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-04 03:52:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-04 03:52:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-04 03:52:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-04 03:52:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-04 03:52:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-04 03:53:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-04 03:53:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-04 03:53:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-04 03:53:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-04 03:53:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-04 03:53:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-04 03:53:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-04 03:53:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-04 03:53:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-04 03:53:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-04 03:53:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-04 03:53:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-04 03:53:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-04 03:53:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-04 03:53:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-04 03:53:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-04 03:54:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-04 03:54:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-04 03:54:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-04 03:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-04 03:54:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-04 03:54:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-04 03:54:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-04 03:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-04 03:54:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-04 03:54:36  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-04 03:54:41  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-04 03:54:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-04 03:54:50  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-04 03:54:51  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-04 03:54:56  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-04 03:55:00  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-04 03:55:05  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-04 03:55:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-04 03:55:14  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-04 03:55:19  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-04 03:55:23  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-04 03:55:28  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-04 03:55:33  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-04 03:55:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-04 03:55:42  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-04 03:55:47  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-04 03:55:51  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-04 03:55:56  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-04 03:56:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-04 03:56:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-04 03:56:10  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-04 03:56:15  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-04 03:56:19  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-04 03:56:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-04 03:56:29  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-04 03:56:33  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-04 03:56:38  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-04 03:56:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-04 03:56:47  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-04 03:56:51  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-04 03:56:56  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-04 03:57:00  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-04 03:57:05  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-04 03:57:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-04 03:57:14  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-04 03:57:18  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-04 03:57:23  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-04 03:57:28  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-04 03:57:32  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-04 03:57:37  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-04 03:57:41  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-04 03:57:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-04 03:57:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-04 03:57:55  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-04 03:58:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-04 03:58:05  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-04 03:58:09  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-04 03:58:14  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-04 03:58:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-04 03:58:23  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-04 03:58:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-04 03:58:32  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-04 03:58:36  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-04 03:58:41  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-04 03:58:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-04 03:58:50  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-04 03:58:54  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-04 03:58:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-04 03:59:04  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-04 03:59:08  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-04 03:59:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-04 03:59:17  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-04 03:59:22  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-04 03:59:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-04 03:59:31  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-04 03:59:36  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-04 03:59:40  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-04 03:59:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-04 03:59:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-04 03:59:55  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-04 03:59:59  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-04 04:00:04  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-04 04:00:09  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-04 04:00:13  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-04 04:00:18  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-04 04:00:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-04 04:00:27  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-04 04:00:32  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-04 04:00:40  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-04 04:00:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-04 04:00:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-04 04:00:54  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-04 04:00:59  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-04 04:01:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-04 04:01:08  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-04 04:01:12  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-04 04:01:17  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-04 04:01:21  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-04 04:01:25  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-04 04:01:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-04 04:01:35  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-04 04:01:39  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-04 04:01:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-04 04:01:48  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-04_04-01-50 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet?_prerender {"code":"ECONNRESET"}
2017-04-04 04:03:53  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-04 04:03:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-04 04:04:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-04 04:04:07  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-04 04:04:12  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-04 04:04:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-04 04:04:22  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-04 04:04:26  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-04 04:04:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-04 04:04:36  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-04 04:04:40  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-04 04:04:45  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-04 04:04:50  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-04 04:04:54  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-04 04:04:59  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-04 04:05:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-04 04:05:08  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-04 04:05:14  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-04 04:05:19  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-04 04:05:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-04 04:05:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-04 04:05:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-04 04:05:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-04 04:05:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-04 04:05:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-04 04:05:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-04 04:05:56  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-04 04:06:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-04 04:06:05  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-04 04:06:10  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-04 04:06:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-04 04:06:18  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-04 04:06:23  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-04 04:06:28  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-04 04:06:32  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-04 04:06:37  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-04 04:06:41  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-04 04:06:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-04 04:06:50  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-04 04:06:55  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-04 04:06:59  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-04 04:07:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-04 04:07:09  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-04 04:07:14  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-04 04:07:18  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-04 04:07:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-04 04:07:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-04 04:07:32  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-04 04:07:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-04 04:07:42  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-04 04:07:46  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-04 04:07:51  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-04 04:07:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-04 04:08:00  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-04 04:08:05  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-04 04:08:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-04 04:08:13  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-04 04:08:18  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-04 04:08:22  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-04 04:08:27  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-04 04:08:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-04 04:08:36  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-04 04:08:40  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-04 04:08:45  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-04 04:08:49  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-04 04:08:54  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-04 04:08:58  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-04 04:09:02  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-04 04:09:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-04 04:09:11  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-04 04:09:16  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-04 04:09:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-04 04:09:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-04 04:09:29  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-04 04:09:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-04 04:09:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-04 04:09:43  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-04 04:09:47  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-04 04:09:51  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-04 04:09:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-04 04:10:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-04 04:10:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-04 04:10:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-04 04:10:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-04 04:10:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-04 04:10:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-04 04:10:28  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-04 04:10:32  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-04 04:10:36  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-04 04:10:41  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-04 04:10:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-04 04:10:50  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-04 04:10:54  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-04 04:10:58  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-04 04:11:03  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-04 04:11:07  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-04 04:11:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-04 04:11:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-04 04:11:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-04 04:11:26  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-04 04:11:26  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-04 04:11:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-04 04:11:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-04 04:11:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-04 04:11:45  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-04 04:11:49  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-04 04:11:54  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-04 04:11:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-04 04:12:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-04 04:12:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-04 04:12:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-04 04:12:16  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-04 04:12:20  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-04 04:12:25  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-04 04:12:29  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-04 04:12:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-04 04:12:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-04 04:12:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-04 04:12:47  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-04 04:12:52  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-04 04:12:57  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-04 04:13:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-04 04:13:05  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-04 04:13:09  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-04 04:13:14  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-04 04:13:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-04 04:13:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-04 04:13:28  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-04 04:13:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-04 04:13:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-04 04:13:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-04 04:13:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-04 04:13:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-04 04:13:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-04 04:13:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-04 04:14:02  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-04 04:14:06  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-04 04:14:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-04 04:14:14  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-04 04:14:18  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-04 04:14:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-04 04:14:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-04 04:14:32  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-04 04:14:36  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-04 04:14:40  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-04 04:14:44  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-04 04:14:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-04 04:14:53  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-04 04:14:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-04 04:15:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-04 04:15:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-04 04:15:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-04 04:15:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-04 04:15:20  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-04 04:15:24  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-04 04:15:28  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-04 04:15:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-04 04:15:37  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-04 04:15:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-04 04:15:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-04 04:15:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-04 04:15:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 04:15:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 04:16:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 04:16:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 04:16:10  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-04 04:16:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 04:16:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 04:16:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-04 04:16:26  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-04 04:16:30  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-04 04:16:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-04 04:16:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-04 04:16:43  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-04 04:16:47  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-04 04:16:51  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-04 04:16:55  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-04 04:16:59  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-04 04:17:03  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-04 04:17:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-04 04:17:12  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-04 04:17:16  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-04 04:17:20  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-04 04:17:24  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-04 04:17:28  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-04 04:17:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-04 04:17:36  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-04 04:17:41  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-04 04:17:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 04:17:49  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 04:17:53  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 04:17:57  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 04:18:01  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 04:18:05  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-04 04:18:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 04:18:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 04:18:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 04:18:21  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 04:18:25  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-04 04:18:29  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 04:18:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 04:18:37  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 04:18:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-04 04:18:45  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-04_04-31-50 Restart Xvfb...
2017-04-04_05-01-50 Restart Xvfb...
2017-04-04_05-31-50 Restart Xvfb...
2017-04-04_06-01-50 Restart Xvfb...
2017-04-04 06:31:46 reset updateRequest
2017-04-04 06:31:47  - 14968  http://www.lymphomahub.com/
2017-04-04_06-31-50 Restart Xvfb...
2017-04-04 06:31:51  - 14968  http://www.lymphomahub.com/
2017-04-04 06:31:54  - 14968  http://www.lymphomahub.com/about
2017-04-04 06:32:00  - 14968  http://www.lymphomahub.com/terms
2017-04-04 06:32:03  - 14968  http://www.lymphomahub.com/undefined
2017-04-04 06:32:04  - 14968  http://www.lymphomahub.com/therapies
2017-04-04 06:32:10  - 14968  http://www.lymphomahub.com/newsletter
2017-04-04 06:32:13  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-04 06:32:16  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-04 06:32:20  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-04 06:32:25  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-04 06:32:29  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-04 06:32:34  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-04 06:32:39  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-04 06:32:43  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-04 06:32:48  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-04 06:32:53  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-04 06:32:57  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-04 06:33:01  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-04 06:33:06  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-04 06:33:11  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-04 06:33:15  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-04 06:33:19  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-04 06:33:24  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-04 06:33:29  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-04 06:33:33  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-04 06:33:38  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-04 06:33:42  - 14968  http://www.lymphomahub.com/therapies/kte-c19
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-04 06:33:47  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-04 06:33:50  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-04 06:33:52  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-04 06:33:55  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-04 06:33:56  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-04 06:34:01  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-04 06:34:01  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-04 06:34:06  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-04 06:34:11  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-04 06:34:15  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-04 06:34:20  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-04 06:34:24  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-04 06:34:30  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-04 06:34:34  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-04 06:34:39  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-04 06:34:43  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-04 06:34:48  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-04 06:34:52  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-04 06:34:57  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-04 06:35:01  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-04 06:35:06  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-04 06:35:10  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-04 06:35:15  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-04 06:35:20  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-04 06:35:24  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-04 06:35:28  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-04 06:35:33  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-04 06:35:38  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-04 06:35:42  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-04 06:35:47  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-04 06:35:51  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-04 06:35:56  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-04 06:36:00  - 14968  http://www.lymphomahub.com/medical-information
2017-04-04 06:36:04  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-04 06:36:09  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-04 06:36:14  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-04 06:36:18  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-04 06:36:22  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-04 06:36:27  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-04 06:36:31  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-04 06:36:36  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-04 06:36:40  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-04 06:36:45  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-04 06:36:49  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-04 06:36:54  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-04 06:36:54  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-04 06:36:59  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-04 06:37:03  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-04 06:37:08  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-04 06:37:12  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-04 06:37:16  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-04 06:37:21  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-04 06:37:25  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-04 06:37:30  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-04 06:37:34  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-04 06:37:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-04 06:37:43  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-04 06:37:48  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-04 06:37:52  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-04 06:37:56  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-04 06:38:01  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-04 06:38:05  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-04 06:38:10  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-04 06:38:14  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-04 06:38:18  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-04 06:38:23  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-04 06:38:27  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-04 06:38:32  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-04 06:38:36  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-04 06:38:40  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-04 06:38:45  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-04 06:38:49  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-04 06:38:54  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-04 06:38:58  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-04 06:39:02  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-04 06:39:07  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-04 06:39:08  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-04 06:39:12  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-04 06:39:17  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-04 06:39:22  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-04 06:39:26  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-04 06:39:31  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-04 06:39:35  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-04 06:39:40  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-04 06:39:44  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-04 06:39:48  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-04 06:39:48  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-04 06:39:53  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-04 06:39:57  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-04 06:40:02  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-04 06:40:06  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-04 06:40:11  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-04 06:40:12  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-04 06:40:16  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-04 06:40:21  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-04 06:40:25  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-04 06:40:29  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-04 06:40:33  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-04 06:40:37  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-04 06:40:41  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-04 06:40:45  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-04 06:40:48  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-04 06:40:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-04 06:40:57  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-04 06:41:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-04 06:41:06  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-04 06:41:10  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-04 06:41:10  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-04 06:41:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-04 06:41:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-04 06:41:24  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-04 06:41:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-04 06:41:32  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-04 06:41:37  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-04 06:41:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-04 06:41:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-04 06:41:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-04 06:41:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-04 06:41:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-04 06:42:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-04 06:42:04  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-04 06:42:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-04 06:42:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-04 06:42:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-04 06:42:22  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-04 06:42:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-04 06:42:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-04 06:42:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-04 06:42:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-04 06:42:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-04 06:42:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-04 06:42:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-04 06:42:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-04 06:43:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-04 06:43:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-04 06:43:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-04 06:43:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-04 06:43:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-04 06:43:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-04 06:43:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-04 06:43:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-04 06:43:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-04 06:43:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-04 06:43:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-04 06:43:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-04 06:43:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-04 06:43:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-04 06:44:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-04 06:44:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-04 06:44:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-04 06:44:16  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-04 06:44:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-04 06:44:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-04 06:44:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-04 06:44:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-04 06:44:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-04 06:44:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-04 06:44:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-04 06:44:48  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-04 06:44:53  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-04 06:44:58  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-04 06:45:02  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-04 06:45:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-04 06:45:11  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-04 06:45:16  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-04 06:45:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-04 06:45:24  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-04 06:45:28  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-04 06:45:32  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-04 06:45:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-04 06:45:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-04 06:45:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-04 06:45:49  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-04 06:45:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-04 06:45:58  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-04 06:46:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-04 06:46:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-04 06:46:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-04 06:46:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-04 06:46:21  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-04 06:46:21  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-04 06:46:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-04 06:46:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-04 06:46:35  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-04 06:46:40  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-04 06:46:44  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-04 06:46:49  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 06:46:53  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 06:46:58  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-04 06:47:02  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 06:47:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-04 06:47:11  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-04 06:47:16  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-04 06:47:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-04 06:47:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-04 06:47:30  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-04 06:47:34  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-04 06:47:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-04 06:47:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-04 06:47:48  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-04 06:47:53  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 06:47:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-04 06:48:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-04 06:48:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-04 06:48:12  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-04 06:48:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-04 06:48:21  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-04 06:48:26  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-04 06:48:30  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-04 06:48:35  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-04 06:48:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-04 06:48:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-04 06:48:49  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-04 06:48:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-04 06:48:58  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-04 06:49:03  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-04 06:49:07  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-04 06:49:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-04 06:49:17  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-04 06:49:21  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-04 06:49:26  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-04 06:49:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-04 06:49:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-04 06:49:36  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-04 06:49:40  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-04 06:49:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-04 06:49:49  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-04 06:49:54  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-04 06:49:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-04 06:50:04  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-04 06:50:08  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-04 06:50:13  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-04 06:50:18  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-04 06:50:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-04 06:50:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-04 06:50:32  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-04 06:50:36  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-04 06:50:41  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-04 06:50:45  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-04 06:50:50  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-04 06:50:55  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-04 06:50:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-04 06:51:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-04 06:51:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-04 06:51:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-04 06:51:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-04 06:51:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-04 06:51:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-04 06:51:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-04 06:51:33  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-04 06:51:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-04 06:51:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-04 06:51:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-04 06:51:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-04 06:51:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-04 06:51:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-04 06:51:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-04 06:52:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-04 06:52:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-04 06:52:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-04 06:52:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-04 06:52:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-04 06:52:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-04 06:52:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-04 06:52:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-04 06:52:30  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-04 06:52:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-04 06:52:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-04 06:52:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-04 06:52:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-04 06:52:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-04 06:52:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-04 06:52:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-04 06:53:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-04 06:53:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-04 06:53:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-04 06:53:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-04 06:53:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-04 06:53:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-04 06:53:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-04 06:53:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-04 06:53:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-04 06:53:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-04 06:53:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-04 06:53:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-04 06:53:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-04 06:53:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-04 06:53:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-04 06:53:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-04 06:53:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-04 06:54:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-04 06:54:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-04 06:54:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-04 06:54:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-04 06:54:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-04 06:54:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-04 06:54:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-04 06:54:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-04 06:54:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-04 06:54:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-04 06:54:41  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-04 06:54:46  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-04 06:54:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-04 06:54:55  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-04 06:54:55  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-04 06:55:00  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-04 06:55:04  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-04 06:55:09  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-04 06:55:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-04 06:55:18  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-04 06:55:23  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-04 06:55:28  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-04 06:55:33  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-04 06:55:37  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-04 06:55:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-04 06:55:47  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-04 06:55:51  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-04 06:55:56  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-04 06:56:00  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-04 06:56:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-04 06:56:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-04 06:56:14  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-04 06:56:18  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-04 06:56:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-04 06:56:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-04 06:56:32  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-04 06:56:37  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-04 06:56:41  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-04 06:56:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-04 06:56:51  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-04 06:56:55  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-04 06:57:00  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-04 06:57:04  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-04 06:57:09  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-04 06:57:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-04 06:57:18  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-04 06:57:22  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-04 06:57:27  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-04 06:57:31  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-04 06:57:36  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-04 06:57:40  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-04 06:57:45  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-04 06:57:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-04 06:57:54  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-04 06:57:59  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-04 06:58:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-04 06:58:08  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-04 06:58:13  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-04 06:58:17  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-04 06:58:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-04 06:58:27  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-04 06:58:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-04 06:58:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-04 06:58:40  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-04 06:58:44  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-04 06:58:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-04 06:58:54  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-04 06:58:58  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-04 06:59:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-04 06:59:08  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-04 06:59:13  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-04 06:59:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-04 06:59:22  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-04 06:59:26  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-04 06:59:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-04 06:59:36  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-04 06:59:40  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-04 06:59:45  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-04 06:59:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-04 06:59:55  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-04 06:59:59  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-04 07:00:04  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-04 07:00:09  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-04 07:00:13  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-04 07:00:18  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-04 07:00:26  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-04 07:00:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-04 07:00:35  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-04 07:00:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-04 07:00:44  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-04 07:00:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-04 07:00:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-04 07:01:00  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-04 07:01:04  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-04 07:01:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-04 07:01:13  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-04 07:01:17  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-04 07:01:22  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-04 07:01:27  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-04 07:01:31  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-04 07:01:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-04 07:01:40  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-04 07:01:44  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-04 07:01:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-04_07-01-50 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet?_prerender {"code":"ECONNRESET"}
2017-04-04 07:03:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-04 07:04:03  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-04 07:04:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-04 07:04:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-04 07:04:17  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-04 07:04:22  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-04 07:04:27  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-04 07:04:32  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-04 07:04:36  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-04 07:04:41  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-04 07:04:45  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-04 07:04:50  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-04 07:04:55  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-04 07:04:59  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-04 07:05:04  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-04 07:05:09  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-04 07:05:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-04 07:05:18  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-04 07:05:23  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-04 07:05:28  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-04 07:05:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-04 07:05:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-04 07:05:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-04 07:05:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-04 07:05:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-04 07:05:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-04 07:06:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-04 07:06:05  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-04 07:06:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-04 07:06:14  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-04 07:06:19  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-04 07:06:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-04 07:06:27  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-04 07:06:32  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-04 07:06:37  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-04 07:06:41  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-04 07:06:46  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-04 07:06:50  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-04 07:06:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-04 07:06:59  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-04 07:07:04  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-04 07:07:09  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-04 07:07:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-04 07:07:18  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-04 07:07:23  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-04 07:07:28  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-04 07:07:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-04 07:07:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-04 07:07:41  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-04 07:07:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-04 07:07:51  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-04 07:07:55  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-04 07:08:00  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-04 07:08:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-04 07:08:09  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-04 07:08:13  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-04 07:08:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-04 07:08:22  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-04 07:08:27  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-04 07:08:31  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-04 07:08:35  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-04 07:08:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-04 07:08:45  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-04 07:08:49  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-04 07:08:53  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-04 07:08:58  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-04 07:09:03  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-04 07:09:08  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-04 07:09:12  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-04 07:09:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-04 07:09:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-04 07:09:26  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-04 07:09:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-04 07:09:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-04 07:09:38  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-04 07:09:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-04 07:09:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-04 07:09:52  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-04 07:09:56  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-04 07:10:00  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-04 07:10:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-04 07:10:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-04 07:10:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-04 07:10:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-04 07:10:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-04 07:10:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-04 07:10:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-04 07:10:37  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-04 07:10:41  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-04 07:10:45  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-04 07:10:50  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-04 07:10:54  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-04 07:10:59  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-04 07:11:03  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-04 07:11:07  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-04 07:11:12  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-04 07:11:16  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-04 07:11:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-04 07:11:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-04 07:11:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-04 07:11:35  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-04 07:11:35  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-04 07:11:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-04 07:11:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-04 07:11:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-04 07:11:54  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-04 07:11:58  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-04 07:12:03  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-04 07:12:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-04 07:12:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-04 07:12:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-04 07:12:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-04 07:12:24  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-04 07:12:29  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-04 07:12:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-04 07:12:38  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-04 07:12:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-04 07:12:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-04 07:12:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-04 07:12:55  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-04 07:13:00  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-04 07:13:05  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-04 07:13:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-04 07:13:13  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-04 07:13:17  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-04 07:13:22  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-04 07:13:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-04 07:13:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-04 07:13:36  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-04 07:13:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-04 07:13:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-04 07:13:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-04 07:13:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-04 07:13:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-04 07:14:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-04 07:14:05  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-04 07:14:09  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-04 07:14:13  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-04 07:14:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-04 07:14:21  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-04 07:14:25  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-04 07:14:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-04 07:14:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-04 07:14:38  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-04 07:14:42  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-04 07:14:46  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-04 07:14:50  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-04 07:14:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-04 07:14:59  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-04 07:15:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-04 07:15:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-04 07:15:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-04 07:15:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-04 07:15:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-04 07:15:26  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-04 07:15:30  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-04 07:15:34  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-04 07:15:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-04 07:15:43  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-04 07:15:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-04 07:15:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-04 07:15:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-04 07:16:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 07:16:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 07:16:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 07:16:12  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 07:16:16  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-04 07:16:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 07:16:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 07:16:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-04 07:16:32  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-04 07:16:36  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-04 07:16:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-04 07:16:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-04 07:16:49  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-04 07:16:53  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-04 07:16:57  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-04 07:17:01  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-04 07:17:05  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-04 07:17:09  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-04 07:17:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-04 07:17:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-04 07:17:21  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-04 07:17:25  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-04 07:17:29  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-04 07:17:33  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-04 07:17:37  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-04 07:17:41  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-04 07:17:46  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-04 07:17:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 07:17:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 07:17:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 07:18:02  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 07:18:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 07:18:10  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-04 07:18:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 07:18:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 07:18:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 07:18:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 07:18:31  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-04 07:18:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 07:18:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 07:18:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 07:18:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-04 07:18:52  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-04_07-31-50 Restart Xvfb...
2017-04-04_08-01-50 Restart Xvfb...
2017-04-04_08-31-50 Restart Xvfb...
2017-04-04_09-01-50 Restart Xvfb...
2017-04-04 09:31:46 reset updateRequest
2017-04-04 09:31:48  - 14968  http://www.lymphomahub.com/
2017-04-04_09-31-50 Restart Xvfb...
2017-04-04 09:31:51  - 14968  http://www.lymphomahub.com/
2017-04-04 09:31:54  - 14968  http://www.lymphomahub.com/about
2017-04-04 09:31:59  - 14968  http://www.lymphomahub.com/terms
2017-04-04 09:32:03  - 14968  http://www.lymphomahub.com/undefined
2017-04-04 09:32:04  - 14968  http://www.lymphomahub.com/therapies
2017-04-04 09:32:10  - 14968  http://www.lymphomahub.com/newsletter
2017-04-04 09:32:13  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-04 09:32:17  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-04 09:32:21  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-04 09:32:26  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-04 09:32:30  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-04 09:32:35  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-04 09:32:39  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-04 09:32:44  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-04 09:32:48  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-04 09:32:53  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-04 09:32:57  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-04 09:33:02  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-04 09:33:06  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-04 09:33:10  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-04 09:33:15  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-04 09:33:19  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-04 09:33:24  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-04 09:33:28  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-04 09:33:33  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-04 09:33:37  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-04 09:33:42  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-04 09:33:46  - 14968  http://www.lymphomahub.com/about/secretariat
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-04 09:33:49  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-04 09:33:53  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-04 09:33:54  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-04 09:33:58  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-04 09:34:00  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-04 09:34:02  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-04 09:34:05  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-04 09:34:07  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-04 09:34:10  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-04 09:34:11  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-04 09:34:15  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-04 09:34:16  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-04 09:34:20  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-04 09:34:21  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-04 09:34:25  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-04 09:34:26  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-04 09:34:30  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-04 09:34:31  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-04 09:34:36  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-04 09:34:36  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-04 09:34:41  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-04 09:34:45  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-04 09:34:50  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-04 09:34:54  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-04 09:34:59  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-04 09:35:03  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-04 09:35:08  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-04 09:35:12  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-04 09:35:17  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-04 09:35:21  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-04 09:35:25  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-04 09:35:30  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-04 09:35:34  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-04 09:35:39  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-04 09:35:43  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-04 09:35:48  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-04 09:35:52  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-04 09:35:57  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-04 09:36:01  - 14968  http://www.lymphomahub.com/medical-information
2017-04-04 09:36:06  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-04 09:36:12  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-04 09:36:17  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-04 09:36:21  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-04 09:36:26  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-04 09:36:30  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-04 09:36:35  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-04 09:36:39  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-04 09:36:44  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-04 09:36:48  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-04 09:36:52  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-04 09:36:57  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-04 09:36:57  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-04 09:37:02  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-04 09:37:06  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-04 09:37:11  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-04 09:37:15  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-04 09:37:20  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-04 09:37:24  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-04 09:37:29  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-04 09:37:33  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-04 09:37:38  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-04 09:37:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-04 09:37:47  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-04 09:37:51  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-04 09:37:55  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-04 09:38:00  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-04 09:38:04  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-04 09:38:09  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-04 09:38:14  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-04 09:38:18  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-04 09:38:23  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-04 09:38:27  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-04 09:38:31  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-04 09:38:36  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-04 09:38:40  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-04 09:38:44  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-04 09:38:49  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-04 09:38:53  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-04 09:38:58  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-04 09:39:02  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-04 09:39:07  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-04 09:39:11  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-04 09:39:12  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-04 09:39:16  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-04 09:39:20  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-04 09:39:25  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-04 09:39:30  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-04 09:39:34  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-04 09:39:39  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-04 09:39:43  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-04 09:39:48  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-04 09:39:51  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-04 09:39:52  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-04 09:39:56  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-04 09:40:00  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-04 09:40:05  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-04 09:40:10  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-04 09:40:14  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-04 09:40:15  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-04 09:40:19  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-04 09:40:24  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-04 09:40:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-04 09:40:32  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-04 09:40:37  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-04 09:40:40  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-04 09:40:44  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-04 09:40:48  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-04 09:40:52  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-04 09:40:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-04 09:41:00  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-04 09:41:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-04 09:41:09  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-04 09:41:13  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-04 09:41:13  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-04 09:41:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-04 09:41:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-04 09:41:28  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-04 09:41:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-04 09:41:36  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-04 09:41:41  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-04 09:41:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-04 09:41:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-04 09:41:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-04 09:41:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-04 09:42:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-04 09:42:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-04 09:42:08  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-04 09:42:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-04 09:42:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-04 09:42:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-04 09:42:25  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-04 09:42:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-04 09:42:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-04 09:42:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-04 09:42:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-04 09:42:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-04 09:42:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-04 09:42:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-04 09:42:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-04 09:43:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-04 09:43:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-04 09:43:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-04 09:43:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-04 09:43:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-04 09:43:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-04 09:43:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-04 09:43:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-04 09:43:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-04 09:43:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-04 09:43:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-04 09:43:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-04 09:43:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-04 09:44:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-04 09:44:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-04 09:44:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-04 09:44:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-04 09:44:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-04 09:44:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-04 09:44:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-04 09:44:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-04 09:44:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-04 09:44:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-04 09:44:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-04 09:44:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-04 09:44:53  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-04 09:44:57  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-04 09:45:02  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-04 09:45:06  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-04 09:45:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-04 09:45:14  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-04 09:45:19  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-04 09:45:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-04 09:45:27  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-04 09:45:31  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-04 09:45:35  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-04 09:45:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-04 09:45:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-04 09:45:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-04 09:45:52  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-04 09:45:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-04 09:46:01  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-04 09:46:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-04 09:46:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-04 09:46:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-04 09:46:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-04 09:46:24  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-04 09:46:25  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-04 09:46:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-04 09:46:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-04 09:46:39  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-04 09:46:44  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-04 09:46:48  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-04 09:46:53  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 09:46:57  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 09:47:02  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-04 09:47:06  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 09:47:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-04 09:47:15  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-04 09:47:20  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-04 09:47:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-04 09:47:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-04 09:47:34  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-04 09:47:38  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-04 09:47:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-04 09:47:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-04 09:47:53  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-04 09:47:57  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 09:48:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-04 09:48:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-04 09:48:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-04 09:48:16  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-04 09:48:21  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-04 09:48:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-04 09:48:30  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-04 09:48:35  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-04 09:48:39  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-04 09:48:44  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-04 09:48:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-04 09:48:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-04 09:48:58  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-04 09:49:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-04 09:49:07  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-04 09:49:12  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-04 09:49:16  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-04 09:49:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-04 09:49:26  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-04 09:49:30  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-04 09:49:35  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-04 09:49:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-04 09:49:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-04 09:49:45  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-04 09:49:50  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-04 09:49:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-04 09:49:59  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-04 09:50:04  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-04 09:50:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-04 09:50:14  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-04 09:50:19  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-04 09:50:24  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-04 09:50:28  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-04 09:50:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-04 09:50:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-04 09:50:42  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-04 09:50:47  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-04 09:50:51  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-04 09:50:56  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-04 09:51:01  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-04 09:51:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-04 09:51:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-04 09:51:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-04 09:51:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-04 09:51:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-04 09:51:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-04 09:51:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-04 09:51:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-04 09:51:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-04 09:51:44  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-04 09:51:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-04 09:51:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-04 09:51:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-04 09:51:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-04 09:52:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-04 09:52:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-04 09:52:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-04 09:52:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-04 09:52:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-04 09:52:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-04 09:52:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-04 09:52:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-04 09:52:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-04 09:52:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-04 09:52:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-04 09:52:43  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-04 09:52:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-04 09:52:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-04 09:52:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-04 09:53:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-04 09:53:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-04 09:53:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-04 09:53:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-04 09:53:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-04 09:53:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-04 09:53:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-04 09:53:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-04 09:53:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-04 09:53:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-04 09:53:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-04 09:53:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-04 09:53:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-04 09:53:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-04 09:53:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-04 09:53:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-04 09:54:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-04 09:54:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-04 09:54:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-04 09:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-04 09:54:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-04 09:54:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-04 09:54:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-04 09:54:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-04 09:54:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-04 09:54:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-04 09:54:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-04 09:54:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-04 09:54:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-04 09:54:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-04 09:54:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-04 09:54:56  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-04 09:55:02  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-04 09:55:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-04 09:55:12  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-04 09:55:12  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-04 09:55:17  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-04 09:55:22  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-04 09:55:26  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-04 09:55:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-04 09:55:36  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-04 09:55:40  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-04 09:55:45  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-04 09:55:50  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-04 09:55:55  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-04 09:55:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-04 09:56:04  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-04 09:56:09  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-04 09:56:13  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-04 09:56:18  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-04 09:56:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-04 09:56:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-04 09:56:33  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-04 09:56:37  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-04 09:56:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-04 09:56:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-04 09:56:51  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-04 09:56:55  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-04 09:57:00  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-04 09:57:04  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-04 09:57:09  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-04 09:57:13  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-04 09:57:18  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-04 09:57:22  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-04 09:57:27  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-04 09:57:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-04 09:57:36  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-04 09:57:41  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-04 09:57:45  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-04 09:57:50  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-04 09:57:55  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-04 09:57:59  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-04 09:58:04  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-04 09:58:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-04 09:58:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-04 09:58:18  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-04 09:58:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-04 09:58:27  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-04 09:58:31  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-04 09:58:36  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-04 09:58:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-04 09:58:46  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-04 09:58:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-04 09:58:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-04 09:58:59  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-04 09:59:04  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-04 09:59:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-04 09:59:13  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-04 09:59:18  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-04 09:59:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-04 09:59:27  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-04 09:59:32  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-04 09:59:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-04 09:59:41  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-04 09:59:46  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-04 09:59:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-04 09:59:55  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-04 10:00:00  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-04 10:00:05  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-04 10:00:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-04 10:00:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-04 10:00:19  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-04 10:00:24  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-04 10:00:29  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-04 10:00:36  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-04 10:00:41  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-04 10:00:45  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-04 10:00:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-04 10:00:55  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-04 10:00:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-04 10:01:04  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-04 10:01:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-04 10:01:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-04 10:01:19  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-04 10:01:23  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-04 10:01:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-04 10:01:33  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-04 10:01:37  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-04 10:01:42  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-04 10:01:47  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-04_10-01-50 Restart Xvfb...
2017-04-04 10:01:51  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-04 10:01:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-04 10:02:00  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-04 10:02:04  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-04 10:02:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-04 10:02:14  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-04 10:02:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-04 10:02:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-04 10:02:28  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-04 10:02:32  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-04 10:02:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-04 10:02:42  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-04 10:02:46  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-04 10:02:51  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-04 10:02:56  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-04 10:03:01  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-04 10:03:05  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-04 10:03:10  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-04 10:03:15  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-04 10:03:20  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-04 10:03:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-04 10:03:29  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-04 10:03:34  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-04 10:03:38  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-04 10:03:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-04 10:03:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-04 10:03:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-04 10:03:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-04 10:04:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-04 10:04:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-04 10:04:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-04 10:04:16  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-04 10:04:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-04 10:04:25  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-04 10:04:29  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-04 10:04:34  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-04 10:04:38  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-04 10:04:43  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-04 10:04:47  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-04 10:04:52  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-04 10:04:56  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-04 10:05:01  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-04 10:05:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-04 10:05:10  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-04 10:05:15  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-04 10:05:20  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-04 10:05:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-04 10:05:29  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-04 10:05:34  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-04 10:05:39  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-04 10:05:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-04 10:05:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-04 10:05:53  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-04 10:05:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-04 10:06:02  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-04 10:06:07  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-04 10:06:12  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-04 10:06:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-04 10:06:21  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-04 10:06:26  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-04 10:06:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-04 10:06:35  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-04 10:06:39  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-04 10:06:43  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-04 10:06:48  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-04 10:06:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-04 10:06:57  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-04 10:07:01  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-04 10:07:06  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-04 10:07:11  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-04 10:07:15  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-04 10:07:20  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-04 10:07:24  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-04 10:07:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-04 10:07:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-04 10:07:38  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-04 10:07:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-04 10:07:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-04 10:07:51  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-04 10:07:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-04 10:08:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-04 10:08:05  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-04 10:08:10  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-04 10:08:14  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-04 10:08:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-04 10:08:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-04 10:08:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-04 10:08:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-04 10:08:37  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-04 10:08:41  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-04 10:08:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-04 10:08:50  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-04 10:08:54  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-04 10:08:59  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-04 10:09:03  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-04 10:09:07  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-04 10:09:12  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-04 10:09:16  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-04 10:09:21  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-04 10:09:25  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-04 10:09:30  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-04 10:09:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-04 10:09:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-04 10:09:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-04 10:09:49  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-04 10:09:49  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-04 10:09:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-04 10:09:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-04 10:10:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-04 10:10:08  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-04 10:10:14  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-04 10:10:18  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-04 10:10:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-04 10:10:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-04 10:10:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-04 10:10:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-04 10:10:40  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-04 10:10:44  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-04 10:10:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-04 10:10:54  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-04 10:10:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-04 10:11:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-04 10:11:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-04 10:11:12  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-04 10:11:16  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-04 10:11:21  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-04 10:11:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-04 10:11:30  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-04 10:11:34  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-04 10:11:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-04 10:11:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-04 10:11:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-04 10:11:52  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-04 10:11:56  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-04 10:12:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-04 10:12:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-04 10:12:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-04 10:12:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-04 10:12:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-04 10:12:21  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-04 10:12:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-04 10:12:30  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-04 10:12:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-04 10:12:38  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-04 10:12:42  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-04 10:12:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-04 10:12:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-04 10:12:55  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-04 10:12:59  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-04 10:13:03  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-04 10:13:07  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-04 10:13:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-04 10:13:16  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-04 10:13:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-04 10:13:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-04 10:13:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-04 10:13:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-04 10:13:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-04 10:13:43  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-04 10:13:47  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-04 10:13:51  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-04 10:13:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-04 10:14:00  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-04 10:14:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-04 10:14:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-04 10:14:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-04 10:14:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 10:14:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 10:14:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 10:14:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 10:14:33  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-04 10:14:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 10:14:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 10:14:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-04 10:14:50  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-04 10:14:54  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-04 10:14:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-04 10:15:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-04 10:15:07  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-04 10:15:11  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-04 10:15:15  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-04 10:15:19  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-04 10:15:24  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-04 10:15:28  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-04 10:15:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-04 10:15:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-04 10:15:41  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-04 10:15:45  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-04 10:15:49  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-04 10:15:53  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-04 10:15:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-04 10:16:02  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-04 10:16:06  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-04 10:16:10  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 10:16:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 10:16:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 10:16:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 10:16:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 10:16:30  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-04 10:16:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 10:16:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 10:16:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 10:16:46  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 10:16:50  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-04 10:16:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 10:16:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 10:17:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 10:17:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-04 10:17:11  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-04_10-31-50 Restart Xvfb...
2017-04-04_11-01-51 Restart Xvfb...
2017-04-04_11-31-51 Restart Xvfb...
2017-04-04_12-01-51 Restart Xvfb...
2017-04-04 12:31:46 reset updateRequest
2017-04-04 12:31:47  - 14968  http://www.lymphomahub.com/
2017-04-04_12-31-51 Restart Xvfb...
2017-04-04 12:31:51  - 14968  http://www.lymphomahub.com/
2017-04-04 12:31:54  - 14968  http://www.lymphomahub.com/about
2017-04-04 12:32:00  - 14968  http://www.lymphomahub.com/terms
2017-04-04 12:32:03  - 14968  http://www.lymphomahub.com/undefined
2017-04-04 12:32:04  - 14968  http://www.lymphomahub.com/therapies
2017-04-04 12:32:10  - 14968  http://www.lymphomahub.com/newsletter
2017-04-04 12:32:13  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-04 12:32:16  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-04 12:32:21  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-04 12:32:25  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-04 12:32:30  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-04 12:32:34  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-04 12:32:38  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-04 12:32:43  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-04 12:32:48  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-04 12:32:52  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-04 12:32:57  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-04 12:33:01  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-04 12:33:06  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-04 12:33:10  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-04 12:33:15  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-04 12:33:20  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-04 12:33:24  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-04 12:33:29  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-04 12:33:33  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-04 12:33:38  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-04 12:33:42  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-04 12:33:47  - 14968  http://www.lymphomahub.com/about/secretariat
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-04 12:33:50  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-04 12:33:52  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-04 12:33:55  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-04 12:33:56  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-04 12:33:59  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-04 12:34:01  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-04 12:34:04  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-04 12:34:05  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-04 12:34:09  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-04 12:34:10  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-04 12:34:14  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-04 12:34:15  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-04 12:34:20  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-04 12:34:25  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-04 12:34:29  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-04 12:34:34  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-04 12:34:38  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-04 12:34:43  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-04 12:34:47  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-04 12:34:52  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-04 12:34:56  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-04 12:35:01  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-04 12:35:05  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-04 12:35:10  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-04 12:35:14  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-04 12:35:19  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-04 12:35:23  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-04 12:35:28  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-04 12:35:33  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-04 12:35:37  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-04 12:35:41  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-04 12:35:46  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-04 12:35:50  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-04 12:35:55  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-04 12:35:59  - 14968  http://www.lymphomahub.com/medical-information
2017-04-04 12:36:03  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-04 12:36:08  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-04 12:36:12  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-04 12:36:17  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-04 12:36:21  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-04 12:36:26  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-04 12:36:30  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-04 12:36:35  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-04 12:36:39  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-04 12:36:44  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-04 12:36:48  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-04 12:36:52  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-04 12:36:53  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-04 12:36:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-04 12:37:02  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-04 12:37:07  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-04 12:37:11  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-04 12:37:16  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-04 12:37:20  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-04 12:37:25  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-04 12:37:29  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-04 12:37:34  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-04 12:37:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-04 12:37:43  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-04 12:37:47  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-04 12:37:51  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-04 12:37:56  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-04 12:38:00  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-04 12:38:05  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-04 12:38:09  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-04 12:38:13  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-04 12:38:18  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-04 12:38:22  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-04 12:38:27  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-04 12:38:31  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-04 12:38:35  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-04 12:38:40  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-04 12:38:45  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-04 12:38:49  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-04 12:38:54  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-04 12:38:58  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-04 12:39:03  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-04 12:39:08  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-04 12:39:08  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-04 12:39:13  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-04 12:39:17  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-04 12:39:22  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-04 12:39:26  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-04 12:39:30  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-04 12:39:35  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-04 12:39:39  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-04 12:39:44  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-04 12:39:47  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-04 12:39:48  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-04 12:39:52  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-04 12:39:57  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-04 12:40:02  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-04 12:40:06  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-04 12:40:10  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-04 12:40:11  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-04 12:40:16  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-04 12:40:21  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-04 12:40:25  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-04 12:40:29  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-04 12:40:33  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-04 12:40:37  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-04 12:40:41  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-04 12:40:45  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-04 12:40:49  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-04 12:40:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-04 12:40:58  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-04 12:41:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-04 12:41:07  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-04 12:41:11  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-04 12:41:11  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-04 12:41:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-04 12:41:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-04 12:41:25  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-04 12:41:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-04 12:41:33  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-04 12:41:38  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-04 12:41:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-04 12:41:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-04 12:41:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-04 12:41:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-04 12:41:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-04 12:42:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-04 12:42:04  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-04 12:42:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-04 12:42:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-04 12:42:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-04 12:42:22  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-04 12:42:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-04 12:42:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-04 12:42:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-04 12:42:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-04 12:42:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-04 12:42:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-04 12:42:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-04 12:42:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-04 12:43:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-04 12:43:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-04 12:43:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-04 12:43:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-04 12:43:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-04 12:43:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-04 12:43:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-04 12:43:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-04 12:43:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-04 12:43:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-04 12:43:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-04 12:43:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-04 12:43:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-04 12:43:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-04 12:44:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-04 12:44:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-04 12:44:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-04 12:44:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-04 12:44:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-04 12:44:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-04 12:44:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-04 12:44:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-04 12:44:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-04 12:44:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-04 12:44:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-04 12:44:51  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-04 12:44:55  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-04 12:45:00  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-04 12:45:04  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-04 12:45:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-04 12:45:12  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-04 12:45:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-04 12:45:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-04 12:45:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-04 12:45:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-04 12:45:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-04 12:45:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-04 12:45:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-04 12:45:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-04 12:45:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-04 12:45:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-04 12:45:59  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-04 12:46:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-04 12:46:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-04 12:46:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-04 12:46:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-04 12:46:23  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-04 12:46:23  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-04 12:46:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-04 12:46:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-04 12:46:37  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-04 12:46:42  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-04 12:46:46  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-04 12:46:51  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 12:46:56  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 12:47:00  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-04 12:47:05  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 12:47:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-04 12:47:14  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-04 12:47:19  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-04 12:47:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-04 12:47:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-04 12:47:33  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-04 12:47:38  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-04 12:47:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-04 12:47:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-04 12:47:51  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-04 12:47:56  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 12:48:01  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-04 12:48:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-04 12:48:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-04 12:48:15  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-04 12:48:19  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-04 12:48:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-04 12:48:29  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-04 12:48:33  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-04 12:48:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-04 12:48:43  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-04 12:48:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-04 12:48:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-04 12:48:56  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-04 12:49:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-04 12:49:06  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-04 12:49:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-04 12:49:15  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-04 12:49:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-04 12:49:24  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-04 12:49:30  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-04 12:49:34  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-04 12:49:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-04 12:49:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-04 12:49:44  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-04 12:49:49  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-04 12:49:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-04 12:49:58  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-04 12:50:03  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-04 12:50:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-04 12:50:12  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-04 12:50:17  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-04 12:50:22  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-04 12:50:26  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-04 12:50:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-04 12:50:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-04 12:50:41  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-04 12:50:45  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-04 12:50:50  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-04 12:50:55  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-04 12:50:59  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-04 12:51:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-04 12:51:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-04 12:51:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-04 12:51:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-04 12:51:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-04 12:51:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-04 12:51:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-04 12:51:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-04 12:51:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-04 12:51:42  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-04 12:51:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-04 12:51:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-04 12:51:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-04 12:51:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-04 12:51:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-04 12:52:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-04 12:52:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-04 12:52:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-04 12:52:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-04 12:52:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-04 12:52:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-04 12:52:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-04 12:52:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-04 12:52:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-04 12:52:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-04 12:52:39  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-04 12:52:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-04 12:52:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-04 12:52:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-04 12:52:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-04 12:52:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-04 12:53:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-04 12:53:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-04 12:53:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-04 12:53:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-04 12:53:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-04 12:53:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-04 12:53:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-04 12:53:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-04 12:53:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-04 12:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-04 12:53:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-04 12:53:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-04 12:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-04 12:53:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-04 12:53:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-04 12:53:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-04 12:54:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-04 12:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-04 12:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-04 12:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-04 12:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-04 12:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-04 12:54:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-04 12:54:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-04 12:54:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-04 12:54:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-04 12:54:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-04 12:54:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-04 12:54:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-04 12:54:49  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-04 12:54:54  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-04 12:54:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-04 12:55:03  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-04 12:55:04  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-04 12:55:08  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-04 12:55:13  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-04 12:55:18  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-04 12:55:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-04 12:55:27  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-04 12:55:31  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-04 12:55:36  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-04 12:55:40  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-04 12:55:45  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-04 12:55:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-04 12:55:54  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-04 12:55:59  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-04 12:56:03  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-04 12:56:08  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-04 12:56:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-04 12:56:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-04 12:56:21  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-04 12:56:26  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-04 12:56:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-04 12:56:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-04 12:56:40  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-04 12:56:44  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-04 12:56:49  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-04 12:56:54  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-04 12:56:58  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-04 12:57:03  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-04 12:57:07  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-04 12:57:12  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-04 12:57:16  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-04 12:57:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-04 12:57:26  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-04 12:57:30  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-04 12:57:35  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-04 12:57:40  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-04 12:57:44  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-04 12:57:49  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-04 12:57:53  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-04 12:57:58  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-04 12:58:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-04 12:58:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-04 12:58:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-04 12:58:16  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-04 12:58:21  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-04 12:58:25  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-04 12:58:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-04 12:58:35  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-04 12:58:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-04 12:58:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-04 12:58:48  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-04 12:58:53  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-04 12:58:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-04 12:59:02  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-04 12:59:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-04 12:59:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-04 12:59:16  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-04 12:59:20  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-04 12:59:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-04 12:59:30  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-04 12:59:34  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-04 12:59:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-04 12:59:43  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-04 12:59:48  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-04 12:59:52  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-04 12:59:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-04 13:00:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-04 13:00:06  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-04 13:00:11  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-04 13:00:15  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-04 13:00:21  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-04 13:00:26  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-04 13:00:31  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-04 13:00:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-04 13:00:44  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-04 13:00:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-04 13:00:55  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-04 13:00:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-04 13:01:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-04 13:01:09  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-04 13:01:13  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-04 13:01:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-04 13:01:22  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-04 13:01:27  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-04 13:01:31  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-04 13:01:36  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-04 13:01:40  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-04 13:01:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-04 13:01:49  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-04_13-01-51 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo?_prerender {"code":"ECONNRESET"}
2017-04-04 13:03:54  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-04 13:03:59  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-04 13:04:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-04 13:04:08  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-04 13:04:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-04 13:04:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-04 13:04:22  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-04 13:04:27  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-04 13:04:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-04 13:04:37  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-04 13:04:41  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-04 13:04:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-04 13:04:51  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-04 13:04:55  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-04 13:05:00  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-04 13:05:04  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-04 13:05:09  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-04 13:05:14  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-04 13:05:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-04 13:05:23  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-04 13:05:27  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-04 13:05:32  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-04 13:05:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-04 13:05:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-04 13:05:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-04 13:05:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-04 13:05:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-04 13:06:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-04 13:06:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-04 13:06:09  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-04 13:06:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-04 13:06:18  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-04 13:06:23  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-04 13:06:28  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-04 13:06:32  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-04 13:06:36  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-04 13:06:41  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-04 13:06:46  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-04 13:06:50  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-04 13:06:55  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-04 13:06:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-04 13:07:04  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-04 13:07:09  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-04 13:07:14  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-04 13:07:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-04 13:07:23  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-04 13:07:28  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-04 13:07:33  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-04 13:07:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-04 13:07:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-04 13:07:47  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-04 13:07:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-04 13:07:56  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-04 13:08:00  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-04 13:08:05  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-04 13:08:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-04 13:08:14  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-04 13:08:19  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-04 13:08:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-04 13:08:28  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-04 13:08:33  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-04 13:08:37  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-04 13:08:42  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-04 13:08:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-04 13:08:51  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-04 13:08:55  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-04 13:08:59  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-04 13:09:04  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-04 13:09:08  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-04 13:09:13  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-04 13:09:17  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-04 13:09:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-04 13:09:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-04 13:09:31  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-04 13:09:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-04 13:09:39  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-04 13:09:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-04 13:09:48  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-04 13:09:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-04 13:09:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-04 13:10:02  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-04 13:10:07  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-04 13:10:14  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-04 13:10:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-04 13:10:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-04 13:10:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-04 13:10:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-04 13:10:42  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-04 13:10:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-04 13:10:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-04 13:10:55  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-04 13:10:59  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-04 13:11:04  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-04 13:11:09  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-04 13:11:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-04 13:11:18  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-04 13:11:22  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-04 13:11:26  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-04 13:11:31  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-04 13:11:36  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-04 13:11:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-04 13:11:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-04 13:11:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-04 13:11:54  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-04 13:11:55  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-04 13:11:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-04 13:12:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-04 13:12:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-04 13:12:12  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-04 13:12:17  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-04 13:12:22  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-04 13:12:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-04 13:12:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-04 13:12:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-04 13:12:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-04 13:12:44  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-04 13:12:48  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-04 13:12:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-04 13:12:57  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-04 13:13:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-04 13:13:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-04 13:13:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-04 13:13:15  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-04 13:13:20  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-04 13:13:24  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-04 13:13:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-04 13:13:33  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-04 13:13:37  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-04 13:13:42  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-04 13:13:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-04 13:13:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-04 13:13:56  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-04 13:14:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-04 13:14:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-04 13:14:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-04 13:14:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-04 13:14:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-04 13:14:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-04 13:14:26  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-04 13:14:30  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-04 13:14:34  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-04 13:14:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-04 13:14:42  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-04 13:14:47  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-04 13:14:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-04 13:14:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-04 13:15:00  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-04 13:15:05  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-04 13:15:09  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-04 13:15:15  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-04 13:15:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-04 13:15:23  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-04 13:15:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-04 13:15:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-04 13:15:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-04 13:15:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-04 13:15:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-04 13:15:50  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-04 13:15:55  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-04 13:15:59  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-04 13:16:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-04 13:16:07  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-04 13:16:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-04 13:16:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-04 13:16:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-04 13:16:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 13:16:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 13:16:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 13:16:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 13:16:41  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-04 13:16:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 13:16:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 13:16:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-04 13:16:59  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-04 13:17:03  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-04 13:17:07  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-04 13:17:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-04 13:17:16  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-04 13:17:20  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-04 13:17:24  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-04 13:17:29  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-04 13:17:33  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-04 13:17:37  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-04 13:17:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-04 13:17:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-04 13:17:49  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-04 13:17:53  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-04 13:17:57  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-04 13:18:02  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-04 13:18:06  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-04 13:18:10  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-04 13:18:14  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-04 13:18:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 13:18:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 13:18:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 13:18:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 13:18:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 13:18:39  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-04 13:18:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 13:18:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 13:18:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 13:18:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 13:19:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-04 13:19:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 13:19:08  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 13:19:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 13:19:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-04 13:19:20  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-04_13-31-51 Restart Xvfb...
2017-04-04_14-01-51 Restart Xvfb...
2017-04-04_14-31-51 Restart Xvfb...
2017-04-04_15-01-51 Restart Xvfb...
2017-04-04 15:31:46 reset updateRequest
2017-04-04 15:31:50  - 14968  http://www.lymphomahub.com/
2017-04-04 15:31:51  - 14968  http://www.lymphomahub.com/
2017-04-04_15-31-51 Restart Xvfb...
2017-04-04 15:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-04 15:31:57  - 14968  http://www.lymphomahub.com/about
2017-04-04 15:32:04  - 14968  http://www.lymphomahub.com/terms
2017-04-04 15:32:04  - 14968  http://www.lymphomahub.com/terms
2017-04-04 15:32:08  - 14968  http://www.lymphomahub.com/undefined
2017-04-04 15:32:09  - 14968  http://www.lymphomahub.com/therapies
2017-04-04 15:32:09  - 14968  http://www.lymphomahub.com/therapies
2017-04-04 15:32:19  - 14968  http://www.lymphomahub.com/newsletter
2017-04-04 15:32:19  - 14968  http://www.lymphomahub.com/newsletter
2017-04-04 15:32:23  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-04 15:32:23  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-04 15:32:27  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-04 15:32:27  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-04 15:32:32  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-04 15:32:33  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-04 15:32:38  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-04 15:32:42  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-04 15:32:47  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-04 15:32:51  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-04 15:32:56  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-04 15:33:00  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-04 15:33:05  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-04 15:33:09  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-04 15:33:14  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-04 15:33:19  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-04 15:33:25  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-04 15:33:29  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-04 15:33:34  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-04 15:33:38  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-04 15:33:43  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-04 15:33:47  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-04 15:33:52  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-04 15:33:57  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-04 15:34:02  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-04 15:34:05  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-04 15:34:09  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-04 15:34:14  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-04 15:34:18  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-04 15:34:23  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-04 15:34:27  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-04 15:34:32  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-04 15:34:36  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-04 15:34:41  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-04 15:34:45  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-04 15:34:50  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-04 15:34:55  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-04 15:34:59  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-04 15:35:03  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-04 15:35:08  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-04 15:35:12  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-04 15:35:17  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-04 15:35:21  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-04 15:35:26  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-04 15:35:31  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-04 15:35:35  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-04 15:35:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-04 15:35:44  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-04 15:35:49  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-04 15:35:53  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-04 15:35:58  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-04 15:36:02  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-04 15:36:06  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-04 15:36:11  - 14968  http://www.lymphomahub.com/medical-information
2017-04-04 15:36:15  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-04 15:36:20  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-04 15:36:25  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-04 15:36:29  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-04 15:36:34  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-04 15:36:38  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-04 15:36:43  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-04 15:36:47  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-04 15:36:52  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-04 15:36:56  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-04 15:37:01  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-04 15:37:05  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-04 15:37:06  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-04 15:37:10  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-04 15:37:15  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-04 15:37:19  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-04 15:37:24  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-04 15:37:28  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-04 15:37:32  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-04 15:37:37  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-04 15:37:41  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-04 15:37:46  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-04 15:37:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-04 15:37:55  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-04 15:37:59  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-04 15:38:04  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-04 15:38:08  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-04 15:38:13  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-04 15:38:17  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-04 15:38:21  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-04 15:38:26  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-04 15:38:30  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-04 15:38:35  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-04 15:38:39  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-04 15:38:44  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-04 15:38:48  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-04 15:38:53  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-04 15:38:57  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-04 15:39:01  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-04 15:39:06  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-04 15:39:10  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-04 15:39:14  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-04 15:39:19  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-04 15:39:20  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-04 15:39:24  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-04 15:39:29  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-04 15:39:34  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-04 15:39:38  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-04 15:39:42  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-04 15:39:47  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-04 15:39:51  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-04 15:39:56  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-04 15:39:59  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-04 15:40:00  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-04 15:40:04  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-04 15:40:09  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-04 15:40:14  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-04 15:40:18  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-04 15:40:23  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-04 15:40:23  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-04 15:40:28  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-04 15:40:31  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-04 15:40:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-04 15:40:39  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-04 15:40:44  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-04 15:40:47  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-04 15:40:51  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-04 15:40:55  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-04 15:40:59  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-04 15:41:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-04 15:41:09  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-04 15:41:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-04 15:41:18  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-04 15:41:22  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-04 15:41:22  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-04 15:41:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-04 15:41:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-04 15:41:36  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-04 15:41:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-04 15:41:44  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-04 15:41:49  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-04 15:41:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-04 15:41:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-04 15:42:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-04 15:42:05  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-04 15:42:09  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-04 15:42:13  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-04 15:42:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-04 15:42:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-04 15:42:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-04 15:42:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-04 15:42:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-04 15:42:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-04 15:42:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-04 15:42:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-04 15:42:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-04 15:42:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-04 15:43:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-04 15:43:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-04 15:43:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-04 15:43:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-04 15:43:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-04 15:43:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-04 15:43:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-04 15:43:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-04 15:43:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-04 15:43:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-04 15:43:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-04 15:43:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-04 15:43:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-04 15:44:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-04 15:44:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-04 15:44:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-04 15:44:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-04 15:44:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-04 15:44:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-04 15:44:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-04 15:44:32  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-04 15:44:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-04 15:44:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-04 15:44:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-04 15:44:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-04 15:44:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-04 15:44:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-04 15:45:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-04 15:45:06  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-04 15:45:11  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-04 15:45:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-04 15:45:19  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-04 15:45:24  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-04 15:45:28  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-04 15:45:32  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-04 15:45:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-04 15:45:41  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-04 15:45:45  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-04 15:45:49  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-04 15:45:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-04 15:45:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-04 15:46:01  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-04 15:46:06  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-04 15:46:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-04 15:46:14  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-04 15:46:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-04 15:46:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-04 15:46:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-04 15:46:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-04 15:46:38  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-04 15:46:38  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-04 15:46:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-04 15:46:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-04 15:46:52  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-04 15:46:56  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-04 15:47:01  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-04 15:47:05  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 15:47:10  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 15:47:15  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-04 15:47:19  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 15:47:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-04 15:47:28  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-04 15:47:33  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-04 15:47:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-04 15:47:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-04 15:47:46  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-04 15:47:51  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-04 15:47:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-04 15:48:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-04 15:48:05  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-04 15:48:11  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 15:48:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-04 15:48:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-04 15:48:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-04 15:48:30  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-04 15:48:35  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-04 15:48:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-04 15:48:44  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-04 15:48:48  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-04 15:48:53  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-04 15:48:57  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-04 15:49:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-04 15:49:06  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-04 15:49:11  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-04 15:49:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-04 15:49:21  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-04 15:49:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-04 15:49:30  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-04 15:49:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-04 15:49:39  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-04 15:49:44  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-04 15:49:49  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-04 15:49:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-04 15:49:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-04 15:49:58  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-04 15:50:03  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-04 15:50:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-04 15:50:13  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-04 15:50:17  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-04 15:50:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-04 15:50:27  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-04 15:50:31  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-04 15:50:36  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-04 15:50:40  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-04 15:50:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-04 15:50:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-04 15:50:54  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-04 15:50:59  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-04 15:51:04  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-04 15:51:09  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-04 15:51:13  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-04 15:51:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-04 15:51:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-04 15:51:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-04 15:51:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-04 15:51:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-04 15:51:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-04 15:51:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-04 15:51:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-04 15:51:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-04 15:51:57  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-04 15:51:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-04 15:52:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-04 15:52:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-04 15:52:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-04 15:52:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-04 15:52:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-04 15:52:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-04 15:52:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-04 15:52:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-04 15:52:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-04 15:52:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-04 15:52:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-04 15:52:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-04 15:52:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-04 15:52:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-04 15:52:55  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-04 15:52:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-04 15:53:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-04 15:53:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-04 15:53:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-04 15:53:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-04 15:53:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-04 15:53:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-04 15:53:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-04 15:53:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-04 15:53:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-04 15:53:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-04 15:53:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-04 15:53:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-04 15:53:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-04 15:53:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-04 15:53:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-04 15:53:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-04 15:54:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-04 15:54:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-04 15:54:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-04 15:54:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-04 15:54:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-04 15:54:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-04 15:54:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-04 15:54:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-04 15:54:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-04 15:54:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-04 15:54:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-04 15:54:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-04 15:54:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-04 15:54:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-04 15:54:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-04 15:54:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-04 15:55:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-04 15:55:05  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-04 15:55:10  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-04 15:55:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-04 15:55:19  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-04 15:55:20  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-04 15:55:25  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-04 15:55:29  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-04 15:55:34  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-04 15:55:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-04 15:55:43  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-04 15:55:48  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-04 15:55:53  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-04 15:55:57  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-04 15:56:02  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-04 15:56:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-04 15:56:11  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-04 15:56:16  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-04 15:56:20  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-04 15:56:25  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-04 15:56:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-04 15:56:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-04 15:56:39  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-04 15:56:43  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-04 15:56:48  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-04 15:56:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-04 15:56:57  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-04 15:57:02  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-04 15:57:06  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-04 15:57:11  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-04 15:57:15  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-04 15:57:20  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-04 15:57:25  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-04 15:57:29  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-04 15:57:34  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-04 15:57:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-04 15:57:43  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-04 15:57:47  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-04 15:57:52  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-04 15:57:57  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-04 15:58:01  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-04 15:58:05  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-04 15:58:10  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-04 15:58:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-04 15:58:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-04 15:58:24  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-04 15:58:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-04 15:58:33  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-04 15:58:38  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-04 15:58:43  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-04 15:58:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-04 15:58:52  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-04 15:58:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-04 15:59:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-04 15:59:06  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-04 15:59:11  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-04 15:59:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-04 15:59:19  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-04 15:59:24  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-04 15:59:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-04 15:59:33  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-04 15:59:38  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-04 15:59:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-04 15:59:47  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-04 15:59:52  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-04 15:59:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-04 16:00:01  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-04 16:00:05  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-04 16:00:10  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-04 16:00:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-04 16:00:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-04 16:00:24  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-04 16:00:32  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-04 16:00:36  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-04 16:00:41  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-04 16:00:45  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-04 16:00:50  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-04 16:00:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-04 16:01:02  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-04 16:01:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-04 16:01:11  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-04 16:01:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-04 16:01:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-04 16:01:25  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-04 16:01:29  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-04 16:01:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-04 16:01:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-04 16:01:43  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-04 16:01:47  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-04_16-01-51 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll?_prerender {"code":"ECONNRESET"}
2017-04-04 16:03:52  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-04 16:03:57  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-04 16:04:01  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-04 16:04:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-04 16:04:10  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-04 16:04:15  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-04 16:04:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-04 16:04:25  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-04 16:04:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-04 16:04:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-04 16:04:39  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-04 16:04:43  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-04 16:04:48  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-04 16:04:53  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-04 16:04:58  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-04 16:05:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-04 16:05:07  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-04 16:05:12  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-04 16:05:17  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-04 16:05:21  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-04 16:05:26  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-04 16:05:31  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-04 16:05:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-04 16:05:40  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-04 16:05:45  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-04 16:05:49  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-04 16:05:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-04 16:05:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-04 16:06:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-04 16:06:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-04 16:06:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-04 16:06:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-04 16:06:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-04 16:06:26  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-04 16:06:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-04 16:06:35  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-04 16:06:40  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-04 16:06:45  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-04 16:06:49  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-04 16:06:53  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-04 16:06:58  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-04 16:07:02  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-04 16:07:06  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-04 16:07:11  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-04 16:07:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-04 16:07:21  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-04 16:07:25  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-04 16:07:30  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-04 16:07:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-04 16:07:39  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-04 16:07:44  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-04 16:07:48  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-04 16:07:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-04 16:07:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-04 16:08:02  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-04 16:08:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-04 16:08:12  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-04 16:08:17  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-04 16:08:21  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-04 16:08:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-04 16:08:30  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-04 16:08:35  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-04 16:08:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-04 16:08:44  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-04 16:08:49  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-04 16:08:53  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-04 16:08:57  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-04 16:09:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-04 16:09:06  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-04 16:09:10  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-04 16:09:15  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-04 16:09:20  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-04 16:09:24  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-04 16:09:29  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-04 16:09:34  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-04 16:09:38  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-04 16:09:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-04 16:09:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-04 16:09:51  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-04 16:09:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-04 16:10:00  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-04 16:10:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-04 16:10:09  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-04 16:10:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-04 16:10:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-04 16:10:22  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-04 16:10:27  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-04 16:10:31  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-04 16:10:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-04 16:10:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-04 16:10:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-04 16:10:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-04 16:10:52  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-04 16:10:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-04 16:11:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-04 16:11:06  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-04 16:11:10  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-04 16:11:14  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-04 16:11:19  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-04 16:11:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-04 16:11:27  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-04 16:11:32  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-04 16:11:36  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-04 16:11:41  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-04 16:11:46  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-04 16:11:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-04 16:11:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-04 16:12:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-04 16:12:05  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-04 16:12:05  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-04 16:12:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-04 16:12:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-04 16:12:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-04 16:12:23  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-04 16:12:28  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-04 16:12:33  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-04 16:12:37  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-04 16:12:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-04 16:12:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-04 16:12:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-04 16:12:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-04 16:12:59  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-04 16:13:03  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-04 16:13:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-04 16:13:12  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-04 16:13:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-04 16:13:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-04 16:13:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-04 16:13:30  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-04 16:13:34  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-04 16:13:39  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-04 16:13:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-04 16:13:48  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-04 16:13:52  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-04 16:13:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-04 16:14:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-04 16:14:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-04 16:14:10  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-04 16:14:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-04 16:14:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-04 16:14:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-04 16:14:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-04 16:14:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-04 16:14:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-04 16:14:40  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-04 16:14:44  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-04 16:14:48  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-04 16:14:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-04 16:14:56  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-04 16:15:00  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-04 16:15:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-04 16:15:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-04 16:15:13  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-04 16:15:17  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-04 16:15:21  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-04 16:15:25  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-04 16:15:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-04 16:15:34  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-04 16:15:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-04 16:15:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-04 16:15:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-04 16:15:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-04 16:15:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-04 16:16:01  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-04 16:16:05  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-04 16:16:09  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-04 16:16:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-04 16:16:17  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-04 16:16:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-04 16:16:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-04 16:16:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-04 16:16:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 16:16:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 16:16:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 16:16:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 16:16:51  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-04 16:16:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 16:16:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 16:17:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-04 16:17:07  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-04 16:17:11  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-04 16:17:16  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-04 16:17:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-04 16:17:24  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-04 16:17:28  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-04 16:17:33  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-04 16:17:37  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-04 16:17:41  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-04 16:17:45  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-04 16:17:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-04 16:17:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-04 16:17:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-04 16:18:01  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-04 16:18:05  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-04 16:18:09  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-04 16:18:13  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-04 16:18:17  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-04 16:18:21  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-04 16:18:25  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 16:18:29  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 16:18:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 16:18:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 16:18:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 16:18:46  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-04 16:18:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 16:18:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 16:18:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 16:19:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 16:19:07  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-04 16:19:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 16:19:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 16:19:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 16:19:24  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-04 16:19:28  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-04_16-31-51 Restart Xvfb...
2017-04-04_17-01-51 Restart Xvfb...
2017-04-04_17-31-51 Restart Xvfb...
2017-04-04_18-01-51 Restart Xvfb...
2017-04-04 18:31:46 reset updateRequest
2017-04-04 18:31:48  - 14968  http://www.lymphomahub.com/
2017-04-04 18:31:51  - 14968  http://www.lymphomahub.com/
2017-04-04_18-31-51 Restart Xvfb...
2017-04-04 18:31:54  - 14968  http://www.lymphomahub.com/about
2017-04-04 18:31:59  - 14968  http://www.lymphomahub.com/terms
2017-04-04 18:32:03  - 14968  http://www.lymphomahub.com/undefined
2017-04-04 18:32:03  - 14968  http://www.lymphomahub.com/therapies
2017-04-04 18:32:09  - 14968  http://www.lymphomahub.com/newsletter
2017-04-04 18:32:12  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-04 18:32:16  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-04 18:32:20  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-04 18:32:25  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-04 18:32:30  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-04 18:32:34  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-04 18:32:39  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-04 18:32:43  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-04 18:32:48  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-04 18:32:52  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-04 18:32:57  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-04 18:33:01  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-04 18:33:05  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-04 18:33:10  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-04 18:33:14  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-04 18:33:20  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-04 18:33:24  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-04 18:33:29  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-04 18:33:34  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-04 18:33:38  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-04 18:33:43  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-04 18:33:47  - 14968  http://www.lymphomahub.com/about/secretariat
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-04 18:33:51  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-04 18:33:53  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-04 18:33:55  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-04 18:33:58  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-04 18:34:00  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-04 18:34:02  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-04 18:34:05  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-04 18:34:06  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-04 18:34:10  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-04 18:34:11  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-04 18:34:16  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-04 18:34:17  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-04 18:34:21  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-04 18:34:21  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-04 18:34:26  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-04 18:34:26  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-04 18:34:32  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-04 18:34:36  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-04 18:34:40  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-04 18:34:45  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-04 18:34:49  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-04 18:34:54  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-04 18:34:58  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-04 18:35:03  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-04 18:35:07  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-04 18:35:12  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-04 18:35:16  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-04 18:35:21  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-04 18:35:25  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-04 18:35:30  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-04 18:35:34  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-04 18:35:38  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-04 18:35:43  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-04 18:35:47  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-04 18:35:52  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-04 18:35:56  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-04 18:36:01  - 14968  http://www.lymphomahub.com/medical-information
2017-04-04 18:36:05  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-04 18:36:10  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-04 18:36:14  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-04 18:36:19  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-04 18:36:23  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-04 18:36:28  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-04 18:36:32  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-04 18:36:37  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-04 18:36:41  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-04 18:36:45  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-04 18:36:50  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-04 18:36:54  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-04 18:36:55  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-04 18:37:00  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-04 18:37:04  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-04 18:37:08  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-04 18:37:13  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-04 18:37:17  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-04 18:37:22  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-04 18:37:26  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-04 18:37:31  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-04 18:37:36  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-04 18:37:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-04 18:37:45  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-04 18:37:49  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-04 18:37:54  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-04 18:37:58  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-04 18:38:02  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-04 18:38:07  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-04 18:38:11  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-04 18:38:16  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-04 18:38:20  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-04 18:38:24  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-04 18:38:29  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-04 18:38:34  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-04 18:38:38  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-04 18:38:43  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-04 18:38:47  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-04 18:38:52  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-04 18:38:56  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-04 18:39:01  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-04 18:39:05  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-04 18:39:10  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-04 18:39:10  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-04 18:39:15  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-04 18:39:19  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-04 18:39:24  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-04 18:39:28  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-04 18:39:33  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-04 18:39:37  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-04 18:39:41  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-04 18:39:46  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-04 18:39:50  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-04 18:39:50  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-04 18:39:55  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-04 18:39:59  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-04 18:40:04  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-04 18:40:08  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-04 18:40:13  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-04 18:40:13  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-04 18:40:18  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-04 18:40:22  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-04 18:40:27  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-04 18:40:31  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-04 18:40:35  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-04 18:40:39  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-04 18:40:43  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-04 18:40:47  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-04 18:40:51  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-04 18:40:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-04 18:40:59  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-04 18:41:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-04 18:41:08  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-04 18:41:12  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-04 18:41:12  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-04 18:41:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-04 18:41:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-04 18:41:25  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-04 18:41:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-04 18:41:34  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-04 18:41:38  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-04 18:41:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-04 18:41:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-04 18:41:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-04 18:41:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-04 18:41:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-04 18:42:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-04 18:42:05  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-04 18:42:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-04 18:42:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-04 18:42:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-04 18:42:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-04 18:42:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-04 18:42:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-04 18:42:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-04 18:42:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-04 18:42:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-04 18:42:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-04 18:42:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-04 18:42:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-04 18:43:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-04 18:43:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-04 18:43:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-04 18:43:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-04 18:43:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-04 18:43:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-04 18:43:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-04 18:43:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-04 18:43:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-04 18:43:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-04 18:43:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-04 18:43:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-04 18:43:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-04 18:43:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-04 18:44:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-04 18:44:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-04 18:44:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-04 18:44:16  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-04 18:44:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-04 18:44:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-04 18:44:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-04 18:44:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-04 18:44:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-04 18:44:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-04 18:44:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-04 18:44:50  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-04 18:44:54  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-04 18:44:59  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-04 18:45:03  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-04 18:45:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-04 18:45:11  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-04 18:45:16  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-04 18:45:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-04 18:45:24  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-04 18:45:28  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-04 18:45:32  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-04 18:45:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-04 18:45:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-04 18:45:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-04 18:45:49  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-04 18:45:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-04 18:45:58  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-04 18:46:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-04 18:46:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-04 18:46:12  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-04 18:46:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-04 18:46:21  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-04 18:46:22  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-04 18:46:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-04 18:46:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-04 18:46:36  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-04 18:46:40  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-04 18:46:44  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-04 18:46:49  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 18:46:54  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 18:46:58  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-04 18:47:03  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 18:47:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-04 18:47:12  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-04 18:47:17  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-04 18:47:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-04 18:47:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-04 18:47:30  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-04 18:47:35  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-04 18:47:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-04 18:47:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-04 18:47:49  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-04 18:47:53  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 18:47:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-04 18:48:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-04 18:48:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-04 18:48:12  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-04 18:48:17  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-04 18:48:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-04 18:48:26  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-04 18:48:31  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-04 18:48:36  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-04 18:48:40  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-04 18:48:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-04 18:48:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-04 18:48:54  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-04 18:48:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-04 18:49:04  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-04 18:49:08  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-04 18:49:13  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-04 18:49:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-04 18:49:22  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-04 18:49:27  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-04 18:49:31  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-04 18:49:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-04 18:49:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-04 18:49:41  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-04 18:49:46  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-04 18:49:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-04 18:49:55  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-04 18:50:00  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-04 18:50:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-04 18:50:09  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-04 18:50:14  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-04 18:50:21  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-04 18:50:29  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-04 18:50:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-04 18:50:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-04 18:50:43  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-04 18:50:47  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-04 18:50:52  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-04 18:50:56  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-04 18:51:01  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-04 18:51:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-04 18:51:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-04 18:51:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-04 18:51:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-04 18:51:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-04 18:51:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-04 18:51:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-04 18:51:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-04 18:51:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-04 18:51:43  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-04 18:51:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-04 18:51:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-04 18:51:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-04 18:51:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-04 18:51:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-04 18:52:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-04 18:52:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-04 18:52:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-04 18:52:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-04 18:52:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-04 18:52:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-04 18:52:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-04 18:52:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-04 18:52:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-04 18:52:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-04 18:52:40  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-04 18:52:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-04 18:52:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-04 18:52:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-04 18:52:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-04 18:52:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-04 18:53:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-04 18:53:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-04 18:53:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-04 18:53:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-04 18:53:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-04 18:53:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-04 18:53:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-04 18:53:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-04 18:53:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-04 18:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-04 18:53:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-04 18:53:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-04 18:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-04 18:53:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-04 18:53:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-04 18:53:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-04 18:54:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-04 18:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-04 18:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-04 18:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-04 18:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-04 18:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-04 18:54:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-04 18:54:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-04 18:54:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-04 18:54:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-04 18:54:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-04 18:54:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-04 18:54:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-04 18:54:49  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-04 18:54:54  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-04 18:54:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-04 18:55:03  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-04 18:55:03  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-04 18:55:08  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-04 18:55:13  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-04 18:55:17  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-04 18:55:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-04 18:55:27  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-04 18:55:32  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-04 18:55:37  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-04 18:55:41  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-04 18:55:46  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-04 18:55:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-04 18:55:55  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-04 18:55:59  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-04 18:56:04  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-04 18:56:09  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-04 18:56:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-04 18:56:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-04 18:56:22  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-04 18:56:27  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-04 18:56:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-04 18:56:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-04 18:56:41  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-04 18:56:45  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-04 18:56:50  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-04 18:56:54  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-04 18:56:59  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-04 18:57:03  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-04 18:57:08  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-04 18:57:13  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-04 18:57:17  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-04 18:57:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-04 18:57:26  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-04 18:57:30  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-04 18:57:35  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-04 18:57:39  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-04 18:57:44  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-04 18:57:48  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-04 18:57:53  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-04 18:57:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-04 18:58:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-04 18:58:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-04 18:58:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-04 18:58:16  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-04 18:58:21  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-04 18:58:25  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-04 18:58:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-04 18:58:34  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-04 18:58:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-04 18:58:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-04 18:58:47  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-04 18:58:52  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-04 18:58:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-04 18:59:01  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-04 18:59:06  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-04 18:59:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-04 18:59:15  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-04 18:59:19  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-04 18:59:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-04 18:59:29  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-04 18:59:34  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-04 18:59:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-04 18:59:43  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-04 18:59:47  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-04 18:59:52  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-04 18:59:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-04 19:00:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-04 19:00:06  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-04 19:00:10  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-04 19:00:15  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-04 19:00:19  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-04 19:00:24  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-04 19:00:28  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-04 19:00:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-04 19:00:41  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-04 19:00:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-04 19:00:51  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-04 19:00:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-04 19:01:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-04 19:01:04  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-04 19:01:08  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-04 19:01:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-04 19:01:17  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-04 19:01:22  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-04 19:01:29  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-04 19:01:34  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-04 19:01:38  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-04 19:01:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-04 19:01:47  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-04_19-01-51 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo?_prerender {"code":"ECONNRESET"}
2017-04-04 19:03:52  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-04 19:03:59  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-04 19:04:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-04 19:04:10  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-04 19:04:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-04 19:04:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-04 19:04:32  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-04 19:04:36  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-04 19:04:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-04 19:04:46  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-04 19:04:54  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-04 19:04:58  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-04 19:05:02  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-04 19:05:06  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-04 19:05:11  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-04 19:05:16  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-04 19:05:27  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-04 19:05:31  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-04 19:05:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-04 19:05:46  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-04 19:05:51  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-04 19:05:56  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-04 19:06:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-04 19:06:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-04 19:06:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-04 19:06:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-04 19:06:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-04 19:06:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-04 19:06:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-04 19:06:34  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-04 19:06:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-04 19:06:43  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-04 19:06:48  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-04 19:06:53  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-04 19:06:57  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-04 19:07:01  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-04 19:07:06  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-04 19:07:10  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-04 19:07:15  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-04 19:07:19  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-04 19:07:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-04 19:07:28  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-04 19:07:33  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-04 19:07:38  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-04 19:07:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-04 19:07:47  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-04 19:07:52  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-04 19:07:57  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-04 19:08:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-04 19:08:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-04 19:08:11  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-04 19:08:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-04 19:08:20  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-04 19:08:25  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-04 19:08:29  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-04 19:08:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-04 19:08:39  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-04 19:08:43  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-04 19:08:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-04 19:08:52  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-04 19:08:56  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-04 19:09:00  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-04 19:09:05  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-04 19:09:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-04 19:09:14  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-04 19:09:18  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-04 19:09:23  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-04 19:09:28  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-04 19:09:32  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-04 19:09:37  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-04 19:09:41  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-04 19:09:46  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-04 19:09:50  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-04 19:09:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-04 19:09:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-04 19:10:03  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-04 19:10:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-04 19:10:12  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-04 19:10:16  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-04 19:10:21  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-04 19:10:25  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-04 19:10:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-04 19:10:34  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-04 19:10:39  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-04 19:10:43  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-04 19:10:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-04 19:10:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-04 19:10:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-04 19:11:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-04 19:11:05  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-04 19:11:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-04 19:11:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-04 19:11:18  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-04 19:11:22  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-04 19:11:27  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-04 19:11:32  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-04 19:11:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-04 19:11:40  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-04 19:11:44  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-04 19:11:49  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-04 19:11:54  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-04 19:11:58  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-04 19:12:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-04 19:12:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-04 19:12:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-04 19:12:17  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-04 19:12:17  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-04 19:12:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-04 19:12:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-04 19:12:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-04 19:12:35  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-04 19:12:39  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-04 19:12:43  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-04 19:12:48  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-04 19:12:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-04 19:12:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-04 19:13:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-04 19:13:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-04 19:13:10  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-04 19:13:14  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-04 19:13:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-04 19:13:23  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-04 19:13:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-04 19:13:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-04 19:13:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-04 19:13:41  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-04 19:13:46  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-04 19:13:51  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-04 19:13:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-04 19:13:59  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-04 19:14:03  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-04 19:14:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-04 19:14:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-04 19:14:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-04 19:14:21  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-04 19:14:25  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-04 19:14:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-04 19:14:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-04 19:14:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-04 19:14:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-04 19:14:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-04 19:14:51  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-04 19:14:55  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-04 19:14:59  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-04 19:15:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-04 19:15:07  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-04 19:15:11  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-04 19:15:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-04 19:15:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-04 19:15:25  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-04 19:15:29  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-04 19:15:33  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-04 19:15:37  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-04 19:15:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-04 19:15:46  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-04 19:15:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-04 19:15:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-04 19:15:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-04 19:16:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-04 19:16:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-04 19:16:13  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-04 19:16:17  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-04 19:16:21  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-04 19:16:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-04 19:16:29  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-04 19:16:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-04 19:16:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-04 19:16:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-04 19:16:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 19:16:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 19:16:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 19:16:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 19:17:02  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-04 19:17:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 19:17:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 19:17:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-04 19:17:19  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-04 19:17:23  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-04 19:17:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-04 19:17:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-04 19:17:36  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-04 19:17:40  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-04 19:17:44  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-04 19:17:48  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-04 19:17:52  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-04 19:17:57  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-04 19:18:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-04 19:18:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-04 19:18:09  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-04 19:18:13  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-04 19:18:17  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-04 19:18:21  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-04 19:18:25  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-04 19:18:29  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-04 19:18:33  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-04 19:18:37  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 19:18:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 19:18:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 19:18:49  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 19:18:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 19:18:58  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-04 19:19:02  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 19:19:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 19:19:10  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 19:19:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 19:19:18  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-04 19:19:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 19:19:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 19:19:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 19:19:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-04 19:19:39  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-04_19-31-51 Restart Xvfb...
2017-04-04_20-01-51 Restart Xvfb...
2017-04-04_20-31-51 Restart Xvfb...
2017-04-04_21-01-51 Restart Xvfb...
2017-04-04 21:31:46 reset updateRequest
2017-04-04 21:31:49  - 14968  http://www.lymphomahub.com/
2017-04-04 21:31:51  - 14968  http://www.lymphomahub.com/
2017-04-04_21-31-51 Restart Xvfb...
2017-04-04 21:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-04 21:32:01  - 14968  http://www.lymphomahub.com/terms
2017-04-04 21:32:04  - 14968  http://www.lymphomahub.com/undefined
2017-04-04 21:32:05  - 14968  http://www.lymphomahub.com/therapies
2017-04-04 21:32:11  - 14968  http://www.lymphomahub.com/newsletter
2017-04-04 21:32:14  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-04 21:32:17  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-04 21:32:21  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-04 21:32:26  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-04 21:32:31  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-04 21:32:35  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-04 21:32:40  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-04 21:32:44  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-04 21:32:49  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-04 21:32:54  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-04 21:32:58  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-04 21:33:03  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-04 21:33:07  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-04 21:33:12  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-04 21:33:17  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-04 21:33:21  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-04 21:33:26  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-04 21:33:30  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-04 21:33:35  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-04 21:33:39  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-04 21:33:44  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-04 21:33:49  - 14968  http://www.lymphomahub.com/about/secretariat
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-04 21:33:52  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-04 21:33:54  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-04 21:33:57  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-04 21:33:58  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-04 21:34:02  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-04 21:34:03  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-04 21:34:07  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-04 21:34:08  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-04 21:34:12  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-04 21:34:12  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-04 21:34:17  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-04 21:34:17  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-04 21:34:24  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-04 21:34:28  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-04 21:34:33  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-04 21:34:37  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-04 21:34:42  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-04 21:34:46  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-04 21:34:51  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-04 21:34:55  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-04 21:34:59  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-04 21:35:04  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-04 21:35:09  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-04 21:35:14  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-04 21:35:19  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-04 21:35:23  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-04 21:35:28  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-04 21:35:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-04 21:35:37  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-04 21:35:42  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-04 21:35:46  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-04 21:35:51  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-04 21:35:55  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-04 21:36:00  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-04 21:36:04  - 14968  http://www.lymphomahub.com/medical-information
2017-04-04 21:36:09  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-04 21:36:13  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-04 21:36:18  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-04 21:36:22  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-04 21:36:27  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-04 21:36:31  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-04 21:36:36  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-04 21:36:41  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-04 21:36:45  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-04 21:36:50  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-04 21:36:54  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-04 21:36:59  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-04 21:36:59  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-04 21:37:04  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-04 21:37:08  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-04 21:37:13  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-04 21:37:17  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-04 21:37:22  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-04 21:37:26  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-04 21:37:31  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-04 21:37:36  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-04 21:37:40  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-04 21:37:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-04 21:37:49  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-04 21:37:54  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-04 21:37:58  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-04 21:38:02  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-04 21:38:07  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-04 21:38:11  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-04 21:38:16  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-04 21:38:21  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-04 21:38:25  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-04 21:38:30  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-04 21:38:34  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-04 21:38:39  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-04 21:38:43  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-04 21:38:48  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-04 21:38:52  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-04 21:38:57  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-04 21:39:01  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-04 21:39:06  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-04 21:39:10  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-04 21:39:15  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-04 21:39:15  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-04 21:39:20  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-04 21:39:24  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-04 21:39:29  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-04 21:39:33  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-04 21:39:38  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-04 21:39:43  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-04 21:39:48  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-04 21:39:52  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-04 21:39:56  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-04 21:39:56  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-04 21:40:01  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-04 21:40:06  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-04 21:40:10  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-04 21:40:15  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-04 21:40:20  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-04 21:40:20  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-04 21:40:25  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-04 21:40:29  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-04 21:40:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-04 21:40:38  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-04 21:40:42  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-04 21:40:46  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-04 21:40:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-04 21:40:54  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-04 21:40:58  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-04 21:41:03  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-04 21:41:07  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-04 21:41:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-04 21:41:15  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-04 21:41:20  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-04 21:41:21  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-04 21:41:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-04 21:41:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-04 21:41:34  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-04 21:41:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-04 21:41:43  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-04 21:41:48  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-04 21:41:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-04 21:41:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-04 21:41:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-04 21:42:03  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-04 21:42:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-04 21:42:11  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-04 21:42:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-04 21:42:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-04 21:42:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-04 21:42:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-04 21:42:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-04 21:42:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-04 21:42:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-04 21:42:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-04 21:42:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-04 21:42:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-04 21:42:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-04 21:43:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-04 21:43:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-04 21:43:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-04 21:43:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-04 21:43:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-04 21:43:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-04 21:43:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-04 21:43:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-04 21:43:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-04 21:43:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-04 21:43:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-04 21:43:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-04 21:43:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-04 21:44:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-04 21:44:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-04 21:44:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-04 21:44:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-04 21:44:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-04 21:44:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-04 21:44:31  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-04 21:44:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-04 21:44:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-04 21:44:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-04 21:44:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-04 21:44:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-04 21:44:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-04 21:45:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-04 21:45:04  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-04 21:45:08  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-04 21:45:13  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-04 21:45:17  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-04 21:45:22  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-04 21:45:26  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-04 21:45:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-04 21:45:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-04 21:45:39  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-04 21:45:43  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-04 21:45:47  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-04 21:45:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-04 21:45:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-04 21:46:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-04 21:46:04  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-04 21:46:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-04 21:46:13  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-04 21:46:18  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-04 21:46:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-04 21:46:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-04 21:46:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-04 21:46:37  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-04 21:46:37  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-04 21:46:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-04 21:46:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-04 21:46:51  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-04 21:46:56  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-04 21:47:00  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-04 21:47:05  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 21:47:09  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 21:47:14  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-04 21:47:18  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 21:47:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-04 21:47:27  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-04 21:47:32  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-04 21:47:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-04 21:47:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-04 21:47:46  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-04 21:47:50  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-04 21:47:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-04 21:47:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-04 21:48:04  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-04 21:48:09  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-04 21:48:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-04 21:48:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-04 21:48:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-04 21:48:28  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-04 21:48:33  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-04 21:48:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-04 21:48:42  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-04 21:48:47  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-04 21:48:52  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-04 21:48:56  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-04 21:49:01  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-04 21:49:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-04 21:49:10  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-04 21:49:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-04 21:49:20  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-04 21:49:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-04 21:49:29  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-04 21:49:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-04 21:49:39  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-04 21:49:44  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-04 21:49:48  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-04 21:49:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-04 21:49:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-04 21:49:58  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-04 21:50:03  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-04 21:50:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-04 21:50:13  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-04 21:50:19  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-04 21:50:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-04 21:50:28  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-04 21:50:33  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-04 21:50:37  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-04 21:50:42  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-04 21:50:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-04 21:50:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-04 21:50:56  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-04 21:51:01  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-04 21:51:05  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-04 21:51:10  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-04 21:51:15  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-04 21:51:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-04 21:51:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-04 21:51:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-04 21:51:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-04 21:51:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-04 21:51:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-04 21:51:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-04 21:51:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-04 21:51:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-04 21:51:58  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-04 21:51:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-04 21:52:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-04 21:52:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-04 21:52:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-04 21:52:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-04 21:52:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-04 21:52:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-04 21:52:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-04 21:52:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-04 21:52:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-04 21:52:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-04 21:52:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-04 21:52:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-04 21:52:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-04 21:52:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-04 21:52:56  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-04 21:53:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-04 21:53:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-04 21:53:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-04 21:53:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-04 21:53:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-04 21:53:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-04 21:53:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-04 21:53:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-04 21:53:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-04 21:53:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-04 21:53:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-04 21:53:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-04 21:53:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-04 21:53:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-04 21:53:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-04 21:53:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-04 21:54:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-04 21:54:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-04 21:54:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-04 21:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-04 21:54:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-04 21:54:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-04 21:54:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-04 21:54:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-04 21:54:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-04 21:54:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-04 21:54:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-04 21:54:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-04 21:54:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-04 21:54:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-04 21:54:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-04 21:54:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-04 21:54:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-04 21:55:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-04 21:55:06  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-04 21:55:11  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-04 21:55:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-04 21:55:21  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-04 21:55:21  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-04 21:55:26  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-04 21:55:30  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-04 21:55:35  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-04 21:55:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-04 21:55:44  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-04 21:55:49  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-04 21:55:54  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-04 21:55:58  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-04 21:56:03  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-04 21:56:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-04 21:56:12  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-04 21:56:17  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-04 21:56:21  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-04 21:56:26  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-04 21:56:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-04 21:56:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-04 21:56:40  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-04 21:56:45  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-04 21:56:49  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-04 21:56:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-04 21:56:58  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-04 21:57:03  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-04 21:57:08  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-04 21:57:12  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-04 21:57:17  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-04 21:57:21  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-04 21:57:26  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-04 21:57:31  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-04 21:57:35  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-04 21:57:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-04 21:57:44  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-04 21:57:49  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-04 21:57:54  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-04 21:57:58  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-04 21:58:02  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-04 21:58:07  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-04 21:58:12  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-04 21:58:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-04 21:58:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-04 21:58:26  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-04 21:58:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-04 21:58:35  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-04 21:58:39  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-04 21:58:44  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-04 21:58:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-04 21:58:54  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-04 21:58:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-04 21:59:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-04 21:59:07  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-04 21:59:12  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-04 21:59:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-04 21:59:21  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-04 21:59:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-04 21:59:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-04 21:59:34  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-04 21:59:39  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-04 21:59:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-04 21:59:48  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-04 21:59:53  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-04 21:59:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-04 22:00:03  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-04 22:00:08  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-04 22:00:13  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-04 22:00:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-04 22:00:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-04 22:00:28  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-04 22:00:33  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-04 22:00:37  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-04 22:00:42  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-04 22:00:47  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-04 22:00:52  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-04 22:00:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-04 22:01:02  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-04 22:01:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-04 22:01:11  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-04 22:01:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-04 22:01:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-04 22:01:25  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-04 22:01:30  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-04 22:01:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-04 22:01:39  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-04 22:01:44  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-04 22:01:49  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-04_22-01-51 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll?_prerender {"code":"ECONNRESET"}
2017-04-04 22:03:54  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-04 22:03:59  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-04 22:04:04  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-04 22:04:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-04 22:04:13  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-04 22:04:18  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-04 22:04:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-04 22:04:28  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-04 22:04:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-04 22:04:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-04 22:04:43  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-04 22:04:47  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-04 22:04:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-04 22:04:57  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-04 22:05:02  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-04 22:05:08  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-04 22:05:13  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-04 22:05:17  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-04 22:05:22  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-04 22:05:27  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-04 22:05:32  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-04 22:05:37  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-04 22:05:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-04 22:05:47  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-04 22:05:51  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-04 22:05:57  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-04 22:06:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-04 22:06:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-04 22:06:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-04 22:06:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-04 22:06:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-04 22:06:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-04 22:06:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-04 22:06:35  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-04 22:06:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-04 22:06:45  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-04 22:06:50  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-04 22:06:55  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-04 22:06:59  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-04 22:07:04  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-04 22:07:08  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-04 22:07:13  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-04 22:07:18  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-04 22:07:22  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-04 22:07:27  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-04 22:07:32  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-04 22:07:37  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-04 22:07:41  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-04 22:07:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-04 22:07:51  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-04 22:07:56  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-04 22:08:01  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-04 22:08:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-04 22:08:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-04 22:08:16  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-04 22:08:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-04 22:08:25  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-04 22:08:30  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-04 22:08:35  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-04 22:08:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-04 22:08:45  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-04 22:08:49  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-04 22:08:54  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-04 22:08:58  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-04 22:09:02  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-04 22:09:07  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-04 22:09:11  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-04 22:09:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-04 22:09:20  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-04 22:09:25  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-04 22:09:30  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-04 22:09:34  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-04 22:09:39  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-04 22:09:44  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-04 22:09:48  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-04 22:09:53  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-04 22:09:57  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-04 22:10:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-04 22:10:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-04 22:10:10  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-04 22:10:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-04 22:10:19  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-04 22:10:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-04 22:10:28  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-04 22:10:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-04 22:10:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-04 22:10:42  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-04 22:10:47  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-04 22:10:51  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-04 22:10:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-04 22:10:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-04 22:11:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-04 22:11:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-04 22:11:13  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-04 22:11:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-04 22:11:22  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-04 22:11:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-04 22:11:30  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-04 22:11:35  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-04 22:11:40  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-04 22:11:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-04 22:11:48  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-04 22:11:52  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-04 22:11:57  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-04 22:12:02  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-04 22:12:06  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-04 22:12:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-04 22:12:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-04 22:12:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-04 22:12:24  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-04 22:12:25  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-04 22:12:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-04 22:12:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-04 22:12:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-04 22:12:43  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-04 22:12:48  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-04 22:12:53  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-04 22:12:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-04 22:13:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-04 22:13:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-04 22:13:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-04 22:13:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-04 22:13:20  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-04 22:13:24  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-04 22:13:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-04 22:13:33  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-04 22:13:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-04 22:13:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-04 22:13:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-04 22:13:51  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-04 22:13:55  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-04 22:14:00  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-04 22:14:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-04 22:14:08  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-04 22:14:13  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-04 22:14:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-04 22:14:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-04 22:14:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-04 22:14:31  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-04 22:14:35  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-04 22:14:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-04 22:14:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-04 22:14:48  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-04 22:14:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-04 22:14:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-04 22:15:01  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-04 22:15:05  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-04 22:15:09  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-04 22:15:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-04 22:15:17  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-04 22:15:21  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-04 22:15:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-04 22:15:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-04 22:15:34  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-04 22:15:38  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-04 22:15:43  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-04 22:15:47  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-04 22:15:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-04 22:15:56  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-04 22:16:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-04 22:16:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-04 22:16:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-04 22:16:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-04 22:16:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-04 22:16:22  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-04 22:16:26  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-04 22:16:31  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-04 22:16:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-04 22:16:39  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-04 22:16:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-04 22:16:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-04 22:16:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-04 22:16:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 22:17:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 22:17:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 22:17:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 22:17:12  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-04 22:17:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 22:17:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-04 22:17:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-04 22:17:29  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-04 22:17:33  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-04 22:17:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-04 22:17:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-04 22:17:46  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-04 22:17:50  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-04 22:17:54  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-04 22:17:58  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-04 22:18:02  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-04 22:18:06  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-04 22:18:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-04 22:18:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-04 22:18:19  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-04 22:18:23  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-04 22:18:27  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-04 22:18:32  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-04 22:18:36  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-04 22:18:40  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-04 22:18:44  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-04 22:18:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 22:18:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 22:18:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 22:19:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 22:19:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-04 22:19:08  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-04 22:19:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 22:19:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 22:19:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 22:19:25  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 22:19:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-04 22:19:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 22:19:37  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 22:19:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-04 22:19:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-04 22:19:49  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-04_22-31-51 Restart Xvfb...
2017-04-04_23-01-51 Restart Xvfb...
2017-04-04_23-31-51 Restart Xvfb...
2017-04-05_00-01-51 Restart Xvfb...
2017-04-05 00:31:46 reset updateRequest
2017-04-05 00:31:51  - 14968  http://www.lymphomahub.com/
2017-04-05 00:31:51  - 14968  http://www.lymphomahub.com/
2017-04-05_00-31-51 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-05 00:33:56  - 14968  http://www.lymphomahub.com/
2017-04-05 00:33:56  - 14968  http://www.lymphomahub.com/
2017-04-05 00:34:01  - 14968  http://www.lymphomahub.com/about
2017-04-05 00:34:01  - 14968  http://www.lymphomahub.com/about
2017-04-05 00:34:08  - 14968  http://www.lymphomahub.com/terms
2017-04-05 00:34:12  - 14968  http://www.lymphomahub.com/undefined
2017-04-05 00:34:12  - 14968  http://www.lymphomahub.com/therapies
2017-04-05 00:34:18  - 14968  http://www.lymphomahub.com/newsletter
2017-04-05 00:34:21  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-05 00:34:24  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-05 00:34:29  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-05 00:34:34  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-05 00:34:38  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-05 00:34:43  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-05 00:34:47  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-05 00:34:51  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-05 00:34:56  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-05 00:35:00  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-05 00:35:05  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-05 00:35:09  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-05 00:35:14  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-05 00:35:18  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-05 00:35:23  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-05 00:35:27  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-05 00:35:32  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-05 00:35:36  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-05 00:35:40  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-05 00:35:45  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-05 00:35:49  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-05 00:35:54  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-05 00:35:57  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-05 00:36:02  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-05 00:36:06  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-05 00:36:11  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-05 00:36:15  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-05 00:36:20  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-05 00:36:24  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-05 00:36:29  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-05 00:36:33  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-05 00:36:38  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-05 00:36:42  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-05 00:36:46  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-05 00:36:51  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-05 00:36:55  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-05 00:36:59  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-05 00:37:04  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-05 00:37:08  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-05 00:37:13  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-05 00:37:17  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-05 00:37:22  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-05 00:37:26  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-05 00:37:30  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-05 00:37:35  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-05 00:37:39  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-05 00:37:44  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-05 00:37:48  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-05 00:37:53  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-05 00:37:57  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-05 00:38:02  - 14968  http://www.lymphomahub.com/medical-information
2017-04-05 00:38:06  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-05 00:38:11  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-05 00:38:15  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-05 00:38:20  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-05 00:38:24  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-05 00:38:29  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-05 00:38:33  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-05 00:38:37  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-05 00:38:42  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-05 00:38:47  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-05 00:38:52  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-05 00:38:56  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-05 00:38:57  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-05 00:39:01  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-05 00:39:06  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-05 00:39:10  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-05 00:39:14  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-05 00:39:19  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-05 00:39:23  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-05 00:39:27  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-05 00:39:32  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-05 00:39:36  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-05 00:39:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-05 00:39:45  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-05 00:39:50  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-05 00:39:54  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-05 00:39:59  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-05 00:40:03  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-05 00:40:08  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-05 00:40:12  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-05 00:40:16  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-05 00:40:21  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-05 00:40:25  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-05 00:40:30  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-05 00:40:34  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-05 00:40:39  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-05 00:40:44  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-05 00:40:49  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-05 00:40:53  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-05 00:40:57  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-05 00:41:02  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-05 00:41:06  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-05 00:41:11  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-05 00:41:12  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-05 00:41:16  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-05 00:41:21  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-05 00:41:25  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-05 00:41:29  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-05 00:41:34  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-05 00:41:38  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-05 00:41:43  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-05 00:41:47  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-05 00:41:51  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-05 00:41:51  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-05 00:41:56  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-05 00:42:01  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-05 00:42:05  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-05 00:42:10  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-05 00:42:14  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-05 00:42:15  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-05 00:42:19  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-05 00:42:24  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-05 00:42:27  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-05 00:42:32  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-05 00:42:36  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-05 00:42:40  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-05 00:42:44  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-05 00:42:48  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-05 00:42:51  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-05 00:42:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-05 00:43:00  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-05 00:43:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-05 00:43:09  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-05 00:43:12  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-05 00:43:13  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-05 00:43:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-05 00:43:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-05 00:43:26  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-05 00:43:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-05 00:43:35  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-05 00:43:39  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-05 00:43:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-05 00:43:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-05 00:43:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-05 00:43:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-05 00:43:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-05 00:44:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-05 00:44:06  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-05 00:44:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-05 00:44:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-05 00:44:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-05 00:44:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-05 00:44:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-05 00:44:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-05 00:44:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-05 00:44:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-05 00:44:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-05 00:44:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-05 00:44:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-05 00:44:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-05 00:45:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-05 00:45:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-05 00:45:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-05 00:45:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-05 00:45:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-05 00:45:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-05 00:45:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-05 00:45:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-05 00:45:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-05 00:45:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-05 00:45:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-05 00:45:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-05 00:45:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-05 00:46:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-05 00:46:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-05 00:46:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-05 00:46:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-05 00:46:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-05 00:46:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-05 00:46:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-05 00:46:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-05 00:46:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-05 00:46:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-05 00:46:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-05 00:46:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-05 00:46:51  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-05 00:46:55  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-05 00:47:00  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-05 00:47:04  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-05 00:47:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-05 00:47:12  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-05 00:47:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-05 00:47:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-05 00:47:25  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-05 00:47:29  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-05 00:47:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-05 00:47:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-05 00:47:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-05 00:47:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-05 00:47:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-05 00:47:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-05 00:47:59  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-05 00:48:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-05 00:48:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-05 00:48:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-05 00:48:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-05 00:48:22  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-05 00:48:23  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-05 00:48:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-05 00:48:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-05 00:48:37  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-05 00:48:41  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-05 00:48:46  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-05 00:48:50  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 00:48:55  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 00:49:00  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-05 00:49:05  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 00:49:09  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-05 00:49:14  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-05 00:49:18  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-05 00:49:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-05 00:49:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-05 00:49:32  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-05 00:49:37  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-05 00:49:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-05 00:49:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-05 00:49:51  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-05 00:49:56  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 00:50:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-05 00:50:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-05 00:50:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-05 00:50:14  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-05 00:50:19  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-05 00:50:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-05 00:50:29  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-05 00:50:33  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-05 00:50:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-05 00:50:42  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-05 00:50:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-05 00:50:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-05 00:50:56  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-05 00:51:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-05 00:51:06  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-05 00:51:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-05 00:51:15  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-05 00:51:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-05 00:51:24  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-05 00:51:29  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-05 00:51:34  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-05 00:51:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-05 00:51:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-05 00:51:43  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-05 00:51:48  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-05 00:51:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-05 00:51:57  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-05 00:52:02  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-05 00:52:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-05 00:52:11  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-05 00:52:16  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-05 00:52:20  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-05 00:52:25  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-05 00:52:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-05 00:52:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-05 00:52:38  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-05 00:52:43  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-05 00:52:48  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-05 00:52:52  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-05 00:52:57  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-05 00:53:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-05 00:53:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-05 00:53:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-05 00:53:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-05 00:53:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-05 00:53:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-05 00:53:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-05 00:53:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-05 00:53:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-05 00:53:41  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-05 00:53:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-05 00:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-05 00:53:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-05 00:53:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-05 00:53:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-05 00:54:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-05 00:54:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-05 00:54:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-05 00:54:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-05 00:54:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-05 00:54:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-05 00:54:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-05 00:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-05 00:54:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-05 00:54:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-05 00:54:38  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-05 00:54:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-05 00:54:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-05 00:54:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-05 00:54:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-05 00:54:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-05 00:55:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-05 00:55:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-05 00:55:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-05 00:55:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-05 00:55:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-05 00:55:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-05 00:55:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-05 00:55:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-05 00:55:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-05 00:55:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-05 00:55:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-05 00:55:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-05 00:55:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-05 00:55:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-05 00:55:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-05 00:55:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-05 00:56:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-05 00:56:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-05 00:56:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-05 00:56:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-05 00:56:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-05 00:56:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-05 00:56:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-05 00:56:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-05 00:56:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-05 00:56:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-05 00:56:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-05 00:56:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-05 00:56:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-05 00:56:48  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-05 00:56:53  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-05 00:56:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-05 00:57:03  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-05 00:57:04  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-05 00:57:08  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-05 00:57:13  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-05 00:57:17  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-05 00:57:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-05 00:57:27  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-05 00:57:31  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-05 00:57:36  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-05 00:57:40  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-05 00:57:45  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-05 00:57:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-05 00:57:54  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-05 00:57:59  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-05 00:58:03  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-05 00:58:08  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-05 00:58:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-05 00:58:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-05 00:58:22  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-05 00:58:26  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-05 00:58:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-05 00:58:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-05 00:58:40  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-05 00:58:44  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-05 00:58:49  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-05 00:58:54  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-05 00:58:59  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-05 00:59:03  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-05 00:59:07  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-05 00:59:12  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-05 00:59:17  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-05 00:59:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-05 00:59:26  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-05 00:59:30  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-05 00:59:35  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-05 00:59:39  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-05 00:59:44  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-05 00:59:48  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-05 00:59:53  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-05 00:59:58  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-05 01:00:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-05 01:00:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-05 01:00:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-05 01:00:16  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-05 01:00:21  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-05 01:00:26  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-05 01:00:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-05 01:00:35  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-05 01:00:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-05 01:00:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-05 01:00:48  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-05 01:00:53  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-05 01:00:58  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-05 01:01:02  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-05 01:01:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-05 01:01:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-05 01:01:16  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-05 01:01:21  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-05 01:01:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-05 01:01:30  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-05 01:01:35  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-05 01:01:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-05 01:01:44  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-05 01:01:49  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-05_01-01-51 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients?_prerender {"code":"ECONNRESET"}
2017-04-05 01:03:54  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-05 01:03:59  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-05 01:04:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-05 01:04:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-05 01:04:13  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-05 01:04:17  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-05 01:04:22  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-05 01:04:27  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-05 01:04:31  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-05 01:04:36  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-05 01:04:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-05 01:04:45  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-05 01:04:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-05 01:04:55  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-05 01:04:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-05 01:05:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-05 01:05:09  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-05 01:05:13  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-05 01:05:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-05 01:05:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-05 01:05:28  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-05 01:05:32  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-05 01:05:37  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-05 01:05:41  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-05 01:05:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-05 01:05:50  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-05 01:05:55  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-05 01:06:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-05 01:06:04  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-05 01:06:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-05 01:06:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-05 01:06:18  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-05 01:06:23  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-05 01:06:27  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-05 01:06:32  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-05 01:06:37  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-05 01:06:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-05 01:06:46  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-05 01:06:51  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-05 01:06:56  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-05 01:07:00  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-05 01:07:05  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-05 01:07:09  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-05 01:07:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-05 01:07:18  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-05 01:07:23  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-05 01:07:27  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-05 01:07:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-05 01:07:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-05 01:07:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-05 01:07:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-05 01:07:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-05 01:07:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-05 01:08:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-05 01:08:05  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-05 01:08:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-05 01:08:14  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-05 01:08:19  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-05 01:08:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-05 01:08:27  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-05 01:08:32  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-05 01:08:37  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-05 01:08:41  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-05 01:08:46  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-05 01:08:50  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-05 01:08:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-05 01:09:00  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-05 01:09:04  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-05 01:09:09  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-05 01:09:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-05 01:09:18  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-05 01:09:23  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-05 01:09:27  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-05 01:09:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-05 01:09:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-05 01:09:41  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-05 01:09:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-05 01:09:51  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-05 01:09:55  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-05 01:10:00  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-05 01:10:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-05 01:10:09  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-05 01:10:14  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-05 01:10:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-05 01:10:22  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-05 01:10:27  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-05 01:10:31  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-05 01:10:35  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-05 01:10:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-05 01:10:45  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-05 01:10:49  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-05 01:10:53  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-05 01:10:58  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-05 01:11:03  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-05 01:11:07  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-05 01:11:12  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-05 01:11:17  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-05 01:11:21  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-05 01:11:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-05 01:11:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-05 01:11:34  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-05 01:11:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-05 01:11:43  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-05 01:11:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-05 01:11:51  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-05 01:11:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-05 01:12:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-05 01:12:04  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-05 01:12:09  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-05 01:12:13  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-05 01:12:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-05 01:12:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-05 01:12:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-05 01:12:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-05 01:12:35  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-05 01:12:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-05 01:12:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-05 01:12:48  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-05 01:12:52  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-05 01:12:57  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-05 01:13:01  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-05 01:13:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-05 01:13:10  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-05 01:13:14  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-05 01:13:19  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-05 01:13:23  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-05 01:13:28  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-05 01:13:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-05 01:13:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-05 01:13:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-05 01:13:47  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-05 01:13:47  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-05 01:13:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-05 01:13:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-05 01:14:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-05 01:14:06  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-05 01:14:10  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-05 01:14:15  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-05 01:14:19  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-05 01:14:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-05 01:14:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-05 01:14:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-05 01:14:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-05 01:14:41  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-05 01:14:45  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-05 01:14:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-05 01:14:55  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-05 01:14:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-05 01:15:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-05 01:15:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-05 01:15:13  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-05 01:15:17  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-05 01:15:22  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-05 01:15:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-05 01:15:31  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-05 01:15:35  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-05 01:15:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-05 01:15:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-05 01:15:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-05 01:15:53  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-05 01:15:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-05 01:16:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-05 01:16:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-05 01:16:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-05 01:16:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-05 01:16:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-05 01:16:22  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-05 01:16:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-05 01:16:31  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-05 01:16:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-05 01:16:39  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-05 01:16:43  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-05 01:16:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-05 01:16:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-05 01:16:57  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-05 01:17:01  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-05 01:17:05  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-05 01:17:09  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-05 01:17:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-05 01:17:17  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-05 01:17:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-05 01:17:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-05 01:17:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-05 01:17:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-05 01:17:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-05 01:17:44  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-05 01:17:49  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-05 01:17:53  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-05 01:17:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-05 01:18:01  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-05 01:18:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-05 01:18:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-05 01:18:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-05 01:18:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 01:18:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 01:18:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 01:18:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 01:18:34  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-05 01:18:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 01:18:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 01:18:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-05 01:18:51  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-05 01:18:55  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-05 01:18:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-05 01:19:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-05 01:19:08  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-05 01:19:12  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-05 01:19:16  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-05 01:19:20  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-05 01:19:24  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-05 01:19:28  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-05 01:19:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-05 01:19:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-05 01:19:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-05 01:19:44  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-05 01:19:48  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-05 01:19:52  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-05 01:19:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-05 01:20:01  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-05 01:20:05  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-05 01:20:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 01:20:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 01:20:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 01:20:21  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 01:20:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 01:20:30  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-05 01:20:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 01:20:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 01:20:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 01:20:46  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 01:20:50  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-05 01:20:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 01:20:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 01:21:02  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 01:21:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-05 01:21:11  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-05_01-31-51 Restart Xvfb...
2017-04-05_02-01-51 Restart Xvfb...
2017-04-05_02-31-51 Restart Xvfb...
2017-04-05_03-01-51 Restart Xvfb...
2017-04-05 03:31:46 reset updateRequest
2017-04-05 03:31:46  - 14968  http://www.lymphomahub.com/
2017-04-05 03:31:51  - 14968  http://www.lymphomahub.com/about
2017-04-05 03:31:51  - 14968  http://www.lymphomahub.com/about
2017-04-05_03-31-51 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-05 03:33:56  - 14968  http://www.lymphomahub.com/about
2017-04-05 03:33:56  - 14968  http://www.lymphomahub.com/about
2017-04-05 03:34:03  - 14968  http://www.lymphomahub.com/terms
2017-04-05 03:34:03  - 14968  http://www.lymphomahub.com/terms
2017-04-05 03:34:07  - 14968  http://www.lymphomahub.com/undefined
2017-04-05 03:34:07  - 14968  http://www.lymphomahub.com/therapies
2017-04-05 03:34:07  - 14968  http://www.lymphomahub.com/therapies
2017-04-05 03:34:17  - 14968  http://www.lymphomahub.com/newsletter
2017-04-05 03:34:17  - 14968  http://www.lymphomahub.com/newsletter
2017-04-05 03:34:21  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-05 03:34:21  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-05 03:34:25  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-05 03:34:25  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-05 03:34:30  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-05 03:34:30  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-05 03:34:36  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-05 03:34:40  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-05 03:34:45  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-05 03:34:49  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-05 03:34:53  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-05 03:34:58  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-05 03:35:03  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-05 03:35:07  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-05 03:35:12  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-05 03:35:16  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-05 03:35:20  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-05 03:35:25  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-05 03:35:29  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-05 03:35:34  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-05 03:35:38  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-05 03:35:43  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-05 03:35:47  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-05 03:35:52  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-05 03:35:56  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-05 03:36:00  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-05 03:36:04  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-05 03:36:09  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-05 03:36:13  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-05 03:36:18  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-05 03:36:22  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-05 03:36:27  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-05 03:36:31  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-05 03:36:36  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-05 03:36:40  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-05 03:36:45  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-05 03:36:49  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-05 03:36:54  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-05 03:36:58  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-05 03:37:03  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-05 03:37:07  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-05 03:37:11  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-05 03:37:16  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-05 03:37:20  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-05 03:37:25  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-05 03:37:29  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-05 03:37:34  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-05 03:37:38  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-05 03:37:42  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-05 03:37:47  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-05 03:37:51  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-05 03:37:56  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-05 03:38:00  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-05 03:38:05  - 14968  http://www.lymphomahub.com/medical-information
2017-04-05 03:38:10  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-05 03:38:14  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-05 03:38:19  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-05 03:38:23  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-05 03:38:28  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-05 03:38:32  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-05 03:38:37  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-05 03:38:42  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-05 03:38:46  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-05 03:38:51  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-05 03:38:55  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-05 03:39:00  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-05 03:39:00  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-05 03:39:05  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-05 03:39:10  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-05 03:39:14  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-05 03:39:18  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-05 03:39:23  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-05 03:39:27  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-05 03:39:32  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-05 03:39:36  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-05 03:39:41  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-05 03:39:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-05 03:39:50  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-05 03:39:54  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-05 03:39:59  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-05 03:40:03  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-05 03:40:08  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-05 03:40:13  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-05 03:40:17  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-05 03:40:21  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-05 03:40:26  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-05 03:40:30  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-05 03:40:35  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-05 03:40:39  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-05 03:40:44  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-05 03:40:48  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-05 03:40:52  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-05 03:40:57  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-05 03:41:01  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-05 03:41:06  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-05 03:41:10  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-05 03:41:14  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-05 03:41:15  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-05 03:41:20  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-05 03:41:24  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-05 03:41:29  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-05 03:41:33  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-05 03:41:38  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-05 03:41:42  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-05 03:41:47  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-05 03:41:51  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-05 03:41:55  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-05 03:41:55  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-05 03:42:00  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-05 03:42:04  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-05 03:42:09  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-05 03:42:13  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-05 03:42:18  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-05 03:42:18  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-05 03:42:23  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-05 03:42:27  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-05 03:42:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-05 03:42:35  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-05 03:42:39  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-05 03:42:43  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-05 03:42:47  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-05 03:42:51  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-05 03:42:55  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-05 03:43:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-05 03:43:04  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-05 03:43:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-05 03:43:13  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-05 03:43:17  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-05 03:43:17  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-05 03:43:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-05 03:43:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-05 03:43:31  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-05 03:43:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-05 03:43:39  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-05 03:43:44  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-05 03:43:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-05 03:43:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-05 03:43:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-05 03:44:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-05 03:44:03  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-05 03:44:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-05 03:44:11  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-05 03:44:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-05 03:44:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-05 03:44:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-05 03:44:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-05 03:44:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-05 03:44:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-05 03:44:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-05 03:44:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-05 03:44:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-05 03:44:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-05 03:44:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-05 03:45:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-05 03:45:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-05 03:45:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-05 03:45:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-05 03:45:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-05 03:45:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-05 03:45:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-05 03:45:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-05 03:45:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-05 03:45:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-05 03:45:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-05 03:45:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-05 03:45:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-05 03:46:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-05 03:46:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-05 03:46:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-05 03:46:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-05 03:46:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-05 03:46:23  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-05 03:46:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-05 03:46:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-05 03:46:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-05 03:46:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-05 03:46:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-05 03:46:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-05 03:46:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-05 03:46:57  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-05 03:47:01  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-05 03:47:06  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-05 03:47:10  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-05 03:47:14  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-05 03:47:18  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-05 03:47:23  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-05 03:47:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-05 03:47:31  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-05 03:47:35  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-05 03:47:39  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-05 03:47:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-05 03:47:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-05 03:47:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-05 03:47:56  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-05 03:48:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-05 03:48:05  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-05 03:48:09  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-05 03:48:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-05 03:48:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-05 03:48:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-05 03:48:28  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-05 03:48:29  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-05 03:48:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-05 03:48:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-05 03:48:42  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-05 03:48:47  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-05 03:48:51  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-05 03:48:56  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 03:49:00  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 03:49:05  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-05 03:49:10  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 03:49:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-05 03:49:19  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-05 03:49:24  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-05 03:49:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-05 03:49:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-05 03:49:38  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-05 03:49:42  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-05 03:49:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-05 03:49:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-05 03:49:56  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-05 03:50:01  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 03:50:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-05 03:50:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-05 03:50:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-05 03:50:19  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-05 03:50:24  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-05 03:50:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-05 03:50:33  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-05 03:50:37  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-05 03:50:43  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-05 03:50:47  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-05 03:50:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-05 03:50:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-05 03:51:01  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-05 03:51:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-05 03:51:11  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-05 03:51:15  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-05 03:51:20  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-05 03:51:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-05 03:51:35  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-05 03:51:39  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-05 03:51:44  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-05 03:51:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-05 03:51:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-05 03:51:54  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-05 03:51:58  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-05 03:52:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-05 03:52:07  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-05 03:52:12  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-05 03:52:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-05 03:52:21  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-05 03:52:26  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-05 03:52:30  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-05 03:52:35  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-05 03:52:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-05 03:52:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-05 03:52:49  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-05 03:52:54  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-05 03:52:58  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-05 03:53:03  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-05 03:53:08  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-05 03:53:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-05 03:53:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-05 03:53:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-05 03:53:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-05 03:53:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-05 03:53:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-05 03:53:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-05 03:53:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-05 03:53:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-05 03:53:50  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-05 03:53:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-05 03:53:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-05 03:54:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-05 03:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-05 03:54:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-05 03:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-05 03:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-05 03:54:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-05 03:54:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-05 03:54:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-05 03:54:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-05 03:54:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-05 03:54:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-05 03:54:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-05 03:54:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-05 03:54:47  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-05 03:54:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-05 03:54:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-05 03:54:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-05 03:55:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-05 03:55:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-05 03:55:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-05 03:55:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-05 03:55:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-05 03:55:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-05 03:55:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-05 03:55:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-05 03:55:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-05 03:55:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-05 03:55:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-05 03:55:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-05 03:55:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-05 03:55:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-05 03:55:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-05 03:55:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-05 03:56:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-05 03:56:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-05 03:56:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-05 03:56:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-05 03:56:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-05 03:56:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-05 03:56:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-05 03:56:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-05 03:56:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-05 03:56:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-05 03:56:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-05 03:56:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-05 03:56:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-05 03:56:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-05 03:56:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-05 03:56:58  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-05 03:57:03  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-05 03:57:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-05 03:57:12  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-05 03:57:12  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-05 03:57:17  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-05 03:57:22  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-05 03:57:26  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-05 03:57:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-05 03:57:36  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-05 03:57:40  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-05 03:57:45  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-05 03:57:49  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-05 03:57:54  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-05 03:57:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-05 03:58:03  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-05 03:58:07  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-05 03:58:12  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-05 03:58:17  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-05 03:58:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-05 03:58:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-05 03:58:31  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-05 03:58:35  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-05 03:58:40  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-05 03:58:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-05 03:58:49  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-05 03:58:54  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-05 03:58:58  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-05 03:59:03  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-05 03:59:07  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-05 03:59:12  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-05 03:59:17  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-05 03:59:21  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-05 03:59:26  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-05 03:59:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-05 03:59:35  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-05 03:59:39  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-05 03:59:44  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-05 03:59:49  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-05 03:59:53  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-05 03:59:58  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-05 04:00:02  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-05 04:00:07  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-05 04:00:11  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-05 04:00:16  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-05 04:00:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-05 04:00:25  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-05 04:00:30  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-05 04:00:34  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-05 04:00:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-05 04:00:43  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-05 04:00:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-05 04:00:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-05 04:00:57  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-05 04:01:01  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-05 04:01:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-05 04:01:10  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-05 04:01:15  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-05 04:01:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-05 04:01:24  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-05 04:01:29  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-05 04:01:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-05 04:01:38  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-05 04:01:42  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-05 04:01:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-05_04-01-51 Restart Xvfb...
2017-04-05 04:01:52  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-05 04:01:56  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-05 04:02:01  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-05 04:02:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-05 04:02:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-05 04:02:15  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-05 04:02:19  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-05 04:02:24  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-05 04:02:29  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-05 04:02:33  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-05 04:02:38  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-05 04:02:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-05 04:02:47  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-05 04:02:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-05 04:02:57  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-05 04:03:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-05 04:03:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-05 04:03:10  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-05 04:03:15  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-05 04:03:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-05 04:03:24  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-05 04:03:28  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-05 04:03:33  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-05 04:03:37  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-05 04:03:41  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-05 04:03:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-05 04:03:51  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-05 04:03:55  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-05 04:04:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-05 04:04:05  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-05 04:04:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-05 04:04:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-05 04:04:19  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-05 04:04:23  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-05 04:04:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-05 04:04:32  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-05 04:04:37  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-05 04:04:41  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-05 04:04:46  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-05 04:04:50  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-05 04:04:55  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-05 04:05:00  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-05 04:05:05  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-05 04:05:10  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-05 04:05:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-05 04:05:19  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-05 04:05:23  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-05 04:05:28  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-05 04:05:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-05 04:05:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-05 04:05:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-05 04:05:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-05 04:05:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-05 04:05:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-05 04:06:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-05 04:06:05  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-05 04:06:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-05 04:06:14  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-05 04:06:19  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-05 04:06:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-05 04:06:27  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-05 04:06:32  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-05 04:06:36  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-05 04:06:41  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-05 04:06:45  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-05 04:06:50  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-05 04:06:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-05 04:06:59  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-05 04:07:04  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-05 04:07:09  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-05 04:07:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-05 04:07:18  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-05 04:07:22  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-05 04:07:27  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-05 04:07:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-05 04:07:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-05 04:07:41  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-05 04:07:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-05 04:07:51  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-05 04:07:55  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-05 04:08:00  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-05 04:08:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-05 04:08:09  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-05 04:08:13  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-05 04:08:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-05 04:08:22  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-05 04:08:27  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-05 04:08:31  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-05 04:08:36  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-05 04:08:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-05 04:08:45  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-05 04:08:49  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-05 04:08:54  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-05 04:08:58  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-05 04:09:03  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-05 04:09:08  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-05 04:09:12  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-05 04:09:17  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-05 04:09:21  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-05 04:09:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-05 04:09:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-05 04:09:34  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-05 04:09:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-05 04:09:43  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-05 04:09:48  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-05 04:09:52  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-05 04:09:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-05 04:10:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-05 04:10:06  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-05 04:10:10  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-05 04:10:14  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-05 04:10:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-05 04:10:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-05 04:10:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-05 04:10:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-05 04:10:36  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-05 04:10:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-05 04:10:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-05 04:10:50  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-05 04:10:54  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-05 04:10:58  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-05 04:11:03  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-05 04:11:07  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-05 04:11:11  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-05 04:11:15  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-05 04:11:20  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-05 04:11:24  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-05 04:11:29  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-05 04:11:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-05 04:11:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-05 04:11:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-05 04:11:48  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-05 04:11:48  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-05 04:11:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-05 04:11:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-05 04:12:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-05 04:12:07  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-05 04:12:11  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-05 04:12:16  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-05 04:12:21  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-05 04:12:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-05 04:12:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-05 04:12:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-05 04:12:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-05 04:12:43  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-05 04:12:47  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-05 04:12:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-05 04:12:56  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-05 04:13:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-05 04:13:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-05 04:13:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-05 04:13:14  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-05 04:13:18  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-05 04:13:23  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-05 04:13:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-05 04:13:32  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-05 04:13:36  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-05 04:13:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-05 04:13:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-05 04:13:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-05 04:13:54  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-05 04:13:58  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-05 04:14:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-05 04:14:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-05 04:14:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-05 04:14:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-05 04:14:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-05 04:14:23  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-05 04:14:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-05 04:14:31  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-05 04:14:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-05 04:14:39  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-05 04:14:43  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-05 04:14:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-05 04:14:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-05 04:14:57  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-05 04:15:01  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-05 04:15:05  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-05 04:15:09  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-05 04:15:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-05 04:15:18  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-05 04:15:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-05 04:15:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-05 04:15:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-05 04:15:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-05 04:15:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-05 04:15:44  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-05 04:15:48  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-05 04:15:52  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-05 04:15:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-05 04:16:01  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-05 04:16:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-05 04:16:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-05 04:16:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-05 04:16:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 04:16:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 04:16:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 04:16:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 04:16:34  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-05 04:16:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 04:16:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 04:16:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-05 04:16:51  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-05 04:16:55  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-05 04:16:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-05 04:17:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-05 04:17:07  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-05 04:17:11  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-05 04:17:15  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-05 04:17:20  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-05 04:17:24  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-05 04:17:28  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-05 04:17:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-05 04:17:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-05 04:17:41  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-05 04:17:45  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-05 04:17:49  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-05 04:17:53  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-05 04:17:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-05 04:18:01  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-05 04:18:05  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-05 04:18:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 04:18:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 04:18:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 04:18:21  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 04:18:25  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 04:18:29  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-05 04:18:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 04:18:37  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 04:18:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 04:18:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 04:18:50  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-05 04:18:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 04:18:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 04:19:02  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 04:19:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-05 04:19:10  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-05_04-31-51 Restart Xvfb...
2017-04-05_05-01-51 Restart Xvfb...
2017-04-05_05-31-51 Restart Xvfb...
2017-04-05_06-01-52 Restart Xvfb...
2017-04-05 06:31:46 reset updateRequest
2017-04-05 06:31:46  - 14968  http://www.lymphomahub.com/
2017-04-05 06:31:50  - 14968  http://www.lymphomahub.com/about
2017-04-05 06:31:51  - 14968  http://www.lymphomahub.com/about
2017-04-05_06-31-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-05 06:33:55  - 14968  http://www.lymphomahub.com/about
2017-04-05 06:33:56  - 14968  http://www.lymphomahub.com/about
2017-04-05 06:34:00  - 14968  http://www.lymphomahub.com/terms
2017-04-05 06:34:02  - 14968  http://www.lymphomahub.com/terms
2017-04-05 06:34:04  - 14968  http://www.lymphomahub.com/undefined
2017-04-05 06:34:05  - 14968  http://www.lymphomahub.com/therapies
2017-04-05 06:34:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-05 06:34:14  - 14968  http://www.lymphomahub.com/newsletter
2017-04-05 06:34:15  - 14968  http://www.lymphomahub.com/newsletter
2017-04-05 06:34:18  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-05 06:34:19  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-05 06:34:22  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-05 06:34:23  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-05 06:34:27  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-05 06:34:28  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-05 06:34:33  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-05 06:34:38  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-05 06:34:42  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-05 06:34:47  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-05 06:34:51  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-05 06:34:56  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-05 06:35:00  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-05 06:35:05  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-05 06:35:09  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-05 06:35:14  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-05 06:35:18  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-05 06:35:23  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-05 06:35:27  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-05 06:35:32  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-05 06:35:36  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-05 06:35:41  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-05 06:35:45  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-05 06:35:50  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-05 06:35:54  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-05 06:35:58  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-05 06:36:03  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-05 06:36:08  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-05 06:36:12  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-05 06:36:17  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-05 06:36:21  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-05 06:36:26  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-05 06:36:30  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-05 06:36:35  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-05 06:36:40  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-05 06:36:44  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-05 06:36:49  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-05 06:36:54  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-05 06:36:59  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-05 06:37:03  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-05 06:37:08  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-05 06:37:12  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-05 06:37:17  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-05 06:37:22  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-05 06:37:26  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-05 06:37:30  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-05 06:37:35  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-05 06:37:40  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-05 06:37:44  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-05 06:37:49  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-05 06:37:53  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-05 06:37:58  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-05 06:38:02  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-05 06:38:07  - 14968  http://www.lymphomahub.com/medical-information
2017-04-05 06:38:11  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-05 06:38:16  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-05 06:38:20  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-05 06:38:25  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-05 06:38:29  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-05 06:38:34  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-05 06:38:38  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-05 06:38:43  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-05 06:38:48  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-05 06:38:52  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-05 06:38:56  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-05 06:39:01  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-05 06:39:01  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-05 06:39:06  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-05 06:39:10  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-05 06:39:15  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-05 06:39:20  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-05 06:39:24  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-05 06:39:29  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-05 06:39:33  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-05 06:39:38  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-05 06:39:42  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-05 06:39:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-05 06:39:51  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-05 06:39:55  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-05 06:40:00  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-05 06:40:04  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-05 06:40:09  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-05 06:40:13  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-05 06:40:18  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-05 06:40:22  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-05 06:40:27  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-05 06:40:31  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-05 06:40:36  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-05 06:40:40  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-05 06:40:45  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-05 06:40:49  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-05 06:40:54  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-05 06:40:58  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-05 06:41:03  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-05 06:41:07  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-05 06:41:11  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-05 06:41:16  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-05 06:41:17  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-05 06:41:21  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-05 06:41:26  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-05 06:41:30  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-05 06:41:35  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-05 06:41:39  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-05 06:41:44  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-05 06:41:48  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-05 06:41:53  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-05 06:41:56  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-05 06:41:57  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-05 06:42:01  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-05 06:42:06  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-05 06:42:11  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-05 06:42:15  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-05 06:42:20  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-05 06:42:20  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-05 06:42:25  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-05 06:42:29  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-05 06:42:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-05 06:42:37  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-05 06:42:42  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-05 06:42:46  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-05 06:42:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-05 06:42:54  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-05 06:42:58  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-05 06:43:03  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-05 06:43:06  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-05 06:43:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-05 06:43:15  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-05 06:43:19  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-05 06:43:20  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-05 06:43:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-05 06:43:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-05 06:43:33  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-05 06:43:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-05 06:43:41  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-05 06:43:46  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-05 06:43:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-05 06:43:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-05 06:43:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-05 06:44:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-05 06:44:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-05 06:44:10  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-05 06:44:13  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-05 06:44:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-05 06:44:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-05 06:44:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-05 06:44:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-05 06:44:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-05 06:44:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-05 06:44:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-05 06:44:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-05 06:44:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-05 06:44:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-05 06:45:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-05 06:45:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-05 06:45:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-05 06:45:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-05 06:45:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-05 06:45:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-05 06:45:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-05 06:45:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-05 06:45:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-05 06:45:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-05 06:45:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-05 06:45:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-05 06:45:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-05 06:45:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-05 06:46:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-05 06:46:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-05 06:46:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-05 06:46:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-05 06:46:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-05 06:46:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-05 06:46:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-05 06:46:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-05 06:46:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-05 06:46:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-05 06:46:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-05 06:46:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-05 06:46:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-05 06:46:59  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-05 06:47:04  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-05 06:47:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-05 06:47:13  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-05 06:47:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-05 06:47:21  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-05 06:47:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-05 06:47:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-05 06:47:34  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-05 06:47:38  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-05 06:47:42  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-05 06:47:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-05 06:47:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-05 06:47:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-05 06:47:59  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-05 06:48:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-05 06:48:08  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-05 06:48:12  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-05 06:48:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-05 06:48:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-05 06:48:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-05 06:48:31  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-05 06:48:32  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-05 06:48:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-05 06:48:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-05 06:48:46  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-05 06:48:50  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-05 06:48:55  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-05 06:48:59  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 06:49:04  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 06:49:09  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-05 06:49:13  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 06:49:18  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-05 06:49:22  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-05 06:49:27  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-05 06:49:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-05 06:49:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-05 06:49:41  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-05 06:49:46  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-05 06:49:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-05 06:49:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-05 06:50:00  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-05 06:50:05  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 06:50:09  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-05 06:50:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-05 06:50:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-05 06:50:24  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-05 06:50:28  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-05 06:50:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-05 06:50:38  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-05 06:50:42  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-05 06:50:47  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-05 06:50:51  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-05 06:50:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-05 06:51:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-05 06:51:05  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-05 06:51:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-05 06:51:14  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-05 06:51:19  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-05 06:51:24  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-05 06:51:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-05 06:51:33  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-05 06:51:38  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-05 06:51:43  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-05 06:51:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-05 06:51:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-05 06:51:52  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-05 06:51:58  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-05 06:52:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-05 06:52:06  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-05 06:52:11  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-05 06:52:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-05 06:52:20  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-05 06:52:25  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-05 06:52:30  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-05 06:52:34  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-05 06:52:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-05 06:52:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-05 06:52:48  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-05 06:52:52  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-05 06:52:57  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-05 06:53:02  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-05 06:53:06  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-05 06:53:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-05 06:53:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-05 06:53:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-05 06:53:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-05 06:53:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-05 06:53:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-05 06:53:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-05 06:53:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-05 06:53:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-05 06:53:50  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-05 06:53:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-05 06:53:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-05 06:53:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-05 06:54:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-05 06:54:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-05 06:54:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-05 06:54:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-05 06:54:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-05 06:54:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-05 06:54:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-05 06:54:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-05 06:54:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-05 06:54:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-05 06:54:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-05 06:54:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-05 06:54:46  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-05 06:54:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-05 06:54:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-05 06:54:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-05 06:55:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-05 06:55:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-05 06:55:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-05 06:55:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-05 06:55:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-05 06:55:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-05 06:55:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-05 06:55:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-05 06:55:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-05 06:55:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-05 06:55:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-05 06:55:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-05 06:55:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-05 06:55:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-05 06:55:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-05 06:55:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-05 06:56:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-05 06:56:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-05 06:56:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-05 06:56:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-05 06:56:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-05 06:56:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-05 06:56:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-05 06:56:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-05 06:56:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-05 06:56:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-05 06:56:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-05 06:56:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-05 06:56:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-05 06:56:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-05 06:56:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-05 06:56:56  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-05 06:57:01  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-05 06:57:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-05 06:57:10  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-05 06:57:11  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-05 06:57:15  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-05 06:57:20  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-05 06:57:24  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-05 06:57:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-05 06:57:34  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-05 06:57:39  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-05 06:57:43  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-05 06:57:48  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-05 06:57:52  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-05 06:57:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-05 06:58:02  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-05 06:58:06  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-05 06:58:11  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-05 06:58:15  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-05 06:58:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-05 06:58:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-05 06:58:30  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-05 06:58:34  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-05 06:58:39  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-05 06:58:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-05 06:58:48  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-05 06:58:52  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-05 06:58:57  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-05 06:59:01  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-05 06:59:06  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-05 06:59:10  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-05 06:59:15  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-05 06:59:19  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-05 06:59:24  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-05 06:59:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-05 06:59:33  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-05 06:59:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-05 06:59:42  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-05 06:59:47  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-05 06:59:52  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-05 06:59:56  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-05 07:00:01  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-05 07:00:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-05 07:00:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-05 07:00:15  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-05 07:00:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-05 07:00:24  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-05 07:00:29  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-05 07:00:33  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-05 07:00:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-05 07:00:43  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-05 07:00:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-05 07:00:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-05 07:00:58  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-05 07:01:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-05 07:01:07  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-05 07:01:11  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-05 07:01:16  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-05 07:01:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-05 07:01:25  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-05 07:01:30  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-05 07:01:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-05 07:01:39  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-05 07:01:44  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-05 07:01:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-05_07-01-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl?_prerender {"code":"ECONNRESET"}
2017-04-05 07:03:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-05 07:03:58  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-05 07:04:03  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-05 07:04:08  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-05 07:04:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-05 07:04:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-05 07:04:22  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-05 07:04:27  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-05 07:04:31  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-05 07:04:36  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-05 07:04:40  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-05 07:04:45  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-05 07:04:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-05 07:04:54  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-05 07:04:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-05 07:05:04  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-05 07:05:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-05 07:05:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-05 07:05:18  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-05 07:05:23  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-05 07:05:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-05 07:05:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-05 07:05:36  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-05 07:05:41  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-05 07:05:46  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-05 07:05:50  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-05 07:05:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-05 07:06:00  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-05 07:06:04  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-05 07:06:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-05 07:06:14  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-05 07:06:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-05 07:06:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-05 07:06:27  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-05 07:06:32  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-05 07:06:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-05 07:06:42  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-05 07:06:46  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-05 07:06:51  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-05 07:06:55  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-05 07:07:00  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-05 07:07:05  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-05 07:07:10  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-05 07:07:14  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-05 07:07:19  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-05 07:07:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-05 07:07:29  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-05 07:07:34  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-05 07:07:39  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-05 07:07:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-05 07:07:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-05 07:07:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-05 07:07:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-05 07:08:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-05 07:08:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-05 07:08:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-05 07:08:16  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-05 07:08:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-05 07:08:25  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-05 07:08:30  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-05 07:08:34  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-05 07:08:38  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-05 07:08:43  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-05 07:08:47  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-05 07:08:52  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-05 07:08:57  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-05 07:09:01  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-05 07:09:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-05 07:09:11  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-05 07:09:15  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-05 07:09:20  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-05 07:09:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-05 07:09:30  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-05 07:09:35  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-05 07:09:39  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-05 07:09:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-05 07:09:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-05 07:09:53  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-05 07:09:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-05 07:10:02  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-05 07:10:07  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-05 07:10:11  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-05 07:10:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-05 07:10:20  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-05 07:10:25  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-05 07:10:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-05 07:10:34  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-05 07:10:38  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-05 07:10:43  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-05 07:10:47  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-05 07:10:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-05 07:10:56  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-05 07:11:00  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-05 07:11:05  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-05 07:11:10  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-05 07:11:14  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-05 07:11:19  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-05 07:11:24  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-05 07:11:28  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-05 07:11:32  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-05 07:11:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-05 07:11:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-05 07:11:45  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-05 07:11:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-05 07:11:54  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-05 07:11:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-05 07:12:03  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-05 07:12:07  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-05 07:12:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-05 07:12:17  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-05 07:12:21  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-05 07:12:26  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-05 07:12:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-05 07:12:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-05 07:12:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-05 07:12:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-05 07:12:48  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-05 07:12:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-05 07:12:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-05 07:13:01  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-05 07:13:05  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-05 07:13:10  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-05 07:13:15  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-05 07:13:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-05 07:13:23  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-05 07:13:27  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-05 07:13:32  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-05 07:13:36  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-05 07:13:41  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-05 07:13:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-05 07:13:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-05 07:13:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-05 07:13:59  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-05 07:14:00  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-05 07:14:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-05 07:14:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-05 07:14:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-05 07:14:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-05 07:14:23  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-05 07:14:28  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-05 07:14:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-05 07:14:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-05 07:14:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-05 07:14:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-05 07:14:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-05 07:14:54  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-05 07:14:58  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-05 07:15:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-05 07:15:08  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-05 07:15:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-05 07:15:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-05 07:15:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-05 07:15:26  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-05 07:15:30  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-05 07:15:35  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-05 07:15:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-05 07:15:43  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-05 07:15:47  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-05 07:15:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-05 07:15:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-05 07:16:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-05 07:16:05  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-05 07:16:09  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-05 07:16:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-05 07:16:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-05 07:16:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-05 07:16:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-05 07:16:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-05 07:16:35  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-05 07:16:39  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-05 07:16:43  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-05 07:16:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-05 07:16:51  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-05 07:16:55  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-05 07:16:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-05 07:17:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-05 07:17:08  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-05 07:17:12  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-05 07:17:16  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-05 07:17:20  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-05 07:17:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-05 07:17:29  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-05 07:17:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-05 07:17:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-05 07:17:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-05 07:17:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-05 07:17:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-05 07:17:56  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-05 07:18:01  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-05 07:18:05  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-05 07:18:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-05 07:18:13  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-05 07:18:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-05 07:18:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-05 07:18:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-05 07:18:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 07:18:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 07:18:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 07:18:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 07:18:46  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-05 07:18:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 07:18:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 07:18:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-05 07:19:02  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-05 07:19:06  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-05 07:19:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-05 07:19:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-05 07:19:19  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-05 07:19:23  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-05 07:19:27  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-05 07:19:31  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-05 07:19:36  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-05 07:19:40  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-05 07:19:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-05 07:19:48  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-05 07:19:52  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-05 07:19:56  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-05 07:20:00  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-05 07:20:04  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-05 07:20:08  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-05 07:20:12  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-05 07:20:16  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-05 07:20:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 07:20:24  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 07:20:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 07:20:32  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 07:20:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 07:20:40  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-05 07:20:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 07:20:49  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 07:20:53  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 07:20:57  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 07:21:01  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-05 07:21:05  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 07:21:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 07:21:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 07:21:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-05 07:21:21  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-05_07-31-52 Restart Xvfb...
2017-04-05_08-01-52 Restart Xvfb...
2017-04-05_08-31-52 Restart Xvfb...
2017-04-05_09-01-52 Restart Xvfb...
2017-04-05 09:31:46 reset updateRequest
2017-04-05 09:31:47  - 14968  http://www.lymphomahub.com/
2017-04-05 09:31:51  - 14968  http://www.lymphomahub.com/
2017-04-05 09:31:51  - 14968  http://www.lymphomahub.com/about
2017-04-05_09-31-52 Restart Xvfb...
2017-04-05 09:31:57  - 14968  http://www.lymphomahub.com/terms
2017-04-05 09:32:00  - 14968  http://www.lymphomahub.com/undefined
2017-04-05 09:32:01  - 14968  http://www.lymphomahub.com/therapies
2017-04-05 09:32:07  - 14968  http://www.lymphomahub.com/newsletter
2017-04-05 09:32:10  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-05 09:32:13  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-05 09:32:18  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-05 09:32:23  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-05 09:32:28  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-05 09:32:32  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-05 09:32:36  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-05 09:32:41  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-05 09:32:45  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-05 09:32:50  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-05 09:32:54  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-05 09:32:59  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-05 09:33:03  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-05 09:33:08  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-05 09:33:12  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-05 09:33:16  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-05 09:33:21  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-05 09:33:25  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-05 09:33:30  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-05 09:33:34  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-05 09:33:39  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-05 09:33:43  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-05 09:33:47  - 14968  http://www.lymphomahub.com/therapies/alt-803
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-05 09:33:51  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-05 09:33:56  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-05 09:33:56  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-05 09:34:01  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-05 09:34:06  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-05 09:34:11  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-05 09:34:16  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-05 09:34:20  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-05 09:34:24  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-05 09:34:29  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-05 09:34:33  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-05 09:34:38  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-05 09:34:42  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-05 09:34:47  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-05 09:34:51  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-05 09:34:55  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-05 09:35:00  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-05 09:35:05  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-05 09:35:10  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-05 09:35:14  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-05 09:35:19  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-05 09:35:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-05 09:35:28  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-05 09:35:32  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-05 09:35:37  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-05 09:35:41  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-05 09:35:46  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-05 09:35:50  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-05 09:35:54  - 14968  http://www.lymphomahub.com/medical-information
2017-04-05 09:35:59  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-05 09:36:04  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-05 09:36:08  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-05 09:36:13  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-05 09:36:17  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-05 09:36:22  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-05 09:36:26  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-05 09:36:31  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-05 09:36:35  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-05 09:36:40  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-05 09:36:44  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-05 09:36:49  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-05 09:36:49  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-05 09:36:54  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-05 09:36:58  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-05 09:37:03  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-05 09:37:07  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-05 09:37:11  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-05 09:37:16  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-05 09:37:20  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-05 09:37:24  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-05 09:37:29  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-05 09:37:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-05 09:37:38  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-05 09:37:42  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-05 09:37:47  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-05 09:37:51  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-05 09:37:55  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-05 09:38:00  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-05 09:38:04  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-05 09:38:09  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-05 09:38:13  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-05 09:38:17  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-05 09:38:22  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-05 09:38:26  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-05 09:38:33  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-05 09:38:37  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-05 09:38:41  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-05 09:38:46  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-05 09:38:50  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-05 09:38:55  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-05 09:38:59  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-05 09:39:04  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-05 09:39:04  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-05 09:39:09  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-05 09:39:14  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-05 09:39:18  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-05 09:39:22  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-05 09:39:27  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-05 09:39:31  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-05 09:39:36  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-05 09:39:40  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-05 09:39:44  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-05 09:39:44  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-05 09:39:49  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-05 09:39:53  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-05 09:39:57  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-05 09:40:02  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-05 09:40:06  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-05 09:40:07  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-05 09:40:12  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-05 09:40:16  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-05 09:40:20  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-05 09:40:24  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-05 09:40:28  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-05 09:40:32  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-05 09:40:36  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-05 09:40:40  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-05 09:40:43  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-05 09:40:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-05 09:40:52  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-05 09:40:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-05 09:41:01  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-05 09:41:05  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-05 09:41:05  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-05 09:41:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-05 09:41:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-05 09:41:18  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-05 09:41:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-05 09:41:27  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-05 09:41:32  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-05 09:41:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-05 09:41:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-05 09:41:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-05 09:41:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-05 09:41:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-05 09:41:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-05 09:41:59  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-05 09:42:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-05 09:42:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-05 09:42:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-05 09:42:16  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-05 09:42:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-05 09:42:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-05 09:42:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-05 09:42:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-05 09:42:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-05 09:42:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-05 09:42:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-05 09:42:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-05 09:42:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-05 09:42:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-05 09:43:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-05 09:43:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-05 09:43:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-05 09:43:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-05 09:43:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-05 09:43:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-05 09:43:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-05 09:43:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-05 09:43:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-05 09:43:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-05 09:43:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-05 09:43:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-05 09:43:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-05 09:44:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-05 09:44:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-05 09:44:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-05 09:44:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-05 09:44:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-05 09:44:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-05 09:44:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-05 09:44:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-05 09:44:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-05 09:44:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-05 09:44:44  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-05 09:44:49  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-05 09:44:53  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-05 09:44:57  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-05 09:45:02  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-05 09:45:06  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-05 09:45:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-05 09:45:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-05 09:45:19  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-05 09:45:23  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-05 09:45:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-05 09:45:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-05 09:45:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-05 09:45:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-05 09:45:44  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-05 09:45:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-05 09:45:52  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-05 09:45:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-05 09:46:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-05 09:46:06  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-05 09:46:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-05 09:46:16  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-05 09:46:17  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-05 09:46:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-05 09:46:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-05 09:46:30  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-05 09:46:35  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-05 09:46:40  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-05 09:46:44  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 09:46:49  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 09:46:53  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-05 09:46:58  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 09:47:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-05 09:47:07  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-05 09:47:12  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-05 09:47:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-05 09:47:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-05 09:47:26  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-05 09:47:30  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-05 09:47:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-05 09:47:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-05 09:47:44  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-05 09:47:49  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 09:47:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-05 09:47:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-05 09:48:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-05 09:48:07  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-05 09:48:12  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-05 09:48:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-05 09:48:21  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-05 09:48:26  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-05 09:48:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-05 09:48:36  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-05 09:48:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-05 09:48:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-05 09:48:50  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-05 09:48:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-05 09:48:59  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-05 09:49:04  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-05 09:49:08  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-05 09:49:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-05 09:49:18  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-05 09:49:23  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-05 09:49:28  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-05 09:49:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-05 09:49:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-05 09:49:37  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-05 09:49:42  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-05 09:49:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-05 09:49:51  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-05 09:49:55  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-05 09:50:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-05 09:50:05  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-05 09:50:09  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-05 09:50:14  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-05 09:50:20  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-05 09:50:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-05 09:50:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-05 09:50:34  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-05 09:50:39  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-05 09:50:43  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-05 09:50:48  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-05 09:50:52  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-05 09:50:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-05 09:51:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-05 09:51:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-05 09:51:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-05 09:51:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-05 09:51:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-05 09:51:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-05 09:51:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-05 09:51:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-05 09:51:35  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-05 09:51:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-05 09:51:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-05 09:51:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-05 09:51:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-05 09:51:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-05 09:51:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-05 09:51:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-05 09:52:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-05 09:52:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-05 09:52:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-05 09:52:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-05 09:52:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-05 09:52:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-05 09:52:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-05 09:52:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-05 09:52:32  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-05 09:52:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-05 09:52:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-05 09:52:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-05 09:52:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-05 09:52:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-05 09:52:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-05 09:52:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-05 09:53:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-05 09:53:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-05 09:53:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-05 09:53:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-05 09:53:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-05 09:53:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-05 09:53:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-05 09:53:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-05 09:53:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-05 09:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-05 09:53:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-05 09:53:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-05 09:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-05 09:53:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-05 09:53:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-05 09:53:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-05 09:54:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-05 09:54:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-05 09:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-05 09:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-05 09:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-05 09:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-05 09:54:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-05 09:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-05 09:54:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-05 09:54:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-05 09:54:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-05 09:54:43  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-05 09:54:48  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-05 09:54:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-05 09:54:57  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-05 09:54:58  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-05 09:55:03  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-05 09:55:07  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-05 09:55:12  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-05 09:55:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-05 09:55:21  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-05 09:55:26  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-05 09:55:30  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-05 09:55:35  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-05 09:55:39  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-05 09:55:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-05 09:55:49  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-05 09:55:53  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-05 09:55:58  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-05 09:56:03  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-05 09:56:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-05 09:56:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-05 09:56:19  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-05 09:56:24  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-05 09:56:28  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-05 09:56:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-05 09:56:37  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-05 09:56:42  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-05 09:56:46  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-05 09:56:51  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-05 09:56:55  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-05 09:57:00  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-05 09:57:04  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-05 09:57:09  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-05 09:57:13  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-05 09:57:18  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-05 09:57:23  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-05 09:57:28  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-05 09:57:32  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-05 09:57:37  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-05 09:57:41  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-05 09:57:46  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-05 09:57:51  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-05 09:57:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-05 09:58:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-05 09:58:05  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-05 09:58:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-05 09:58:14  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-05 09:58:18  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-05 09:58:23  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-05 09:58:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-05 09:58:32  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-05 09:58:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-05 09:58:41  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-05 09:58:46  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-05 09:58:50  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-05 09:58:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-05 09:59:00  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-05 09:59:04  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-05 09:59:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-05 09:59:14  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-05 09:59:18  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-05 09:59:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-05 09:59:27  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-05 09:59:32  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-05 09:59:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-05 09:59:41  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-05 09:59:46  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-05 09:59:51  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-05 09:59:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-05 10:00:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-05 10:00:05  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-05 10:00:10  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-05 10:00:14  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-05 10:00:19  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-05 10:00:24  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-05 10:00:29  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-05 10:00:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-05 10:00:42  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-05 10:00:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-05 10:00:51  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-05 10:00:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-05 10:01:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-05 10:01:05  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-05 10:01:09  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-05 10:01:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-05 10:01:18  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-05 10:01:23  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-05 10:01:27  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-05 10:01:32  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-05 10:01:36  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-05 10:01:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-05 10:01:45  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-05 10:01:50  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-05_10-01-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd?_prerender {"code":"ECONNRESET"}
2017-04-05 10:03:55  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-05 10:03:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-05 10:04:04  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-05 10:04:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-05 10:04:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-05 10:04:18  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-05 10:04:23  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-05 10:04:27  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-05 10:04:32  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-05 10:04:37  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-05 10:04:41  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-05 10:04:46  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-05 10:04:51  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-05 10:04:55  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-05 10:05:00  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-05 10:05:05  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-05 10:05:09  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-05 10:05:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-05 10:05:19  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-05 10:05:24  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-05 10:05:28  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-05 10:05:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-05 10:05:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-05 10:05:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-05 10:05:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-05 10:05:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-05 10:05:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-05 10:06:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-05 10:06:05  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-05 10:06:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-05 10:06:14  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-05 10:06:19  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-05 10:06:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-05 10:06:28  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-05 10:06:33  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-05 10:06:37  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-05 10:06:42  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-05 10:06:46  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-05 10:06:51  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-05 10:06:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-05 10:07:01  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-05 10:07:05  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-05 10:07:10  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-05 10:07:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-05 10:07:19  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-05 10:07:23  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-05 10:07:28  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-05 10:07:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-05 10:07:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-05 10:07:42  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-05 10:07:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-05 10:07:51  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-05 10:07:56  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-05 10:08:00  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-05 10:08:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-05 10:08:10  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-05 10:08:14  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-05 10:08:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-05 10:08:22  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-05 10:08:27  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-05 10:08:31  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-05 10:08:36  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-05 10:08:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-05 10:08:45  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-05 10:08:49  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-05 10:08:53  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-05 10:08:58  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-05 10:09:03  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-05 10:09:07  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-05 10:09:12  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-05 10:09:17  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-05 10:09:21  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-05 10:09:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-05 10:09:30  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-05 10:09:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-05 10:09:39  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-05 10:09:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-05 10:09:48  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-05 10:09:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-05 10:09:56  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-05 10:10:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-05 10:10:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-05 10:10:10  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-05 10:10:15  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-05 10:10:22  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-05 10:10:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-05 10:10:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-05 10:10:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-05 10:10:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-05 10:10:47  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-05 10:10:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-05 10:10:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-05 10:11:01  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-05 10:11:05  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-05 10:11:09  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-05 10:11:14  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-05 10:11:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-05 10:11:23  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-05 10:11:27  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-05 10:11:32  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-05 10:11:36  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-05 10:11:41  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-05 10:11:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-05 10:11:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-05 10:11:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-05 10:12:00  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-05 10:12:00  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-05 10:12:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-05 10:12:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-05 10:12:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-05 10:12:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-05 10:12:23  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-05 10:12:27  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-05 10:12:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-05 10:12:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-05 10:12:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-05 10:12:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-05 10:12:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-05 10:12:54  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-05 10:12:58  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-05 10:13:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-05 10:13:07  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-05 10:13:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-05 10:13:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-05 10:13:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-05 10:13:26  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-05 10:13:30  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-05 10:13:35  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-05 10:13:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-05 10:13:43  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-05 10:13:48  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-05 10:13:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-05 10:13:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-05 10:14:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-05 10:14:06  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-05 10:14:10  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-05 10:14:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-05 10:14:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-05 10:14:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-05 10:14:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-05 10:14:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-05 10:14:36  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-05 10:14:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-05 10:14:44  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-05 10:14:48  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-05 10:14:52  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-05 10:14:56  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-05 10:15:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-05 10:15:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-05 10:15:09  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-05 10:15:13  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-05 10:15:17  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-05 10:15:22  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-05 10:15:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-05 10:15:30  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-05 10:15:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-05 10:15:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-05 10:15:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-05 10:15:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-05 10:15:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-05 10:15:57  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-05 10:16:01  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-05 10:16:05  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-05 10:16:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-05 10:16:14  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-05 10:16:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-05 10:16:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-05 10:16:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-05 10:16:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 10:16:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 10:16:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 10:16:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 10:16:47  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-05 10:16:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 10:16:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 10:16:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-05 10:17:03  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-05 10:17:07  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-05 10:17:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-05 10:17:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-05 10:17:20  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-05 10:17:24  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-05 10:17:28  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-05 10:17:32  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-05 10:17:36  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-05 10:17:40  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-05 10:17:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-05 10:17:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-05 10:17:53  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-05 10:17:57  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-05 10:18:02  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-05 10:18:06  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-05 10:18:10  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-05 10:18:14  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-05 10:18:18  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-05 10:18:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 10:18:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 10:18:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 10:18:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 10:18:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 10:18:43  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-05 10:18:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 10:18:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 10:18:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 10:18:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 10:19:03  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-05 10:19:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 10:19:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 10:19:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 10:19:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-05 10:19:23  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-05_10-31-52 Restart Xvfb...
2017-04-05_11-01-52 Restart Xvfb...
2017-04-05_11-31-52 Restart Xvfb...
2017-04-05_12-01-52 Restart Xvfb...
2017-04-05 12:31:46 reset updateRequest
2017-04-05 12:31:49  - 14968  http://www.lymphomahub.com/
2017-04-05 12:31:51  - 14968  http://www.lymphomahub.com/
2017-04-05_12-31-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-05 12:33:54  - 14968  http://www.lymphomahub.com/
2017-04-05 12:33:56  - 14968  http://www.lymphomahub.com/
2017-04-05 12:33:58  - 14968  http://www.lymphomahub.com/about
2017-04-05 12:34:00  - 14968  http://www.lymphomahub.com/about
2017-04-05 12:34:04  - 14968  http://www.lymphomahub.com/terms
2017-04-05 12:34:04  - 14968  http://www.lymphomahub.com/terms
2017-04-05 12:34:08  - 14968  http://www.lymphomahub.com/undefined
2017-04-05 12:34:09  - 14968  http://www.lymphomahub.com/undefined
2017-04-05 12:34:09  - 14968  http://www.lymphomahub.com/therapies
2017-04-05 12:34:09  - 14968  http://www.lymphomahub.com/therapies
2017-04-05 12:34:19  - 14968  http://www.lymphomahub.com/newsletter
2017-04-05 12:34:20  - 14968  http://www.lymphomahub.com/newsletter
2017-04-05 12:34:24  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-05 12:34:24  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-05 12:34:28  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-05 12:34:29  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-05 12:34:34  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-05 12:34:38  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-05 12:34:43  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-05 12:34:47  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-05 12:34:52  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-05 12:34:56  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-05 12:35:01  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-05 12:35:06  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-05 12:35:10  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-05 12:35:15  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-05 12:35:19  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-05 12:35:23  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-05 12:35:28  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-05 12:35:32  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-05 12:35:37  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-05 12:35:41  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-05 12:35:45  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-05 12:35:50  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-05 12:35:55  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-05 12:36:00  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-05 12:36:04  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-05 12:36:08  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-05 12:36:13  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-05 12:36:17  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-05 12:36:22  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-05 12:36:26  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-05 12:36:31  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-05 12:36:35  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-05 12:36:40  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-05 12:36:44  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-05 12:36:48  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-05 12:36:53  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-05 12:36:57  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-05 12:37:02  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-05 12:37:06  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-05 12:37:10  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-05 12:37:15  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-05 12:37:19  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-05 12:37:24  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-05 12:37:28  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-05 12:37:33  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-05 12:37:37  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-05 12:37:42  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-05 12:37:46  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-05 12:37:51  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-05 12:37:55  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-05 12:37:59  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-05 12:38:04  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-05 12:38:08  - 14968  http://www.lymphomahub.com/medical-information
2017-04-05 12:38:12  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-05 12:38:16  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-05 12:38:21  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-05 12:38:25  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-05 12:38:30  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-05 12:38:34  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-05 12:38:39  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-05 12:38:44  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-05 12:38:48  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-05 12:38:52  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-05 12:38:57  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-05 12:39:01  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-05 12:39:02  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-05 12:39:07  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-05 12:39:11  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-05 12:39:16  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-05 12:39:20  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-05 12:39:24  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-05 12:39:29  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-05 12:39:33  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-05 12:39:38  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-05 12:39:42  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-05 12:39:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-05 12:39:51  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-05 12:39:55  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-05 12:40:00  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-05 12:40:04  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-05 12:40:09  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-05 12:40:13  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-05 12:40:18  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-05 12:40:22  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-05 12:40:27  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-05 12:40:31  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-05 12:40:39  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-05 12:40:43  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-05 12:40:47  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-05 12:40:55  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-05 12:41:00  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-05 12:41:05  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-05 12:41:09  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-05 12:41:13  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-05 12:41:18  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-05 12:41:22  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-05 12:41:23  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-05 12:41:28  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-05 12:41:32  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-05 12:41:37  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-05 12:41:41  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-05 12:41:46  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-05 12:41:50  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-05 12:41:55  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-05 12:41:59  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-05 12:42:03  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-05 12:42:03  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-05 12:42:08  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-05 12:42:12  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-05 12:42:16  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-05 12:42:21  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-05 12:42:25  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-05 12:42:26  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-05 12:42:30  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-05 12:42:35  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-05 12:42:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-05 12:42:42  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-05 12:42:47  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-05 12:42:51  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-05 12:42:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-05 12:42:58  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-05 12:43:02  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-05 12:43:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-05 12:43:11  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-05 12:43:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-05 12:43:19  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-05 12:43:23  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-05 12:43:24  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-05 12:43:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-05 12:43:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-05 12:43:37  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-05 12:43:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-05 12:43:46  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-05 12:43:50  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-05 12:43:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-05 12:43:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-05 12:44:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-05 12:44:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-05 12:44:09  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-05 12:44:13  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-05 12:44:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-05 12:44:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-05 12:44:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-05 12:44:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-05 12:44:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-05 12:44:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-05 12:44:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-05 12:44:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-05 12:44:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-05 12:44:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-05 12:44:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-05 12:45:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-05 12:45:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-05 12:45:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-05 12:45:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-05 12:45:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-05 12:45:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-05 12:45:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-05 12:45:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-05 12:45:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-05 12:45:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-05 12:45:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-05 12:45:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-05 12:45:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-05 12:46:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-05 12:46:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-05 12:46:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-05 12:46:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-05 12:46:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-05 12:46:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-05 12:46:29  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-05 12:46:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-05 12:46:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-05 12:46:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-05 12:46:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-05 12:46:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-05 12:46:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-05 12:47:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-05 12:47:04  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-05 12:47:09  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-05 12:47:13  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-05 12:47:17  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-05 12:47:21  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-05 12:47:25  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-05 12:47:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-05 12:47:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-05 12:47:38  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-05 12:47:42  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-05 12:47:46  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-05 12:47:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-05 12:47:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-05 12:47:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-05 12:48:03  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-05 12:48:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-05 12:48:12  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-05 12:48:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-05 12:48:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-05 12:48:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-05 12:48:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-05 12:48:35  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-05 12:48:36  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-05 12:48:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-05 12:48:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-05 12:48:50  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-05 12:48:54  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-05 12:48:59  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-05 12:49:04  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 12:49:08  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 12:49:13  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-05 12:49:17  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 12:49:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-05 12:49:26  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-05 12:49:31  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-05 12:49:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-05 12:49:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-05 12:49:44  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-05 12:49:49  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-05 12:49:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-05 12:49:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-05 12:50:03  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-05 12:50:08  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 12:50:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-05 12:50:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-05 12:50:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-05 12:50:26  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-05 12:50:31  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-05 12:50:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-05 12:50:41  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-05 12:50:45  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-05 12:50:52  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-05 12:50:57  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-05 12:51:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-05 12:51:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-05 12:51:11  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-05 12:51:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-05 12:51:20  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-05 12:51:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-05 12:51:29  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-05 12:51:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-05 12:51:39  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-05 12:51:43  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-05 12:51:48  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-05 12:51:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-05 12:51:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-05 12:51:57  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-05 12:52:02  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-05 12:52:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-05 12:52:12  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-05 12:52:16  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-05 12:52:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-05 12:52:26  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-05 12:52:30  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-05 12:52:35  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-05 12:52:39  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-05 12:52:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-05 12:52:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-05 12:52:54  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-05 12:52:58  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-05 12:53:02  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-05 12:53:07  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-05 12:53:12  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-05 12:53:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-05 12:53:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-05 12:53:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-05 12:53:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-05 12:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-05 12:53:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-05 12:53:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-05 12:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-05 12:53:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-05 12:53:55  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-05 12:53:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-05 12:54:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-05 12:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-05 12:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-05 12:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-05 12:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-05 12:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-05 12:54:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-05 12:54:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-05 12:54:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-05 12:54:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-05 12:54:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-05 12:54:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-05 12:54:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-05 12:54:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-05 12:54:51  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-05 12:54:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-05 12:55:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-05 12:55:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-05 12:55:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-05 12:55:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-05 12:55:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-05 12:55:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-05 12:55:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-05 12:55:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-05 12:55:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-05 12:55:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-05 12:55:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-05 12:55:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-05 12:55:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-05 12:55:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-05 12:55:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-05 12:55:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-05 12:55:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-05 12:56:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-05 12:56:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-05 12:56:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-05 12:56:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-05 12:56:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-05 12:56:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-05 12:56:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-05 12:56:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-05 12:56:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-05 12:56:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-05 12:56:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-05 12:56:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-05 12:56:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-05 12:56:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-05 12:56:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-05 12:57:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-05 12:57:05  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-05 12:57:09  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-05 12:57:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-05 12:57:19  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-05 12:57:19  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-05 12:57:24  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-05 12:57:28  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-05 12:57:33  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-05 12:57:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-05 12:57:42  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-05 12:57:47  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-05 12:57:51  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-05 12:57:56  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-05 12:58:01  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-05 12:58:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-05 12:58:10  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-05 12:58:14  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-05 12:58:19  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-05 12:58:24  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-05 12:58:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-05 12:58:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-05 12:58:37  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-05 12:58:42  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-05 12:58:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-05 12:58:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-05 12:58:55  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-05 12:59:00  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-05 12:59:04  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-05 12:59:09  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-05 12:59:14  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-05 12:59:18  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-05 12:59:23  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-05 12:59:27  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-05 12:59:32  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-05 12:59:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-05 12:59:41  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-05 12:59:45  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-05 12:59:50  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-05 12:59:55  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-05 12:59:59  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-05 13:00:04  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-05 13:00:11  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-05 13:00:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-05 13:00:20  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-05 13:00:26  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-05 13:00:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-05 13:00:36  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-05 13:00:41  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-05 13:00:45  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-05 13:00:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-05 13:00:54  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-05 13:00:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-05 13:01:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-05 13:01:08  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-05 13:01:12  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-05 13:01:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-05 13:01:21  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-05 13:01:26  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-05 13:01:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-05 13:01:35  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-05 13:01:40  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-05 13:01:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-05_13-01-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday?_prerender {"code":"ECONNRESET"}
2017-04-05 13:03:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-05 13:03:54  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-05 13:03:59  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-05 13:04:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-05 13:04:08  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-05 13:04:13  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-05 13:04:17  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-05 13:04:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-05 13:04:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-05 13:04:33  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-05 13:04:38  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-05 13:04:43  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-05 13:04:48  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-05 13:04:54  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-05 13:04:59  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-05 13:05:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-05 13:05:08  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-05 13:05:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-05 13:05:17  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-05 13:05:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-05 13:05:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-05 13:05:31  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-05 13:05:36  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-05 13:05:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-05 13:05:45  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-05 13:05:50  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-05 13:05:54  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-05 13:05:59  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-05 13:06:03  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-05 13:06:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-05 13:06:12  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-05 13:06:16  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-05 13:06:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-05 13:06:26  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-05 13:06:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-05 13:06:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-05 13:06:40  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-05 13:06:44  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-05 13:06:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-05 13:06:54  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-05 13:06:58  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-05 13:07:03  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-05 13:07:07  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-05 13:07:12  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-05 13:07:17  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-05 13:07:21  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-05 13:07:26  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-05 13:07:30  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-05 13:07:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-05 13:07:39  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-05 13:07:44  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-05 13:07:48  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-05 13:07:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-05 13:07:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-05 13:08:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-05 13:08:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-05 13:08:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-05 13:08:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-05 13:08:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-05 13:08:26  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-05 13:08:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-05 13:08:35  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-05 13:08:40  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-05 13:08:45  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-05 13:08:48  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-05 13:08:53  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-05 13:08:57  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-05 13:09:02  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-05 13:09:07  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-05 13:09:11  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-05 13:09:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-05 13:09:22  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-05 13:09:26  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-05 13:09:31  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-05 13:09:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-05 13:09:40  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-05 13:09:45  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-05 13:09:49  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-05 13:09:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-05 13:09:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-05 13:10:03  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-05 13:10:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-05 13:10:12  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-05 13:10:17  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-05 13:10:21  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-05 13:10:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-05 13:10:31  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-05 13:10:35  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-05 13:10:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-05 13:10:44  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-05 13:10:48  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-05 13:10:52  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-05 13:10:57  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-05 13:11:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-05 13:11:06  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-05 13:11:10  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-05 13:11:15  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-05 13:11:20  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-05 13:11:24  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-05 13:11:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-05 13:11:34  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-05 13:11:39  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-05 13:11:43  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-05 13:11:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-05 13:11:51  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-05 13:11:56  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-05 13:12:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-05 13:12:05  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-05 13:12:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-05 13:12:14  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-05 13:12:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-05 13:12:23  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-05 13:12:27  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-05 13:12:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-05 13:12:37  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-05 13:12:41  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-05 13:12:45  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-05 13:12:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-05 13:12:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-05 13:12:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-05 13:13:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-05 13:13:09  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-05 13:13:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-05 13:13:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-05 13:13:22  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-05 13:13:26  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-05 13:13:31  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-05 13:13:36  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-05 13:13:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-05 13:13:44  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-05 13:13:48  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-05 13:13:53  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-05 13:13:57  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-05 13:14:02  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-05 13:14:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-05 13:14:11  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-05 13:14:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-05 13:14:20  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-05 13:14:21  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-05 13:14:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-05 13:14:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-05 13:14:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-05 13:14:39  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-05 13:14:44  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-05 13:14:48  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-05 13:14:53  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-05 13:14:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-05 13:15:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-05 13:15:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-05 13:15:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-05 13:15:15  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-05 13:15:19  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-05 13:15:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-05 13:15:28  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-05 13:15:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-05 13:15:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-05 13:15:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-05 13:15:47  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-05 13:15:52  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-05 13:15:57  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-05 13:16:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-05 13:16:06  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-05 13:16:10  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-05 13:16:14  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-05 13:16:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-05 13:16:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-05 13:16:28  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-05 13:16:33  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-05 13:16:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-05 13:16:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-05 13:16:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-05 13:16:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-05 13:16:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-05 13:16:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-05 13:17:02  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-05 13:17:06  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-05 13:17:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-05 13:17:14  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-05 13:17:18  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-05 13:17:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-05 13:17:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-05 13:17:31  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-05 13:17:35  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-05 13:17:39  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-05 13:17:43  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-05 13:17:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-05 13:17:52  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-05 13:17:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-05 13:18:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-05 13:18:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-05 13:18:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-05 13:18:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-05 13:18:20  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-05 13:18:24  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-05 13:18:28  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-05 13:18:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-05 13:18:37  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-05 13:18:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-05 13:18:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-05 13:18:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-05 13:18:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 13:18:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 13:19:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 13:19:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 13:19:10  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-05 13:19:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 13:19:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 13:19:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-05 13:19:26  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-05 13:19:30  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-05 13:19:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-05 13:19:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-05 13:19:42  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-05 13:19:47  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-05 13:19:50  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-05 13:19:55  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-05 13:19:59  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-05 13:20:03  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-05 13:20:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-05 13:20:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-05 13:20:15  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-05 13:20:19  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-05 13:20:23  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-05 13:20:27  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-05 13:20:31  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-05 13:20:35  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-05 13:20:39  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-05 13:20:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 13:20:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 13:20:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 13:20:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 13:21:02  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 13:21:06  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-05 13:21:10  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 13:21:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 13:21:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 13:21:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 13:21:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-05 13:21:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 13:21:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 13:21:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 13:21:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-05 13:21:47  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-05_13-31-52 Restart Xvfb...
2017-04-05_14-01-52 Restart Xvfb...
2017-04-05_14-31-52 Restart Xvfb...
2017-04-05_15-01-52 Restart Xvfb...
2017-04-05 15:31:46 reset updateRequest
2017-04-05 15:31:48  - 14968  http://www.lymphomahub.com/
2017-04-05 15:31:51  - 14968  http://www.lymphomahub.com/
2017-04-05 15:31:52  - 14968  http://www.lymphomahub.com/about
2017-04-05_15-31-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-05 15:33:56  - 14968  http://www.lymphomahub.com/about
2017-04-05 15:33:57  - 14968  http://www.lymphomahub.com/about
2017-04-05 15:34:02  - 14968  http://www.lymphomahub.com/terms
2017-04-05 15:34:03  - 14968  http://www.lymphomahub.com/terms
2017-04-05 15:34:06  - 14968  http://www.lymphomahub.com/undefined
2017-04-05 15:34:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-05 15:34:07  - 14968  http://www.lymphomahub.com/therapies
2017-04-05 15:34:16  - 14968  http://www.lymphomahub.com/newsletter
2017-04-05 15:34:16  - 14968  http://www.lymphomahub.com/newsletter
2017-04-05 15:34:20  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-05 15:34:20  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-05 15:34:24  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-05 15:34:24  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-05 15:34:29  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-05 15:34:29  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-05 15:34:34  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-05 15:34:39  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-05 15:34:43  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-05 15:34:48  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-05 15:34:52  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-05 15:34:57  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-05 15:35:01  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-05 15:35:06  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-05 15:35:10  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-05 15:35:15  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-05 15:35:19  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-05 15:35:24  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-05 15:35:28  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-05 15:35:33  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-05 15:35:37  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-05 15:35:42  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-05 15:35:46  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-05 15:35:51  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-05 15:35:55  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-05 15:35:59  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-05 15:36:03  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-05 15:36:08  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-05 15:36:12  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-05 15:36:17  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-05 15:36:21  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-05 15:36:26  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-05 15:36:30  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-05 15:36:35  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-05 15:36:39  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-05 15:36:43  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-05 15:36:48  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-05 15:36:52  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-05 15:36:57  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-05 15:37:01  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-05 15:37:05  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-05 15:37:10  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-05 15:37:14  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-05 15:37:19  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-05 15:37:24  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-05 15:37:28  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-05 15:37:33  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-05 15:37:37  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-05 15:37:41  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-05 15:37:46  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-05 15:37:50  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-05 15:37:55  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-05 15:37:59  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-05 15:38:04  - 14968  http://www.lymphomahub.com/medical-information
2017-04-05 15:38:07  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-05 15:38:12  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-05 15:38:16  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-05 15:38:21  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-05 15:38:25  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-05 15:38:30  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-05 15:38:34  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-05 15:38:39  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-05 15:38:44  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-05 15:38:48  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-05 15:38:52  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-05 15:38:57  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-05 15:38:57  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-05 15:39:02  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-05 15:39:07  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-05 15:39:11  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-05 15:39:15  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-05 15:39:20  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-05 15:39:24  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-05 15:39:29  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-05 15:39:33  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-05 15:39:37  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-05 15:39:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-05 15:39:46  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-05 15:39:51  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-05 15:39:55  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-05 15:40:00  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-05 15:40:04  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-05 15:40:10  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-05 15:40:15  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-05 15:40:19  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-05 15:40:24  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-05 15:40:30  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-05 15:40:35  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-05 15:40:40  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-05 15:40:44  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-05 15:40:48  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-05 15:40:53  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-05 15:40:57  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-05 15:41:01  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-05 15:41:06  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-05 15:41:10  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-05 15:41:15  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-05 15:41:15  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-05 15:41:20  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-05 15:41:24  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-05 15:41:29  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-05 15:41:34  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-05 15:41:38  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-05 15:41:42  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-05 15:41:47  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-05 15:41:51  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-05 15:41:56  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-05 15:41:57  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-05 15:42:01  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-05 15:42:05  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-05 15:42:10  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-05 15:42:14  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-05 15:42:19  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-05 15:42:19  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-05 15:42:24  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-05 15:42:28  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-05 15:42:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-05 15:42:36  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-05 15:42:40  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-05 15:42:44  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-05 15:42:48  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-05 15:42:52  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-05 15:42:55  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-05 15:43:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-05 15:43:05  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-05 15:43:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-05 15:43:13  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-05 15:43:17  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-05 15:43:18  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-05 15:43:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-05 15:43:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-05 15:43:31  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-05 15:43:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-05 15:43:40  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-05 15:43:44  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-05 15:43:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-05 15:43:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-05 15:43:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-05 15:44:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-05 15:44:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-05 15:44:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-05 15:44:11  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-05 15:44:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-05 15:44:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-05 15:44:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-05 15:44:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-05 15:44:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-05 15:44:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-05 15:44:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-05 15:44:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-05 15:44:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-05 15:44:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-05 15:44:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-05 15:45:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-05 15:45:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-05 15:45:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-05 15:45:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-05 15:45:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-05 15:45:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-05 15:45:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-05 15:45:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-05 15:45:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-05 15:45:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-05 15:45:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-05 15:45:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-05 15:45:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-05 15:46:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-05 15:46:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-05 15:46:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-05 15:46:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-05 15:46:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-05 15:46:24  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-05 15:46:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-05 15:46:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-05 15:46:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-05 15:46:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-05 15:46:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-05 15:46:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-05 15:46:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-05 15:46:58  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-05 15:47:03  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-05 15:47:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-05 15:47:12  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-05 15:47:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-05 15:47:22  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-05 15:47:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-05 15:47:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-05 15:47:35  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-05 15:47:39  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-05 15:47:43  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-05 15:47:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-05 15:47:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-05 15:47:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-05 15:48:01  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-05 15:48:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-05 15:48:09  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-05 15:48:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-05 15:48:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-05 15:48:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-05 15:48:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-05 15:48:32  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-05 15:48:33  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-05 15:48:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-05 15:48:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-05 15:48:47  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-05 15:48:51  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-05 15:48:56  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-05 15:49:00  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 15:49:05  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 15:49:10  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-05 15:49:14  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 15:49:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-05 15:49:23  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-05 15:49:28  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-05 15:49:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-05 15:49:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-05 15:49:42  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-05 15:49:46  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-05 15:49:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-05 15:49:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-05 15:50:00  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-05 15:50:05  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 15:50:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-05 15:50:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-05 15:50:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-05 15:50:24  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-05 15:50:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-05 15:50:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-05 15:50:38  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-05 15:50:43  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-05 15:50:47  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-05 15:50:52  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-05 15:50:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-05 15:51:01  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-05 15:51:06  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-05 15:51:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-05 15:51:15  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-05 15:51:20  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-05 15:51:24  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-05 15:51:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-05 15:51:34  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-05 15:51:38  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-05 15:51:43  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-05 15:51:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-05 15:51:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-05 15:51:53  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-05 15:51:58  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-05 15:52:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-05 15:52:07  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-05 15:52:12  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-05 15:52:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-05 15:52:21  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-05 15:52:26  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-05 15:52:30  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-05 15:52:36  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-05 15:52:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-05 15:52:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-05 15:52:50  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-05 15:52:55  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-05 15:52:59  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-05 15:53:04  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-05 15:53:08  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-05 15:53:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-05 15:53:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-05 15:53:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-05 15:53:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-05 15:53:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-05 15:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-05 15:53:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-05 15:53:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-05 15:53:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-05 15:53:51  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-05 15:53:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-05 15:53:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-05 15:54:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-05 15:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-05 15:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-05 15:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-05 15:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-05 15:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-05 15:54:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-05 15:54:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-05 15:54:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-05 15:54:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-05 15:54:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-05 15:54:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-05 15:54:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-05 15:54:48  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-05 15:54:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-05 15:54:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-05 15:54:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-05 15:55:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-05 15:55:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-05 15:55:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-05 15:55:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-05 15:55:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-05 15:55:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-05 15:55:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-05 15:55:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-05 15:55:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-05 15:55:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-05 15:55:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-05 15:55:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-05 15:55:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-05 15:55:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-05 15:55:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-05 15:55:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-05 15:56:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-05 15:56:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-05 15:56:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-05 15:56:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-05 15:56:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-05 15:56:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-05 15:56:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-05 15:56:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-05 15:56:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-05 15:56:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-05 15:56:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-05 15:56:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-05 15:56:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-05 15:56:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-05 15:56:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-05 15:56:58  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-05 15:57:03  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-05 15:57:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-05 15:57:13  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-05 15:57:13  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-05 15:57:18  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-05 15:57:23  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-05 15:57:27  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-05 15:57:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-05 15:57:36  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-05 15:57:41  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-05 15:57:46  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-05 15:57:50  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-05 15:57:55  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-05 15:57:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-05 15:58:04  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-05 15:58:09  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-05 15:58:13  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-05 15:58:18  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-05 15:58:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-05 15:58:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-05 15:58:32  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-05 15:58:36  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-05 15:58:41  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-05 15:58:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-05 15:58:50  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-05 15:58:54  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-05 15:58:59  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-05 15:59:03  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-05 15:59:08  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-05 15:59:13  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-05 15:59:17  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-05 15:59:22  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-05 15:59:26  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-05 15:59:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-05 15:59:35  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-05 15:59:40  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-05 15:59:44  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-05 15:59:49  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-05 15:59:53  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-05 15:59:58  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-05 16:00:03  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-05 16:00:07  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-05 16:00:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-05 16:00:17  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-05 16:00:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-05 16:00:26  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-05 16:00:31  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-05 16:00:36  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-05 16:00:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-05 16:00:45  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-05 16:00:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-05 16:00:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-05 16:01:02  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-05 16:01:06  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-05 16:01:11  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-05 16:01:15  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-05 16:01:20  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-05 16:01:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-05 16:01:30  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-05 16:01:34  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-05 16:01:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-05 16:01:43  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-05 16:01:48  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-05_16-01-52 Restart Xvfb...
2017-04-05 16:01:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-05 16:01:57  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-05 16:02:01  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-05 16:02:06  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-05 16:02:11  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-05 16:02:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-05 16:02:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-05 16:02:25  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-05 16:02:31  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-05 16:02:35  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-05 16:02:40  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-05 16:02:44  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-05 16:02:49  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-05 16:02:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-05 16:02:58  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-05 16:03:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-05 16:03:08  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-05 16:03:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-05 16:03:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-05 16:03:22  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-05 16:03:26  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-05 16:03:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-05 16:03:36  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-05 16:03:40  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-05 16:03:45  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-05 16:03:50  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-05 16:03:54  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-05 16:03:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-05 16:04:03  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-05 16:04:08  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-05 16:04:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-05 16:04:17  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-05 16:04:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-05 16:04:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-05 16:04:32  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-05 16:04:36  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-05 16:04:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-05 16:04:45  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-05 16:04:50  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-05 16:04:55  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-05 16:05:00  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-05 16:05:05  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-05 16:05:09  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-05 16:05:14  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-05 16:05:18  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-05 16:05:23  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-05 16:05:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-05 16:05:32  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-05 16:05:37  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-05 16:05:42  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-05 16:05:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-05 16:05:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-05 16:05:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-05 16:06:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-05 16:06:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-05 16:06:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-05 16:06:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-05 16:06:19  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-05 16:06:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-05 16:06:28  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-05 16:06:33  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-05 16:06:37  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-05 16:06:41  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-05 16:06:46  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-05 16:06:50  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-05 16:06:55  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-05 16:06:59  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-05 16:07:04  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-05 16:07:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-05 16:07:13  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-05 16:07:18  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-05 16:07:23  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-05 16:07:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-05 16:07:32  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-05 16:07:37  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-05 16:07:41  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-05 16:07:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-05 16:07:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-05 16:07:55  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-05 16:08:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-05 16:08:05  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-05 16:08:10  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-05 16:08:14  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-05 16:08:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-05 16:08:24  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-05 16:08:28  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-05 16:08:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-05 16:08:37  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-05 16:08:41  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-05 16:08:46  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-05 16:08:50  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-05 16:08:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-05 16:09:00  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-05 16:09:04  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-05 16:09:08  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-05 16:09:13  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-05 16:09:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-05 16:09:22  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-05 16:09:27  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-05 16:09:32  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-05 16:09:36  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-05 16:09:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-05 16:09:44  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-05 16:09:49  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-05 16:09:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-05 16:09:57  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-05 16:10:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-05 16:10:06  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-05 16:10:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-05 16:10:15  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-05 16:10:20  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-05 16:10:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-05 16:10:29  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-05 16:10:34  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-05 16:10:38  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-05 16:10:42  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-05 16:10:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-05 16:10:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-05 16:10:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-05 16:11:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-05 16:11:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-05 16:11:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-05 16:11:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-05 16:11:18  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-05 16:11:23  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-05 16:11:28  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-05 16:11:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-05 16:11:36  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-05 16:11:40  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-05 16:11:45  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-05 16:11:49  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-05 16:11:54  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-05 16:11:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-05 16:12:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-05 16:12:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-05 16:12:13  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-05 16:12:13  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-05 16:12:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-05 16:12:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-05 16:12:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-05 16:12:31  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-05 16:12:36  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-05 16:12:40  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-05 16:12:45  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-05 16:12:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-05 16:12:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-05 16:12:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-05 16:13:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-05 16:13:07  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-05 16:13:11  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-05 16:13:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-05 16:13:21  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-05 16:13:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-05 16:13:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-05 16:13:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-05 16:13:38  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-05 16:13:43  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-05 16:13:48  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-05 16:13:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-05 16:13:56  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-05 16:14:01  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-05 16:14:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-05 16:14:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-05 16:14:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-05 16:14:18  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-05 16:14:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-05 16:14:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-05 16:14:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-05 16:14:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-05 16:14:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-05 16:14:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-05 16:14:48  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-05 16:14:53  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-05 16:14:57  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-05 16:15:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-05 16:15:05  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-05 16:15:09  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-05 16:15:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-05 16:15:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-05 16:15:22  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-05 16:15:26  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-05 16:15:30  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-05 16:15:34  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-05 16:15:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-05 16:15:43  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-05 16:15:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-05 16:15:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-05 16:15:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-05 16:16:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-05 16:16:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-05 16:16:10  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-05 16:16:15  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-05 16:16:19  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-05 16:16:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-05 16:16:28  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-05 16:16:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-05 16:16:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-05 16:16:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-05 16:16:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 16:16:48  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 16:16:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 16:16:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 16:17:01  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-05 16:17:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 16:17:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 16:17:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-05 16:17:17  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-05 16:17:21  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-05 16:17:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-05 16:17:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-05 16:17:34  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-05 16:17:39  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-05 16:17:43  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-05 16:17:47  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-05 16:17:51  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-05 16:17:55  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-05 16:17:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-05 16:18:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-05 16:18:08  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-05 16:18:11  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-05 16:18:15  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-05 16:18:20  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-05 16:18:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-05 16:18:28  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-05 16:18:32  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-05 16:18:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 16:18:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 16:18:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 16:18:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 16:18:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 16:18:57  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-05 16:19:01  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 16:19:05  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 16:19:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 16:19:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 16:19:17  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-05 16:19:21  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 16:19:25  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 16:19:29  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 16:19:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-05 16:19:37  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-05_16-31-52 Restart Xvfb...
2017-04-05_17-01-52 Restart Xvfb...
2017-04-05_17-31-52 Restart Xvfb...
2017-04-05_18-01-52 Restart Xvfb...
2017-04-05 18:31:46 reset updateRequest
2017-04-05 18:31:48  - 14968  http://www.lymphomahub.com/
2017-04-05 18:31:51  - 14968  http://www.lymphomahub.com/
2017-04-05_18-31-52 Restart Xvfb...
2017-04-05 18:31:58  - 14968  http://www.lymphomahub.com/about
2017-04-05 18:32:06  - 14968  http://www.lymphomahub.com/terms
2017-04-05 18:32:09  - 14968  http://www.lymphomahub.com/undefined
2017-04-05 18:32:10  - 14968  http://www.lymphomahub.com/therapies
2017-04-05 18:32:16  - 14968  http://www.lymphomahub.com/newsletter
2017-04-05 18:32:23  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-05 18:32:27  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-05 18:32:32  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-05 18:32:37  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-05 18:32:41  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-05 18:32:46  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-05 18:32:50  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-05 18:32:55  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-05 18:32:59  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-05 18:33:04  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-05 18:33:08  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-05 18:33:14  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-05 18:33:18  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-05 18:33:23  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-05 18:33:27  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-05 18:33:32  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-05 18:33:36  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-05 18:33:40  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-05 18:33:45  - 14968  http://www.lymphomahub.com/therapies/actr087
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-05 18:33:50  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-05 18:33:53  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-05 18:33:54  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-05 18:33:58  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-05 18:34:00  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-05 18:34:03  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-05 18:34:04  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-05 18:34:06  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-05 18:34:09  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-05 18:34:10  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-05 18:34:14  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-05 18:34:15  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-05 18:34:19  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-05 18:34:20  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-05 18:34:25  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-05 18:34:29  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-05 18:34:34  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-05 18:34:38  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-05 18:34:42  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-05 18:34:47  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-05 18:34:51  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-05 18:34:55  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-05 18:35:00  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-05 18:35:04  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-05 18:35:09  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-05 18:35:13  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-05 18:35:17  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-05 18:35:22  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-05 18:35:26  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-05 18:35:31  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-05 18:35:35  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-05 18:35:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-05 18:35:44  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-05 18:35:48  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-05 18:35:53  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-05 18:35:57  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-05 18:36:02  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-05 18:36:06  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-05 18:36:11  - 14968  http://www.lymphomahub.com/medical-information
2017-04-05 18:36:16  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-05 18:36:21  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-05 18:36:26  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-05 18:36:30  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-05 18:36:35  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-05 18:36:39  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-05 18:36:43  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-05 18:36:48  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-05 18:36:52  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-05 18:36:57  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-05 18:37:01  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-05 18:37:05  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-05 18:37:06  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-05 18:37:11  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-05 18:37:15  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-05 18:37:19  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-05 18:37:24  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-05 18:37:28  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-05 18:37:33  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-05 18:37:37  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-05 18:37:41  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-05 18:37:46  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-05 18:37:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-05 18:37:55  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-05 18:37:59  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-05 18:38:04  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-05 18:38:09  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-05 18:38:13  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-05 18:38:17  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-05 18:38:23  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-05 18:38:28  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-05 18:38:32  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-05 18:38:36  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-05 18:38:41  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-05 18:38:45  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-05 18:38:50  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-05 18:38:54  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-05 18:38:58  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-05 18:39:03  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-05 18:39:07  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-05 18:39:11  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-05 18:39:16  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-05 18:39:20  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-05 18:39:21  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-05 18:39:25  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-05 18:39:30  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-05 18:39:34  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-05 18:39:39  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-05 18:39:43  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-05 18:39:48  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-05 18:39:52  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-05 18:39:57  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-05 18:40:00  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-05 18:40:01  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-05 18:40:05  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-05 18:40:10  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-05 18:40:14  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-05 18:40:19  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-05 18:40:23  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-05 18:40:24  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-05 18:40:28  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-05 18:40:33  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-05 18:40:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-05 18:40:40  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-05 18:40:45  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-05 18:40:49  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-05 18:40:52  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-05 18:40:56  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-05 18:41:00  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-05 18:41:05  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-05 18:41:09  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-05 18:41:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-05 18:41:17  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-05 18:41:22  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-05 18:41:22  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-05 18:41:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-05 18:41:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-05 18:41:35  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-05 18:41:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-05 18:41:44  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-05 18:41:49  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-05 18:41:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-05 18:41:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-05 18:42:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-05 18:42:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-05 18:42:08  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-05 18:42:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-05 18:42:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-05 18:42:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-05 18:42:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-05 18:42:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-05 18:42:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-05 18:42:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-05 18:42:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-05 18:42:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-05 18:42:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-05 18:42:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-05 18:42:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-05 18:43:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-05 18:43:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-05 18:43:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-05 18:43:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-05 18:43:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-05 18:43:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-05 18:43:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-05 18:43:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-05 18:43:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-05 18:43:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-05 18:43:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-05 18:43:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-05 18:43:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-05 18:43:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-05 18:44:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-05 18:44:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-05 18:44:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-05 18:44:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-05 18:44:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-05 18:44:25  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-05 18:44:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-05 18:44:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-05 18:44:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-05 18:44:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-05 18:44:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-05 18:44:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-05 18:44:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-05 18:44:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-05 18:45:03  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-05 18:45:07  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-05 18:45:12  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-05 18:45:16  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-05 18:45:20  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-05 18:45:24  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-05 18:45:29  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-05 18:45:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-05 18:45:37  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-05 18:45:41  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-05 18:45:45  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-05 18:45:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-05 18:45:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-05 18:45:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-05 18:46:02  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-05 18:46:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-05 18:46:10  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-05 18:46:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-05 18:46:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-05 18:46:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-05 18:46:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-05 18:46:34  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-05 18:46:35  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-05 18:46:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-05 18:46:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-05 18:46:49  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-05 18:46:53  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-05 18:46:58  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-05 18:47:02  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 18:47:07  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 18:47:12  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-05 18:47:17  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 18:47:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-05 18:47:26  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-05 18:47:30  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-05 18:47:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-05 18:47:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-05 18:47:44  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-05 18:47:49  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-05 18:47:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-05 18:47:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-05 18:48:02  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-05 18:48:07  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 18:48:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-05 18:48:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-05 18:48:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-05 18:48:26  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-05 18:48:30  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-05 18:48:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-05 18:48:40  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-05 18:48:44  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-05 18:48:49  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-05 18:48:53  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-05 18:48:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-05 18:49:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-05 18:49:07  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-05 18:49:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-05 18:49:16  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-05 18:49:21  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-05 18:49:25  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-05 18:49:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-05 18:49:35  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-05 18:49:40  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-05 18:49:44  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-05 18:49:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-05 18:49:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-05 18:49:54  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-05 18:49:59  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-05 18:50:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-05 18:50:08  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-05 18:50:13  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-05 18:50:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-05 18:50:22  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-05 18:50:27  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-05 18:50:31  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-05 18:50:36  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-05 18:50:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-05 18:50:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-05 18:50:49  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-05 18:50:54  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-05 18:50:59  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-05 18:51:03  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-05 18:51:08  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-05 18:51:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-05 18:51:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-05 18:51:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-05 18:51:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-05 18:51:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-05 18:51:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-05 18:51:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-05 18:51:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-05 18:51:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-05 18:51:52  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-05 18:51:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-05 18:51:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-05 18:52:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-05 18:52:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-05 18:52:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-05 18:52:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-05 18:52:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-05 18:52:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-05 18:52:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-05 18:52:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-05 18:52:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-05 18:52:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-05 18:52:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-05 18:52:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-05 18:52:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-05 18:52:50  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-05 18:52:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-05 18:52:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-05 18:53:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-05 18:53:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-05 18:53:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-05 18:53:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-05 18:53:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-05 18:53:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-05 18:53:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-05 18:53:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-05 18:53:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-05 18:53:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-05 18:53:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-05 18:53:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-05 18:53:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-05 18:53:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-05 18:53:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-05 18:53:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-05 18:54:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-05 18:54:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-05 18:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-05 18:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-05 18:54:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-05 18:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-05 18:54:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-05 18:54:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-05 18:54:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-05 18:54:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-05 18:54:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-05 18:54:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-05 18:54:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-05 18:54:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-05 18:54:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-05 18:54:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-05 18:55:02  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-05 18:55:06  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-05 18:55:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-05 18:55:16  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-05 18:55:16  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-05 18:55:21  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-05 18:55:26  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-05 18:55:30  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-05 18:55:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-05 18:55:39  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-05 18:55:44  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-05 18:55:49  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-05 18:55:53  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-05 18:55:58  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-05 18:56:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-05 18:56:08  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-05 18:56:13  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-05 18:56:17  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-05 18:56:22  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-05 18:56:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-05 18:56:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-05 18:56:36  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-05 18:56:41  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-05 18:56:45  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-05 18:56:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-05 18:56:54  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-05 18:56:59  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-05 18:57:03  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-05 18:57:08  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-05 18:57:13  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-05 18:57:17  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-05 18:57:22  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-05 18:57:26  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-05 18:57:31  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-05 18:57:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-05 18:57:40  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-05 18:57:44  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-05 18:57:49  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-05 18:57:53  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-05 18:57:59  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-05 18:58:03  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-05 18:58:08  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-05 18:58:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-05 18:58:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-05 18:58:21  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-05 18:58:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-05 18:58:31  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-05 18:58:35  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-05 18:58:40  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-05 18:58:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-05 18:58:49  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-05 18:58:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-05 18:58:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-05 18:59:02  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-05 18:59:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-05 18:59:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-05 18:59:16  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-05 18:59:22  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-05 18:59:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-05 18:59:31  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-05 18:59:35  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-05 18:59:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-05 18:59:45  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-05 18:59:49  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-05 18:59:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-05 18:59:58  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-05 19:00:03  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-05 19:00:08  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-05 19:00:12  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-05 19:00:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-05 19:00:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-05 19:00:26  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-05 19:00:33  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-05 19:00:38  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-05 19:00:43  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-05 19:00:48  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-05 19:00:55  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-05 19:01:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-05 19:01:05  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-05 19:01:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-05 19:01:17  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-05 19:01:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-05 19:01:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-05 19:01:30  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-05 19:01:35  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-05 19:01:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-05 19:01:49  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-05_19-01-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld?_prerender {"code":"ECONNRESET"}
2017-04-05 19:03:54  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-05 19:03:59  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-05 19:04:03  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-05 19:04:08  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-05 19:04:12  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-05 19:04:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-05 19:04:22  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-05 19:04:27  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-05 19:04:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-05 19:04:37  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-05 19:04:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-05 19:04:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-05 19:04:51  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-05 19:04:56  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-05 19:05:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-05 19:05:05  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-05 19:05:09  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-05 19:05:14  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-05 19:05:18  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-05 19:05:23  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-05 19:05:28  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-05 19:05:33  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-05 19:05:37  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-05 19:05:42  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-05 19:05:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-05 19:05:51  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-05 19:05:55  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-05 19:06:00  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-05 19:06:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-05 19:06:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-05 19:06:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-05 19:06:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-05 19:06:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-05 19:06:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-05 19:06:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-05 19:06:38  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-05 19:06:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-05 19:06:47  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-05 19:06:52  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-05 19:06:56  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-05 19:07:00  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-05 19:07:05  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-05 19:07:09  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-05 19:07:14  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-05 19:07:19  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-05 19:07:23  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-05 19:07:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-05 19:07:32  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-05 19:07:37  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-05 19:07:42  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-05 19:07:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-05 19:07:51  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-05 19:07:56  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-05 19:08:00  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-05 19:08:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-05 19:08:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-05 19:08:14  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-05 19:08:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-05 19:08:23  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-05 19:08:27  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-05 19:08:32  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-05 19:08:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-05 19:08:41  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-05 19:08:46  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-05 19:08:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-05 19:08:54  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-05 19:08:59  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-05 19:09:03  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-05 19:09:07  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-05 19:09:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-05 19:09:17  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-05 19:09:21  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-05 19:09:25  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-05 19:09:30  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-05 19:09:34  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-05 19:09:39  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-05 19:09:44  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-05 19:09:49  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-05 19:09:53  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-05 19:09:57  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-05 19:10:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-05 19:10:06  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-05 19:10:10  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-05 19:10:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-05 19:10:19  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-05 19:10:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-05 19:10:28  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-05 19:10:33  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-05 19:10:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-05 19:10:41  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-05 19:10:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-05 19:10:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-05 19:10:55  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-05 19:11:00  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-05 19:11:04  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-05 19:11:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-05 19:11:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-05 19:11:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-05 19:11:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-05 19:11:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-05 19:11:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-05 19:11:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-05 19:11:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-05 19:11:44  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-05 19:11:49  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-05 19:11:53  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-05 19:11:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-05 19:12:02  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-05 19:12:06  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-05 19:12:10  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-05 19:12:15  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-05 19:12:20  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-05 19:12:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-05 19:12:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-05 19:12:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-05 19:12:39  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-05 19:12:40  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-05 19:12:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-05 19:12:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-05 19:12:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-05 19:12:58  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-05 19:13:02  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-05 19:13:09  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-05 19:13:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-05 19:13:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-05 19:13:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-05 19:13:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-05 19:13:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-05 19:13:36  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-05 19:13:40  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-05 19:13:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-05 19:13:49  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-05 19:13:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-05 19:13:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-05 19:14:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-05 19:14:07  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-05 19:14:12  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-05 19:14:16  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-05 19:14:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-05 19:14:25  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-05 19:14:29  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-05 19:14:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-05 19:14:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-05 19:14:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-05 19:14:48  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-05 19:14:52  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-05 19:14:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-05 19:15:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-05 19:15:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-05 19:15:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-05 19:15:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-05 19:15:18  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-05 19:15:22  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-05 19:15:26  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-05 19:15:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-05 19:15:34  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-05 19:15:38  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-05 19:15:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-05 19:15:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-05 19:15:51  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-05 19:15:55  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-05 19:15:59  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-05 19:16:03  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-05 19:16:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-05 19:16:11  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-05 19:16:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-05 19:16:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-05 19:16:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-05 19:16:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-05 19:16:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-05 19:16:38  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-05 19:16:42  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-05 19:16:46  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-05 19:16:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-05 19:16:55  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-05 19:16:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-05 19:17:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-05 19:17:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-05 19:17:12  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 19:17:16  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 19:17:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 19:17:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 19:17:29  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-05 19:17:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 19:17:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 19:17:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-05 19:17:45  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-05 19:17:49  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-05 19:17:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-05 19:17:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-05 19:18:01  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-05 19:18:05  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-05 19:18:09  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-05 19:18:13  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-05 19:18:17  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-05 19:18:21  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-05 19:18:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-05 19:18:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-05 19:18:34  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-05 19:18:38  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-05 19:18:42  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-05 19:18:46  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-05 19:18:50  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-05 19:18:55  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-05 19:18:59  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-05 19:19:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 19:19:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 19:19:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 19:19:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 19:19:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 19:19:24  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-05 19:19:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 19:19:32  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 19:19:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 19:19:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 19:19:44  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-05 19:19:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 19:19:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 19:19:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 19:20:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-05 19:20:05  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-05_19-31-52 Restart Xvfb...
2017-04-05_20-01-52 Restart Xvfb...
2017-04-05_20-31-52 Restart Xvfb...
2017-04-05_21-01-52 Restart Xvfb...
2017-04-05 21:31:46 reset updateRequest
2017-04-05 21:31:51  - 14968  http://www.lymphomahub.com/
2017-04-05_21-31-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-05 21:33:56  - 14968  http://www.lymphomahub.com/
2017-04-05 21:34:00  - 14968  http://www.lymphomahub.com/about
2017-04-05 21:34:06  - 14968  http://www.lymphomahub.com/terms
2017-04-05 21:34:09  - 14968  http://www.lymphomahub.com/undefined
2017-04-05 21:34:10  - 14968  http://www.lymphomahub.com/therapies
2017-04-05 21:34:16  - 14968  http://www.lymphomahub.com/newsletter
2017-04-05 21:34:19  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-05 21:34:22  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-05 21:34:27  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-05 21:34:32  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-05 21:34:36  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-05 21:34:41  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-05 21:34:45  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-05 21:34:50  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-05 21:34:55  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-05 21:34:59  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-05 21:35:04  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-05 21:35:08  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-05 21:35:13  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-05 21:35:17  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-05 21:35:22  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-05 21:35:27  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-05 21:35:31  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-05 21:35:36  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-05 21:35:41  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-05 21:35:46  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-05 21:35:50  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-05 21:35:54  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-05 21:35:58  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-05 21:36:03  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-05 21:36:07  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-05 21:36:12  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-05 21:36:16  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-05 21:36:20  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-05 21:36:25  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-05 21:36:29  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-05 21:36:34  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-05 21:36:38  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-05 21:36:43  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-05 21:36:48  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-05 21:36:52  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-05 21:36:57  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-05 21:37:01  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-05 21:37:06  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-05 21:37:10  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-05 21:37:15  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-05 21:37:20  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-05 21:37:24  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-05 21:37:29  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-05 21:37:33  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-05 21:37:38  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-05 21:37:42  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-05 21:37:47  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-05 21:37:51  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-05 21:37:55  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-05 21:38:00  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-05 21:38:04  - 14968  http://www.lymphomahub.com/medical-information
2017-04-05 21:38:09  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-05 21:38:14  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-05 21:38:18  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-05 21:38:23  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-05 21:38:27  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-05 21:38:31  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-05 21:38:36  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-05 21:38:40  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-05 21:38:45  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-05 21:38:49  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-05 21:38:54  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-05 21:38:59  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-05 21:38:59  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-05 21:39:04  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-05 21:39:09  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-05 21:39:13  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-05 21:39:18  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-05 21:39:24  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-05 21:39:30  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-05 21:39:34  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-05 21:39:38  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-05 21:39:43  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-05 21:39:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-05 21:39:52  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-05 21:39:56  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-05 21:40:01  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-05 21:40:06  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-05 21:40:10  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-05 21:40:14  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-05 21:40:19  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-05 21:40:24  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-05 21:40:28  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-05 21:40:33  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-05 21:40:37  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-05 21:40:41  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-05 21:40:46  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-05 21:40:50  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-05 21:40:55  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-05 21:40:59  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-05 21:41:03  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-05 21:41:08  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-05 21:41:12  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-05 21:41:16  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-05 21:41:17  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-05 21:41:22  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-05 21:41:26  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-05 21:41:31  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-05 21:41:35  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-05 21:41:40  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-05 21:41:44  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-05 21:41:48  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-05 21:41:53  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-05 21:41:56  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-05 21:41:57  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-05 21:42:01  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-05 21:42:06  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-05 21:42:10  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-05 21:42:15  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-05 21:42:19  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-05 21:42:20  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-05 21:42:24  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-05 21:42:28  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-05 21:42:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-05 21:42:37  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-05 21:42:41  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-05 21:42:45  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-05 21:42:48  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-05 21:42:52  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-05 21:42:56  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-05 21:43:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-05 21:43:05  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-05 21:43:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-05 21:43:13  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-05 21:43:17  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-05 21:43:18  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-05 21:43:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-05 21:43:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-05 21:43:31  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-05 21:43:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-05 21:43:40  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-05 21:43:44  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-05 21:43:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-05 21:43:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-05 21:43:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-05 21:44:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-05 21:44:03  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-05 21:44:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-05 21:44:11  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-05 21:44:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-05 21:44:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-05 21:44:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-05 21:44:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-05 21:44:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-05 21:44:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-05 21:44:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-05 21:44:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-05 21:44:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-05 21:44:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-05 21:44:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-05 21:45:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-05 21:45:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-05 21:45:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-05 21:45:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-05 21:45:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-05 21:45:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-05 21:45:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-05 21:45:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-05 21:45:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-05 21:45:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-05 21:45:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-05 21:45:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-05 21:45:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-05 21:46:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-05 21:46:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-05 21:46:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-05 21:46:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-05 21:46:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-05 21:46:25  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-05 21:46:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-05 21:46:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-05 21:46:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-05 21:46:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-05 21:46:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-05 21:46:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-05 21:46:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-05 21:46:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-05 21:47:02  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-05 21:47:07  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-05 21:47:12  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-05 21:47:15  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-05 21:47:20  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-05 21:47:24  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-05 21:47:29  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-05 21:47:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-05 21:47:37  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-05 21:47:41  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-05 21:47:45  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-05 21:47:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-05 21:47:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-05 21:47:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-05 21:48:02  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-05 21:48:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-05 21:48:11  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-05 21:48:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-05 21:48:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-05 21:48:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-05 21:48:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-05 21:48:34  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-05 21:48:35  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-05 21:48:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-05 21:48:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-05 21:48:49  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-05 21:48:53  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-05 21:48:58  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-05 21:49:02  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 21:49:07  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 21:49:11  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-05 21:49:16  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 21:49:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-05 21:49:26  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-05 21:49:30  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-05 21:49:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-05 21:49:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-05 21:49:44  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-05 21:49:49  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-05 21:49:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-05 21:49:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-05 21:50:03  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-05 21:50:08  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-05 21:50:12  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-05 21:50:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-05 21:50:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-05 21:50:27  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-05 21:50:31  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-05 21:50:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-05 21:50:41  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-05 21:50:45  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-05 21:50:50  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-05 21:50:55  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-05 21:51:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-05 21:51:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-05 21:51:09  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-05 21:51:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-05 21:51:18  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-05 21:51:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-05 21:51:27  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-05 21:51:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-05 21:51:37  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-05 21:51:41  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-05 21:51:46  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-05 21:51:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-05 21:51:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-05 21:51:56  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-05 21:52:00  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-05 21:52:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-05 21:52:10  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-05 21:52:15  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-05 21:52:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-05 21:52:24  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-05 21:52:29  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-05 21:52:33  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-05 21:52:38  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-05 21:52:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-05 21:52:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-05 21:52:52  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-05 21:52:57  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-05 21:53:01  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-05 21:53:06  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-05 21:53:11  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-05 21:53:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-05 21:53:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-05 21:53:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-05 21:53:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-05 21:53:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-05 21:53:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-05 21:53:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-05 21:53:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-05 21:53:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-05 21:53:54  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-05 21:53:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-05 21:53:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-05 21:54:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-05 21:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-05 21:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-05 21:54:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-05 21:54:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-05 21:54:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-05 21:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-05 21:54:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-05 21:54:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-05 21:54:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-05 21:54:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-05 21:54:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-05 21:54:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-05 21:54:53  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-05 21:54:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-05 21:55:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-05 21:55:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-05 21:55:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-05 21:55:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-05 21:55:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-05 21:55:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-05 21:55:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-05 21:55:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-05 21:55:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-05 21:55:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-05 21:55:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-05 21:55:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-05 21:55:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-05 21:55:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-05 21:55:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-05 21:55:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-05 21:55:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-05 21:56:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-05 21:56:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-05 21:56:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-05 21:56:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-05 21:56:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-05 21:56:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-05 21:56:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-05 21:56:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-05 21:56:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-05 21:56:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-05 21:56:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-05 21:56:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-05 21:56:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-05 21:56:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-05 21:56:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-05 21:56:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-05 21:57:04  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-05 21:57:08  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-05 21:57:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-05 21:57:18  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-05 21:57:18  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-05 21:57:23  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-05 21:57:28  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-05 21:57:32  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-05 21:57:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-05 21:57:41  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-05 21:57:46  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-05 21:57:51  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-05 21:57:55  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-05 21:58:00  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-05 21:58:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-05 21:58:10  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-05 21:58:14  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-05 21:58:19  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-05 21:58:24  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-05 21:58:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-05 21:58:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-05 21:58:37  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-05 21:58:42  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-05 21:58:47  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-05 21:58:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-05 21:58:56  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-05 21:59:00  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-05 21:59:05  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-05 21:59:09  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-05 21:59:14  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-05 21:59:18  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-05 21:59:23  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-05 21:59:28  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-05 21:59:32  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-05 21:59:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-05 21:59:41  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-05 21:59:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-05 21:59:50  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-05 21:59:55  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-05 22:00:00  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-05 22:00:04  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-05 22:00:09  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-05 22:00:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-05 22:00:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-05 22:00:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-05 22:00:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-05 22:00:32  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-05 22:00:37  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-05 22:00:42  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-05 22:00:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-05 22:00:51  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-05 22:00:55  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-05 22:00:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-05 22:01:04  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-05 22:01:09  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-05 22:01:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-05 22:01:18  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-05 22:01:22  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-05 22:01:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-05 22:01:32  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-05 22:01:36  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-05 22:01:41  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-05 22:01:45  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-05 22:01:50  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-05_22-01-52 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration?_prerender {"code":"ECONNRESET"}
2017-04-05 22:03:55  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-05 22:03:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-05 22:04:04  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-05 22:04:09  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-05 22:04:13  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-05 22:04:18  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-05 22:04:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-05 22:04:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-05 22:04:32  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-05 22:04:37  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-05 22:04:42  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-05 22:04:46  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-05 22:04:51  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-05 22:04:55  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-05 22:05:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-05 22:05:05  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-05 22:05:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-05 22:05:14  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-05 22:05:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-05 22:05:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-05 22:05:28  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-05 22:05:33  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-05 22:05:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-05 22:05:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-05 22:05:47  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-05 22:05:51  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-05 22:05:56  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-05 22:06:00  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-05 22:06:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-05 22:06:09  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-05 22:06:14  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-05 22:06:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-05 22:06:23  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-05 22:06:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-05 22:06:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-05 22:06:38  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-05 22:06:43  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-05 22:06:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-05 22:06:52  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-05 22:06:57  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-05 22:07:01  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-05 22:07:06  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-05 22:07:10  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-05 22:07:15  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-05 22:07:20  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-05 22:07:25  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-05 22:07:29  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-05 22:07:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-05 22:07:38  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-05 22:07:43  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-05 22:07:48  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-05 22:07:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-05 22:07:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-05 22:08:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-05 22:08:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-05 22:08:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-05 22:08:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-05 22:08:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-05 22:08:25  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-05 22:08:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-05 22:08:34  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-05 22:08:39  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-05 22:08:43  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-05 22:08:47  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-05 22:08:52  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-05 22:08:56  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-05 22:09:01  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-05 22:09:06  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-05 22:09:10  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-05 22:09:14  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-05 22:09:19  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-05 22:09:24  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-05 22:09:28  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-05 22:09:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-05 22:09:38  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-05 22:09:43  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-05 22:09:47  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-05 22:09:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-05 22:09:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-05 22:10:01  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-05 22:10:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-05 22:10:11  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-05 22:10:15  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-05 22:10:20  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-05 22:10:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-05 22:10:29  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-05 22:10:34  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-05 22:10:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-05 22:10:42  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-05 22:10:47  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-05 22:10:51  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-05 22:10:55  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-05 22:11:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-05 22:11:05  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-05 22:11:09  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-05 22:11:13  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-05 22:11:18  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-05 22:11:23  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-05 22:11:27  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-05 22:11:32  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-05 22:11:37  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-05 22:11:41  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-05 22:11:45  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-05 22:11:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-05 22:11:54  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-05 22:11:59  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-05 22:12:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-05 22:12:08  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-05 22:12:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-05 22:12:17  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-05 22:12:21  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-05 22:12:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-05 22:12:30  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-05 22:12:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-05 22:12:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-05 22:12:43  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-05 22:12:48  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-05 22:12:52  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-05 22:12:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-05 22:13:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-05 22:13:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-05 22:13:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-05 22:13:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-05 22:13:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-05 22:13:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-05 22:13:28  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-05 22:13:32  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-05 22:13:36  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-05 22:13:41  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-05 22:13:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-05 22:13:49  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-05 22:13:53  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-05 22:13:58  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-05 22:14:03  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-05 22:14:07  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-05 22:14:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-05 22:14:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-05 22:14:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-05 22:14:26  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-05 22:14:26  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-05 22:14:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-05 22:14:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-05 22:14:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-05 22:14:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-05 22:14:49  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-05 22:14:54  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-05 22:14:59  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-05 22:15:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-05 22:15:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-05 22:15:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-05 22:15:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-05 22:15:24  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-05 22:15:28  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-05 22:15:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-05 22:15:37  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-05 22:15:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-05 22:15:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-05 22:15:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-05 22:15:55  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-05 22:16:00  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-05 22:16:04  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-05 22:16:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-05 22:16:13  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-05 22:16:17  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-05 22:16:22  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-05 22:16:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-05 22:16:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-05 22:16:35  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-05 22:16:39  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-05 22:16:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-05 22:16:48  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-05 22:16:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-05 22:16:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-05 22:17:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-05 22:17:05  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-05 22:17:09  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-05 22:17:13  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-05 22:17:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-05 22:17:21  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-05 22:17:25  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-05 22:17:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-05 22:17:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-05 22:17:39  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-05 22:17:43  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-05 22:17:47  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-05 22:17:51  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-05 22:17:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-05 22:18:00  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-05 22:18:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-05 22:18:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-05 22:18:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-05 22:18:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-05 22:18:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-05 22:18:27  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-05 22:18:31  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-05 22:18:35  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-05 22:18:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-05 22:18:43  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-05 22:18:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-05 22:18:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-05 22:18:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-05 22:19:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 22:19:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 22:19:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 22:19:12  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 22:19:16  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-05 22:19:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 22:19:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-05 22:19:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-05 22:19:32  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-05 22:19:36  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-05 22:19:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-05 22:19:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-05 22:19:49  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-05 22:19:53  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-05 22:19:58  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-05 22:20:02  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-05 22:20:06  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-05 22:20:10  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-05 22:20:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-05 22:20:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-05 22:20:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-05 22:20:27  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-05 22:20:31  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-05 22:20:35  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-05 22:20:39  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-05 22:20:43  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-05 22:20:47  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-05 22:20:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 22:20:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 22:20:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 22:21:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 22:21:08  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-05 22:21:12  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-05 22:21:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 22:21:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 22:21:24  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 22:21:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 22:21:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-05 22:21:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 22:21:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 22:21:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-05 22:21:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-05 22:21:52  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-05_22-31-52 Restart Xvfb...
2017-04-05_23-01-52 Restart Xvfb...
2017-04-05_23-31-52 Restart Xvfb...
2017-04-06_00-01-53 Restart Xvfb...
2017-04-06 00:31:46 reset updateRequest
2017-04-06 00:31:48  - 14968  http://www.lymphomahub.com/
2017-04-06 00:31:51  - 14968  http://www.lymphomahub.com/
2017-04-06 00:31:52  - 14968  http://www.lymphomahub.com/about
2017-04-06_00-31-53 Restart Xvfb...
2017-04-06 00:31:58  - 14968  http://www.lymphomahub.com/terms
2017-04-06 00:32:01  - 14968  http://www.lymphomahub.com/undefined
2017-04-06 00:32:02  - 14968  http://www.lymphomahub.com/therapies
2017-04-06 00:32:08  - 14968  http://www.lymphomahub.com/newsletter
2017-04-06 00:32:11  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-06 00:32:14  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-06 00:32:18  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-06 00:32:23  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-06 00:32:28  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-06 00:32:32  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-06 00:32:37  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-06 00:32:41  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-06 00:32:46  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-06 00:32:51  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-06 00:32:55  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-06 00:32:59  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-06 00:33:04  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-06 00:33:08  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-06 00:33:13  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-06 00:33:18  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-06 00:33:22  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-06 00:33:27  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-06 00:33:31  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-06 00:33:36  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-06 00:33:41  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-06 00:33:45  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-06 00:33:49  - 14968  http://www.lymphomahub.com/therapies/alt-803
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-06 00:33:53  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-06 00:33:56  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-06 00:33:58  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-06 00:34:00  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-06 00:34:03  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-06 00:34:04  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-06 00:34:08  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-06 00:34:09  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-06 00:34:13  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-06 00:34:14  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-06 00:34:17  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-06 00:34:19  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-06 00:34:22  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-06 00:34:23  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-06 00:34:27  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-06 00:34:28  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-06 00:34:32  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-06 00:34:33  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-06 00:34:37  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-06 00:34:38  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-06 00:34:43  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-06 00:34:47  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-06 00:34:52  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-06 00:34:58  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-06 00:35:03  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-06 00:35:07  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-06 00:35:12  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-06 00:35:16  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-06 00:35:21  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-06 00:35:25  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-06 00:35:30  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-06 00:35:34  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-06 00:35:39  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-06 00:35:43  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-06 00:35:48  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-06 00:35:52  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-06 00:35:56  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-06 00:36:01  - 14968  http://www.lymphomahub.com/medical-information
2017-04-06 00:36:06  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-06 00:36:10  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-06 00:36:15  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-06 00:36:19  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-06 00:36:24  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-06 00:36:28  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-06 00:36:33  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-06 00:36:37  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-06 00:36:42  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-06 00:36:46  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-06 00:36:50  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-06 00:36:55  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-06 00:36:56  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-06 00:37:00  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-06 00:37:05  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-06 00:37:09  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-06 00:37:14  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-06 00:37:18  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-06 00:37:22  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-06 00:37:27  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-06 00:37:31  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-06 00:37:36  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-06 00:37:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-06 00:37:45  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-06 00:37:49  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-06 00:37:54  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-06 00:37:58  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-06 00:38:03  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-06 00:38:07  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-06 00:38:12  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-06 00:38:16  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-06 00:38:20  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-06 00:38:25  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-06 00:38:29  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-06 00:38:34  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-06 00:38:38  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-06 00:38:42  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-06 00:38:47  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-06 00:38:51  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-06 00:38:56  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-06 00:39:00  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-06 00:39:05  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-06 00:39:09  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-06 00:39:10  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-06 00:39:14  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-06 00:39:19  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-06 00:39:23  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-06 00:39:28  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-06 00:39:32  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-06 00:39:36  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-06 00:39:41  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-06 00:39:45  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-06 00:39:49  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-06 00:39:50  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-06 00:39:54  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-06 00:39:59  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-06 00:40:03  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-06 00:40:08  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-06 00:40:12  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-06 00:40:13  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-06 00:40:17  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-06 00:40:22  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-06 00:40:26  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-06 00:40:30  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-06 00:40:34  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-06 00:40:38  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-06 00:40:42  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-06 00:40:46  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-06 00:40:50  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-06 00:40:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-06 00:40:58  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-06 00:41:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-06 00:41:07  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-06 00:41:11  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-06 00:41:12  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-06 00:41:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-06 00:41:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-06 00:41:25  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-06 00:41:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-06 00:41:33  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-06 00:41:38  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-06 00:41:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-06 00:41:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-06 00:41:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-06 00:41:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-06 00:41:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-06 00:42:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-06 00:42:06  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-06 00:42:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-06 00:42:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-06 00:42:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-06 00:42:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-06 00:42:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-06 00:42:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-06 00:42:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-06 00:42:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-06 00:42:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-06 00:42:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-06 00:42:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-06 00:42:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-06 00:43:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-06 00:43:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-06 00:43:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-06 00:43:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-06 00:43:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-06 00:43:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-06 00:43:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-06 00:43:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-06 00:43:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-06 00:43:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-06 00:43:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-06 00:43:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-06 00:43:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-06 00:43:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-06 00:44:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-06 00:44:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-06 00:44:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-06 00:44:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-06 00:44:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-06 00:44:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-06 00:44:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-06 00:44:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-06 00:44:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-06 00:44:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-06 00:44:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-06 00:44:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-06 00:44:55  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-06 00:44:59  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-06 00:45:04  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-06 00:45:08  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-06 00:45:13  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-06 00:45:17  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-06 00:45:21  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-06 00:45:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-06 00:45:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-06 00:45:34  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-06 00:45:38  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-06 00:45:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-06 00:45:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-06 00:45:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-06 00:45:55  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-06 00:45:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-06 00:46:03  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-06 00:46:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-06 00:46:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-06 00:46:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-06 00:46:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-06 00:46:27  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-06 00:46:27  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-06 00:46:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-06 00:46:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-06 00:46:41  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-06 00:46:46  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-06 00:46:50  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-06 00:46:55  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 00:46:59  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 00:47:04  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-06 00:47:09  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 00:47:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-06 00:47:18  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-06 00:47:23  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-06 00:47:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-06 00:47:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-06 00:47:36  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-06 00:47:41  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-06 00:47:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-06 00:47:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-06 00:47:55  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-06 00:48:00  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 00:48:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-06 00:48:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-06 00:48:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-06 00:48:19  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-06 00:48:23  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-06 00:48:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-06 00:48:33  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-06 00:48:37  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-06 00:48:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-06 00:48:47  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-06 00:48:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-06 00:48:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-06 00:49:00  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-06 00:49:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-06 00:49:10  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-06 00:49:14  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-06 00:49:19  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-06 00:49:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-06 00:49:28  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-06 00:49:33  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-06 00:49:37  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-06 00:49:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-06 00:49:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-06 00:49:47  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-06 00:49:52  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-06 00:49:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-06 00:50:01  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-06 00:50:06  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-06 00:50:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-06 00:50:15  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-06 00:50:20  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-06 00:50:24  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-06 00:50:29  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-06 00:50:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-06 00:50:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-06 00:50:44  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-06 00:50:48  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-06 00:50:53  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-06 00:50:57  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-06 00:51:02  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-06 00:51:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-06 00:51:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-06 00:51:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-06 00:51:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-06 00:51:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-06 00:51:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-06 00:51:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-06 00:51:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-06 00:51:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-06 00:51:45  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-06 00:51:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-06 00:51:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-06 00:51:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-06 00:51:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-06 00:52:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-06 00:52:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-06 00:52:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-06 00:52:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-06 00:52:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-06 00:52:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-06 00:52:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-06 00:52:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-06 00:52:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-06 00:52:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-06 00:52:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-06 00:52:42  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-06 00:52:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-06 00:52:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-06 00:52:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-06 00:52:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-06 00:53:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-06 00:53:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-06 00:53:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-06 00:53:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-06 00:53:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-06 00:53:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-06 00:53:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-06 00:53:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-06 00:53:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-06 00:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-06 00:53:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-06 00:53:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-06 00:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-06 00:53:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-06 00:53:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-06 00:53:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-06 00:54:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-06 00:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-06 00:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-06 00:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-06 00:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-06 00:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-06 00:54:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-06 00:54:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-06 00:54:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-06 00:54:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-06 00:54:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-06 00:54:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-06 00:54:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-06 00:54:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-06 00:54:53  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-06 00:54:57  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-06 00:55:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-06 00:55:07  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-06 00:55:08  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-06 00:55:12  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-06 00:55:17  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-06 00:55:22  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-06 00:55:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-06 00:55:31  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-06 00:55:35  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-06 00:55:40  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-06 00:55:45  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-06 00:55:49  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-06 00:55:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-06 00:55:59  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-06 00:56:03  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-06 00:56:08  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-06 00:56:12  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-06 00:56:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-06 00:56:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-06 00:56:27  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-06 00:56:31  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-06 00:56:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-06 00:56:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-06 00:56:45  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-06 00:56:49  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-06 00:56:54  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-06 00:56:58  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-06 00:57:03  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-06 00:57:07  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-06 00:57:12  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-06 00:57:16  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-06 00:57:21  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-06 00:57:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-06 00:57:30  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-06 00:57:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-06 00:57:39  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-06 00:57:44  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-06 00:57:48  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-06 00:57:53  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-06 00:57:57  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-06 00:58:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-06 00:58:07  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-06 00:58:11  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-06 00:58:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-06 00:58:21  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-06 00:58:26  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-06 00:58:30  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-06 00:58:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-06 00:58:39  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-06 00:58:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-06 00:58:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-06 00:58:52  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-06 00:58:57  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-06 00:59:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-06 00:59:06  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-06 00:59:11  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-06 00:59:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-06 00:59:20  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-06 00:59:25  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-06 00:59:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-06 00:59:34  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-06 00:59:38  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-06 00:59:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-06 00:59:48  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-06 00:59:52  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-06 00:59:57  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-06 01:00:02  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-06 01:00:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-06 01:00:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-06 01:00:16  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-06 01:00:20  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-06 01:00:25  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-06 01:00:30  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-06 01:00:34  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-06 01:00:39  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-06 01:00:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-06 01:00:48  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-06 01:00:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-06 01:00:57  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-06 01:01:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-06 01:01:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-06 01:01:11  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-06 01:01:15  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-06 01:01:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-06 01:01:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-06 01:01:29  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-06 01:01:34  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-06 01:01:39  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-06 01:01:43  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-06 01:01:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-06 01:01:52  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-06_01-01-53 Restart Xvfb...
2017-04-06 01:01:57  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-06 01:02:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-06 01:02:06  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-06 01:02:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-06 01:02:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-06 01:02:20  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-06 01:02:25  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-06 01:02:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-06 01:02:34  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-06 01:02:39  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-06 01:02:44  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-06 01:02:49  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-06 01:02:53  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-06 01:02:58  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-06 01:03:03  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-06 01:03:07  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-06 01:03:12  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-06 01:03:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-06 01:03:21  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-06 01:03:25  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-06 01:03:30  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-06 01:03:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-06 01:03:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-06 01:03:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-06 01:03:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-06 01:03:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-06 01:03:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-06 01:04:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-06 01:04:07  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-06 01:04:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-06 01:04:16  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-06 01:04:21  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-06 01:04:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-06 01:04:30  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-06 01:04:35  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-06 01:04:39  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-06 01:04:44  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-06 01:04:48  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-06 01:04:53  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-06 01:04:58  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-06 01:05:02  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-06 01:05:07  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-06 01:05:12  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-06 01:05:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-06 01:05:21  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-06 01:05:26  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-06 01:05:30  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-06 01:05:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-06 01:05:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-06 01:05:44  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-06 01:05:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-06 01:05:53  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-06 01:05:58  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-06 01:06:03  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-06 01:06:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-06 01:06:12  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-06 01:06:17  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-06 01:06:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-06 01:06:26  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-06 01:06:30  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-06 01:06:34  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-06 01:06:39  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-06 01:06:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-06 01:06:48  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-06 01:06:53  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-06 01:06:57  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-06 01:07:02  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-06 01:07:06  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-06 01:07:11  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-06 01:07:15  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-06 01:07:19  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-06 01:07:24  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-06 01:07:28  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-06 01:07:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-06 01:07:37  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-06 01:07:41  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-06 01:07:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-06 01:07:50  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-06 01:07:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-06 01:07:59  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-06 01:08:04  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-06 01:08:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-06 01:08:12  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-06 01:08:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-06 01:08:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-06 01:08:26  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-06 01:08:31  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-06 01:08:35  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-06 01:08:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-06 01:08:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-06 01:08:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-06 01:08:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-06 01:08:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-06 01:09:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-06 01:09:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-06 01:09:11  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-06 01:09:15  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-06 01:09:19  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-06 01:09:24  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-06 01:09:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-06 01:09:33  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-06 01:09:37  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-06 01:09:42  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-06 01:09:47  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-06 01:09:51  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-06 01:09:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-06 01:10:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-06 01:10:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-06 01:10:10  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-06 01:10:11  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-06 01:10:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-06 01:10:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-06 01:10:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-06 01:10:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-06 01:10:34  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-06 01:10:39  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-06 01:10:43  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-06 01:10:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-06 01:10:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-06 01:10:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-06 01:11:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-06 01:11:05  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-06 01:11:09  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-06 01:11:14  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-06 01:11:18  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-06 01:11:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-06 01:11:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-06 01:11:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-06 01:11:36  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-06 01:11:41  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-06 01:11:46  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-06 01:11:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-06 01:11:54  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-06 01:11:58  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-06 01:12:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-06 01:12:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-06 01:12:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-06 01:12:17  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-06 01:12:21  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-06 01:12:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-06 01:12:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-06 01:12:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-06 01:12:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-06 01:12:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-06 01:12:46  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-06 01:12:50  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-06 01:12:54  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-06 01:12:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-06 01:13:02  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-06 01:13:06  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-06 01:13:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-06 01:13:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-06 01:13:20  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-06 01:13:24  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-06 01:13:28  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-06 01:13:32  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-06 01:13:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-06 01:13:41  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-06 01:13:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-06 01:13:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-06 01:13:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-06 01:13:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-06 01:14:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-06 01:14:08  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-06 01:14:12  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-06 01:14:16  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-06 01:14:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-06 01:14:25  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-06 01:14:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-06 01:14:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-06 01:14:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-06 01:14:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 01:14:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 01:14:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 01:14:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 01:14:58  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-06 01:15:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 01:15:07  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 01:15:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-06 01:15:15  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-06 01:15:19  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-06 01:15:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-06 01:15:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-06 01:15:32  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-06 01:15:36  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-06 01:15:40  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-06 01:15:44  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-06 01:15:48  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-06 01:15:52  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-06 01:15:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-06 01:16:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-06 01:16:05  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-06 01:16:09  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-06 01:16:13  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-06 01:16:17  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-06 01:16:21  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-06 01:16:25  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-06 01:16:29  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-06 01:16:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 01:16:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 01:16:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 01:16:46  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 01:16:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 01:16:54  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-06 01:16:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 01:17:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 01:17:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 01:17:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 01:17:15  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-06 01:17:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 01:17:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 01:17:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 01:17:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-06 01:17:36  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-06_01-31-53 Restart Xvfb...
2017-04-06_02-01-53 Restart Xvfb...
2017-04-06_02-31-53 Restart Xvfb...
2017-04-06_03-01-53 Restart Xvfb...
2017-04-06 03:31:46 reset updateRequest
2017-04-06 03:31:47  - 14968  http://www.lymphomahub.com/
2017-04-06 03:31:51  - 14968  http://www.lymphomahub.com/
2017-04-06 03:31:52  - 14968  http://www.lymphomahub.com/about
2017-04-06_03-31-53 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-06 03:33:56  - 14968  http://www.lymphomahub.com/about
2017-04-06 03:33:57  - 14968  http://www.lymphomahub.com/about
2017-04-06 03:34:02  - 14968  http://www.lymphomahub.com/terms
2017-04-06 03:34:05  - 14968  http://www.lymphomahub.com/undefined
2017-04-06 03:34:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-06 03:34:12  - 14968  http://www.lymphomahub.com/newsletter
2017-04-06 03:34:15  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-06 03:34:18  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-06 03:34:22  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-06 03:34:27  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-06 03:34:31  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-06 03:34:36  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-06 03:34:40  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-06 03:34:45  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-06 03:34:49  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-06 03:34:54  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-06 03:34:58  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-06 03:35:03  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-06 03:35:08  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-06 03:35:12  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-06 03:35:17  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-06 03:35:22  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-06 03:35:26  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-06 03:35:30  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-06 03:35:35  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-06 03:35:39  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-06 03:35:44  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-06 03:35:48  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-06 03:35:52  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-06 03:35:56  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-06 03:36:01  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-06 03:36:05  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-06 03:36:10  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-06 03:36:15  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-06 03:36:19  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-06 03:36:23  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-06 03:36:28  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-06 03:36:32  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-06 03:36:37  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-06 03:36:42  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-06 03:36:46  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-06 03:36:51  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-06 03:36:55  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-06 03:37:00  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-06 03:37:04  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-06 03:37:09  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-06 03:37:13  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-06 03:37:17  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-06 03:37:22  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-06 03:37:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-06 03:37:31  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-06 03:37:35  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-06 03:37:40  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-06 03:37:44  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-06 03:37:49  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-06 03:37:53  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-06 03:37:58  - 14968  http://www.lymphomahub.com/medical-information
2017-04-06 03:38:02  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-06 03:38:07  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-06 03:38:11  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-06 03:38:16  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-06 03:38:20  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-06 03:38:25  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-06 03:38:29  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-06 03:38:34  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-06 03:38:38  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-06 03:38:43  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-06 03:38:47  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-06 03:38:51  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-06 03:38:52  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-06 03:38:57  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-06 03:39:01  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-06 03:39:06  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-06 03:39:10  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-06 03:39:14  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-06 03:39:19  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-06 03:39:23  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-06 03:39:28  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-06 03:39:33  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-06 03:39:37  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-06 03:39:42  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-06 03:39:46  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-06 03:39:51  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-06 03:39:55  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-06 03:39:59  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-06 03:40:04  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-06 03:40:09  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-06 03:40:13  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-06 03:40:17  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-06 03:40:22  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-06 03:40:26  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-06 03:40:31  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-06 03:40:35  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-06 03:40:40  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-06 03:40:44  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-06 03:40:49  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-06 03:40:53  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-06 03:40:58  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-06 03:41:02  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-06 03:41:07  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-06 03:41:07  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-06 03:41:12  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-06 03:41:17  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-06 03:41:21  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-06 03:41:26  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-06 03:41:30  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-06 03:41:34  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-06 03:41:39  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-06 03:41:43  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-06 03:41:47  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-06 03:41:48  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-06 03:41:52  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-06 03:41:57  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-06 03:42:01  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-06 03:42:06  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-06 03:42:10  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-06 03:42:11  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-06 03:42:15  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-06 03:42:19  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-06 03:42:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-06 03:42:28  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-06 03:42:32  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-06 03:42:36  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-06 03:42:40  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-06 03:42:44  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-06 03:42:48  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-06 03:42:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-06 03:42:56  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-06 03:43:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-06 03:43:05  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-06 03:43:09  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-06 03:43:09  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-06 03:43:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-06 03:43:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-06 03:43:23  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-06 03:43:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-06 03:43:32  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-06 03:43:36  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-06 03:43:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-06 03:43:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-06 03:43:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-06 03:43:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-06 03:43:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-06 03:43:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-06 03:44:03  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-06 03:44:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-06 03:44:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-06 03:44:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-06 03:44:20  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-06 03:44:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-06 03:44:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-06 03:44:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-06 03:44:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-06 03:44:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-06 03:44:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-06 03:44:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-06 03:44:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-06 03:44:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-06 03:45:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-06 03:45:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-06 03:45:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-06 03:45:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-06 03:45:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-06 03:45:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-06 03:45:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-06 03:45:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-06 03:45:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-06 03:45:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-06 03:45:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-06 03:45:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-06 03:45:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-06 03:46:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-06 03:46:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-06 03:46:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-06 03:46:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-06 03:46:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-06 03:46:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-06 03:46:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-06 03:46:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-06 03:46:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-06 03:46:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-06 03:46:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-06 03:46:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-06 03:46:52  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-06 03:46:56  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-06 03:47:01  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-06 03:47:05  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-06 03:47:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-06 03:47:13  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-06 03:47:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-06 03:47:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-06 03:47:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-06 03:47:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-06 03:47:34  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-06 03:47:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-06 03:47:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-06 03:47:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-06 03:47:52  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-06 03:47:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-06 03:48:01  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-06 03:48:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-06 03:48:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-06 03:48:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-06 03:48:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-06 03:48:24  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-06 03:48:25  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-06 03:48:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-06 03:48:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-06 03:48:38  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-06 03:48:43  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-06 03:48:47  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-06 03:48:52  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 03:48:57  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 03:49:01  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-06 03:49:06  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 03:49:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-06 03:49:15  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-06 03:49:20  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-06 03:49:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-06 03:49:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-06 03:49:34  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-06 03:49:38  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-06 03:49:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-06 03:49:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-06 03:49:52  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-06 03:49:57  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 03:50:01  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-06 03:50:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-06 03:50:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-06 03:50:15  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-06 03:50:20  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-06 03:50:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-06 03:50:30  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-06 03:50:34  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-06 03:50:39  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-06 03:50:43  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-06 03:50:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-06 03:50:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-06 03:50:57  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-06 03:51:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-06 03:51:06  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-06 03:51:11  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-06 03:51:15  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-06 03:51:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-06 03:51:25  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-06 03:51:29  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-06 03:51:34  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-06 03:51:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-06 03:51:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-06 03:51:44  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-06 03:51:48  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-06 03:51:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-06 03:51:58  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-06 03:52:02  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-06 03:52:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-06 03:52:11  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-06 03:52:16  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-06 03:52:21  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-06 03:52:25  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-06 03:52:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-06 03:52:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-06 03:52:39  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-06 03:52:44  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-06 03:52:49  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-06 03:52:53  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-06 03:52:58  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-06 03:53:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-06 03:53:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-06 03:53:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-06 03:53:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-06 03:53:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-06 03:53:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-06 03:53:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-06 03:53:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-06 03:53:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-06 03:53:41  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-06 03:53:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-06 03:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-06 03:53:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-06 03:53:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-06 03:53:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-06 03:54:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-06 03:54:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-06 03:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-06 03:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-06 03:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-06 03:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-06 03:54:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-06 03:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-06 03:54:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-06 03:54:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-06 03:54:38  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-06 03:54:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-06 03:54:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-06 03:54:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-06 03:54:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-06 03:54:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-06 03:55:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-06 03:55:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-06 03:55:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-06 03:55:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-06 03:55:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-06 03:55:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-06 03:55:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-06 03:55:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-06 03:55:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-06 03:55:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-06 03:55:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-06 03:55:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-06 03:55:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-06 03:55:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-06 03:55:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-06 03:55:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-06 03:55:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-06 03:56:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-06 03:56:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-06 03:56:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-06 03:56:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-06 03:56:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-06 03:56:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-06 03:56:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-06 03:56:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-06 03:56:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-06 03:56:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-06 03:56:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-06 03:56:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-06 03:56:48  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-06 03:56:53  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-06 03:56:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-06 03:57:03  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-06 03:57:03  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-06 03:57:08  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-06 03:57:12  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-06 03:57:17  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-06 03:57:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-06 03:57:26  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-06 03:57:31  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-06 03:57:35  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-06 03:57:40  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-06 03:57:44  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-06 03:57:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-06 03:57:54  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-06 03:57:58  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-06 03:58:03  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-06 03:58:08  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-06 03:58:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-06 03:58:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-06 03:58:21  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-06 03:58:26  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-06 03:58:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-06 03:58:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-06 03:58:40  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-06 03:58:45  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-06 03:58:50  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-06 03:58:54  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-06 03:58:59  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-06 03:59:03  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-06 03:59:08  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-06 03:59:13  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-06 03:59:17  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-06 03:59:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-06 03:59:26  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-06 03:59:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-06 03:59:35  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-06 03:59:40  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-06 03:59:44  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-06 03:59:49  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-06 03:59:53  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-06 03:59:58  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-06 04:00:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-06 04:00:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-06 04:00:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-06 04:00:17  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-06 04:00:21  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-06 04:00:26  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-06 04:00:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-06 04:00:35  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-06 04:00:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-06 04:00:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-06 04:00:49  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-06 04:00:53  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-06 04:00:58  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-06 04:01:02  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-06 04:01:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-06 04:01:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-06 04:01:16  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-06 04:01:21  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-06 04:01:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-06 04:01:30  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-06 04:01:35  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-06 04:01:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-06 04:01:44  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-06 04:01:48  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-06_04-01-53 Restart Xvfb...
2017-04-06 04:01:53  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-06 04:01:58  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-06 04:02:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-06 04:02:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-06 04:02:11  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-06 04:02:16  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-06 04:02:21  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-06 04:02:25  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-06 04:02:30  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-06 04:02:35  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-06 04:02:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-06 04:02:44  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-06 04:02:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-06 04:02:53  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-06 04:02:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-06 04:03:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-06 04:03:07  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-06 04:03:11  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-06 04:03:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-06 04:03:20  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-06 04:03:25  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-06 04:03:30  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-06 04:03:34  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-06 04:03:38  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-06 04:03:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-06 04:03:47  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-06 04:03:52  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-06 04:03:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-06 04:04:01  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-06 04:04:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-06 04:04:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-06 04:04:15  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-06 04:04:20  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-06 04:04:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-06 04:04:29  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-06 04:04:33  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-06 04:04:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-06 04:04:43  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-06 04:04:47  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-06 04:04:52  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-06 04:04:57  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-06 04:05:01  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-06 04:05:06  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-06 04:05:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-06 04:05:15  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-06 04:05:20  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-06 04:05:25  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-06 04:05:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-06 04:05:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-06 04:05:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-06 04:05:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-06 04:05:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-06 04:05:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-06 04:05:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-06 04:06:02  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-06 04:06:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-06 04:06:11  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-06 04:06:16  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-06 04:06:20  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-06 04:06:24  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-06 04:06:29  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-06 04:06:33  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-06 04:06:38  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-06 04:06:43  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-06 04:06:47  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-06 04:06:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-06 04:06:56  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-06 04:07:01  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-06 04:07:06  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-06 04:07:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-06 04:07:15  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-06 04:07:20  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-06 04:07:24  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-06 04:07:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-06 04:07:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-06 04:07:39  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-06 04:07:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-06 04:07:48  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-06 04:07:52  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-06 04:07:57  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-06 04:08:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-06 04:08:07  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-06 04:08:11  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-06 04:08:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-06 04:08:20  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-06 04:08:24  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-06 04:08:28  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-06 04:08:33  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-06 04:08:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-06 04:08:42  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-06 04:08:46  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-06 04:08:51  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-06 04:08:55  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-06 04:09:00  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-06 04:09:05  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-06 04:09:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-06 04:09:14  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-06 04:09:18  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-06 04:09:22  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-06 04:09:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-06 04:09:31  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-06 04:09:36  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-06 04:09:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-06 04:09:45  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-06 04:09:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-06 04:09:54  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-06 04:09:59  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-06 04:10:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-06 04:10:07  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-06 04:10:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-06 04:10:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-06 04:10:21  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-06 04:10:26  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-06 04:10:30  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-06 04:10:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-06 04:10:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-06 04:10:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-06 04:10:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-06 04:10:52  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-06 04:10:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-06 04:11:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-06 04:11:05  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-06 04:11:09  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-06 04:11:14  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-06 04:11:19  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-06 04:11:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-06 04:11:27  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-06 04:11:31  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-06 04:11:36  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-06 04:11:41  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-06 04:11:45  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-06 04:11:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-06 04:11:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-06 04:11:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-06 04:12:04  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-06 04:12:05  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-06 04:12:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-06 04:12:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-06 04:12:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-06 04:12:23  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-06 04:12:27  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-06 04:12:32  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-06 04:12:37  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-06 04:12:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-06 04:12:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-06 04:12:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-06 04:12:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-06 04:12:59  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-06 04:13:03  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-06 04:13:07  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-06 04:13:11  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-06 04:13:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-06 04:13:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-06 04:13:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-06 04:13:30  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-06 04:13:34  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-06 04:13:39  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-06 04:13:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-06 04:13:47  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-06 04:13:51  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-06 04:13:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-06 04:14:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-06 04:14:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-06 04:14:10  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-06 04:14:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-06 04:14:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-06 04:14:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-06 04:14:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-06 04:14:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-06 04:14:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-06 04:14:39  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-06 04:14:43  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-06 04:14:47  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-06 04:14:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-06 04:14:55  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-06 04:14:59  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-06 04:15:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-06 04:15:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-06 04:15:13  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-06 04:15:17  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-06 04:15:21  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-06 04:15:25  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-06 04:15:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-06 04:15:34  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-06 04:15:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-06 04:15:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-06 04:15:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-06 04:15:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-06 04:15:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-06 04:16:01  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-06 04:16:05  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-06 04:16:09  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-06 04:16:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-06 04:16:18  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-06 04:16:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-06 04:16:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-06 04:16:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-06 04:16:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 04:16:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 04:16:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 04:16:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 04:16:50  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-06 04:16:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 04:16:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 04:17:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-06 04:17:07  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-06 04:17:11  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-06 04:17:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-06 04:17:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-06 04:17:23  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-06 04:17:27  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-06 04:17:31  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-06 04:17:36  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-06 04:17:40  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-06 04:17:44  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-06 04:17:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-06 04:17:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-06 04:17:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-06 04:18:01  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-06 04:18:05  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-06 04:18:09  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-06 04:18:13  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-06 04:18:17  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-06 04:18:21  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-06 04:18:25  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 04:18:29  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 04:18:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 04:18:37  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 04:18:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 04:18:45  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-06 04:18:49  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 04:18:53  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 04:18:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 04:19:02  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 04:19:06  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-06 04:19:10  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 04:19:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 04:19:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 04:19:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-06 04:19:26  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-06_04-31-53 Restart Xvfb...
2017-04-06_05-01-53 Restart Xvfb...
2017-04-06_05-31-53 Restart Xvfb...
2017-04-06_06-01-53 Restart Xvfb...
2017-04-06 06:31:46 reset updateRequest
2017-04-06 06:31:48  - 14968  http://www.lymphomahub.com/
2017-04-06 06:31:51  - 14968  http://www.lymphomahub.com/
2017-04-06 06:31:52  - 14968  http://www.lymphomahub.com/about
2017-04-06_06-31-53 Restart Xvfb...
2017-04-06 06:31:58  - 14968  http://www.lymphomahub.com/terms
2017-04-06 06:32:02  - 14968  http://www.lymphomahub.com/undefined
2017-04-06 06:32:02  - 14968  http://www.lymphomahub.com/therapies
2017-04-06 06:32:08  - 14968  http://www.lymphomahub.com/newsletter
2017-04-06 06:32:11  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-06 06:32:15  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-06 06:32:19  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-06 06:32:24  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-06 06:32:28  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-06 06:32:33  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-06 06:32:38  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-06 06:32:42  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-06 06:32:47  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-06 06:32:51  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-06 06:32:56  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-06 06:33:00  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-06 06:33:06  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-06 06:33:11  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-06 06:33:15  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-06 06:33:20  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-06 06:33:24  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-06 06:33:29  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-06 06:33:33  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-06 06:33:38  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-06 06:33:42  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-06 06:33:47  - 14968  http://www.lymphomahub.com/about/secretariat
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-06 06:33:51  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-06 06:33:55  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-06 06:33:56  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-06 06:34:00  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-06 06:34:00  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-06 06:34:05  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-06 06:34:06  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-06 06:34:11  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-06 06:34:15  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-06 06:34:20  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-06 06:34:24  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-06 06:34:29  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-06 06:34:33  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-06 06:34:38  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-06 06:34:42  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-06 06:34:47  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-06 06:34:51  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-06 06:34:55  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-06 06:35:00  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-06 06:35:04  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-06 06:35:09  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-06 06:35:13  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-06 06:35:18  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-06 06:35:22  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-06 06:35:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-06 06:35:31  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-06 06:35:36  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-06 06:35:40  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-06 06:35:44  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-06 06:35:49  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-06 06:35:54  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-06 06:35:58  - 14968  http://www.lymphomahub.com/medical-information
2017-04-06 06:36:03  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-06 06:36:07  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-06 06:36:12  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-06 06:36:16  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-06 06:36:21  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-06 06:36:25  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-06 06:36:30  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-06 06:36:35  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-06 06:36:39  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-06 06:36:44  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-06 06:36:48  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-06 06:36:52  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-06 06:36:53  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-06 06:36:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-06 06:37:02  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-06 06:37:07  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-06 06:37:11  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-06 06:37:15  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-06 06:37:20  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-06 06:37:24  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-06 06:37:29  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-06 06:37:33  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-06 06:37:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-06 06:37:42  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-06 06:37:46  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-06 06:37:51  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-06 06:37:55  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-06 06:38:00  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-06 06:38:04  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-06 06:38:08  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-06 06:38:13  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-06 06:38:17  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-06 06:38:22  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-06 06:38:26  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-06 06:38:31  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-06 06:38:35  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-06 06:38:39  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-06 06:38:44  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-06 06:38:48  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-06 06:38:53  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-06 06:38:57  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-06 06:39:01  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-06 06:39:06  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-06 06:39:07  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-06 06:39:11  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-06 06:39:15  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-06 06:39:20  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-06 06:39:24  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-06 06:39:29  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-06 06:39:33  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-06 06:39:38  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-06 06:39:42  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-06 06:39:46  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-06 06:39:46  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-06 06:39:51  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-06 06:39:55  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-06 06:39:59  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-06 06:40:04  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-06 06:40:09  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-06 06:40:10  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-06 06:40:14  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-06 06:40:18  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-06 06:40:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-06 06:40:27  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-06 06:40:31  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-06 06:40:35  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-06 06:40:39  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-06 06:40:43  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-06 06:40:47  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-06 06:40:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-06 06:40:55  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-06 06:40:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-06 06:41:04  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-06 06:41:08  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-06 06:41:08  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-06 06:41:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-06 06:41:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-06 06:41:21  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-06 06:41:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-06 06:41:30  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-06 06:41:34  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-06 06:41:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-06 06:41:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-06 06:41:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-06 06:41:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-06 06:41:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-06 06:41:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-06 06:42:02  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-06 06:42:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-06 06:42:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-06 06:42:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-06 06:42:20  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-06 06:42:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-06 06:42:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-06 06:42:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-06 06:42:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-06 06:42:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-06 06:42:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-06 06:42:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-06 06:42:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-06 06:42:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-06 06:43:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-06 06:43:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-06 06:43:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-06 06:43:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-06 06:43:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-06 06:43:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-06 06:43:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-06 06:43:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-06 06:43:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-06 06:43:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-06 06:43:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-06 06:43:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-06 06:43:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-06 06:44:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-06 06:44:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-06 06:44:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-06 06:44:14  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-06 06:44:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-06 06:44:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-06 06:44:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-06 06:44:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-06 06:44:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-06 06:44:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-06 06:44:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-06 06:44:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-06 06:44:51  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-06 06:44:56  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-06 06:45:00  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-06 06:45:04  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-06 06:45:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-06 06:45:12  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-06 06:45:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-06 06:45:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-06 06:45:25  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-06 06:45:29  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-06 06:45:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-06 06:45:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-06 06:45:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-06 06:45:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-06 06:45:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-06 06:45:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-06 06:45:59  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-06 06:46:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-06 06:46:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-06 06:46:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-06 06:46:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-06 06:46:22  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-06 06:46:23  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-06 06:46:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-06 06:46:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-06 06:46:37  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-06 06:46:41  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-06 06:46:46  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-06 06:46:50  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 06:46:55  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 06:47:00  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-06 06:47:05  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 06:47:09  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-06 06:47:14  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-06 06:47:19  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-06 06:47:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-06 06:47:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-06 06:47:32  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-06 06:47:37  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-06 06:47:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-06 06:47:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-06 06:47:51  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-06 06:47:56  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 06:48:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-06 06:48:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-06 06:48:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-06 06:48:15  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-06 06:48:20  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-06 06:48:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-06 06:48:29  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-06 06:48:34  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-06 06:48:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-06 06:48:43  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-06 06:48:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-06 06:48:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-06 06:48:57  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-06 06:49:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-06 06:49:06  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-06 06:49:11  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-06 06:49:15  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-06 06:49:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-06 06:49:25  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-06 06:49:29  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-06 06:49:34  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-06 06:49:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-06 06:49:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-06 06:49:44  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-06 06:49:49  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-06 06:49:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-06 06:49:58  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-06 06:50:02  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-06 06:50:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-06 06:50:12  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-06 06:50:16  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-06 06:50:21  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-06 06:50:26  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-06 06:50:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-06 06:50:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-06 06:50:40  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-06 06:50:44  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-06 06:50:49  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-06 06:50:54  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-06 06:50:58  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-06 06:51:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-06 06:51:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-06 06:51:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-06 06:51:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-06 06:51:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-06 06:51:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-06 06:51:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-06 06:51:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-06 06:51:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-06 06:51:43  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-06 06:51:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-06 06:51:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-06 06:51:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-06 06:51:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-06 06:51:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-06 06:52:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-06 06:52:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-06 06:52:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-06 06:52:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-06 06:52:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-06 06:52:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-06 06:52:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-06 06:52:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-06 06:52:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-06 06:52:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-06 06:52:39  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-06 06:52:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-06 06:52:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-06 06:52:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-06 06:52:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-06 06:52:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-06 06:53:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-06 06:53:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-06 06:53:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-06 06:53:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-06 06:53:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-06 06:53:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-06 06:53:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-06 06:53:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-06 06:53:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-06 06:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-06 06:53:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-06 06:53:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-06 06:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-06 06:53:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-06 06:53:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-06 06:53:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-06 06:54:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-06 06:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-06 06:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-06 06:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-06 06:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-06 06:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-06 06:54:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-06 06:54:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-06 06:54:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-06 06:54:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-06 06:54:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-06 06:54:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-06 06:54:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-06 06:54:49  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-06 06:54:54  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-06 06:54:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-06 06:55:03  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-06 06:55:04  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-06 06:55:09  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-06 06:55:13  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-06 06:55:18  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-06 06:55:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-06 06:55:27  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-06 06:55:32  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-06 06:55:36  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-06 06:55:41  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-06 06:55:45  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-06 06:55:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-06 06:55:55  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-06 06:55:59  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-06 06:56:04  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-06 06:56:09  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-06 06:56:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-06 06:56:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-06 06:56:22  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-06 06:56:27  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-06 06:56:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-06 06:56:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-06 06:56:41  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-06 06:56:46  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-06 06:56:50  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-06 06:56:55  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-06 06:56:59  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-06 06:57:04  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-06 06:57:08  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-06 06:57:13  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-06 06:57:17  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-06 06:57:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-06 06:57:26  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-06 06:57:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-06 06:57:36  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-06 06:57:40  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-06 06:57:45  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-06 06:57:49  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-06 06:57:54  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-06 06:57:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-06 06:58:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-06 06:58:08  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-06 06:58:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-06 06:58:17  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-06 06:58:21  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-06 06:58:26  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-06 06:58:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-06 06:58:35  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-06 06:58:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-06 06:58:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-06 06:58:49  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-06 06:58:53  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-06 06:58:58  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-06 06:59:03  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-06 06:59:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-06 06:59:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-06 06:59:17  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-06 06:59:22  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-06 06:59:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-06 06:59:31  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-06 06:59:35  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-06 06:59:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-06 06:59:44  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-06 06:59:49  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-06 06:59:53  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-06 06:59:58  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-06 07:00:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-06 07:00:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-06 07:00:12  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-06 07:00:16  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-06 07:00:21  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-06 07:00:26  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-06 07:00:30  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-06 07:00:35  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-06 07:00:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-06 07:00:44  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-06 07:00:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-06 07:00:53  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-06 07:00:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-06 07:01:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-06 07:01:08  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-06 07:01:12  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-06 07:01:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-06 07:01:21  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-06 07:01:26  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-06 07:01:31  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-06 07:01:35  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-06 07:01:39  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-06 07:01:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-06 07:01:48  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-06 07:01:53  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-06_07-01-53 Restart Xvfb...
2017-04-06 07:01:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-06 07:02:02  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-06 07:02:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-06 07:02:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-06 07:02:16  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-06 07:02:21  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-06 07:02:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-06 07:02:31  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-06 07:02:35  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-06 07:02:40  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-06 07:02:45  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-06 07:02:50  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-06 07:02:55  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-06 07:03:00  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-06 07:03:05  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-06 07:03:09  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-06 07:03:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-06 07:03:18  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-06 07:03:23  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-06 07:03:28  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-06 07:03:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-06 07:03:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-06 07:03:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-06 07:03:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-06 07:03:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-06 07:03:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-06 07:03:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-06 07:04:04  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-06 07:04:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-06 07:04:13  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-06 07:04:18  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-06 07:04:22  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-06 07:04:27  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-06 07:04:31  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-06 07:04:36  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-06 07:04:40  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-06 07:04:46  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-06 07:04:50  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-06 07:04:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-06 07:04:59  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-06 07:05:04  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-06 07:05:09  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-06 07:05:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-06 07:05:18  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-06 07:05:23  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-06 07:05:27  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-06 07:05:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-06 07:05:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-06 07:05:41  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-06 07:05:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-06 07:05:50  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-06 07:05:55  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-06 07:05:59  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-06 07:06:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-06 07:06:09  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-06 07:06:14  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-06 07:06:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-06 07:06:23  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-06 07:06:27  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-06 07:06:31  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-06 07:06:36  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-06 07:06:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-06 07:06:45  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-06 07:06:49  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-06 07:06:54  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-06 07:06:59  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-06 07:07:04  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-06 07:07:08  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-06 07:07:13  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-06 07:07:18  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-06 07:07:23  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-06 07:07:27  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-06 07:07:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-06 07:07:36  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-06 07:07:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-06 07:07:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-06 07:07:50  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-06 07:07:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-06 07:07:58  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-06 07:08:03  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-06 07:08:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-06 07:08:12  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-06 07:08:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-06 07:08:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-06 07:08:26  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-06 07:08:31  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-06 07:08:35  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-06 07:08:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-06 07:08:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-06 07:08:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-06 07:08:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-06 07:08:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-06 07:09:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-06 07:09:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-06 07:09:10  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-06 07:09:14  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-06 07:09:19  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-06 07:09:23  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-06 07:09:27  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-06 07:09:32  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-06 07:09:36  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-06 07:09:41  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-06 07:09:45  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-06 07:09:50  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-06 07:09:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-06 07:09:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-06 07:10:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-06 07:10:09  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-06 07:10:09  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-06 07:10:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-06 07:10:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-06 07:10:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-06 07:10:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-06 07:10:33  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-06 07:10:38  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-06 07:10:43  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-06 07:10:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-06 07:10:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-06 07:10:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-06 07:11:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-06 07:11:05  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-06 07:11:09  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-06 07:11:14  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-06 07:11:18  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-06 07:11:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-06 07:11:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-06 07:11:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-06 07:11:36  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-06 07:11:41  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-06 07:11:45  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-06 07:11:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-06 07:11:54  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-06 07:11:58  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-06 07:12:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-06 07:12:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-06 07:12:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-06 07:12:16  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-06 07:12:20  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-06 07:12:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-06 07:12:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-06 07:12:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-06 07:12:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-06 07:12:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-06 07:12:46  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-06 07:12:50  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-06 07:12:54  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-06 07:12:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-06 07:13:02  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-06 07:13:06  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-06 07:13:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-06 07:13:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-06 07:13:19  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-06 07:13:23  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-06 07:13:27  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-06 07:13:31  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-06 07:13:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-06 07:13:40  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-06 07:13:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-06 07:13:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-06 07:13:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-06 07:13:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-06 07:14:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-06 07:14:07  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-06 07:14:11  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-06 07:14:16  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-06 07:14:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-06 07:14:26  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-06 07:14:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-06 07:14:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-06 07:14:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-06 07:14:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 07:14:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 07:14:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 07:14:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 07:14:59  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-06 07:15:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 07:15:07  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 07:15:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-06 07:15:15  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-06 07:15:20  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-06 07:15:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-06 07:15:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-06 07:15:32  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-06 07:15:36  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-06 07:15:40  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-06 07:15:44  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-06 07:15:48  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-06 07:15:52  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-06 07:15:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-06 07:16:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-06 07:16:05  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-06 07:16:09  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-06 07:16:13  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-06 07:16:17  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-06 07:16:21  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-06 07:16:26  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-06 07:16:30  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-06 07:16:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 07:16:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 07:16:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 07:16:46  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 07:16:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 07:16:54  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-06 07:16:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 07:17:02  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 07:17:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 07:17:10  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 07:17:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-06 07:17:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 07:17:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 07:17:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 07:17:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-06 07:17:35  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-06_07-31-53 Restart Xvfb...
2017-04-06_08-01-53 Restart Xvfb...
2017-04-06_08-31-53 Restart Xvfb...
2017-04-06_09-01-53 Restart Xvfb...
2017-04-06 09:31:46 reset updateRequest
2017-04-06 09:31:46  - 14968  http://www.lymphomahub.com/
2017-04-06 09:31:50  - 14968  http://www.lymphomahub.com/about
2017-04-06 09:31:51  - 14968  http://www.lymphomahub.com/about
2017-04-06_09-31-53 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-06 09:33:55  - 14968  http://www.lymphomahub.com/about
2017-04-06 09:33:56  - 14968  http://www.lymphomahub.com/about
2017-04-06 09:34:00  - 14968  http://www.lymphomahub.com/terms
2017-04-06 09:34:02  - 14968  http://www.lymphomahub.com/terms
2017-04-06 09:34:03  - 14968  http://www.lymphomahub.com/undefined
2017-04-06 09:34:04  - 14968  http://www.lymphomahub.com/therapies
2017-04-06 09:34:05  - 14968  http://www.lymphomahub.com/therapies
2017-04-06 09:34:13  - 14968  http://www.lymphomahub.com/newsletter
2017-04-06 09:34:14  - 14968  http://www.lymphomahub.com/newsletter
2017-04-06 09:34:17  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-06 09:34:18  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-06 09:34:22  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-06 09:34:22  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-06 09:34:27  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-06 09:34:28  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-06 09:34:32  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-06 09:34:33  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-06 09:34:37  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-06 09:34:38  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-06 09:34:43  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-06 09:34:47  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-06 09:34:52  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-06 09:34:56  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-06 09:35:01  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-06 09:35:05  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-06 09:35:10  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-06 09:35:14  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-06 09:35:19  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-06 09:35:23  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-06 09:35:27  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-06 09:35:32  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-06 09:35:36  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-06 09:35:41  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-06 09:35:46  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-06 09:35:50  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-06 09:35:54  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-06 09:35:58  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-06 09:36:03  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-06 09:36:07  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-06 09:36:11  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-06 09:36:16  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-06 09:36:21  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-06 09:36:25  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-06 09:36:30  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-06 09:36:34  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-06 09:36:38  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-06 09:36:43  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-06 09:36:47  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-06 09:36:52  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-06 09:36:56  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-06 09:37:01  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-06 09:37:05  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-06 09:37:10  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-06 09:37:14  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-06 09:37:19  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-06 09:37:23  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-06 09:37:28  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-06 09:37:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-06 09:37:37  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-06 09:37:41  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-06 09:37:46  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-06 09:37:50  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-06 09:37:55  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-06 09:37:59  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-06 09:38:04  - 14968  http://www.lymphomahub.com/medical-information
2017-04-06 09:38:08  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-06 09:38:13  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-06 09:38:17  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-06 09:38:22  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-06 09:38:26  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-06 09:38:31  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-06 09:38:35  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-06 09:38:40  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-06 09:38:44  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-06 09:38:49  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-06 09:38:53  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-06 09:38:57  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-06 09:38:58  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-06 09:39:03  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-06 09:39:07  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-06 09:39:11  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-06 09:39:16  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-06 09:39:20  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-06 09:39:25  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-06 09:39:29  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-06 09:39:34  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-06 09:39:38  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-06 09:39:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-06 09:39:47  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-06 09:39:52  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-06 09:39:56  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-06 09:40:01  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-06 09:40:05  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-06 09:40:10  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-06 09:40:14  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-06 09:40:19  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-06 09:40:23  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-06 09:40:28  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-06 09:40:32  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-06 09:40:38  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-06 09:40:43  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-06 09:40:47  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-06 09:40:51  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-06 09:40:56  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-06 09:41:01  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-06 09:41:05  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-06 09:41:09  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-06 09:41:14  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-06 09:41:14  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-06 09:41:19  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-06 09:41:23  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-06 09:41:28  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-06 09:41:32  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-06 09:41:37  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-06 09:41:41  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-06 09:41:45  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-06 09:41:50  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-06 09:41:54  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-06 09:41:54  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-06 09:41:59  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-06 09:42:03  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-06 09:42:07  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-06 09:42:12  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-06 09:42:17  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-06 09:42:17  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-06 09:42:22  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-06 09:42:26  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-06 09:42:30  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-06 09:42:34  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-06 09:42:39  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-06 09:42:43  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-06 09:42:46  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-06 09:42:50  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-06 09:42:54  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-06 09:43:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-06 09:43:04  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-06 09:43:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-06 09:43:13  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-06 09:43:17  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-06 09:43:18  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-06 09:43:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-06 09:43:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-06 09:43:31  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-06 09:43:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-06 09:43:39  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-06 09:43:44  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-06 09:43:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-06 09:43:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-06 09:43:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-06 09:43:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-06 09:44:03  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-06 09:44:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-06 09:44:11  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-06 09:44:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-06 09:44:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-06 09:44:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-06 09:44:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-06 09:44:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-06 09:44:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-06 09:44:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-06 09:44:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-06 09:44:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-06 09:44:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-06 09:44:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-06 09:45:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-06 09:45:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-06 09:45:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-06 09:45:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-06 09:45:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-06 09:45:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-06 09:45:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-06 09:45:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-06 09:45:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-06 09:45:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-06 09:45:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-06 09:45:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-06 09:45:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-06 09:46:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-06 09:46:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-06 09:46:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-06 09:46:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-06 09:46:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-06 09:46:24  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-06 09:46:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-06 09:46:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-06 09:46:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-06 09:46:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-06 09:46:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-06 09:46:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-06 09:46:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-06 09:46:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-06 09:47:03  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-06 09:47:07  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-06 09:47:12  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-06 09:47:16  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-06 09:47:20  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-06 09:47:24  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-06 09:47:29  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-06 09:47:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-06 09:47:37  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-06 09:47:41  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-06 09:47:45  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-06 09:47:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-06 09:47:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-06 09:47:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-06 09:48:02  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-06 09:48:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-06 09:48:10  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-06 09:48:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-06 09:48:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-06 09:48:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-06 09:48:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-06 09:48:35  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-06 09:48:36  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-06 09:48:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-06 09:48:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-06 09:48:50  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-06 09:48:54  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-06 09:48:59  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-06 09:49:04  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 09:49:08  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 09:49:13  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-06 09:49:17  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 09:49:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-06 09:49:26  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-06 09:49:31  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-06 09:49:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-06 09:49:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-06 09:49:45  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-06 09:49:49  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-06 09:49:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-06 09:49:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-06 09:50:04  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-06 09:50:08  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 09:50:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-06 09:50:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-06 09:50:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-06 09:50:27  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-06 09:50:32  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-06 09:50:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-06 09:50:42  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-06 09:50:46  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-06 09:50:51  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-06 09:50:55  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-06 09:51:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-06 09:51:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-06 09:51:09  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-06 09:51:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-06 09:51:19  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-06 09:51:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-06 09:51:28  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-06 09:51:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-06 09:51:37  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-06 09:51:42  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-06 09:51:47  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-06 09:51:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-06 09:51:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-06 09:51:57  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-06 09:52:02  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-06 09:52:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-06 09:52:11  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-06 09:52:15  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-06 09:52:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-06 09:52:25  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-06 09:52:30  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-06 09:52:35  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-06 09:52:39  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-06 09:52:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-06 09:52:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-06 09:52:53  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-06 09:52:58  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-06 09:53:03  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-06 09:53:07  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-06 09:53:12  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-06 09:53:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-06 09:53:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-06 09:53:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-06 09:53:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-06 09:53:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-06 09:53:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-06 09:53:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-06 09:53:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-06 09:53:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-06 09:53:55  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-06 09:53:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-06 09:54:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-06 09:54:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-06 09:54:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-06 09:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-06 09:54:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-06 09:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-06 09:54:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-06 09:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-06 09:54:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-06 09:54:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-06 09:54:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-06 09:54:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-06 09:54:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-06 09:54:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-06 09:54:53  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-06 09:54:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-06 09:55:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-06 09:55:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-06 09:55:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-06 09:55:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-06 09:55:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-06 09:55:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-06 09:55:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-06 09:55:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-06 09:55:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-06 09:55:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-06 09:55:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-06 09:55:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-06 09:55:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-06 09:55:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-06 09:55:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-06 09:55:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-06 09:56:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-06 09:56:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-06 09:56:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-06 09:56:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-06 09:56:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-06 09:56:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-06 09:56:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-06 09:56:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-06 09:56:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-06 09:56:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-06 09:56:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-06 09:56:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-06 09:56:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-06 09:56:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-06 09:56:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-06 09:56:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-06 09:56:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-06 09:57:03  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-06 09:57:07  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-06 09:57:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-06 09:57:18  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-06 09:57:18  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-06 09:57:23  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-06 09:57:28  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-06 09:57:33  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-06 09:57:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-06 09:57:42  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-06 09:57:47  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-06 09:57:51  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-06 09:57:56  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-06 09:58:01  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-06 09:58:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-06 09:58:11  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-06 09:58:16  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-06 09:58:20  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-06 09:58:25  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-06 09:58:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-06 09:58:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-06 09:58:38  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-06 09:58:43  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-06 09:58:48  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-06 09:58:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-06 09:58:57  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-06 09:59:02  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-06 09:59:06  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-06 09:59:11  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-06 09:59:16  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-06 09:59:20  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-06 09:59:25  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-06 09:59:30  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-06 09:59:34  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-06 09:59:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-06 09:59:43  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-06 09:59:48  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-06 09:59:52  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-06 09:59:58  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-06 10:00:03  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-06 10:00:07  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-06 10:00:14  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-06 10:00:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-06 10:00:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-06 10:00:28  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-06 10:00:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-06 10:00:41  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-06 10:00:47  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-06 10:00:51  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-06 10:00:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-06 10:01:01  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-06 10:01:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-06 10:01:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-06 10:01:14  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-06 10:01:19  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-06 10:01:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-06 10:01:28  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-06 10:01:33  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-06 10:01:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-06 10:01:42  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-06 10:01:47  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-06 10:01:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-06_10-01-53 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday?_prerender {"code":"ECONNRESET"}
2017-04-06 10:03:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-06 10:04:01  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-06 10:04:06  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-06 10:04:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-06 10:04:15  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-06 10:04:20  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-06 10:04:25  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-06 10:04:29  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-06 10:04:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-06 10:04:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-06 10:04:44  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-06 10:04:48  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-06 10:04:53  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-06 10:04:58  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-06 10:05:02  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-06 10:05:07  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-06 10:05:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-06 10:05:16  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-06 10:05:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-06 10:05:26  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-06 10:05:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-06 10:05:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-06 10:05:40  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-06 10:05:45  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-06 10:05:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-06 10:05:54  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-06 10:05:59  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-06 10:06:03  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-06 10:06:10  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-06 10:06:14  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-06 10:06:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-06 10:06:23  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-06 10:06:27  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-06 10:06:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-06 10:06:37  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-06 10:06:41  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-06 10:06:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-06 10:06:51  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-06 10:06:56  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-06 10:07:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-06 10:07:05  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-06 10:07:10  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-06 10:07:14  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-06 10:07:19  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-06 10:07:24  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-06 10:07:28  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-06 10:07:33  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-06 10:07:38  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-06 10:07:42  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-06 10:07:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-06 10:07:51  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-06 10:07:56  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-06 10:08:00  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-06 10:08:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-06 10:08:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-06 10:08:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-06 10:08:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-06 10:08:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-06 10:08:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-06 10:08:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-06 10:08:38  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-06 10:08:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-06 10:08:47  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-06 10:08:51  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-06 10:08:56  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-06 10:09:00  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-06 10:09:05  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-06 10:09:09  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-06 10:09:14  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-06 10:09:18  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-06 10:09:23  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-06 10:09:27  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-06 10:09:32  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-06 10:09:36  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-06 10:09:41  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-06 10:09:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-06 10:09:50  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-06 10:09:55  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-06 10:10:00  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-06 10:10:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-06 10:10:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-06 10:10:13  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-06 10:10:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-06 10:10:23  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-06 10:10:27  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-06 10:10:32  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-06 10:10:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-06 10:10:42  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-06 10:10:46  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-06 10:10:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-06 10:10:55  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-06 10:10:59  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-06 10:11:04  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-06 10:11:08  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-06 10:11:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-06 10:11:18  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-06 10:11:22  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-06 10:11:26  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-06 10:11:31  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-06 10:11:35  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-06 10:11:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-06 10:11:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-06 10:11:50  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-06 10:11:54  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-06 10:11:58  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-06 10:12:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-06 10:12:07  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-06 10:12:11  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-06 10:12:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-06 10:12:21  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-06 10:12:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-06 10:12:30  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-06 10:12:35  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-06 10:12:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-06 10:12:44  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-06 10:12:48  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-06 10:12:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-06 10:12:57  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-06 10:13:02  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-06 10:13:06  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-06 10:13:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-06 10:13:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-06 10:13:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-06 10:13:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-06 10:13:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-06 10:13:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-06 10:13:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-06 10:13:42  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-06 10:13:46  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-06 10:13:50  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-06 10:13:55  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-06 10:14:00  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-06 10:14:04  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-06 10:14:08  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-06 10:14:12  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-06 10:14:17  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-06 10:14:21  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-06 10:14:26  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-06 10:14:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-06 10:14:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-06 10:14:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-06 10:14:44  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-06 10:14:45  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-06 10:14:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-06 10:14:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-06 10:14:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-06 10:15:03  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-06 10:15:07  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-06 10:15:12  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-06 10:15:17  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-06 10:15:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-06 10:15:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-06 10:15:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-06 10:15:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-06 10:15:39  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-06 10:15:43  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-06 10:15:48  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-06 10:15:52  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-06 10:15:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-06 10:16:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-06 10:16:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-06 10:16:10  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-06 10:16:15  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-06 10:16:20  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-06 10:16:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-06 10:16:28  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-06 10:16:32  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-06 10:16:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-06 10:16:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-06 10:16:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-06 10:16:51  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-06 10:16:56  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-06 10:17:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-06 10:17:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-06 10:17:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-06 10:17:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-06 10:17:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-06 10:17:21  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-06 10:17:25  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-06 10:17:29  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-06 10:17:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-06 10:17:37  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-06 10:17:41  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-06 10:17:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-06 10:17:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-06 10:17:56  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-06 10:18:00  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-06 10:18:04  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-06 10:18:08  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-06 10:18:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-06 10:18:17  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-06 10:18:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-06 10:18:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-06 10:18:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-06 10:18:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-06 10:18:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-06 10:18:44  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-06 10:18:48  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-06 10:18:52  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-06 10:18:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-06 10:19:01  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-06 10:19:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-06 10:19:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-06 10:19:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-06 10:19:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 10:19:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 10:19:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 10:19:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 10:19:33  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-06 10:19:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 10:19:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 10:19:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-06 10:19:50  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-06 10:19:54  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-06 10:19:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-06 10:20:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-06 10:20:07  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-06 10:20:11  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-06 10:20:15  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-06 10:20:19  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-06 10:20:23  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-06 10:20:27  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-06 10:20:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-06 10:20:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-06 10:20:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-06 10:20:44  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-06 10:20:48  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-06 10:20:52  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-06 10:20:56  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-06 10:21:00  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-06 10:21:04  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-06 10:21:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 10:21:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 10:21:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 10:21:21  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 10:21:25  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 10:21:29  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-06 10:21:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 10:21:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 10:21:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 10:21:46  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 10:21:50  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-06 10:21:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 10:21:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 10:22:02  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 10:22:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-06 10:22:10  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-06_10-31-53 Restart Xvfb...
2017-04-06_11-01-53 Restart Xvfb...
2017-04-06_11-31-53 Restart Xvfb...
2017-04-06_12-01-53 Restart Xvfb...
2017-04-06 12:31:46 reset updateRequest
2017-04-06 12:31:51  - 14968  http://www.lymphomahub.com/
2017-04-06 12:31:51  - 14968  http://www.lymphomahub.com/
2017-04-06_12-31-53 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-06 12:33:56  - 14968  http://www.lymphomahub.com/
2017-04-06 12:33:56  - 14968  http://www.lymphomahub.com/
2017-04-06 12:34:00  - 14968  http://www.lymphomahub.com/about
2017-04-06 12:34:02  - 14968  http://www.lymphomahub.com/about
2017-04-06 12:34:07  - 14968  http://www.lymphomahub.com/terms
2017-04-06 12:34:10  - 14968  http://www.lymphomahub.com/undefined
2017-04-06 12:34:11  - 14968  http://www.lymphomahub.com/therapies
2017-04-06 12:34:16  - 14968  http://www.lymphomahub.com/newsletter
2017-04-06 12:34:20  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-06 12:34:23  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-06 12:34:28  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-06 12:34:32  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-06 12:34:37  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-06 12:34:42  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-06 12:34:46  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-06 12:34:51  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-06 12:34:55  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-06 12:34:59  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-06 12:35:04  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-06 12:35:09  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-06 12:35:13  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-06 12:35:18  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-06 12:35:22  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-06 12:35:27  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-06 12:35:31  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-06 12:35:36  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-06 12:35:40  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-06 12:35:45  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-06 12:35:49  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-06 12:35:54  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-06 12:35:57  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-06 12:36:02  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-06 12:36:06  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-06 12:36:11  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-06 12:36:15  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-06 12:36:20  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-06 12:36:24  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-06 12:36:29  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-06 12:36:33  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-06 12:36:38  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-06 12:36:42  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-06 12:36:46  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-06 12:36:51  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-06 12:36:55  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-06 12:37:00  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-06 12:37:05  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-06 12:37:09  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-06 12:37:15  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-06 12:37:19  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-06 12:37:24  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-06 12:37:29  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-06 12:37:33  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-06 12:37:37  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-06 12:37:42  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-06 12:37:46  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-06 12:37:51  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-06 12:37:55  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-06 12:38:00  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-06 12:38:04  - 14968  http://www.lymphomahub.com/medical-information
2017-04-06 12:38:09  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-06 12:38:13  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-06 12:38:18  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-06 12:38:22  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-06 12:38:27  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-06 12:38:32  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-06 12:38:36  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-06 12:38:41  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-06 12:38:45  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-06 12:38:50  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-06 12:38:54  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-06 12:38:59  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-06 12:38:59  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-06 12:39:04  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-06 12:39:08  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-06 12:39:13  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-06 12:39:17  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-06 12:39:21  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-06 12:39:26  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-06 12:39:30  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-06 12:39:35  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-06 12:39:39  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-06 12:39:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-06 12:39:49  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-06 12:39:53  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-06 12:39:58  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-06 12:40:02  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-06 12:40:07  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-06 12:40:11  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-06 12:40:15  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-06 12:40:19  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-06 12:40:23  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-06 12:40:28  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-06 12:40:32  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-06 12:40:36  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-06 12:40:41  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-06 12:40:45  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-06 12:40:50  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-06 12:40:54  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-06 12:40:59  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-06 12:41:03  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-06 12:41:08  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-06 12:41:12  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-06 12:41:13  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-06 12:41:17  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-06 12:41:22  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-06 12:41:26  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-06 12:41:30  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-06 12:41:35  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-06 12:41:40  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-06 12:41:44  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-06 12:41:49  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-06 12:41:52  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-06 12:41:53  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-06 12:41:57  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-06 12:42:02  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-06 12:42:07  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-06 12:42:11  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-06 12:42:16  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-06 12:42:16  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-06 12:42:21  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-06 12:42:26  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-06 12:42:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-06 12:42:34  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-06 12:42:38  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-06 12:42:42  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-06 12:42:46  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-06 12:42:50  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-06 12:42:54  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-06 12:42:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-06 12:43:02  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-06 12:43:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-06 12:43:11  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-06 12:43:15  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-06 12:43:15  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-06 12:43:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-06 12:43:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-06 12:43:29  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-06 12:43:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-06 12:43:37  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-06 12:43:42  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-06 12:43:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-06 12:43:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-06 12:43:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-06 12:43:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-06 12:44:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-06 12:44:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-06 12:44:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-06 12:44:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-06 12:44:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-06 12:44:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-06 12:44:27  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-06 12:44:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-06 12:44:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-06 12:44:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-06 12:44:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-06 12:44:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-06 12:44:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-06 12:44:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-06 12:45:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-06 12:45:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-06 12:45:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-06 12:45:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-06 12:45:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-06 12:45:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-06 12:45:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-06 12:45:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-06 12:45:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-06 12:45:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-06 12:45:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-06 12:45:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-06 12:45:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-06 12:45:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-06 12:46:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-06 12:46:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-06 12:46:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-06 12:46:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-06 12:46:22  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-06 12:46:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-06 12:46:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-06 12:46:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-06 12:46:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-06 12:46:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-06 12:46:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-06 12:46:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-06 12:46:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-06 12:47:00  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-06 12:47:05  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-06 12:47:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-06 12:47:13  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-06 12:47:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-06 12:47:21  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-06 12:47:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-06 12:47:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-06 12:47:36  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-06 12:47:40  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-06 12:47:44  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-06 12:47:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-06 12:47:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-06 12:47:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-06 12:48:00  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-06 12:48:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-06 12:48:09  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-06 12:48:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-06 12:48:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-06 12:48:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-06 12:48:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-06 12:48:32  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-06 12:48:33  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-06 12:48:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-06 12:48:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-06 12:48:47  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-06 12:48:51  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-06 12:48:56  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-06 12:49:00  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 12:49:05  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 12:49:10  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-06 12:49:14  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 12:49:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-06 12:49:23  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-06 12:49:28  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-06 12:49:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-06 12:49:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-06 12:49:42  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-06 12:49:47  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-06 12:49:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-06 12:49:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-06 12:50:01  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-06 12:50:06  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 12:50:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-06 12:50:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-06 12:50:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-06 12:50:24  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-06 12:50:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-06 12:50:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-06 12:50:38  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-06 12:50:43  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-06 12:50:47  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-06 12:50:52  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-06 12:50:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-06 12:51:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-06 12:51:07  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-06 12:51:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-06 12:51:16  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-06 12:51:20  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-06 12:51:25  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-06 12:51:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-06 12:51:35  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-06 12:51:39  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-06 12:51:44  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-06 12:51:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-06 12:51:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-06 12:51:54  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-06 12:51:59  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-06 12:52:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-06 12:52:08  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-06 12:52:13  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-06 12:52:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-06 12:52:22  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-06 12:52:27  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-06 12:52:31  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-06 12:52:36  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-06 12:52:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-06 12:52:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-06 12:52:50  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-06 12:52:55  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-06 12:53:00  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-06 12:53:04  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-06 12:53:09  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-06 12:53:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-06 12:53:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-06 12:53:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-06 12:53:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-06 12:53:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-06 12:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-06 12:53:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-06 12:53:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-06 12:53:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-06 12:53:51  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-06 12:53:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-06 12:53:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-06 12:54:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-06 12:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-06 12:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-06 12:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-06 12:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-06 12:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-06 12:54:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-06 12:54:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-06 12:54:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-06 12:54:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-06 12:54:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-06 12:54:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-06 12:54:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-06 12:54:48  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-06 12:54:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-06 12:54:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-06 12:55:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-06 12:55:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-06 12:55:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-06 12:55:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-06 12:55:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-06 12:55:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-06 12:55:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-06 12:55:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-06 12:55:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-06 12:55:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-06 12:55:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-06 12:55:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-06 12:55:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-06 12:55:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-06 12:55:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-06 12:55:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-06 12:56:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-06 12:56:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-06 12:56:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-06 12:56:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-06 12:56:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-06 12:56:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-06 12:56:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-06 12:56:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-06 12:56:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-06 12:56:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-06 12:56:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-06 12:56:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-06 12:56:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-06 12:56:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-06 12:56:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-06 12:56:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-06 12:57:01  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-06 12:57:05  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-06 12:57:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-06 12:57:15  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-06 12:57:15  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-06 12:57:20  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-06 12:57:25  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-06 12:57:29  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-06 12:57:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-06 12:57:38  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-06 12:57:43  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-06 12:57:48  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-06 12:57:52  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-06 12:57:57  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-06 12:58:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-06 12:58:06  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-06 12:58:11  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-06 12:58:15  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-06 12:58:20  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-06 12:58:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-06 12:58:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-06 12:58:33  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-06 12:58:38  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-06 12:58:43  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-06 12:58:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-06 12:58:52  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-06 12:58:56  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-06 12:59:01  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-06 12:59:06  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-06 12:59:10  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-06 12:59:15  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-06 12:59:19  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-06 12:59:24  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-06 12:59:29  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-06 12:59:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-06 12:59:38  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-06 12:59:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-06 12:59:47  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-06 12:59:52  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-06 12:59:57  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-06 13:00:02  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-06 13:00:07  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-06 13:00:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-06 13:00:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-06 13:00:24  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-06 13:00:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-06 13:00:33  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-06 13:00:38  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-06 13:00:42  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-06 13:00:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-06 13:00:53  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-06 13:00:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-06 13:01:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-06 13:01:07  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-06 13:01:12  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-06 13:01:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-06 13:01:21  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-06 13:01:26  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-06 13:01:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-06 13:01:35  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-06 13:01:40  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-06 13:01:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-06 13:01:49  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-06_13-01-53 Restart Xvfb...
2017-04-06 13:01:53  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-06 13:01:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-06 13:02:03  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-06 13:02:08  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-06 13:02:13  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-06 13:02:17  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-06 13:02:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-06 13:02:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-06 13:02:31  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-06 13:02:35  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-06 13:02:40  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-06 13:02:45  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-06 13:02:49  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-06 13:02:54  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-06 13:02:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-06 13:03:03  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-06 13:03:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-06 13:03:13  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-06 13:03:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-06 13:03:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-06 13:03:26  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-06 13:03:31  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-06 13:03:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-06 13:03:40  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-06 13:03:45  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-06 13:03:50  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-06 13:03:55  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-06 13:03:59  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-06 13:04:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-06 13:04:09  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-06 13:04:14  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-06 13:04:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-06 13:04:24  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-06 13:04:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-06 13:04:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-06 13:04:38  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-06 13:04:42  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-06 13:04:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-06 13:04:52  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-06 13:04:56  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-06 13:05:01  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-06 13:05:05  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-06 13:05:10  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-06 13:05:15  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-06 13:05:19  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-06 13:05:24  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-06 13:05:28  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-06 13:05:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-06 13:05:37  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-06 13:05:42  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-06 13:05:46  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-06 13:05:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-06 13:05:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-06 13:06:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-06 13:06:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-06 13:06:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-06 13:06:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-06 13:06:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-06 13:06:24  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-06 13:06:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-06 13:06:33  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-06 13:06:38  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-06 13:06:42  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-06 13:06:47  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-06 13:06:50  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-06 13:06:55  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-06 13:07:02  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-06 13:07:06  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-06 13:07:11  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-06 13:07:16  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-06 13:07:20  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-06 13:07:25  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-06 13:07:29  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-06 13:07:34  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-06 13:07:39  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-06 13:07:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-06 13:07:48  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-06 13:07:52  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-06 13:07:57  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-06 13:08:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-06 13:08:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-06 13:08:11  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-06 13:08:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-06 13:08:20  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-06 13:08:25  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-06 13:08:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-06 13:08:34  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-06 13:08:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-06 13:08:43  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-06 13:08:47  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-06 13:08:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-06 13:08:56  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-06 13:09:01  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-06 13:09:05  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-06 13:09:10  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-06 13:09:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-06 13:09:19  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-06 13:09:23  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-06 13:09:28  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-06 13:09:32  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-06 13:09:37  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-06 13:09:42  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-06 13:09:46  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-06 13:09:51  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-06 13:09:56  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-06 13:10:00  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-06 13:10:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-06 13:10:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-06 13:10:14  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-06 13:10:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-06 13:10:24  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-06 13:10:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-06 13:10:32  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-06 13:10:37  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-06 13:10:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-06 13:10:46  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-06 13:10:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-06 13:10:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-06 13:11:00  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-06 13:11:05  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-06 13:11:09  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-06 13:11:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-06 13:11:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-06 13:11:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-06 13:11:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-06 13:11:31  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-06 13:11:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-06 13:11:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-06 13:11:44  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-06 13:11:49  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-06 13:11:54  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-06 13:11:59  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-06 13:12:04  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-06 13:12:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-06 13:12:12  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-06 13:12:16  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-06 13:12:21  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-06 13:12:26  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-06 13:12:30  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-06 13:12:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-06 13:12:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-06 13:12:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-06 13:12:49  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-06 13:12:49  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-06 13:12:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-06 13:12:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-06 13:13:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-06 13:13:07  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-06 13:13:12  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-06 13:13:17  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-06 13:13:21  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-06 13:13:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-06 13:13:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-06 13:13:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-06 13:13:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-06 13:13:44  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-06 13:13:48  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-06 13:13:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-06 13:13:57  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-06 13:14:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-06 13:14:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-06 13:14:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-06 13:14:15  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-06 13:14:19  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-06 13:14:24  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-06 13:14:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-06 13:14:33  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-06 13:14:37  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-06 13:14:42  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-06 13:14:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-06 13:14:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-06 13:14:55  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-06 13:14:59  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-06 13:15:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-06 13:15:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-06 13:15:12  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-06 13:15:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-06 13:15:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-06 13:15:25  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-06 13:15:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-06 13:15:34  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-06 13:15:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-06 13:15:42  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-06 13:15:46  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-06 13:15:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-06 13:15:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-06 13:15:59  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-06 13:16:03  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-06 13:16:07  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-06 13:16:11  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-06 13:16:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-06 13:16:20  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-06 13:16:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-06 13:16:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-06 13:16:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-06 13:16:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-06 13:16:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-06 13:16:47  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-06 13:16:51  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-06 13:16:55  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-06 13:16:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-06 13:17:04  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-06 13:17:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-06 13:17:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-06 13:17:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-06 13:17:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 13:17:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 13:17:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 13:17:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 13:17:37  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-06 13:17:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 13:17:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 13:17:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-06 13:17:53  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-06 13:17:57  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-06 13:18:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-06 13:18:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-06 13:18:10  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-06 13:18:14  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-06 13:18:19  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-06 13:18:23  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-06 13:18:27  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-06 13:18:31  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-06 13:18:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-06 13:18:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-06 13:18:44  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-06 13:18:48  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-06 13:18:51  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-06 13:18:56  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-06 13:19:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-06 13:19:04  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-06 13:19:08  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-06 13:19:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 13:19:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 13:19:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 13:19:24  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 13:19:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 13:19:32  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-06 13:19:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 13:19:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 13:19:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 13:19:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 13:19:52  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-06 13:19:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 13:20:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 13:20:05  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 13:20:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-06 13:20:13  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-06_13-31-53 Restart Xvfb...
2017-04-06_14-01-53 Restart Xvfb...
2017-04-06_14-31-53 Restart Xvfb...
2017-04-06_15-01-53 Restart Xvfb...
2017-04-06 15:31:46 reset updateRequest
2017-04-06 15:31:49  - 14968  http://www.lymphomahub.com/
2017-04-06 15:31:51  - 14968  http://www.lymphomahub.com/
2017-04-06 15:31:52  - 14968  http://www.lymphomahub.com/about
2017-04-06_15-31-53 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-06 15:33:56  - 14968  http://www.lymphomahub.com/about
2017-04-06 15:33:58  - 14968  http://www.lymphomahub.com/about
2017-04-06 15:34:02  - 14968  http://www.lymphomahub.com/terms
2017-04-06 15:34:03  - 14968  http://www.lymphomahub.com/terms
2017-04-06 15:34:06  - 14968  http://www.lymphomahub.com/undefined
2017-04-06 15:34:07  - 14968  http://www.lymphomahub.com/therapies
2017-04-06 15:34:12  - 14968  http://www.lymphomahub.com/newsletter
2017-04-06 15:34:15  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-06 15:34:19  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-06 15:34:23  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-06 15:34:28  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-06 15:34:32  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-06 15:34:37  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-06 15:34:41  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-06 15:34:46  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-06 15:34:50  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-06 15:34:54  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-06 15:34:59  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-06 15:35:03  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-06 15:35:08  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-06 15:35:13  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-06 15:35:17  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-06 15:35:22  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-06 15:35:27  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-06 15:35:31  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-06 15:35:36  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-06 15:35:41  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-06 15:35:45  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-06 15:35:49  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-06 15:35:53  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-06 15:35:58  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-06 15:36:02  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-06 15:36:07  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-06 15:36:11  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-06 15:36:15  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-06 15:36:20  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-06 15:36:24  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-06 15:36:29  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-06 15:36:34  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-06 15:36:38  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-06 15:36:43  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-06 15:36:47  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-06 15:36:52  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-06 15:36:57  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-06 15:37:01  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-06 15:37:05  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-06 15:37:10  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-06 15:37:15  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-06 15:37:19  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-06 15:37:24  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-06 15:37:28  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-06 15:37:32  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-06 15:37:37  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-06 15:37:41  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-06 15:37:46  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-06 15:37:50  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-06 15:37:55  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-06 15:37:59  - 14968  http://www.lymphomahub.com/medical-information
2017-04-06 15:38:03  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-06 15:38:07  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-06 15:38:12  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-06 15:38:16  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-06 15:38:21  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-06 15:38:25  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-06 15:38:30  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-06 15:38:34  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-06 15:38:39  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-06 15:38:44  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-06 15:38:48  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-06 15:38:53  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-06 15:38:53  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-06 15:38:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-06 15:39:02  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-06 15:39:07  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-06 15:39:11  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-06 15:39:16  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-06 15:39:20  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-06 15:39:25  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-06 15:39:29  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-06 15:39:34  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-06 15:39:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-06 15:39:43  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-06 15:39:47  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-06 15:39:51  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-06 15:39:56  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-06 15:40:00  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-06 15:40:05  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-06 15:40:09  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-06 15:40:13  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-06 15:40:18  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-06 15:40:22  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-06 15:40:27  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-06 15:40:31  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-06 15:40:36  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-06 15:40:41  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-06 15:40:45  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-06 15:40:50  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-06 15:40:54  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-06 15:40:59  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-06 15:41:02  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-06 15:41:07  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-06 15:41:07  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-06 15:41:12  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-06 15:41:17  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-06 15:41:21  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-06 15:41:25  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-06 15:41:30  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-06 15:41:34  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-06 15:41:38  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-06 15:41:43  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-06 15:41:46  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-06 15:41:47  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-06 15:41:51  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-06 15:41:56  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-06 15:42:00  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-06 15:42:05  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-06 15:42:09  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-06 15:42:10  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-06 15:42:14  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-06 15:42:19  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-06 15:42:22  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-06 15:42:27  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-06 15:42:31  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-06 15:42:35  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-06 15:42:39  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-06 15:42:43  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-06 15:42:47  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-06 15:42:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-06 15:42:56  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-06 15:43:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-06 15:43:05  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-06 15:43:09  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-06 15:43:09  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-06 15:43:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-06 15:43:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-06 15:43:22  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-06 15:43:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-06 15:43:31  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-06 15:43:36  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-06 15:43:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-06 15:43:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-06 15:43:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-06 15:43:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-06 15:43:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-06 15:43:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-06 15:44:02  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-06 15:44:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-06 15:44:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-06 15:44:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-06 15:44:20  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-06 15:44:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-06 15:44:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-06 15:44:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-06 15:44:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-06 15:44:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-06 15:44:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-06 15:44:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-06 15:44:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-06 15:44:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-06 15:45:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-06 15:45:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-06 15:45:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-06 15:45:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-06 15:45:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-06 15:45:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-06 15:45:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-06 15:45:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-06 15:45:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-06 15:45:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-06 15:45:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-06 15:45:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-06 15:45:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-06 15:46:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-06 15:46:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-06 15:46:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-06 15:46:16  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-06 15:46:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-06 15:46:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-06 15:46:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-06 15:46:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-06 15:46:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-06 15:46:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-06 15:46:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-06 15:46:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-06 15:46:54  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-06 15:46:59  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-06 15:47:04  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-06 15:47:08  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-06 15:47:13  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-06 15:47:16  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-06 15:47:21  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-06 15:47:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-06 15:47:29  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-06 15:47:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-06 15:47:37  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-06 15:47:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-06 15:47:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-06 15:47:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-06 15:47:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-06 15:47:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-06 15:48:02  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-06 15:48:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-06 15:48:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-06 15:48:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-06 15:48:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-06 15:48:27  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-06 15:48:27  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-06 15:48:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-06 15:48:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-06 15:48:41  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-06 15:48:46  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-06 15:48:50  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-06 15:48:55  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 15:48:59  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 15:49:04  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-06 15:49:09  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 15:49:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-06 15:49:18  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-06 15:49:23  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-06 15:49:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-06 15:49:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-06 15:49:37  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-06 15:49:41  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-06 15:49:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-06 15:49:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-06 15:49:55  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-06 15:50:00  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 15:50:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-06 15:50:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-06 15:50:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-06 15:50:19  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-06 15:50:25  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-06 15:50:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-06 15:50:39  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-06 15:50:44  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-06 15:50:49  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-06 15:50:53  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-06 15:50:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-06 15:51:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-06 15:51:07  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-06 15:51:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-06 15:51:16  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-06 15:51:21  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-06 15:51:25  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-06 15:51:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-06 15:51:35  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-06 15:51:40  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-06 15:51:44  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-06 15:51:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-06 15:51:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-06 15:51:54  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-06 15:51:59  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-06 15:52:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-06 15:52:09  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-06 15:52:13  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-06 15:52:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-06 15:52:23  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-06 15:52:27  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-06 15:52:32  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-06 15:52:36  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-06 15:52:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-06 15:52:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-06 15:52:51  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-06 15:52:55  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-06 15:53:00  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-06 15:53:04  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-06 15:53:09  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-06 15:53:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-06 15:53:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-06 15:53:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-06 15:53:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-06 15:53:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-06 15:53:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-06 15:53:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-06 15:53:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-06 15:53:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-06 15:53:53  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-06 15:53:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-06 15:53:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-06 15:54:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-06 15:54:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-06 15:54:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-06 15:54:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-06 15:54:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-06 15:54:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-06 15:54:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-06 15:54:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-06 15:54:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-06 15:54:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-06 15:54:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-06 15:54:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-06 15:54:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-06 15:54:51  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-06 15:54:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-06 15:55:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-06 15:55:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-06 15:55:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-06 15:55:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-06 15:55:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-06 15:55:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-06 15:55:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-06 15:55:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-06 15:55:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-06 15:55:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-06 15:55:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-06 15:55:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-06 15:55:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-06 15:55:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-06 15:55:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-06 15:55:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-06 15:55:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-06 15:56:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-06 15:56:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-06 15:56:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-06 15:56:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-06 15:56:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-06 15:56:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-06 15:56:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-06 15:56:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-06 15:56:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-06 15:56:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-06 15:56:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-06 15:56:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-06 15:56:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-06 15:56:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-06 15:56:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-06 15:56:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-06 15:57:01  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-06 15:57:05  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-06 15:57:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-06 15:57:15  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-06 15:57:16  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-06 15:57:21  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-06 15:57:25  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-06 15:57:30  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-06 15:57:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-06 15:57:39  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-06 15:57:44  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-06 15:57:49  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-06 15:57:54  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-06 15:57:58  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-06 15:58:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-06 15:58:08  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-06 15:58:13  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-06 15:58:18  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-06 15:58:23  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-06 15:58:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-06 15:58:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-06 15:58:36  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-06 15:58:41  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-06 15:58:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-06 15:58:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-06 15:58:55  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-06 15:59:00  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-06 15:59:04  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-06 15:59:09  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-06 15:59:14  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-06 15:59:18  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-06 15:59:23  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-06 15:59:27  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-06 15:59:32  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-06 15:59:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-06 15:59:41  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-06 15:59:45  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-06 15:59:50  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-06 15:59:54  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-06 15:59:59  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-06 16:00:04  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-06 16:00:08  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-06 16:00:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-06 16:00:22  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-06 16:00:28  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-06 16:00:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-06 16:00:41  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-06 16:00:46  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-06 16:00:50  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-06 16:00:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-06 16:01:02  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-06 16:01:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-06 16:01:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-06 16:01:20  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-06 16:01:27  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-06 16:01:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-06 16:01:37  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-06 16:01:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-06 16:01:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-06 16:01:53  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-06_16-01-53 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl?_prerender {"code":"ECONNRESET"}
2017-04-06 16:03:58  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-06 16:04:03  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-06 16:04:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-06 16:04:12  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-06 16:04:16  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-06 16:04:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-06 16:04:26  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-06 16:04:30  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-06 16:04:35  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-06 16:04:39  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-06 16:04:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-06 16:04:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-06 16:04:53  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-06 16:04:58  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-06 16:05:03  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-06 16:05:07  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-06 16:05:12  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-06 16:05:20  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-06 16:05:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-06 16:05:30  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-06 16:05:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-06 16:05:39  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-06 16:05:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-06 16:05:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-06 16:05:53  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-06 16:05:58  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-06 16:06:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-06 16:06:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-06 16:06:12  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-06 16:06:16  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-06 16:06:21  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-06 16:06:25  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-06 16:06:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-06 16:06:34  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-06 16:06:39  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-06 16:06:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-06 16:06:49  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-06 16:06:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-06 16:06:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-06 16:07:03  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-06 16:07:08  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-06 16:07:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-06 16:07:17  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-06 16:07:22  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-06 16:07:27  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-06 16:07:31  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-06 16:07:36  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-06 16:07:41  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-06 16:07:45  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-06 16:07:50  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-06 16:07:54  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-06 16:07:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-06 16:08:04  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-06 16:08:08  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-06 16:08:13  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-06 16:08:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-06 16:08:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-06 16:08:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-06 16:08:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-06 16:08:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-06 16:08:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-06 16:08:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-06 16:08:50  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-06 16:08:55  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-06 16:09:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-06 16:09:04  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-06 16:09:09  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-06 16:09:14  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-06 16:09:18  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-06 16:09:23  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-06 16:09:28  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-06 16:09:32  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-06 16:09:37  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-06 16:09:42  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-06 16:09:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-06 16:09:51  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-06 16:09:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-06 16:10:00  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-06 16:10:05  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-06 16:10:09  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-06 16:10:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-06 16:10:19  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-06 16:10:24  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-06 16:10:29  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-06 16:10:36  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-06 16:10:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-06 16:10:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-06 16:10:52  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-06 16:10:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-06 16:11:01  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-06 16:11:05  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-06 16:11:10  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-06 16:11:15  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-06 16:11:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-06 16:11:24  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-06 16:11:28  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-06 16:11:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-06 16:11:37  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-06 16:11:41  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-06 16:11:46  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-06 16:11:50  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-06 16:11:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-06 16:12:00  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-06 16:12:04  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-06 16:12:08  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-06 16:12:13  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-06 16:12:17  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-06 16:12:22  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-06 16:12:27  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-06 16:12:31  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-06 16:12:36  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-06 16:12:40  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-06 16:12:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-06 16:12:49  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-06 16:12:54  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-06 16:12:58  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-06 16:13:03  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-06 16:13:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-06 16:13:12  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-06 16:13:16  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-06 16:13:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-06 16:13:25  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-06 16:13:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-06 16:13:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-06 16:13:39  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-06 16:13:44  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-06 16:13:47  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-06 16:13:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-06 16:13:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-06 16:14:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-06 16:14:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-06 16:14:11  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-06 16:14:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-06 16:14:20  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-06 16:14:24  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-06 16:14:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-06 16:14:33  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-06 16:14:37  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-06 16:14:42  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-06 16:14:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-06 16:14:51  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-06 16:14:55  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-06 16:14:59  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-06 16:15:04  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-06 16:15:09  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-06 16:15:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-06 16:15:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-06 16:15:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-06 16:15:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-06 16:15:32  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-06 16:15:33  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-06 16:15:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-06 16:15:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-06 16:15:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-06 16:15:51  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-06 16:15:55  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-06 16:16:00  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-06 16:16:05  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-06 16:16:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-06 16:16:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-06 16:16:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-06 16:16:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-06 16:16:29  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-06 16:16:33  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-06 16:16:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-06 16:16:43  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-06 16:16:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-06 16:16:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-06 16:16:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-06 16:17:01  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-06 16:17:05  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-06 16:17:10  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-06 16:17:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-06 16:17:19  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-06 16:17:23  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-06 16:17:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-06 16:17:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-06 16:17:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-06 16:17:42  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-06 16:17:46  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-06 16:17:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-06 16:17:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-06 16:17:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-06 16:18:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-06 16:18:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-06 16:18:12  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-06 16:18:17  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-06 16:18:21  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-06 16:18:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-06 16:18:29  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-06 16:18:33  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-06 16:18:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-06 16:18:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-06 16:18:47  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-06 16:18:51  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-06 16:18:55  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-06 16:18:59  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-06 16:19:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-06 16:19:09  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-06 16:19:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-06 16:19:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-06 16:19:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-06 16:19:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-06 16:19:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-06 16:19:36  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-06 16:19:40  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-06 16:19:44  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-06 16:19:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-06 16:19:53  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-06 16:19:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-06 16:20:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-06 16:20:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-06 16:20:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 16:20:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 16:20:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 16:20:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 16:20:26  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-06 16:20:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 16:20:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 16:20:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-06 16:20:43  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-06 16:20:47  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-06 16:20:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-06 16:20:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-06 16:21:00  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-06 16:21:04  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-06 16:21:08  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-06 16:21:13  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-06 16:21:17  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-06 16:21:21  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-06 16:21:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-06 16:21:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-06 16:21:35  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-06 16:21:39  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-06 16:21:43  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-06 16:21:47  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-06 16:21:51  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-06 16:21:55  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-06 16:22:00  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-06 16:22:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 16:22:08  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 16:22:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 16:22:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 16:22:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 16:22:26  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-06 16:22:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 16:22:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 16:22:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 16:22:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 16:22:47  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-06 16:22:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 16:22:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 16:22:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 16:23:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-06 16:23:07  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-06_16-31-53 Restart Xvfb...
2017-04-06_17-01-53 Restart Xvfb...
2017-04-06_17-31-53 Restart Xvfb...
2017-04-06_18-01-53 Restart Xvfb...
2017-04-06 18:31:46 reset updateRequest
2017-04-06 18:31:47  - 14968  http://www.lymphomahub.com/
2017-04-06 18:31:51  - 14968  http://www.lymphomahub.com/
2017-04-06 18:31:52  - 14968  http://www.lymphomahub.com/about
2017-04-06_18-31-54 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-06 18:33:56  - 14968  http://www.lymphomahub.com/about
2017-04-06 18:33:57  - 14968  http://www.lymphomahub.com/about
2017-04-06 18:34:02  - 14968  http://www.lymphomahub.com/terms
2017-04-06 18:34:05  - 14968  http://www.lymphomahub.com/undefined
2017-04-06 18:34:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-06 18:34:12  - 14968  http://www.lymphomahub.com/newsletter
2017-04-06 18:34:15  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-06 18:34:18  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-06 18:34:22  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-06 18:34:27  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-06 18:34:32  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-06 18:34:36  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-06 18:34:41  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-06 18:34:46  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-06 18:34:50  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-06 18:34:55  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-06 18:34:59  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-06 18:35:04  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-06 18:35:08  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-06 18:35:13  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-06 18:35:17  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-06 18:35:22  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-06 18:35:26  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-06 18:35:31  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-06 18:35:35  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-06 18:35:40  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-06 18:35:44  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-06 18:35:49  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-06 18:35:53  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-06 18:35:57  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-06 18:36:02  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-06 18:36:06  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-06 18:36:11  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-06 18:36:15  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-06 18:36:20  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-06 18:36:24  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-06 18:36:29  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-06 18:36:34  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-06 18:36:38  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-06 18:36:43  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-06 18:36:47  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-06 18:36:51  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-06 18:36:56  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-06 18:37:00  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-06 18:37:05  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-06 18:37:09  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-06 18:37:14  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-06 18:37:18  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-06 18:37:23  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-06 18:37:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-06 18:37:32  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-06 18:37:36  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-06 18:37:41  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-06 18:37:45  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-06 18:37:50  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-06 18:37:54  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-06 18:37:58  - 14968  http://www.lymphomahub.com/medical-information
2017-04-06 18:38:03  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-06 18:38:07  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-06 18:38:12  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-06 18:38:16  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-06 18:38:21  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-06 18:38:25  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-06 18:38:30  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-06 18:38:35  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-06 18:38:40  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-06 18:38:44  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-06 18:38:48  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-06 18:38:53  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-06 18:38:53  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-06 18:38:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-06 18:39:03  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-06 18:39:07  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-06 18:39:12  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-06 18:39:16  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-06 18:39:21  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-06 18:39:25  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-06 18:39:30  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-06 18:39:34  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-06 18:39:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-06 18:39:43  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-06 18:39:47  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-06 18:39:52  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-06 18:39:56  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-06 18:40:00  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-06 18:40:05  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-06 18:40:09  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-06 18:40:14  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-06 18:40:18  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-06 18:40:23  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-06 18:40:27  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-06 18:40:32  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-06 18:40:36  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-06 18:40:40  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-06 18:40:45  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-06 18:40:49  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-06 18:40:53  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-06 18:40:58  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-06 18:41:03  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-06 18:41:07  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-06 18:41:08  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-06 18:41:12  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-06 18:41:17  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-06 18:41:21  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-06 18:41:26  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-06 18:41:30  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-06 18:41:35  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-06 18:41:39  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-06 18:41:44  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-06 18:41:48  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-06 18:41:48  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-06 18:41:52  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-06 18:41:57  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-06 18:42:01  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-06 18:42:06  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-06 18:42:10  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-06 18:42:11  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-06 18:42:16  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-06 18:42:20  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-06 18:42:24  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-06 18:42:28  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-06 18:42:32  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-06 18:42:36  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-06 18:42:40  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-06 18:42:44  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-06 18:42:48  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-06 18:42:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-06 18:42:56  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-06 18:43:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-06 18:43:05  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-06 18:43:09  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-06 18:43:10  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-06 18:43:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-06 18:43:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-06 18:43:23  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-06 18:43:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-06 18:43:31  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-06 18:43:36  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-06 18:43:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-06 18:43:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-06 18:43:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-06 18:43:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-06 18:43:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-06 18:43:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-06 18:44:02  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-06 18:44:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-06 18:44:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-06 18:44:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-06 18:44:20  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-06 18:44:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-06 18:44:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-06 18:44:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-06 18:44:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-06 18:44:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-06 18:44:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-06 18:44:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-06 18:44:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-06 18:44:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-06 18:45:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-06 18:45:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-06 18:45:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-06 18:45:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-06 18:45:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-06 18:45:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-06 18:45:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-06 18:45:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-06 18:45:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-06 18:45:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-06 18:45:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-06 18:45:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-06 18:45:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-06 18:46:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-06 18:46:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-06 18:46:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-06 18:46:14  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-06 18:46:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-06 18:46:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-06 18:46:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-06 18:46:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-06 18:46:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-06 18:46:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-06 18:46:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-06 18:46:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-06 18:46:52  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-06 18:46:57  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-06 18:47:01  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-06 18:47:05  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-06 18:47:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-06 18:47:14  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-06 18:47:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-06 18:47:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-06 18:47:27  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-06 18:47:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-06 18:47:34  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-06 18:47:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-06 18:47:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-06 18:47:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-06 18:47:51  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-06 18:47:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-06 18:48:00  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-06 18:48:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-06 18:48:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-06 18:48:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-06 18:48:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-06 18:48:24  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-06 18:48:24  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-06 18:48:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-06 18:48:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-06 18:48:38  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-06 18:48:42  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-06 18:48:47  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-06 18:48:51  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 18:48:57  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 18:49:02  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-06 18:49:07  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 18:49:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-06 18:49:16  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-06 18:49:21  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-06 18:49:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-06 18:49:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-06 18:49:35  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-06 18:49:39  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-06 18:49:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-06 18:49:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-06 18:49:53  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-06 18:49:58  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 18:50:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-06 18:50:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-06 18:50:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-06 18:50:17  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-06 18:50:22  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-06 18:50:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-06 18:50:31  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-06 18:50:36  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-06 18:50:40  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-06 18:50:45  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-06 18:50:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-06 18:50:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-06 18:50:59  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-06 18:51:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-06 18:51:08  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-06 18:51:13  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-06 18:51:18  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-06 18:51:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-06 18:51:27  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-06 18:51:32  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-06 18:51:37  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-06 18:51:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-06 18:51:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-06 18:51:47  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-06 18:51:52  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-06 18:51:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-06 18:52:01  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-06 18:52:06  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-06 18:52:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-06 18:52:15  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-06 18:52:20  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-06 18:52:24  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-06 18:52:29  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-06 18:52:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-06 18:52:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-06 18:52:44  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-06 18:52:48  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-06 18:52:53  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-06 18:52:58  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-06 18:53:02  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-06 18:53:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-06 18:53:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-06 18:53:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-06 18:53:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-06 18:53:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-06 18:53:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-06 18:53:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-06 18:53:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-06 18:53:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-06 18:53:45  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-06 18:53:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-06 18:53:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-06 18:53:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-06 18:53:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-06 18:54:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-06 18:54:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-06 18:54:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-06 18:54:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-06 18:54:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-06 18:54:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-06 18:54:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-06 18:54:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-06 18:54:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-06 18:54:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-06 18:54:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-06 18:54:42  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-06 18:54:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-06 18:54:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-06 18:54:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-06 18:54:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-06 18:55:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-06 18:55:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-06 18:55:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-06 18:55:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-06 18:55:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-06 18:55:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-06 18:55:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-06 18:55:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-06 18:55:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-06 18:55:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-06 18:55:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-06 18:55:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-06 18:55:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-06 18:55:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-06 18:55:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-06 18:55:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-06 18:56:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-06 18:56:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-06 18:56:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-06 18:56:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-06 18:56:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-06 18:56:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-06 18:56:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-06 18:56:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-06 18:56:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-06 18:56:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-06 18:56:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-06 18:56:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-06 18:56:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-06 18:56:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-06 18:56:53  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-06 18:56:58  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-06 18:57:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-06 18:57:07  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-06 18:57:07  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-06 18:57:12  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-06 18:57:17  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-06 18:57:21  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-06 18:57:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-06 18:57:31  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-06 18:57:36  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-06 18:57:41  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-06 18:57:45  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-06 18:57:50  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-06 18:57:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-06 18:57:59  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-06 18:58:04  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-06 18:58:08  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-06 18:58:13  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-06 18:58:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-06 18:58:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-06 18:58:27  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-06 18:58:31  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-06 18:58:36  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-06 18:58:41  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-06 18:58:45  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-06 18:58:50  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-06 18:58:54  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-06 18:58:59  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-06 18:59:04  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-06 18:59:08  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-06 18:59:13  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-06 18:59:18  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-06 18:59:23  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-06 18:59:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-06 18:59:32  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-06 18:59:36  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-06 18:59:41  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-06 18:59:45  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-06 18:59:50  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-06 18:59:54  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-06 18:59:59  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-06 19:00:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-06 19:00:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-06 19:00:13  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-06 19:00:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-06 19:00:22  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-06 19:00:27  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-06 19:00:32  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-06 19:00:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-06 19:00:41  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-06 19:00:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-06 19:00:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-06 19:00:54  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-06 19:00:59  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-06 19:01:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-06 19:01:08  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-06 19:01:12  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-06 19:01:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-06 19:01:22  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-06 19:01:27  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-06 19:01:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-06 19:01:36  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-06 19:01:40  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-06 19:01:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-06 19:01:50  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-06_19-01-54 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma?_prerender {"code":"ECONNRESET"}
2017-04-06 19:03:55  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-06 19:03:59  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-06 19:04:04  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-06 19:04:09  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-06 19:04:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-06 19:04:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-06 19:04:23  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-06 19:04:28  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-06 19:04:33  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-06 19:04:37  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-06 19:04:42  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-06 19:04:46  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-06 19:04:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-06 19:04:56  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-06 19:05:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-06 19:05:05  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-06 19:05:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-06 19:05:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-06 19:05:19  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-06 19:05:24  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-06 19:05:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-06 19:05:33  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-06 19:05:38  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-06 19:05:42  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-06 19:05:47  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-06 19:05:51  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-06 19:05:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-06 19:06:00  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-06 19:06:05  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-06 19:06:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-06 19:06:14  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-06 19:06:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-06 19:06:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-06 19:06:28  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-06 19:06:33  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-06 19:06:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-06 19:06:42  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-06 19:06:46  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-06 19:06:51  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-06 19:06:56  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-06 19:07:00  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-06 19:07:05  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-06 19:07:09  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-06 19:07:14  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-06 19:07:19  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-06 19:07:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-06 19:07:28  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-06 19:07:33  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-06 19:07:38  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-06 19:07:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-06 19:07:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-06 19:07:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-06 19:07:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-06 19:08:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-06 19:08:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-06 19:08:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-06 19:08:15  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-06 19:08:20  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-06 19:08:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-06 19:08:29  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-06 19:08:34  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-06 19:08:38  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-06 19:08:43  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-06 19:08:47  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-06 19:08:51  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-06 19:08:56  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-06 19:09:01  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-06 19:09:05  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-06 19:09:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-06 19:09:14  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-06 19:09:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-06 19:09:24  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-06 19:09:28  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-06 19:09:33  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-06 19:09:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-06 19:09:42  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-06 19:09:47  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-06 19:09:51  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-06 19:09:56  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-06 19:10:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-06 19:10:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-06 19:10:13  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-06 19:10:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-06 19:10:22  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-06 19:10:27  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-06 19:10:31  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-06 19:10:36  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-06 19:10:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-06 19:10:45  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-06 19:10:50  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-06 19:10:54  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-06 19:10:59  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-06 19:11:03  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-06 19:11:07  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-06 19:11:12  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-06 19:11:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-06 19:11:21  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-06 19:11:25  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-06 19:11:30  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-06 19:11:34  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-06 19:11:39  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-06 19:11:43  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-06 19:11:48  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-06 19:11:52  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-06 19:11:57  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-06 19:12:02  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-06 19:12:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-06 19:12:10  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-06 19:12:15  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-06 19:12:20  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-06 19:12:24  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-06 19:12:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-06 19:12:33  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-06 19:12:38  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-06 19:12:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-06 19:12:47  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-06 19:12:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-06 19:12:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-06 19:13:01  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-06 19:13:05  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-06 19:13:09  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-06 19:13:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-06 19:13:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-06 19:13:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-06 19:13:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-06 19:13:31  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-06 19:13:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-06 19:13:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-06 19:13:44  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-06 19:13:49  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-06 19:13:53  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-06 19:13:58  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-06 19:14:02  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-06 19:14:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-06 19:14:11  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-06 19:14:15  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-06 19:14:20  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-06 19:14:25  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-06 19:14:29  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-06 19:14:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-06 19:14:39  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-06 19:14:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-06 19:14:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-06 19:14:52  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-06 19:14:53  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-06 19:14:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-06 19:15:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-06 19:15:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-06 19:15:12  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-06 19:15:18  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-06 19:15:23  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-06 19:15:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-06 19:15:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-06 19:15:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-06 19:15:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-06 19:15:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-06 19:15:50  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-06 19:15:54  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-06 19:15:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-06 19:16:03  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-06 19:16:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-06 19:16:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-06 19:16:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-06 19:16:22  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-06 19:16:28  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-06 19:16:32  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-06 19:16:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-06 19:16:41  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-06 19:16:45  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-06 19:16:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-06 19:16:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-06 19:16:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-06 19:17:03  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-06 19:17:07  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-06 19:17:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-06 19:17:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-06 19:17:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-06 19:17:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-06 19:17:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-06 19:17:32  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-06 19:17:36  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-06 19:17:40  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-06 19:17:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-06 19:17:48  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-06 19:17:52  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-06 19:17:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-06 19:18:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-06 19:18:06  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-06 19:18:10  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-06 19:18:14  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-06 19:18:18  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-06 19:18:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-06 19:18:27  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-06 19:18:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-06 19:18:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-06 19:18:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-06 19:18:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-06 19:18:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-06 19:18:54  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-06 19:18:58  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-06 19:19:02  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-06 19:19:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-06 19:19:10  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-06 19:19:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-06 19:19:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-06 19:19:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-06 19:19:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 19:19:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 19:19:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 19:19:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 19:19:44  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-06 19:19:48  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 19:19:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 19:19:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-06 19:20:00  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-06 19:20:05  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-06 19:20:12  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-06 19:20:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-06 19:20:21  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-06 19:20:28  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-06 19:20:32  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-06 19:20:36  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-06 19:20:40  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-06 19:20:44  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-06 19:20:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-06 19:20:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-06 19:20:59  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-06 19:21:03  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-06 19:21:07  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-06 19:21:12  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-06 19:21:16  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-06 19:21:20  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-06 19:21:24  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-06 19:21:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 19:21:32  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 19:21:37  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 19:21:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 19:21:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 19:21:49  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-06 19:21:53  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 19:21:57  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 19:22:02  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 19:22:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 19:22:10  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-06 19:22:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 19:22:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 19:22:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 19:22:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-06 19:22:31  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-06_19-31-54 Restart Xvfb...
2017-04-06_20-01-54 Restart Xvfb...
2017-04-06_20-31-54 Restart Xvfb...
2017-04-06_21-01-54 Restart Xvfb...
2017-04-06 21:31:46 reset updateRequest
2017-04-06 21:31:46  - 14968  http://www.lymphomahub.com/
2017-04-06 21:31:50  - 14968  http://www.lymphomahub.com/about
2017-04-06 21:31:51  - 14968  http://www.lymphomahub.com/about
2017-04-06_21-31-54 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-06 21:33:55  - 14968  http://www.lymphomahub.com/about
2017-04-06 21:33:56  - 14968  http://www.lymphomahub.com/about
2017-04-06 21:34:00  - 14968  http://www.lymphomahub.com/terms
2017-04-06 21:34:01  - 14968  http://www.lymphomahub.com/terms
2017-04-06 21:34:04  - 14968  http://www.lymphomahub.com/undefined
2017-04-06 21:34:05  - 14968  http://www.lymphomahub.com/therapies
2017-04-06 21:34:05  - 14968  http://www.lymphomahub.com/therapies
2017-04-06 21:34:14  - 14968  http://www.lymphomahub.com/newsletter
2017-04-06 21:34:14  - 14968  http://www.lymphomahub.com/newsletter
2017-04-06 21:34:18  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-06 21:34:19  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-06 21:34:22  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-06 21:34:23  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-06 21:34:28  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-06 21:34:28  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-06 21:34:33  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-06 21:34:38  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-06 21:34:42  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-06 21:34:47  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-06 21:34:51  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-06 21:34:56  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-06 21:35:00  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-06 21:35:05  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-06 21:35:09  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-06 21:35:14  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-06 21:35:19  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-06 21:35:23  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-06 21:35:28  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-06 21:35:33  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-06 21:35:37  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-06 21:35:41  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-06 21:35:46  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-06 21:35:50  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-06 21:35:55  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-06 21:35:59  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-06 21:36:03  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-06 21:36:08  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-06 21:36:12  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-06 21:36:16  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-06 21:36:21  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-06 21:36:25  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-06 21:36:30  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-06 21:36:34  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-06 21:36:38  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-06 21:36:43  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-06 21:36:47  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-06 21:36:51  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-06 21:36:56  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-06 21:37:00  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-06 21:37:05  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-06 21:37:09  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-06 21:37:13  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-06 21:37:18  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-06 21:37:22  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-06 21:37:27  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-06 21:37:31  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-06 21:37:36  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-06 21:37:40  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-06 21:37:45  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-06 21:37:49  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-06 21:37:54  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-06 21:37:58  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-06 21:38:03  - 14968  http://www.lymphomahub.com/medical-information
2017-04-06 21:38:07  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-06 21:38:12  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-06 21:38:16  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-06 21:38:21  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-06 21:38:25  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-06 21:38:30  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-06 21:38:34  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-06 21:38:39  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-06 21:38:43  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-06 21:38:48  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-06 21:38:52  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-06 21:38:56  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-06 21:38:57  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-06 21:39:02  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-06 21:39:06  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-06 21:39:10  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-06 21:39:15  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-06 21:39:19  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-06 21:39:24  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-06 21:39:28  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-06 21:39:32  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-06 21:39:37  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-06 21:39:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-06 21:39:46  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-06 21:39:50  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-06 21:39:55  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-06 21:39:59  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-06 21:40:04  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-06 21:40:08  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-06 21:40:13  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-06 21:40:17  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-06 21:40:21  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-06 21:40:26  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-06 21:40:30  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-06 21:40:35  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-06 21:40:39  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-06 21:40:43  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-06 21:40:48  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-06 21:40:52  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-06 21:40:57  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-06 21:41:01  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-06 21:41:06  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-06 21:41:10  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-06 21:41:11  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-06 21:41:15  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-06 21:41:20  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-06 21:41:24  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-06 21:41:29  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-06 21:41:33  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-06 21:41:38  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-06 21:41:42  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-06 21:41:47  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-06 21:41:50  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-06 21:41:51  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-06 21:41:56  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-06 21:42:00  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-06 21:42:05  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-06 21:42:10  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-06 21:42:14  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-06 21:42:15  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-06 21:42:19  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-06 21:42:24  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-06 21:42:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-06 21:42:32  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-06 21:42:36  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-06 21:42:40  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-06 21:42:44  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-06 21:42:48  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-06 21:42:52  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-06 21:42:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-06 21:43:00  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-06 21:43:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-06 21:43:09  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-06 21:43:13  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-06 21:43:13  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-06 21:43:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-06 21:43:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-06 21:43:27  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-06 21:43:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-06 21:43:35  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-06 21:43:40  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-06 21:43:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-06 21:43:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-06 21:43:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-06 21:43:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-06 21:43:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-06 21:44:03  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-06 21:44:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-06 21:44:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-06 21:44:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-06 21:44:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-06 21:44:24  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-06 21:44:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-06 21:44:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-06 21:44:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-06 21:44:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-06 21:44:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-06 21:44:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-06 21:44:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-06 21:44:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-06 21:45:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-06 21:45:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-06 21:45:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-06 21:45:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-06 21:45:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-06 21:45:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-06 21:45:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-06 21:45:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-06 21:45:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-06 21:45:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-06 21:45:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-06 21:45:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-06 21:45:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-06 21:46:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-06 21:46:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-06 21:46:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-06 21:46:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-06 21:46:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-06 21:46:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-06 21:46:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-06 21:46:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-06 21:46:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-06 21:46:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-06 21:46:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-06 21:46:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-06 21:46:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-06 21:46:56  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-06 21:47:01  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-06 21:47:06  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-06 21:47:11  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-06 21:47:16  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-06 21:47:19  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-06 21:47:24  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-06 21:47:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-06 21:47:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-06 21:47:36  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-06 21:47:40  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-06 21:47:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-06 21:47:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-06 21:47:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-06 21:47:57  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-06 21:48:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-06 21:48:06  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-06 21:48:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-06 21:48:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-06 21:48:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-06 21:48:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-06 21:48:29  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-06 21:48:30  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-06 21:48:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-06 21:48:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-06 21:48:44  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-06 21:48:48  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-06 21:48:53  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-06 21:48:58  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 21:49:02  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 21:49:07  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-06 21:49:11  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 21:49:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-06 21:49:20  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-06 21:49:25  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-06 21:49:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-06 21:49:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-06 21:49:38  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-06 21:49:43  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-06 21:49:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-06 21:49:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-06 21:49:57  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-06 21:50:02  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-06 21:50:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-06 21:50:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-06 21:50:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-06 21:50:20  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-06 21:50:25  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-06 21:50:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-06 21:50:34  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-06 21:50:39  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-06 21:50:44  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-06 21:50:48  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-06 21:50:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-06 21:50:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-06 21:51:02  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-06 21:51:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-06 21:51:11  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-06 21:51:16  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-06 21:51:20  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-06 21:51:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-06 21:51:30  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-06 21:51:34  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-06 21:51:39  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-06 21:51:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-06 21:51:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-06 21:51:49  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-06 21:51:53  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-06 21:51:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-06 21:52:03  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-06 21:52:07  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-06 21:52:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-06 21:52:16  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-06 21:52:21  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-06 21:52:26  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-06 21:52:31  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-06 21:52:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-06 21:52:41  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-06 21:52:45  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-06 21:52:50  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-06 21:52:54  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-06 21:52:59  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-06 21:53:03  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-06 21:53:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-06 21:53:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-06 21:53:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-06 21:53:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-06 21:53:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-06 21:53:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-06 21:53:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-06 21:53:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-06 21:53:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-06 21:53:46  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-06 21:53:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-06 21:53:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-06 21:53:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-06 21:53:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-06 21:54:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-06 21:54:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-06 21:54:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-06 21:54:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-06 21:54:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-06 21:54:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-06 21:54:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-06 21:54:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-06 21:54:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-06 21:54:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-06 21:54:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-06 21:54:43  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-06 21:54:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-06 21:54:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-06 21:54:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-06 21:54:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-06 21:55:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-06 21:55:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-06 21:55:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-06 21:55:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-06 21:55:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-06 21:55:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-06 21:55:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-06 21:55:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-06 21:55:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-06 21:55:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-06 21:55:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-06 21:55:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-06 21:55:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-06 21:55:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-06 21:55:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-06 21:55:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-06 21:56:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-06 21:56:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-06 21:56:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-06 21:56:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-06 21:56:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-06 21:56:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-06 21:56:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-06 21:56:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-06 21:56:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-06 21:56:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-06 21:56:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-06 21:56:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-06 21:56:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-06 21:56:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-06 21:56:53  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-06 21:56:58  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-06 21:57:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-06 21:57:07  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-06 21:57:08  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-06 21:57:13  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-06 21:57:17  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-06 21:57:22  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-06 21:57:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-06 21:57:32  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-06 21:57:36  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-06 21:57:41  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-06 21:57:45  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-06 21:57:50  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-06 21:57:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-06 21:58:00  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-06 21:58:04  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-06 21:58:09  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-06 21:58:13  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-06 21:58:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-06 21:58:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-06 21:58:27  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-06 21:58:32  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-06 21:58:36  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-06 21:58:41  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-06 21:58:45  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-06 21:58:50  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-06 21:58:55  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-06 21:58:59  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-06 21:59:04  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-06 21:59:08  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-06 21:59:13  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-06 21:59:17  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-06 21:59:22  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-06 21:59:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-06 21:59:31  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-06 21:59:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-06 21:59:40  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-06 21:59:45  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-06 21:59:49  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-06 21:59:54  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-06 21:59:58  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-06 22:00:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-06 22:00:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-06 22:00:13  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-06 22:00:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-06 22:00:22  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-06 22:00:26  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-06 22:00:31  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-06 22:00:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-06 22:00:42  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-06 22:00:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-06 22:00:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-06 22:00:57  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-06 22:01:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-06 22:01:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-06 22:01:11  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-06 22:01:15  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-06 22:01:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-06 22:01:25  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-06 22:01:29  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-06 22:01:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-06 22:01:39  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-06 22:01:43  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-06 22:01:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-06 22:01:52  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-06_22-01-54 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma?_prerender {"code":"ECONNRESET"}
2017-04-06 22:03:57  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-06 22:04:02  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-06 22:04:06  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-06 22:04:11  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-06 22:04:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-06 22:04:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-06 22:04:25  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-06 22:04:30  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-06 22:04:34  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-06 22:04:39  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-06 22:04:43  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-06 22:04:48  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-06 22:04:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-06 22:04:58  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-06 22:05:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-06 22:05:07  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-06 22:05:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-06 22:05:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-06 22:05:21  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-06 22:05:26  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-06 22:05:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-06 22:05:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-06 22:05:39  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-06 22:05:44  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-06 22:05:49  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-06 22:05:53  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-06 22:05:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-06 22:06:02  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-06 22:06:07  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-06 22:06:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-06 22:06:16  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-06 22:06:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-06 22:06:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-06 22:06:30  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-06 22:06:35  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-06 22:06:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-06 22:06:44  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-06 22:06:48  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-06 22:06:53  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-06 22:06:57  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-06 22:07:02  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-06 22:07:07  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-06 22:07:11  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-06 22:07:16  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-06 22:07:21  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-06 22:07:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-06 22:07:30  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-06 22:07:34  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-06 22:07:39  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-06 22:07:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-06 22:07:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-06 22:07:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-06 22:07:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-06 22:08:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-06 22:08:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-06 22:08:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-06 22:08:16  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-06 22:08:21  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-06 22:08:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-06 22:08:30  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-06 22:08:35  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-06 22:08:39  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-06 22:08:44  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-06 22:08:48  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-06 22:08:52  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-06 22:08:57  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-06 22:09:02  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-06 22:09:06  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-06 22:09:11  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-06 22:09:15  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-06 22:09:20  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-06 22:09:25  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-06 22:09:29  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-06 22:09:34  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-06 22:09:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-06 22:09:43  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-06 22:09:48  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-06 22:09:52  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-06 22:09:57  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-06 22:10:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-06 22:10:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-06 22:10:11  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-06 22:10:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-06 22:10:20  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-06 22:10:25  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-06 22:10:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-06 22:10:34  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-06 22:10:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-06 22:10:43  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-06 22:10:48  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-06 22:10:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-06 22:10:56  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-06 22:11:00  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-06 22:11:05  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-06 22:11:09  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-06 22:11:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-06 22:11:18  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-06 22:11:22  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-06 22:11:27  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-06 22:11:32  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-06 22:11:36  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-06 22:11:41  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-06 22:11:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-06 22:11:50  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-06 22:11:54  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-06 22:11:59  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-06 22:12:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-06 22:12:07  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-06 22:12:12  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-06 22:12:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-06 22:12:21  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-06 22:12:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-06 22:12:30  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-06 22:12:35  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-06 22:12:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-06 22:12:43  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-06 22:12:48  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-06 22:12:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-06 22:12:57  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-06 22:13:01  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-06 22:13:05  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-06 22:13:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-06 22:13:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-06 22:13:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-06 22:13:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-06 22:13:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-06 22:13:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-06 22:13:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-06 22:13:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-06 22:13:45  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-06 22:13:49  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-06 22:13:53  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-06 22:13:58  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-06 22:14:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-06 22:14:07  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-06 22:14:12  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-06 22:14:17  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-06 22:14:22  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-06 22:14:27  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-06 22:14:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-06 22:14:36  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-06 22:14:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-06 22:14:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-06 22:14:50  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-06 22:14:50  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-06 22:14:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-06 22:15:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-06 22:15:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-06 22:15:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-06 22:15:14  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-06 22:15:18  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-06 22:15:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-06 22:15:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-06 22:15:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-06 22:15:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-06 22:15:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-06 22:15:45  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-06 22:15:49  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-06 22:15:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-06 22:15:58  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-06 22:16:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-06 22:16:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-06 22:16:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-06 22:16:16  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-06 22:16:20  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-06 22:16:25  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-06 22:16:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-06 22:16:34  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-06 22:16:38  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-06 22:16:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-06 22:16:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-06 22:16:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-06 22:16:56  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-06 22:17:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-06 22:17:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-06 22:17:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-06 22:17:12  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-06 22:17:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-06 22:17:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-06 22:17:25  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-06 22:17:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-06 22:17:34  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-06 22:17:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-06 22:17:41  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-06 22:17:45  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-06 22:17:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-06 22:17:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-06 22:17:59  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-06 22:18:04  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-06 22:18:08  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-06 22:18:12  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-06 22:18:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-06 22:18:21  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-06 22:18:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-06 22:18:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-06 22:18:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-06 22:18:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-06 22:18:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-06 22:18:48  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-06 22:18:52  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-06 22:18:56  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-06 22:19:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-06 22:19:05  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-06 22:19:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-06 22:19:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-06 22:19:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-06 22:19:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 22:19:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 22:19:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 22:19:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 22:19:38  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-06 22:19:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 22:19:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-06 22:19:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-06 22:19:54  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-06 22:19:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-06 22:20:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-06 22:20:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-06 22:20:14  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-06 22:20:18  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-06 22:20:22  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-06 22:20:26  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-06 22:20:31  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-06 22:20:36  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-06 22:20:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-06 22:20:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-06 22:20:48  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-06 22:20:52  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-06 22:20:56  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-06 22:21:00  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-06 22:21:04  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-06 22:21:08  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-06 22:21:12  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-06 22:21:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 22:21:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 22:21:25  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 22:21:29  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 22:21:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-06 22:21:37  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-06 22:21:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 22:21:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 22:21:49  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 22:21:53  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 22:21:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-06 22:22:01  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 22:22:05  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 22:22:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-06 22:22:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-06 22:22:17  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-06_22-31-54 Restart Xvfb...
2017-04-06_23-01-54 Restart Xvfb...
2017-04-06_23-31-54 Restart Xvfb...
2017-04-07_00-01-54 Restart Xvfb...
2017-04-07 00:31:46 reset updateRequest
2017-04-07 00:31:48  - 14968  http://www.lymphomahub.com/
2017-04-07 00:31:51  - 14968  http://www.lymphomahub.com/
2017-04-07 00:31:52  - 14968  http://www.lymphomahub.com/about
2017-04-07_00-31-54 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-07 00:33:56  - 14968  http://www.lymphomahub.com/about
2017-04-07 00:33:57  - 14968  http://www.lymphomahub.com/about
2017-04-07 00:34:01  - 14968  http://www.lymphomahub.com/terms
2017-04-07 00:34:05  - 14968  http://www.lymphomahub.com/undefined
2017-04-07 00:34:05  - 14968  http://www.lymphomahub.com/therapies
2017-04-07 00:34:11  - 14968  http://www.lymphomahub.com/newsletter
2017-04-07 00:34:14  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-07 00:34:17  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-07 00:34:22  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-07 00:34:27  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-07 00:34:31  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-07 00:34:35  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-07 00:34:40  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-07 00:34:44  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-07 00:34:49  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-07 00:34:53  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-07 00:34:58  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-07 00:35:02  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-07 00:35:07  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-07 00:35:11  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-07 00:35:16  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-07 00:35:20  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-07 00:35:25  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-07 00:35:29  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-07 00:35:34  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-07 00:35:38  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-07 00:35:43  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-07 00:35:47  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-07 00:35:51  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-07 00:35:55  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-07 00:36:00  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-07 00:36:05  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-07 00:36:10  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-07 00:36:15  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-07 00:36:19  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-07 00:36:24  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-07 00:36:29  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-07 00:36:33  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-07 00:36:37  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-07 00:36:42  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-07 00:36:46  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-07 00:36:51  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-07 00:36:55  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-07 00:37:00  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-07 00:37:04  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-07 00:37:09  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-07 00:37:13  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-07 00:37:18  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-07 00:37:22  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-07 00:37:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-07 00:37:31  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-07 00:37:36  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-07 00:37:40  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-07 00:37:45  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-07 00:37:49  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-07 00:37:53  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-07 00:37:58  - 14968  http://www.lymphomahub.com/medical-information
2017-04-07 00:38:03  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-07 00:38:07  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-07 00:38:12  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-07 00:38:16  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-07 00:38:21  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-07 00:38:25  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-07 00:38:30  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-07 00:38:34  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-07 00:38:39  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-07 00:38:44  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-07 00:38:48  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-07 00:38:53  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-07 00:38:54  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-07 00:38:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-07 00:39:03  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-07 00:39:07  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-07 00:39:12  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-07 00:39:16  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-07 00:39:20  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-07 00:39:25  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-07 00:39:29  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-07 00:39:34  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-07 00:39:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-07 00:39:43  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-07 00:39:48  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-07 00:39:52  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-07 00:39:56  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-07 00:40:01  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-07 00:40:05  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-07 00:40:10  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-07 00:40:14  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-07 00:40:19  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-07 00:40:23  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-07 00:40:28  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-07 00:40:32  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-07 00:40:37  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-07 00:40:41  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-07 00:40:46  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-07 00:40:50  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-07 00:40:54  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-07 00:40:59  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-07 00:41:03  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-07 00:41:08  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-07 00:41:08  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-07 00:41:13  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-07 00:41:18  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-07 00:41:22  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-07 00:41:27  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-07 00:41:31  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-07 00:41:35  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-07 00:41:40  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-07 00:41:44  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-07 00:41:48  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-07 00:41:49  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-07 00:41:53  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-07 00:41:57  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-07 00:42:02  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-07 00:42:06  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-07 00:42:11  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-07 00:42:12  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-07 00:42:16  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-07 00:42:21  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-07 00:42:25  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-07 00:42:29  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-07 00:42:33  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-07 00:42:37  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-07 00:42:41  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-07 00:42:45  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-07 00:42:49  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-07 00:42:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-07 00:42:57  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-07 00:43:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-07 00:43:06  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-07 00:43:10  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-07 00:43:11  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-07 00:43:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-07 00:43:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-07 00:43:24  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-07 00:43:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-07 00:43:33  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-07 00:43:37  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-07 00:43:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-07 00:43:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-07 00:43:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-07 00:43:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-07 00:43:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-07 00:44:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-07 00:44:04  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-07 00:44:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-07 00:44:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-07 00:44:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-07 00:44:21  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-07 00:44:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-07 00:44:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-07 00:44:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-07 00:44:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-07 00:44:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-07 00:44:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-07 00:44:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-07 00:44:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-07 00:45:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-07 00:45:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-07 00:45:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-07 00:45:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-07 00:45:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-07 00:45:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-07 00:45:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-07 00:45:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-07 00:45:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-07 00:45:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-07 00:45:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-07 00:45:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-07 00:45:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-07 00:45:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-07 00:46:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-07 00:46:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-07 00:46:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-07 00:46:16  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-07 00:46:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-07 00:46:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-07 00:46:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-07 00:46:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-07 00:46:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-07 00:46:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-07 00:46:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-07 00:46:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-07 00:46:55  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-07 00:46:59  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-07 00:47:04  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-07 00:47:08  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-07 00:47:12  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-07 00:47:16  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-07 00:47:20  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-07 00:47:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-07 00:47:29  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-07 00:47:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-07 00:47:37  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-07 00:47:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-07 00:47:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-07 00:47:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-07 00:47:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-07 00:47:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-07 00:48:02  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-07 00:48:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-07 00:48:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-07 00:48:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-07 00:48:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-07 00:48:26  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-07 00:48:27  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-07 00:48:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-07 00:48:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-07 00:48:41  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-07 00:48:45  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-07 00:48:50  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-07 00:48:54  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 00:48:59  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 00:49:03  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-07 00:49:08  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 00:49:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-07 00:49:17  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-07 00:49:22  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-07 00:49:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-07 00:49:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-07 00:49:36  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-07 00:49:41  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-07 00:49:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-07 00:49:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-07 00:49:55  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-07 00:50:00  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 00:50:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-07 00:50:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-07 00:50:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-07 00:50:19  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-07 00:50:23  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-07 00:50:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-07 00:50:33  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-07 00:50:37  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-07 00:50:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-07 00:50:46  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-07 00:50:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-07 00:50:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-07 00:51:00  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-07 00:51:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-07 00:51:09  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-07 00:51:14  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-07 00:51:19  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-07 00:51:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-07 00:51:29  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-07 00:51:33  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-07 00:51:38  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-07 00:51:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-07 00:51:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-07 00:51:48  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-07 00:51:53  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-07 00:51:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-07 00:52:02  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-07 00:52:07  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-07 00:52:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-07 00:52:16  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-07 00:52:20  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-07 00:52:25  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-07 00:52:30  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-07 00:52:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-07 00:52:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-07 00:52:44  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-07 00:52:48  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-07 00:52:53  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-07 00:52:58  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-07 00:53:02  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-07 00:53:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-07 00:53:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-07 00:53:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-07 00:53:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-07 00:53:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-07 00:53:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-07 00:53:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-07 00:53:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-07 00:53:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-07 00:53:46  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-07 00:53:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-07 00:53:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-07 00:53:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-07 00:54:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-07 00:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-07 00:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-07 00:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-07 00:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-07 00:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-07 00:54:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-07 00:54:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-07 00:54:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-07 00:54:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-07 00:54:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-07 00:54:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-07 00:54:45  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-07 00:54:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-07 00:54:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-07 00:54:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-07 00:55:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-07 00:55:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-07 00:55:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-07 00:55:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-07 00:55:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-07 00:55:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-07 00:55:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-07 00:55:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-07 00:55:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-07 00:55:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-07 00:55:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-07 00:55:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-07 00:55:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-07 00:55:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-07 00:55:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-07 00:55:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-07 00:55:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-07 00:56:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-07 00:56:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-07 00:56:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-07 00:56:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-07 00:56:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-07 00:56:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-07 00:56:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-07 00:56:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-07 00:56:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-07 00:56:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-07 00:56:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-07 00:56:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-07 00:56:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-07 00:56:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-07 00:56:56  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-07 00:57:00  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-07 00:57:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-07 00:57:10  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-07 00:57:11  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-07 00:57:15  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-07 00:57:20  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-07 00:57:25  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-07 00:57:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-07 00:57:34  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-07 00:57:39  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-07 00:57:44  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-07 00:57:48  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-07 00:57:53  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-07 00:57:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-07 00:58:03  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-07 00:58:07  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-07 00:58:12  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-07 00:58:16  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-07 00:58:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-07 00:58:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-07 00:58:30  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-07 00:58:35  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-07 00:58:40  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-07 00:58:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-07 00:58:49  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-07 00:58:53  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-07 00:58:58  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-07 00:59:03  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-07 00:59:07  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-07 00:59:12  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-07 00:59:16  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-07 00:59:21  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-07 00:59:26  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-07 00:59:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-07 00:59:35  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-07 00:59:40  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-07 00:59:44  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-07 00:59:49  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-07 00:59:54  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-07 00:59:58  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-07 01:00:03  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-07 01:00:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-07 01:00:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-07 01:00:18  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-07 01:00:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-07 01:00:27  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-07 01:00:32  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-07 01:00:38  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-07 01:00:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-07 01:00:47  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-07 01:00:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-07 01:00:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-07 01:01:00  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-07 01:01:05  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-07 01:01:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-07 01:01:14  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-07 01:01:19  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-07 01:01:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-07 01:01:29  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-07 01:01:33  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-07 01:01:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-07 01:01:43  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-07 01:01:47  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-07 01:01:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-07_01-01-54 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl?_prerender {"code":"ECONNRESET"}
2017-04-07 01:03:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-07 01:04:02  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-07 01:04:07  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-07 01:04:12  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-07 01:04:16  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-07 01:04:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-07 01:04:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-07 01:04:31  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-07 01:04:36  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-07 01:04:41  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-07 01:04:45  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-07 01:04:50  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-07 01:04:55  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-07 01:04:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-07 01:05:04  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-07 01:05:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-07 01:05:14  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-07 01:05:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-07 01:05:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-07 01:05:28  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-07 01:05:33  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-07 01:05:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-07 01:05:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-07 01:05:47  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-07 01:05:51  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-07 01:05:56  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-07 01:06:00  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-07 01:06:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-07 01:06:10  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-07 01:06:14  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-07 01:06:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-07 01:06:24  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-07 01:06:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-07 01:06:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-07 01:06:39  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-07 01:06:43  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-07 01:06:48  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-07 01:06:53  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-07 01:06:58  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-07 01:07:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-07 01:07:07  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-07 01:07:11  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-07 01:07:16  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-07 01:07:20  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-07 01:07:25  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-07 01:07:29  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-07 01:07:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-07 01:07:39  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-07 01:07:43  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-07 01:07:48  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-07 01:07:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-07 01:07:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-07 01:08:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-07 01:08:07  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-07 01:08:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-07 01:08:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-07 01:08:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-07 01:08:26  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-07 01:08:30  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-07 01:08:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-07 01:08:40  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-07 01:08:44  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-07 01:08:49  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-07 01:08:54  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-07 01:08:58  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-07 01:09:03  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-07 01:09:07  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-07 01:09:12  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-07 01:09:17  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-07 01:09:22  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-07 01:09:26  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-07 01:09:31  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-07 01:09:35  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-07 01:09:40  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-07 01:09:45  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-07 01:09:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-07 01:09:54  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-07 01:09:59  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-07 01:10:04  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-07 01:10:08  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-07 01:10:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-07 01:10:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-07 01:10:22  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-07 01:10:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-07 01:10:32  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-07 01:10:37  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-07 01:10:41  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-07 01:10:46  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-07 01:10:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-07 01:10:55  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-07 01:10:59  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-07 01:11:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-07 01:11:08  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-07 01:11:12  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-07 01:11:16  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-07 01:11:21  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-07 01:11:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-07 01:11:31  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-07 01:11:35  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-07 01:11:39  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-07 01:11:44  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-07 01:11:49  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-07 01:11:54  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-07 01:11:58  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-07 01:12:03  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-07 01:12:08  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-07 01:12:12  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-07 01:12:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-07 01:12:20  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-07 01:12:25  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-07 01:12:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-07 01:12:34  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-07 01:12:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-07 01:12:43  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-07 01:12:47  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-07 01:12:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-07 01:12:56  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-07 01:13:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-07 01:13:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-07 01:13:10  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-07 01:13:15  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-07 01:13:19  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-07 01:13:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-07 01:13:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-07 01:13:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-07 01:13:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-07 01:13:42  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-07 01:13:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-07 01:13:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-07 01:13:55  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-07 01:14:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-07 01:14:04  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-07 01:14:09  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-07 01:14:13  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-07 01:14:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-07 01:14:22  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-07 01:14:26  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-07 01:14:31  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-07 01:14:35  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-07 01:14:40  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-07 01:14:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-07 01:14:49  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-07 01:14:54  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-07 01:14:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-07 01:15:03  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-07 01:15:04  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-07 01:15:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-07 01:15:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-07 01:15:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-07 01:15:22  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-07 01:15:27  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-07 01:15:31  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-07 01:15:36  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-07 01:15:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-07 01:15:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-07 01:15:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-07 01:15:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-07 01:15:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-07 01:16:03  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-07 01:16:07  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-07 01:16:12  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-07 01:16:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-07 01:16:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-07 01:16:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-07 01:16:30  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-07 01:16:34  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-07 01:16:40  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-07 01:16:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-07 01:16:48  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-07 01:16:52  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-07 01:16:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-07 01:17:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-07 01:17:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-07 01:17:11  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-07 01:17:15  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-07 01:17:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-07 01:17:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-07 01:17:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-07 01:17:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-07 01:17:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-07 01:17:41  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-07 01:17:45  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-07 01:17:49  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-07 01:17:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-07 01:17:57  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-07 01:18:02  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-07 01:18:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-07 01:18:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-07 01:18:15  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-07 01:18:19  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-07 01:18:23  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-07 01:18:27  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-07 01:18:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-07 01:18:36  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-07 01:18:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-07 01:18:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-07 01:18:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-07 01:18:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-07 01:18:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-07 01:19:04  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-07 01:19:08  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-07 01:19:12  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-07 01:19:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-07 01:19:21  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-07 01:19:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-07 01:19:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-07 01:19:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-07 01:19:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 01:19:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 01:19:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 01:19:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 01:19:54  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-07 01:19:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 01:20:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 01:20:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-07 01:20:11  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-07 01:20:15  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-07 01:20:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-07 01:20:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-07 01:20:28  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-07 01:20:32  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-07 01:20:36  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-07 01:20:40  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-07 01:20:44  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-07 01:20:48  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-07 01:20:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-07 01:20:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-07 01:21:01  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-07 01:21:05  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-07 01:21:09  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-07 01:21:13  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-07 01:21:17  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-07 01:21:22  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-07 01:21:26  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-07 01:21:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 01:21:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 01:21:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 01:21:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 01:21:46  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 01:21:50  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-07 01:21:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 01:21:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 01:22:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 01:22:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 01:22:11  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-07 01:22:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 01:22:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 01:22:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 01:22:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-07 01:22:31  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-07_01-31-54 Restart Xvfb...
2017-04-07_02-01-54 Restart Xvfb...
2017-04-07_02-31-54 Restart Xvfb...
2017-04-07_03-01-54 Restart Xvfb...
2017-04-07 03:31:46 reset updateRequest
2017-04-07 03:31:47  - 14968  http://www.lymphomahub.com/
2017-04-07 03:31:51  - 14968  http://www.lymphomahub.com/
2017-04-07 03:31:52  - 14968  http://www.lymphomahub.com/about
2017-04-07_03-31-54 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-07 03:33:56  - 14968  http://www.lymphomahub.com/about
2017-04-07 03:33:57  - 14968  http://www.lymphomahub.com/about
2017-04-07 03:34:02  - 14968  http://www.lymphomahub.com/terms
2017-04-07 03:34:05  - 14968  http://www.lymphomahub.com/undefined
2017-04-07 03:34:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-07 03:34:12  - 14968  http://www.lymphomahub.com/newsletter
2017-04-07 03:34:15  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-07 03:34:18  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-07 03:34:23  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-07 03:34:27  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-07 03:34:32  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-07 03:34:36  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-07 03:34:41  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-07 03:34:45  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-07 03:34:50  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-07 03:34:56  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-07 03:35:00  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-07 03:35:04  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-07 03:35:09  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-07 03:35:14  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-07 03:35:18  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-07 03:35:22  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-07 03:35:27  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-07 03:35:31  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-07 03:35:36  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-07 03:35:41  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-07 03:35:46  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-07 03:35:50  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-07 03:35:54  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-07 03:35:59  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-07 03:36:04  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-07 03:36:08  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-07 03:36:13  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-07 03:36:17  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-07 03:36:22  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-07 03:36:27  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-07 03:36:31  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-07 03:36:36  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-07 03:36:40  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-07 03:36:44  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-07 03:36:49  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-07 03:36:53  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-07 03:36:58  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-07 03:37:02  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-07 03:37:07  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-07 03:37:11  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-07 03:37:16  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-07 03:37:20  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-07 03:37:25  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-07 03:37:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-07 03:37:34  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-07 03:37:38  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-07 03:37:43  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-07 03:37:47  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-07 03:37:52  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-07 03:37:56  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-07 03:38:01  - 14968  http://www.lymphomahub.com/medical-information
2017-04-07 03:38:07  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-07 03:38:12  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-07 03:38:17  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-07 03:38:22  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-07 03:38:27  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-07 03:38:31  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-07 03:38:35  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-07 03:38:41  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-07 03:38:45  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-07 03:38:50  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-07 03:38:54  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-07 03:38:59  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-07 03:39:00  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-07 03:39:05  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-07 03:39:10  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-07 03:39:14  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-07 03:39:19  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-07 03:39:23  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-07 03:39:28  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-07 03:39:33  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-07 03:39:37  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-07 03:39:42  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-07 03:39:46  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-07 03:39:50  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-07 03:39:55  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-07 03:40:00  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-07 03:40:04  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-07 03:40:09  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-07 03:40:13  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-07 03:40:18  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-07 03:40:22  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-07 03:40:26  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-07 03:40:31  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-07 03:40:35  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-07 03:40:40  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-07 03:40:44  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-07 03:40:49  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-07 03:40:53  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-07 03:40:58  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-07 03:41:02  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-07 03:41:07  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-07 03:41:11  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-07 03:41:16  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-07 03:41:16  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-07 03:41:21  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-07 03:41:25  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-07 03:41:30  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-07 03:41:34  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-07 03:41:38  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-07 03:41:43  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-07 03:41:47  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-07 03:41:52  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-07 03:41:55  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-07 03:41:56  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-07 03:42:00  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-07 03:42:05  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-07 03:42:09  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-07 03:42:14  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-07 03:42:19  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-07 03:42:19  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-07 03:42:24  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-07 03:42:28  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-07 03:42:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-07 03:42:37  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-07 03:42:41  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-07 03:42:45  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-07 03:42:49  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-07 03:42:53  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-07 03:42:56  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-07 03:43:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-07 03:43:05  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-07 03:43:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-07 03:43:14  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-07 03:43:18  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-07 03:43:18  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-07 03:43:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-07 03:43:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-07 03:43:32  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-07 03:43:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-07 03:43:40  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-07 03:43:45  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-07 03:43:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-07 03:43:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-07 03:43:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-07 03:44:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-07 03:44:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-07 03:44:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-07 03:44:11  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-07 03:44:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-07 03:44:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-07 03:44:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-07 03:44:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-07 03:44:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-07 03:44:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-07 03:44:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-07 03:44:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-07 03:44:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-07 03:44:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-07 03:44:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-07 03:45:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-07 03:45:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-07 03:45:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-07 03:45:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-07 03:45:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-07 03:45:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-07 03:45:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-07 03:45:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-07 03:45:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-07 03:45:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-07 03:45:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-07 03:45:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-07 03:45:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-07 03:46:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-07 03:46:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-07 03:46:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-07 03:46:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-07 03:46:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-07 03:46:24  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-07 03:46:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-07 03:46:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-07 03:46:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-07 03:46:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-07 03:46:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-07 03:46:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-07 03:46:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-07 03:46:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-07 03:47:02  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-07 03:47:07  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-07 03:47:12  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-07 03:47:16  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-07 03:47:20  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-07 03:47:24  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-07 03:47:29  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-07 03:47:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-07 03:47:37  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-07 03:47:41  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-07 03:47:45  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-07 03:47:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-07 03:47:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-07 03:47:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-07 03:48:02  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-07 03:48:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-07 03:48:11  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-07 03:48:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-07 03:48:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-07 03:48:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-07 03:48:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-07 03:48:34  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-07 03:48:35  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-07 03:48:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-07 03:48:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-07 03:48:49  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-07 03:48:53  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-07 03:48:58  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-07 03:49:03  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 03:49:07  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 03:49:12  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-07 03:49:17  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 03:49:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-07 03:49:26  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-07 03:49:30  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-07 03:49:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-07 03:49:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-07 03:49:44  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-07 03:49:49  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-07 03:49:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-07 03:49:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-07 03:50:03  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-07 03:50:07  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 03:50:12  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-07 03:50:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-07 03:50:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-07 03:50:26  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-07 03:50:30  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-07 03:50:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-07 03:50:40  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-07 03:50:44  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-07 03:50:49  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-07 03:50:53  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-07 03:50:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-07 03:51:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-07 03:51:07  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-07 03:51:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-07 03:51:16  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-07 03:51:21  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-07 03:51:26  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-07 03:51:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-07 03:51:35  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-07 03:51:40  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-07 03:51:44  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-07 03:51:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-07 03:51:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-07 03:51:54  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-07 03:51:59  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-07 03:52:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-07 03:52:08  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-07 03:52:12  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-07 03:52:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-07 03:52:22  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-07 03:52:26  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-07 03:52:31  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-07 03:52:36  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-07 03:52:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-07 03:52:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-07 03:52:50  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-07 03:52:55  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-07 03:52:59  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-07 03:53:04  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-07 03:53:09  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-07 03:53:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-07 03:53:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-07 03:53:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-07 03:53:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-07 03:53:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-07 03:53:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-07 03:53:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-07 03:53:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-07 03:53:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-07 03:53:53  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-07 03:53:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-07 03:53:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-07 03:54:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-07 03:54:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-07 03:54:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-07 03:54:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-07 03:54:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-07 03:54:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-07 03:54:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-07 03:54:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-07 03:54:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-07 03:54:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-07 03:54:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-07 03:54:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-07 03:54:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-07 03:54:50  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-07 03:54:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-07 03:54:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-07 03:55:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-07 03:55:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-07 03:55:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-07 03:55:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-07 03:55:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-07 03:55:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-07 03:55:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-07 03:55:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-07 03:55:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-07 03:55:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-07 03:55:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-07 03:55:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-07 03:55:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-07 03:55:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-07 03:55:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-07 03:55:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-07 03:56:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-07 03:56:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-07 03:56:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-07 03:56:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-07 03:56:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-07 03:56:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-07 03:56:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-07 03:56:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-07 03:56:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-07 03:56:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-07 03:56:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-07 03:56:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-07 03:56:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-07 03:56:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-07 03:56:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-07 03:56:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-07 03:57:01  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-07 03:57:06  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-07 03:57:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-07 03:57:16  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-07 03:57:17  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-07 03:57:22  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-07 03:57:26  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-07 03:57:31  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-07 03:57:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-07 03:57:40  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-07 03:57:45  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-07 03:57:50  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-07 03:57:54  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-07 03:57:59  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-07 03:58:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-07 03:58:08  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-07 03:58:13  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-07 03:58:18  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-07 03:58:23  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-07 03:58:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-07 03:58:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-07 03:58:37  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-07 03:58:42  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-07 03:58:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-07 03:58:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-07 03:58:56  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-07 03:59:01  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-07 03:59:05  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-07 03:59:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-07 03:59:14  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-07 03:59:19  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-07 03:59:23  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-07 03:59:28  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-07 03:59:32  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-07 03:59:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-07 03:59:41  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-07 03:59:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-07 03:59:50  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-07 03:59:55  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-07 03:59:59  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-07 04:00:04  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-07 04:00:09  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-07 04:00:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-07 04:00:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-07 04:00:27  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-07 04:00:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-07 04:00:37  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-07 04:00:41  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-07 04:00:46  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-07 04:00:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-07 04:00:57  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-07 04:01:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-07 04:01:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-07 04:01:11  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-07 04:01:15  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-07 04:01:20  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-07 04:01:26  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-07 04:01:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-07 04:01:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-07 04:01:40  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-07 04:01:45  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-07 04:01:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-07_04-01-54 Restart Xvfb...
2017-04-07 04:01:54  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-07 04:01:59  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-07 04:02:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-07 04:02:08  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-07 04:02:13  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-07 04:02:18  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-07 04:02:22  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-07 04:02:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-07 04:02:32  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-07 04:02:36  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-07 04:02:41  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-07 04:02:45  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-07 04:02:50  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-07 04:02:55  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-07 04:02:59  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-07 04:03:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-07 04:03:09  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-07 04:03:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-07 04:03:18  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-07 04:03:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-07 04:03:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-07 04:03:32  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-07 04:03:36  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-07 04:03:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-07 04:03:45  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-07 04:03:50  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-07 04:03:55  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-07 04:03:59  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-07 04:04:04  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-07 04:04:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-07 04:04:13  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-07 04:04:17  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-07 04:04:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-07 04:04:27  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-07 04:04:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-07 04:04:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-07 04:04:42  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-07 04:04:47  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-07 04:04:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-07 04:04:56  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-07 04:05:01  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-07 04:05:06  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-07 04:05:11  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-07 04:05:15  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-07 04:05:20  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-07 04:05:24  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-07 04:05:29  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-07 04:05:34  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-07 04:05:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-07 04:05:43  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-07 04:05:48  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-07 04:05:52  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-07 04:05:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-07 04:06:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-07 04:06:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-07 04:06:11  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-07 04:06:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-07 04:06:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-07 04:06:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-07 04:06:30  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-07 04:06:35  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-07 04:06:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-07 04:06:44  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-07 04:06:49  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-07 04:06:53  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-07 04:06:58  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-07 04:07:02  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-07 04:07:07  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-07 04:07:11  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-07 04:07:16  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-07 04:07:21  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-07 04:07:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-07 04:07:30  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-07 04:07:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-07 04:07:39  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-07 04:07:44  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-07 04:07:49  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-07 04:07:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-07 04:07:58  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-07 04:08:03  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-07 04:08:08  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-07 04:08:12  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-07 04:08:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-07 04:08:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-07 04:08:26  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-07 04:08:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-07 04:08:35  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-07 04:08:40  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-07 04:08:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-07 04:08:50  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-07 04:08:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-07 04:08:59  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-07 04:09:04  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-07 04:09:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-07 04:09:12  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-07 04:09:17  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-07 04:09:21  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-07 04:09:26  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-07 04:09:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-07 04:09:35  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-07 04:09:39  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-07 04:09:44  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-07 04:09:49  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-07 04:09:53  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-07 04:09:58  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-07 04:10:03  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-07 04:10:08  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-07 04:10:12  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-07 04:10:17  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-07 04:10:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-07 04:10:25  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-07 04:10:30  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-07 04:10:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-07 04:10:39  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-07 04:10:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-07 04:10:48  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-07 04:10:53  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-07 04:10:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-07 04:11:01  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-07 04:11:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-07 04:11:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-07 04:11:15  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-07 04:11:20  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-07 04:11:24  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-07 04:11:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-07 04:11:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-07 04:11:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-07 04:11:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-07 04:11:46  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-07 04:11:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-07 04:11:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-07 04:11:59  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-07 04:12:04  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-07 04:12:08  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-07 04:12:13  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-07 04:12:17  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-07 04:12:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-07 04:12:26  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-07 04:12:30  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-07 04:12:35  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-07 04:12:39  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-07 04:12:44  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-07 04:12:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-07 04:12:53  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-07 04:12:58  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-07 04:13:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-07 04:13:08  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-07 04:13:08  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-07 04:13:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-07 04:13:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-07 04:13:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-07 04:13:26  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-07 04:13:31  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-07 04:13:36  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-07 04:13:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-07 04:13:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-07 04:13:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-07 04:13:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-07 04:13:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-07 04:14:02  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-07 04:14:06  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-07 04:14:11  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-07 04:14:15  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-07 04:14:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-07 04:14:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-07 04:14:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-07 04:14:33  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-07 04:14:38  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-07 04:14:43  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-07 04:14:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-07 04:14:51  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-07 04:14:55  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-07 04:15:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-07 04:15:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-07 04:15:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-07 04:15:14  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-07 04:15:18  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-07 04:15:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-07 04:15:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-07 04:15:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-07 04:15:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-07 04:15:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-07 04:15:43  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-07 04:15:48  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-07 04:15:52  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-07 04:15:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-07 04:16:00  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-07 04:16:04  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-07 04:16:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-07 04:16:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-07 04:16:17  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-07 04:16:21  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-07 04:16:25  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-07 04:16:29  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-07 04:16:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-07 04:16:38  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-07 04:16:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-07 04:16:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-07 04:16:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-07 04:16:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-07 04:17:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-07 04:17:05  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-07 04:17:09  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-07 04:17:13  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-07 04:17:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-07 04:17:21  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-07 04:17:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-07 04:17:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-07 04:17:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-07 04:17:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 04:17:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 04:17:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 04:17:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 04:17:55  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-07 04:17:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 04:18:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 04:18:07  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-07 04:18:11  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-07 04:18:15  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-07 04:18:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-07 04:18:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-07 04:18:28  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-07 04:18:32  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-07 04:18:36  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-07 04:18:40  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-07 04:18:44  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-07 04:18:48  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-07 04:18:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-07 04:18:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-07 04:19:01  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-07 04:19:05  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-07 04:19:10  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-07 04:19:14  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-07 04:19:18  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-07 04:19:22  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-07 04:19:26  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-07 04:19:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 04:19:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 04:19:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 04:19:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 04:19:46  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 04:19:50  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-07 04:19:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 04:19:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 04:20:02  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 04:20:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 04:20:10  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-07 04:20:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 04:20:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 04:20:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 04:20:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-07 04:20:31  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-07_04-31-54 Restart Xvfb...
2017-04-07_05-01-54 Restart Xvfb...
2017-04-07_05-31-54 Restart Xvfb...
2017-04-07_06-01-54 Restart Xvfb...
2017-04-07 06:31:46 reset updateRequest
2017-04-07 06:31:47  - 14968  http://www.lymphomahub.com/
2017-04-07 06:31:51  - 14968  http://www.lymphomahub.com/
2017-04-07 06:31:52  - 14968  http://www.lymphomahub.com/about
2017-04-07_06-31-54 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-07 06:33:56  - 14968  http://www.lymphomahub.com/about
2017-04-07 06:33:57  - 14968  http://www.lymphomahub.com/about
2017-04-07 06:34:02  - 14968  http://www.lymphomahub.com/terms
2017-04-07 06:34:05  - 14968  http://www.lymphomahub.com/undefined
2017-04-07 06:34:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-07 06:34:12  - 14968  http://www.lymphomahub.com/newsletter
2017-04-07 06:34:15  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-07 06:34:18  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-07 06:34:23  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-07 06:34:27  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-07 06:34:32  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-07 06:34:36  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-07 06:34:41  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-07 06:34:45  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-07 06:34:50  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-07 06:34:54  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-07 06:34:59  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-07 06:35:03  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-07 06:35:08  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-07 06:35:12  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-07 06:35:17  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-07 06:35:21  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-07 06:35:26  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-07 06:35:31  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-07 06:35:35  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-07 06:35:40  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-07 06:35:44  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-07 06:35:49  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-07 06:35:53  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-07 06:35:57  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-07 06:36:02  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-07 06:36:07  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-07 06:36:11  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-07 06:36:16  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-07 06:36:20  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-07 06:36:25  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-07 06:36:29  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-07 06:36:34  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-07 06:36:38  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-07 06:36:42  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-07 06:36:47  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-07 06:36:51  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-07 06:36:56  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-07 06:37:00  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-07 06:37:05  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-07 06:37:10  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-07 06:37:14  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-07 06:37:19  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-07 06:37:23  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-07 06:37:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-07 06:37:32  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-07 06:37:36  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-07 06:37:41  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-07 06:37:45  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-07 06:37:50  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-07 06:37:54  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-07 06:37:58  - 14968  http://www.lymphomahub.com/medical-information
2017-04-07 06:38:03  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-07 06:38:08  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-07 06:38:12  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-07 06:38:17  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-07 06:38:21  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-07 06:38:26  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-07 06:38:30  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-07 06:38:35  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-07 06:38:39  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-07 06:38:44  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-07 06:38:48  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-07 06:38:53  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-07 06:38:53  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-07 06:38:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-07 06:39:03  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-07 06:39:07  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-07 06:39:12  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-07 06:39:16  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-07 06:39:21  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-07 06:39:26  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-07 06:39:30  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-07 06:39:35  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-07 06:39:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-07 06:39:44  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-07 06:39:48  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-07 06:39:53  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-07 06:39:57  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-07 06:40:02  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-07 06:40:06  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-07 06:40:11  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-07 06:40:15  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-07 06:40:20  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-07 06:40:24  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-07 06:40:29  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-07 06:40:34  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-07 06:40:38  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-07 06:40:42  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-07 06:40:47  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-07 06:40:52  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-07 06:40:56  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-07 06:41:00  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-07 06:41:05  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-07 06:41:09  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-07 06:41:10  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-07 06:41:15  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-07 06:41:19  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-07 06:41:23  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-07 06:41:28  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-07 06:41:32  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-07 06:41:37  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-07 06:41:43  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-07 06:41:47  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-07 06:41:51  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-07 06:41:51  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-07 06:41:56  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-07 06:42:00  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-07 06:42:05  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-07 06:42:09  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-07 06:42:14  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-07 06:42:14  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-07 06:42:19  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-07 06:42:23  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-07 06:42:27  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-07 06:42:31  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-07 06:42:36  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-07 06:42:39  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-07 06:42:44  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-07 06:42:47  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-07 06:42:53  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-07 06:42:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-07 06:43:02  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-07 06:43:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-07 06:43:11  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-07 06:43:14  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-07 06:43:15  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-07 06:43:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-07 06:43:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-07 06:43:28  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-07 06:43:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-07 06:43:37  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-07 06:43:41  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-07 06:43:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-07 06:43:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-07 06:43:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-07 06:43:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-07 06:44:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-07 06:44:05  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-07 06:44:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-07 06:44:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-07 06:44:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-07 06:44:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-07 06:44:27  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-07 06:44:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-07 06:44:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-07 06:44:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-07 06:44:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-07 06:44:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-07 06:44:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-07 06:44:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-07 06:45:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-07 06:45:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-07 06:45:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-07 06:45:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-07 06:45:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-07 06:45:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-07 06:45:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-07 06:45:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-07 06:45:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-07 06:45:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-07 06:45:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-07 06:45:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-07 06:45:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-07 06:45:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-07 06:46:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-07 06:46:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-07 06:46:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-07 06:46:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-07 06:46:21  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-07 06:46:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-07 06:46:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-07 06:46:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-07 06:46:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-07 06:46:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-07 06:46:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-07 06:46:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-07 06:46:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-07 06:47:00  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-07 06:47:05  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-07 06:47:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-07 06:47:13  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-07 06:47:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-07 06:47:22  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-07 06:47:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-07 06:47:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-07 06:47:35  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-07 06:47:38  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-07 06:47:42  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-07 06:47:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-07 06:47:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-07 06:47:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-07 06:48:00  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-07 06:48:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-07 06:48:09  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-07 06:48:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-07 06:48:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-07 06:48:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-07 06:48:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-07 06:48:33  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-07 06:48:33  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-07 06:48:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-07 06:48:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-07 06:48:47  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-07 06:48:51  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-07 06:48:56  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-07 06:49:01  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 06:49:05  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 06:49:10  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-07 06:49:14  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 06:49:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-07 06:49:24  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-07 06:49:28  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-07 06:49:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-07 06:49:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-07 06:49:42  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-07 06:49:47  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-07 06:49:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-07 06:49:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-07 06:50:01  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-07 06:50:06  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 06:50:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-07 06:50:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-07 06:50:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-07 06:50:25  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-07 06:50:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-07 06:50:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-07 06:50:38  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-07 06:50:43  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-07 06:50:47  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-07 06:50:52  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-07 06:50:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-07 06:51:01  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-07 06:51:06  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-07 06:51:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-07 06:51:15  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-07 06:51:19  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-07 06:51:24  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-07 06:51:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-07 06:51:34  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-07 06:51:38  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-07 06:51:43  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-07 06:51:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-07 06:51:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-07 06:51:52  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-07 06:51:57  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-07 06:52:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-07 06:52:07  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-07 06:52:11  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-07 06:52:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-07 06:52:21  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-07 06:52:25  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-07 06:52:30  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-07 06:52:35  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-07 06:52:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-07 06:52:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-07 06:52:49  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-07 06:52:54  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-07 06:52:58  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-07 06:53:03  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-07 06:53:08  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-07 06:53:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-07 06:53:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-07 06:53:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-07 06:53:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-07 06:53:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-07 06:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-07 06:53:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-07 06:53:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-07 06:53:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-07 06:53:52  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-07 06:53:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-07 06:53:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-07 06:54:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-07 06:54:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-07 06:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-07 06:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-07 06:54:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-07 06:54:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-07 06:54:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-07 06:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-07 06:54:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-07 06:54:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-07 06:54:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-07 06:54:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-07 06:54:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-07 06:54:49  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-07 06:54:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-07 06:54:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-07 06:55:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-07 06:55:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-07 06:55:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-07 06:55:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-07 06:55:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-07 06:55:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-07 06:55:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-07 06:55:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-07 06:55:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-07 06:55:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-07 06:55:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-07 06:55:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-07 06:55:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-07 06:55:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-07 06:55:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-07 06:55:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-07 06:56:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-07 06:56:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-07 06:56:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-07 06:56:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-07 06:56:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-07 06:56:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-07 06:56:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-07 06:56:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-07 06:56:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-07 06:56:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-07 06:56:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-07 06:56:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-07 06:56:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-07 06:56:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-07 06:56:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-07 06:56:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-07 06:57:02  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-07 06:57:07  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-07 06:57:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-07 06:57:17  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-07 06:57:17  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-07 06:57:22  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-07 06:57:27  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-07 06:57:31  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-07 06:57:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-07 06:57:41  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-07 06:57:45  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-07 06:57:50  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-07 06:57:54  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-07 06:57:59  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-07 06:58:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-07 06:58:08  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-07 06:58:13  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-07 06:58:18  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-07 06:58:22  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-07 06:58:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-07 06:58:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-07 06:58:36  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-07 06:58:41  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-07 06:58:45  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-07 06:58:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-07 06:58:55  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-07 06:58:59  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-07 06:59:04  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-07 06:59:09  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-07 06:59:14  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-07 06:59:18  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-07 06:59:23  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-07 06:59:27  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-07 06:59:32  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-07 06:59:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-07 06:59:41  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-07 06:59:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-07 06:59:51  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-07 06:59:55  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-07 07:00:00  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-07 07:00:05  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-07 07:00:10  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-07 07:00:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-07 07:00:20  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-07 07:00:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-07 07:00:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-07 07:00:34  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-07 07:00:38  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-07 07:00:43  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-07 07:00:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-07 07:00:52  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-07 07:00:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-07 07:01:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-07 07:01:06  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-07 07:01:11  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-07 07:01:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-07 07:01:20  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-07 07:01:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-07 07:01:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-07 07:01:34  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-07 07:01:39  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-07 07:01:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-07 07:01:48  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-07 07:01:53  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-07_07-01-54 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration?_prerender {"code":"ECONNRESET"}
2017-04-07 07:03:58  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-07 07:04:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-07 07:04:07  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-07 07:04:12  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-07 07:04:17  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-07 07:04:22  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-07 07:04:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-07 07:04:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-07 07:04:36  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-07 07:04:40  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-07 07:04:45  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-07 07:04:50  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-07 07:04:55  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-07 07:04:59  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-07 07:05:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-07 07:05:09  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-07 07:05:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-07 07:05:18  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-07 07:05:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-07 07:05:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-07 07:05:32  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-07 07:05:37  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-07 07:05:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-07 07:05:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-07 07:05:51  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-07 07:05:55  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-07 07:06:00  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-07 07:06:05  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-07 07:06:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-07 07:06:14  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-07 07:06:19  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-07 07:06:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-07 07:06:28  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-07 07:06:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-07 07:06:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-07 07:06:42  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-07 07:06:47  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-07 07:06:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-07 07:06:56  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-07 07:07:01  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-07 07:07:05  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-07 07:07:10  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-07 07:07:15  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-07 07:07:19  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-07 07:07:24  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-07 07:07:29  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-07 07:07:33  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-07 07:07:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-07 07:07:43  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-07 07:07:47  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-07 07:07:52  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-07 07:07:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-07 07:08:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-07 07:08:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-07 07:08:11  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-07 07:08:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-07 07:08:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-07 07:08:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-07 07:08:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-07 07:08:34  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-07 07:08:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-07 07:08:43  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-07 07:08:48  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-07 07:08:53  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-07 07:08:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-07 07:09:01  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-07 07:09:06  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-07 07:09:11  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-07 07:09:15  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-07 07:09:20  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-07 07:09:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-07 07:09:29  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-07 07:09:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-07 07:09:39  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-07 07:09:43  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-07 07:09:48  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-07 07:09:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-07 07:09:57  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-07 07:10:02  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-07 07:10:07  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-07 07:10:12  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-07 07:10:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-07 07:10:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-07 07:10:26  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-07 07:10:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-07 07:10:36  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-07 07:10:40  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-07 07:10:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-07 07:10:49  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-07 07:10:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-07 07:10:59  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-07 07:11:03  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-07 07:11:07  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-07 07:11:12  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-07 07:11:17  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-07 07:11:21  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-07 07:11:25  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-07 07:11:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-07 07:11:35  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-07 07:11:39  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-07 07:11:44  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-07 07:11:48  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-07 07:11:53  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-07 07:11:57  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-07 07:12:02  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-07 07:12:07  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-07 07:12:11  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-07 07:12:15  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-07 07:12:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-07 07:12:25  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-07 07:12:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-07 07:12:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-07 07:12:38  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-07 07:12:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-07 07:12:47  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-07 07:12:52  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-07 07:12:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-07 07:13:01  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-07 07:13:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-07 07:13:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-07 07:13:15  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-07 07:13:20  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-07 07:13:24  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-07 07:13:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-07 07:13:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-07 07:13:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-07 07:13:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-07 07:13:47  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-07 07:13:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-07 07:13:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-07 07:14:00  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-07 07:14:05  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-07 07:14:09  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-07 07:14:13  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-07 07:14:18  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-07 07:14:22  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-07 07:14:27  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-07 07:14:31  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-07 07:14:36  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-07 07:14:40  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-07 07:14:45  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-07 07:14:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-07 07:14:54  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-07 07:14:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-07 07:15:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-07 07:15:09  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-07 07:15:09  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-07 07:15:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-07 07:15:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-07 07:15:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-07 07:15:27  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-07 07:15:32  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-07 07:15:36  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-07 07:15:41  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-07 07:15:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-07 07:15:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-07 07:15:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-07 07:15:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-07 07:16:03  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-07 07:16:07  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-07 07:16:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-07 07:16:17  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-07 07:16:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-07 07:16:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-07 07:16:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-07 07:16:35  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-07 07:16:39  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-07 07:16:44  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-07 07:16:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-07 07:16:52  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-07 07:16:57  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-07 07:17:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-07 07:17:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-07 07:17:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-07 07:17:15  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-07 07:17:19  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-07 07:17:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-07 07:17:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-07 07:17:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-07 07:17:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-07 07:17:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-07 07:17:44  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-07 07:17:48  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-07 07:17:52  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-07 07:17:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-07 07:18:00  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-07 07:18:04  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-07 07:18:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-07 07:18:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-07 07:18:18  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-07 07:18:22  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-07 07:18:26  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-07 07:18:30  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-07 07:18:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-07 07:18:39  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-07 07:18:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-07 07:18:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-07 07:18:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-07 07:18:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-07 07:19:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-07 07:19:06  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-07 07:19:10  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-07 07:19:15  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-07 07:19:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-07 07:19:25  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-07 07:19:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-07 07:19:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-07 07:19:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-07 07:19:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 07:19:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 07:19:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 07:19:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 07:19:58  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-07 07:20:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 07:20:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 07:20:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-07 07:20:17  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-07 07:20:21  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-07 07:20:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-07 07:20:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-07 07:20:34  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-07 07:20:38  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-07 07:20:42  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-07 07:20:46  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-07 07:20:50  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-07 07:20:54  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-07 07:20:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-07 07:21:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-07 07:21:07  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-07 07:21:11  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-07 07:21:16  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-07 07:21:20  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-07 07:21:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-07 07:21:28  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-07 07:21:32  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-07 07:21:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 07:21:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 07:21:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 07:21:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 07:21:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 07:21:56  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-07 07:22:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 07:22:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 07:22:08  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 07:22:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 07:22:16  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-07 07:22:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 07:22:24  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 07:22:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 07:22:32  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-07 07:22:36  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-07_07-31-54 Restart Xvfb...
2017-04-07_08-01-54 Restart Xvfb...
2017-04-07_08-31-54 Restart Xvfb...
2017-04-07_09-01-54 Restart Xvfb...
2017-04-07 09:31:46 reset updateRequest
2017-04-07 09:31:47  - 14968  http://www.lymphomahub.com/
2017-04-07 09:31:50  - 14968  http://www.lymphomahub.com/about
2017-04-07 09:31:51  - 14968  http://www.lymphomahub.com/about
2017-04-07_09-31-54 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-07 09:33:56  - 14968  http://www.lymphomahub.com/about
2017-04-07 09:33:56  - 14968  http://www.lymphomahub.com/about
2017-04-07 09:34:01  - 14968  http://www.lymphomahub.com/terms
2017-04-07 09:34:02  - 14968  http://www.lymphomahub.com/terms
2017-04-07 09:34:05  - 14968  http://www.lymphomahub.com/undefined
2017-04-07 09:34:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-07 09:34:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-07 09:34:16  - 14968  http://www.lymphomahub.com/newsletter
2017-04-07 09:34:16  - 14968  http://www.lymphomahub.com/newsletter
2017-04-07 09:34:20  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-07 09:34:20  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-07 09:34:24  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-07 09:34:25  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-07 09:34:30  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-07 09:34:30  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-07 09:34:36  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-07 09:34:40  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-07 09:34:45  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-07 09:34:49  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-07 09:34:54  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-07 09:34:58  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-07 09:35:03  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-07 09:35:08  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-07 09:35:13  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-07 09:35:17  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-07 09:35:22  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-07 09:35:26  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-07 09:35:31  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-07 09:35:36  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-07 09:35:40  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-07 09:35:45  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-07 09:35:50  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-07 09:35:54  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-07 09:35:59  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-07 09:36:02  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-07 09:36:07  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-07 09:36:11  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-07 09:36:16  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-07 09:36:20  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-07 09:36:25  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-07 09:36:30  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-07 09:36:34  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-07 09:36:38  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-07 09:36:43  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-07 09:36:47  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-07 09:36:52  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-07 09:36:56  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-07 09:37:01  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-07 09:37:05  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-07 09:37:10  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-07 09:37:14  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-07 09:37:18  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-07 09:37:23  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-07 09:37:28  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-07 09:37:32  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-07 09:37:37  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-07 09:37:41  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-07 09:37:46  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-07 09:37:50  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-07 09:37:55  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-07 09:37:59  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-07 09:38:04  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-07 09:38:08  - 14968  http://www.lymphomahub.com/medical-information
2017-04-07 09:38:12  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-07 09:38:17  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-07 09:38:21  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-07 09:38:26  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-07 09:38:30  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-07 09:38:35  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-07 09:38:39  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-07 09:38:44  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-07 09:38:48  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-07 09:38:53  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-07 09:38:57  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-07 09:39:02  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-07 09:39:03  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-07 09:39:07  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-07 09:39:12  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-07 09:39:16  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-07 09:39:21  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-07 09:39:25  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-07 09:39:29  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-07 09:39:34  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-07 09:39:39  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-07 09:39:44  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-07 09:39:49  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-07 09:39:53  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-07 09:39:58  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-07 09:40:03  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-07 09:40:07  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-07 09:40:12  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-07 09:40:17  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-07 09:40:21  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-07 09:40:25  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-07 09:40:30  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-07 09:40:34  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-07 09:40:39  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-07 09:40:43  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-07 09:40:48  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-07 09:40:52  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-07 09:40:57  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-07 09:41:01  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-07 09:41:05  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-07 09:41:10  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-07 09:41:14  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-07 09:41:19  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-07 09:41:19  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-07 09:41:24  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-07 09:41:28  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-07 09:41:33  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-07 09:41:37  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-07 09:41:42  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-07 09:41:47  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-07 09:41:51  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-07 09:41:56  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-07 09:41:59  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-07 09:42:00  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-07 09:42:04  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-07 09:42:09  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-07 09:42:13  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-07 09:42:18  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-07 09:42:22  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-07 09:42:23  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-07 09:42:27  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-07 09:42:32  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-07 09:42:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-07 09:42:40  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-07 09:42:45  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-07 09:42:49  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-07 09:42:52  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-07 09:42:56  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-07 09:43:00  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-07 09:43:05  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-07 09:43:09  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-07 09:43:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-07 09:43:18  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-07 09:43:22  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-07 09:43:22  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-07 09:43:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-07 09:43:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-07 09:43:36  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-07 09:43:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-07 09:43:44  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-07 09:43:49  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-07 09:43:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-07 09:43:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-07 09:44:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-07 09:44:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-07 09:44:08  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-07 09:44:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-07 09:44:16  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-07 09:44:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-07 09:44:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-07 09:44:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-07 09:44:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-07 09:44:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-07 09:44:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-07 09:44:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-07 09:44:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-07 09:44:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-07 09:44:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-07 09:45:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-07 09:45:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-07 09:45:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-07 09:45:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-07 09:45:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-07 09:45:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-07 09:45:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-07 09:45:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-07 09:45:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-07 09:45:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-07 09:45:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-07 09:45:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-07 09:45:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-07 09:46:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-07 09:46:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-07 09:46:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-07 09:46:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-07 09:46:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-07 09:46:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-07 09:46:28  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-07 09:46:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-07 09:46:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-07 09:46:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-07 09:46:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-07 09:46:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-07 09:46:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-07 09:46:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-07 09:47:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-07 09:47:08  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-07 09:47:13  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-07 09:47:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-07 09:47:21  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-07 09:47:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-07 09:47:30  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-07 09:47:34  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-07 09:47:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-07 09:47:43  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-07 09:47:47  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-07 09:47:51  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-07 09:47:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-07 09:48:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-07 09:48:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-07 09:48:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-07 09:48:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-07 09:48:17  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-07 09:48:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-07 09:48:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-07 09:48:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-07 09:48:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-07 09:48:41  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-07 09:48:42  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-07 09:48:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-07 09:48:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-07 09:48:56  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-07 09:49:01  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-07 09:49:05  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-07 09:49:10  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 09:49:15  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 09:49:19  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-07 09:49:24  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 09:49:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-07 09:49:34  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-07 09:49:38  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-07 09:49:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-07 09:49:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-07 09:49:52  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-07 09:49:57  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-07 09:50:01  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-07 09:50:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-07 09:50:11  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-07 09:50:20  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 09:50:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-07 09:50:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-07 09:50:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-07 09:50:39  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-07 09:50:43  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-07 09:50:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-07 09:50:52  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-07 09:50:57  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-07 09:51:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-07 09:51:06  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-07 09:51:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-07 09:51:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-07 09:51:21  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-07 09:51:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-07 09:51:31  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-07 09:51:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-07 09:51:40  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-07 09:51:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-07 09:51:49  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-07 09:51:54  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-07 09:51:59  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-07 09:51:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-07 09:52:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-07 09:52:08  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-07 09:52:13  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-07 09:52:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-07 09:52:22  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-07 09:52:27  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-07 09:52:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-07 09:52:36  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-07 09:52:41  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-07 09:52:46  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-07 09:52:52  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-07 09:52:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-07 09:53:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-07 09:53:12  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-07 09:53:17  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-07 09:53:21  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-07 09:53:26  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-07 09:53:31  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-07 09:53:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-07 09:53:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-07 09:53:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-07 09:53:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-07 09:53:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-07 09:53:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-07 09:54:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-07 09:54:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-07 09:54:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-07 09:54:14  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-07 09:54:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-07 09:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-07 09:54:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-07 09:54:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-07 09:54:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-07 09:54:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-07 09:54:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-07 09:54:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-07 09:54:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-07 09:54:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-07 09:54:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-07 09:54:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-07 09:55:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-07 09:55:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-07 09:55:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-07 09:55:14  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-07 09:55:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-07 09:55:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-07 09:55:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-07 09:55:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-07 09:55:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-07 09:55:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-07 09:55:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-07 09:55:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-07 09:55:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-07 09:55:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-07 09:55:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-07 09:56:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-07 09:56:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-07 09:56:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-07 09:56:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-07 09:56:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-07 09:56:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-07 09:56:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-07 09:56:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-07 09:56:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-07 09:56:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-07 09:56:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-07 09:56:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-07 09:56:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-07 09:56:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-07 09:56:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-07 09:56:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-07 09:57:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-07 09:57:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-07 09:57:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-07 09:57:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-07 09:57:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-07 09:57:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-07 09:57:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-07 09:57:29  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-07 09:57:33  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-07 09:57:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-07 09:57:43  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-07 09:57:44  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-07 09:57:48  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-07 09:57:53  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-07 09:57:58  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-07 09:58:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-07 09:58:07  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-07 09:58:12  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-07 09:58:16  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-07 09:58:21  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-07 09:58:26  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-07 09:58:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-07 09:58:36  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-07 09:58:40  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-07 09:58:45  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-07 09:58:49  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-07 09:58:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-07 09:58:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-07 09:59:03  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-07 09:59:08  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-07 09:59:12  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-07 09:59:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-07 09:59:23  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-07 09:59:27  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-07 09:59:32  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-07 09:59:36  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-07 09:59:41  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-07 09:59:45  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-07 09:59:50  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-07 09:59:55  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-07 09:59:59  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-07 10:00:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-07 10:00:12  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-07 10:00:16  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-07 10:00:21  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-07 10:00:26  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-07 10:00:30  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-07 10:00:35  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-07 10:00:39  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-07 10:00:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-07 10:00:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-07 10:00:56  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-07 10:01:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-07 10:01:05  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-07 10:01:10  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-07 10:01:15  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-07 10:01:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-07 10:01:24  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-07 10:01:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-07 10:01:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-07 10:01:38  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-07 10:01:43  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-07 10:01:48  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-07 10:01:52  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-07_10-01-54 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl?_prerender {"code":"ECONNRESET"}
2017-04-07 10:03:57  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-07 10:04:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-07 10:04:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-07 10:04:12  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-07 10:04:16  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-07 10:04:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-07 10:04:26  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-07 10:04:30  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-07 10:04:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-07 10:04:39  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-07 10:04:44  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-07 10:04:49  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-07 10:04:54  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-07 10:04:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-07 10:05:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-07 10:05:08  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-07 10:05:13  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-07 10:05:17  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-07 10:05:22  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-07 10:05:27  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-07 10:05:31  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-07 10:05:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-07 10:05:41  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-07 10:05:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-07 10:05:51  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-07 10:05:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-07 10:06:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-07 10:06:09  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-07 10:06:13  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-07 10:06:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-07 10:06:22  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-07 10:06:27  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-07 10:06:32  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-07 10:06:36  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-07 10:06:40  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-07 10:06:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-07 10:06:53  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-07 10:06:58  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-07 10:07:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-07 10:07:08  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-07 10:07:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-07 10:07:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-07 10:07:28  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-07 10:07:35  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-07 10:07:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-07 10:07:44  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-07 10:07:52  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-07 10:07:56  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-07 10:08:01  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-07 10:08:06  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-07 10:08:10  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-07 10:08:15  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-07 10:08:19  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-07 10:08:24  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-07 10:08:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-07 10:08:33  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-07 10:08:38  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-07 10:08:43  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-07 10:08:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-07 10:08:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-07 10:08:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-07 10:09:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-07 10:09:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-07 10:09:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-07 10:09:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-07 10:09:20  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-07 10:09:25  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-07 10:09:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-07 10:09:34  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-07 10:09:39  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-07 10:09:44  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-07 10:09:49  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-07 10:09:53  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-07 10:09:58  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-07 10:10:02  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-07 10:10:07  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-07 10:10:12  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-07 10:10:16  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-07 10:10:22  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-07 10:10:27  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-07 10:10:31  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-07 10:10:36  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-07 10:10:41  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-07 10:10:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-07 10:10:50  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-07 10:10:55  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-07 10:11:00  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-07 10:11:04  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-07 10:11:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-07 10:11:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-07 10:11:18  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-07 10:11:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-07 10:11:28  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-07 10:11:32  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-07 10:11:37  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-07 10:11:41  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-07 10:11:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-07 10:11:51  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-07 10:11:56  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-07 10:12:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-07 10:12:04  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-07 10:12:09  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-07 10:12:13  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-07 10:12:18  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-07 10:12:22  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-07 10:12:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-07 10:12:32  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-07 10:12:36  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-07 10:12:41  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-07 10:12:45  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-07 10:12:50  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-07 10:12:55  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-07 10:13:00  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-07 10:13:04  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-07 10:13:09  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-07 10:13:13  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-07 10:13:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-07 10:13:23  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-07 10:13:27  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-07 10:13:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-07 10:13:37  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-07 10:13:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-07 10:13:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-07 10:13:50  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-07 10:13:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-07 10:13:59  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-07 10:14:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-07 10:14:08  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-07 10:14:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-07 10:14:17  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-07 10:14:21  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-07 10:14:26  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-07 10:14:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-07 10:14:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-07 10:14:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-07 10:14:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-07 10:14:50  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-07 10:14:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-07 10:14:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-07 10:15:04  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-07 10:15:09  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-07 10:15:13  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-07 10:15:17  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-07 10:15:22  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-07 10:15:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-07 10:15:31  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-07 10:15:35  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-07 10:15:40  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-07 10:15:44  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-07 10:15:49  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-07 10:15:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-07 10:15:58  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-07 10:16:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-07 10:16:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-07 10:16:12  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-07 10:16:13  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-07 10:16:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-07 10:16:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-07 10:16:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-07 10:16:31  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-07 10:16:36  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-07 10:16:41  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-07 10:16:46  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-07 10:16:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-07 10:16:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-07 10:16:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-07 10:17:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-07 10:17:08  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-07 10:17:12  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-07 10:17:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-07 10:17:21  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-07 10:17:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-07 10:17:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-07 10:17:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-07 10:17:39  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-07 10:17:45  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-07 10:17:50  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-07 10:17:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-07 10:17:59  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-07 10:18:03  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-07 10:18:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-07 10:18:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-07 10:18:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-07 10:18:22  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-07 10:18:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-07 10:18:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-07 10:18:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-07 10:18:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-07 10:18:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-07 10:18:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-07 10:18:53  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-07 10:18:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-07 10:19:01  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-07 10:19:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-07 10:19:09  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-07 10:19:13  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-07 10:19:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-07 10:19:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-07 10:19:27  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-07 10:19:31  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-07 10:19:35  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-07 10:19:39  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-07 10:19:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-07 10:19:48  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-07 10:19:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-07 10:19:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-07 10:20:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-07 10:20:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-07 10:20:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-07 10:20:16  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-07 10:20:20  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-07 10:20:24  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-07 10:20:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-07 10:20:33  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-07 10:20:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-07 10:20:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-07 10:20:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-07 10:20:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 10:20:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 10:20:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 10:21:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 10:21:07  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-07 10:21:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 10:21:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 10:21:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-07 10:21:23  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-07 10:21:27  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-07 10:21:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-07 10:21:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-07 10:21:39  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-07 10:21:43  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-07 10:21:47  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-07 10:21:51  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-07 10:21:55  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-07 10:22:00  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-07 10:22:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-07 10:22:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-07 10:22:13  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-07 10:22:17  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-07 10:22:21  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-07 10:22:25  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-07 10:22:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-07 10:22:33  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-07 10:22:37  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-07 10:22:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 10:22:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 10:22:49  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 10:22:53  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 10:22:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 10:23:02  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-07 10:23:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 10:23:10  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 10:23:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 10:23:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 10:23:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-07 10:23:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 10:23:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 10:23:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 10:23:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-07 10:23:44  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-07_10-31-55 Restart Xvfb...
2017-04-07_11-01-55 Restart Xvfb...
2017-04-07_11-31-55 Restart Xvfb...
2017-04-07_12-01-55 Restart Xvfb...
2017-04-07 12:31:46 reset updateRequest
2017-04-07 12:31:49  - 14968  http://www.lymphomahub.com/
2017-04-07 12:31:51  - 14968  http://www.lymphomahub.com/
2017-04-07 12:31:54  - 14968  http://www.lymphomahub.com/about
2017-04-07_12-31-55 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-07 12:33:56  - 14968  http://www.lymphomahub.com/about
2017-04-07 12:33:59  - 14968  http://www.lymphomahub.com/about
2017-04-07 12:34:02  - 14968  http://www.lymphomahub.com/terms
2017-04-07 12:34:04  - 14968  http://www.lymphomahub.com/terms
2017-04-07 12:34:06  - 14968  http://www.lymphomahub.com/undefined
2017-04-07 12:34:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-07 12:34:07  - 14968  http://www.lymphomahub.com/therapies
2017-04-07 12:34:16  - 14968  http://www.lymphomahub.com/newsletter
2017-04-07 12:34:17  - 14968  http://www.lymphomahub.com/newsletter
2017-04-07 12:34:20  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-07 12:34:21  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-07 12:34:25  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-07 12:34:25  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-07 12:34:30  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-07 12:34:30  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-07 12:34:36  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-07 12:34:41  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-07 12:34:45  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-07 12:34:50  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-07 12:34:54  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-07 12:34:59  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-07 12:35:04  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-07 12:35:08  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-07 12:35:13  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-07 12:35:18  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-07 12:35:22  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-07 12:35:27  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-07 12:35:31  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-07 12:35:36  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-07 12:35:40  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-07 12:35:45  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-07 12:35:49  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-07 12:35:54  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-07 12:35:58  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-07 12:36:02  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-07 12:36:07  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-07 12:36:11  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-07 12:36:16  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-07 12:36:20  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-07 12:36:25  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-07 12:36:30  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-07 12:36:34  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-07 12:36:39  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-07 12:36:43  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-07 12:36:48  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-07 12:36:52  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-07 12:36:56  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-07 12:37:01  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-07 12:37:05  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-07 12:37:10  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-07 12:37:16  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-07 12:37:20  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-07 12:37:25  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-07 12:37:29  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-07 12:37:34  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-07 12:37:39  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-07 12:37:43  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-07 12:37:47  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-07 12:37:52  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-07 12:37:56  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-07 12:38:01  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-07 12:38:06  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-07 12:38:10  - 14968  http://www.lymphomahub.com/medical-information
2017-04-07 12:38:15  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-07 12:38:20  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-07 12:38:24  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-07 12:38:28  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-07 12:38:33  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-07 12:38:37  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-07 12:38:42  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-07 12:38:46  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-07 12:38:51  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-07 12:38:55  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-07 12:39:00  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-07 12:39:04  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-07 12:39:05  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-07 12:39:10  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-07 12:39:14  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-07 12:39:18  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-07 12:39:23  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-07 12:39:27  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-07 12:39:32  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-07 12:39:36  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-07 12:39:41  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-07 12:39:45  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-07 12:39:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-07 12:39:54  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-07 12:39:59  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-07 12:40:03  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-07 12:40:08  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-07 12:40:13  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-07 12:40:16  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-07 12:40:21  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-07 12:40:25  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-07 12:40:30  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-07 12:40:34  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-07 12:40:38  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-07 12:40:43  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-07 12:40:46  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-07 12:40:51  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-07 12:40:56  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-07 12:41:00  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-07 12:41:08  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-07 12:41:12  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-07 12:41:17  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-07 12:41:22  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-07 12:41:22  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-07 12:41:27  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-07 12:41:31  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-07 12:41:37  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-07 12:41:42  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-07 12:41:46  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-07 12:41:51  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-07 12:41:55  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-07 12:42:00  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-07 12:42:04  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-07 12:42:05  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-07 12:42:09  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-07 12:42:14  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-07 12:42:18  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-07 12:42:23  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-07 12:42:27  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-07 12:42:28  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-07 12:42:32  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-07 12:42:36  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-07 12:42:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-07 12:42:45  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-07 12:42:49  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-07 12:42:53  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-07 12:42:57  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-07 12:43:00  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-07 12:43:04  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-07 12:43:09  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-07 12:43:13  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-07 12:43:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-07 12:43:22  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-07 12:43:26  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-07 12:43:26  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-07 12:43:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-07 12:43:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-07 12:43:40  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-07 12:43:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-07 12:43:48  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-07 12:43:53  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-07 12:43:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-07 12:44:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-07 12:44:05  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-07 12:44:08  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-07 12:44:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-07 12:44:16  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-07 12:44:20  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-07 12:44:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-07 12:44:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-07 12:44:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-07 12:44:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-07 12:44:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-07 12:44:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-07 12:44:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-07 12:44:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-07 12:45:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-07 12:45:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-07 12:45:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-07 12:45:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-07 12:45:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-07 12:45:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-07 12:45:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-07 12:45:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-07 12:45:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-07 12:45:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-07 12:45:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-07 12:45:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-07 12:45:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-07 12:45:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-07 12:46:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-07 12:46:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-07 12:46:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-07 12:46:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-07 12:46:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-07 12:46:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-07 12:46:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-07 12:46:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-07 12:46:38  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-07 12:46:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-07 12:46:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-07 12:46:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-07 12:46:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-07 12:47:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-07 12:47:05  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-07 12:47:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-07 12:47:13  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-07 12:47:17  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-07 12:47:22  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-07 12:47:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-07 12:47:30  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-07 12:47:35  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-07 12:47:39  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-07 12:47:44  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-07 12:47:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-07 12:47:53  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-07 12:47:57  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-07 12:48:00  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-07 12:48:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-07 12:48:09  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-07 12:48:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-07 12:48:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-07 12:48:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-07 12:48:27  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-07 12:48:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-07 12:48:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-07 12:48:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-07 12:48:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-07 12:48:51  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-07 12:48:52  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-07 12:48:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-07 12:49:01  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-07 12:49:05  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-07 12:49:10  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-07 12:49:17  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-07 12:49:21  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 12:49:26  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 12:49:30  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-07 12:49:35  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 12:49:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-07 12:49:45  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-07 12:49:49  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-07 12:49:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-07 12:49:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-07 12:50:04  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-07 12:50:09  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-07 12:50:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-07 12:50:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-07 12:50:23  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-07 12:50:27  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 12:50:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-07 12:50:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-07 12:50:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-07 12:50:46  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-07 12:50:51  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-07 12:50:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-07 12:51:00  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-07 12:51:05  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-07 12:51:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-07 12:51:14  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-07 12:51:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-07 12:51:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-07 12:51:29  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-07 12:51:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-07 12:51:38  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-07 12:51:43  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-07 12:51:47  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-07 12:51:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-07 12:51:56  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-07 12:52:03  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-07 12:52:07  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-07 12:52:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-07 12:52:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-07 12:52:17  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-07 12:52:22  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-07 12:52:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-07 12:52:32  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-07 12:52:37  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-07 12:52:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-07 12:52:46  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-07 12:52:51  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-07 12:52:56  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-07 12:53:00  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-07 12:53:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-07 12:53:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-07 12:53:14  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-07 12:53:19  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-07 12:53:24  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-07 12:53:28  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-07 12:53:34  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-07 12:53:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-07 12:53:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-07 12:53:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-07 12:53:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-07 12:53:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-07 12:54:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-07 12:54:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-07 12:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-07 12:54:12  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-07 12:54:17  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-07 12:54:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-07 12:54:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-07 12:54:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-07 12:54:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-07 12:54:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-07 12:54:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-07 12:54:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-07 12:54:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-07 12:54:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-07 12:54:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-07 12:54:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-07 12:55:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-07 12:55:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-07 12:55:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-07 12:55:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-07 12:55:15  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-07 12:55:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-07 12:55:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-07 12:55:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-07 12:55:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-07 12:55:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-07 12:55:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-07 12:55:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-07 12:55:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-07 12:55:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-07 12:55:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-07 12:55:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-07 12:56:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-07 12:56:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-07 12:56:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-07 12:56:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-07 12:56:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-07 12:56:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-07 12:56:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-07 12:56:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-07 12:56:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-07 12:56:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-07 12:56:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-07 12:56:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-07 12:56:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-07 12:56:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-07 12:56:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-07 12:56:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-07 12:57:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-07 12:57:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-07 12:57:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-07 12:57:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-07 12:57:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-07 12:57:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-07 12:57:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-07 12:57:27  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-07 12:57:32  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-07 12:57:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-07 12:57:42  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-07 12:57:42  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-07 12:57:47  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-07 12:57:52  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-07 12:57:57  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-07 12:58:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-07 12:58:06  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-07 12:58:11  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-07 12:58:16  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-07 12:58:20  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-07 12:58:25  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-07 12:58:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-07 12:58:35  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-07 12:58:39  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-07 12:58:44  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-07 12:58:49  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-07 12:58:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-07 12:58:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-07 12:59:02  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-07 12:59:07  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-07 12:59:12  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-07 12:59:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-07 12:59:21  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-07 12:59:26  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-07 12:59:31  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-07 12:59:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-07 12:59:40  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-07 12:59:44  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-07 12:59:49  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-07 12:59:53  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-07 12:59:58  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-07 13:00:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-07 13:00:08  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-07 13:00:12  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-07 13:00:17  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-07 13:00:22  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-07 13:00:26  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-07 13:00:31  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-07 13:00:36  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-07 13:00:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-07 13:00:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-07 13:00:53  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-07 13:00:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-07 13:01:03  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-07 13:01:07  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-07 13:01:12  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-07 13:01:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-07 13:01:24  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-07 13:01:28  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-07 13:01:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-07 13:01:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-07 13:01:44  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-07 13:01:49  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-07 13:01:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-07_13-01-55 Restart Xvfb...
2017-04-07 13:02:00  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-07 13:02:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-07 13:02:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-07 13:02:17  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-07 13:02:22  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-07 13:02:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-07 13:02:31  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-07 13:02:39  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-07 13:02:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-07 13:02:48  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-07 13:02:53  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-07 13:02:58  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-07 13:03:05  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-07 13:03:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-07 13:03:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-07 13:03:20  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-07 13:03:27  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-07 13:03:32  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-07 13:03:36  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-07 13:03:42  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-07 13:03:48  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-07 13:03:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-07 13:04:00  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-07 13:04:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-07 13:04:09  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-07 13:04:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-07 13:04:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-07 13:04:24  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-07 13:04:28  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-07 13:04:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-07 13:04:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-07 13:04:42  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-07 13:04:47  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-07 13:04:52  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-07 13:04:56  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-07 13:05:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-07 13:05:05  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-07 13:05:10  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-07 13:05:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-07 13:05:19  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-07 13:05:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-07 13:05:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-07 13:05:33  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-07 13:05:39  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-07 13:05:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-07 13:05:48  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-07 13:05:53  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-07 13:05:57  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-07 13:06:02  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-07 13:06:07  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-07 13:06:12  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-07 13:06:16  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-07 13:06:21  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-07 13:06:26  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-07 13:06:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-07 13:06:35  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-07 13:06:40  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-07 13:06:44  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-07 13:06:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-07 13:06:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-07 13:06:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-07 13:07:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-07 13:07:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-07 13:07:12  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-07 13:07:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-07 13:07:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-07 13:07:26  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-07 13:07:31  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-07 13:07:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-07 13:07:40  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-07 13:07:45  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-07 13:07:49  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-07 13:07:54  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-07 13:07:58  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-07 13:08:02  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-07 13:08:07  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-07 13:08:12  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-07 13:08:16  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-07 13:08:21  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-07 13:08:26  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-07 13:08:31  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-07 13:08:35  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-07 13:08:40  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-07 13:08:45  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-07 13:08:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-07 13:08:54  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-07 13:08:59  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-07 13:09:04  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-07 13:09:08  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-07 13:09:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-07 13:09:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-07 13:09:22  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-07 13:09:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-07 13:09:31  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-07 13:09:36  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-07 13:09:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-07 13:09:45  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-07 13:09:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-07 13:09:54  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-07 13:09:59  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-07 13:10:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-07 13:10:11  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-07 13:10:15  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-07 13:10:19  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-07 13:10:24  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-07 13:10:29  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-07 13:10:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-07 13:10:38  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-07 13:10:42  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-07 13:10:47  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-07 13:10:51  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-07 13:10:56  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-07 13:11:00  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-07 13:11:05  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-07 13:11:10  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-07 13:11:14  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-07 13:11:18  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-07 13:11:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-07 13:11:27  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-07 13:11:32  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-07 13:11:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-07 13:11:41  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-07 13:11:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-07 13:11:50  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-07 13:11:56  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-07 13:12:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-07 13:12:04  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-07 13:12:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-07 13:12:13  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-07 13:12:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-07 13:12:23  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-07 13:12:27  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-07 13:12:31  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-07 13:12:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-07 13:12:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-07 13:12:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-07 13:12:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-07 13:12:54  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-07 13:12:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-07 13:13:04  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-07 13:13:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-07 13:13:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-07 13:13:18  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-07 13:13:23  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-07 13:13:27  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-07 13:13:31  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-07 13:13:36  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-07 13:13:41  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-07 13:13:45  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-07 13:13:50  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-07 13:13:55  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-07 13:13:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-07 13:14:04  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-07 13:14:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-07 13:14:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-07 13:14:18  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-07 13:14:18  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-07 13:14:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-07 13:14:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-07 13:14:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-07 13:14:37  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-07 13:14:41  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-07 13:14:46  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-07 13:14:51  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-07 13:14:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-07 13:14:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-07 13:15:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-07 13:15:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-07 13:15:14  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-07 13:15:18  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-07 13:15:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-07 13:15:28  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-07 13:15:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-07 13:15:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-07 13:15:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-07 13:15:46  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-07 13:15:50  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-07 13:15:55  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-07 13:15:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-07 13:16:04  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-07 13:16:09  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-07 13:16:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-07 13:16:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-07 13:16:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-07 13:16:26  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-07 13:16:34  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-07 13:16:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-07 13:16:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-07 13:16:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-07 13:16:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-07 13:16:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-07 13:16:59  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-07 13:17:06  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-07 13:17:11  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-07 13:17:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-07 13:17:20  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-07 13:17:24  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-07 13:17:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-07 13:17:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-07 13:17:38  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-07 13:17:42  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-07 13:17:46  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-07 13:17:50  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-07 13:17:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-07 13:17:58  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-07 13:18:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-07 13:18:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-07 13:18:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-07 13:18:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-07 13:18:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-07 13:18:26  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-07 13:18:30  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-07 13:18:34  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-07 13:18:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-07 13:18:42  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-07 13:18:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-07 13:18:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-07 13:18:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-07 13:18:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 13:19:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 13:19:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 13:19:12  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 13:19:16  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-07 13:19:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 13:19:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 13:19:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-07 13:19:32  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-07 13:19:36  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-07 13:19:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-07 13:19:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-07 13:19:49  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-07 13:19:53  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-07 13:19:57  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-07 13:20:01  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-07 13:20:05  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-07 13:20:09  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-07 13:20:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-07 13:20:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-07 13:20:22  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-07 13:20:26  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-07 13:20:30  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-07 13:20:34  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-07 13:20:38  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-07 13:20:42  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-07 13:20:46  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-07 13:20:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 13:20:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 13:20:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 13:21:05  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 13:21:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 13:21:13  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-07 13:21:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 13:21:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 13:21:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 13:21:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 13:21:34  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-07 13:21:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 13:21:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 13:21:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 13:21:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-07 13:21:55  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-07_13-31-55 Restart Xvfb...
2017-04-07_14-01-55 Restart Xvfb...
2017-04-07_14-31-55 Restart Xvfb...
2017-04-07_15-01-55 Restart Xvfb...
2017-04-07 15:31:46 reset updateRequest
2017-04-07 15:31:46  - 14968  http://www.lymphomahub.com/
2017-04-07 15:31:50  - 14968  http://www.lymphomahub.com/about
2017-04-07 15:31:51  - 14968  http://www.lymphomahub.com/about
2017-04-07 15:31:54  - 14968  http://www.lymphomahub.com/terms
2017-04-07_15-31-55 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/terms?_prerender {"code":"ECONNRESET"}
2017-04-07 15:33:56  - 14968  http://www.lymphomahub.com/terms
2017-04-07 15:33:59  - 14968  http://www.lymphomahub.com/undefined
2017-04-07 15:33:59  - 14968  http://www.lymphomahub.com/undefined
2017-04-07 15:34:00  - 14968  http://www.lymphomahub.com/therapies
2017-04-07 15:34:00  - 14968  http://www.lymphomahub.com/therapies
2017-04-07 15:34:12  - 14968  http://www.lymphomahub.com/newsletter
2017-04-07 15:34:14  - 14968  http://www.lymphomahub.com/newsletter
2017-04-07 15:34:16  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-07 15:34:18  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-07 15:34:20  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-07 15:34:21  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-07 15:34:25  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-07 15:34:26  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-07 15:34:30  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-07 15:34:31  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-07 15:34:35  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-07 15:34:40  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-07 15:34:44  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-07 15:34:49  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-07 15:34:53  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-07 15:34:58  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-07 15:35:02  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-07 15:35:07  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-07 15:35:12  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-07 15:35:16  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-07 15:35:24  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-07 15:35:28  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-07 15:35:33  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-07 15:35:37  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-07 15:35:41  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-07 15:35:49  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-07 15:35:53  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-07 15:35:58  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-07 15:36:02  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-07 15:36:06  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-07 15:36:11  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-07 15:36:15  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-07 15:36:19  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-07 15:36:24  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-07 15:36:28  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-07 15:36:33  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-07 15:36:38  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-07 15:36:44  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-07 15:36:48  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-07 15:36:53  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-07 15:36:57  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-07 15:37:02  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-07 15:37:06  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-07 15:37:11  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-07 15:37:15  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-07 15:37:20  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-07 15:37:24  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-07 15:37:29  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-07 15:37:33  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-07 15:37:38  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-07 15:37:42  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-07 15:37:47  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-07 15:37:51  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-07 15:37:55  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-07 15:38:00  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-07 15:38:04  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-07 15:38:09  - 14968  http://www.lymphomahub.com/medical-information
2017-04-07 15:38:13  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-07 15:38:17  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-07 15:38:22  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-07 15:38:27  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-07 15:38:31  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-07 15:38:35  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-07 15:38:40  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-07 15:38:44  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-07 15:38:49  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-07 15:38:53  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-07 15:38:58  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-07 15:39:02  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-07 15:39:03  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-07 15:39:07  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-07 15:39:12  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-07 15:39:16  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-07 15:39:20  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-07 15:39:25  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-07 15:39:29  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-07 15:39:33  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-07 15:39:38  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-07 15:39:43  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-07 15:39:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-07 15:39:52  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-07 15:39:56  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-07 15:40:00  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-07 15:40:05  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-07 15:40:09  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-07 15:40:17  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-07 15:40:21  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-07 15:40:26  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-07 15:40:30  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-07 15:40:34  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-07 15:40:39  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-07 15:40:43  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-07 15:40:48  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-07 15:40:52  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-07 15:40:57  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-07 15:41:01  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-07 15:41:05  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-07 15:41:10  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-07 15:41:14  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-07 15:41:19  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-07 15:41:19  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-07 15:41:24  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-07 15:41:28  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-07 15:41:33  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-07 15:41:37  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-07 15:41:41  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-07 15:41:46  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-07 15:41:50  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-07 15:41:55  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-07 15:41:58  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-07 15:41:59  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-07 15:42:03  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-07 15:42:07  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-07 15:42:12  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-07 15:42:16  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-07 15:42:21  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-07 15:42:22  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-07 15:42:26  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-07 15:42:31  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-07 15:42:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-07 15:42:39  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-07 15:42:44  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-07 15:42:47  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-07 15:42:51  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-07 15:42:55  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-07 15:42:59  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-07 15:43:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-07 15:43:08  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-07 15:43:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-07 15:43:17  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-07 15:43:20  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-07 15:43:21  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-07 15:43:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-07 15:43:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-07 15:43:35  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-07 15:43:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-07 15:43:44  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-07 15:43:48  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-07 15:43:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-07 15:43:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-07 15:44:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-07 15:44:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-07 15:44:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-07 15:44:11  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-07 15:44:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-07 15:44:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-07 15:44:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-07 15:44:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-07 15:44:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-07 15:44:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-07 15:44:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-07 15:44:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-07 15:44:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-07 15:44:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-07 15:44:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-07 15:45:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-07 15:45:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-07 15:45:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-07 15:45:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-07 15:45:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-07 15:45:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-07 15:45:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-07 15:45:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-07 15:45:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-07 15:45:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-07 15:45:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-07 15:45:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-07 15:45:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-07 15:46:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-07 15:46:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-07 15:46:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-07 15:46:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-07 15:46:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-07 15:46:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-07 15:46:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-07 15:46:32  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-07 15:46:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-07 15:46:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-07 15:46:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-07 15:46:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-07 15:46:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-07 15:46:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-07 15:47:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-07 15:47:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-07 15:47:10  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-07 15:47:15  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-07 15:47:20  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-07 15:47:23  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-07 15:47:28  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-07 15:47:32  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-07 15:47:36  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-07 15:47:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-07 15:47:45  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-07 15:47:48  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-07 15:47:53  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-07 15:47:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-07 15:48:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-07 15:48:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-07 15:48:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-07 15:48:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-07 15:48:18  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-07 15:48:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-07 15:48:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-07 15:48:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-07 15:48:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-07 15:48:41  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-07 15:48:42  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-07 15:48:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-07 15:48:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-07 15:48:56  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-07 15:49:00  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-07 15:49:05  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-07 15:49:10  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 15:49:14  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 15:49:19  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-07 15:49:23  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 15:49:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-07 15:49:33  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-07 15:49:37  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-07 15:49:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-07 15:49:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-07 15:49:50  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-07 15:49:55  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-07 15:50:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-07 15:50:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-07 15:50:09  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-07 15:50:14  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 15:50:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-07 15:50:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-07 15:50:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-07 15:50:33  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-07 15:50:37  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-07 15:50:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-07 15:50:47  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-07 15:50:51  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-07 15:50:56  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-07 15:51:01  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-07 15:51:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-07 15:51:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-07 15:51:14  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-07 15:51:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-07 15:51:23  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-07 15:51:28  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-07 15:51:33  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-07 15:51:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-07 15:51:42  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-07 15:51:46  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-07 15:51:51  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-07 15:51:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-07 15:51:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-07 15:52:01  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-07 15:52:06  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-07 15:52:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-07 15:52:15  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-07 15:52:19  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-07 15:52:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-07 15:52:29  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-07 15:52:33  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-07 15:52:38  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-07 15:52:43  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-07 15:52:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-07 15:52:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-07 15:52:58  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-07 15:53:03  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-07 15:53:07  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-07 15:53:12  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-07 15:53:16  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-07 15:53:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-07 15:53:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-07 15:53:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-07 15:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-07 15:53:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-07 15:53:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-07 15:53:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-07 15:53:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-07 15:53:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-07 15:54:00  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-07 15:54:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-07 15:54:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-07 15:54:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-07 15:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-07 15:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-07 15:54:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-07 15:54:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-07 15:54:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-07 15:54:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-07 15:54:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-07 15:54:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-07 15:54:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-07 15:54:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-07 15:54:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-07 15:54:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-07 15:54:58  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-07 15:55:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-07 15:55:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-07 15:55:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-07 15:55:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-07 15:55:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-07 15:55:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-07 15:55:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-07 15:55:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-07 15:55:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-07 15:55:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-07 15:55:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-07 15:55:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-07 15:55:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-07 15:55:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-07 15:55:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-07 15:55:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-07 15:56:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-07 15:56:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-07 15:56:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-07 15:56:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-07 15:56:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-07 15:56:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-07 15:56:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-07 15:56:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-07 15:56:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-07 15:56:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-07 15:56:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-07 15:56:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-07 15:56:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-07 15:56:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-07 15:56:52  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-07 15:56:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-07 15:57:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-07 15:57:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-07 15:57:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-07 15:57:12  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-07 15:57:17  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-07 15:57:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-07 15:57:27  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-07 15:57:27  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-07 15:57:32  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-07 15:57:37  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-07 15:57:41  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-07 15:57:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-07 15:57:51  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-07 15:57:55  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-07 15:58:00  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-07 15:58:05  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-07 15:58:10  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-07 15:58:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-07 15:58:20  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-07 15:58:25  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-07 15:58:29  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-07 15:58:34  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-07 15:58:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-07 15:58:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-07 15:58:48  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-07 15:58:52  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-07 15:58:57  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-07 15:59:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-07 15:59:06  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-07 15:59:11  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-07 15:59:16  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-07 15:59:20  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-07 15:59:25  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-07 15:59:29  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-07 15:59:34  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-07 15:59:38  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-07 15:59:43  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-07 15:59:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-07 15:59:53  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-07 15:59:57  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-07 16:00:02  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-07 16:00:07  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-07 16:00:14  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-07 16:00:19  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-07 16:00:24  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-07 16:00:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-07 16:00:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-07 16:00:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-07 16:00:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-07 16:00:48  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-07 16:00:55  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-07 16:01:00  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-07 16:01:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-07 16:01:09  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-07 16:01:17  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-07 16:01:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-07 16:01:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-07 16:01:31  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-07 16:01:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-07 16:01:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-07 16:01:48  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-07 16:01:52  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-07_16-01-55 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl?_prerender {"code":"ECONNRESET"}
2017-04-07 16:03:57  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-07 16:04:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-07 16:04:06  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-07 16:04:11  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-07 16:04:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-07 16:04:20  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-07 16:04:24  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-07 16:04:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-07 16:04:34  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-07 16:04:39  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-07 16:04:44  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-07 16:04:48  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-07 16:04:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-07 16:04:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-07 16:05:02  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-07 16:05:07  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-07 16:05:12  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-07 16:05:17  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-07 16:05:21  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-07 16:05:26  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-07 16:05:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-07 16:05:36  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-07 16:05:41  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-07 16:05:45  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-07 16:05:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-07 16:05:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-07 16:05:59  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-07 16:06:04  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-07 16:06:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-07 16:06:13  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-07 16:06:18  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-07 16:06:22  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-07 16:06:27  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-07 16:06:31  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-07 16:06:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-07 16:06:40  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-07 16:06:45  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-07 16:06:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-07 16:06:55  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-07 16:07:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-07 16:07:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-07 16:07:09  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-07 16:07:14  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-07 16:07:19  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-07 16:07:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-07 16:07:28  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-07 16:07:33  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-07 16:07:37  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-07 16:07:42  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-07 16:07:47  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-07 16:07:51  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-07 16:07:56  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-07 16:08:00  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-07 16:08:06  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-07 16:08:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-07 16:08:15  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-07 16:08:20  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-07 16:08:25  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-07 16:08:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-07 16:08:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-07 16:08:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-07 16:08:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-07 16:08:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-07 16:08:53  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-07 16:08:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-07 16:09:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-07 16:09:07  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-07 16:09:12  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-07 16:09:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-07 16:09:21  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-07 16:09:25  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-07 16:09:30  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-07 16:09:35  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-07 16:09:39  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-07 16:09:43  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-07 16:09:48  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-07 16:09:52  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-07 16:09:57  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-07 16:10:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-07 16:10:06  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-07 16:10:11  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-07 16:10:16  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-07 16:10:21  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-07 16:10:25  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-07 16:10:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-07 16:10:35  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-07 16:10:39  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-07 16:10:44  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-07 16:10:48  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-07 16:10:53  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-07 16:10:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-07 16:11:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-07 16:11:07  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-07 16:11:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-07 16:11:16  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-07 16:11:21  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-07 16:11:25  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-07 16:11:30  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-07 16:11:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-07 16:11:39  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-07 16:11:44  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-07 16:11:48  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-07 16:11:53  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-07 16:11:57  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-07 16:12:01  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-07 16:12:06  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-07 16:12:11  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-07 16:12:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-07 16:12:20  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-07 16:12:24  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-07 16:12:29  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-07 16:12:33  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-07 16:12:38  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-07 16:12:43  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-07 16:12:47  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-07 16:12:52  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-07 16:12:57  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-07 16:13:01  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-07 16:13:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-07 16:13:10  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-07 16:13:15  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-07 16:13:20  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-07 16:13:24  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-07 16:13:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-07 16:13:33  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-07 16:13:38  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-07 16:13:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-07 16:13:47  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-07 16:13:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-07 16:13:56  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-07 16:14:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-07 16:14:05  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-07 16:14:10  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-07 16:14:14  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-07 16:14:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-07 16:14:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-07 16:14:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-07 16:14:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-07 16:14:36  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-07 16:14:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-07 16:14:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-07 16:14:50  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-07 16:14:54  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-07 16:14:58  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-07 16:15:03  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-07 16:15:08  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-07 16:15:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-07 16:15:16  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-07 16:15:20  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-07 16:15:27  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-07 16:15:31  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-07 16:15:36  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-07 16:15:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-07 16:15:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-07 16:15:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-07 16:15:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-07 16:15:59  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-07 16:16:00  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-07 16:16:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-07 16:16:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-07 16:16:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-07 16:16:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-07 16:16:22  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-07 16:16:27  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-07 16:16:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-07 16:16:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-07 16:16:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-07 16:16:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-07 16:16:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-07 16:16:53  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-07 16:16:57  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-07 16:17:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-07 16:17:07  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-07 16:17:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-07 16:17:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-07 16:17:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-07 16:17:25  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-07 16:17:31  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-07 16:17:35  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-07 16:17:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-07 16:17:44  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-07 16:17:48  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-07 16:17:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-07 16:17:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-07 16:18:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-07 16:18:06  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-07 16:18:11  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-07 16:18:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-07 16:18:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-07 16:18:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-07 16:18:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-07 16:18:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-07 16:18:37  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-07 16:18:41  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-07 16:18:45  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-07 16:18:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-07 16:18:53  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-07 16:18:57  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-07 16:19:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-07 16:19:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-07 16:19:10  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-07 16:19:14  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-07 16:19:18  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-07 16:19:22  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-07 16:19:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-07 16:19:32  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-07 16:19:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-07 16:19:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-07 16:19:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-07 16:19:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-07 16:19:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-07 16:19:59  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-07 16:20:03  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-07 16:20:07  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-07 16:20:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-07 16:20:16  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-07 16:20:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-07 16:20:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-07 16:20:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-07 16:20:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 16:20:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 16:20:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 16:20:48  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 16:20:53  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-07 16:20:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 16:21:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 16:21:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-07 16:21:09  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-07 16:21:13  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-07 16:21:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-07 16:21:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-07 16:21:26  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-07 16:21:31  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-07 16:21:35  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-07 16:21:39  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-07 16:21:43  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-07 16:21:47  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-07 16:21:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-07 16:21:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-07 16:22:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-07 16:22:04  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-07 16:22:08  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-07 16:22:12  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-07 16:22:16  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-07 16:22:20  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-07 16:22:24  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-07 16:22:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 16:22:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 16:22:37  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 16:22:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 16:22:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 16:22:49  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-07 16:22:53  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 16:22:57  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 16:23:02  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 16:23:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 16:23:10  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-07 16:23:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 16:23:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 16:23:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 16:23:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-07 16:23:30  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-07_16-31-55 Restart Xvfb...
2017-04-07_17-01-55 Restart Xvfb...
2017-04-07_17-31-55 Restart Xvfb...
2017-04-07_18-01-55 Restart Xvfb...
2017-04-07 18:31:46 reset updateRequest
2017-04-07 18:31:50  - 14968  http://www.lymphomahub.com/
2017-04-07 18:31:51  - 14968  http://www.lymphomahub.com/
2017-04-07_18-31-55 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-07 18:33:56  - 14968  http://www.lymphomahub.com/
2017-04-07 18:33:56  - 14968  http://www.lymphomahub.com/
2017-04-07 18:34:01  - 14968  http://www.lymphomahub.com/about
2017-04-07 18:34:01  - 14968  http://www.lymphomahub.com/about
2017-04-07 18:34:06  - 14968  http://www.lymphomahub.com/terms
2017-04-07 18:34:07  - 14968  http://www.lymphomahub.com/terms
2017-04-07 18:34:11  - 14968  http://www.lymphomahub.com/undefined
2017-04-07 18:34:11  - 14968  http://www.lymphomahub.com/therapies
2017-04-07 18:34:11  - 14968  http://www.lymphomahub.com/therapies
2017-04-07 18:34:21  - 14968  http://www.lymphomahub.com/newsletter
2017-04-07 18:34:21  - 14968  http://www.lymphomahub.com/newsletter
2017-04-07 18:34:25  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-07 18:34:26  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-07 18:34:29  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-07 18:34:30  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-07 18:34:35  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-07 18:34:35  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-07 18:34:40  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-07 18:34:45  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-07 18:34:51  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-07 18:34:56  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-07 18:35:01  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-07 18:35:05  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-07 18:35:10  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-07 18:35:14  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-07 18:35:19  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-07 18:35:23  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-07 18:35:28  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-07 18:35:32  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-07 18:35:37  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-07 18:35:41  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-07 18:35:45  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-07 18:35:50  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-07 18:35:54  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-07 18:35:59  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-07 18:36:04  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-07 18:36:08  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-07 18:36:11  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-07 18:36:16  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-07 18:36:21  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-07 18:36:25  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-07 18:36:30  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-07 18:36:34  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-07 18:36:38  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-07 18:36:43  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-07 18:36:47  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-07 18:36:52  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-07 18:36:56  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-07 18:37:01  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-07 18:37:05  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-07 18:37:09  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-07 18:37:14  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-07 18:37:18  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-07 18:37:23  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-07 18:37:27  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-07 18:37:32  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-07 18:37:36  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-07 18:37:40  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-07 18:37:45  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-07 18:37:50  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-07 18:37:54  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-07 18:37:59  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-07 18:38:03  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-07 18:38:08  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-07 18:38:12  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-07 18:38:16  - 14968  http://www.lymphomahub.com/medical-information
2017-04-07 18:38:21  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-07 18:38:26  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-07 18:38:30  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-07 18:38:34  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-07 18:38:39  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-07 18:38:43  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-07 18:38:48  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-07 18:38:53  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-07 18:38:57  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-07 18:39:01  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-07 18:39:06  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-07 18:39:10  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-07 18:39:11  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-07 18:39:16  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-07 18:39:20  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-07 18:39:24  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-07 18:39:29  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-07 18:39:33  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-07 18:39:38  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-07 18:39:42  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-07 18:39:47  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-07 18:39:51  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-07 18:39:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-07 18:40:00  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-07 18:40:05  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-07 18:40:12  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-07 18:40:17  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-07 18:40:23  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-07 18:40:27  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-07 18:40:32  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-07 18:40:36  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-07 18:40:40  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-07 18:40:45  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-07 18:40:49  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-07 18:40:54  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-07 18:40:58  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-07 18:41:02  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-07 18:41:07  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-07 18:41:11  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-07 18:41:16  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-07 18:41:21  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-07 18:41:25  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-07 18:41:29  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-07 18:41:30  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-07 18:41:34  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-07 18:41:39  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-07 18:41:43  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-07 18:41:48  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-07 18:41:52  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-07 18:41:57  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-07 18:42:01  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-07 18:42:06  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-07 18:42:11  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-07 18:42:11  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-07 18:42:16  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-07 18:42:21  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-07 18:42:25  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-07 18:42:30  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-07 18:42:34  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-07 18:42:35  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-07 18:42:39  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-07 18:42:44  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-07 18:42:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-07 18:42:52  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-07 18:42:57  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-07 18:43:01  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-07 18:43:04  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-07 18:43:08  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-07 18:43:12  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-07 18:43:17  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-07 18:43:21  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-07 18:43:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-07 18:43:29  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-07 18:43:33  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-07 18:43:34  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-07 18:43:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-07 18:43:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-07 18:43:47  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-07 18:43:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-07 18:43:55  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-07 18:44:00  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-07 18:44:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-07 18:44:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-07 18:44:11  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-07 18:44:15  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-07 18:44:19  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-07 18:44:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-07 18:44:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-07 18:44:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-07 18:44:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-07 18:44:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-07 18:44:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-07 18:44:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-07 18:44:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-07 18:44:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-07 18:45:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-07 18:45:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-07 18:45:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-07 18:45:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-07 18:45:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-07 18:45:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-07 18:45:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-07 18:45:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-07 18:45:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-07 18:45:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-07 18:45:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-07 18:45:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-07 18:45:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-07 18:45:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-07 18:46:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-07 18:46:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-07 18:46:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-07 18:46:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-07 18:46:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-07 18:46:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-07 18:46:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-07 18:46:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-07 18:46:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-07 18:46:41  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-07 18:46:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-07 18:46:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-07 18:46:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-07 18:46:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-07 18:47:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-07 18:47:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-07 18:47:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-07 18:47:15  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-07 18:47:18  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-07 18:47:23  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-07 18:47:28  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-07 18:47:32  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-07 18:47:36  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-07 18:47:40  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-07 18:47:45  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-07 18:47:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-07 18:47:53  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-07 18:47:57  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-07 18:48:01  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-07 18:48:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-07 18:48:10  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-07 18:48:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-07 18:48:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-07 18:48:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-07 18:48:27  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-07 18:48:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-07 18:48:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-07 18:48:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-07 18:48:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-07 18:48:50  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-07 18:48:51  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-07 18:48:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-07 18:49:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-07 18:49:04  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-07 18:49:09  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-07 18:49:14  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-07 18:49:18  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 18:49:23  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 18:49:27  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-07 18:49:32  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 18:49:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-07 18:49:41  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-07 18:49:45  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-07 18:49:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-07 18:49:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-07 18:49:59  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-07 18:50:04  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-07 18:50:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-07 18:50:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-07 18:50:18  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-07 18:50:22  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 18:50:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-07 18:50:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-07 18:50:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-07 18:50:41  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-07 18:50:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-07 18:50:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-07 18:50:54  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-07 18:50:59  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-07 18:51:03  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-07 18:51:08  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-07 18:51:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-07 18:51:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-07 18:51:22  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-07 18:51:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-07 18:51:32  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-07 18:51:37  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-07 18:51:41  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-07 18:51:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-07 18:51:51  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-07 18:51:55  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-07 18:52:00  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-07 18:52:01  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-07 18:52:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-07 18:52:10  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-07 18:52:15  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-07 18:52:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-07 18:52:24  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-07 18:52:28  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-07 18:52:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-07 18:52:37  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-07 18:52:42  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-07 18:52:47  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-07 18:52:51  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-07 18:52:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-07 18:53:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-07 18:53:05  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-07 18:53:10  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-07 18:53:14  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-07 18:53:19  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-07 18:53:24  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-07 18:53:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-07 18:53:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-07 18:53:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-07 18:53:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-07 18:53:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-07 18:53:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-07 18:53:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-07 18:53:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-07 18:54:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-07 18:54:08  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-07 18:54:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-07 18:54:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-07 18:54:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-07 18:54:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-07 18:54:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-07 18:54:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-07 18:54:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-07 18:54:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-07 18:54:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-07 18:54:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-07 18:54:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-07 18:54:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-07 18:54:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-07 18:55:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-07 18:55:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-07 18:55:09  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-07 18:55:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-07 18:55:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-07 18:55:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-07 18:55:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-07 18:55:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-07 18:55:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-07 18:55:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-07 18:55:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-07 18:55:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-07 18:55:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-07 18:55:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-07 18:55:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-07 18:55:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-07 18:56:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-07 18:56:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-07 18:56:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-07 18:56:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-07 18:56:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-07 18:56:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-07 18:56:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-07 18:56:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-07 18:56:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-07 18:56:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-07 18:56:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-07 18:56:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-07 18:56:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-07 18:56:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-07 18:56:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-07 18:56:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-07 18:57:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-07 18:57:05  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-07 18:57:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-07 18:57:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-07 18:57:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-07 18:57:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-07 18:57:25  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-07 18:57:30  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-07 18:57:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-07 18:57:39  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-07 18:57:40  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-07 18:57:45  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-07 18:57:49  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-07 18:57:54  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-07 18:57:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-07 18:58:03  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-07 18:58:08  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-07 18:58:12  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-07 18:58:17  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-07 18:58:22  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-07 18:58:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-07 18:58:31  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-07 18:58:36  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-07 18:58:40  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-07 18:58:45  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-07 18:58:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-07 18:58:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-07 18:58:59  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-07 18:59:04  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-07 18:59:08  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-07 18:59:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-07 18:59:17  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-07 18:59:22  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-07 18:59:26  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-07 18:59:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-07 18:59:36  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-07 18:59:41  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-07 18:59:45  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-07 18:59:50  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-07 18:59:54  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-07 18:59:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-07 19:00:04  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-07 19:00:08  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-07 19:00:13  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-07 19:00:18  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-07 19:00:22  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-07 19:00:27  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-07 19:00:31  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-07 19:00:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-07 19:00:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-07 19:00:45  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-07 19:00:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-07 19:00:55  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-07 19:00:59  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-07 19:01:04  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-07 19:01:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-07 19:01:13  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-07 19:01:17  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-07 19:01:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-07 19:01:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-07 19:01:31  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-07 19:01:36  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-07 19:01:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-07 19:01:45  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-07 19:01:50  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-07 19:01:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-07_19-01-55 Restart Xvfb...
2017-04-07 19:01:59  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-07 19:02:04  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-07 19:02:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-07 19:02:13  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-07 19:02:18  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-07 19:02:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-07 19:02:27  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-07 19:02:33  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-07 19:02:38  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-07 19:02:43  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-07 19:02:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-07 19:02:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-07 19:02:57  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-07 19:03:02  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-07 19:03:07  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-07 19:03:11  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-07 19:03:16  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-07 19:03:20  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-07 19:03:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-07 19:03:30  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-07 19:03:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-07 19:03:39  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-07 19:03:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-07 19:03:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-07 19:03:53  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-07 19:03:57  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-07 19:04:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-07 19:04:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-07 19:04:11  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-07 19:04:16  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-07 19:04:21  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-07 19:04:25  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-07 19:04:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-07 19:04:34  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-07 19:04:39  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-07 19:04:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-07 19:04:48  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-07 19:04:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-07 19:04:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-07 19:05:02  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-07 19:05:08  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-07 19:05:13  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-07 19:05:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-07 19:05:22  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-07 19:05:27  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-07 19:05:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-07 19:05:36  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-07 19:05:41  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-07 19:05:46  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-07 19:05:50  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-07 19:05:55  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-07 19:06:00  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-07 19:06:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-07 19:06:09  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-07 19:06:13  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-07 19:06:18  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-07 19:06:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-07 19:06:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-07 19:06:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-07 19:06:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-07 19:06:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-07 19:06:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-07 19:06:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-07 19:06:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-07 19:06:59  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-07 19:07:03  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-07 19:07:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-07 19:07:13  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-07 19:07:17  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-07 19:07:22  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-07 19:07:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-07 19:07:31  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-07 19:07:36  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-07 19:07:41  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-07 19:07:45  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-07 19:07:50  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-07 19:07:55  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-07 19:07:59  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-07 19:08:04  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-07 19:08:08  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-07 19:08:13  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-07 19:08:18  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-07 19:08:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-07 19:08:28  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-07 19:08:32  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-07 19:08:37  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-07 19:08:42  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-07 19:08:46  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-07 19:08:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-07 19:08:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-07 19:09:00  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-07 19:09:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-07 19:09:09  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-07 19:09:14  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-07 19:09:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-07 19:09:23  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-07 19:09:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-07 19:09:32  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-07 19:09:37  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-07 19:09:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-07 19:09:46  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-07 19:09:51  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-07 19:09:55  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-07 19:09:59  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-07 19:10:04  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-07 19:10:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-07 19:10:13  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-07 19:10:18  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-07 19:10:22  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-07 19:10:27  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-07 19:10:31  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-07 19:10:36  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-07 19:10:41  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-07 19:10:45  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-07 19:10:50  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-07 19:10:54  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-07 19:10:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-07 19:11:02  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-07 19:11:07  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-07 19:11:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-07 19:11:16  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-07 19:11:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-07 19:11:25  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-07 19:11:30  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-07 19:11:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-07 19:11:39  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-07 19:11:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-07 19:11:48  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-07 19:11:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-07 19:11:57  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-07 19:12:03  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-07 19:12:07  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-07 19:12:11  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-07 19:12:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-07 19:12:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-07 19:12:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-07 19:12:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-07 19:12:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-07 19:12:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-07 19:12:42  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-07 19:12:47  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-07 19:12:51  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-07 19:12:56  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-07 19:13:00  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-07 19:13:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-07 19:13:09  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-07 19:13:13  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-07 19:13:18  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-07 19:13:23  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-07 19:13:27  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-07 19:13:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-07 19:13:36  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-07 19:13:42  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-07 19:13:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-07 19:13:51  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-07 19:13:51  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-07 19:13:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-07 19:14:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-07 19:14:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-07 19:14:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-07 19:14:14  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-07 19:14:18  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-07 19:14:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-07 19:14:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-07 19:14:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-07 19:14:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-07 19:14:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-07 19:14:45  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-07 19:14:49  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-07 19:14:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-07 19:14:58  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-07 19:15:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-07 19:15:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-07 19:15:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-07 19:15:15  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-07 19:15:20  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-07 19:15:25  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-07 19:15:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-07 19:15:33  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-07 19:15:37  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-07 19:15:42  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-07 19:15:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-07 19:15:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-07 19:15:56  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-07 19:16:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-07 19:16:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-07 19:16:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-07 19:16:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-07 19:16:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-07 19:16:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-07 19:16:26  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-07 19:16:30  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-07 19:16:34  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-07 19:16:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-07 19:16:42  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-07 19:16:46  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-07 19:16:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-07 19:16:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-07 19:16:59  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-07 19:17:04  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-07 19:17:08  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-07 19:17:12  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-07 19:17:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-07 19:17:22  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-07 19:17:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-07 19:17:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-07 19:17:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-07 19:17:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-07 19:17:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-07 19:17:49  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-07 19:17:54  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-07 19:17:58  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-07 19:18:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-07 19:18:07  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-07 19:18:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-07 19:18:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-07 19:18:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-07 19:18:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 19:18:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 19:18:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 19:18:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 19:18:40  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-07 19:18:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 19:18:48  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 19:18:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-07 19:18:56  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-07 19:19:00  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-07 19:19:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-07 19:19:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-07 19:19:13  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-07 19:19:17  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-07 19:19:21  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-07 19:19:25  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-07 19:19:29  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-07 19:19:33  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-07 19:19:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-07 19:19:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-07 19:19:46  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-07 19:19:50  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-07 19:19:54  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-07 19:19:58  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-07 19:20:02  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-07 19:20:06  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-07 19:20:10  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-07 19:20:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 19:20:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 19:20:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 19:20:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 19:20:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 19:20:35  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-07 19:20:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 19:20:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 19:20:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 19:20:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 19:20:55  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-07 19:20:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 19:21:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 19:21:08  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 19:21:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-07 19:21:16  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-07_19-31-55 Restart Xvfb...
2017-04-07_20-01-55 Restart Xvfb...
2017-04-07_20-31-55 Restart Xvfb...
2017-04-07_21-01-55 Restart Xvfb...
2017-04-07 21:31:46 reset updateRequest
2017-04-07 21:31:46  - 14968  http://www.lymphomahub.com/
2017-04-07 21:31:51  - 14968  http://www.lymphomahub.com/
2017-04-07 21:31:51  - 14968  http://www.lymphomahub.com/about
2017-04-07_21-31-55 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-07 21:33:56  - 14968  http://www.lymphomahub.com/about
2017-04-07 21:33:56  - 14968  http://www.lymphomahub.com/about
2017-04-07 21:34:00  - 14968  http://www.lymphomahub.com/terms
2017-04-07 21:34:02  - 14968  http://www.lymphomahub.com/terms
2017-04-07 21:34:04  - 14968  http://www.lymphomahub.com/undefined
2017-04-07 21:34:05  - 14968  http://www.lymphomahub.com/therapies
2017-04-07 21:34:05  - 14968  http://www.lymphomahub.com/therapies
2017-04-07 21:34:14  - 14968  http://www.lymphomahub.com/newsletter
2017-04-07 21:34:15  - 14968  http://www.lymphomahub.com/newsletter
2017-04-07 21:34:18  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-07 21:34:19  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-07 21:34:22  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-07 21:34:22  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-07 21:34:27  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-07 21:34:27  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-07 21:34:32  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-07 21:34:32  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-07 21:34:37  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-07 21:34:42  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-07 21:34:47  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-07 21:34:52  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-07 21:34:57  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-07 21:35:02  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-07 21:35:07  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-07 21:35:11  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-07 21:35:16  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-07 21:35:21  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-07 21:35:26  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-07 21:35:31  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-07 21:35:35  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-07 21:35:40  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-07 21:35:45  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-07 21:35:50  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-07 21:35:54  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-07 21:35:59  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-07 21:36:03  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-07 21:36:07  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-07 21:36:12  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-07 21:36:16  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-07 21:36:21  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-07 21:36:26  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-07 21:36:31  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-07 21:36:36  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-07 21:36:40  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-07 21:36:45  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-07 21:36:49  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-07 21:36:54  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-07 21:36:59  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-07 21:37:04  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-07 21:37:09  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-07 21:37:13  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-07 21:37:18  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-07 21:37:23  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-07 21:37:27  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-07 21:37:33  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-07 21:37:37  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-07 21:37:42  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-07 21:37:47  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-07 21:37:51  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-07 21:37:57  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-07 21:38:02  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-07 21:38:06  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-07 21:38:10  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-07 21:38:15  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-07 21:38:19  - 14968  http://www.lymphomahub.com/medical-information
2017-04-07 21:38:24  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-07 21:38:29  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-07 21:38:34  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-07 21:38:39  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-07 21:38:44  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-07 21:38:49  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-07 21:38:53  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-07 21:38:58  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-07 21:39:03  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-07 21:39:08  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-07 21:39:13  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-07 21:39:17  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-07 21:39:18  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-07 21:39:23  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-07 21:39:28  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-07 21:39:32  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-07 21:39:37  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-07 21:39:42  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-07 21:39:46  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-07 21:39:51  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-07 21:39:55  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-07 21:40:00  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-07 21:40:05  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-07 21:40:10  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-07 21:40:15  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-07 21:40:19  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-07 21:40:24  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-07 21:40:29  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-07 21:40:34  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-07 21:40:39  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-07 21:40:44  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-07 21:40:48  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-07 21:40:53  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-07 21:40:58  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-07 21:41:02  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-07 21:41:07  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-07 21:41:11  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-07 21:41:16  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-07 21:41:21  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-07 21:41:26  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-07 21:41:30  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-07 21:41:35  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-07 21:41:39  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-07 21:41:40  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-07 21:41:45  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-07 21:41:49  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-07 21:41:54  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-07 21:41:59  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-07 21:42:03  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-07 21:42:08  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-07 21:42:12  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-07 21:42:17  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-07 21:42:21  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-07 21:42:21  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-07 21:42:26  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-07 21:42:30  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-07 21:42:35  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-07 21:42:39  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-07 21:42:44  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-07 21:42:45  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-07 21:42:49  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-07 21:42:54  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-07 21:42:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-07 21:43:02  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-07 21:43:07  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-07 21:43:11  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-07 21:43:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-07 21:43:19  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-07 21:43:23  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-07 21:43:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-07 21:43:32  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-07 21:43:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-07 21:43:42  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-07 21:43:45  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-07 21:43:46  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-07 21:43:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-07 21:43:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-07 21:43:59  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-07 21:44:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-07 21:44:08  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-07 21:44:12  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-07 21:44:16  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-07 21:44:20  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-07 21:44:24  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-07 21:44:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-07 21:44:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-07 21:44:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-07 21:44:39  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-07 21:44:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-07 21:44:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-07 21:44:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-07 21:44:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-07 21:45:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-07 21:45:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-07 21:45:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-07 21:45:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-07 21:45:20  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-07 21:45:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-07 21:45:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-07 21:45:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-07 21:45:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-07 21:45:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-07 21:45:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-07 21:45:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-07 21:45:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-07 21:45:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-07 21:46:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-07 21:46:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-07 21:46:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-07 21:46:17  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-07 21:46:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-07 21:46:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-07 21:46:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-07 21:46:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-07 21:46:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-07 21:46:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-07 21:46:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-07 21:46:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-07 21:46:57  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-07 21:47:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-07 21:47:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-07 21:47:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-07 21:47:16  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-07 21:47:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-07 21:47:24  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-07 21:47:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-07 21:47:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-07 21:47:37  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-07 21:47:42  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-07 21:47:46  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-07 21:47:50  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-07 21:47:55  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-07 21:47:59  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-07 21:48:03  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-07 21:48:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-07 21:48:12  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-07 21:48:16  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-07 21:48:19  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-07 21:48:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-07 21:48:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-07 21:48:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-07 21:48:37  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-07 21:48:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-07 21:48:45  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-07 21:48:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-07 21:48:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-07 21:48:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-07 21:49:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-07 21:49:08  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-07 21:49:09  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-07 21:49:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-07 21:49:18  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-07 21:49:23  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-07 21:49:28  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-07 21:49:33  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-07 21:49:37  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 21:49:42  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 21:49:47  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-07 21:49:51  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 21:49:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-07 21:50:01  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-07 21:50:06  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-07 21:50:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-07 21:50:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-07 21:50:20  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-07 21:50:25  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-07 21:50:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-07 21:50:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-07 21:50:40  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-07 21:50:45  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-07 21:50:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-07 21:50:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-07 21:51:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-07 21:51:05  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-07 21:51:10  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-07 21:51:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-07 21:51:21  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-07 21:51:26  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-07 21:51:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-07 21:51:36  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-07 21:51:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-07 21:51:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-07 21:51:51  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-07 21:51:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-07 21:52:01  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-07 21:52:06  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-07 21:52:11  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-07 21:52:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-07 21:52:21  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-07 21:52:26  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-07 21:52:30  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-07 21:52:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-07 21:52:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-07 21:52:42  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-07 21:52:47  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-07 21:52:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-07 21:52:57  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-07 21:53:02  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-07 21:53:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-07 21:53:11  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-07 21:53:15  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-07 21:53:20  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-07 21:53:25  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-07 21:53:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-07 21:53:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-07 21:53:39  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-07 21:53:44  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-07 21:53:49  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-07 21:53:53  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-07 21:53:58  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-07 21:54:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-07 21:54:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-07 21:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-07 21:54:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-07 21:54:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-07 21:54:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-07 21:54:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-07 21:54:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-07 21:54:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-07 21:54:41  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-07 21:54:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-07 21:54:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-07 21:54:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-07 21:54:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-07 21:54:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-07 21:55:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-07 21:55:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-07 21:55:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-07 21:55:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-07 21:55:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-07 21:55:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-07 21:55:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-07 21:55:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-07 21:55:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-07 21:55:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-07 21:55:40  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-07 21:55:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-07 21:55:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-07 21:55:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-07 21:55:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-07 21:56:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-07 21:56:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-07 21:56:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-07 21:56:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-07 21:56:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-07 21:56:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-07 21:56:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-07 21:56:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-07 21:56:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-07 21:56:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-07 21:56:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-07 21:56:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-07 21:56:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-07 21:56:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-07 21:56:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-07 21:56:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-07 21:56:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-07 21:57:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-07 21:57:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-07 21:57:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-07 21:57:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-07 21:57:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-07 21:57:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-07 21:57:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-07 21:57:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-07 21:57:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-07 21:57:35  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-07 21:57:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-07 21:57:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-07 21:57:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-07 21:57:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-07 21:57:55  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-07 21:58:00  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-07 21:58:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-07 21:58:09  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-07 21:58:10  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-07 21:58:14  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-07 21:58:19  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-07 21:58:24  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-07 21:58:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-07 21:58:33  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-07 21:58:38  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-07 21:58:43  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-07 21:58:47  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-07 21:58:52  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-07 21:58:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-07 21:59:01  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-07 21:59:06  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-07 21:59:10  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-07 21:59:15  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-07 21:59:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-07 21:59:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-07 21:59:29  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-07 21:59:34  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-07 21:59:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-07 21:59:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-07 21:59:47  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-07 21:59:52  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-07 21:59:56  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-07 22:00:01  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-07 22:00:06  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-07 22:00:11  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-07 22:00:15  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-07 22:00:20  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-07 22:00:25  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-07 22:00:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-07 22:00:34  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-07 22:00:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-07 22:00:43  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-07 22:00:48  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-07 22:00:53  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-07 22:00:57  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-07 22:01:02  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-07 22:01:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-07 22:01:11  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-07 22:01:15  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-07 22:01:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-07 22:01:25  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-07 22:01:29  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-07 22:01:34  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-07 22:01:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-07 22:01:43  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-07 22:01:47  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-07 22:01:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-07_22-01-55 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics?_prerender {"code":"ECONNRESET"}
2017-04-07 22:03:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-07 22:04:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-07 22:04:06  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-07 22:04:11  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-07 22:04:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-07 22:04:20  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-07 22:04:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-07 22:04:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-07 22:04:35  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-07 22:04:40  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-07 22:04:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-07 22:04:50  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-07 22:04:54  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-07 22:04:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-07 22:05:03  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-07 22:05:08  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-07 22:05:13  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-07 22:05:18  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-07 22:05:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-07 22:05:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-07 22:05:31  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-07 22:05:36  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-07 22:05:41  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-07 22:05:45  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-07 22:05:50  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-07 22:05:55  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-07 22:05:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-07 22:06:04  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-07 22:06:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-07 22:06:13  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-07 22:06:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-07 22:06:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-07 22:06:27  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-07 22:06:32  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-07 22:06:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-07 22:06:41  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-07 22:06:45  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-07 22:06:50  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-07 22:06:55  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-07 22:06:59  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-07 22:07:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-07 22:07:08  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-07 22:07:13  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-07 22:07:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-07 22:07:22  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-07 22:07:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-07 22:07:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-07 22:07:36  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-07 22:07:40  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-07 22:07:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-07 22:07:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-07 22:07:54  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-07 22:07:59  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-07 22:08:03  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-07 22:08:08  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-07 22:08:13  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-07 22:08:17  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-07 22:08:22  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-07 22:08:27  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-07 22:08:31  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-07 22:08:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-07 22:08:40  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-07 22:08:45  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-07 22:08:50  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-07 22:08:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-07 22:08:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-07 22:09:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-07 22:09:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-07 22:09:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-07 22:09:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-07 22:09:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-07 22:09:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-07 22:09:32  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-07 22:09:37  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-07 22:09:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-07 22:09:46  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-07 22:09:51  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-07 22:09:55  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-07 22:10:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-07 22:10:04  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-07 22:10:09  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-07 22:10:13  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-07 22:10:18  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-07 22:10:22  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-07 22:10:27  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-07 22:10:32  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-07 22:10:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-07 22:10:41  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-07 22:10:45  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-07 22:10:50  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-07 22:10:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-07 22:10:59  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-07 22:11:05  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-07 22:11:10  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-07 22:11:14  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-07 22:11:19  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-07 22:11:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-07 22:11:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-07 22:11:32  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-07 22:11:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-07 22:11:42  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-07 22:11:46  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-07 22:11:51  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-07 22:11:55  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-07 22:12:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-07 22:12:05  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-07 22:12:09  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-07 22:12:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-07 22:12:18  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-07 22:12:22  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-07 22:12:26  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-07 22:12:31  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-07 22:12:35  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-07 22:12:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-07 22:12:45  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-07 22:12:49  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-07 22:12:54  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-07 22:12:58  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-07 22:13:03  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-07 22:13:07  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-07 22:13:12  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-07 22:13:17  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-07 22:13:22  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-07 22:13:26  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-07 22:13:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-07 22:13:34  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-07 22:13:39  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-07 22:13:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-07 22:13:48  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-07 22:13:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-07 22:13:57  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-07 22:14:02  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-07 22:14:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-07 22:14:11  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-07 22:14:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-07 22:14:20  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-07 22:14:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-07 22:14:29  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-07 22:14:34  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-07 22:14:38  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-07 22:14:42  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-07 22:14:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-07 22:14:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-07 22:14:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-07 22:15:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-07 22:15:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-07 22:15:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-07 22:15:16  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-07 22:15:20  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-07 22:15:24  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-07 22:15:32  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-07 22:15:37  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-07 22:15:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-07 22:15:45  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-07 22:15:50  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-07 22:15:55  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-07 22:16:00  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-07 22:16:04  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-07 22:16:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-07 22:16:13  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-07 22:16:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-07 22:16:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-07 22:16:27  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-07 22:16:28  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-07 22:16:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-07 22:16:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-07 22:16:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-07 22:16:46  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-07 22:16:51  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-07 22:16:55  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-07 22:17:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-07 22:17:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-07 22:17:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-07 22:17:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-07 22:17:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-07 22:17:23  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-07 22:17:27  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-07 22:17:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-07 22:17:37  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-07 22:17:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-07 22:17:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-07 22:17:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-07 22:17:55  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-07 22:17:59  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-07 22:18:04  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-07 22:18:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-07 22:18:12  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-07 22:18:17  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-07 22:18:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-07 22:18:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-07 22:18:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-07 22:18:35  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-07 22:18:39  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-07 22:18:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-07 22:18:48  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-07 22:18:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-07 22:18:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-07 22:19:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-07 22:19:05  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-07 22:19:09  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-07 22:19:13  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-07 22:19:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-07 22:19:21  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-07 22:19:26  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-07 22:19:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-07 22:19:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-07 22:19:39  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-07 22:19:43  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-07 22:19:47  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-07 22:19:51  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-07 22:19:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-07 22:20:00  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-07 22:20:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-07 22:20:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-07 22:20:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-07 22:20:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-07 22:20:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-07 22:20:27  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-07 22:20:31  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-07 22:20:35  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-07 22:20:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-07 22:20:44  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-07 22:20:48  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-07 22:20:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-07 22:20:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-07 22:21:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 22:21:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 22:21:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 22:21:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 22:21:17  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-07 22:21:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 22:21:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-07 22:21:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-07 22:21:33  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-07 22:21:37  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-07 22:21:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-07 22:21:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-07 22:21:50  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-07 22:21:54  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-07 22:21:58  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-07 22:22:02  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-07 22:22:06  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-07 22:22:10  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-07 22:22:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-07 22:22:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-07 22:22:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-07 22:22:27  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-07 22:22:31  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-07 22:22:35  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-07 22:22:39  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-07 22:22:43  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-07 22:22:48  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-07 22:22:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 22:22:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 22:23:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 22:23:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 22:23:08  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-07 22:23:12  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-07 22:23:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 22:23:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 22:23:24  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 22:23:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 22:23:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-07 22:23:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 22:23:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 22:23:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-07 22:23:49  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-07 22:23:53  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-07_22-31-55 Restart Xvfb...
2017-04-07_23-01-55 Restart Xvfb...
2017-04-07_23-31-55 Restart Xvfb...
2017-04-08_00-01-55 Restart Xvfb...
2017-04-08 00:31:46 reset updateRequest
2017-04-08 00:31:48  - 14968  http://www.lymphomahub.com/
2017-04-08 00:31:51  - 14968  http://www.lymphomahub.com/
2017-04-08 00:31:52  - 14968  http://www.lymphomahub.com/about
2017-04-08_00-31-55 Restart Xvfb...
2017-04-08 00:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-08 00:32:01  - 14968  http://www.lymphomahub.com/terms
2017-04-08 00:32:04  - 14968  http://www.lymphomahub.com/undefined
2017-04-08 00:32:05  - 14968  http://www.lymphomahub.com/therapies
2017-04-08 00:32:11  - 14968  http://www.lymphomahub.com/newsletter
2017-04-08 00:32:15  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-08 00:32:18  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-08 00:32:24  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-08 00:32:28  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-08 00:32:33  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-08 00:32:37  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-08 00:32:42  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-08 00:32:47  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-08 00:32:51  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-08 00:32:56  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-08 00:33:00  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-08 00:33:05  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-08 00:33:09  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-08 00:33:14  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-08 00:33:18  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-08 00:33:22  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-08 00:33:27  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-08 00:33:32  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-08 00:33:37  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-08 00:33:41  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-08 00:33:46  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-08 00:33:51  - 14968  http://www.lymphomahub.com/therapies/kte-c19
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-08 00:33:55  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-08 00:33:57  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-08 00:33:59  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-08 00:34:00  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-08 00:34:03  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-08 00:34:05  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-08 00:34:08  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-08 00:34:09  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-08 00:34:13  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-08 00:34:14  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-08 00:34:18  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-08 00:34:19  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-08 00:34:24  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-08 00:34:24  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-08 00:34:29  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-08 00:34:33  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-08 00:34:38  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-08 00:34:42  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-08 00:34:47  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-08 00:34:51  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-08 00:34:56  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-08 00:35:00  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-08 00:35:05  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-08 00:35:10  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-08 00:35:14  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-08 00:35:20  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-08 00:35:25  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-08 00:35:30  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-08 00:35:34  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-08 00:35:39  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-08 00:35:43  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-08 00:35:48  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-08 00:35:52  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-08 00:35:57  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-08 00:36:01  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-08 00:36:06  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-08 00:36:10  - 14968  http://www.lymphomahub.com/medical-information
2017-04-08 00:36:14  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-08 00:36:18  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-08 00:36:23  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-08 00:36:28  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-08 00:36:32  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-08 00:36:36  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-08 00:36:41  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-08 00:36:46  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-08 00:36:50  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-08 00:36:54  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-08 00:36:59  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-08 00:37:03  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-08 00:37:04  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-08 00:37:08  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-08 00:37:13  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-08 00:37:17  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-08 00:37:21  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-08 00:37:26  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-08 00:37:31  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-08 00:37:35  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-08 00:37:40  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-08 00:37:44  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-08 00:37:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-08 00:37:53  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-08 00:37:57  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-08 00:38:02  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-08 00:38:06  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-08 00:38:11  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-08 00:38:15  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-08 00:38:20  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-08 00:38:24  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-08 00:38:28  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-08 00:38:33  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-08 00:38:37  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-08 00:38:42  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-08 00:38:46  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-08 00:38:50  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-08 00:38:55  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-08 00:38:59  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-08 00:39:04  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-08 00:39:08  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-08 00:39:13  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-08 00:39:17  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-08 00:39:18  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-08 00:39:22  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-08 00:39:27  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-08 00:39:31  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-08 00:39:36  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-08 00:39:40  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-08 00:39:44  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-08 00:39:49  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-08 00:39:53  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-08 00:39:57  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-08 00:39:58  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-08 00:40:02  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-08 00:40:06  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-08 00:40:11  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-08 00:40:15  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-08 00:40:20  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-08 00:40:21  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-08 00:40:25  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-08 00:40:29  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-08 00:40:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-08 00:40:37  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-08 00:40:42  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-08 00:40:46  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-08 00:40:49  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-08 00:40:53  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-08 00:40:57  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-08 00:41:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-08 00:41:06  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-08 00:41:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-08 00:41:15  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-08 00:41:19  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-08 00:41:19  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-08 00:41:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-08 00:41:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-08 00:41:33  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-08 00:41:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-08 00:41:41  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-08 00:41:45  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-08 00:41:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-08 00:41:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-08 00:41:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-08 00:42:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-08 00:42:05  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-08 00:42:09  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-08 00:42:13  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-08 00:42:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-08 00:42:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-08 00:42:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-08 00:42:30  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-08 00:42:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-08 00:42:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-08 00:42:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-08 00:42:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-08 00:42:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-08 00:42:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-08 00:43:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-08 00:43:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-08 00:43:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-08 00:43:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-08 00:43:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-08 00:43:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-08 00:43:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-08 00:43:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-08 00:43:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-08 00:43:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-08 00:43:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-08 00:43:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-08 00:43:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-08 00:43:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-08 00:44:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-08 00:44:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-08 00:44:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-08 00:44:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-08 00:44:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-08 00:44:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-08 00:44:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-08 00:44:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-08 00:44:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-08 00:44:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-08 00:44:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-08 00:44:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-08 00:44:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-08 00:45:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-08 00:45:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-08 00:45:08  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-08 00:45:13  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-08 00:45:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-08 00:45:22  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-08 00:45:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-08 00:45:30  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-08 00:45:34  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-08 00:45:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-08 00:45:43  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-08 00:45:47  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-08 00:45:51  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-08 00:45:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-08 00:46:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-08 00:46:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-08 00:46:08  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-08 00:46:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-08 00:46:17  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-08 00:46:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-08 00:46:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-08 00:46:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-08 00:46:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-08 00:46:40  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-08 00:46:41  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-08 00:46:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-08 00:46:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-08 00:46:54  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-08 00:46:59  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-08 00:47:03  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-08 00:47:08  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 00:47:12  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 00:47:17  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-08 00:47:22  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 00:47:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-08 00:47:31  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-08 00:47:36  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-08 00:47:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-08 00:47:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-08 00:47:49  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-08 00:47:54  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-08 00:47:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-08 00:48:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-08 00:48:08  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-08 00:48:13  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 00:48:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-08 00:48:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-08 00:48:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-08 00:48:31  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-08 00:48:36  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-08 00:48:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-08 00:48:45  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-08 00:48:50  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-08 00:48:54  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-08 00:48:59  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-08 00:49:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-08 00:49:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-08 00:49:13  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-08 00:49:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-08 00:49:22  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-08 00:49:27  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-08 00:49:31  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-08 00:49:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-08 00:49:41  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-08 00:49:45  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-08 00:49:50  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-08 00:49:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-08 00:49:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-08 00:50:00  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-08 00:50:04  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-08 00:50:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-08 00:50:14  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-08 00:50:19  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-08 00:50:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-08 00:50:28  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-08 00:50:33  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-08 00:50:37  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-08 00:50:42  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-08 00:50:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-08 00:50:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-08 00:50:56  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-08 00:51:01  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-08 00:51:05  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-08 00:51:10  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-08 00:51:15  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-08 00:51:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-08 00:51:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-08 00:51:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-08 00:51:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-08 00:51:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-08 00:51:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-08 00:51:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-08 00:51:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-08 00:51:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-08 00:51:58  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-08 00:51:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-08 00:52:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-08 00:52:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-08 00:52:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-08 00:52:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-08 00:52:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-08 00:52:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-08 00:52:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-08 00:52:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-08 00:52:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-08 00:52:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-08 00:52:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-08 00:52:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-08 00:52:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-08 00:52:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-08 00:52:55  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-08 00:53:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-08 00:53:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-08 00:53:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-08 00:53:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-08 00:53:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-08 00:53:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-08 00:53:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-08 00:53:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-08 00:53:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-08 00:53:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-08 00:53:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-08 00:53:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-08 00:53:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-08 00:53:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-08 00:53:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-08 00:53:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-08 00:53:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-08 00:54:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-08 00:54:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-08 00:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-08 00:54:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-08 00:54:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-08 00:54:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-08 00:54:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-08 00:54:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-08 00:54:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-08 00:54:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-08 00:54:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-08 00:54:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-08 00:54:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-08 00:54:51  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-08 00:54:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-08 00:54:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-08 00:55:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-08 00:55:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-08 00:55:11  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-08 00:55:16  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-08 00:55:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-08 00:55:25  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-08 00:55:26  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-08 00:55:30  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-08 00:55:35  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-08 00:55:40  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-08 00:55:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-08 00:55:49  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-08 00:55:54  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-08 00:55:58  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-08 00:56:03  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-08 00:56:08  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-08 00:56:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-08 00:56:17  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-08 00:56:21  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-08 00:56:26  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-08 00:56:31  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-08 00:56:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-08 00:56:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-08 00:56:45  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-08 00:56:50  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-08 00:56:55  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-08 00:56:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-08 00:57:04  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-08 00:57:08  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-08 00:57:13  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-08 00:57:17  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-08 00:57:22  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-08 00:57:27  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-08 00:57:31  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-08 00:57:36  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-08 00:57:41  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-08 00:57:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-08 00:57:50  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-08 00:57:54  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-08 00:57:59  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-08 00:58:03  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-08 00:58:08  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-08 00:58:12  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-08 00:58:17  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-08 00:58:22  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-08 00:58:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-08 00:58:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-08 00:58:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-08 00:58:40  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-08 00:58:45  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-08 00:58:49  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-08 00:58:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-08 00:58:58  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-08 00:59:03  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-08 00:59:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-08 00:59:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-08 00:59:16  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-08 00:59:21  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-08 00:59:25  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-08 00:59:30  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-08 00:59:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-08 00:59:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-08 00:59:44  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-08 00:59:48  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-08 00:59:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-08 00:59:58  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-08 01:00:02  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-08 01:00:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-08 01:00:12  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-08 01:00:16  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-08 01:00:22  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-08 01:00:26  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-08 01:00:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-08 01:00:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-08 01:00:40  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-08 01:00:45  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-08 01:00:49  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-08 01:00:54  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-08 01:00:59  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-08 01:01:03  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-08 01:01:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-08 01:01:13  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-08 01:01:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-08 01:01:22  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-08 01:01:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-08 01:01:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-08 01:01:36  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-08 01:01:41  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-08 01:01:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-08 01:01:51  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-08 01:01:55  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-08_01-01-55 Restart Xvfb...
2017-04-08 01:02:00  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-08 01:02:04  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-08 01:02:09  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-08 01:02:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-08 01:02:18  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-08 01:02:22  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-08 01:02:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-08 01:02:32  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-08 01:02:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-08 01:02:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-08 01:02:46  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-08 01:02:51  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-08 01:02:55  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-08 01:03:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-08 01:03:05  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-08 01:03:09  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-08 01:03:14  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-08 01:03:19  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-08 01:03:24  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-08 01:03:28  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-08 01:03:33  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-08 01:03:38  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-08 01:03:42  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-08 01:03:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-08 01:03:51  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-08 01:03:56  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-08 01:04:01  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-08 01:04:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-08 01:04:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-08 01:04:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-08 01:04:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-08 01:04:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-08 01:04:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-08 01:04:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-08 01:04:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-08 01:04:43  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-08 01:04:47  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-08 01:04:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-08 01:04:57  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-08 01:05:01  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-08 01:05:06  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-08 01:05:11  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-08 01:05:15  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-08 01:05:19  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-08 01:05:24  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-08 01:05:29  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-08 01:05:33  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-08 01:05:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-08 01:05:43  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-08 01:05:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-08 01:05:52  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-08 01:05:57  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-08 01:06:01  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-08 01:06:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-08 01:06:12  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-08 01:06:17  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-08 01:06:22  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-08 01:06:26  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-08 01:06:31  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-08 01:06:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-08 01:06:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-08 01:06:44  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-08 01:06:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-08 01:06:54  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-08 01:06:58  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-08 01:07:03  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-08 01:07:08  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-08 01:07:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-08 01:07:17  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-08 01:07:22  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-08 01:07:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-08 01:07:31  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-08 01:07:35  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-08 01:07:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-08 01:07:44  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-08 01:07:49  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-08 01:07:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-08 01:07:58  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-08 01:08:02  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-08 01:08:07  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-08 01:08:12  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-08 01:08:16  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-08 01:08:21  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-08 01:08:26  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-08 01:08:30  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-08 01:08:35  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-08 01:08:39  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-08 01:08:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-08 01:08:48  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-08 01:08:53  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-08 01:08:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-08 01:09:02  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-08 01:09:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-08 01:09:11  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-08 01:09:15  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-08 01:09:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-08 01:09:24  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-08 01:09:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-08 01:09:33  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-08 01:09:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-08 01:09:43  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-08 01:09:47  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-08 01:09:51  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-08 01:09:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-08 01:10:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-08 01:10:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-08 01:10:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-08 01:10:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-08 01:10:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-08 01:10:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-08 01:10:27  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-08 01:10:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-08 01:10:36  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-08 01:10:41  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-08 01:10:45  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-08 01:10:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-08 01:10:54  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-08 01:10:58  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-08 01:11:03  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-08 01:11:07  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-08 01:11:12  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-08 01:11:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-08 01:11:22  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-08 01:11:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-08 01:11:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-08 01:11:36  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-08 01:11:36  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-08 01:11:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-08 01:11:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-08 01:11:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-08 01:11:54  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-08 01:11:59  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-08 01:12:04  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-08 01:12:09  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-08 01:12:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-08 01:12:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-08 01:12:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-08 01:12:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-08 01:12:32  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-08 01:12:36  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-08 01:12:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-08 01:12:45  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-08 01:12:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-08 01:12:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-08 01:12:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-08 01:13:03  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-08 01:13:08  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-08 01:13:12  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-08 01:13:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-08 01:13:21  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-08 01:13:25  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-08 01:13:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-08 01:13:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-08 01:13:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-08 01:13:44  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-08 01:13:48  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-08 01:13:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-08 01:13:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-08 01:14:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-08 01:14:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-08 01:14:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-08 01:14:14  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-08 01:14:18  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-08 01:14:22  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-08 01:14:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-08 01:14:30  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-08 01:14:34  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-08 01:14:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-08 01:14:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-08 01:14:48  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-08 01:14:52  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-08 01:14:56  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-08 01:15:00  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-08 01:15:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-08 01:15:08  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-08 01:15:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-08 01:15:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-08 01:15:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-08 01:15:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-08 01:15:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-08 01:15:36  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-08 01:15:40  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-08 01:15:44  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-08 01:15:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-08 01:15:52  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-08 01:15:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-08 01:16:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-08 01:16:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-08 01:16:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 01:16:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 01:16:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 01:16:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 01:16:26  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-08 01:16:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 01:16:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 01:16:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-08 01:16:42  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-08 01:16:46  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-08 01:16:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-08 01:16:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-08 01:16:59  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-08 01:17:03  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-08 01:17:07  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-08 01:17:11  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-08 01:17:15  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-08 01:17:19  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-08 01:17:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-08 01:17:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-08 01:17:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-08 01:17:36  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-08 01:17:40  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-08 01:17:44  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-08 01:17:48  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-08 01:17:53  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-08 01:17:57  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-08 01:18:01  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 01:18:05  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 01:18:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 01:18:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 01:18:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 01:18:21  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-08 01:18:25  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 01:18:29  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 01:18:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 01:18:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 01:18:42  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-08 01:18:46  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 01:18:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 01:18:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 01:18:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-08 01:19:02  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-08_01-31-55 Restart Xvfb...
2017-04-08_02-01-55 Restart Xvfb...
2017-04-08_02-31-55 Restart Xvfb...
2017-04-08_03-01-55 Restart Xvfb...
2017-04-08 03:31:46 reset updateRequest
2017-04-08 03:31:48  - 14968  http://www.lymphomahub.com/
2017-04-08 03:31:51  - 14968  http://www.lymphomahub.com/
2017-04-08 03:31:52  - 14968  http://www.lymphomahub.com/about
2017-04-08_03-31-55 Restart Xvfb...
2017-04-08 03:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-08 03:31:59  - 14968  http://www.lymphomahub.com/terms
2017-04-08 03:32:02  - 14968  http://www.lymphomahub.com/undefined
2017-04-08 03:32:03  - 14968  http://www.lymphomahub.com/therapies
2017-04-08 03:32:09  - 14968  http://www.lymphomahub.com/newsletter
2017-04-08 03:32:12  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-08 03:32:15  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-08 03:32:20  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-08 03:32:24  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-08 03:32:29  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-08 03:32:34  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-08 03:32:38  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-08 03:32:43  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-08 03:32:47  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-08 03:32:52  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-08 03:32:56  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-08 03:33:01  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-08 03:33:05  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-08 03:33:10  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-08 03:33:14  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-08 03:33:18  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-08 03:33:23  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-08 03:33:27  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-08 03:33:31  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-08 03:33:37  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-08 03:33:41  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-08 03:33:46  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-08 03:33:50  - 14968  http://www.lymphomahub.com/about/secretariat
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-08 03:33:54  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-08 03:33:57  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-08 03:33:58  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-08 03:34:02  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-08 03:34:04  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-08 03:34:06  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-08 03:34:09  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-08 03:34:11  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-08 03:34:13  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-08 03:34:15  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-08 03:34:18  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-08 03:34:20  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-08 03:34:23  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-08 03:34:24  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-08 03:34:28  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-08 03:34:29  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-08 03:34:34  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-08 03:34:34  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-08 03:34:39  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-08 03:34:44  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-08 03:34:48  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-08 03:34:53  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-08 03:34:57  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-08 03:35:02  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-08 03:35:06  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-08 03:35:11  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-08 03:35:15  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-08 03:35:20  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-08 03:35:24  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-08 03:35:29  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-08 03:35:33  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-08 03:35:38  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-08 03:35:42  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-08 03:35:47  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-08 03:35:52  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-08 03:35:56  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-08 03:36:00  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-08 03:36:05  - 14968  http://www.lymphomahub.com/medical-information
2017-04-08 03:36:10  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-08 03:36:15  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-08 03:36:19  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-08 03:36:24  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-08 03:36:28  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-08 03:36:33  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-08 03:36:37  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-08 03:36:41  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-08 03:36:46  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-08 03:36:50  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-08 03:36:55  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-08 03:36:59  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-08 03:37:00  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-08 03:37:04  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-08 03:37:09  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-08 03:37:13  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-08 03:37:18  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-08 03:37:22  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-08 03:37:27  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-08 03:37:31  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-08 03:37:35  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-08 03:37:40  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-08 03:37:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-08 03:37:49  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-08 03:37:53  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-08 03:37:58  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-08 03:38:03  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-08 03:38:07  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-08 03:38:12  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-08 03:38:16  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-08 03:38:21  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-08 03:38:25  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-08 03:38:29  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-08 03:38:34  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-08 03:38:39  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-08 03:38:43  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-08 03:38:48  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-08 03:38:52  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-08 03:38:57  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-08 03:39:01  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-08 03:39:06  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-08 03:39:11  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-08 03:39:16  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-08 03:39:16  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-08 03:39:21  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-08 03:39:26  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-08 03:39:30  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-08 03:39:35  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-08 03:39:39  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-08 03:39:44  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-08 03:39:48  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-08 03:39:53  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-08 03:39:56  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-08 03:39:57  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-08 03:40:01  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-08 03:40:06  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-08 03:40:10  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-08 03:40:15  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-08 03:40:19  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-08 03:40:20  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-08 03:40:24  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-08 03:40:29  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-08 03:40:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-08 03:40:37  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-08 03:40:42  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-08 03:40:46  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-08 03:40:49  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-08 03:40:53  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-08 03:40:57  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-08 03:41:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-08 03:41:06  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-08 03:41:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-08 03:41:14  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-08 03:41:18  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-08 03:41:19  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-08 03:41:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-08 03:41:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-08 03:41:32  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-08 03:41:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-08 03:41:40  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-08 03:41:45  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-08 03:41:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-08 03:41:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-08 03:41:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-08 03:42:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-08 03:42:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-08 03:42:08  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-08 03:42:12  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-08 03:42:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-08 03:42:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-08 03:42:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-08 03:42:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-08 03:42:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-08 03:42:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-08 03:42:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-08 03:42:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-08 03:42:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-08 03:42:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-08 03:43:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-08 03:43:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-08 03:43:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-08 03:43:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-08 03:43:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-08 03:43:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-08 03:43:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-08 03:43:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-08 03:43:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-08 03:43:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-08 03:43:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-08 03:43:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-08 03:43:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-08 03:43:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-08 03:44:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-08 03:44:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-08 03:44:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-08 03:44:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-08 03:44:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-08 03:44:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-08 03:44:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-08 03:44:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-08 03:44:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-08 03:44:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-08 03:44:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-08 03:44:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-08 03:44:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-08 03:44:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-08 03:45:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-08 03:45:08  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-08 03:45:13  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-08 03:45:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-08 03:45:21  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-08 03:45:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-08 03:45:30  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-08 03:45:34  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-08 03:45:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-08 03:45:43  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-08 03:45:47  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-08 03:45:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-08 03:45:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-08 03:45:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-08 03:46:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-08 03:46:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-08 03:46:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-08 03:46:16  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-08 03:46:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-08 03:46:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-08 03:46:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-08 03:46:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-08 03:46:40  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-08 03:46:40  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-08 03:46:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-08 03:46:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-08 03:46:54  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-08 03:46:58  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-08 03:47:03  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-08 03:47:08  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 03:47:12  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 03:47:17  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-08 03:47:22  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 03:47:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-08 03:47:31  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-08 03:47:35  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-08 03:47:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-08 03:47:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-08 03:47:49  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-08 03:47:54  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-08 03:47:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-08 03:48:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-08 03:48:08  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-08 03:48:13  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 03:48:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-08 03:48:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-08 03:48:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-08 03:48:31  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-08 03:48:36  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-08 03:48:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-08 03:48:46  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-08 03:48:50  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-08 03:48:55  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-08 03:48:59  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-08 03:49:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-08 03:49:09  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-08 03:49:13  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-08 03:49:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-08 03:49:22  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-08 03:49:27  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-08 03:49:32  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-08 03:49:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-08 03:49:41  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-08 03:49:46  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-08 03:49:50  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-08 03:49:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-08 03:49:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-08 03:50:00  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-08 03:50:05  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-08 03:50:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-08 03:50:14  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-08 03:50:19  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-08 03:50:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-08 03:50:28  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-08 03:50:33  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-08 03:50:38  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-08 03:50:42  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-08 03:50:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-08 03:50:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-08 03:50:56  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-08 03:51:01  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-08 03:51:06  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-08 03:51:11  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-08 03:51:16  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-08 03:51:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-08 03:51:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-08 03:51:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-08 03:51:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-08 03:51:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-08 03:51:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-08 03:51:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-08 03:51:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-08 03:51:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-08 03:51:59  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-08 03:51:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-08 03:52:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-08 03:52:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-08 03:52:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-08 03:52:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-08 03:52:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-08 03:52:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-08 03:52:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-08 03:52:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-08 03:52:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-08 03:52:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-08 03:52:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-08 03:52:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-08 03:52:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-08 03:52:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-08 03:52:56  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-08 03:53:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-08 03:53:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-08 03:53:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-08 03:53:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-08 03:53:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-08 03:53:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-08 03:53:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-08 03:53:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-08 03:53:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-08 03:53:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-08 03:53:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-08 03:53:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-08 03:53:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-08 03:53:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-08 03:53:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-08 03:53:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-08 03:53:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-08 03:54:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-08 03:54:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-08 03:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-08 03:54:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-08 03:54:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-08 03:54:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-08 03:54:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-08 03:54:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-08 03:54:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-08 03:54:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-08 03:54:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-08 03:54:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-08 03:54:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-08 03:54:51  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-08 03:54:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-08 03:54:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-08 03:55:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-08 03:55:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-08 03:55:11  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-08 03:55:16  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-08 03:55:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-08 03:55:26  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-08 03:55:26  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-08 03:55:31  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-08 03:55:36  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-08 03:55:40  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-08 03:55:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-08 03:55:50  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-08 03:55:54  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-08 03:55:59  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-08 03:56:04  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-08 03:56:08  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-08 03:56:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-08 03:56:17  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-08 03:56:22  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-08 03:56:27  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-08 03:56:31  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-08 03:56:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-08 03:56:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-08 03:56:45  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-08 03:56:50  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-08 03:56:54  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-08 03:56:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-08 03:57:04  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-08 03:57:08  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-08 03:57:13  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-08 03:57:18  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-08 03:57:22  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-08 03:57:27  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-08 03:57:32  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-08 03:57:36  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-08 03:57:41  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-08 03:57:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-08 03:57:50  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-08 03:57:55  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-08 03:57:59  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-08 03:58:04  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-08 03:58:08  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-08 03:58:13  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-08 03:58:18  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-08 03:58:22  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-08 03:58:27  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-08 03:58:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-08 03:58:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-08 03:58:41  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-08 03:58:46  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-08 03:58:51  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-08 03:58:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-08 03:59:00  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-08 03:59:04  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-08 03:59:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-08 03:59:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-08 03:59:21  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-08 03:59:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-08 03:59:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-08 03:59:40  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-08 03:59:44  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-08 03:59:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-08 03:59:54  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-08 03:59:59  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-08 04:00:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-08 04:00:08  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-08 04:00:13  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-08 04:00:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-08 04:00:22  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-08 04:00:27  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-08 04:00:32  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-08 04:00:36  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-08 04:00:41  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-08 04:00:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-08 04:00:50  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-08 04:00:55  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-08 04:01:00  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-08 04:01:04  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-08 04:01:09  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-08 04:01:13  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-08 04:01:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-08 04:01:23  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-08 04:01:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-08 04:01:32  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-08 04:01:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-08 04:01:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-08 04:01:46  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-08 04:01:50  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-08 04:01:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-08_04-01-55 Restart Xvfb...
2017-04-08 04:02:00  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-08 04:02:04  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-08 04:02:09  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-08 04:02:14  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-08 04:02:18  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-08 04:02:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-08 04:02:27  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-08 04:02:32  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-08 04:02:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-08 04:02:41  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-08 04:02:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-08 04:02:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-08 04:02:56  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-08 04:03:01  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-08 04:03:05  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-08 04:03:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-08 04:03:15  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-08 04:03:19  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-08 04:03:24  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-08 04:03:29  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-08 04:03:34  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-08 04:03:38  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-08 04:03:43  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-08 04:03:48  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-08 04:03:52  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-08 04:03:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-08 04:04:01  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-08 04:04:06  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-08 04:04:10  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-08 04:04:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-08 04:04:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-08 04:04:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-08 04:04:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-08 04:04:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-08 04:04:38  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-08 04:04:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-08 04:04:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-08 04:04:52  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-08 04:04:56  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-08 04:05:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-08 04:05:06  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-08 04:05:10  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-08 04:05:15  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-08 04:05:20  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-08 04:05:24  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-08 04:05:28  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-08 04:05:33  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-08 04:05:37  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-08 04:05:42  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-08 04:05:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-08 04:05:51  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-08 04:05:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-08 04:06:00  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-08 04:06:05  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-08 04:06:09  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-08 04:06:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-08 04:06:19  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-08 04:06:24  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-08 04:06:28  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-08 04:06:33  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-08 04:06:38  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-08 04:06:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-08 04:06:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-08 04:06:52  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-08 04:06:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-08 04:07:01  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-08 04:07:05  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-08 04:07:10  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-08 04:07:14  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-08 04:07:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-08 04:07:24  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-08 04:07:28  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-08 04:07:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-08 04:07:37  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-08 04:07:41  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-08 04:07:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-08 04:07:50  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-08 04:07:54  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-08 04:07:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-08 04:08:04  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-08 04:08:08  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-08 04:08:12  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-08 04:08:17  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-08 04:08:22  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-08 04:08:26  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-08 04:08:31  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-08 04:08:36  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-08 04:08:40  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-08 04:08:44  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-08 04:08:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-08 04:08:53  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-08 04:08:58  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-08 04:09:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-08 04:09:07  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-08 04:09:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-08 04:09:16  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-08 04:09:20  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-08 04:09:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-08 04:09:29  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-08 04:09:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-08 04:09:38  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-08 04:09:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-08 04:09:48  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-08 04:09:53  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-08 04:09:57  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-08 04:10:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-08 04:10:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-08 04:10:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-08 04:10:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-08 04:10:20  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-08 04:10:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-08 04:10:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-08 04:10:33  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-08 04:10:37  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-08 04:10:42  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-08 04:10:46  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-08 04:10:51  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-08 04:10:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-08 04:11:00  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-08 04:11:04  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-08 04:11:08  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-08 04:11:13  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-08 04:11:18  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-08 04:11:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-08 04:11:27  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-08 04:11:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-08 04:11:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-08 04:11:41  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-08 04:11:42  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-08 04:11:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-08 04:11:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-08 04:11:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-08 04:11:59  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-08 04:12:04  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-08 04:12:09  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-08 04:12:13  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-08 04:12:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-08 04:12:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-08 04:12:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-08 04:12:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-08 04:12:36  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-08 04:12:40  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-08 04:12:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-08 04:12:49  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-08 04:12:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-08 04:12:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-08 04:13:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-08 04:13:07  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-08 04:13:12  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-08 04:13:17  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-08 04:13:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-08 04:13:26  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-08 04:13:30  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-08 04:13:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-08 04:13:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-08 04:13:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-08 04:13:48  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-08 04:13:52  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-08 04:13:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-08 04:14:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-08 04:14:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-08 04:14:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-08 04:14:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-08 04:14:17  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-08 04:14:21  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-08 04:14:25  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-08 04:14:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-08 04:14:34  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-08 04:14:38  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-08 04:14:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-08 04:14:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-08 04:14:51  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-08 04:14:55  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-08 04:14:59  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-08 04:15:03  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-08 04:15:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-08 04:15:12  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-08 04:15:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-08 04:15:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-08 04:15:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-08 04:15:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-08 04:15:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-08 04:15:39  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-08 04:15:43  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-08 04:15:47  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-08 04:15:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-08 04:15:56  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-08 04:16:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-08 04:16:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-08 04:16:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-08 04:16:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 04:16:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 04:16:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 04:16:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 04:16:29  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-08 04:16:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 04:16:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 04:16:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-08 04:16:45  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-08 04:16:49  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-08 04:16:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-08 04:16:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-08 04:17:02  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-08 04:17:06  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-08 04:17:10  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-08 04:17:14  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-08 04:17:19  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-08 04:17:23  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-08 04:17:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-08 04:17:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-08 04:17:36  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-08 04:17:40  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-08 04:17:44  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-08 04:17:48  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-08 04:17:52  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-08 04:17:56  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-08 04:18:00  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-08 04:18:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 04:18:08  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 04:18:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 04:18:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 04:18:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 04:18:24  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-08 04:18:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 04:18:32  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 04:18:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 04:18:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 04:18:45  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-08 04:18:49  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 04:18:53  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 04:18:57  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 04:19:01  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-08 04:19:05  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-08_04-31-55 Restart Xvfb...
2017-04-08_05-01-55 Restart Xvfb...
2017-04-08_05-31-55 Restart Xvfb...
2017-04-08_06-01-56 Restart Xvfb...
2017-04-08 06:31:46 reset updateRequest
2017-04-08 06:31:50  - 14968  http://www.lymphomahub.com/
2017-04-08 06:31:51  - 14968  http://www.lymphomahub.com/
2017-04-08_06-31-56 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-08 06:33:56  - 14968  http://www.lymphomahub.com/
2017-04-08 06:33:56  - 14968  http://www.lymphomahub.com/
2017-04-08 06:34:01  - 14968  http://www.lymphomahub.com/about
2017-04-08 06:34:02  - 14968  http://www.lymphomahub.com/about
2017-04-08 06:34:07  - 14968  http://www.lymphomahub.com/terms
2017-04-08 06:34:11  - 14968  http://www.lymphomahub.com/undefined
2017-04-08 06:34:11  - 14968  http://www.lymphomahub.com/therapies
2017-04-08 06:34:17  - 14968  http://www.lymphomahub.com/newsletter
2017-04-08 06:34:20  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-08 06:34:24  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-08 06:34:28  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-08 06:34:33  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-08 06:34:37  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-08 06:34:42  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-08 06:34:46  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-08 06:34:50  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-08 06:34:55  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-08 06:34:59  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-08 06:35:04  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-08 06:35:09  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-08 06:35:13  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-08 06:35:18  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-08 06:35:22  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-08 06:35:27  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-08 06:35:31  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-08 06:35:36  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-08 06:35:40  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-08 06:35:44  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-08 06:35:49  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-08 06:35:54  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-08 06:35:58  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-08 06:36:02  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-08 06:36:06  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-08 06:36:11  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-08 06:36:15  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-08 06:36:20  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-08 06:36:24  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-08 06:36:29  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-08 06:36:34  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-08 06:36:38  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-08 06:36:42  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-08 06:36:47  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-08 06:36:52  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-08 06:36:56  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-08 06:37:01  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-08 06:37:05  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-08 06:37:09  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-08 06:37:14  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-08 06:37:18  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-08 06:37:23  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-08 06:37:27  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-08 06:37:32  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-08 06:37:37  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-08 06:37:41  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-08 06:37:46  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-08 06:37:50  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-08 06:37:54  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-08 06:37:59  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-08 06:38:04  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-08 06:38:08  - 14968  http://www.lymphomahub.com/medical-information
2017-04-08 06:38:13  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-08 06:38:18  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-08 06:38:22  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-08 06:38:27  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-08 06:38:31  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-08 06:38:36  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-08 06:38:41  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-08 06:38:45  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-08 06:38:50  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-08 06:38:54  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-08 06:38:59  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-08 06:39:03  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-08 06:39:04  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-08 06:39:08  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-08 06:39:13  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-08 06:39:17  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-08 06:39:22  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-08 06:39:27  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-08 06:39:31  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-08 06:39:35  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-08 06:39:40  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-08 06:39:44  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-08 06:39:49  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-08 06:39:54  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-08 06:39:58  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-08 06:40:03  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-08 06:40:08  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-08 06:40:12  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-08 06:40:17  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-08 06:40:21  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-08 06:40:26  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-08 06:40:30  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-08 06:40:34  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-08 06:40:39  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-08 06:40:44  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-08 06:40:48  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-08 06:40:53  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-08 06:40:57  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-08 06:41:01  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-08 06:41:06  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-08 06:41:10  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-08 06:41:14  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-08 06:41:19  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-08 06:41:20  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-08 06:41:24  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-08 06:41:29  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-08 06:41:33  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-08 06:41:38  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-08 06:41:42  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-08 06:41:47  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-08 06:41:51  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-08 06:41:56  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-08 06:41:59  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-08 06:42:00  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-08 06:42:04  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-08 06:42:09  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-08 06:42:13  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-08 06:42:18  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-08 06:42:22  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-08 06:42:23  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-08 06:42:27  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-08 06:42:32  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-08 06:42:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-08 06:42:40  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-08 06:42:44  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-08 06:42:48  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-08 06:42:52  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-08 06:42:56  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-08 06:43:00  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-08 06:43:05  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-08 06:43:09  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-08 06:43:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-08 06:43:18  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-08 06:43:22  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-08 06:43:22  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-08 06:43:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-08 06:43:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-08 06:43:35  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-08 06:43:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-08 06:43:44  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-08 06:43:49  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-08 06:43:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-08 06:43:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-08 06:44:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-08 06:44:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-08 06:44:08  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-08 06:44:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-08 06:44:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-08 06:44:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-08 06:44:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-08 06:44:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-08 06:44:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-08 06:44:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-08 06:44:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-08 06:44:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-08 06:44:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-08 06:44:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-08 06:44:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-08 06:45:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-08 06:45:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-08 06:45:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-08 06:45:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-08 06:45:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-08 06:45:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-08 06:45:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-08 06:45:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-08 06:45:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-08 06:45:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-08 06:45:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-08 06:45:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-08 06:45:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-08 06:46:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-08 06:46:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-08 06:46:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-08 06:46:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-08 06:46:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-08 06:46:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-08 06:46:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-08 06:46:32  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-08 06:46:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-08 06:46:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-08 06:46:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-08 06:46:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-08 06:46:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-08 06:46:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-08 06:47:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-08 06:47:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-08 06:47:10  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-08 06:47:15  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-08 06:47:20  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-08 06:47:23  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-08 06:47:28  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-08 06:47:32  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-08 06:47:36  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-08 06:47:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-08 06:47:45  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-08 06:47:49  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-08 06:47:53  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-08 06:47:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-08 06:48:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-08 06:48:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-08 06:48:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-08 06:48:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-08 06:48:18  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-08 06:48:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-08 06:48:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-08 06:48:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-08 06:48:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-08 06:48:43  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-08 06:48:44  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-08 06:48:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-08 06:48:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-08 06:48:57  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-08 06:49:02  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-08 06:49:06  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-08 06:49:11  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 06:49:15  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 06:49:20  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-08 06:49:25  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 06:49:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-08 06:49:34  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-08 06:49:39  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-08 06:49:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-08 06:49:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-08 06:49:53  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-08 06:49:57  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-08 06:50:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-08 06:50:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-08 06:50:12  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-08 06:50:17  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 06:50:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-08 06:50:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-08 06:50:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-08 06:50:35  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-08 06:50:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-08 06:50:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-08 06:50:49  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-08 06:50:54  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-08 06:50:59  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-08 06:51:03  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-08 06:51:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-08 06:51:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-08 06:51:17  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-08 06:51:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-08 06:51:27  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-08 06:51:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-08 06:51:36  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-08 06:51:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-08 06:51:45  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-08 06:51:50  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-08 06:51:55  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-08 06:51:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-08 06:52:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-08 06:52:04  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-08 06:52:09  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-08 06:52:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-08 06:52:19  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-08 06:52:23  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-08 06:52:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-08 06:52:33  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-08 06:52:37  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-08 06:52:42  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-08 06:52:47  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-08 06:52:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-08 06:52:55  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-08 06:53:00  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-08 06:53:05  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-08 06:53:09  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-08 06:53:14  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-08 06:53:19  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-08 06:53:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-08 06:53:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-08 06:53:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-08 06:53:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-08 06:53:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-08 06:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-08 06:53:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-08 06:53:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-08 06:53:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-08 06:54:02  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-08 06:54:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-08 06:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-08 06:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-08 06:54:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-08 06:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-08 06:54:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-08 06:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-08 06:54:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-08 06:54:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-08 06:54:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-08 06:54:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-08 06:54:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-08 06:54:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-08 06:54:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-08 06:54:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-08 06:55:00  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-08 06:55:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-08 06:55:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-08 06:55:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-08 06:55:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-08 06:55:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-08 06:55:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-08 06:55:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-08 06:55:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-08 06:55:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-08 06:55:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-08 06:55:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-08 06:55:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-08 06:55:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-08 06:55:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-08 06:55:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-08 06:55:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-08 06:56:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-08 06:56:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-08 06:56:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-08 06:56:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-08 06:56:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-08 06:56:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-08 06:56:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-08 06:56:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-08 06:56:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-08 06:56:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-08 06:56:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-08 06:56:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-08 06:56:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-08 06:56:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-08 06:56:54  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-08 06:56:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-08 06:57:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-08 06:57:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-08 06:57:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-08 06:57:15  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-08 06:57:19  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-08 06:57:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-08 06:57:29  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-08 06:57:29  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-08 06:57:34  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-08 06:57:38  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-08 06:57:43  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-08 06:57:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-08 06:57:52  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-08 06:57:57  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-08 06:58:02  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-08 06:58:06  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-08 06:58:11  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-08 06:58:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-08 06:58:21  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-08 06:58:25  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-08 06:58:30  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-08 06:58:35  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-08 06:58:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-08 06:58:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-08 06:58:48  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-08 06:58:52  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-08 06:58:57  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-08 06:59:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-08 06:59:06  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-08 06:59:11  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-08 06:59:15  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-08 06:59:20  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-08 06:59:25  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-08 06:59:29  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-08 06:59:34  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-08 06:59:39  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-08 06:59:43  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-08 06:59:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-08 06:59:52  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-08 06:59:57  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-08 07:00:02  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-08 07:00:06  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-08 07:00:11  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-08 07:00:16  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-08 07:00:21  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-08 07:00:27  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-08 07:00:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-08 07:00:37  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-08 07:00:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-08 07:00:46  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-08 07:00:50  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-08 07:00:55  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-08 07:01:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-08 07:01:05  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-08 07:01:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-08 07:01:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-08 07:01:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-08 07:01:23  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-08 07:01:28  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-08 07:01:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-08 07:01:37  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-08 07:01:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-08 07:01:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-08 07:01:51  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-08_07-01-56 Restart Xvfb...
2017-04-08 07:01:56  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-08 07:02:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-08 07:02:05  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-08 07:02:10  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-08 07:02:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-08 07:02:19  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-08 07:02:23  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-08 07:02:28  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-08 07:02:33  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-08 07:02:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-08 07:02:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-08 07:02:47  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-08 07:02:52  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-08 07:02:56  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-08 07:03:01  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-08 07:03:06  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-08 07:03:10  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-08 07:03:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-08 07:03:20  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-08 07:03:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-08 07:03:29  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-08 07:03:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-08 07:03:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-08 07:03:43  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-08 07:03:48  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-08 07:03:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-08 07:03:56  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-08 07:04:01  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-08 07:04:06  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-08 07:04:11  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-08 07:04:15  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-08 07:04:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-08 07:04:24  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-08 07:04:28  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-08 07:04:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-08 07:04:38  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-08 07:04:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-08 07:04:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-08 07:04:52  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-08 07:04:57  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-08 07:05:01  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-08 07:05:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-08 07:05:11  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-08 07:05:16  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-08 07:05:20  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-08 07:05:25  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-08 07:05:30  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-08 07:05:35  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-08 07:05:40  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-08 07:05:45  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-08 07:05:49  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-08 07:05:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-08 07:05:59  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-08 07:06:03  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-08 07:06:08  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-08 07:06:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-08 07:06:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-08 07:06:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-08 07:06:27  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-08 07:06:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-08 07:06:36  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-08 07:06:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-08 07:06:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-08 07:06:50  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-08 07:06:55  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-08 07:07:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-08 07:07:05  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-08 07:07:09  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-08 07:07:14  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-08 07:07:18  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-08 07:07:22  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-08 07:07:27  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-08 07:07:32  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-08 07:07:36  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-08 07:07:41  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-08 07:07:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-08 07:07:50  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-08 07:07:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-08 07:07:59  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-08 07:08:04  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-08 07:08:09  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-08 07:08:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-08 07:08:19  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-08 07:08:24  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-08 07:08:28  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-08 07:08:33  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-08 07:08:37  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-08 07:08:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-08 07:08:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-08 07:08:51  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-08 07:08:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-08 07:09:00  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-08 07:09:05  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-08 07:09:10  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-08 07:09:15  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-08 07:09:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-08 07:09:24  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-08 07:09:29  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-08 07:09:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-08 07:09:37  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-08 07:09:42  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-08 07:09:46  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-08 07:09:51  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-08 07:09:55  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-08 07:10:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-08 07:10:05  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-08 07:10:09  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-08 07:10:14  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-08 07:10:19  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-08 07:10:23  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-08 07:10:28  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-08 07:10:33  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-08 07:10:37  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-08 07:10:42  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-08 07:10:46  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-08 07:10:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-08 07:10:55  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-08 07:11:00  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-08 07:11:04  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-08 07:11:09  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-08 07:11:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-08 07:11:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-08 07:11:23  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-08 07:11:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-08 07:11:31  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-08 07:11:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-08 07:11:41  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-08 07:11:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-08 07:11:50  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-08 07:11:54  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-08 07:11:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-08 07:12:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-08 07:12:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-08 07:12:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-08 07:12:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-08 07:12:21  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-08 07:12:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-08 07:12:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-08 07:12:35  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-08 07:12:39  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-08 07:12:43  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-08 07:12:48  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-08 07:12:52  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-08 07:12:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-08 07:13:01  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-08 07:13:05  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-08 07:13:10  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-08 07:13:14  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-08 07:13:19  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-08 07:13:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-08 07:13:28  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-08 07:13:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-08 07:13:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-08 07:13:42  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-08 07:13:43  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-08 07:13:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-08 07:13:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-08 07:13:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-08 07:14:01  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-08 07:14:06  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-08 07:14:11  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-08 07:14:15  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-08 07:14:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-08 07:14:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-08 07:14:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-08 07:14:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-08 07:14:37  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-08 07:14:42  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-08 07:14:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-08 07:14:51  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-08 07:14:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-08 07:14:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-08 07:15:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-08 07:15:09  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-08 07:15:13  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-08 07:15:18  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-08 07:15:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-08 07:15:27  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-08 07:15:31  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-08 07:15:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-08 07:15:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-08 07:15:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-08 07:15:49  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-08 07:15:53  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-08 07:15:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-08 07:16:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-08 07:16:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-08 07:16:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-08 07:16:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-08 07:16:19  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-08 07:16:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-08 07:16:28  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-08 07:16:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-08 07:16:36  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-08 07:16:40  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-08 07:16:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-08 07:16:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-08 07:16:53  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-08 07:16:57  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-08 07:17:01  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-08 07:17:06  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-08 07:17:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-08 07:17:14  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-08 07:17:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-08 07:17:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-08 07:17:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-08 07:17:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-08 07:17:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-08 07:17:42  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-08 07:17:46  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-08 07:17:50  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-08 07:17:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-08 07:17:58  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-08 07:18:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-08 07:18:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-08 07:18:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-08 07:18:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 07:18:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 07:18:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 07:18:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 07:18:31  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-08 07:18:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 07:18:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 07:18:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-08 07:18:48  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-08 07:18:52  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-08 07:18:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-08 07:19:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-08 07:19:05  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-08 07:19:09  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-08 07:19:13  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-08 07:19:17  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-08 07:19:21  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-08 07:19:25  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-08 07:19:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-08 07:19:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-08 07:19:38  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-08 07:19:42  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-08 07:19:46  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-08 07:19:50  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-08 07:19:54  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-08 07:19:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-08 07:20:02  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-08 07:20:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 07:20:10  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 07:20:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 07:20:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 07:20:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 07:20:27  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-08 07:20:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 07:20:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 07:20:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 07:20:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 07:20:47  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-08 07:20:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 07:20:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 07:20:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 07:21:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-08 07:21:07  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-08_07-31-56 Restart Xvfb...
2017-04-08_08-01-56 Restart Xvfb...
2017-04-08_08-31-56 Restart Xvfb...
2017-04-08_09-01-56 Restart Xvfb...
2017-04-08 09:31:46 reset updateRequest
2017-04-08 09:31:48  - 14968  http://www.lymphomahub.com/
2017-04-08 09:31:51  - 14968  http://www.lymphomahub.com/
2017-04-08 09:31:52  - 14968  http://www.lymphomahub.com/about
2017-04-08 09:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-08_09-31-56 Restart Xvfb...
2017-04-08 09:31:59  - 14968  http://www.lymphomahub.com/terms
2017-04-08 09:32:02  - 14968  http://www.lymphomahub.com/undefined
2017-04-08 09:32:03  - 14968  http://www.lymphomahub.com/therapies
2017-04-08 09:32:08  - 14968  http://www.lymphomahub.com/newsletter
2017-04-08 09:32:12  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-08 09:32:15  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-08 09:32:19  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-08 09:32:24  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-08 09:32:28  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-08 09:32:33  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-08 09:32:38  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-08 09:32:42  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-08 09:32:47  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-08 09:32:52  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-08 09:32:56  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-08 09:33:01  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-08 09:33:05  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-08 09:33:10  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-08 09:33:14  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-08 09:33:19  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-08 09:33:23  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-08 09:33:28  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-08 09:33:32  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-08 09:33:37  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-08 09:33:42  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-08 09:33:46  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-08 09:33:51  - 14968  http://www.lymphomahub.com/about/secretariat
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-08 09:33:55  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-08 09:33:57  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-08 09:33:59  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-08 09:34:02  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-08 09:34:04  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-08 09:34:06  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-08 09:34:10  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-08 09:34:10  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-08 09:34:15  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-08 09:34:15  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-08 09:34:20  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-08 09:34:20  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-08 09:34:25  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-08 09:34:25  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-08 09:34:31  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-08 09:34:35  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-08 09:34:40  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-08 09:34:45  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-08 09:34:49  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-08 09:34:54  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-08 09:34:58  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-08 09:35:03  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-08 09:35:07  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-08 09:35:13  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-08 09:35:18  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-08 09:35:23  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-08 09:35:27  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-08 09:35:32  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-08 09:35:36  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-08 09:35:41  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-08 09:35:45  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-08 09:35:50  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-08 09:35:55  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-08 09:35:59  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-08 09:36:04  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-08 09:36:08  - 14968  http://www.lymphomahub.com/medical-information
2017-04-08 09:36:13  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-08 09:36:17  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-08 09:36:22  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-08 09:36:28  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-08 09:36:33  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-08 09:36:37  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-08 09:36:42  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-08 09:36:46  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-08 09:36:51  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-08 09:36:56  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-08 09:37:00  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-08 09:37:04  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-08 09:37:05  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-08 09:37:10  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-08 09:37:14  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-08 09:37:19  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-08 09:37:23  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-08 09:37:28  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-08 09:37:32  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-08 09:37:37  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-08 09:37:41  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-08 09:37:46  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-08 09:37:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-08 09:37:55  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-08 09:37:59  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-08 09:38:04  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-08 09:38:09  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-08 09:38:13  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-08 09:38:18  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-08 09:38:22  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-08 09:38:27  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-08 09:38:31  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-08 09:38:36  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-08 09:38:40  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-08 09:38:44  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-08 09:38:49  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-08 09:38:53  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-08 09:38:58  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-08 09:39:02  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-08 09:39:07  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-08 09:39:11  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-08 09:39:16  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-08 09:39:20  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-08 09:39:21  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-08 09:39:26  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-08 09:39:30  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-08 09:39:35  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-08 09:39:39  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-08 09:39:44  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-08 09:39:48  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-08 09:39:53  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-08 09:39:57  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-08 09:40:01  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-08 09:40:01  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-08 09:40:06  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-08 09:40:11  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-08 09:40:15  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-08 09:40:20  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-08 09:40:24  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-08 09:40:25  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-08 09:40:30  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-08 09:40:34  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-08 09:40:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-08 09:40:42  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-08 09:40:46  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-08 09:40:50  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-08 09:40:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-08 09:40:58  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-08 09:41:02  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-08 09:41:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-08 09:41:11  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-08 09:41:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-08 09:41:20  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-08 09:41:23  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-08 09:41:24  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-08 09:41:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-08 09:41:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-08 09:41:37  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-08 09:41:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-08 09:41:46  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-08 09:41:51  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-08 09:41:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-08 09:41:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-08 09:42:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-08 09:42:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-08 09:42:10  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-08 09:42:14  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-08 09:42:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-08 09:42:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-08 09:42:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-08 09:42:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-08 09:42:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-08 09:42:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-08 09:42:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-08 09:42:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-08 09:42:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-08 09:42:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-08 09:43:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-08 09:43:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-08 09:43:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-08 09:43:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-08 09:43:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-08 09:43:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-08 09:43:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-08 09:43:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-08 09:43:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-08 09:43:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-08 09:43:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-08 09:43:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-08 09:43:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-08 09:44:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-08 09:44:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-08 09:44:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-08 09:44:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-08 09:44:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-08 09:44:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-08 09:44:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-08 09:44:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-08 09:44:36  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-08 09:44:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-08 09:44:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-08 09:44:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-08 09:44:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-08 09:44:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-08 09:45:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-08 09:45:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-08 09:45:11  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-08 09:45:15  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-08 09:45:19  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-08 09:45:24  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-08 09:45:27  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-08 09:45:32  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-08 09:45:36  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-08 09:45:41  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-08 09:45:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-08 09:45:49  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-08 09:45:53  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-08 09:45:57  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-08 09:46:01  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-08 09:46:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-08 09:46:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-08 09:46:14  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-08 09:46:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-08 09:46:23  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-08 09:46:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-08 09:46:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-08 09:46:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-08 09:46:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-08 09:46:47  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-08 09:46:48  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-08 09:46:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-08 09:46:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-08 09:47:02  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-08 09:47:06  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-08 09:47:11  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-08 09:47:15  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 09:47:20  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 09:47:25  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-08 09:47:29  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 09:47:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-08 09:47:39  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-08 09:47:44  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-08 09:47:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-08 09:47:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-08 09:47:57  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-08 09:48:02  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-08 09:48:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-08 09:48:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-08 09:48:17  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-08 09:48:21  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 09:48:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-08 09:48:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-08 09:48:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-08 09:48:40  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-08 09:48:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-08 09:48:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-08 09:48:54  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-08 09:48:59  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-08 09:49:04  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-08 09:49:08  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-08 09:49:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-08 09:49:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-08 09:49:22  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-08 09:49:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-08 09:49:31  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-08 09:49:36  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-08 09:49:40  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-08 09:49:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-08 09:49:50  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-08 09:49:54  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-08 09:49:59  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-08 09:50:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-08 09:50:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-08 09:50:09  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-08 09:50:14  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-08 09:50:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-08 09:50:23  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-08 09:50:28  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-08 09:50:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-08 09:50:37  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-08 09:50:41  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-08 09:50:46  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-08 09:50:51  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-08 09:50:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-08 09:51:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-08 09:51:04  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-08 09:51:09  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-08 09:51:14  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-08 09:51:19  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-08 09:51:23  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-08 09:51:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-08 09:51:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-08 09:51:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-08 09:51:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-08 09:51:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-08 09:51:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-08 09:51:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-08 09:51:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-08 09:52:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-08 09:52:06  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-08 09:52:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-08 09:52:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-08 09:52:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-08 09:52:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-08 09:52:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-08 09:52:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-08 09:52:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-08 09:52:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-08 09:52:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-08 09:52:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-08 09:52:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-08 09:52:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-08 09:52:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-08 09:52:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-08 09:53:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-08 09:53:04  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-08 09:53:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-08 09:53:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-08 09:53:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-08 09:53:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-08 09:53:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-08 09:53:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-08 09:53:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-08 09:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-08 09:53:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-08 09:53:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-08 09:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-08 09:53:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-08 09:53:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-08 09:53:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-08 09:54:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-08 09:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-08 09:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-08 09:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-08 09:54:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-08 09:54:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-08 09:54:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-08 09:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-08 09:54:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-08 09:54:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-08 09:54:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-08 09:54:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-08 09:54:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-08 09:54:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-08 09:54:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-08 09:54:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-08 09:55:00  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-08 09:55:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-08 09:55:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-08 09:55:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-08 09:55:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-08 09:55:21  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-08 09:55:25  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-08 09:55:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-08 09:55:35  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-08 09:55:36  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-08 09:55:40  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-08 09:55:45  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-08 09:55:50  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-08 09:55:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-08 09:55:59  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-08 09:56:04  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-08 09:56:09  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-08 09:56:13  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-08 09:56:18  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-08 09:56:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-08 09:56:28  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-08 09:56:33  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-08 09:56:37  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-08 09:56:42  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-08 09:56:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-08 09:56:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-08 09:56:55  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-08 09:57:00  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-08 09:57:04  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-08 09:57:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-08 09:57:14  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-08 09:57:19  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-08 09:57:23  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-08 09:57:28  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-08 09:57:32  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-08 09:57:37  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-08 09:57:41  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-08 09:57:46  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-08 09:57:51  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-08 09:57:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-08 09:58:00  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-08 09:58:04  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-08 09:58:10  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-08 09:58:15  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-08 09:58:19  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-08 09:58:24  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-08 09:58:28  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-08 09:58:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-08 09:58:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-08 09:58:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-08 09:58:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-08 09:58:52  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-08 09:58:56  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-08 09:59:01  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-08 09:59:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-08 09:59:10  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-08 09:59:14  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-08 09:59:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-08 09:59:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-08 09:59:28  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-08 09:59:33  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-08 09:59:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-08 09:59:42  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-08 09:59:47  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-08 09:59:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-08 09:59:56  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-08 10:00:01  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-08 10:00:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-08 10:00:10  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-08 10:00:14  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-08 10:00:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-08 10:00:24  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-08 10:00:29  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-08 10:00:33  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-08 10:00:38  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-08 10:00:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-08 10:00:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-08 10:00:52  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-08 10:00:57  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-08 10:01:02  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-08 10:01:06  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-08 10:01:11  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-08 10:01:16  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-08 10:01:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-08 10:01:25  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-08 10:01:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-08 10:01:35  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-08 10:01:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-08 10:01:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-08 10:01:48  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-08 10:01:53  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-08_10-01-56 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator?_prerender {"code":"ECONNRESET"}
2017-04-08 10:03:58  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-08 10:04:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-08 10:04:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-08 10:04:11  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-08 10:04:16  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-08 10:04:21  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-08 10:04:25  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-08 10:04:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-08 10:04:35  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-08 10:04:39  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-08 10:04:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-08 10:04:48  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-08 10:04:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-08 10:04:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-08 10:05:02  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-08 10:05:07  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-08 10:05:12  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-08 10:05:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-08 10:05:21  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-08 10:05:26  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-08 10:05:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-08 10:05:35  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-08 10:05:40  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-08 10:05:45  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-08 10:05:49  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-08 10:05:54  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-08 10:05:58  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-08 10:06:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-08 10:06:07  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-08 10:06:12  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-08 10:06:17  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-08 10:06:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-08 10:06:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-08 10:06:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-08 10:06:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-08 10:06:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-08 10:06:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-08 10:06:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-08 10:06:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-08 10:06:59  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-08 10:07:04  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-08 10:07:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-08 10:07:13  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-08 10:07:18  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-08 10:07:22  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-08 10:07:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-08 10:07:31  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-08 10:07:36  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-08 10:07:41  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-08 10:07:45  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-08 10:07:50  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-08 10:07:55  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-08 10:07:59  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-08 10:08:04  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-08 10:08:09  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-08 10:08:13  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-08 10:08:18  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-08 10:08:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-08 10:08:27  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-08 10:08:32  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-08 10:08:36  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-08 10:08:41  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-08 10:08:46  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-08 10:08:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-08 10:08:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-08 10:09:00  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-08 10:09:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-08 10:09:09  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-08 10:09:15  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-08 10:09:19  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-08 10:09:24  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-08 10:09:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-08 10:09:33  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-08 10:09:38  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-08 10:09:42  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-08 10:09:47  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-08 10:09:52  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-08 10:09:56  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-08 10:10:00  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-08 10:10:05  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-08 10:10:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-08 10:10:15  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-08 10:10:19  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-08 10:10:24  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-08 10:10:28  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-08 10:10:33  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-08 10:10:37  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-08 10:10:42  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-08 10:10:47  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-08 10:10:51  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-08 10:10:55  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-08 10:11:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-08 10:11:04  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-08 10:11:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-08 10:11:14  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-08 10:11:18  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-08 10:11:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-08 10:11:27  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-08 10:11:31  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-08 10:11:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-08 10:11:40  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-08 10:11:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-08 10:11:50  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-08 10:11:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-08 10:11:59  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-08 10:12:04  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-08 10:12:08  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-08 10:12:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-08 10:12:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-08 10:12:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-08 10:12:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-08 10:12:31  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-08 10:12:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-08 10:12:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-08 10:12:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-08 10:12:49  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-08 10:12:53  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-08 10:12:58  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-08 10:13:02  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-08 10:13:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-08 10:13:11  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-08 10:13:15  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-08 10:13:20  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-08 10:13:24  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-08 10:13:29  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-08 10:13:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-08 10:13:38  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-08 10:13:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-08 10:13:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-08 10:13:52  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-08 10:13:53  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-08 10:13:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-08 10:14:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-08 10:14:07  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-08 10:14:11  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-08 10:14:16  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-08 10:14:20  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-08 10:14:25  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-08 10:14:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-08 10:14:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-08 10:14:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-08 10:14:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-08 10:14:47  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-08 10:14:51  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-08 10:14:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-08 10:15:00  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-08 10:15:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-08 10:15:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-08 10:15:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-08 10:15:18  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-08 10:15:22  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-08 10:15:27  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-08 10:15:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-08 10:15:36  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-08 10:15:40  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-08 10:15:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-08 10:15:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-08 10:15:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-08 10:15:58  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-08 10:16:02  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-08 10:16:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-08 10:16:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-08 10:16:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-08 10:16:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-08 10:16:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-08 10:16:28  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-08 10:16:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-08 10:16:36  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-08 10:16:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-08 10:16:44  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-08 10:16:48  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-08 10:16:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-08 10:16:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-08 10:17:01  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-08 10:17:05  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-08 10:17:09  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-08 10:17:13  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-08 10:17:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-08 10:17:22  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-08 10:17:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-08 10:17:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-08 10:17:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-08 10:17:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-08 10:17:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-08 10:17:49  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-08 10:17:53  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-08 10:17:57  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-08 10:18:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-08 10:18:06  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-08 10:18:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-08 10:18:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-08 10:18:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-08 10:18:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 10:18:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 10:18:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 10:18:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 10:18:39  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-08 10:18:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 10:18:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 10:18:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-08 10:18:55  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-08 10:19:00  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-08 10:19:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-08 10:19:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-08 10:19:12  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-08 10:19:16  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-08 10:19:20  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-08 10:19:24  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-08 10:19:29  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-08 10:19:33  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-08 10:19:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-08 10:19:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-08 10:19:46  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-08 10:19:50  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-08 10:19:54  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-08 10:19:58  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-08 10:20:02  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-08 10:20:06  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-08 10:20:10  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-08 10:20:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 10:20:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 10:20:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 10:20:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 10:20:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 10:20:35  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-08 10:20:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 10:20:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 10:20:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 10:20:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 10:20:55  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-08 10:20:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 10:21:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 10:21:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 10:21:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-08 10:21:15  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-08_10-31-56 Restart Xvfb...
2017-04-08_11-01-56 Restart Xvfb...
2017-04-08_11-31-56 Restart Xvfb...
2017-04-08_12-01-56 Restart Xvfb...
2017-04-08 12:31:46 reset updateRequest
2017-04-08 12:31:51  - 14968  http://www.lymphomahub.com/
2017-04-08_12-31-56 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-08 12:33:56  - 14968  http://www.lymphomahub.com/
2017-04-08 12:34:00  - 14968  http://www.lymphomahub.com/about
2017-04-08 12:34:05  - 14968  http://www.lymphomahub.com/terms
2017-04-08 12:34:09  - 14968  http://www.lymphomahub.com/undefined
2017-04-08 12:34:09  - 14968  http://www.lymphomahub.com/therapies
2017-04-08 12:34:15  - 14968  http://www.lymphomahub.com/newsletter
2017-04-08 12:34:18  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-08 12:34:22  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-08 12:34:26  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-08 12:34:31  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-08 12:34:36  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-08 12:34:40  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-08 12:34:45  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-08 12:34:49  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-08 12:34:54  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-08 12:34:58  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-08 12:35:03  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-08 12:35:07  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-08 12:35:12  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-08 12:35:16  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-08 12:35:21  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-08 12:35:25  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-08 12:35:30  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-08 12:35:34  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-08 12:35:39  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-08 12:35:43  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-08 12:35:48  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-08 12:35:53  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-08 12:35:57  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-08 12:36:01  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-08 12:36:05  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-08 12:36:10  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-08 12:36:15  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-08 12:36:19  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-08 12:36:24  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-08 12:36:28  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-08 12:36:33  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-08 12:36:37  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-08 12:36:42  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-08 12:36:46  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-08 12:36:51  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-08 12:36:55  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-08 12:37:00  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-08 12:37:04  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-08 12:37:09  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-08 12:37:13  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-08 12:37:18  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-08 12:37:22  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-08 12:37:27  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-08 12:37:31  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-08 12:37:36  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-08 12:37:40  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-08 12:37:45  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-08 12:37:49  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-08 12:37:54  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-08 12:37:58  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-08 12:38:03  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-08 12:38:07  - 14968  http://www.lymphomahub.com/medical-information
2017-04-08 12:38:12  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-08 12:38:16  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-08 12:38:21  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-08 12:38:25  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-08 12:38:30  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-08 12:38:34  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-08 12:38:39  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-08 12:38:43  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-08 12:38:48  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-08 12:38:52  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-08 12:38:57  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-08 12:39:01  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-08 12:39:02  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-08 12:39:07  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-08 12:39:11  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-08 12:39:15  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-08 12:39:20  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-08 12:39:24  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-08 12:39:29  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-08 12:39:33  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-08 12:39:37  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-08 12:39:42  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-08 12:39:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-08 12:39:51  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-08 12:39:55  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-08 12:40:00  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-08 12:40:04  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-08 12:40:09  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-08 12:40:13  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-08 12:40:18  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-08 12:40:22  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-08 12:40:26  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-08 12:40:31  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-08 12:40:35  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-08 12:40:40  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-08 12:40:45  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-08 12:40:49  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-08 12:40:54  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-08 12:40:58  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-08 12:41:03  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-08 12:41:07  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-08 12:41:11  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-08 12:41:16  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-08 12:41:16  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-08 12:41:21  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-08 12:41:25  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-08 12:41:30  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-08 12:41:35  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-08 12:41:39  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-08 12:41:44  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-08 12:41:48  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-08 12:41:53  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-08 12:41:56  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-08 12:41:57  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-08 12:42:01  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-08 12:42:07  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-08 12:42:12  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-08 12:42:16  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-08 12:42:21  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-08 12:42:21  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-08 12:42:26  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-08 12:42:30  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-08 12:42:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-08 12:42:38  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-08 12:42:43  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-08 12:42:46  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-08 12:42:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-08 12:42:54  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-08 12:42:58  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-08 12:43:03  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-08 12:43:07  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-08 12:43:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-08 12:43:16  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-08 12:43:20  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-08 12:43:20  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-08 12:43:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-08 12:43:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-08 12:43:34  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-08 12:43:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-08 12:43:42  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-08 12:43:47  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-08 12:43:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-08 12:43:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-08 12:43:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-08 12:44:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-08 12:44:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-08 12:44:10  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-08 12:44:14  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-08 12:44:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-08 12:44:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-08 12:44:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-08 12:44:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-08 12:44:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-08 12:44:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-08 12:44:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-08 12:44:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-08 12:44:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-08 12:44:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-08 12:45:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-08 12:45:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-08 12:45:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-08 12:45:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-08 12:45:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-08 12:45:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-08 12:45:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-08 12:45:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-08 12:45:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-08 12:45:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-08 12:45:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-08 12:45:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-08 12:45:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-08 12:45:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-08 12:46:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-08 12:46:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-08 12:46:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-08 12:46:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-08 12:46:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-08 12:46:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-08 12:46:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-08 12:46:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-08 12:46:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-08 12:46:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-08 12:46:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-08 12:46:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-08 12:46:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-08 12:47:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-08 12:47:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-08 12:47:11  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-08 12:47:15  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-08 12:47:20  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-08 12:47:24  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-08 12:47:29  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-08 12:47:33  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-08 12:47:37  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-08 12:47:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-08 12:47:46  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-08 12:47:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-08 12:47:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-08 12:47:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-08 12:48:03  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-08 12:48:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-08 12:48:12  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-08 12:48:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-08 12:48:20  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-08 12:48:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-08 12:48:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-08 12:48:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-08 12:48:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-08 12:48:43  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-08 12:48:44  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-08 12:48:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-08 12:48:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-08 12:48:58  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-08 12:49:03  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-08 12:49:07  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-08 12:49:12  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 12:49:16  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 12:49:21  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-08 12:49:25  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 12:49:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-08 12:49:34  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-08 12:49:39  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-08 12:49:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-08 12:49:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-08 12:49:53  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-08 12:49:58  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-08 12:50:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-08 12:50:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-08 12:50:12  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-08 12:50:17  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 12:50:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-08 12:50:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-08 12:50:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-08 12:50:36  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-08 12:50:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-08 12:50:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-08 12:50:50  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-08 12:50:54  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-08 12:50:59  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-08 12:51:04  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-08 12:51:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-08 12:51:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-08 12:51:18  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-08 12:51:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-08 12:51:27  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-08 12:51:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-08 12:51:36  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-08 12:51:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-08 12:51:45  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-08 12:51:50  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-08 12:51:55  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-08 12:51:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-08 12:52:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-08 12:52:04  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-08 12:52:09  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-08 12:52:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-08 12:52:19  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-08 12:52:23  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-08 12:52:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-08 12:52:33  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-08 12:52:37  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-08 12:52:42  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-08 12:52:46  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-08 12:52:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-08 12:52:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-08 12:53:00  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-08 12:53:05  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-08 12:53:10  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-08 12:53:14  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-08 12:53:19  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-08 12:53:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-08 12:53:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-08 12:53:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-08 12:53:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-08 12:53:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-08 12:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-08 12:53:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-08 12:53:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-08 12:53:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-08 12:54:02  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-08 12:54:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-08 12:54:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-08 12:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-08 12:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-08 12:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-08 12:54:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-08 12:54:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-08 12:54:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-08 12:54:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-08 12:54:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-08 12:54:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-08 12:54:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-08 12:54:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-08 12:54:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-08 12:54:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-08 12:54:59  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-08 12:55:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-08 12:55:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-08 12:55:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-08 12:55:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-08 12:55:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-08 12:55:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-08 12:55:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-08 12:55:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-08 12:55:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-08 12:55:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-08 12:55:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-08 12:55:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-08 12:55:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-08 12:55:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-08 12:55:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-08 12:55:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-08 12:56:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-08 12:56:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-08 12:56:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-08 12:56:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-08 12:56:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-08 12:56:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-08 12:56:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-08 12:56:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-08 12:56:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-08 12:56:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-08 12:56:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-08 12:56:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-08 12:56:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-08 12:56:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-08 12:56:53  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-08 12:56:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-08 12:57:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-08 12:57:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-08 12:57:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-08 12:57:15  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-08 12:57:20  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-08 12:57:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-08 12:57:30  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-08 12:57:30  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-08 12:57:35  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-08 12:57:39  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-08 12:57:44  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-08 12:57:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-08 12:57:54  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-08 12:57:58  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-08 12:58:03  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-08 12:58:07  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-08 12:58:12  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-08 12:58:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-08 12:58:21  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-08 12:58:26  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-08 12:58:30  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-08 12:58:35  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-08 12:58:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-08 12:58:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-08 12:58:49  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-08 12:58:53  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-08 12:58:58  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-08 12:59:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-08 12:59:07  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-08 12:59:12  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-08 12:59:16  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-08 12:59:21  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-08 12:59:25  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-08 12:59:30  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-08 12:59:35  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-08 12:59:39  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-08 12:59:44  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-08 12:59:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-08 12:59:53  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-08 12:59:57  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-08 13:00:02  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-08 13:00:07  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-08 13:00:12  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-08 13:00:16  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-08 13:00:21  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-08 13:00:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-08 13:00:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-08 13:00:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-08 13:00:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-08 13:00:44  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-08 13:00:49  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-08 13:00:53  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-08 13:00:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-08 13:01:03  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-08 13:01:07  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-08 13:01:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-08 13:01:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-08 13:01:21  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-08 13:01:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-08 13:01:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-08 13:01:35  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-08 13:01:40  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-08 13:01:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-08 13:01:49  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-08 13:01:53  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-08_13-01-56 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation?_prerender {"code":"ECONNRESET"}
2017-04-08 13:03:58  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-08 13:04:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-08 13:04:07  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-08 13:04:12  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-08 13:04:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-08 13:04:21  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-08 13:04:26  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-08 13:04:31  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-08 13:04:36  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-08 13:04:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-08 13:04:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-08 13:04:50  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-08 13:04:55  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-08 13:04:59  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-08 13:05:04  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-08 13:05:08  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-08 13:05:13  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-08 13:05:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-08 13:05:22  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-08 13:05:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-08 13:05:31  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-08 13:05:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-08 13:05:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-08 13:05:46  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-08 13:05:50  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-08 13:05:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-08 13:05:59  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-08 13:06:04  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-08 13:06:09  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-08 13:06:14  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-08 13:06:18  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-08 13:06:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-08 13:06:27  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-08 13:06:31  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-08 13:06:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-08 13:06:40  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-08 13:06:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-08 13:06:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-08 13:06:54  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-08 13:06:59  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-08 13:07:04  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-08 13:07:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-08 13:07:14  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-08 13:07:18  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-08 13:07:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-08 13:07:28  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-08 13:07:33  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-08 13:07:37  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-08 13:07:42  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-08 13:07:46  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-08 13:07:51  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-08 13:07:55  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-08 13:08:00  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-08 13:08:05  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-08 13:08:10  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-08 13:08:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-08 13:08:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-08 13:08:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-08 13:08:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-08 13:08:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-08 13:08:38  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-08 13:08:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-08 13:08:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-08 13:08:52  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-08 13:08:57  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-08 13:09:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-08 13:09:06  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-08 13:09:11  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-08 13:09:15  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-08 13:09:20  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-08 13:09:24  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-08 13:09:29  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-08 13:09:33  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-08 13:09:38  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-08 13:09:42  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-08 13:09:47  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-08 13:09:52  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-08 13:09:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-08 13:10:01  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-08 13:10:06  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-08 13:10:11  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-08 13:10:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-08 13:10:20  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-08 13:10:25  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-08 13:10:30  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-08 13:10:34  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-08 13:10:39  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-08 13:10:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-08 13:10:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-08 13:10:53  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-08 13:10:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-08 13:11:02  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-08 13:11:07  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-08 13:11:11  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-08 13:11:16  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-08 13:11:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-08 13:11:25  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-08 13:11:30  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-08 13:11:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-08 13:11:39  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-08 13:11:43  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-08 13:11:47  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-08 13:11:52  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-08 13:11:57  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-08 13:12:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-08 13:12:06  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-08 13:12:10  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-08 13:12:14  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-08 13:12:19  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-08 13:12:24  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-08 13:12:28  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-08 13:12:33  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-08 13:12:38  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-08 13:12:42  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-08 13:12:46  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-08 13:12:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-08 13:12:55  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-08 13:13:00  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-08 13:13:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-08 13:13:09  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-08 13:13:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-08 13:13:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-08 13:13:23  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-08 13:13:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-08 13:13:31  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-08 13:13:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-08 13:13:41  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-08 13:13:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-08 13:13:50  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-08 13:13:55  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-08 13:13:59  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-08 13:14:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-08 13:14:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-08 13:14:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-08 13:14:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-08 13:14:21  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-08 13:14:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-08 13:14:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-08 13:14:34  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-08 13:14:38  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-08 13:14:42  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-08 13:14:47  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-08 13:14:52  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-08 13:14:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-08 13:15:00  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-08 13:15:04  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-08 13:15:09  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-08 13:15:13  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-08 13:15:18  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-08 13:15:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-08 13:15:27  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-08 13:15:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-08 13:15:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-08 13:15:41  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-08 13:15:42  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-08 13:15:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-08 13:15:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-08 13:15:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-08 13:16:00  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-08 13:16:05  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-08 13:16:10  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-08 13:16:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-08 13:16:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-08 13:16:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-08 13:16:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-08 13:16:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-08 13:16:37  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-08 13:16:42  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-08 13:16:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-08 13:16:51  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-08 13:16:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-08 13:16:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-08 13:17:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-08 13:17:09  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-08 13:17:13  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-08 13:17:18  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-08 13:17:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-08 13:17:27  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-08 13:17:31  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-08 13:17:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-08 13:17:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-08 13:17:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-08 13:17:50  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-08 13:17:54  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-08 13:17:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-08 13:18:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-08 13:18:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-08 13:18:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-08 13:18:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-08 13:18:19  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-08 13:18:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-08 13:18:28  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-08 13:18:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-08 13:18:36  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-08 13:18:40  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-08 13:18:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-08 13:18:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-08 13:18:53  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-08 13:18:57  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-08 13:19:01  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-08 13:19:05  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-08 13:19:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-08 13:19:14  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-08 13:19:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-08 13:19:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-08 13:19:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-08 13:19:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-08 13:19:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-08 13:19:41  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-08 13:19:45  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-08 13:19:50  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-08 13:19:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-08 13:19:59  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-08 13:20:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-08 13:20:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-08 13:20:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-08 13:20:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 13:20:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 13:20:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 13:20:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 13:20:31  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-08 13:20:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 13:20:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 13:20:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-08 13:20:48  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-08 13:20:52  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-08 13:20:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-08 13:21:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-08 13:21:04  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-08 13:21:08  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-08 13:21:12  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-08 13:21:16  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-08 13:21:20  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-08 13:21:24  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-08 13:21:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-08 13:21:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-08 13:21:37  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-08 13:21:41  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-08 13:21:45  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-08 13:21:49  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-08 13:21:53  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-08 13:21:57  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-08 13:22:01  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-08 13:22:05  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 13:22:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 13:22:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 13:22:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 13:22:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 13:22:26  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-08 13:22:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 13:22:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 13:22:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 13:22:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 13:22:46  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-08 13:22:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 13:22:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 13:22:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 13:23:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-08 13:23:07  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-08_13-31-56 Restart Xvfb...
2017-04-08_14-01-56 Restart Xvfb...
2017-04-08_14-31-56 Restart Xvfb...
2017-04-08_15-01-56 Restart Xvfb...
2017-04-08 15:31:46 reset updateRequest
2017-04-08 15:31:47  - 14968  http://www.lymphomahub.com/
2017-04-08 15:31:51  - 14968  http://www.lymphomahub.com/
2017-04-08 15:31:51  - 14968  http://www.lymphomahub.com/about
2017-04-08 15:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-08_15-31-56 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-08 15:33:56  - 14968  http://www.lymphomahub.com/about
2017-04-08 15:34:00  - 14968  http://www.lymphomahub.com/terms
2017-04-08 15:34:01  - 14968  http://www.lymphomahub.com/terms
2017-04-08 15:34:04  - 14968  http://www.lymphomahub.com/undefined
2017-04-08 15:34:05  - 14968  http://www.lymphomahub.com/therapies
2017-04-08 15:34:05  - 14968  http://www.lymphomahub.com/therapies
2017-04-08 15:34:14  - 14968  http://www.lymphomahub.com/newsletter
2017-04-08 15:34:15  - 14968  http://www.lymphomahub.com/newsletter
2017-04-08 15:34:18  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-08 15:34:19  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-08 15:34:21  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-08 15:34:23  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-08 15:34:26  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-08 15:34:28  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-08 15:34:31  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-08 15:34:33  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-08 15:34:37  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-08 15:34:38  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-08 15:34:42  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-08 15:34:42  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-08 15:34:47  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-08 15:34:47  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-08 15:34:52  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-08 15:34:57  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-08 15:35:01  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-08 15:35:06  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-08 15:35:11  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-08 15:35:15  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-08 15:35:20  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-08 15:35:24  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-08 15:35:29  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-08 15:35:33  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-08 15:35:38  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-08 15:35:42  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-08 15:35:47  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-08 15:35:52  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-08 15:35:56  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-08 15:36:00  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-08 15:36:04  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-08 15:36:09  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-08 15:36:13  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-08 15:36:18  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-08 15:36:22  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-08 15:36:27  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-08 15:36:31  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-08 15:36:36  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-08 15:36:40  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-08 15:36:45  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-08 15:36:50  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-08 15:36:54  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-08 15:36:59  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-08 15:37:03  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-08 15:37:08  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-08 15:37:13  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-08 15:37:17  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-08 15:37:22  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-08 15:37:26  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-08 15:37:31  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-08 15:37:35  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-08 15:37:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-08 15:37:44  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-08 15:37:49  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-08 15:37:53  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-08 15:37:57  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-08 15:38:02  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-08 15:38:07  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-08 15:38:11  - 14968  http://www.lymphomahub.com/medical-information
2017-04-08 15:38:16  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-08 15:38:21  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-08 15:38:25  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-08 15:38:30  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-08 15:38:34  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-08 15:38:39  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-08 15:38:43  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-08 15:38:48  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-08 15:38:53  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-08 15:38:57  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-08 15:39:02  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-08 15:39:06  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-08 15:39:07  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-08 15:39:11  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-08 15:39:16  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-08 15:39:20  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-08 15:39:25  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-08 15:39:29  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-08 15:39:33  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-08 15:39:38  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-08 15:39:42  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-08 15:39:47  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-08 15:39:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-08 15:39:55  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-08 15:40:00  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-08 15:40:04  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-08 15:40:09  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-08 15:40:13  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-08 15:40:18  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-08 15:40:23  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-08 15:40:27  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-08 15:40:33  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-08 15:40:38  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-08 15:40:42  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-08 15:40:47  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-08 15:40:51  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-08 15:40:56  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-08 15:41:00  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-08 15:41:05  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-08 15:41:09  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-08 15:41:13  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-08 15:41:18  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-08 15:41:22  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-08 15:41:23  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-08 15:41:28  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-08 15:41:32  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-08 15:41:37  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-08 15:41:41  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-08 15:41:46  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-08 15:41:50  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-08 15:41:55  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-08 15:41:59  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-08 15:42:03  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-08 15:42:03  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-08 15:42:08  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-08 15:42:12  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-08 15:42:17  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-08 15:42:21  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-08 15:42:26  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-08 15:42:26  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-08 15:42:31  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-08 15:42:35  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-08 15:42:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-08 15:42:44  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-08 15:42:48  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-08 15:42:52  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-08 15:42:56  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-08 15:43:00  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-08 15:43:04  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-08 15:43:08  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-08 15:43:12  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-08 15:43:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-08 15:43:21  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-08 15:43:25  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-08 15:43:26  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-08 15:43:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-08 15:43:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-08 15:43:39  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-08 15:43:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-08 15:43:47  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-08 15:43:52  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-08 15:43:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-08 15:43:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-08 15:44:03  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-08 15:44:08  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-08 15:44:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-08 15:44:15  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-08 15:44:19  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-08 15:44:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-08 15:44:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-08 15:44:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-08 15:44:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-08 15:44:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-08 15:44:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-08 15:44:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-08 15:44:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-08 15:44:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-08 15:45:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-08 15:45:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-08 15:45:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-08 15:45:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-08 15:45:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-08 15:45:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-08 15:45:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-08 15:45:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-08 15:45:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-08 15:45:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-08 15:45:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-08 15:45:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-08 15:45:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-08 15:45:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-08 15:46:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-08 15:46:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-08 15:46:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-08 15:46:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-08 15:46:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-08 15:46:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-08 15:46:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-08 15:46:35  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-08 15:46:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-08 15:46:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-08 15:46:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-08 15:46:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-08 15:46:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-08 15:47:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-08 15:47:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-08 15:47:10  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-08 15:47:14  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-08 15:47:19  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-08 15:47:24  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-08 15:47:28  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-08 15:47:32  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-08 15:47:36  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-08 15:47:40  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-08 15:47:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-08 15:47:49  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-08 15:47:53  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-08 15:47:57  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-08 15:48:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-08 15:48:05  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-08 15:48:09  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-08 15:48:14  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-08 15:48:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-08 15:48:22  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-08 15:48:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-08 15:48:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-08 15:48:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-08 15:48:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-08 15:48:46  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-08 15:48:47  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-08 15:48:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-08 15:48:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-08 15:49:00  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-08 15:49:05  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-08 15:49:10  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-08 15:49:14  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 15:49:19  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 15:49:24  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-08 15:49:28  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 15:49:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-08 15:49:37  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-08 15:49:42  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-08 15:49:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-08 15:49:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-08 15:49:56  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-08 15:50:00  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-08 15:50:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-08 15:50:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-08 15:50:15  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-08 15:50:19  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 15:50:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-08 15:50:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-08 15:50:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-08 15:50:38  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-08 15:50:43  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-08 15:50:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-08 15:50:52  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-08 15:50:57  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-08 15:51:01  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-08 15:51:06  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-08 15:51:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-08 15:51:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-08 15:51:20  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-08 15:51:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-08 15:51:29  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-08 15:51:33  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-08 15:51:38  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-08 15:51:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-08 15:51:47  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-08 15:51:52  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-08 15:51:57  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-08 15:51:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-08 15:52:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-08 15:52:07  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-08 15:52:12  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-08 15:52:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-08 15:52:21  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-08 15:52:26  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-08 15:52:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-08 15:52:35  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-08 15:52:40  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-08 15:52:45  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-08 15:52:50  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-08 15:52:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-08 15:52:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-08 15:53:03  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-08 15:53:08  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-08 15:53:13  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-08 15:53:17  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-08 15:53:22  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-08 15:53:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-08 15:53:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-08 15:53:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-08 15:53:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-08 15:53:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-08 15:53:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-08 15:53:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-08 15:53:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-08 15:54:01  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-08 15:54:05  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-08 15:54:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-08 15:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-08 15:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-08 15:54:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-08 15:54:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-08 15:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-08 15:54:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-08 15:54:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-08 15:54:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-08 15:54:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-08 15:54:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-08 15:54:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-08 15:54:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-08 15:54:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-08 15:55:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-08 15:55:04  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-08 15:55:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-08 15:55:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-08 15:55:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-08 15:55:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-08 15:55:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-08 15:55:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-08 15:55:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-08 15:55:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-08 15:55:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-08 15:55:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-08 15:55:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-08 15:55:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-08 15:55:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-08 15:55:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-08 15:55:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-08 15:56:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-08 15:56:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-08 15:56:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-08 15:56:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-08 15:56:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-08 15:56:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-08 15:56:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-08 15:56:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-08 15:56:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-08 15:56:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-08 15:56:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-08 15:56:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-08 15:56:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-08 15:56:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-08 15:56:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-08 15:56:57  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-08 15:57:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-08 15:57:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-08 15:57:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-08 15:57:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-08 15:57:17  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-08 15:57:22  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-08 15:57:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-08 15:57:32  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-08 15:57:33  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-08 15:57:37  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-08 15:57:42  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-08 15:57:46  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-08 15:57:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-08 15:57:55  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-08 15:58:00  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-08 15:58:05  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-08 15:58:09  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-08 15:58:14  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-08 15:58:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-08 15:58:24  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-08 15:58:28  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-08 15:58:33  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-08 15:58:37  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-08 15:58:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-08 15:58:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-08 15:58:51  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-08 15:58:56  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-08 15:59:00  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-08 15:59:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-08 15:59:09  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-08 15:59:14  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-08 15:59:18  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-08 15:59:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-08 15:59:28  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-08 15:59:33  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-08 15:59:37  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-08 15:59:42  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-08 15:59:46  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-08 15:59:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-08 15:59:55  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-08 16:00:00  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-08 16:00:05  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-08 16:00:09  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-08 16:00:14  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-08 16:00:19  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-08 16:00:24  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-08 16:00:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-08 16:00:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-08 16:00:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-08 16:00:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-08 16:00:47  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-08 16:00:52  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-08 16:00:56  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-08 16:01:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-08 16:01:05  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-08 16:01:10  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-08 16:01:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-08 16:01:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-08 16:01:24  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-08 16:01:28  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-08 16:01:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-08 16:01:37  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-08 16:01:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-08 16:01:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-08 16:01:51  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-08 16:01:56  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-08_16-01-56 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation?_prerender {"code":"ECONNRESET"}
2017-04-08 16:04:01  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-08 16:04:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-08 16:04:10  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-08 16:04:15  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-08 16:04:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-08 16:04:25  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-08 16:04:30  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-08 16:04:35  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-08 16:04:39  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-08 16:04:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-08 16:04:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-08 16:04:53  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-08 16:04:58  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-08 16:05:03  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-08 16:05:07  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-08 16:05:12  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-08 16:05:17  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-08 16:05:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-08 16:05:26  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-08 16:05:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-08 16:05:36  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-08 16:05:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-08 16:05:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-08 16:05:50  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-08 16:05:54  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-08 16:05:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-08 16:06:03  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-08 16:06:08  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-08 16:06:12  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-08 16:06:17  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-08 16:06:21  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-08 16:06:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-08 16:06:31  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-08 16:06:35  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-08 16:06:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-08 16:06:44  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-08 16:06:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-08 16:06:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-08 16:06:59  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-08 16:07:03  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-08 16:07:08  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-08 16:07:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-08 16:07:17  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-08 16:07:22  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-08 16:07:26  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-08 16:07:31  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-08 16:07:36  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-08 16:07:40  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-08 16:07:45  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-08 16:07:50  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-08 16:07:55  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-08 16:08:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-08 16:08:04  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-08 16:08:09  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-08 16:08:14  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-08 16:08:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-08 16:08:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-08 16:08:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-08 16:08:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-08 16:08:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-08 16:08:43  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-08 16:08:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-08 16:08:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-08 16:08:57  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-08 16:09:01  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-08 16:09:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-08 16:09:11  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-08 16:09:15  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-08 16:09:20  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-08 16:09:25  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-08 16:09:29  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-08 16:09:33  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-08 16:09:38  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-08 16:09:43  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-08 16:09:47  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-08 16:09:52  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-08 16:09:57  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-08 16:10:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-08 16:10:07  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-08 16:10:11  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-08 16:10:16  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-08 16:10:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-08 16:10:25  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-08 16:10:30  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-08 16:10:34  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-08 16:10:39  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-08 16:10:44  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-08 16:10:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-08 16:10:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-08 16:10:58  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-08 16:11:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-08 16:11:07  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-08 16:11:12  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-08 16:11:16  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-08 16:11:21  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-08 16:11:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-08 16:11:31  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-08 16:11:37  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-08 16:11:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-08 16:11:45  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-08 16:11:50  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-08 16:11:54  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-08 16:11:58  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-08 16:12:03  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-08 16:12:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-08 16:12:12  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-08 16:12:16  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-08 16:12:21  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-08 16:12:26  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-08 16:12:30  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-08 16:12:35  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-08 16:12:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-08 16:12:45  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-08 16:12:49  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-08 16:12:53  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-08 16:12:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-08 16:13:02  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-08 16:13:07  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-08 16:13:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-08 16:13:16  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-08 16:13:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-08 16:13:25  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-08 16:13:30  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-08 16:13:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-08 16:13:38  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-08 16:13:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-08 16:13:47  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-08 16:13:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-08 16:13:57  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-08 16:14:01  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-08 16:14:05  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-08 16:14:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-08 16:14:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-08 16:14:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-08 16:14:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-08 16:14:28  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-08 16:14:32  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-08 16:14:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-08 16:14:41  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-08 16:14:45  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-08 16:14:49  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-08 16:14:54  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-08 16:14:59  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-08 16:15:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-08 16:15:07  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-08 16:15:11  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-08 16:15:16  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-08 16:15:20  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-08 16:15:25  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-08 16:15:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-08 16:15:34  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-08 16:15:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-08 16:15:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-08 16:15:48  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-08 16:15:48  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-08 16:15:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-08 16:15:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-08 16:16:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-08 16:16:06  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-08 16:16:11  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-08 16:16:16  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-08 16:16:21  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-08 16:16:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-08 16:16:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-08 16:16:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-08 16:16:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-08 16:16:43  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-08 16:16:47  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-08 16:16:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-08 16:16:56  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-08 16:17:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-08 16:17:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-08 16:17:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-08 16:17:14  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-08 16:17:19  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-08 16:17:24  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-08 16:17:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-08 16:17:32  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-08 16:17:36  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-08 16:17:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-08 16:17:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-08 16:17:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-08 16:17:55  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-08 16:17:59  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-08 16:18:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-08 16:18:07  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-08 16:18:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-08 16:18:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-08 16:18:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-08 16:18:24  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-08 16:18:28  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-08 16:18:32  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-08 16:18:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-08 16:18:40  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-08 16:18:44  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-08 16:18:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-08 16:18:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-08 16:18:57  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-08 16:19:01  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-08 16:19:05  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-08 16:19:09  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-08 16:19:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-08 16:19:18  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-08 16:19:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-08 16:19:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-08 16:19:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-08 16:19:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-08 16:19:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-08 16:19:45  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-08 16:19:49  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-08 16:19:53  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-08 16:19:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-08 16:20:02  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-08 16:20:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-08 16:20:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-08 16:20:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-08 16:20:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 16:20:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 16:20:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 16:20:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 16:20:35  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-08 16:20:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 16:20:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 16:20:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-08 16:20:51  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-08 16:20:55  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-08 16:20:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-08 16:21:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-08 16:21:08  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-08 16:21:12  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-08 16:21:16  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-08 16:21:20  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-08 16:21:24  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-08 16:21:28  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-08 16:21:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-08 16:21:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-08 16:21:41  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-08 16:21:45  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-08 16:21:48  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-08 16:21:53  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-08 16:21:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-08 16:22:01  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-08 16:22:05  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-08 16:22:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 16:22:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 16:22:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 16:22:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 16:22:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 16:22:30  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-08 16:22:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 16:22:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 16:22:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 16:22:46  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 16:22:51  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-08 16:22:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 16:22:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 16:23:02  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 16:23:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-08 16:23:11  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-08_16-31-56 Restart Xvfb...
2017-04-08_17-01-56 Restart Xvfb...
2017-04-08_17-31-56 Restart Xvfb...
2017-04-08_18-01-56 Restart Xvfb...
2017-04-08 18:31:46 reset updateRequest
2017-04-08 18:31:46  - 14968  http://www.lymphomahub.com/
2017-04-08 18:31:51  - 14968  http://www.lymphomahub.com/about
2017-04-08_18-31-56 Restart Xvfb...
2017-04-08 18:31:56  - 14968  http://www.lymphomahub.com/terms
2017-04-08 18:32:00  - 14968  http://www.lymphomahub.com/undefined
2017-04-08 18:32:01  - 14968  http://www.lymphomahub.com/therapies
2017-04-08 18:32:07  - 14968  http://www.lymphomahub.com/newsletter
2017-04-08 18:32:10  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-08 18:32:13  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-08 18:32:18  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-08 18:32:23  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-08 18:32:28  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-08 18:32:32  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-08 18:32:37  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-08 18:32:41  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-08 18:32:46  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-08 18:32:50  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-08 18:32:55  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-08 18:32:59  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-08 18:33:04  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-08 18:33:08  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-08 18:33:13  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-08 18:33:17  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-08 18:33:22  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-08 18:33:26  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-08 18:33:30  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-08 18:33:35  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-08 18:33:40  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-08 18:33:44  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-08 18:33:49  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-08 18:33:53  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-08 18:33:57  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-08 18:34:02  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-08 18:34:06  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-08 18:34:11  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-08 18:34:15  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-08 18:34:19  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-08 18:34:24  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-08 18:34:28  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-08 18:34:33  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-08 18:34:37  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-08 18:34:42  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-08 18:34:46  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-08 18:34:51  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-08 18:34:55  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-08 18:34:59  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-08 18:35:04  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-08 18:35:08  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-08 18:35:13  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-08 18:35:18  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-08 18:35:22  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-08 18:35:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-08 18:35:31  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-08 18:35:36  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-08 18:35:40  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-08 18:35:45  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-08 18:35:49  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-08 18:35:54  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-08 18:35:58  - 14968  http://www.lymphomahub.com/medical-information
2017-04-08 18:36:03  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-08 18:36:07  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-08 18:36:12  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-08 18:36:16  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-08 18:36:21  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-08 18:36:25  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-08 18:36:30  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-08 18:36:34  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-08 18:36:40  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-08 18:36:44  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-08 18:36:48  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-08 18:36:53  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-08 18:36:53  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-08 18:36:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-08 18:37:02  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-08 18:37:07  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-08 18:37:11  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-08 18:37:15  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-08 18:37:20  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-08 18:37:24  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-08 18:37:29  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-08 18:37:33  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-08 18:37:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-08 18:37:42  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-08 18:37:47  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-08 18:37:51  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-08 18:37:56  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-08 18:38:00  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-08 18:38:04  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-08 18:38:09  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-08 18:38:13  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-08 18:38:18  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-08 18:38:22  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-08 18:38:27  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-08 18:38:31  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-08 18:38:36  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-08 18:38:41  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-08 18:38:45  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-08 18:38:50  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-08 18:38:55  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-08 18:38:59  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-08 18:39:04  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-08 18:39:08  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-08 18:39:09  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-08 18:39:13  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-08 18:39:18  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-08 18:39:22  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-08 18:39:27  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-08 18:39:31  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-08 18:39:36  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-08 18:39:40  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-08 18:39:45  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-08 18:39:48  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-08 18:39:49  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-08 18:39:53  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-08 18:39:57  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-08 18:40:02  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-08 18:40:07  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-08 18:40:11  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-08 18:40:12  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-08 18:40:16  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-08 18:40:21  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-08 18:40:25  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-08 18:40:29  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-08 18:40:34  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-08 18:40:37  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-08 18:40:41  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-08 18:40:45  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-08 18:40:49  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-08 18:40:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-08 18:40:58  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-08 18:41:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-08 18:41:06  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-08 18:41:10  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-08 18:41:11  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-08 18:41:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-08 18:41:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-08 18:41:24  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-08 18:41:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-08 18:41:33  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-08 18:41:38  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-08 18:41:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-08 18:41:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-08 18:41:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-08 18:41:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-08 18:41:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-08 18:42:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-08 18:42:05  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-08 18:42:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-08 18:42:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-08 18:42:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-08 18:42:22  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-08 18:42:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-08 18:42:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-08 18:42:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-08 18:42:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-08 18:42:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-08 18:42:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-08 18:42:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-08 18:42:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-08 18:43:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-08 18:43:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-08 18:43:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-08 18:43:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-08 18:43:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-08 18:43:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-08 18:43:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-08 18:43:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-08 18:43:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-08 18:43:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-08 18:43:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-08 18:43:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-08 18:43:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-08 18:43:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-08 18:44:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-08 18:44:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-08 18:44:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-08 18:44:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-08 18:44:21  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-08 18:44:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-08 18:44:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-08 18:44:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-08 18:44:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-08 18:44:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-08 18:44:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-08 18:44:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-08 18:44:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-08 18:45:00  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-08 18:45:05  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-08 18:45:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-08 18:45:13  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-08 18:45:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-08 18:45:22  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-08 18:45:27  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-08 18:45:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-08 18:45:35  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-08 18:45:39  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-08 18:45:43  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-08 18:45:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-08 18:45:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-08 18:45:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-08 18:46:00  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-08 18:46:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-08 18:46:09  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-08 18:46:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-08 18:46:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-08 18:46:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-08 18:46:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-08 18:46:32  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-08 18:46:33  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-08 18:46:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-08 18:46:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-08 18:46:47  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-08 18:46:51  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-08 18:46:56  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-08 18:47:01  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 18:47:05  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 18:47:10  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-08 18:47:14  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 18:47:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-08 18:47:24  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-08 18:47:29  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-08 18:47:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-08 18:47:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-08 18:47:43  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-08 18:47:47  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-08 18:47:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-08 18:47:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-08 18:48:01  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-08 18:48:06  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 18:48:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-08 18:48:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-08 18:48:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-08 18:48:26  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-08 18:48:30  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-08 18:48:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-08 18:48:40  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-08 18:48:44  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-08 18:48:49  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-08 18:48:54  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-08 18:48:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-08 18:49:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-08 18:49:08  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-08 18:49:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-08 18:49:17  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-08 18:49:22  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-08 18:49:26  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-08 18:49:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-08 18:49:36  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-08 18:49:40  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-08 18:49:45  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-08 18:49:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-08 18:49:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-08 18:49:55  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-08 18:50:00  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-08 18:50:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-08 18:50:09  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-08 18:50:14  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-08 18:50:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-08 18:50:24  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-08 18:50:28  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-08 18:50:33  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-08 18:50:37  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-08 18:50:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-08 18:50:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-08 18:50:52  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-08 18:50:56  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-08 18:51:01  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-08 18:51:06  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-08 18:51:11  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-08 18:51:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-08 18:51:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-08 18:51:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-08 18:51:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-08 18:51:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-08 18:51:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-08 18:51:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-08 18:51:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-08 18:51:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-08 18:51:54  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-08 18:51:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-08 18:51:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-08 18:52:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-08 18:52:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-08 18:52:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-08 18:52:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-08 18:52:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-08 18:52:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-08 18:52:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-08 18:52:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-08 18:52:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-08 18:52:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-08 18:52:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-08 18:52:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-08 18:52:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-08 18:52:51  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-08 18:52:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-08 18:53:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-08 18:53:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-08 18:53:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-08 18:53:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-08 18:53:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-08 18:53:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-08 18:53:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-08 18:53:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-08 18:53:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-08 18:53:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-08 18:53:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-08 18:53:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-08 18:53:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-08 18:53:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-08 18:53:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-08 18:53:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-08 18:53:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-08 18:54:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-08 18:54:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-08 18:54:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-08 18:54:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-08 18:54:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-08 18:54:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-08 18:54:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-08 18:54:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-08 18:54:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-08 18:54:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-08 18:54:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-08 18:54:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-08 18:54:47  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-08 18:54:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-08 18:54:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-08 18:54:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-08 18:55:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-08 18:55:07  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-08 18:55:12  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-08 18:55:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-08 18:55:21  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-08 18:55:22  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-08 18:55:27  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-08 18:55:31  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-08 18:55:36  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-08 18:55:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-08 18:55:46  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-08 18:55:51  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-08 18:55:55  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-08 18:56:00  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-08 18:56:04  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-08 18:56:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-08 18:56:14  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-08 18:56:19  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-08 18:56:24  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-08 18:56:28  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-08 18:56:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-08 18:56:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-08 18:56:42  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-08 18:56:46  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-08 18:56:51  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-08 18:56:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-08 18:57:00  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-08 18:57:05  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-08 18:57:09  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-08 18:57:14  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-08 18:57:19  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-08 18:57:24  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-08 18:57:28  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-08 18:57:33  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-08 18:57:37  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-08 18:57:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-08 18:57:46  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-08 18:57:51  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-08 18:57:55  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-08 18:58:00  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-08 18:58:05  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-08 18:58:09  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-08 18:58:14  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-08 18:58:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-08 18:58:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-08 18:58:28  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-08 18:58:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-08 18:58:37  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-08 18:58:42  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-08 18:58:46  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-08 18:58:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-08 18:58:55  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-08 18:59:00  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-08 18:59:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-08 18:59:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-08 18:59:13  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-08 18:59:18  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-08 18:59:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-08 18:59:27  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-08 18:59:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-08 18:59:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-08 18:59:41  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-08 18:59:46  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-08 18:59:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-08 18:59:55  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-08 18:59:59  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-08 19:00:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-08 19:00:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-08 19:00:14  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-08 19:00:19  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-08 19:00:23  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-08 19:00:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-08 19:00:32  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-08 19:00:37  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-08 19:00:42  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-08 19:00:46  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-08 19:00:51  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-08 19:00:55  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-08 19:01:00  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-08 19:01:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-08 19:01:10  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-08 19:01:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-08 19:01:19  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-08 19:01:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-08 19:01:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-08 19:01:33  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-08 19:01:38  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-08 19:01:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-08 19:01:48  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-08 19:01:52  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-08_19-01-56 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients?_prerender {"code":"ECONNRESET"}
2017-04-08 19:03:57  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-08 19:04:02  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-08 19:04:06  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-08 19:04:11  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-08 19:04:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-08 19:04:20  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-08 19:04:25  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-08 19:04:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-08 19:04:34  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-08 19:04:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-08 19:04:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-08 19:04:48  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-08 19:04:53  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-08 19:04:58  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-08 19:05:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-08 19:05:07  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-08 19:05:18  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-08 19:05:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-08 19:05:28  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-08 19:05:33  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-08 19:05:37  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-08 19:05:42  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-08 19:05:46  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-08 19:05:52  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-08 19:05:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-08 19:06:01  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-08 19:06:05  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-08 19:06:12  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-08 19:06:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-08 19:06:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-08 19:06:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-08 19:06:31  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-08 19:06:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-08 19:06:41  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-08 19:06:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-08 19:06:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-08 19:06:55  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-08 19:06:59  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-08 19:07:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-08 19:07:09  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-08 19:07:13  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-08 19:07:18  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-08 19:07:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-08 19:07:26  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-08 19:07:31  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-08 19:07:36  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-08 19:07:40  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-08 19:07:45  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-08 19:07:50  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-08 19:07:54  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-08 19:07:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-08 19:08:04  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-08 19:08:08  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-08 19:08:13  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-08 19:08:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-08 19:08:22  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-08 19:08:27  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-08 19:08:31  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-08 19:08:36  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-08 19:08:41  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-08 19:08:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-08 19:08:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-08 19:08:55  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-08 19:08:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-08 19:09:04  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-08 19:09:09  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-08 19:09:13  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-08 19:09:18  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-08 19:09:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-08 19:09:27  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-08 19:09:32  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-08 19:09:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-08 19:09:40  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-08 19:09:45  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-08 19:09:49  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-08 19:09:53  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-08 19:09:58  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-08 19:10:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-08 19:10:09  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-08 19:10:13  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-08 19:10:18  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-08 19:10:23  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-08 19:10:27  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-08 19:10:32  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-08 19:10:37  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-08 19:10:41  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-08 19:10:46  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-08 19:10:50  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-08 19:10:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-08 19:10:59  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-08 19:11:04  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-08 19:11:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-08 19:11:13  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-08 19:11:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-08 19:11:22  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-08 19:11:27  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-08 19:11:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-08 19:11:35  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-08 19:11:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-08 19:11:44  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-08 19:11:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-08 19:11:53  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-08 19:11:58  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-08 19:12:02  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-08 19:12:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-08 19:12:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-08 19:12:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-08 19:12:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-08 19:12:25  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-08 19:12:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-08 19:12:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-08 19:12:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-08 19:12:44  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-08 19:12:48  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-08 19:12:53  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-08 19:12:58  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-08 19:13:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-08 19:13:06  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-08 19:13:10  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-08 19:13:15  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-08 19:13:20  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-08 19:13:24  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-08 19:13:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-08 19:13:34  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-08 19:13:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-08 19:13:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-08 19:13:48  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-08 19:13:49  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-08 19:13:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-08 19:13:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-08 19:14:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-08 19:14:07  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-08 19:14:12  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-08 19:14:16  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-08 19:14:22  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-08 19:14:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-08 19:14:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-08 19:14:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-08 19:14:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-08 19:14:44  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-08 19:14:48  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-08 19:14:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-08 19:14:57  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-08 19:15:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-08 19:15:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-08 19:15:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-08 19:15:15  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-08 19:15:20  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-08 19:15:25  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-08 19:15:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-08 19:15:33  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-08 19:15:37  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-08 19:15:42  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-08 19:15:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-08 19:15:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-08 19:15:56  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-08 19:16:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-08 19:16:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-08 19:16:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-08 19:16:12  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-08 19:16:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-08 19:16:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-08 19:16:25  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-08 19:16:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-08 19:16:33  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-08 19:16:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-08 19:16:42  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-08 19:16:46  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-08 19:16:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-08 19:16:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-08 19:17:00  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-08 19:17:04  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-08 19:17:08  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-08 19:17:12  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-08 19:17:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-08 19:17:20  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-08 19:17:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-08 19:17:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-08 19:17:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-08 19:17:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-08 19:17:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-08 19:17:47  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-08 19:17:51  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-08 19:17:55  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-08 19:17:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-08 19:18:04  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-08 19:18:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-08 19:18:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-08 19:18:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-08 19:18:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 19:18:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 19:18:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 19:18:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 19:18:37  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-08 19:18:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 19:18:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 19:18:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-08 19:18:54  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-08 19:18:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-08 19:19:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-08 19:19:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-08 19:19:11  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-08 19:19:15  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-08 19:19:19  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-08 19:19:23  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-08 19:19:28  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-08 19:19:32  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-08 19:19:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-08 19:19:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-08 19:19:45  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-08 19:19:49  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-08 19:19:53  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-08 19:19:57  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-08 19:20:01  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-08 19:20:06  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-08 19:20:10  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-08 19:20:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 19:20:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 19:20:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 19:20:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 19:20:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 19:20:35  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-08 19:20:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 19:20:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 19:20:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 19:20:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 19:20:55  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-08 19:20:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 19:21:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 19:21:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 19:21:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-08 19:21:15  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-08_19-31-56 Restart Xvfb...
2017-04-08_20-01-56 Restart Xvfb...
2017-04-08_20-31-56 Restart Xvfb...
2017-04-08_21-01-56 Restart Xvfb...
2017-04-08 21:31:46 reset updateRequest
2017-04-08 21:31:46  - 14968  http://www.lymphomahub.com/
2017-04-08 21:31:50  - 14968  http://www.lymphomahub.com/about
2017-04-08 21:31:51  - 14968  http://www.lymphomahub.com/about
2017-04-08 21:31:56  - 14968  http://www.lymphomahub.com/terms
2017-04-08_21-31-56 Restart Xvfb...
2017-04-08 21:31:56  - 14968  http://www.lymphomahub.com/terms
2017-04-08 21:32:00  - 14968  http://www.lymphomahub.com/undefined
2017-04-08 21:32:00  - 14968  http://www.lymphomahub.com/undefined
2017-04-08 21:32:01  - 14968  http://www.lymphomahub.com/therapies
2017-04-08 21:32:08  - 14968  http://www.lymphomahub.com/newsletter
2017-04-08 21:32:12  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-08 21:32:15  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-08 21:32:19  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-08 21:32:24  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-08 21:32:29  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-08 21:32:34  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-08 21:32:38  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-08 21:32:43  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-08 21:32:47  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-08 21:32:52  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-08 21:32:57  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-08 21:33:02  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-08 21:33:06  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-08 21:33:11  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-08 21:33:16  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-08 21:33:20  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-08 21:33:25  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-08 21:33:30  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-08 21:33:34  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-08 21:33:39  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-08 21:33:43  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-08 21:33:48  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-08 21:33:53  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-08 21:33:58  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-08 21:34:02  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-08 21:34:06  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-08 21:34:11  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-08 21:34:16  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-08 21:34:20  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-08 21:34:25  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-08 21:34:30  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-08 21:34:34  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-08 21:34:38  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-08 21:34:43  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-08 21:34:48  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-08 21:34:52  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-08 21:34:57  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-08 21:35:01  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-08 21:35:05  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-08 21:35:10  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-08 21:35:14  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-08 21:35:19  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-08 21:35:24  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-08 21:35:28  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-08 21:35:33  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-08 21:35:37  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-08 21:35:42  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-08 21:35:47  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-08 21:35:51  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-08 21:35:56  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-08 21:36:00  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-08 21:36:05  - 14968  http://www.lymphomahub.com/medical-information
2017-04-08 21:36:11  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-08 21:36:15  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-08 21:36:20  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-08 21:36:24  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-08 21:36:29  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-08 21:36:33  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-08 21:36:38  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-08 21:36:42  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-08 21:36:47  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-08 21:36:52  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-08 21:36:56  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-08 21:37:00  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-08 21:37:01  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-08 21:37:05  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-08 21:37:10  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-08 21:37:15  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-08 21:37:19  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-08 21:37:24  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-08 21:37:28  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-08 21:37:33  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-08 21:37:37  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-08 21:37:42  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-08 21:37:46  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-08 21:37:51  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-08 21:37:56  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-08 21:38:00  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-08 21:38:05  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-08 21:38:09  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-08 21:38:13  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-08 21:38:18  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-08 21:38:22  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-08 21:38:27  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-08 21:38:31  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-08 21:38:36  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-08 21:38:40  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-08 21:38:45  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-08 21:38:49  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-08 21:38:54  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-08 21:38:58  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-08 21:39:03  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-08 21:39:08  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-08 21:39:12  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-08 21:39:16  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-08 21:39:17  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-08 21:39:22  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-08 21:39:27  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-08 21:39:32  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-08 21:39:36  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-08 21:39:41  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-08 21:39:45  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-08 21:39:50  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-08 21:39:55  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-08 21:39:59  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-08 21:39:59  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-08 21:40:04  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-08 21:40:09  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-08 21:40:13  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-08 21:40:18  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-08 21:40:22  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-08 21:40:23  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-08 21:40:27  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-08 21:40:32  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-08 21:40:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-08 21:40:40  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-08 21:40:45  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-08 21:40:48  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-08 21:40:52  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-08 21:40:56  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-08 21:41:00  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-08 21:41:05  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-08 21:41:09  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-08 21:41:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-08 21:41:18  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-08 21:41:21  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-08 21:41:22  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-08 21:41:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-08 21:41:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-08 21:41:36  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-08 21:41:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-08 21:41:45  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-08 21:41:49  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-08 21:41:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-08 21:41:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-08 21:42:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-08 21:42:05  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-08 21:42:09  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-08 21:42:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-08 21:42:16  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-08 21:42:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-08 21:42:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-08 21:42:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-08 21:42:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-08 21:42:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-08 21:42:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-08 21:42:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-08 21:42:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-08 21:42:58  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-08 21:43:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-08 21:43:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-08 21:43:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-08 21:43:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-08 21:43:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-08 21:43:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-08 21:43:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-08 21:43:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-08 21:43:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-08 21:43:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-08 21:43:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-08 21:43:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-08 21:43:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-08 21:43:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-08 21:44:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-08 21:44:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-08 21:44:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-08 21:44:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-08 21:44:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-08 21:44:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-08 21:44:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-08 21:44:36  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-08 21:44:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-08 21:44:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-08 21:44:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-08 21:44:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-08 21:44:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-08 21:45:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-08 21:45:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-08 21:45:11  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-08 21:45:15  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-08 21:45:19  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-08 21:45:24  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-08 21:45:28  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-08 21:45:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-08 21:45:36  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-08 21:45:41  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-08 21:45:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-08 21:45:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-08 21:45:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-08 21:45:57  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-08 21:46:01  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-08 21:46:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-08 21:46:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-08 21:46:14  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-08 21:46:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-08 21:46:23  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-08 21:46:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-08 21:46:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-08 21:46:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-08 21:46:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-08 21:46:46  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-08 21:46:47  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-08 21:46:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-08 21:46:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-08 21:47:00  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-08 21:47:05  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-08 21:47:10  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-08 21:47:14  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 21:47:19  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 21:47:23  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-08 21:47:28  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 21:47:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-08 21:47:37  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-08 21:47:42  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-08 21:47:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-08 21:47:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-08 21:47:56  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-08 21:48:00  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-08 21:48:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-08 21:48:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-08 21:48:14  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-08 21:48:19  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-08 21:48:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-08 21:48:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-08 21:48:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-08 21:48:38  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-08 21:48:43  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-08 21:48:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-08 21:48:52  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-08 21:48:57  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-08 21:49:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-08 21:49:06  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-08 21:49:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-08 21:49:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-08 21:49:20  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-08 21:49:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-08 21:49:29  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-08 21:49:34  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-08 21:49:38  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-08 21:49:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-08 21:49:48  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-08 21:49:53  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-08 21:49:57  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-08 21:49:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-08 21:50:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-08 21:50:08  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-08 21:50:13  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-08 21:50:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-08 21:50:22  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-08 21:50:27  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-08 21:50:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-08 21:50:36  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-08 21:50:41  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-08 21:50:46  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-08 21:50:50  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-08 21:50:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-08 21:51:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-08 21:51:04  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-08 21:51:09  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-08 21:51:14  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-08 21:51:18  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-08 21:51:23  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-08 21:51:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-08 21:51:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-08 21:51:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-08 21:51:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-08 21:51:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-08 21:51:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-08 21:51:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-08 21:51:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-08 21:52:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-08 21:52:06  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-08 21:52:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-08 21:52:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-08 21:52:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-08 21:52:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-08 21:52:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-08 21:52:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-08 21:52:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-08 21:52:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-08 21:52:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-08 21:52:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-08 21:52:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-08 21:52:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-08 21:52:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-08 21:52:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-08 21:53:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-08 21:53:05  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-08 21:53:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-08 21:53:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-08 21:53:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-08 21:53:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-08 21:53:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-08 21:53:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-08 21:53:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-08 21:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-08 21:53:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-08 21:53:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-08 21:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-08 21:53:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-08 21:53:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-08 21:53:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-08 21:54:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-08 21:54:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-08 21:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-08 21:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-08 21:54:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-08 21:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-08 21:54:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-08 21:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-08 21:54:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-08 21:54:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-08 21:54:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-08 21:54:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-08 21:54:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-08 21:54:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-08 21:54:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-08 21:54:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-08 21:55:00  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-08 21:55:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-08 21:55:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-08 21:55:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-08 21:55:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-08 21:55:20  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-08 21:55:25  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-08 21:55:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-08 21:55:34  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-08 21:55:35  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-08 21:55:40  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-08 21:55:44  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-08 21:55:49  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-08 21:55:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-08 21:55:59  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-08 21:56:03  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-08 21:56:08  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-08 21:56:13  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-08 21:56:18  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-08 21:56:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-08 21:56:27  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-08 21:56:32  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-08 21:56:36  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-08 21:56:41  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-08 21:56:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-08 21:56:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-08 21:56:55  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-08 21:57:00  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-08 21:57:04  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-08 21:57:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-08 21:57:13  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-08 21:57:18  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-08 21:57:23  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-08 21:57:27  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-08 21:57:32  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-08 21:57:37  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-08 21:57:41  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-08 21:57:46  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-08 21:57:51  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-08 21:57:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-08 21:58:00  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-08 21:58:04  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-08 21:58:09  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-08 21:58:13  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-08 21:58:18  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-08 21:58:23  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-08 21:58:27  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-08 21:58:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-08 21:58:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-08 21:58:41  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-08 21:58:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-08 21:58:50  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-08 21:58:55  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-08 21:59:00  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-08 21:59:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-08 21:59:09  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-08 21:59:13  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-08 21:59:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-08 21:59:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-08 21:59:27  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-08 21:59:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-08 21:59:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-08 21:59:41  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-08 21:59:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-08 21:59:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-08 21:59:56  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-08 22:00:00  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-08 22:00:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-08 22:00:10  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-08 22:00:14  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-08 22:00:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-08 22:00:23  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-08 22:00:28  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-08 22:00:33  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-08 22:00:37  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-08 22:00:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-08 22:00:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-08 22:00:52  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-08 22:00:56  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-08 22:01:01  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-08 22:01:05  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-08 22:01:10  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-08 22:01:15  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-08 22:01:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-08 22:01:24  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-08 22:01:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-08 22:01:33  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-08 22:01:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-08 22:01:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-08 22:01:47  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-08 22:01:52  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-08 22:01:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-08_22-01-56 Restart Xvfb...
2017-04-08 22:02:01  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-08 22:02:06  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-08 22:02:10  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-08 22:02:15  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-08 22:02:19  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-08 22:02:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-08 22:02:28  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-08 22:02:33  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-08 22:02:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-08 22:02:42  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-08 22:02:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-08 22:02:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-08 22:02:56  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-08 22:03:01  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-08 22:03:06  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-08 22:03:11  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-08 22:03:15  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-08 22:03:20  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-08 22:03:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-08 22:03:30  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-08 22:03:34  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-08 22:03:39  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-08 22:03:44  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-08 22:03:48  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-08 22:03:53  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-08 22:03:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-08 22:04:02  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-08 22:04:07  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-08 22:04:12  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-08 22:04:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-08 22:04:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-08 22:04:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-08 22:04:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-08 22:04:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-08 22:04:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-08 22:04:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-08 22:04:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-08 22:04:55  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-08 22:05:00  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-08 22:05:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-08 22:05:09  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-08 22:05:14  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-08 22:05:19  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-08 22:05:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-08 22:05:27  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-08 22:05:32  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-08 22:05:37  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-08 22:05:42  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-08 22:05:46  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-08 22:05:51  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-08 22:05:55  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-08 22:06:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-08 22:06:05  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-08 22:06:09  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-08 22:06:14  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-08 22:06:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-08 22:06:24  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-08 22:06:29  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-08 22:06:34  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-08 22:06:38  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-08 22:06:43  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-08 22:06:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-08 22:06:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-08 22:06:57  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-08 22:07:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-08 22:07:06  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-08 22:07:10  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-08 22:07:15  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-08 22:07:20  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-08 22:07:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-08 22:07:29  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-08 22:07:34  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-08 22:07:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-08 22:07:42  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-08 22:07:47  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-08 22:07:51  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-08 22:07:56  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-08 22:08:00  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-08 22:08:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-08 22:08:10  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-08 22:08:14  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-08 22:08:19  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-08 22:08:24  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-08 22:08:28  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-08 22:08:33  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-08 22:08:38  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-08 22:08:42  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-08 22:08:47  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-08 22:08:51  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-08 22:08:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-08 22:09:00  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-08 22:09:05  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-08 22:09:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-08 22:09:14  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-08 22:09:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-08 22:09:23  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-08 22:09:28  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-08 22:09:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-08 22:09:36  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-08 22:09:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-08 22:09:46  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-08 22:09:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-08 22:09:55  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-08 22:10:00  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-08 22:10:04  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-08 22:10:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-08 22:10:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-08 22:10:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-08 22:10:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-08 22:10:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-08 22:10:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-08 22:10:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-08 22:10:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-08 22:10:44  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-08 22:10:48  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-08 22:10:53  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-08 22:10:58  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-08 22:11:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-08 22:11:07  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-08 22:11:11  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-08 22:11:16  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-08 22:11:20  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-08 22:11:25  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-08 22:11:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-08 22:11:35  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-08 22:11:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-08 22:11:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-08 22:11:49  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-08 22:11:49  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-08 22:11:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-08 22:11:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-08 22:12:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-08 22:12:07  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-08 22:12:12  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-08 22:12:16  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-08 22:12:21  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-08 22:12:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-08 22:12:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-08 22:12:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-08 22:12:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-08 22:12:44  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-08 22:12:48  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-08 22:12:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-08 22:12:58  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-08 22:13:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-08 22:13:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-08 22:13:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-08 22:13:16  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-08 22:13:21  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-08 22:13:25  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-08 22:13:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-08 22:13:34  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-08 22:13:38  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-08 22:13:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-08 22:13:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-08 22:13:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-08 22:13:58  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-08 22:14:02  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-08 22:14:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-08 22:14:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-08 22:14:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-08 22:14:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-08 22:14:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-08 22:14:28  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-08 22:14:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-08 22:14:36  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-08 22:14:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-08 22:14:45  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-08 22:14:49  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-08 22:14:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-08 22:14:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-08 22:15:02  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-08 22:15:07  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-08 22:15:12  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-08 22:15:16  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-08 22:15:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-08 22:15:25  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-08 22:15:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-08 22:15:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-08 22:15:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-08 22:15:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-08 22:15:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-08 22:15:52  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-08 22:15:56  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-08 22:16:00  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-08 22:16:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-08 22:16:09  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-08 22:16:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-08 22:16:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-08 22:16:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-08 22:16:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 22:16:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 22:16:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 22:16:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 22:16:42  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-08 22:16:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 22:16:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-08 22:16:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-08 22:16:59  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-08 22:17:03  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-08 22:17:07  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-08 22:17:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-08 22:17:15  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-08 22:17:20  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-08 22:17:24  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-08 22:17:28  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-08 22:17:32  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-08 22:17:36  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-08 22:17:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-08 22:17:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-08 22:17:50  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-08 22:17:54  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-08 22:17:58  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-08 22:18:02  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-08 22:18:06  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-08 22:18:10  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-08 22:18:15  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-08 22:18:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 22:18:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 22:18:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 22:18:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 22:18:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-08 22:18:39  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-08 22:18:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 22:18:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 22:18:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 22:18:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 22:19:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-08 22:19:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 22:19:08  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 22:19:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-08 22:19:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-08 22:19:20  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-08_22-31-56 Restart Xvfb...
2017-04-08_23-01-56 Restart Xvfb...
2017-04-08_23-31-56 Restart Xvfb...
2017-04-09_00-01-56 Restart Xvfb...
2017-04-09 00:31:46 reset updateRequest
2017-04-09 00:31:47  - 14968  http://www.lymphomahub.com/
2017-04-09 00:31:51  - 14968  http://www.lymphomahub.com/
2017-04-09 00:31:51  - 14968  http://www.lymphomahub.com/about
2017-04-09 00:31:56  - 14968  http://www.lymphomahub.com/terms
2017-04-09 00:31:56  - 14968  http://www.lymphomahub.com/terms
2017-04-09_00-31-56 Restart Xvfb...
2017-04-09 00:32:00  - 14968  http://www.lymphomahub.com/undefined
2017-04-09 00:32:00  - 14968  http://www.lymphomahub.com/therapies
2017-04-09 00:32:06  - 14968  http://www.lymphomahub.com/newsletter
2017-04-09 00:32:09  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-09 00:32:12  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-09 00:32:17  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-09 00:32:22  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-09 00:32:26  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-09 00:32:31  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-09 00:32:36  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-09 00:32:40  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-09 00:32:45  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-09 00:32:50  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-09 00:32:55  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-09 00:32:59  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-09 00:33:04  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-09 00:33:08  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-09 00:33:13  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-09 00:33:17  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-09 00:33:22  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-09 00:33:26  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-09 00:33:31  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-09 00:33:35  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-09 00:33:40  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-09 00:33:44  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-09 00:33:49  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-09 00:33:53  - 14968  http://www.lymphomahub.com/therapies/alt-803
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/terms?_prerender {"code":"ECONNRESET"}
2017-04-09 00:33:58  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-09 00:34:01  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-09 00:34:02  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-09 00:34:05  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-09 00:34:08  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-09 00:34:09  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-09 00:34:13  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-09 00:34:14  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-09 00:34:18  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-09 00:34:19  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-09 00:34:23  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-09 00:34:23  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-09 00:34:28  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-09 00:34:28  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-09 00:34:34  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-09 00:34:38  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-09 00:34:43  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-09 00:34:48  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-09 00:34:53  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-09 00:34:57  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-09 00:35:02  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-09 00:35:06  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-09 00:35:11  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-09 00:35:15  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-09 00:35:20  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-09 00:35:25  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-09 00:35:29  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-09 00:35:34  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-09 00:35:38  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-09 00:35:43  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-09 00:35:48  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-09 00:35:52  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-09 00:35:57  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-09 00:36:01  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-09 00:36:06  - 14968  http://www.lymphomahub.com/medical-information
2017-04-09 00:36:10  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-09 00:36:15  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-09 00:36:20  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-09 00:36:24  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-09 00:36:29  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-09 00:36:33  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-09 00:36:38  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-09 00:36:42  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-09 00:36:47  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-09 00:36:52  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-09 00:36:56  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-09 00:37:01  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-09 00:37:02  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-09 00:37:06  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-09 00:37:11  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-09 00:37:15  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-09 00:37:20  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-09 00:37:24  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-09 00:37:28  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-09 00:37:33  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-09 00:37:37  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-09 00:37:42  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-09 00:37:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-09 00:37:51  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-09 00:37:56  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-09 00:38:00  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-09 00:38:05  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-09 00:38:09  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-09 00:38:14  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-09 00:38:18  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-09 00:38:23  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-09 00:38:27  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-09 00:38:32  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-09 00:38:36  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-09 00:38:41  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-09 00:38:45  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-09 00:38:50  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-09 00:38:55  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-09 00:38:59  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-09 00:39:04  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-09 00:39:08  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-09 00:39:13  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-09 00:39:17  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-09 00:39:18  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-09 00:39:22  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-09 00:39:27  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-09 00:39:31  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-09 00:39:36  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-09 00:39:40  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-09 00:39:45  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-09 00:39:49  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-09 00:39:54  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-09 00:39:58  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-09 00:39:58  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-09 00:40:03  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-09 00:40:07  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-09 00:40:12  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-09 00:40:17  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-09 00:40:21  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-09 00:40:22  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-09 00:40:26  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-09 00:40:31  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-09 00:40:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-09 00:40:39  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-09 00:40:44  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-09 00:40:48  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-09 00:40:51  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-09 00:40:56  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-09 00:40:59  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-09 00:41:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-09 00:41:08  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-09 00:41:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-09 00:41:17  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-09 00:41:21  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-09 00:41:22  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-09 00:41:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-09 00:41:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-09 00:41:35  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-09 00:41:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-09 00:41:44  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-09 00:41:48  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-09 00:41:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-09 00:41:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-09 00:42:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-09 00:42:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-09 00:42:08  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-09 00:42:11  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-09 00:42:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-09 00:42:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-09 00:42:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-09 00:42:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-09 00:42:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-09 00:42:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-09 00:42:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-09 00:42:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-09 00:42:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-09 00:42:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-09 00:42:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-09 00:43:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-09 00:43:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-09 00:43:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-09 00:43:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-09 00:43:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-09 00:43:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-09 00:43:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-09 00:43:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-09 00:43:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-09 00:43:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-09 00:43:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-09 00:43:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-09 00:43:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-09 00:44:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-09 00:44:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-09 00:44:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-09 00:44:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-09 00:44:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-09 00:44:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-09 00:44:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-09 00:44:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-09 00:44:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-09 00:44:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-09 00:44:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-09 00:44:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-09 00:44:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-09 00:44:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-09 00:45:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-09 00:45:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-09 00:45:11  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-09 00:45:16  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-09 00:45:21  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-09 00:45:25  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-09 00:45:29  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-09 00:45:33  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-09 00:45:38  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-09 00:45:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-09 00:45:47  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-09 00:45:51  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-09 00:45:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-09 00:45:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-09 00:46:03  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-09 00:46:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-09 00:46:12  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-09 00:46:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-09 00:46:20  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-09 00:46:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-09 00:46:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-09 00:46:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-09 00:46:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-09 00:46:44  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-09 00:46:44  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-09 00:46:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-09 00:46:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-09 00:46:58  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-09 00:47:03  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-09 00:47:07  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-09 00:47:12  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 00:47:17  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 00:47:22  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-09 00:47:26  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 00:47:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-09 00:47:35  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-09 00:47:40  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-09 00:47:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-09 00:47:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-09 00:47:54  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-09 00:47:59  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-09 00:48:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-09 00:48:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-09 00:48:14  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-09 00:48:18  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 00:48:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-09 00:48:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-09 00:48:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-09 00:48:37  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-09 00:48:42  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-09 00:48:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-09 00:48:52  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-09 00:48:57  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-09 00:49:01  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-09 00:49:06  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-09 00:49:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-09 00:49:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-09 00:49:20  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-09 00:49:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-09 00:49:29  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-09 00:49:34  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-09 00:49:39  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-09 00:49:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-09 00:49:48  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-09 00:49:53  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-09 00:49:58  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-09 00:49:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-09 00:50:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-09 00:50:08  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-09 00:50:13  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-09 00:50:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-09 00:50:22  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-09 00:50:27  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-09 00:50:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-09 00:50:36  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-09 00:50:41  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-09 00:50:46  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-09 00:50:50  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-09 00:50:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-09 00:51:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-09 00:51:04  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-09 00:51:09  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-09 00:51:14  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-09 00:51:19  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-09 00:51:23  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-09 00:51:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-09 00:51:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-09 00:51:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-09 00:51:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-09 00:51:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-09 00:51:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-09 00:51:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-09 00:51:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-09 00:52:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-09 00:52:07  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-09 00:52:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-09 00:52:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-09 00:52:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-09 00:52:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-09 00:52:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-09 00:52:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-09 00:52:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-09 00:52:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-09 00:52:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-09 00:52:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-09 00:52:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-09 00:52:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-09 00:52:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-09 00:52:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-09 00:53:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-09 00:53:04  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-09 00:53:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-09 00:53:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-09 00:53:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-09 00:53:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-09 00:53:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-09 00:53:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-09 00:53:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-09 00:53:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-09 00:53:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-09 00:53:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-09 00:53:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-09 00:53:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-09 00:53:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-09 00:53:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-09 00:53:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-09 00:54:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-09 00:54:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-09 00:54:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-09 00:54:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-09 00:54:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-09 00:54:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-09 00:54:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-09 00:54:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-09 00:54:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-09 00:54:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-09 00:54:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-09 00:54:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-09 00:54:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-09 00:54:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-09 00:54:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-09 00:54:58  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-09 00:55:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-09 00:55:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-09 00:55:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-09 00:55:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-09 00:55:18  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-09 00:55:23  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-09 00:55:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-09 00:55:33  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-09 00:55:33  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-09 00:55:38  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-09 00:55:43  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-09 00:55:47  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-09 00:55:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-09 00:55:57  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-09 00:56:01  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-09 00:56:06  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-09 00:56:10  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-09 00:56:15  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-09 00:56:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-09 00:56:25  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-09 00:56:30  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-09 00:56:34  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-09 00:56:39  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-09 00:56:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-09 00:56:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-09 00:56:53  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-09 00:56:58  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-09 00:57:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-09 00:57:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-09 00:57:12  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-09 00:57:17  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-09 00:57:21  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-09 00:57:26  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-09 00:57:31  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-09 00:57:35  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-09 00:57:39  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-09 00:57:44  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-09 00:57:49  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-09 00:57:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-09 00:57:58  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-09 00:58:03  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-09 00:58:07  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-09 00:58:12  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-09 00:58:17  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-09 00:58:21  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-09 00:58:26  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-09 00:58:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-09 00:58:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-09 00:58:40  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-09 00:58:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-09 00:58:49  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-09 00:58:54  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-09 00:58:59  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-09 00:59:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-09 00:59:09  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-09 00:59:13  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-09 00:59:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-09 00:59:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-09 00:59:27  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-09 00:59:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-09 00:59:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-09 00:59:41  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-09 00:59:45  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-09 00:59:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-09 00:59:55  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-09 00:59:59  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-09 01:00:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-09 01:00:09  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-09 01:00:14  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-09 01:00:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-09 01:00:23  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-09 01:00:28  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-09 01:00:33  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-09 01:00:38  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-09 01:00:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-09 01:00:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-09 01:00:52  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-09 01:00:57  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-09 01:01:02  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-09 01:01:06  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-09 01:01:11  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-09 01:01:16  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-09 01:01:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-09 01:01:25  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-09 01:01:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-09 01:01:35  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-09 01:01:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-09 01:01:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-09 01:01:49  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-09 01:01:54  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-09_01-01-57 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator?_prerender {"code":"ECONNRESET"}
2017-04-09 01:03:59  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-09 01:04:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-09 01:04:09  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-09 01:04:13  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-09 01:04:18  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-09 01:04:23  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-09 01:04:27  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-09 01:04:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-09 01:04:37  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-09 01:04:42  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-09 01:04:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-09 01:04:51  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-09 01:04:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-09 01:05:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-09 01:05:06  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-09 01:05:11  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-09 01:05:16  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-09 01:05:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-09 01:05:26  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-09 01:05:30  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-09 01:05:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-09 01:05:40  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-09 01:05:45  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-09 01:05:50  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-09 01:05:54  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-09 01:05:59  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-09 01:06:04  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-09 01:06:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-09 01:06:13  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-09 01:06:18  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-09 01:06:22  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-09 01:06:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-09 01:06:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-09 01:06:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-09 01:06:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-09 01:06:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-09 01:06:51  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-09 01:06:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-09 01:07:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-09 01:07:04  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-09 01:07:09  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-09 01:07:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-09 01:07:19  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-09 01:07:24  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-09 01:07:28  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-09 01:07:33  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-09 01:07:37  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-09 01:07:42  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-09 01:07:46  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-09 01:07:51  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-09 01:07:56  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-09 01:08:01  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-09 01:08:06  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-09 01:08:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-09 01:08:15  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-09 01:08:20  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-09 01:08:24  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-09 01:08:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-09 01:08:34  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-09 01:08:38  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-09 01:08:43  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-09 01:08:48  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-09 01:08:52  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-09 01:08:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-09 01:09:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-09 01:09:06  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-09 01:09:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-09 01:09:16  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-09 01:09:20  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-09 01:09:25  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-09 01:09:30  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-09 01:09:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-09 01:09:40  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-09 01:09:44  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-09 01:09:48  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-09 01:09:53  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-09 01:09:58  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-09 01:10:02  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-09 01:10:07  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-09 01:10:12  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-09 01:10:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-09 01:10:21  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-09 01:10:25  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-09 01:10:30  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-09 01:10:34  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-09 01:10:39  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-09 01:10:44  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-09 01:10:49  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-09 01:10:53  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-09 01:10:58  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-09 01:11:02  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-09 01:11:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-09 01:11:11  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-09 01:11:15  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-09 01:11:20  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-09 01:11:25  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-09 01:11:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-09 01:11:34  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-09 01:11:38  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-09 01:11:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-09 01:11:47  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-09 01:11:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-09 01:11:57  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-09 01:12:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-09 01:12:06  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-09 01:12:11  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-09 01:12:15  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-09 01:12:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-09 01:12:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-09 01:12:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-09 01:12:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-09 01:12:38  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-09 01:12:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-09 01:12:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-09 01:12:51  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-09 01:12:56  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-09 01:13:00  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-09 01:13:05  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-09 01:13:09  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-09 01:13:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-09 01:13:18  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-09 01:13:22  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-09 01:13:26  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-09 01:13:31  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-09 01:13:36  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-09 01:13:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-09 01:13:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-09 01:13:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-09 01:13:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-09 01:13:59  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-09 01:14:00  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-09 01:14:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-09 01:14:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-09 01:14:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-09 01:14:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-09 01:14:23  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-09 01:14:28  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-09 01:14:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-09 01:14:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-09 01:14:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-09 01:14:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-09 01:14:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-09 01:14:54  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-09 01:14:58  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-09 01:15:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-09 01:15:08  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-09 01:15:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-09 01:15:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-09 01:15:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-09 01:15:26  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-09 01:15:31  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-09 01:15:35  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-09 01:15:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-09 01:15:44  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-09 01:15:48  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-09 01:15:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-09 01:15:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-09 01:16:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-09 01:16:06  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-09 01:16:11  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-09 01:16:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-09 01:16:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-09 01:16:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-09 01:16:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-09 01:16:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-09 01:16:36  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-09 01:16:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-09 01:16:44  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-09 01:16:48  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-09 01:16:52  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-09 01:16:56  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-09 01:17:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-09 01:17:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-09 01:17:10  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-09 01:17:14  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-09 01:17:18  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-09 01:17:22  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-09 01:17:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-09 01:17:31  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-09 01:17:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-09 01:17:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-09 01:17:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-09 01:17:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-09 01:17:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-09 01:17:58  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-09 01:18:02  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-09 01:18:06  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-09 01:18:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-09 01:18:15  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-09 01:18:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-09 01:18:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-09 01:18:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-09 01:18:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 01:18:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 01:18:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 01:18:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 01:18:48  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-09 01:18:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 01:18:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 01:19:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-09 01:19:05  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-09 01:19:09  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-09 01:19:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-09 01:19:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-09 01:19:22  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-09 01:19:26  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-09 01:19:30  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-09 01:19:34  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-09 01:19:38  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-09 01:19:43  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-09 01:19:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-09 01:19:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-09 01:19:55  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-09 01:19:59  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-09 01:20:04  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-09 01:20:08  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-09 01:20:12  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-09 01:20:16  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-09 01:20:21  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-09 01:20:25  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 01:20:29  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 01:20:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 01:20:37  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 01:20:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 01:20:46  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-09 01:20:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 01:20:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 01:20:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 01:21:02  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 01:21:06  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-09 01:21:10  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 01:21:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 01:21:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 01:21:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-09 01:21:27  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-09_01-31-57 Restart Xvfb...
2017-04-09_02-01-57 Restart Xvfb...
2017-04-09_02-31-57 Restart Xvfb...
2017-04-09_03-01-57 Restart Xvfb...
2017-04-09 03:31:46 reset updateRequest
2017-04-09 03:31:48  - 14968  http://www.lymphomahub.com/
2017-04-09 03:31:51  - 14968  http://www.lymphomahub.com/
2017-04-09 03:31:53  - 14968  http://www.lymphomahub.com/about
2017-04-09 03:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-09_03-31-57 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-09 03:33:58  - 14968  http://www.lymphomahub.com/about
2017-04-09 03:34:00  - 14968  http://www.lymphomahub.com/about
2017-04-09 03:34:02  - 14968  http://www.lymphomahub.com/terms
2017-04-09 03:34:04  - 14968  http://www.lymphomahub.com/terms
2017-04-09 03:34:06  - 14968  http://www.lymphomahub.com/undefined
2017-04-09 03:34:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-09 03:34:07  - 14968  http://www.lymphomahub.com/therapies
2017-04-09 03:34:15  - 14968  http://www.lymphomahub.com/newsletter
2017-04-09 03:34:16  - 14968  http://www.lymphomahub.com/newsletter
2017-04-09 03:34:19  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-09 03:34:21  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-09 03:34:22  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-09 03:34:24  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-09 03:34:27  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-09 03:34:29  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-09 03:34:32  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-09 03:34:33  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-09 03:34:37  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-09 03:34:38  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-09 03:34:43  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-09 03:34:43  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-09 03:34:48  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-09 03:34:53  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-09 03:34:58  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-09 03:35:02  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-09 03:35:07  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-09 03:35:11  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-09 03:35:16  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-09 03:35:20  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-09 03:35:25  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-09 03:35:30  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-09 03:35:34  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-09 03:35:39  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-09 03:35:43  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-09 03:35:48  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-09 03:35:52  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-09 03:35:57  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-09 03:36:02  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-09 03:36:05  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-09 03:36:10  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-09 03:36:14  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-09 03:36:19  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-09 03:36:24  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-09 03:36:28  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-09 03:36:33  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-09 03:36:38  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-09 03:36:42  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-09 03:36:47  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-09 03:36:51  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-09 03:36:56  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-09 03:37:01  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-09 03:37:05  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-09 03:37:10  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-09 03:37:14  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-09 03:37:19  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-09 03:37:24  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-09 03:37:28  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-09 03:37:33  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-09 03:37:38  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-09 03:37:42  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-09 03:37:47  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-09 03:37:52  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-09 03:37:56  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-09 03:38:01  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-09 03:38:05  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-09 03:38:10  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-09 03:38:15  - 14968  http://www.lymphomahub.com/medical-information
2017-04-09 03:38:20  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-09 03:38:24  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-09 03:38:29  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-09 03:38:34  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-09 03:38:38  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-09 03:38:43  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-09 03:38:48  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-09 03:38:52  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-09 03:38:57  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-09 03:39:01  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-09 03:39:06  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-09 03:39:11  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-09 03:39:12  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-09 03:39:17  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-09 03:39:21  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-09 03:39:26  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-09 03:39:31  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-09 03:39:35  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-09 03:39:40  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-09 03:39:44  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-09 03:39:49  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-09 03:39:54  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-09 03:39:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-09 03:40:04  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-09 03:40:08  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-09 03:40:14  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-09 03:40:18  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-09 03:40:23  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-09 03:40:27  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-09 03:40:32  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-09 03:40:37  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-09 03:40:41  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-09 03:40:46  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-09 03:40:50  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-09 03:40:55  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-09 03:41:00  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-09 03:41:04  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-09 03:41:09  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-09 03:41:13  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-09 03:41:18  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-09 03:41:22  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-09 03:41:27  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-09 03:41:31  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-09 03:41:32  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-09 03:41:37  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-09 03:41:41  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-09 03:41:46  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-09 03:41:51  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-09 03:41:55  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-09 03:42:00  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-09 03:42:04  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-09 03:42:09  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-09 03:42:13  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-09 03:42:13  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-09 03:42:18  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-09 03:42:23  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-09 03:42:27  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-09 03:42:32  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-09 03:42:36  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-09 03:42:37  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-09 03:42:42  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-09 03:42:46  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-09 03:42:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-09 03:42:54  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-09 03:42:59  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-09 03:43:03  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-09 03:43:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-09 03:43:11  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-09 03:43:15  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-09 03:43:20  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-09 03:43:24  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-09 03:43:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-09 03:43:33  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-09 03:43:37  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-09 03:43:38  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-09 03:43:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-09 03:43:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-09 03:43:52  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-09 03:43:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-09 03:44:01  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-09 03:44:05  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-09 03:44:09  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-09 03:44:13  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-09 03:44:17  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-09 03:44:21  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-09 03:44:25  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-09 03:44:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-09 03:44:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-09 03:44:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-09 03:44:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-09 03:44:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-09 03:44:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-09 03:44:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-09 03:44:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-09 03:45:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-09 03:45:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-09 03:45:13  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-09 03:45:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-09 03:45:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-09 03:45:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-09 03:45:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-09 03:45:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-09 03:45:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-09 03:45:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-09 03:45:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-09 03:45:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-09 03:45:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-09 03:46:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-09 03:46:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-09 03:46:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-09 03:46:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-09 03:46:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-09 03:46:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-09 03:46:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-09 03:46:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-09 03:46:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-09 03:46:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-09 03:46:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-09 03:46:53  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-09 03:46:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-09 03:47:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-09 03:47:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-09 03:47:11  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-09 03:47:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-09 03:47:21  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-09 03:47:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-09 03:47:30  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-09 03:47:34  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-09 03:47:39  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-09 03:47:44  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-09 03:47:48  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-09 03:47:52  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-09 03:47:56  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-09 03:48:01  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-09 03:48:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-09 03:48:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-09 03:48:14  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-09 03:48:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-09 03:48:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-09 03:48:27  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-09 03:48:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-09 03:48:36  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-09 03:48:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-09 03:48:45  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-09 03:48:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-09 03:48:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-09 03:49:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-09 03:49:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-09 03:49:09  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-09 03:49:10  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-09 03:49:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-09 03:49:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-09 03:49:24  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-09 03:49:29  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-09 03:49:34  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-09 03:49:39  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 03:49:43  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 03:49:48  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-09 03:49:53  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 03:49:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-09 03:50:02  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-09 03:50:07  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-09 03:50:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-09 03:50:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-09 03:50:21  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-09 03:50:26  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-09 03:50:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-09 03:50:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-09 03:50:40  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-09 03:50:45  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 03:50:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-09 03:50:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-09 03:51:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-09 03:51:05  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-09 03:51:10  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-09 03:51:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-09 03:51:20  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-09 03:51:25  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-09 03:51:29  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-09 03:51:34  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-09 03:51:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-09 03:51:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-09 03:51:48  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-09 03:51:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-09 03:51:58  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-09 03:52:03  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-09 03:52:07  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-09 03:52:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-09 03:52:17  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-09 03:52:22  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-09 03:52:27  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-09 03:52:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-09 03:52:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-09 03:52:37  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-09 03:52:42  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-09 03:52:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-09 03:52:52  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-09 03:52:57  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-09 03:53:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-09 03:53:06  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-09 03:53:11  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-09 03:53:16  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-09 03:53:21  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-09 03:53:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-09 03:53:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-09 03:53:35  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-09 03:53:40  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-09 03:53:45  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-09 03:53:49  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-09 03:53:54  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-09 03:53:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-09 03:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-09 03:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-09 03:54:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-09 03:54:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-09 03:54:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-09 03:54:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-09 03:54:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-09 03:54:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-09 03:54:38  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-09 03:54:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-09 03:54:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-09 03:54:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-09 03:54:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-09 03:54:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-09 03:54:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-09 03:55:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-09 03:55:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-09 03:55:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-09 03:55:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-09 03:55:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-09 03:55:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-09 03:55:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-09 03:55:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-09 03:55:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-09 03:55:37  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-09 03:55:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-09 03:55:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-09 03:55:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-09 03:55:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-09 03:55:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-09 03:56:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-09 03:56:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-09 03:56:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-09 03:56:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-09 03:56:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-09 03:56:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-09 03:56:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-09 03:56:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-09 03:56:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-09 03:56:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-09 03:56:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-09 03:56:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-09 03:56:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-09 03:56:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-09 03:56:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-09 03:56:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-09 03:56:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-09 03:57:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-09 03:57:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-09 03:57:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-09 03:57:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-09 03:57:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-09 03:57:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-09 03:57:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-09 03:57:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-09 03:57:31  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-09 03:57:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-09 03:57:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-09 03:57:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-09 03:57:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-09 03:57:52  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-09 03:57:57  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-09 03:58:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-09 03:58:07  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-09 03:58:08  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-09 03:58:13  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-09 03:58:17  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-09 03:58:22  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-09 03:58:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-09 03:58:32  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-09 03:58:37  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-09 03:58:42  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-09 03:58:47  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-09 03:58:51  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-09 03:58:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-09 03:59:00  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-09 03:59:05  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-09 03:59:10  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-09 03:59:15  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-09 03:59:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-09 03:59:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-09 03:59:30  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-09 03:59:34  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-09 03:59:39  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-09 03:59:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-09 03:59:49  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-09 03:59:54  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-09 03:59:58  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-09 04:00:03  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-09 04:00:08  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-09 04:00:13  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-09 04:00:18  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-09 04:00:23  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-09 04:00:27  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-09 04:00:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-09 04:00:37  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-09 04:00:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-09 04:00:46  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-09 04:00:51  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-09 04:00:56  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-09 04:01:00  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-09 04:01:05  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-09 04:01:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-09 04:01:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-09 04:01:20  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-09 04:01:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-09 04:01:29  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-09 04:01:34  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-09 04:01:38  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-09 04:01:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-09 04:01:48  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-09 04:01:52  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-09_04-01-57 Restart Xvfb...
2017-04-09 04:01:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-09 04:02:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-09 04:02:07  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-09 04:02:11  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-09 04:02:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-09 04:02:21  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-09 04:02:26  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-09 04:02:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-09 04:02:36  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-09 04:02:41  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-09 04:02:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-09 04:02:50  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-09 04:02:55  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-09 04:03:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-09 04:03:05  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-09 04:03:10  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-09 04:03:15  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-09 04:03:19  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-09 04:03:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-09 04:03:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-09 04:03:34  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-09 04:03:39  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-09 04:03:43  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-09 04:03:48  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-09 04:03:53  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-09 04:03:58  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-09 04:04:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-09 04:04:07  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-09 04:04:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-09 04:04:17  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-09 04:04:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-09 04:04:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-09 04:04:31  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-09 04:04:36  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-09 04:04:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-09 04:04:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-09 04:04:50  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-09 04:04:55  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-09 04:05:00  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-09 04:05:04  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-09 04:05:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-09 04:05:14  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-09 04:05:19  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-09 04:05:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-09 04:05:28  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-09 04:05:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-09 04:05:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-09 04:05:43  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-09 04:05:47  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-09 04:05:52  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-09 04:05:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-09 04:06:02  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-09 04:06:06  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-09 04:06:11  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-09 04:06:16  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-09 04:06:21  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-09 04:06:26  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-09 04:06:31  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-09 04:06:35  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-09 04:06:40  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-09 04:06:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-09 04:06:50  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-09 04:06:54  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-09 04:06:59  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-09 04:07:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-09 04:07:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-09 04:07:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-09 04:07:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-09 04:07:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-09 04:07:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-09 04:07:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-09 04:07:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-09 04:07:43  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-09 04:07:48  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-09 04:07:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-09 04:07:57  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-09 04:08:02  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-09 04:08:07  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-09 04:08:12  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-09 04:08:16  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-09 04:08:21  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-09 04:08:26  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-09 04:08:31  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-09 04:08:35  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-09 04:08:40  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-09 04:08:45  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-09 04:08:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-09 04:08:54  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-09 04:09:00  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-09 04:09:05  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-09 04:09:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-09 04:09:16  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-09 04:09:21  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-09 04:09:26  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-09 04:09:31  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-09 04:09:36  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-09 04:09:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-09 04:09:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-09 04:09:50  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-09 04:09:55  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-09 04:10:00  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-09 04:10:04  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-09 04:10:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-09 04:10:14  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-09 04:10:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-09 04:10:24  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-09 04:10:28  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-09 04:10:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-09 04:10:37  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-09 04:10:42  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-09 04:10:46  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-09 04:10:51  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-09 04:10:56  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-09 04:11:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-09 04:11:06  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-09 04:11:10  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-09 04:11:14  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-09 04:11:19  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-09 04:11:24  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-09 04:11:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-09 04:11:34  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-09 04:11:39  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-09 04:11:43  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-09 04:11:48  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-09 04:11:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-09 04:11:56  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-09 04:12:01  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-09 04:12:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-09 04:12:11  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-09 04:12:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-09 04:12:20  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-09 04:12:25  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-09 04:12:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-09 04:12:34  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-09 04:12:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-09 04:12:43  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-09 04:12:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-09 04:12:53  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-09 04:12:57  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-09 04:13:02  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-09 04:13:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-09 04:13:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-09 04:13:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-09 04:13:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-09 04:13:25  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-09 04:13:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-09 04:13:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-09 04:13:39  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-09 04:13:43  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-09 04:13:48  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-09 04:13:52  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-09 04:13:57  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-09 04:14:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-09 04:14:06  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-09 04:14:11  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-09 04:14:15  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-09 04:14:20  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-09 04:14:25  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-09 04:14:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-09 04:14:34  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-09 04:14:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-09 04:14:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-09 04:14:48  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-09 04:14:49  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-09 04:14:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-09 04:14:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-09 04:15:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-09 04:15:08  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-09 04:15:13  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-09 04:15:17  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-09 04:15:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-09 04:15:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-09 04:15:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-09 04:15:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-09 04:15:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-09 04:15:47  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-09 04:15:51  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-09 04:15:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-09 04:16:00  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-09 04:16:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-09 04:16:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-09 04:16:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-09 04:16:19  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-09 04:16:24  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-09 04:16:29  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-09 04:16:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-09 04:16:38  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-09 04:16:42  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-09 04:16:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-09 04:16:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-09 04:16:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-09 04:17:01  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-09 04:17:05  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-09 04:17:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-09 04:17:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-09 04:17:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-09 04:17:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-09 04:17:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-09 04:17:31  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-09 04:17:35  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-09 04:17:39  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-09 04:17:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-09 04:17:48  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-09 04:17:52  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-09 04:17:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-09 04:18:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-09 04:18:06  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-09 04:18:10  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-09 04:18:14  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-09 04:18:18  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-09 04:18:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-09 04:18:27  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-09 04:18:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-09 04:18:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-09 04:18:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-09 04:18:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-09 04:18:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-09 04:18:55  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-09 04:19:00  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-09 04:19:04  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-09 04:19:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-09 04:19:13  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-09 04:19:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-09 04:19:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-09 04:19:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-09 04:19:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 04:19:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 04:19:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 04:19:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 04:19:47  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-09 04:19:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 04:19:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 04:20:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-09 04:20:04  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-09 04:20:08  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-09 04:20:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-09 04:20:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-09 04:20:22  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-09 04:20:26  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-09 04:20:31  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-09 04:20:35  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-09 04:20:39  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-09 04:20:43  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-09 04:20:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-09 04:20:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-09 04:20:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-09 04:21:01  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-09 04:21:05  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-09 04:21:09  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-09 04:21:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-09 04:21:18  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-09 04:21:22  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-09 04:21:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 04:21:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 04:21:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 04:21:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 04:21:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 04:21:48  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-09 04:21:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 04:21:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 04:22:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 04:22:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 04:22:09  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-09 04:22:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 04:22:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 04:22:21  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 04:22:25  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-09 04:22:30  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-09_04-31-57 Restart Xvfb...
2017-04-09_05-01-57 Restart Xvfb...
2017-04-09_05-31-57 Restart Xvfb...
2017-04-09_06-01-57 Restart Xvfb...
2017-04-09 06:31:46 reset updateRequest
2017-04-09 06:31:50  - 14968  http://www.lymphomahub.com/
2017-04-09 06:31:51  - 14968  http://www.lymphomahub.com/
2017-04-09 06:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-09 06:31:57  - 14968  http://www.lymphomahub.com/about
2017-04-09_06-31-57 Restart Xvfb...
2017-04-09 06:32:02  - 14968  http://www.lymphomahub.com/terms
2017-04-09 06:32:06  - 14968  http://www.lymphomahub.com/undefined
2017-04-09 06:32:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-09 06:32:13  - 14968  http://www.lymphomahub.com/newsletter
2017-04-09 06:32:16  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-09 06:32:19  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-09 06:32:24  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-09 06:32:29  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-09 06:32:34  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-09 06:32:39  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-09 06:32:44  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-09 06:32:49  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-09 06:32:53  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-09 06:32:58  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-09 06:33:03  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-09 06:33:07  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-09 06:33:12  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-09 06:33:17  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-09 06:33:21  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-09 06:33:26  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-09 06:33:30  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-09 06:33:35  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-09 06:33:40  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-09 06:33:45  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-09 06:33:50  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-09 06:33:54  - 14968  http://www.lymphomahub.com/therapies/kte-c19
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-09 06:33:59  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-09 06:34:01  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-09 06:34:03  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-09 06:34:05  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-09 06:34:08  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-09 06:34:09  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-09 06:34:13  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-09 06:34:14  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-09 06:34:18  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-09 06:34:19  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-09 06:34:23  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-09 06:34:24  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-09 06:34:29  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-09 06:34:29  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-09 06:34:34  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-09 06:34:39  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-09 06:34:44  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-09 06:34:48  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-09 06:34:53  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-09 06:34:58  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-09 06:35:02  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-09 06:35:07  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-09 06:35:12  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-09 06:35:16  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-09 06:35:21  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-09 06:35:26  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-09 06:35:31  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-09 06:35:35  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-09 06:35:40  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-09 06:35:44  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-09 06:35:49  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-09 06:35:54  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-09 06:35:58  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-09 06:36:03  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-09 06:36:08  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-09 06:36:13  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-09 06:36:18  - 14968  http://www.lymphomahub.com/medical-information
2017-04-09 06:36:22  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-09 06:36:27  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-09 06:36:32  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-09 06:36:36  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-09 06:36:41  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-09 06:36:46  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-09 06:36:50  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-09 06:36:55  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-09 06:37:00  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-09 06:37:04  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-09 06:37:09  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-09 06:37:13  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-09 06:37:14  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-09 06:37:19  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-09 06:37:23  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-09 06:37:28  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-09 06:37:33  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-09 06:37:37  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-09 06:37:42  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-09 06:37:46  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-09 06:37:51  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-09 06:37:56  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-09 06:38:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-09 06:38:05  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-09 06:38:10  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-09 06:38:15  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-09 06:38:19  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-09 06:38:24  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-09 06:38:29  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-09 06:38:33  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-09 06:38:38  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-09 06:38:42  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-09 06:38:47  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-09 06:38:51  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-09 06:38:56  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-09 06:39:00  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-09 06:39:05  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-09 06:39:10  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-09 06:39:14  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-09 06:39:19  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-09 06:39:24  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-09 06:39:28  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-09 06:39:33  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-09 06:39:33  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-09 06:39:38  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-09 06:39:43  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-09 06:39:47  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-09 06:39:52  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-09 06:39:57  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-09 06:40:01  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-09 06:40:06  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-09 06:40:11  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-09 06:40:15  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-09 06:40:15  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-09 06:40:20  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-09 06:40:25  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-09 06:40:30  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-09 06:40:34  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-09 06:40:39  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-09 06:40:40  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-09 06:40:45  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-09 06:40:49  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-09 06:40:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-09 06:40:58  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-09 06:41:02  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-09 06:41:06  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-09 06:41:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-09 06:41:14  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-09 06:41:18  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-09 06:41:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-09 06:41:27  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-09 06:41:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-09 06:41:37  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-09 06:41:41  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-09 06:41:41  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-09 06:41:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-09 06:41:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-09 06:41:55  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-09 06:41:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-09 06:42:04  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-09 06:42:09  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-09 06:42:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-09 06:42:17  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-09 06:42:21  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-09 06:42:25  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-09 06:42:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-09 06:42:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-09 06:42:37  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-09 06:42:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-09 06:42:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-09 06:42:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-09 06:42:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-09 06:43:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-09 06:43:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-09 06:43:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-09 06:43:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-09 06:43:19  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-09 06:43:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-09 06:43:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-09 06:43:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-09 06:43:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-09 06:43:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-09 06:43:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-09 06:43:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-09 06:43:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-09 06:44:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-09 06:44:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-09 06:44:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-09 06:44:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-09 06:44:18  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-09 06:44:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-09 06:44:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-09 06:44:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-09 06:44:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-09 06:44:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-09 06:44:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-09 06:44:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-09 06:44:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-09 06:45:00  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-09 06:45:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-09 06:45:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-09 06:45:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-09 06:45:19  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-09 06:45:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-09 06:45:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-09 06:45:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-09 06:45:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-09 06:45:40  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-09 06:45:45  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-09 06:45:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-09 06:45:54  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-09 06:45:58  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-09 06:46:02  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-09 06:46:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-09 06:46:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-09 06:46:16  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-09 06:46:21  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-09 06:46:25  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-09 06:46:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-09 06:46:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-09 06:46:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-09 06:46:42  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-09 06:46:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-09 06:46:52  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-09 06:46:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-09 06:47:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-09 06:47:09  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-09 06:47:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-09 06:47:19  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-09 06:47:20  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-09 06:47:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-09 06:47:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-09 06:47:35  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-09 06:47:39  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-09 06:47:44  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-09 06:47:49  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 06:47:54  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 06:47:59  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-09 06:48:04  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 06:48:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-09 06:48:13  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-09 06:48:18  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-09 06:48:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-09 06:48:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-09 06:48:33  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-09 06:48:38  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-09 06:48:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-09 06:48:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-09 06:48:52  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-09 06:48:57  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 06:49:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-09 06:49:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-09 06:49:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-09 06:49:17  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-09 06:49:22  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-09 06:49:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-09 06:49:32  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-09 06:49:37  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-09 06:49:43  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-09 06:49:47  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-09 06:49:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-09 06:49:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-09 06:50:02  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-09 06:50:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-09 06:50:11  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-09 06:50:16  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-09 06:50:21  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-09 06:50:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-09 06:50:30  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-09 06:50:36  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-09 06:50:41  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-09 06:50:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-09 06:50:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-09 06:50:51  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-09 06:50:56  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-09 06:51:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-09 06:51:05  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-09 06:51:10  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-09 06:51:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-09 06:51:20  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-09 06:51:25  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-09 06:51:30  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-09 06:51:35  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-09 06:51:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-09 06:51:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-09 06:51:49  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-09 06:51:54  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-09 06:51:59  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-09 06:52:04  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-09 06:52:09  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-09 06:52:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-09 06:52:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-09 06:52:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-09 06:52:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-09 06:52:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-09 06:52:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-09 06:52:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-09 06:52:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-09 06:52:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-09 06:52:52  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-09 06:52:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-09 06:52:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-09 06:53:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-09 06:53:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-09 06:53:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-09 06:53:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-09 06:53:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-09 06:53:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-09 06:53:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-09 06:53:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-09 06:53:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-09 06:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-09 06:53:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-09 06:53:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-09 06:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-09 06:53:50  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-09 06:53:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-09 06:53:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-09 06:54:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-09 06:54:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-09 06:54:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-09 06:54:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-09 06:54:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-09 06:54:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-09 06:54:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-09 06:54:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-09 06:54:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-09 06:54:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-09 06:54:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-09 06:54:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-09 06:54:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-09 06:54:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-09 06:54:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-09 06:54:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-09 06:55:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-09 06:55:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-09 06:55:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-09 06:55:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-09 06:55:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-09 06:55:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-09 06:55:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-09 06:55:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-09 06:55:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-09 06:55:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-09 06:55:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-09 06:55:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-09 06:55:46  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-09 06:55:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-09 06:55:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-09 06:55:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-09 06:56:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-09 06:56:07  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-09 06:56:11  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-09 06:56:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-09 06:56:22  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-09 06:56:22  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-09 06:56:27  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-09 06:56:32  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-09 06:56:37  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-09 06:56:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-09 06:56:46  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-09 06:56:51  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-09 06:56:56  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-09 06:57:01  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-09 06:57:06  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-09 06:57:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-09 06:57:15  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-09 06:57:20  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-09 06:57:25  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-09 06:57:30  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-09 06:57:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-09 06:57:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-09 06:57:44  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-09 06:57:49  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-09 06:57:54  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-09 06:57:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-09 06:58:03  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-09 06:58:08  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-09 06:58:13  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-09 06:58:17  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-09 06:58:22  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-09 06:58:27  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-09 06:58:32  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-09 06:58:37  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-09 06:58:41  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-09 06:58:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-09 06:58:51  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-09 06:58:56  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-09 06:59:01  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-09 06:59:05  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-09 06:59:10  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-09 06:59:15  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-09 06:59:20  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-09 06:59:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-09 06:59:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-09 06:59:34  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-09 06:59:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-09 06:59:44  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-09 06:59:48  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-09 06:59:53  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-09 06:59:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-09 07:00:03  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-09 07:00:08  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-09 07:00:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-09 07:00:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-09 07:00:22  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-09 07:00:28  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-09 07:00:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-09 07:00:38  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-09 07:00:43  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-09 07:00:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-09 07:00:52  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-09 07:00:57  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-09 07:01:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-09 07:01:06  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-09 07:01:11  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-09 07:01:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-09 07:01:21  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-09 07:01:26  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-09 07:01:30  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-09 07:01:35  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-09 07:01:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-09 07:01:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-09 07:01:49  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-09 07:01:54  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-09_07-01-57 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos?_prerender {"code":"ECONNRESET"}
2017-04-09 07:03:59  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-09 07:04:03  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-09 07:04:08  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-09 07:04:13  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-09 07:04:18  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-09 07:04:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-09 07:04:28  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-09 07:04:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-09 07:04:40  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-09 07:04:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-09 07:04:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-09 07:04:55  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-09 07:05:00  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-09 07:05:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-09 07:05:09  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-09 07:05:14  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-09 07:05:19  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-09 07:05:24  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-09 07:05:28  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-09 07:05:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-09 07:05:38  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-09 07:05:43  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-09 07:05:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-09 07:05:52  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-09 07:05:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-09 07:06:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-09 07:06:07  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-09 07:06:12  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-09 07:06:17  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-09 07:06:22  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-09 07:06:27  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-09 07:06:32  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-09 07:06:37  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-09 07:06:41  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-09 07:06:46  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-09 07:06:51  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-09 07:06:56  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-09 07:07:01  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-09 07:07:05  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-09 07:07:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-09 07:07:16  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-09 07:07:21  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-09 07:07:25  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-09 07:07:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-09 07:07:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-09 07:07:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-09 07:07:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-09 07:07:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-09 07:07:55  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-09 07:08:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-09 07:08:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-09 07:08:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-09 07:08:14  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-09 07:08:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-09 07:08:24  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-09 07:08:29  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-09 07:08:34  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-09 07:08:39  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-09 07:08:43  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-09 07:08:47  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-09 07:08:52  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-09 07:08:57  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-09 07:09:01  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-09 07:09:06  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-09 07:09:11  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-09 07:09:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-09 07:09:21  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-09 07:09:25  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-09 07:09:30  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-09 07:09:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-09 07:09:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-09 07:09:45  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-09 07:09:49  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-09 07:09:54  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-09 07:09:59  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-09 07:10:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-09 07:10:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-09 07:10:14  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-09 07:10:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-09 07:10:24  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-09 07:10:29  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-09 07:10:33  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-09 07:10:39  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-09 07:10:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-09 07:10:48  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-09 07:10:53  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-09 07:10:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-09 07:11:02  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-09 07:11:07  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-09 07:11:11  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-09 07:11:16  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-09 07:11:21  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-09 07:11:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-09 07:11:30  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-09 07:11:35  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-09 07:11:39  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-09 07:11:44  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-09 07:11:49  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-09 07:11:54  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-09 07:11:59  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-09 07:12:03  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-09 07:12:08  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-09 07:12:12  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-09 07:12:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-09 07:12:21  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-09 07:12:26  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-09 07:12:31  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-09 07:12:36  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-09 07:12:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-09 07:12:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-09 07:12:49  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-09 07:12:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-09 07:12:58  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-09 07:13:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-09 07:13:08  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-09 07:13:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-09 07:13:17  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-09 07:13:22  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-09 07:13:26  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-09 07:13:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-09 07:13:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-09 07:13:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-09 07:13:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-09 07:13:49  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-09 07:13:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-09 07:13:58  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-09 07:14:03  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-09 07:14:08  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-09 07:14:12  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-09 07:14:16  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-09 07:14:21  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-09 07:14:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-09 07:14:30  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-09 07:14:34  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-09 07:14:39  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-09 07:14:44  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-09 07:14:49  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-09 07:14:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-09 07:14:59  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-09 07:15:04  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-09 07:15:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-09 07:15:13  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-09 07:15:14  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-09 07:15:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-09 07:15:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-09 07:15:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-09 07:15:33  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-09 07:15:37  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-09 07:15:42  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-09 07:15:47  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-09 07:15:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-09 07:15:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-09 07:16:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-09 07:16:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-09 07:16:10  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-09 07:16:14  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-09 07:16:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-09 07:16:24  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-09 07:16:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-09 07:16:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-09 07:16:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-09 07:16:42  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-09 07:16:47  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-09 07:16:52  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-09 07:16:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-09 07:17:01  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-09 07:17:05  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-09 07:17:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-09 07:17:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-09 07:17:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-09 07:17:24  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-09 07:17:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-09 07:17:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-09 07:17:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-09 07:17:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-09 07:17:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-09 07:17:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-09 07:17:55  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-09 07:17:59  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-09 07:18:03  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-09 07:18:07  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-09 07:18:12  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-09 07:18:16  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-09 07:18:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-09 07:18:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-09 07:18:30  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-09 07:18:34  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-09 07:18:38  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-09 07:18:42  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-09 07:18:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-09 07:18:51  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-09 07:18:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-09 07:19:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-09 07:19:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-09 07:19:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-09 07:19:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-09 07:19:20  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-09 07:19:24  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-09 07:19:29  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-09 07:19:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-09 07:19:38  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-09 07:19:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-09 07:19:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-09 07:19:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-09 07:19:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 07:20:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 07:20:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 07:20:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 07:20:13  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-09 07:20:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 07:20:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 07:20:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-09 07:20:30  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-09 07:20:34  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-09 07:20:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-09 07:20:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-09 07:20:48  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-09 07:20:52  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-09 07:20:56  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-09 07:21:01  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-09 07:21:05  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-09 07:21:10  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-09 07:21:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-09 07:21:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-09 07:21:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-09 07:21:28  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-09 07:21:32  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-09 07:21:36  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-09 07:21:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-09 07:21:45  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-09 07:21:49  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-09 07:21:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 07:21:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 07:22:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 07:22:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 07:22:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 07:22:16  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-09 07:22:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 07:22:25  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 07:22:29  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 07:22:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 07:22:38  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-09 07:22:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 07:22:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 07:22:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 07:22:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-09 07:23:00  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-09_07-31-57 Restart Xvfb...
2017-04-09_08-01-57 Restart Xvfb...
2017-04-09_08-31-57 Restart Xvfb...
2017-04-09_09-01-57 Restart Xvfb...
2017-04-09 09:31:46 reset updateRequest
2017-04-09 09:31:50  - 14968  http://www.lymphomahub.com/
2017-04-09 09:31:51  - 14968  http://www.lymphomahub.com/
2017-04-09 09:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-09 09:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-09_09-31-57 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-09 09:34:01  - 14968  http://www.lymphomahub.com/about
2017-04-09 09:34:01  - 14968  http://www.lymphomahub.com/about
2017-04-09 09:34:07  - 14968  http://www.lymphomahub.com/terms
2017-04-09 09:34:10  - 14968  http://www.lymphomahub.com/undefined
2017-04-09 09:34:11  - 14968  http://www.lymphomahub.com/therapies
2017-04-09 09:34:17  - 14968  http://www.lymphomahub.com/newsletter
2017-04-09 09:34:20  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-09 09:34:24  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-09 09:34:28  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-09 09:34:33  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-09 09:34:37  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-09 09:34:42  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-09 09:34:47  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-09 09:34:51  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-09 09:34:56  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-09 09:35:01  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-09 09:35:05  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-09 09:35:10  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-09 09:35:15  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-09 09:35:19  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-09 09:35:24  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-09 09:35:29  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-09 09:35:33  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-09 09:35:37  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-09 09:35:42  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-09 09:35:46  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-09 09:35:51  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-09 09:35:56  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-09 09:36:00  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-09 09:36:04  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-09 09:36:08  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-09 09:36:13  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-09 09:36:18  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-09 09:36:22  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-09 09:36:27  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-09 09:36:31  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-09 09:36:36  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-09 09:36:41  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-09 09:36:45  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-09 09:36:50  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-09 09:36:55  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-09 09:36:59  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-09 09:37:04  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-09 09:37:08  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-09 09:37:13  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-09 09:37:17  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-09 09:37:22  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-09 09:37:27  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-09 09:37:31  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-09 09:37:36  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-09 09:37:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-09 09:37:45  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-09 09:37:50  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-09 09:37:54  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-09 09:37:59  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-09 09:38:03  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-09 09:38:08  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-09 09:38:12  - 14968  http://www.lymphomahub.com/medical-information
2017-04-09 09:38:16  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-09 09:38:21  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-09 09:38:26  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-09 09:38:30  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-09 09:38:35  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-09 09:38:40  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-09 09:38:44  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-09 09:38:49  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-09 09:38:54  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-09 09:38:58  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-09 09:39:03  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-09 09:39:07  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-09 09:39:08  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-09 09:39:13  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-09 09:39:18  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-09 09:39:22  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-09 09:39:27  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-09 09:39:31  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-09 09:39:36  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-09 09:39:41  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-09 09:39:45  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-09 09:39:50  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-09 09:39:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-09 09:39:59  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-09 09:40:04  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-09 09:40:09  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-09 09:40:13  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-09 09:40:18  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-09 09:40:22  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-09 09:40:27  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-09 09:40:32  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-09 09:40:37  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-09 09:40:41  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-09 09:40:46  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-09 09:40:50  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-09 09:40:55  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-09 09:40:59  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-09 09:41:04  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-09 09:41:08  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-09 09:41:13  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-09 09:41:17  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-09 09:41:22  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-09 09:41:26  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-09 09:41:27  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-09 09:41:32  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-09 09:41:36  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-09 09:41:41  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-09 09:41:45  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-09 09:41:50  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-09 09:41:55  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-09 09:41:59  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-09 09:42:04  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-09 09:42:08  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-09 09:42:08  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-09 09:42:13  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-09 09:42:17  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-09 09:42:22  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-09 09:42:27  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-09 09:42:31  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-09 09:42:32  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-09 09:42:36  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-09 09:42:41  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-09 09:42:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-09 09:42:49  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-09 09:42:54  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-09 09:42:58  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-09 09:43:02  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-09 09:43:06  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-09 09:43:10  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-09 09:43:15  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-09 09:43:19  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-09 09:43:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-09 09:43:28  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-09 09:43:33  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-09 09:43:33  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-09 09:43:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-09 09:43:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-09 09:43:47  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-09 09:43:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-09 09:43:55  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-09 09:44:00  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-09 09:44:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-09 09:44:08  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-09 09:44:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-09 09:44:16  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-09 09:44:20  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-09 09:44:24  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-09 09:44:28  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-09 09:44:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-09 09:44:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-09 09:44:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-09 09:44:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-09 09:44:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-09 09:44:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-09 09:44:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-09 09:45:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-09 09:45:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-09 09:45:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-09 09:45:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-09 09:45:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-09 09:45:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-09 09:45:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-09 09:45:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-09 09:45:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-09 09:45:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-09 09:45:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-09 09:45:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-09 09:45:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-09 09:46:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-09 09:46:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-09 09:46:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-09 09:46:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-09 09:46:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-09 09:46:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-09 09:46:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-09 09:46:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-09 09:46:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-09 09:46:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-09 09:46:48  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-09 09:46:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-09 09:46:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-09 09:47:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-09 09:47:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-09 09:47:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-09 09:47:15  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-09 09:47:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-09 09:47:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-09 09:47:27  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-09 09:47:32  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-09 09:47:37  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-09 09:47:41  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-09 09:47:46  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-09 09:47:50  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-09 09:47:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-09 09:47:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-09 09:48:03  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-09 09:48:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-09 09:48:11  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-09 09:48:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-09 09:48:20  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-09 09:48:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-09 09:48:29  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-09 09:48:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-09 09:48:39  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-09 09:48:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-09 09:48:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-09 09:48:53  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-09 09:48:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-09 09:49:03  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-09 09:49:04  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-09 09:49:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-09 09:49:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-09 09:49:17  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-09 09:49:22  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-09 09:49:27  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-09 09:49:32  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 09:49:36  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 09:49:41  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-09 09:49:46  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 09:49:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-09 09:49:55  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-09 09:50:00  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-09 09:50:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-09 09:50:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-09 09:50:15  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-09 09:50:20  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-09 09:50:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-09 09:50:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-09 09:50:34  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-09 09:50:39  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 09:50:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-09 09:50:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-09 09:50:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-09 09:50:59  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-09 09:51:03  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-09 09:51:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-09 09:51:13  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-09 09:51:19  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-09 09:51:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-09 09:51:28  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-09 09:51:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-09 09:51:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-09 09:51:43  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-09 09:51:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-09 09:51:53  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-09 09:51:58  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-09 09:52:02  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-09 09:52:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-09 09:52:12  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-09 09:52:17  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-09 09:52:22  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-09 09:52:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-09 09:52:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-09 09:52:32  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-09 09:52:38  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-09 09:52:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-09 09:52:47  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-09 09:52:52  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-09 09:52:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-09 09:53:02  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-09 09:53:08  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-09 09:53:13  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-09 09:53:18  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-09 09:53:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-09 09:53:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-09 09:53:32  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-09 09:53:37  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-09 09:53:42  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-09 09:53:47  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-09 09:53:51  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-09 09:53:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-09 09:54:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-09 09:54:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-09 09:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-09 09:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-09 09:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-09 09:54:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-09 09:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-09 09:54:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-09 09:54:35  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-09 09:54:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-09 09:54:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-09 09:54:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-09 09:54:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-09 09:54:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-09 09:54:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-09 09:55:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-09 09:55:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-09 09:55:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-09 09:55:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-09 09:55:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-09 09:55:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-09 09:55:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-09 09:55:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-09 09:55:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-09 09:55:33  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-09 09:55:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-09 09:55:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-09 09:55:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-09 09:55:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-09 09:55:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-09 09:55:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-09 09:56:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-09 09:56:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-09 09:56:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-09 09:56:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-09 09:56:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-09 09:56:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-09 09:56:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-09 09:56:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-09 09:56:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-09 09:56:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-09 09:56:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-09 09:56:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-09 09:56:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-09 09:56:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-09 09:56:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-09 09:56:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-09 09:56:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-09 09:57:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-09 09:57:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-09 09:57:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-09 09:57:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-09 09:57:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-09 09:57:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-09 09:57:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-09 09:57:28  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-09 09:57:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-09 09:57:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-09 09:57:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-09 09:57:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-09 09:57:49  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-09 09:57:54  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-09 09:57:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-09 09:58:04  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-09 09:58:04  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-09 09:58:09  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-09 09:58:14  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-09 09:58:19  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-09 09:58:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-09 09:58:29  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-09 09:58:33  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-09 09:58:38  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-09 09:58:43  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-09 09:58:48  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-09 09:58:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-09 09:58:57  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-09 09:59:02  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-09 09:59:07  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-09 09:59:11  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-09 09:59:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-09 09:59:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-09 09:59:26  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-09 09:59:31  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-09 09:59:36  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-09 09:59:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-09 09:59:45  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-09 09:59:50  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-09 09:59:54  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-09 09:59:59  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-09 10:00:04  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-09 10:00:09  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-09 10:00:14  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-09 10:00:18  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-09 10:00:23  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-09 10:00:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-09 10:00:32  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-09 10:00:37  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-09 10:00:42  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-09 10:00:47  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-09 10:00:51  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-09 10:00:56  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-09 10:01:00  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-09 10:01:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-09 10:01:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-09 10:01:15  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-09 10:01:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-09 10:01:24  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-09 10:01:29  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-09 10:01:34  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-09 10:01:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-09 10:01:43  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-09 10:01:48  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-09 10:01:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-09_10-01-57 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics?_prerender {"code":"ECONNRESET"}
2017-04-09 10:03:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-09 10:04:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-09 10:04:08  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-09 10:04:12  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-09 10:04:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-09 10:04:22  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-09 10:04:27  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-09 10:04:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-09 10:04:37  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-09 10:04:42  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-09 10:04:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-09 10:04:51  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-09 10:04:56  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-09 10:05:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-09 10:05:06  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-09 10:05:10  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-09 10:05:15  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-09 10:05:22  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-09 10:05:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-09 10:05:32  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-09 10:05:37  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-09 10:05:43  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-09 10:05:47  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-09 10:05:52  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-09 10:05:57  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-09 10:06:02  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-09 10:06:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-09 10:06:11  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-09 10:06:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-09 10:06:21  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-09 10:06:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-09 10:06:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-09 10:06:35  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-09 10:06:40  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-09 10:06:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-09 10:06:50  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-09 10:06:54  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-09 10:06:59  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-09 10:07:04  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-09 10:07:08  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-09 10:07:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-09 10:07:18  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-09 10:07:23  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-09 10:07:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-09 10:07:32  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-09 10:07:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-09 10:07:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-09 10:07:47  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-09 10:07:52  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-09 10:07:56  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-09 10:08:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-09 10:08:06  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-09 10:08:11  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-09 10:08:16  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-09 10:08:21  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-09 10:08:25  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-09 10:08:30  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-09 10:08:35  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-09 10:08:40  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-09 10:08:45  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-09 10:08:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-09 10:08:54  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-09 10:08:59  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-09 10:09:04  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-09 10:09:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-09 10:09:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-09 10:09:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-09 10:09:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-09 10:09:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-09 10:09:32  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-09 10:09:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-09 10:09:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-09 10:09:46  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-09 10:09:51  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-09 10:09:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-09 10:10:00  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-09 10:10:05  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-09 10:10:10  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-09 10:10:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-09 10:10:19  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-09 10:10:23  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-09 10:10:28  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-09 10:10:33  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-09 10:10:38  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-09 10:10:43  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-09 10:10:47  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-09 10:10:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-09 10:10:57  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-09 10:11:02  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-09 10:11:06  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-09 10:11:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-09 10:11:16  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-09 10:11:21  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-09 10:11:26  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-09 10:11:30  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-09 10:11:35  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-09 10:11:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-09 10:11:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-09 10:11:50  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-09 10:11:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-09 10:11:59  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-09 10:12:03  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-09 10:12:08  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-09 10:12:13  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-09 10:12:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-09 10:12:22  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-09 10:12:27  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-09 10:12:31  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-09 10:12:36  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-09 10:12:41  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-09 10:12:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-09 10:12:50  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-09 10:12:55  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-09 10:12:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-09 10:13:04  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-09 10:13:08  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-09 10:13:13  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-09 10:13:18  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-09 10:13:23  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-09 10:13:28  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-09 10:13:33  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-09 10:13:37  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-09 10:13:42  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-09 10:13:46  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-09 10:13:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-09 10:13:55  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-09 10:14:00  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-09 10:14:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-09 10:14:09  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-09 10:14:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-09 10:14:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-09 10:14:23  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-09 10:14:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-09 10:14:32  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-09 10:14:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-09 10:14:41  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-09 10:14:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-09 10:14:51  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-09 10:14:56  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-09 10:15:00  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-09 10:15:04  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-09 10:15:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-09 10:15:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-09 10:15:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-09 10:15:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-09 10:15:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-09 10:15:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-09 10:15:37  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-09 10:15:42  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-09 10:15:46  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-09 10:15:51  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-09 10:15:56  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-09 10:16:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-09 10:16:04  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-09 10:16:08  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-09 10:16:13  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-09 10:16:18  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-09 10:16:22  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-09 10:16:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-09 10:16:32  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-09 10:16:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-09 10:16:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-09 10:16:46  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-09 10:16:47  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-09 10:16:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-09 10:16:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-09 10:17:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-09 10:17:06  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-09 10:17:11  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-09 10:17:15  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-09 10:17:20  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-09 10:17:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-09 10:17:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-09 10:17:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-09 10:17:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-09 10:17:42  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-09 10:17:46  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-09 10:17:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-09 10:17:56  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-09 10:18:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-09 10:18:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-09 10:18:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-09 10:18:14  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-09 10:18:19  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-09 10:18:24  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-09 10:18:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-09 10:18:33  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-09 10:18:37  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-09 10:18:42  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-09 10:18:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-09 10:18:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-09 10:18:56  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-09 10:19:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-09 10:19:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-09 10:19:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-09 10:19:12  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-09 10:19:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-09 10:19:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-09 10:19:26  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-09 10:19:31  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-09 10:19:35  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-09 10:19:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-09 10:19:43  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-09 10:19:47  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-09 10:19:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-09 10:19:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-09 10:20:00  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-09 10:20:04  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-09 10:20:09  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-09 10:20:13  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-09 10:20:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-09 10:20:22  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-09 10:20:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-09 10:20:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-09 10:20:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-09 10:20:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-09 10:20:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-09 10:20:50  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-09 10:20:54  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-09 10:20:58  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-09 10:21:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-09 10:21:07  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-09 10:21:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-09 10:21:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-09 10:21:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-09 10:21:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 10:21:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 10:21:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 10:21:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 10:21:41  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-09 10:21:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 10:21:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 10:21:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-09 10:21:58  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-09 10:22:02  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-09 10:22:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-09 10:22:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-09 10:22:15  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-09 10:22:19  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-09 10:22:23  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-09 10:22:27  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-09 10:22:32  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-09 10:22:36  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-09 10:22:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-09 10:22:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-09 10:22:49  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-09 10:22:53  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-09 10:22:57  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-09 10:23:01  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-09 10:23:05  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-09 10:23:10  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-09 10:23:14  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-09 10:23:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 10:23:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 10:23:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 10:23:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 10:23:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 10:23:39  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-09 10:23:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 10:23:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 10:23:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 10:23:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 10:24:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-09 10:24:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 10:24:08  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 10:24:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 10:24:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-09 10:24:22  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-09_10-31-57 Restart Xvfb...
2017-04-09_11-01-57 Restart Xvfb...
2017-04-09_11-31-57 Restart Xvfb...
2017-04-09_12-01-57 Restart Xvfb...
2017-04-09 12:31:46 reset updateRequest
2017-04-09 12:31:48  - 14968  http://www.lymphomahub.com/
2017-04-09 12:31:51  - 14968  http://www.lymphomahub.com/
2017-04-09 12:31:53  - 14968  http://www.lymphomahub.com/about
2017-04-09 12:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-09_12-31-57 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-09 12:33:58  - 14968  http://www.lymphomahub.com/about
2017-04-09 12:34:00  - 14968  http://www.lymphomahub.com/about
2017-04-09 12:34:02  - 14968  http://www.lymphomahub.com/terms
2017-04-09 12:34:04  - 14968  http://www.lymphomahub.com/terms
2017-04-09 12:34:06  - 14968  http://www.lymphomahub.com/undefined
2017-04-09 12:34:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-09 12:34:08  - 14968  http://www.lymphomahub.com/therapies
2017-04-09 12:34:15  - 14968  http://www.lymphomahub.com/newsletter
2017-04-09 12:34:17  - 14968  http://www.lymphomahub.com/newsletter
2017-04-09 12:34:18  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-09 12:34:21  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-09 12:34:22  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-09 12:34:25  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-09 12:34:28  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-09 12:34:30  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-09 12:34:33  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-09 12:34:35  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-09 12:34:38  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-09 12:34:39  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-09 12:34:44  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-09 12:34:44  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-09 12:34:49  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-09 12:34:54  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-09 12:34:58  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-09 12:35:03  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-09 12:35:08  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-09 12:35:13  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-09 12:35:17  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-09 12:35:22  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-09 12:35:26  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-09 12:35:31  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-09 12:35:36  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-09 12:35:41  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-09 12:35:45  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-09 12:35:50  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-09 12:35:54  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-09 12:35:59  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-09 12:36:04  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-09 12:36:07  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-09 12:36:12  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-09 12:36:17  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-09 12:36:21  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-09 12:36:26  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-09 12:36:30  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-09 12:36:35  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-09 12:36:40  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-09 12:36:44  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-09 12:36:49  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-09 12:36:54  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-09 12:36:58  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-09 12:37:03  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-09 12:37:08  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-09 12:37:12  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-09 12:37:17  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-09 12:37:21  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-09 12:37:26  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-09 12:37:30  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-09 12:37:35  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-09 12:37:39  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-09 12:37:44  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-09 12:37:49  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-09 12:37:54  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-09 12:37:59  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-09 12:38:03  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-09 12:38:08  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-09 12:38:12  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-09 12:38:17  - 14968  http://www.lymphomahub.com/medical-information
2017-04-09 12:38:22  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-09 12:38:27  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-09 12:38:31  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-09 12:38:36  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-09 12:38:40  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-09 12:38:45  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-09 12:38:49  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-09 12:38:54  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-09 12:38:59  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-09 12:39:03  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-09 12:39:08  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-09 12:39:12  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-09 12:39:13  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-09 12:39:18  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-09 12:39:23  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-09 12:39:27  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-09 12:39:32  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-09 12:39:36  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-09 12:39:41  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-09 12:39:46  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-09 12:39:50  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-09 12:39:55  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-09 12:39:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-09 12:40:04  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-09 12:40:08  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-09 12:40:13  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-09 12:40:18  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-09 12:40:22  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-09 12:40:27  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-09 12:40:31  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-09 12:40:36  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-09 12:40:40  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-09 12:40:45  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-09 12:40:49  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-09 12:40:54  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-09 12:40:58  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-09 12:41:03  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-09 12:41:08  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-09 12:41:12  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-09 12:41:16  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-09 12:41:21  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-09 12:41:26  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-09 12:41:30  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-09 12:41:31  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-09 12:41:36  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-09 12:41:40  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-09 12:41:45  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-09 12:41:49  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-09 12:41:54  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-09 12:41:58  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-09 12:42:03  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-09 12:42:08  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-09 12:42:11  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-09 12:42:12  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-09 12:42:17  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-09 12:42:22  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-09 12:42:26  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-09 12:42:31  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-09 12:42:35  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-09 12:42:36  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-09 12:42:41  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-09 12:42:45  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-09 12:42:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-09 12:42:53  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-09 12:42:58  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-09 12:43:02  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-09 12:43:06  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-09 12:43:10  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-09 12:43:14  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-09 12:43:19  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-09 12:43:23  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-09 12:43:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-09 12:43:32  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-09 12:43:36  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-09 12:43:36  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-09 12:43:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-09 12:43:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-09 12:43:50  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-09 12:43:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-09 12:43:59  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-09 12:44:04  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-09 12:44:08  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-09 12:44:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-09 12:44:16  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-09 12:44:20  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-09 12:44:24  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-09 12:44:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-09 12:44:32  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-09 12:44:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-09 12:44:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-09 12:44:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-09 12:44:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-09 12:44:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-09 12:44:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-09 12:45:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-09 12:45:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-09 12:45:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-09 12:45:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-09 12:45:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-09 12:45:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-09 12:45:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-09 12:45:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-09 12:45:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-09 12:45:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-09 12:45:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-09 12:45:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-09 12:45:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-09 12:46:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-09 12:46:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-09 12:46:10  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-09 12:46:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-09 12:46:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-09 12:46:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-09 12:46:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-09 12:46:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-09 12:46:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-09 12:46:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-09 12:46:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-09 12:46:51  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-09 12:46:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-09 12:46:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-09 12:47:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-09 12:47:09  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-09 12:47:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-09 12:47:19  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-09 12:47:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-09 12:47:27  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-09 12:47:31  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-09 12:47:36  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-09 12:47:41  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-09 12:47:45  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-09 12:47:49  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-09 12:47:53  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-09 12:47:58  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-09 12:48:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-09 12:48:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-09 12:48:11  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-09 12:48:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-09 12:48:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-09 12:48:24  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-09 12:48:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-09 12:48:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-09 12:48:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-09 12:48:42  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-09 12:48:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-09 12:48:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-09 12:48:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-09 12:49:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-09 12:49:06  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-09 12:49:06  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-09 12:49:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-09 12:49:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-09 12:49:20  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-09 12:49:25  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-09 12:49:30  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-09 12:49:34  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 12:49:40  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 12:49:44  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-09 12:49:49  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 12:49:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-09 12:49:58  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-09 12:50:03  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-09 12:50:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-09 12:50:12  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-09 12:50:17  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-09 12:50:22  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-09 12:50:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-09 12:50:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-09 12:50:36  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-09 12:50:41  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 12:50:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-09 12:50:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-09 12:50:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-09 12:51:00  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-09 12:51:05  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-09 12:51:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-09 12:51:14  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-09 12:51:20  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-09 12:51:24  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-09 12:51:29  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-09 12:51:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-09 12:51:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-09 12:51:43  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-09 12:51:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-09 12:51:52  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-09 12:51:57  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-09 12:52:02  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-09 12:52:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-09 12:52:12  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-09 12:52:17  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-09 12:52:22  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-09 12:52:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-09 12:52:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-09 12:52:32  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-09 12:52:37  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-09 12:52:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-09 12:52:46  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-09 12:52:51  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-09 12:52:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-09 12:53:00  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-09 12:53:05  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-09 12:53:10  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-09 12:53:15  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-09 12:53:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-09 12:53:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-09 12:53:30  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-09 12:53:34  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-09 12:53:40  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-09 12:53:44  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-09 12:53:49  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-09 12:53:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-09 12:53:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-09 12:54:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-09 12:54:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-09 12:54:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-09 12:54:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-09 12:54:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-09 12:54:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-09 12:54:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-09 12:54:33  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-09 12:54:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-09 12:54:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-09 12:54:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-09 12:54:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-09 12:54:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-09 12:54:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-09 12:54:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-09 12:55:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-09 12:55:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-09 12:55:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-09 12:55:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-09 12:55:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-09 12:55:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-09 12:55:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-09 12:55:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-09 12:55:31  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-09 12:55:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-09 12:55:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-09 12:55:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-09 12:55:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-09 12:55:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-09 12:55:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-09 12:55:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-09 12:56:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-09 12:56:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-09 12:56:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-09 12:56:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-09 12:56:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-09 12:56:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-09 12:56:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-09 12:56:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-09 12:56:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-09 12:56:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-09 12:56:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-09 12:56:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-09 12:56:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-09 12:56:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-09 12:56:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-09 12:56:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-09 12:57:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-09 12:57:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-09 12:57:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-09 12:57:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-09 12:57:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-09 12:57:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-09 12:57:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-09 12:57:27  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-09 12:57:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-09 12:57:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-09 12:57:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-09 12:57:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-09 12:57:48  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-09 12:57:53  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-09 12:57:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-09 12:58:03  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-09 12:58:04  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-09 12:58:08  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-09 12:58:13  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-09 12:58:18  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-09 12:58:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-09 12:58:28  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-09 12:58:33  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-09 12:58:38  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-09 12:58:43  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-09 12:58:47  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-09 12:58:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-09 12:58:57  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-09 12:59:02  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-09 12:59:06  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-09 12:59:11  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-09 12:59:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-09 12:59:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-09 12:59:25  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-09 12:59:30  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-09 12:59:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-09 12:59:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-09 12:59:44  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-09 12:59:49  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-09 12:59:54  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-09 12:59:58  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-09 13:00:03  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-09 13:00:08  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-09 13:00:13  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-09 13:00:21  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-09 13:00:25  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-09 13:00:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-09 13:00:34  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-09 13:00:39  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-09 13:00:44  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-09 13:00:49  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-09 13:00:53  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-09 13:00:58  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-09 13:01:02  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-09 13:01:07  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-09 13:01:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-09 13:01:16  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-09 13:01:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-09 13:01:26  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-09 13:01:31  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-09 13:01:36  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-09 13:01:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-09 13:01:45  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-09 13:01:49  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-09 13:01:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-09_13-01-57 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics?_prerender {"code":"ECONNRESET"}
2017-04-09 13:03:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-09 13:04:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-09 13:04:09  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-09 13:04:13  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-09 13:04:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-09 13:04:23  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-09 13:04:28  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-09 13:04:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-09 13:04:38  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-09 13:04:43  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-09 13:04:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-09 13:04:53  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-09 13:04:58  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-09 13:05:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-09 13:05:07  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-09 13:05:12  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-09 13:05:17  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-09 13:05:22  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-09 13:05:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-09 13:05:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-09 13:05:36  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-09 13:05:41  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-09 13:05:45  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-09 13:05:50  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-09 13:05:55  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-09 13:06:00  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-09 13:06:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-09 13:06:09  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-09 13:06:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-09 13:06:19  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-09 13:06:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-09 13:06:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-09 13:06:33  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-09 13:06:38  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-09 13:06:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-09 13:06:48  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-09 13:06:52  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-09 13:06:57  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-09 13:07:02  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-09 13:07:06  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-09 13:07:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-09 13:07:15  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-09 13:07:20  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-09 13:07:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-09 13:07:30  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-09 13:07:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-09 13:07:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-09 13:07:44  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-09 13:07:49  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-09 13:07:54  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-09 13:07:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-09 13:08:04  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-09 13:08:08  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-09 13:08:13  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-09 13:08:17  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-09 13:08:22  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-09 13:08:27  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-09 13:08:32  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-09 13:08:36  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-09 13:08:41  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-09 13:08:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-09 13:08:50  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-09 13:08:55  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-09 13:08:59  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-09 13:09:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-09 13:09:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-09 13:09:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-09 13:09:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-09 13:09:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-09 13:09:28  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-09 13:09:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-09 13:09:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-09 13:09:42  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-09 13:09:47  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-09 13:09:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-09 13:09:56  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-09 13:10:01  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-09 13:10:06  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-09 13:10:11  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-09 13:10:15  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-09 13:10:21  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-09 13:10:25  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-09 13:10:30  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-09 13:10:35  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-09 13:10:39  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-09 13:10:44  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-09 13:10:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-09 13:10:54  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-09 13:10:58  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-09 13:11:03  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-09 13:11:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-09 13:11:13  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-09 13:11:18  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-09 13:11:22  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-09 13:11:27  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-09 13:11:32  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-09 13:11:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-09 13:11:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-09 13:11:46  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-09 13:11:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-09 13:11:56  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-09 13:12:00  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-09 13:12:05  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-09 13:12:10  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-09 13:12:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-09 13:12:20  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-09 13:12:25  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-09 13:12:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-09 13:12:34  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-09 13:12:39  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-09 13:12:43  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-09 13:12:48  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-09 13:12:53  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-09 13:12:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-09 13:13:02  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-09 13:13:07  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-09 13:13:11  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-09 13:13:16  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-09 13:13:21  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-09 13:13:25  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-09 13:13:30  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-09 13:13:35  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-09 13:13:40  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-09 13:13:44  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-09 13:13:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-09 13:13:53  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-09 13:13:57  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-09 13:14:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-09 13:14:07  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-09 13:14:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-09 13:14:15  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-09 13:14:20  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-09 13:14:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-09 13:14:29  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-09 13:14:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-09 13:14:38  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-09 13:14:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-09 13:14:48  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-09 13:14:53  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-09 13:14:57  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-09 13:15:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-09 13:15:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-09 13:15:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-09 13:15:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-09 13:15:21  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-09 13:15:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-09 13:15:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-09 13:15:34  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-09 13:15:39  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-09 13:15:43  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-09 13:15:48  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-09 13:15:52  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-09 13:15:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-09 13:16:01  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-09 13:16:05  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-09 13:16:10  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-09 13:16:15  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-09 13:16:19  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-09 13:16:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-09 13:16:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-09 13:16:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-09 13:16:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-09 13:16:43  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-09 13:16:44  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-09 13:16:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-09 13:16:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-09 13:16:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-09 13:17:02  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-09 13:17:07  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-09 13:17:11  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-09 13:17:16  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-09 13:17:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-09 13:17:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-09 13:17:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-09 13:17:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-09 13:17:38  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-09 13:17:42  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-09 13:17:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-09 13:17:52  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-09 13:17:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-09 13:18:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-09 13:18:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-09 13:18:10  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-09 13:18:15  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-09 13:18:20  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-09 13:18:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-09 13:18:28  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-09 13:18:33  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-09 13:18:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-09 13:18:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-09 13:18:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-09 13:18:51  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-09 13:18:55  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-09 13:19:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-09 13:19:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-09 13:19:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-09 13:19:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-09 13:19:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-09 13:19:21  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-09 13:19:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-09 13:19:30  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-09 13:19:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-09 13:19:38  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-09 13:19:42  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-09 13:19:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-09 13:19:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-09 13:19:55  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-09 13:19:59  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-09 13:20:04  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-09 13:20:08  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-09 13:20:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-09 13:20:17  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-09 13:20:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-09 13:20:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-09 13:20:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-09 13:20:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-09 13:20:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-09 13:20:44  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-09 13:20:48  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-09 13:20:53  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-09 13:20:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-09 13:21:03  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-09 13:21:07  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-09 13:21:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-09 13:21:16  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-09 13:21:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 13:21:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 13:21:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 13:21:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 13:21:37  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-09 13:21:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 13:21:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 13:21:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-09 13:21:54  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-09 13:21:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-09 13:22:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-09 13:22:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-09 13:22:11  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-09 13:22:15  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-09 13:22:19  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-09 13:22:23  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-09 13:22:27  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-09 13:22:32  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-09 13:22:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-09 13:22:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-09 13:22:45  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-09 13:22:49  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-09 13:22:53  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-09 13:22:57  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-09 13:23:01  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-09 13:23:05  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-09 13:23:10  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-09 13:23:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 13:23:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 13:23:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 13:23:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 13:23:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 13:23:35  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-09 13:23:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 13:23:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 13:23:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 13:23:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 13:23:56  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-09 13:24:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 13:24:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 13:24:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 13:24:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-09 13:24:17  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-09_13-31-57 Restart Xvfb...
2017-04-09_14-01-57 Restart Xvfb...
2017-04-09_14-31-57 Restart Xvfb...
2017-04-09_15-01-57 Restart Xvfb...
2017-04-09 15:31:46 reset updateRequest
2017-04-09 15:31:48  - 14968  http://www.lymphomahub.com/
2017-04-09 15:31:51  - 14968  http://www.lymphomahub.com/
2017-04-09 15:31:53  - 14968  http://www.lymphomahub.com/about
2017-04-09 15:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-09_15-31-57 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-09 15:33:58  - 14968  http://www.lymphomahub.com/about
2017-04-09 15:34:00  - 14968  http://www.lymphomahub.com/about
2017-04-09 15:34:01  - 14968  http://www.lymphomahub.com/terms
2017-04-09 15:34:04  - 14968  http://www.lymphomahub.com/terms
2017-04-09 15:34:05  - 14968  http://www.lymphomahub.com/undefined
2017-04-09 15:34:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-09 15:34:07  - 14968  http://www.lymphomahub.com/therapies
2017-04-09 15:34:16  - 14968  http://www.lymphomahub.com/newsletter
2017-04-09 15:34:16  - 14968  http://www.lymphomahub.com/newsletter
2017-04-09 15:34:20  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-09 15:34:20  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-09 15:34:24  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-09 15:34:25  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-09 15:34:30  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-09 15:34:34  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-09 15:34:39  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-09 15:34:44  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-09 15:34:48  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-09 15:34:53  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-09 15:34:58  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-09 15:35:02  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-09 15:35:07  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-09 15:35:11  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-09 15:35:16  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-09 15:35:21  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-09 15:35:25  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-09 15:35:30  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-09 15:35:34  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-09 15:35:39  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-09 15:35:43  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-09 15:35:48  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-09 15:35:53  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-09 15:35:57  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-09 15:36:02  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-09 15:36:06  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-09 15:36:10  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-09 15:36:15  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-09 15:36:19  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-09 15:36:24  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-09 15:36:28  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-09 15:36:33  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-09 15:36:38  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-09 15:36:42  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-09 15:36:47  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-09 15:36:51  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-09 15:36:56  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-09 15:37:00  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-09 15:37:05  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-09 15:37:09  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-09 15:37:14  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-09 15:37:18  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-09 15:37:23  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-09 15:37:28  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-09 15:37:33  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-09 15:37:37  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-09 15:37:42  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-09 15:37:46  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-09 15:37:51  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-09 15:37:55  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-09 15:38:00  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-09 15:38:04  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-09 15:38:09  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-09 15:38:14  - 14968  http://www.lymphomahub.com/medical-information
2017-04-09 15:38:19  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-09 15:38:24  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-09 15:38:29  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-09 15:38:34  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-09 15:38:38  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-09 15:38:43  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-09 15:38:47  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-09 15:38:52  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-09 15:38:57  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-09 15:39:01  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-09 15:39:06  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-09 15:39:11  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-09 15:39:11  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-09 15:39:16  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-09 15:39:20  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-09 15:39:25  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-09 15:39:29  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-09 15:39:34  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-09 15:39:39  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-09 15:39:44  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-09 15:39:49  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-09 15:39:53  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-09 15:39:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-09 15:40:02  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-09 15:40:07  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-09 15:40:12  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-09 15:40:16  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-09 15:40:21  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-09 15:40:25  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-09 15:40:30  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-09 15:40:34  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-09 15:40:39  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-09 15:40:44  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-09 15:40:48  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-09 15:40:53  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-09 15:40:57  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-09 15:41:02  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-09 15:41:06  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-09 15:41:11  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-09 15:41:15  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-09 15:41:20  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-09 15:41:24  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-09 15:41:29  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-09 15:41:29  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-09 15:41:34  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-09 15:41:39  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-09 15:41:43  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-09 15:41:48  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-09 15:41:52  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-09 15:41:57  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-09 15:42:01  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-09 15:42:06  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-09 15:42:09  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-09 15:42:10  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-09 15:42:14  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-09 15:42:19  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-09 15:42:24  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-09 15:42:28  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-09 15:42:33  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-09 15:42:33  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-09 15:42:38  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-09 15:42:42  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-09 15:42:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-09 15:42:51  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-09 15:42:55  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-09 15:42:59  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-09 15:43:03  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-09 15:43:07  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-09 15:43:11  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-09 15:43:16  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-09 15:43:20  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-09 15:43:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-09 15:43:29  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-09 15:43:33  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-09 15:43:33  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-09 15:43:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-09 15:43:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-09 15:43:47  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-09 15:43:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-09 15:43:56  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-09 15:44:00  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-09 15:44:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-09 15:44:08  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-09 15:44:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-09 15:44:16  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-09 15:44:20  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-09 15:44:24  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-09 15:44:28  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-09 15:44:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-09 15:44:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-09 15:44:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-09 15:44:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-09 15:44:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-09 15:44:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-09 15:44:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-09 15:45:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-09 15:45:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-09 15:45:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-09 15:45:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-09 15:45:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-09 15:45:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-09 15:45:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-09 15:45:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-09 15:45:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-09 15:45:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-09 15:45:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-09 15:45:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-09 15:45:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-09 15:46:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-09 15:46:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-09 15:46:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-09 15:46:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-09 15:46:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-09 15:46:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-09 15:46:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-09 15:46:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-09 15:46:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-09 15:46:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-09 15:46:48  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-09 15:46:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-09 15:46:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-09 15:47:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-09 15:47:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-09 15:47:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-09 15:47:15  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-09 15:47:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-09 15:47:24  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-09 15:47:28  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-09 15:47:32  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-09 15:47:37  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-09 15:47:41  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-09 15:47:46  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-09 15:47:50  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-09 15:47:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-09 15:47:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-09 15:48:04  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-09 15:48:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-09 15:48:13  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-09 15:48:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-09 15:48:22  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-09 15:48:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-09 15:48:31  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-09 15:48:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-09 15:48:40  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-09 15:48:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-09 15:48:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-09 15:48:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-09 15:48:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-09 15:49:03  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-09 15:49:04  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-09 15:49:09  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-09 15:49:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-09 15:49:18  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-09 15:49:23  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-09 15:49:27  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-09 15:49:32  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 15:49:37  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 15:49:42  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-09 15:49:46  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 15:49:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-09 15:49:57  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-09 15:50:01  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-09 15:50:06  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-09 15:50:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-09 15:50:15  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-09 15:50:21  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-09 15:50:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-09 15:50:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-09 15:50:35  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-09 15:50:40  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 15:50:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-09 15:50:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-09 15:50:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-09 15:50:59  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-09 15:51:04  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-09 15:51:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-09 15:51:13  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-09 15:51:18  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-09 15:51:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-09 15:51:28  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-09 15:51:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-09 15:51:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-09 15:51:42  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-09 15:51:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-09 15:51:51  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-09 15:51:56  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-09 15:52:01  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-09 15:52:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-09 15:52:10  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-09 15:52:15  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-09 15:52:20  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-09 15:52:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-09 15:52:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-09 15:52:30  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-09 15:52:35  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-09 15:52:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-09 15:52:45  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-09 15:52:50  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-09 15:52:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-09 15:52:59  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-09 15:53:04  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-09 15:53:09  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-09 15:53:13  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-09 15:53:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-09 15:53:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-09 15:53:28  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-09 15:53:33  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-09 15:53:37  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-09 15:53:42  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-09 15:53:46  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-09 15:53:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-09 15:53:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-09 15:54:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-09 15:54:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-09 15:54:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-09 15:54:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-09 15:54:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-09 15:54:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-09 15:54:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-09 15:54:30  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-09 15:54:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-09 15:54:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-09 15:54:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-09 15:54:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-09 15:54:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-09 15:54:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-09 15:54:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-09 15:54:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-09 15:55:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-09 15:55:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-09 15:55:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-09 15:55:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-09 15:55:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-09 15:55:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-09 15:55:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-09 15:55:28  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-09 15:55:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-09 15:55:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-09 15:55:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-09 15:55:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-09 15:55:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-09 15:55:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-09 15:55:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-09 15:55:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-09 15:56:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-09 15:56:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-09 15:56:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-09 15:56:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-09 15:56:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-09 15:56:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-09 15:56:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-09 15:56:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-09 15:56:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-09 15:56:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-09 15:56:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-09 15:56:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-09 15:56:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-09 15:56:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-09 15:56:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-09 15:56:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-09 15:57:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-09 15:57:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-09 15:57:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-09 15:57:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-09 15:57:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-09 15:57:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-09 15:57:26  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-09 15:57:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-09 15:57:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-09 15:57:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-09 15:57:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-09 15:57:47  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-09 15:57:52  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-09 15:57:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-09 15:58:02  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-09 15:58:02  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-09 15:58:07  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-09 15:58:12  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-09 15:58:16  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-09 15:58:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-09 15:58:26  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-09 15:58:30  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-09 15:58:35  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-09 15:58:40  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-09 15:58:45  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-09 15:58:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-09 15:58:54  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-09 15:58:59  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-09 15:59:04  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-09 15:59:08  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-09 15:59:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-09 15:59:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-09 15:59:23  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-09 15:59:27  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-09 15:59:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-09 15:59:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-09 15:59:41  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-09 15:59:46  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-09 15:59:50  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-09 15:59:55  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-09 16:00:00  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-09 16:00:05  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-09 16:00:09  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-09 16:00:14  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-09 16:00:19  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-09 16:00:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-09 16:00:28  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-09 16:00:33  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-09 16:00:37  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-09 16:00:42  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-09 16:00:47  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-09 16:00:52  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-09 16:00:56  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-09 16:01:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-09 16:01:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-09 16:01:11  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-09 16:01:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-09 16:01:20  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-09 16:01:25  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-09 16:01:30  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-09 16:01:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-09 16:01:40  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-09 16:01:44  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-09 16:01:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-09 16:01:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-09_16-01-57 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment?_prerender {"code":"ECONNRESET"}
2017-04-09 16:03:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-09 16:04:03  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-09 16:04:08  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-09 16:04:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-09 16:04:17  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-09 16:04:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-09 16:04:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-09 16:04:33  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-09 16:04:38  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-09 16:04:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-09 16:04:47  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-09 16:04:52  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-09 16:04:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-09 16:05:02  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-09 16:05:07  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-09 16:05:13  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-09 16:05:17  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-09 16:05:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-09 16:05:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-09 16:05:32  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-09 16:05:36  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-09 16:05:41  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-09 16:05:46  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-09 16:05:50  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-09 16:05:55  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-09 16:06:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-09 16:06:05  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-09 16:06:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-09 16:06:14  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-09 16:06:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-09 16:06:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-09 16:06:29  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-09 16:06:33  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-09 16:06:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-09 16:06:43  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-09 16:06:48  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-09 16:06:52  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-09 16:06:57  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-09 16:07:01  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-09 16:07:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-09 16:07:11  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-09 16:07:16  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-09 16:07:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-09 16:07:25  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-09 16:07:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-09 16:07:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-09 16:07:39  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-09 16:07:44  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-09 16:07:48  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-09 16:07:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-09 16:07:58  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-09 16:08:02  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-09 16:08:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-09 16:08:12  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-09 16:08:16  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-09 16:08:21  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-09 16:08:26  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-09 16:08:31  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-09 16:08:35  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-09 16:08:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-09 16:08:45  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-09 16:08:50  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-09 16:08:54  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-09 16:08:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-09 16:09:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-09 16:09:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-09 16:09:14  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-09 16:09:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-09 16:09:23  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-09 16:09:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-09 16:09:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-09 16:09:38  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-09 16:09:42  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-09 16:09:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-09 16:09:52  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-09 16:09:56  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-09 16:10:01  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-09 16:10:06  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-09 16:10:10  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-09 16:10:15  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-09 16:10:21  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-09 16:10:26  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-09 16:10:30  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-09 16:10:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-09 16:10:40  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-09 16:10:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-09 16:10:49  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-09 16:10:54  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-09 16:10:58  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-09 16:11:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-09 16:11:08  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-09 16:11:12  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-09 16:11:18  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-09 16:11:22  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-09 16:11:27  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-09 16:11:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-09 16:11:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-09 16:11:43  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-09 16:11:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-09 16:11:52  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-09 16:11:56  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-09 16:12:01  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-09 16:12:06  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-09 16:12:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-09 16:12:15  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-09 16:12:20  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-09 16:12:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-09 16:12:29  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-09 16:12:34  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-09 16:12:38  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-09 16:12:42  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-09 16:12:47  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-09 16:12:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-09 16:12:56  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-09 16:13:01  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-09 16:13:05  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-09 16:13:10  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-09 16:13:15  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-09 16:13:20  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-09 16:13:25  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-09 16:13:30  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-09 16:13:34  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-09 16:13:38  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-09 16:13:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-09 16:13:48  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-09 16:13:52  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-09 16:13:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-09 16:14:02  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-09 16:14:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-09 16:14:11  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-09 16:14:15  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-09 16:14:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-09 16:14:24  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-09 16:14:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-09 16:14:34  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-09 16:14:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-09 16:14:43  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-09 16:14:48  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-09 16:14:52  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-09 16:14:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-09 16:15:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-09 16:15:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-09 16:15:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-09 16:15:15  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-09 16:15:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-09 16:15:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-09 16:15:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-09 16:15:34  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-09 16:15:38  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-09 16:15:43  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-09 16:15:48  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-09 16:15:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-09 16:15:56  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-09 16:16:01  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-09 16:16:05  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-09 16:16:10  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-09 16:16:15  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-09 16:16:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-09 16:16:25  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-09 16:16:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-09 16:16:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-09 16:16:39  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-09 16:16:39  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-09 16:16:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-09 16:16:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-09 16:16:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-09 16:16:58  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-09 16:17:03  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-09 16:17:07  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-09 16:17:12  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-09 16:17:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-09 16:17:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-09 16:17:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-09 16:17:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-09 16:17:35  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-09 16:17:39  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-09 16:17:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-09 16:17:49  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-09 16:17:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-09 16:17:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-09 16:18:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-09 16:18:07  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-09 16:18:12  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-09 16:18:16  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-09 16:18:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-09 16:18:25  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-09 16:18:29  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-09 16:18:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-09 16:18:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-09 16:18:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-09 16:18:48  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-09 16:18:52  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-09 16:18:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-09 16:19:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-09 16:19:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-09 16:19:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-09 16:19:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-09 16:19:18  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-09 16:19:22  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-09 16:19:26  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-09 16:19:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-09 16:19:35  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-09 16:19:39  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-09 16:19:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-09 16:19:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-09 16:19:53  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-09 16:19:57  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-09 16:20:01  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-09 16:20:06  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-09 16:20:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-09 16:20:14  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-09 16:20:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-09 16:20:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-09 16:20:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-09 16:20:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-09 16:20:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-09 16:20:42  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-09 16:20:46  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-09 16:20:51  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-09 16:20:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-09 16:20:59  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-09 16:21:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-09 16:21:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-09 16:21:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-09 16:21:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 16:21:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 16:21:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 16:21:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 16:21:34  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-09 16:21:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 16:21:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 16:21:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-09 16:21:50  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-09 16:21:54  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-09 16:21:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-09 16:22:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-09 16:22:07  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-09 16:22:12  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-09 16:22:16  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-09 16:22:20  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-09 16:22:24  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-09 16:22:28  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-09 16:22:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-09 16:22:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-09 16:22:41  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-09 16:22:46  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-09 16:22:50  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-09 16:22:54  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-09 16:22:58  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-09 16:23:02  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-09 16:23:06  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-09 16:23:10  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 16:23:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 16:23:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 16:23:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 16:23:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 16:23:31  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-09 16:23:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 16:23:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 16:23:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 16:23:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 16:23:52  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-09 16:23:57  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 16:24:01  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 16:24:05  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 16:24:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-09 16:24:13  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-09_16-31-57 Restart Xvfb...
2017-04-09_17-01-57 Restart Xvfb...
2017-04-09_17-31-57 Restart Xvfb...
2017-04-09_18-01-57 Restart Xvfb...
2017-04-09 18:31:46 reset updateRequest
2017-04-09 18:31:48  - 14968  http://www.lymphomahub.com/
2017-04-09 18:31:51  - 14968  http://www.lymphomahub.com/
2017-04-09 18:31:54  - 14968  http://www.lymphomahub.com/about
2017-04-09 18:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-09_18-31-57 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-09 18:33:59  - 14968  http://www.lymphomahub.com/about
2017-04-09 18:34:00  - 14968  http://www.lymphomahub.com/about
2017-04-09 18:34:03  - 14968  http://www.lymphomahub.com/terms
2017-04-09 18:34:05  - 14968  http://www.lymphomahub.com/terms
2017-04-09 18:34:07  - 14968  http://www.lymphomahub.com/undefined
2017-04-09 18:34:08  - 14968  http://www.lymphomahub.com/therapies
2017-04-09 18:34:08  - 14968  http://www.lymphomahub.com/therapies
2017-04-09 18:34:17  - 14968  http://www.lymphomahub.com/newsletter
2017-04-09 18:34:17  - 14968  http://www.lymphomahub.com/newsletter
2017-04-09 18:34:21  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-09 18:34:21  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-09 18:34:25  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-09 18:34:26  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-09 18:34:31  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-09 18:34:31  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-09 18:34:37  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-09 18:34:41  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-09 18:34:46  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-09 18:34:52  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-09 18:34:56  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-09 18:35:01  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-09 18:35:05  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-09 18:35:10  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-09 18:35:15  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-09 18:35:19  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-09 18:35:24  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-09 18:35:29  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-09 18:35:33  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-09 18:35:38  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-09 18:35:42  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-09 18:35:47  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-09 18:35:51  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-09 18:35:56  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-09 18:36:01  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-09 18:36:05  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-09 18:36:09  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-09 18:36:13  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-09 18:36:18  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-09 18:36:23  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-09 18:36:27  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-09 18:36:32  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-09 18:36:36  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-09 18:36:41  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-09 18:36:46  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-09 18:36:50  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-09 18:36:55  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-09 18:36:59  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-09 18:37:04  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-09 18:37:09  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-09 18:37:13  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-09 18:37:17  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-09 18:37:22  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-09 18:37:27  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-09 18:37:31  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-09 18:37:36  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-09 18:37:41  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-09 18:37:45  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-09 18:37:50  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-09 18:37:55  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-09 18:38:00  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-09 18:38:04  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-09 18:38:08  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-09 18:38:13  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-09 18:38:18  - 14968  http://www.lymphomahub.com/medical-information
2017-04-09 18:38:23  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-09 18:38:27  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-09 18:38:32  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-09 18:38:37  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-09 18:38:41  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-09 18:38:46  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-09 18:38:51  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-09 18:38:56  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-09 18:39:01  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-09 18:39:05  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-09 18:39:10  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-09 18:39:14  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-09 18:39:15  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-09 18:39:20  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-09 18:39:24  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-09 18:39:29  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-09 18:39:33  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-09 18:39:38  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-09 18:39:42  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-09 18:39:47  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-09 18:39:52  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-09 18:39:56  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-09 18:40:01  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-09 18:40:05  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-09 18:40:10  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-09 18:40:15  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-09 18:40:19  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-09 18:40:23  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-09 18:40:28  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-09 18:40:32  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-09 18:40:37  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-09 18:40:42  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-09 18:40:46  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-09 18:40:51  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-09 18:40:55  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-09 18:41:00  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-09 18:41:05  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-09 18:41:09  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-09 18:41:15  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-09 18:41:19  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-09 18:41:24  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-09 18:41:29  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-09 18:41:33  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-09 18:41:34  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-09 18:41:39  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-09 18:41:43  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-09 18:41:48  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-09 18:41:53  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-09 18:41:57  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-09 18:42:02  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-09 18:42:06  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-09 18:42:11  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-09 18:42:15  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-09 18:42:15  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-09 18:42:20  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-09 18:42:25  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-09 18:42:30  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-09 18:42:34  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-09 18:42:39  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-09 18:42:40  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-09 18:42:45  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-09 18:42:49  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-09 18:42:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-09 18:42:57  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-09 18:43:02  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-09 18:43:06  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-09 18:43:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-09 18:43:14  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-09 18:43:18  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-09 18:43:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-09 18:43:27  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-09 18:43:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-09 18:43:36  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-09 18:43:40  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-09 18:43:41  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-09 18:43:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-09 18:43:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-09 18:43:55  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-09 18:43:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-09 18:44:04  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-09 18:44:09  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-09 18:44:13  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-09 18:44:17  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-09 18:44:21  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-09 18:44:25  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-09 18:44:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-09 18:44:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-09 18:44:37  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-09 18:44:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-09 18:44:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-09 18:44:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-09 18:44:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-09 18:44:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-09 18:45:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-09 18:45:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-09 18:45:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-09 18:45:16  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-09 18:45:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-09 18:45:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-09 18:45:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-09 18:45:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-09 18:45:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-09 18:45:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-09 18:45:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-09 18:45:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-09 18:45:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-09 18:46:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-09 18:46:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-09 18:46:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-09 18:46:14  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-09 18:46:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-09 18:46:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-09 18:46:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-09 18:46:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-09 18:46:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-09 18:46:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-09 18:46:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-09 18:46:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-09 18:46:55  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-09 18:46:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-09 18:47:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-09 18:47:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-09 18:47:13  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-09 18:47:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-09 18:47:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-09 18:47:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-09 18:47:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-09 18:47:35  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-09 18:47:40  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-09 18:47:45  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-09 18:47:49  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-09 18:47:53  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-09 18:47:57  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-09 18:48:02  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-09 18:48:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-09 18:48:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-09 18:48:14  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-09 18:48:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-09 18:48:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-09 18:48:27  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-09 18:48:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-09 18:48:36  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-09 18:48:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-09 18:48:45  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-09 18:48:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-09 18:48:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-09 18:48:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-09 18:49:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-09 18:49:09  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-09 18:49:09  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-09 18:49:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-09 18:49:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-09 18:49:23  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-09 18:49:28  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-09 18:49:33  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-09 18:49:37  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 18:49:42  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 18:49:47  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-09 18:49:52  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 18:49:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-09 18:50:01  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-09 18:50:06  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-09 18:50:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-09 18:50:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-09 18:50:20  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-09 18:50:25  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-09 18:50:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-09 18:50:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-09 18:50:39  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-09 18:50:43  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 18:50:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-09 18:50:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-09 18:50:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-09 18:51:03  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-09 18:51:08  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-09 18:51:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-09 18:51:17  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-09 18:51:22  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-09 18:51:27  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-09 18:51:32  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-09 18:51:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-09 18:51:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-09 18:51:47  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-09 18:51:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-09 18:51:56  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-09 18:52:01  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-09 18:52:06  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-09 18:52:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-09 18:52:16  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-09 18:52:21  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-09 18:52:26  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-09 18:52:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-09 18:52:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-09 18:52:36  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-09 18:52:41  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-09 18:52:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-09 18:52:51  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-09 18:52:56  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-09 18:53:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-09 18:53:05  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-09 18:53:10  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-09 18:53:15  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-09 18:53:20  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-09 18:53:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-09 18:53:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-09 18:53:35  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-09 18:53:40  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-09 18:53:45  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-09 18:53:50  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-09 18:53:54  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-09 18:53:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-09 18:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-09 18:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-09 18:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-09 18:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-09 18:54:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-09 18:54:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-09 18:54:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-09 18:54:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-09 18:54:39  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-09 18:54:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-09 18:54:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-09 18:54:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-09 18:54:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-09 18:54:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-09 18:55:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-09 18:55:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-09 18:55:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-09 18:55:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-09 18:55:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-09 18:55:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-09 18:55:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-09 18:55:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-09 18:55:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-09 18:55:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-09 18:55:37  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-09 18:55:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-09 18:55:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-09 18:55:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-09 18:55:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-09 18:55:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-09 18:56:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-09 18:56:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-09 18:56:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-09 18:56:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-09 18:56:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-09 18:56:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-09 18:56:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-09 18:56:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-09 18:56:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-09 18:56:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-09 18:56:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-09 18:56:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-09 18:56:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-09 18:56:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-09 18:56:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-09 18:56:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-09 18:57:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-09 18:57:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-09 18:57:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-09 18:57:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-09 18:57:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-09 18:57:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-09 18:57:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-09 18:57:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-09 18:57:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-09 18:57:35  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-09 18:57:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-09 18:57:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-09 18:57:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-09 18:57:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-09 18:57:56  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-09 18:58:00  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-09 18:58:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-09 18:58:10  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-09 18:58:11  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-09 18:58:16  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-09 18:58:21  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-09 18:58:25  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-09 18:58:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-09 18:58:35  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-09 18:58:40  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-09 18:58:44  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-09 18:58:49  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-09 18:58:54  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-09 18:58:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-09 18:59:04  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-09 18:59:08  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-09 18:59:13  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-09 18:59:17  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-09 18:59:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-09 18:59:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-09 18:59:32  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-09 18:59:36  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-09 18:59:41  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-09 18:59:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-09 18:59:51  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-09 18:59:55  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-09 19:00:00  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-09 19:00:05  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-09 19:00:09  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-09 19:00:14  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-09 19:00:19  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-09 19:00:24  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-09 19:00:29  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-09 19:00:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-09 19:00:38  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-09 19:00:43  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-09 19:00:48  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-09 19:00:52  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-09 19:00:57  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-09 19:01:02  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-09 19:01:06  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-09 19:01:11  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-09 19:01:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-09 19:01:20  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-09 19:01:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-09 19:01:30  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-09 19:01:34  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-09 19:01:39  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-09 19:01:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-09 19:01:48  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-09 19:01:53  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-09 19:01:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-09_19-01-58 Restart Xvfb...
2017-04-09 19:02:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-09 19:02:07  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-09 19:02:12  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-09 19:02:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-09 19:02:21  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-09 19:02:26  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-09 19:02:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-09 19:02:35  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-09 19:02:40  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-09 19:02:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-09 19:02:50  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-09 19:02:54  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-09 19:02:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-09 19:03:04  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-09 19:03:08  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-09 19:03:14  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-09 19:03:18  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-09 19:03:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-09 19:03:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-09 19:03:32  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-09 19:03:37  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-09 19:03:42  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-09 19:03:47  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-09 19:03:51  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-09 19:03:56  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-09 19:04:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-09 19:04:06  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-09 19:04:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-09 19:04:15  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-09 19:04:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-09 19:04:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-09 19:04:29  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-09 19:04:34  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-09 19:04:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-09 19:04:44  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-09 19:04:48  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-09 19:04:53  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-09 19:04:58  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-09 19:05:02  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-09 19:05:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-09 19:05:12  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-09 19:05:17  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-09 19:05:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-09 19:05:27  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-09 19:05:32  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-09 19:05:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-09 19:05:41  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-09 19:05:46  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-09 19:05:51  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-09 19:05:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-09 19:06:00  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-09 19:06:05  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-09 19:06:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-09 19:06:14  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-09 19:06:19  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-09 19:06:24  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-09 19:06:28  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-09 19:06:33  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-09 19:06:38  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-09 19:06:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-09 19:06:47  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-09 19:06:52  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-09 19:06:57  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-09 19:07:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-09 19:07:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-09 19:07:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-09 19:07:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-09 19:07:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-09 19:07:25  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-09 19:07:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-09 19:07:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-09 19:07:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-09 19:07:45  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-09 19:07:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-09 19:07:54  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-09 19:07:59  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-09 19:08:03  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-09 19:08:08  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-09 19:08:12  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-09 19:08:17  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-09 19:08:22  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-09 19:08:27  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-09 19:08:31  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-09 19:08:36  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-09 19:08:41  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-09 19:08:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-09 19:08:50  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-09 19:08:55  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-09 19:08:59  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-09 19:09:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-09 19:09:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-09 19:09:14  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-09 19:09:19  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-09 19:09:24  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-09 19:09:28  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-09 19:09:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-09 19:09:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-09 19:09:43  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-09 19:09:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-09 19:09:52  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-09 19:09:57  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-09 19:10:01  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-09 19:10:06  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-09 19:10:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-09 19:10:15  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-09 19:10:20  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-09 19:10:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-09 19:10:29  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-09 19:10:33  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-09 19:10:38  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-09 19:10:42  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-09 19:10:47  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-09 19:10:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-09 19:10:57  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-09 19:11:01  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-09 19:11:05  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-09 19:11:10  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-09 19:11:15  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-09 19:11:19  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-09 19:11:24  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-09 19:11:29  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-09 19:11:34  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-09 19:11:38  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-09 19:11:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-09 19:11:47  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-09 19:11:52  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-09 19:11:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-09 19:12:01  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-09 19:12:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-09 19:12:10  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-09 19:12:15  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-09 19:12:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-09 19:12:24  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-09 19:12:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-09 19:12:33  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-09 19:12:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-09 19:12:43  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-09 19:12:48  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-09 19:12:52  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-09 19:12:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-09 19:13:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-09 19:13:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-09 19:13:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-09 19:13:15  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-09 19:13:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-09 19:13:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-09 19:13:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-09 19:13:34  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-09 19:13:38  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-09 19:13:43  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-09 19:13:47  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-09 19:13:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-09 19:13:56  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-09 19:14:00  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-09 19:14:05  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-09 19:14:09  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-09 19:14:14  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-09 19:14:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-09 19:14:23  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-09 19:14:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-09 19:14:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-09 19:14:38  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-09 19:14:38  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-09 19:14:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-09 19:14:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-09 19:14:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-09 19:14:56  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-09 19:15:01  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-09 19:15:06  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-09 19:15:11  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-09 19:15:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-09 19:15:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-09 19:15:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-09 19:15:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-09 19:15:34  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-09 19:15:38  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-09 19:15:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-09 19:15:48  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-09 19:15:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-09 19:15:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-09 19:16:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-09 19:16:06  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-09 19:16:10  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-09 19:16:15  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-09 19:16:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-09 19:16:24  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-09 19:16:28  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-09 19:16:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-09 19:16:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-09 19:16:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-09 19:16:47  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-09 19:16:51  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-09 19:16:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-09 19:17:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-09 19:17:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-09 19:17:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-09 19:17:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-09 19:17:17  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-09 19:17:21  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-09 19:17:25  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-09 19:17:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-09 19:17:34  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-09 19:17:38  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-09 19:17:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-09 19:17:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-09 19:17:52  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-09 19:17:56  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-09 19:18:00  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-09 19:18:04  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-09 19:18:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-09 19:18:13  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-09 19:18:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-09 19:18:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-09 19:18:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-09 19:18:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-09 19:18:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-09 19:18:41  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-09 19:18:45  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-09 19:18:50  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-09 19:18:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-09 19:18:59  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-09 19:19:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-09 19:19:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-09 19:19:12  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-09 19:19:16  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 19:19:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 19:19:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 19:19:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 19:19:33  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-09 19:19:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 19:19:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 19:19:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-09 19:19:49  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-09 19:19:54  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-09 19:19:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-09 19:20:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-09 19:20:07  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-09 19:20:11  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-09 19:20:16  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-09 19:20:20  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-09 19:20:24  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-09 19:20:28  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-09 19:20:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-09 19:20:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-09 19:20:41  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-09 19:20:45  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-09 19:20:50  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-09 19:20:54  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-09 19:20:58  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-09 19:21:02  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-09 19:21:06  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-09 19:21:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 19:21:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 19:21:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 19:21:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 19:21:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 19:21:32  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-09 19:21:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 19:21:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 19:21:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 19:21:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 19:21:53  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-09 19:21:57  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 19:22:01  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 19:22:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 19:22:10  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-09 19:22:14  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-09_19-31-58 Restart Xvfb...
2017-04-09_20-01-58 Restart Xvfb...
2017-04-09_20-31-58 Restart Xvfb...
2017-04-09_21-01-58 Restart Xvfb...
2017-04-09 21:31:46 reset updateRequest
2017-04-09 21:31:50  - 14968  http://www.lymphomahub.com/
2017-04-09 21:31:51  - 14968  http://www.lymphomahub.com/
2017-04-09 21:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-09 21:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-09_21-31-58 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-09 21:34:00  - 14968  http://www.lymphomahub.com/about
2017-04-09 21:34:01  - 14968  http://www.lymphomahub.com/about
2017-04-09 21:34:07  - 14968  http://www.lymphomahub.com/terms
2017-04-09 21:34:10  - 14968  http://www.lymphomahub.com/undefined
2017-04-09 21:34:11  - 14968  http://www.lymphomahub.com/therapies
2017-04-09 21:34:17  - 14968  http://www.lymphomahub.com/newsletter
2017-04-09 21:34:21  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-09 21:34:24  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-09 21:34:29  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-09 21:34:34  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-09 21:34:38  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-09 21:34:43  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-09 21:34:48  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-09 21:34:53  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-09 21:34:57  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-09 21:35:02  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-09 21:35:07  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-09 21:35:11  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-09 21:35:16  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-09 21:35:20  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-09 21:35:25  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-09 21:35:29  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-09 21:35:34  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-09 21:35:39  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-09 21:35:43  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-09 21:35:48  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-09 21:35:52  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-09 21:35:57  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-09 21:36:01  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-09 21:36:05  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-09 21:36:10  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-09 21:36:14  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-09 21:36:19  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-09 21:36:23  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-09 21:36:28  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-09 21:36:33  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-09 21:36:37  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-09 21:36:42  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-09 21:36:47  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-09 21:36:51  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-09 21:36:56  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-09 21:37:00  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-09 21:37:05  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-09 21:37:09  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-09 21:37:14  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-09 21:37:18  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-09 21:37:23  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-09 21:37:28  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-09 21:37:32  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-09 21:37:37  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-09 21:37:41  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-09 21:37:46  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-09 21:37:50  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-09 21:37:55  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-09 21:37:59  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-09 21:38:04  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-09 21:38:08  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-09 21:38:13  - 14968  http://www.lymphomahub.com/medical-information
2017-04-09 21:38:17  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-09 21:38:22  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-09 21:38:27  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-09 21:38:31  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-09 21:38:36  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-09 21:38:41  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-09 21:38:45  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-09 21:38:50  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-09 21:38:54  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-09 21:38:59  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-09 21:39:03  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-09 21:39:08  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-09 21:39:08  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-09 21:39:13  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-09 21:39:18  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-09 21:39:22  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-09 21:39:27  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-09 21:39:31  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-09 21:39:36  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-09 21:39:40  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-09 21:39:44  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-09 21:39:49  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-09 21:39:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-09 21:39:58  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-09 21:40:03  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-09 21:40:07  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-09 21:40:12  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-09 21:40:17  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-09 21:40:21  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-09 21:40:26  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-09 21:40:30  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-09 21:40:35  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-09 21:40:40  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-09 21:40:44  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-09 21:40:49  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-09 21:40:54  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-09 21:40:58  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-09 21:41:02  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-09 21:41:07  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-09 21:41:11  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-09 21:41:16  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-09 21:41:20  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-09 21:41:25  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-09 21:41:26  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-09 21:41:30  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-09 21:41:35  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-09 21:41:39  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-09 21:41:44  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-09 21:41:49  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-09 21:41:53  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-09 21:41:58  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-09 21:42:02  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-09 21:42:06  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-09 21:42:07  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-09 21:42:11  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-09 21:42:16  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-09 21:42:21  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-09 21:42:26  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-09 21:42:30  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-09 21:42:31  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-09 21:42:36  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-09 21:42:40  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-09 21:42:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-09 21:42:48  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-09 21:42:53  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-09 21:42:57  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-09 21:43:01  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-09 21:43:05  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-09 21:43:09  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-09 21:43:14  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-09 21:43:18  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-09 21:43:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-09 21:43:27  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-09 21:43:31  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-09 21:43:32  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-09 21:43:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-09 21:43:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-09 21:43:46  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-09 21:43:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-09 21:43:54  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-09 21:43:59  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-09 21:44:03  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-09 21:44:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-09 21:44:11  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-09 21:44:15  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-09 21:44:19  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-09 21:44:23  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-09 21:44:27  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-09 21:44:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-09 21:44:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-09 21:44:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-09 21:44:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-09 21:44:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-09 21:44:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-09 21:44:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-09 21:45:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-09 21:45:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-09 21:45:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-09 21:45:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-09 21:45:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-09 21:45:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-09 21:45:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-09 21:45:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-09 21:45:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-09 21:45:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-09 21:45:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-09 21:45:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-09 21:45:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-09 21:46:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-09 21:46:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-09 21:46:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-09 21:46:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-09 21:46:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-09 21:46:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-09 21:46:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-09 21:46:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-09 21:46:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-09 21:46:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-09 21:46:45  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-09 21:46:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-09 21:46:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-09 21:46:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-09 21:47:03  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-09 21:47:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-09 21:47:11  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-09 21:47:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-09 21:47:20  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-09 21:47:24  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-09 21:47:29  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-09 21:47:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-09 21:47:37  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-09 21:47:42  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-09 21:47:46  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-09 21:47:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-09 21:47:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-09 21:47:59  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-09 21:48:03  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-09 21:48:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-09 21:48:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-09 21:48:16  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-09 21:48:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-09 21:48:24  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-09 21:48:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-09 21:48:33  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-09 21:48:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-09 21:48:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-09 21:48:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-09 21:48:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-09 21:48:57  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-09 21:48:57  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-09 21:49:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-09 21:49:06  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-09 21:49:11  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-09 21:49:16  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-09 21:49:21  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-09 21:49:26  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 21:49:30  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 21:49:35  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-09 21:49:39  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 21:49:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-09 21:49:49  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-09 21:49:53  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-09 21:49:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-09 21:50:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-09 21:50:08  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-09 21:50:12  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-09 21:50:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-09 21:50:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-09 21:50:27  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-09 21:50:32  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-09 21:50:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-09 21:50:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-09 21:50:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-09 21:50:51  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-09 21:50:56  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-09 21:51:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-09 21:51:06  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-09 21:51:10  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-09 21:51:15  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-09 21:51:20  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-09 21:51:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-09 21:51:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-09 21:51:34  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-09 21:51:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-09 21:51:43  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-09 21:51:48  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-09 21:51:53  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-09 21:51:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-09 21:52:02  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-09 21:52:07  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-09 21:52:12  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-09 21:52:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-09 21:52:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-09 21:52:22  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-09 21:52:27  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-09 21:52:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-09 21:52:36  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-09 21:52:41  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-09 21:52:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-09 21:52:50  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-09 21:52:55  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-09 21:52:59  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-09 21:53:04  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-09 21:53:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-09 21:53:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-09 21:53:18  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-09 21:53:23  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-09 21:53:28  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-09 21:53:33  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-09 21:53:38  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-09 21:53:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-09 21:53:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-09 21:53:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-09 21:53:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-09 21:54:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-09 21:54:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-09 21:54:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-09 21:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-09 21:54:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-09 21:54:21  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-09 21:54:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-09 21:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-09 21:54:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-09 21:54:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-09 21:54:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-09 21:54:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-09 21:54:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-09 21:54:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-09 21:54:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-09 21:54:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-09 21:55:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-09 21:55:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-09 21:55:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-09 21:55:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-09 21:55:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-09 21:55:18  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-09 21:55:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-09 21:55:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-09 21:55:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-09 21:55:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-09 21:55:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-09 21:55:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-09 21:55:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-09 21:55:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-09 21:55:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-09 21:55:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-09 21:56:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-09 21:56:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-09 21:56:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-09 21:56:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-09 21:56:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-09 21:56:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-09 21:56:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-09 21:56:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-09 21:56:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-09 21:56:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-09 21:56:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-09 21:56:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-09 21:56:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-09 21:56:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-09 21:56:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-09 21:56:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-09 21:57:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-09 21:57:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-09 21:57:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-09 21:57:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-09 21:57:15  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-09 21:57:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-09 21:57:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-09 21:57:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-09 21:57:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-09 21:57:36  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-09 21:57:41  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-09 21:57:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-09 21:57:51  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-09 21:57:51  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-09 21:57:56  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-09 21:58:01  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-09 21:58:05  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-09 21:58:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-09 21:58:15  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-09 21:58:19  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-09 21:58:24  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-09 21:58:29  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-09 21:58:34  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-09 21:58:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-09 21:58:44  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-09 21:58:48  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-09 21:58:53  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-09 21:58:58  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-09 21:59:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-09 21:59:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-09 21:59:12  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-09 21:59:16  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-09 21:59:21  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-09 21:59:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-09 21:59:31  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-09 21:59:35  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-09 21:59:40  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-09 21:59:45  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-09 21:59:50  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-09 21:59:54  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-09 21:59:59  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-09 22:00:04  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-09 22:00:08  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-09 22:00:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-09 22:00:17  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-09 22:00:22  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-09 22:00:27  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-09 22:00:31  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-09 22:00:36  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-09 22:00:41  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-09 22:00:45  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-09 22:00:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-09 22:00:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-09 22:01:00  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-09 22:01:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-09 22:01:09  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-09 22:01:14  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-09 22:01:19  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-09 22:01:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-09 22:01:28  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-09 22:01:32  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-09 22:01:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-09 22:01:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-09 22:01:48  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-09 22:01:52  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-09 22:01:57  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-09_22-01-58 Restart Xvfb...
2017-04-09 22:02:02  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-09 22:02:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-09 22:02:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-09 22:02:16  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-09 22:02:21  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-09 22:02:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-09 22:02:30  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-09 22:02:35  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-09 22:02:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-09 22:02:44  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-09 22:02:49  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-09 22:02:54  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-09 22:02:59  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-09 22:03:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-09 22:03:09  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-09 22:03:14  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-09 22:03:19  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-09 22:03:23  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-09 22:03:28  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-09 22:03:33  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-09 22:03:37  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-09 22:03:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-09 22:03:47  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-09 22:03:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-09 22:03:56  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-09 22:04:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-09 22:04:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-09 22:04:11  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-09 22:04:16  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-09 22:04:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-09 22:04:26  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-09 22:04:31  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-09 22:04:35  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-09 22:04:40  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-09 22:04:44  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-09 22:04:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-09 22:04:54  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-09 22:04:58  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-09 22:05:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-09 22:05:08  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-09 22:05:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-09 22:05:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-09 22:05:22  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-09 22:05:27  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-09 22:05:32  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-09 22:05:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-09 22:05:42  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-09 22:05:46  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-09 22:05:51  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-09 22:05:56  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-09 22:06:01  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-09 22:06:06  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-09 22:06:10  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-09 22:06:15  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-09 22:06:20  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-09 22:06:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-09 22:06:31  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-09 22:06:35  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-09 22:06:40  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-09 22:06:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-09 22:06:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-09 22:06:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-09 22:06:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-09 22:07:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-09 22:07:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-09 22:07:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-09 22:07:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-09 22:07:24  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-09 22:07:29  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-09 22:07:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-09 22:07:38  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-09 22:07:43  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-09 22:07:48  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-09 22:07:53  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-09 22:07:57  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-09 22:08:02  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-09 22:08:07  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-09 22:08:11  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-09 22:08:16  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-09 22:08:21  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-09 22:08:26  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-09 22:08:31  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-09 22:08:36  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-09 22:08:40  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-09 22:08:45  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-09 22:08:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-09 22:08:55  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-09 22:08:59  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-09 22:09:04  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-09 22:09:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-09 22:09:14  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-09 22:09:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-09 22:09:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-09 22:09:28  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-09 22:09:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-09 22:09:37  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-09 22:09:42  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-09 22:09:47  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-09 22:09:52  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-09 22:09:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-09 22:10:01  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-09 22:10:06  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-09 22:10:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-09 22:10:15  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-09 22:10:20  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-09 22:10:25  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-09 22:10:29  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-09 22:10:35  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-09 22:10:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-09 22:10:44  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-09 22:10:48  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-09 22:10:53  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-09 22:10:58  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-09 22:11:02  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-09 22:11:07  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-09 22:11:12  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-09 22:11:17  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-09 22:11:22  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-09 22:11:26  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-09 22:11:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-09 22:11:35  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-09 22:11:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-09 22:11:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-09 22:11:49  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-09 22:11:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-09 22:11:58  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-09 22:12:03  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-09 22:12:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-09 22:12:13  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-09 22:12:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-09 22:12:22  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-09 22:12:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-09 22:12:32  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-09 22:12:37  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-09 22:12:41  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-09 22:12:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-09 22:12:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-09 22:12:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-09 22:12:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-09 22:13:04  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-09 22:13:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-09 22:13:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-09 22:13:17  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-09 22:13:22  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-09 22:13:26  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-09 22:13:31  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-09 22:13:35  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-09 22:13:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-09 22:13:44  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-09 22:13:48  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-09 22:13:53  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-09 22:13:58  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-09 22:14:03  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-09 22:14:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-09 22:14:13  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-09 22:14:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-09 22:14:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-09 22:14:27  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-09 22:14:27  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-09 22:14:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-09 22:14:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-09 22:14:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-09 22:14:46  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-09 22:14:51  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-09 22:14:56  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-09 22:15:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-09 22:15:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-09 22:15:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-09 22:15:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-09 22:15:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-09 22:15:23  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-09 22:15:27  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-09 22:15:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-09 22:15:37  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-09 22:15:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-09 22:15:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-09 22:15:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-09 22:15:55  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-09 22:16:00  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-09 22:16:05  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-09 22:16:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-09 22:16:13  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-09 22:16:18  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-09 22:16:22  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-09 22:16:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-09 22:16:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-09 22:16:37  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-09 22:16:41  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-09 22:16:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-09 22:16:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-09 22:16:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-09 22:16:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-09 22:17:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-09 22:17:07  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-09 22:17:11  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-09 22:17:15  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-09 22:17:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-09 22:17:24  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-09 22:17:28  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-09 22:17:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-09 22:17:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-09 22:17:42  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-09 22:17:46  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-09 22:17:50  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-09 22:17:54  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-09 22:17:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-09 22:18:03  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-09 22:18:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-09 22:18:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-09 22:18:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-09 22:18:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-09 22:18:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-09 22:18:31  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-09 22:18:35  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-09 22:18:39  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-09 22:18:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-09 22:18:48  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-09 22:18:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-09 22:18:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-09 22:19:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-09 22:19:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 22:19:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 22:19:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 22:19:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 22:19:22  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-09 22:19:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 22:19:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-09 22:19:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-09 22:19:39  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-09 22:19:43  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-09 22:19:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-09 22:19:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-09 22:19:56  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-09 22:20:00  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-09 22:20:05  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-09 22:20:09  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-09 22:20:13  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-09 22:20:17  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-09 22:20:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-09 22:20:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-09 22:20:31  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-09 22:20:35  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-09 22:20:39  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-09 22:20:43  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-09 22:20:47  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-09 22:20:51  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-09 22:20:55  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-09 22:21:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 22:21:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 22:21:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 22:21:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 22:21:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-09 22:21:21  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-09 22:21:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 22:21:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 22:21:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 22:21:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 22:21:43  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-09 22:21:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 22:21:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 22:21:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-09 22:21:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-09 22:22:03  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-09_22-31-58 Restart Xvfb...
2017-04-09_23-01-58 Restart Xvfb...
2017-04-09_23-31-58 Restart Xvfb...
2017-04-10_00-01-58 Restart Xvfb...
2017-04-10 00:31:46 reset updateRequest
2017-04-10 00:31:49  - 14968  http://www.lymphomahub.com/
2017-04-10 00:31:51  - 14968  http://www.lymphomahub.com/
2017-04-10 00:31:57  - 14968  http://www.lymphomahub.com/about
2017-04-10_00-31-58 Restart Xvfb...
2017-04-10 00:32:03  - 14968  http://www.lymphomahub.com/terms
2017-04-10 00:32:06  - 14968  http://www.lymphomahub.com/undefined
2017-04-10 00:32:07  - 14968  http://www.lymphomahub.com/therapies
2017-04-10 00:32:13  - 14968  http://www.lymphomahub.com/newsletter
2017-04-10 00:32:17  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-10 00:32:20  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-10 00:32:26  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-10 00:32:30  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-10 00:32:35  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-10 00:32:40  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-10 00:32:44  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-10 00:32:49  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-10 00:32:53  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-10 00:32:58  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-10 00:33:03  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-10 00:33:07  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-10 00:33:12  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-10 00:33:16  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-10 00:33:21  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-10 00:33:25  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-10 00:33:30  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-10 00:33:35  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-10 00:33:40  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-10 00:33:45  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-10 00:33:49  - 14968  http://www.lymphomahub.com/therapies/epz6438
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/?_prerender {"code":"ECONNRESET"}
2017-04-10 00:33:54  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-10 00:33:56  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-10 00:33:58  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-10 00:34:00  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-10 00:34:03  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-10 00:34:04  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-10 00:34:08  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-10 00:34:09  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-10 00:34:13  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-10 00:34:14  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-10 00:34:19  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-10 00:34:19  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-10 00:34:24  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-10 00:34:24  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-10 00:34:29  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-10 00:34:34  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-10 00:34:39  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-10 00:34:44  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-10 00:34:48  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-10 00:34:53  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-10 00:34:57  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-10 00:35:02  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-10 00:35:06  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-10 00:35:11  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-10 00:35:16  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-10 00:35:20  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-10 00:35:25  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-10 00:35:29  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-10 00:35:34  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-10 00:35:39  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-10 00:35:43  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-10 00:35:48  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-10 00:35:53  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-10 00:35:57  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-10 00:36:02  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-10 00:36:07  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-10 00:36:11  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-10 00:36:16  - 14968  http://www.lymphomahub.com/medical-information
2017-04-10 00:36:20  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-10 00:36:26  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-10 00:36:30  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-10 00:36:35  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-10 00:36:39  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-10 00:36:44  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-10 00:36:49  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-10 00:36:53  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-10 00:36:58  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-10 00:37:02  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-10 00:37:07  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-10 00:37:12  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-10 00:37:12  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-10 00:37:17  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-10 00:37:22  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-10 00:37:26  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-10 00:37:31  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-10 00:37:36  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-10 00:37:40  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-10 00:37:45  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-10 00:37:49  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-10 00:37:54  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-10 00:37:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-10 00:38:03  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-10 00:38:08  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-10 00:38:13  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-10 00:38:17  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-10 00:38:22  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-10 00:38:26  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-10 00:38:31  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-10 00:38:36  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-10 00:38:40  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-10 00:38:45  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-10 00:38:49  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-10 00:38:54  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-10 00:38:59  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-10 00:39:03  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-10 00:39:08  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-10 00:39:13  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-10 00:39:17  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-10 00:39:22  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-10 00:39:26  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-10 00:39:31  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-10 00:39:32  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-10 00:39:37  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-10 00:39:41  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-10 00:39:46  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-10 00:39:51  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-10 00:39:55  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-10 00:40:00  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-10 00:40:04  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-10 00:40:09  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-10 00:40:13  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-10 00:40:13  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-10 00:40:18  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-10 00:40:22  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-10 00:40:27  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-10 00:40:31  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-10 00:40:36  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-10 00:40:37  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-10 00:40:41  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-10 00:40:46  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-10 00:40:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-10 00:40:54  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-10 00:40:59  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-10 00:41:03  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-10 00:41:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-10 00:41:11  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-10 00:41:15  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-10 00:41:20  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-10 00:41:24  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-10 00:41:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-10 00:41:33  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-10 00:41:37  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-10 00:41:37  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-10 00:41:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-10 00:41:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-10 00:41:51  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-10 00:41:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-10 00:42:00  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-10 00:42:05  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-10 00:42:09  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-10 00:42:13  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-10 00:42:17  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-10 00:42:21  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-10 00:42:25  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-10 00:42:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-10 00:42:34  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-10 00:42:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-10 00:42:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-10 00:42:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-10 00:42:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-10 00:42:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-10 00:42:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-10 00:43:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-10 00:43:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-10 00:43:14  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-10 00:43:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-10 00:43:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-10 00:43:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-10 00:43:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-10 00:43:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-10 00:43:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-10 00:43:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-10 00:43:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-10 00:43:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-10 00:43:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-10 00:44:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-10 00:44:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-10 00:44:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-10 00:44:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-10 00:44:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-10 00:44:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-10 00:44:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-10 00:44:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-10 00:44:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-10 00:44:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-10 00:44:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-10 00:44:53  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-10 00:44:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-10 00:45:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-10 00:45:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-10 00:45:11  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-10 00:45:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-10 00:45:20  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-10 00:45:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-10 00:45:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-10 00:45:32  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-10 00:45:37  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-10 00:45:42  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-10 00:45:46  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-10 00:45:51  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-10 00:45:55  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-10 00:46:00  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-10 00:46:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-10 00:46:08  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-10 00:46:12  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-10 00:46:16  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-10 00:46:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-10 00:46:26  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-10 00:46:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-10 00:46:35  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-10 00:46:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-10 00:46:44  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-10 00:46:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-10 00:46:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-10 00:46:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-10 00:47:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-10 00:47:08  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-10 00:47:09  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-10 00:47:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-10 00:47:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-10 00:47:24  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-10 00:47:28  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-10 00:47:33  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-10 00:47:38  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 00:47:42  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 00:47:47  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-10 00:47:52  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 00:47:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-10 00:48:02  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-10 00:48:06  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-10 00:48:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-10 00:48:16  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-10 00:48:21  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-10 00:48:25  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-10 00:48:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-10 00:48:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-10 00:48:40  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-10 00:48:45  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 00:48:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-10 00:48:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-10 00:48:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-10 00:49:04  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-10 00:49:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-10 00:49:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-10 00:49:19  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-10 00:49:24  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-10 00:49:28  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-10 00:49:33  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-10 00:49:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-10 00:49:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-10 00:49:47  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-10 00:49:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-10 00:49:57  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-10 00:50:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-10 00:50:07  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-10 00:50:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-10 00:50:17  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-10 00:50:22  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-10 00:50:27  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-10 00:50:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-10 00:50:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-10 00:50:37  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-10 00:50:42  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-10 00:50:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-10 00:50:51  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-10 00:50:56  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-10 00:51:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-10 00:51:06  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-10 00:51:10  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-10 00:51:15  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-10 00:51:20  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-10 00:51:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-10 00:51:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-10 00:51:35  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-10 00:51:40  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-10 00:51:44  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-10 00:51:49  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-10 00:51:54  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-10 00:51:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-10 00:52:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-10 00:52:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-10 00:52:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-10 00:52:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-10 00:52:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-10 00:52:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-10 00:52:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-10 00:52:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-10 00:52:37  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-10 00:52:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-10 00:52:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-10 00:52:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-10 00:52:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-10 00:52:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-10 00:52:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-10 00:53:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-10 00:53:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-10 00:53:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-10 00:53:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-10 00:53:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-10 00:53:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-10 00:53:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-10 00:53:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-10 00:53:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-10 00:53:36  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-10 00:53:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-10 00:53:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-10 00:53:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-10 00:53:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-10 00:53:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-10 00:53:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-10 00:54:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-10 00:54:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-10 00:54:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-10 00:54:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-10 00:54:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-10 00:54:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-10 00:54:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-10 00:54:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-10 00:54:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-10 00:54:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-10 00:54:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-10 00:54:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-10 00:54:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-10 00:54:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-10 00:54:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-10 00:54:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-10 00:55:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-10 00:55:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-10 00:55:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-10 00:55:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-10 00:55:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-10 00:55:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-10 00:55:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-10 00:55:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-10 00:55:32  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-10 00:55:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-10 00:55:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-10 00:55:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-10 00:55:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-10 00:55:53  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-10 00:55:58  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-10 00:56:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-10 00:56:08  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-10 00:56:08  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-10 00:56:13  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-10 00:56:18  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-10 00:56:23  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-10 00:56:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-10 00:56:32  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-10 00:56:37  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-10 00:56:42  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-10 00:56:46  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-10 00:56:51  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-10 00:56:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-10 00:57:03  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-10 00:57:07  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-10 00:57:12  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-10 00:57:17  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-10 00:57:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-10 00:57:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-10 00:57:31  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-10 00:57:36  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-10 00:57:41  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-10 00:57:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-10 00:57:51  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-10 00:57:56  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-10 00:58:01  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-10 00:58:05  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-10 00:58:10  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-10 00:58:16  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-10 00:58:20  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-10 00:58:25  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-10 00:58:30  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-10 00:58:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-10 00:58:39  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-10 00:58:44  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-10 00:58:48  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-10 00:58:53  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-10 00:58:58  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-10 00:59:02  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-10 00:59:07  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-10 00:59:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-10 00:59:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-10 00:59:21  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-10 00:59:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-10 00:59:31  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-10 00:59:35  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-10 00:59:40  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-10 00:59:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-10 00:59:50  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-10 00:59:54  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-10 00:59:59  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-10 01:00:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-10 01:00:08  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-10 01:00:13  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-10 01:00:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-10 01:00:23  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-10 01:00:27  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-10 01:00:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-10 01:00:37  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-10 01:00:42  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-10 01:00:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-10 01:00:52  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-10 01:00:56  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-10 01:01:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-10 01:01:06  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-10 01:01:10  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-10 01:01:15  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-10 01:01:20  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-10 01:01:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-10 01:01:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-10 01:01:34  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-10 01:01:39  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-10 01:01:44  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-10 01:01:48  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-10 01:01:53  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-10_01-01-58 Restart Xvfb...
2017-04-10 01:01:58  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-10 01:02:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-10 01:02:07  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-10 01:02:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-10 01:02:17  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-10 01:02:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-10 01:02:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-10 01:02:31  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-10 01:02:36  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-10 01:02:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-10 01:02:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-10 01:02:50  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-10 01:02:55  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-10 01:03:00  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-10 01:03:04  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-10 01:03:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-10 01:03:13  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-10 01:03:18  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-10 01:03:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-10 01:03:28  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-10 01:03:32  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-10 01:03:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-10 01:03:42  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-10 01:03:47  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-10 01:03:51  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-10 01:03:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-10 01:04:01  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-10 01:04:06  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-10 01:04:11  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-10 01:04:15  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-10 01:04:20  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-10 01:04:25  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-10 01:04:30  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-10 01:04:35  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-10 01:04:40  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-10 01:04:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-10 01:04:50  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-10 01:04:54  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-10 01:04:59  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-10 01:05:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-10 01:05:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-10 01:05:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-10 01:05:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-10 01:05:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-10 01:05:28  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-10 01:05:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-10 01:05:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-10 01:05:43  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-10 01:05:47  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-10 01:05:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-10 01:05:57  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-10 01:06:01  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-10 01:06:06  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-10 01:06:11  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-10 01:06:15  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-10 01:06:20  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-10 01:06:24  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-10 01:06:29  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-10 01:06:34  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-10 01:06:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-10 01:06:43  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-10 01:06:48  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-10 01:06:52  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-10 01:06:57  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-10 01:07:02  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-10 01:07:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-10 01:07:11  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-10 01:07:16  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-10 01:07:21  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-10 01:07:26  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-10 01:07:31  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-10 01:07:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-10 01:07:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-10 01:07:45  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-10 01:07:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-10 01:07:54  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-10 01:07:59  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-10 01:08:04  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-10 01:08:09  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-10 01:08:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-10 01:08:18  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-10 01:08:23  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-10 01:08:27  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-10 01:08:32  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-10 01:08:37  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-10 01:08:41  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-10 01:08:46  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-10 01:08:50  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-10 01:08:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-10 01:09:00  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-10 01:09:04  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-10 01:09:09  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-10 01:09:13  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-10 01:09:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-10 01:09:23  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-10 01:09:28  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-10 01:09:32  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-10 01:09:37  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-10 01:09:41  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-10 01:09:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-10 01:09:50  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-10 01:09:55  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-10 01:09:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-10 01:10:04  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-10 01:10:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-10 01:10:13  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-10 01:10:18  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-10 01:10:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-10 01:10:27  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-10 01:10:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-10 01:10:36  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-10 01:10:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-10 01:10:46  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-10 01:10:50  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-10 01:10:54  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-10 01:10:58  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-10 01:11:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-10 01:11:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-10 01:11:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-10 01:11:17  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-10 01:11:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-10 01:11:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-10 01:11:31  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-10 01:11:35  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-10 01:11:40  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-10 01:11:44  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-10 01:11:49  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-10 01:11:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-10 01:11:58  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-10 01:12:02  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-10 01:12:07  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-10 01:12:12  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-10 01:12:16  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-10 01:12:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-10 01:12:26  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-10 01:12:31  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-10 01:12:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-10 01:12:40  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-10 01:12:41  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-10 01:12:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-10 01:12:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-10 01:12:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-10 01:12:59  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-10 01:13:04  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-10 01:13:09  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-10 01:13:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-10 01:13:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-10 01:13:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-10 01:13:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-10 01:13:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-10 01:13:37  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-10 01:13:41  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-10 01:13:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-10 01:13:51  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-10 01:13:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-10 01:14:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-10 01:14:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-10 01:14:10  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-10 01:14:14  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-10 01:14:19  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-10 01:14:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-10 01:14:28  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-10 01:14:32  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-10 01:14:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-10 01:14:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-10 01:14:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-10 01:14:51  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-10 01:14:55  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-10 01:15:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-10 01:15:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-10 01:15:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-10 01:15:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-10 01:15:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-10 01:15:22  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-10 01:15:26  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-10 01:15:30  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-10 01:15:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-10 01:15:38  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-10 01:15:43  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-10 01:15:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-10 01:15:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-10 01:15:56  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-10 01:16:00  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-10 01:16:05  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-10 01:16:09  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-10 01:16:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-10 01:16:17  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-10 01:16:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-10 01:16:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-10 01:16:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-10 01:16:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-10 01:16:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-10 01:16:45  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-10 01:16:49  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-10 01:16:53  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-10 01:16:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-10 01:17:02  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-10 01:17:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-10 01:17:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-10 01:17:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-10 01:17:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 01:17:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 01:17:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 01:17:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 01:17:36  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-10 01:17:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 01:17:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 01:17:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-10 01:17:53  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-10 01:17:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-10 01:18:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-10 01:18:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-10 01:18:11  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-10 01:18:15  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-10 01:18:19  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-10 01:18:23  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-10 01:18:28  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-10 01:18:32  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-10 01:18:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-10 01:18:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-10 01:18:45  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-10 01:18:49  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-10 01:18:53  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-10 01:18:57  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-10 01:19:01  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-10 01:19:06  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-10 01:19:10  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-10 01:19:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 01:19:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 01:19:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 01:19:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 01:19:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 01:19:35  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-10 01:19:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 01:19:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 01:19:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 01:19:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 01:19:56  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-10 01:20:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 01:20:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 01:20:08  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 01:20:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-10 01:20:16  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-10_01-31-58 Restart Xvfb...
2017-04-10_02-01-58 Restart Xvfb...
2017-04-10_02-31-58 Restart Xvfb...
2017-04-10_03-01-58 Restart Xvfb...
2017-04-10 03:31:46 reset updateRequest
2017-04-10 03:31:48  - 14968  http://www.lymphomahub.com/
2017-04-10 03:31:51  - 14968  http://www.lymphomahub.com/
2017-04-10 03:31:52  - 14968  http://www.lymphomahub.com/about
2017-04-10 03:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-10_03-31-58 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-10 03:33:57  - 14968  http://www.lymphomahub.com/about
2017-04-10 03:34:01  - 14968  http://www.lymphomahub.com/about
2017-04-10 03:34:01  - 14968  http://www.lymphomahub.com/terms
2017-04-10 03:34:05  - 14968  http://www.lymphomahub.com/terms
2017-04-10 03:34:05  - 14968  http://www.lymphomahub.com/undefined
2017-04-10 03:34:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-10 03:34:09  - 14968  http://www.lymphomahub.com/therapies
2017-04-10 03:34:15  - 14968  http://www.lymphomahub.com/newsletter
2017-04-10 03:34:17  - 14968  http://www.lymphomahub.com/newsletter
2017-04-10 03:34:19  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-10 03:34:21  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-10 03:34:22  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-10 03:34:24  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-10 03:34:27  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-10 03:34:28  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-10 03:34:32  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-10 03:34:33  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-10 03:34:37  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-10 03:34:37  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-10 03:34:42  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-10 03:34:42  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-10 03:34:47  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-10 03:34:51  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-10 03:34:56  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-10 03:35:00  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-10 03:35:04  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-10 03:35:09  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-10 03:35:13  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-10 03:35:17  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-10 03:35:22  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-10 03:35:26  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-10 03:35:30  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-10 03:35:35  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-10 03:35:39  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-10 03:35:43  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-10 03:35:48  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-10 03:35:52  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-10 03:35:56  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-10 03:36:01  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-10 03:36:05  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-10 03:36:09  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-10 03:36:14  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-10 03:36:18  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-10 03:36:23  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-10 03:36:27  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-10 03:36:31  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-10 03:36:36  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-10 03:36:40  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-10 03:36:44  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-10 03:36:49  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-10 03:36:53  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-10 03:36:58  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-10 03:37:02  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-10 03:37:06  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-10 03:37:10  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-10 03:37:15  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-10 03:37:19  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-10 03:37:24  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-10 03:37:28  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-10 03:37:33  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-10 03:37:37  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-10 03:37:41  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-10 03:37:45  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-10 03:37:49  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-10 03:37:54  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-10 03:37:58  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-10 03:38:02  - 14968  http://www.lymphomahub.com/medical-information
2017-04-10 03:38:07  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-10 03:38:11  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-10 03:38:15  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-10 03:38:20  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-10 03:38:24  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-10 03:38:28  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-10 03:38:33  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-10 03:38:37  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-10 03:38:42  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-10 03:38:46  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-10 03:38:50  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-10 03:38:54  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-10 03:38:55  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-10 03:38:59  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-10 03:39:04  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-10 03:39:08  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-10 03:39:12  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-10 03:39:17  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-10 03:39:21  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-10 03:39:25  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-10 03:39:29  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-10 03:39:34  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-10 03:39:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-10 03:39:43  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-10 03:39:47  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-10 03:39:51  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-10 03:39:55  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-10 03:40:00  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-10 03:40:04  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-10 03:40:08  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-10 03:40:13  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-10 03:40:17  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-10 03:40:21  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-10 03:40:26  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-10 03:40:30  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-10 03:40:34  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-10 03:40:38  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-10 03:40:43  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-10 03:40:47  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-10 03:40:51  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-10 03:40:55  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-10 03:41:00  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-10 03:41:04  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-10 03:41:04  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-10 03:41:09  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-10 03:41:13  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-10 03:41:17  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-10 03:41:21  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-10 03:41:26  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-10 03:41:30  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-10 03:41:34  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-10 03:41:39  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-10 03:41:42  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-10 03:41:43  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-10 03:41:47  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-10 03:41:51  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-10 03:41:56  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-10 03:42:00  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-10 03:42:04  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-10 03:42:05  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-10 03:42:09  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-10 03:42:13  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-10 03:42:17  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-10 03:42:21  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-10 03:42:25  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-10 03:42:29  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-10 03:42:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-10 03:42:36  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-10 03:42:40  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-10 03:42:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-10 03:42:49  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-10 03:42:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-10 03:42:58  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-10 03:43:02  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-10 03:43:02  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-10 03:43:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-10 03:43:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-10 03:43:15  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-10 03:43:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-10 03:43:24  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-10 03:43:28  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-10 03:43:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-10 03:43:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-10 03:43:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-10 03:43:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-10 03:43:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-10 03:43:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-10 03:43:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-10 03:43:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-10 03:44:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-10 03:44:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-10 03:44:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-10 03:44:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-10 03:44:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-10 03:44:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-10 03:44:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-10 03:44:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-10 03:44:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-10 03:44:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-10 03:44:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-10 03:44:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-10 03:44:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-10 03:44:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-10 03:45:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-10 03:45:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-10 03:45:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-10 03:45:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-10 03:45:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-10 03:45:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-10 03:45:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-10 03:45:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-10 03:45:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-10 03:45:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-10 03:45:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-10 03:45:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-10 03:45:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-10 03:45:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-10 03:46:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-10 03:46:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-10 03:46:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-10 03:46:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-10 03:46:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-10 03:46:26  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-10 03:46:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-10 03:46:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-10 03:46:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-10 03:46:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-10 03:46:46  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-10 03:46:50  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-10 03:46:55  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-10 03:46:58  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-10 03:47:03  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-10 03:47:08  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-10 03:47:12  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-10 03:47:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-10 03:47:20  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-10 03:47:24  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-10 03:47:28  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-10 03:47:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-10 03:47:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-10 03:47:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-10 03:47:45  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-10 03:47:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-10 03:47:53  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-10 03:47:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-10 03:48:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-10 03:48:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-10 03:48:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-10 03:48:15  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-10 03:48:16  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-10 03:48:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-10 03:48:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-10 03:48:29  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-10 03:48:34  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-10 03:48:38  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-10 03:48:43  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 03:48:47  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 03:48:51  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-10 03:48:56  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 03:49:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-10 03:49:04  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-10 03:49:09  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-10 03:49:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-10 03:49:18  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-10 03:49:22  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-10 03:49:27  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-10 03:49:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-10 03:49:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-10 03:49:40  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-10 03:49:44  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 03:49:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-10 03:49:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-10 03:49:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-10 03:50:02  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-10 03:50:07  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-10 03:50:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-10 03:50:16  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-10 03:50:20  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-10 03:50:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-10 03:50:30  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-10 03:50:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-10 03:50:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-10 03:50:43  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-10 03:50:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-10 03:50:52  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-10 03:50:56  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-10 03:51:00  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-10 03:51:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-10 03:51:09  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-10 03:51:14  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-10 03:51:18  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-10 03:51:18  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-10 03:51:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-10 03:51:27  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-10 03:51:32  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-10 03:51:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-10 03:51:40  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-10 03:51:45  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-10 03:51:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-10 03:51:54  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-10 03:51:58  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-10 03:52:03  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-10 03:52:07  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-10 03:52:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-10 03:52:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-10 03:52:21  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-10 03:52:25  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-10 03:52:30  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-10 03:52:34  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-10 03:52:39  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-10 03:52:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-10 03:52:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-10 03:52:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-10 03:52:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-10 03:53:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-10 03:53:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-10 03:53:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-10 03:53:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-10 03:53:18  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-10 03:53:22  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-10 03:53:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-10 03:53:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-10 03:53:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-10 03:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-10 03:53:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-10 03:53:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-10 03:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-10 03:53:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-10 03:53:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-10 03:53:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-10 03:54:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-10 03:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-10 03:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-10 03:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-10 03:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-10 03:54:19  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-10 03:54:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-10 03:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-10 03:54:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-10 03:54:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-10 03:54:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-10 03:54:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-10 03:54:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-10 03:54:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-10 03:54:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-10 03:54:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-10 03:55:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-10 03:55:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-10 03:55:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-10 03:55:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-10 03:55:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-10 03:55:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-10 03:55:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-10 03:55:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-10 03:55:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-10 03:55:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-10 03:55:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-10 03:55:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-10 03:55:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-10 03:55:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-10 03:55:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-10 03:55:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-10 03:56:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-10 03:56:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-10 03:56:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-10 03:56:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-10 03:56:14  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-10 03:56:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-10 03:56:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-10 03:56:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-10 03:56:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-10 03:56:34  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-10 03:56:39  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-10 03:56:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-10 03:56:48  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-10 03:56:48  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-10 03:56:53  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-10 03:56:57  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-10 03:57:02  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-10 03:57:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-10 03:57:11  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-10 03:57:15  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-10 03:57:20  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-10 03:57:24  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-10 03:57:28  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-10 03:57:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-10 03:57:37  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-10 03:57:42  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-10 03:57:46  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-10 03:57:50  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-10 03:57:55  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-10 03:57:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-10 03:58:04  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-10 03:58:08  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-10 03:58:12  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-10 03:58:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-10 03:58:21  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-10 03:58:25  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-10 03:58:30  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-10 03:58:34  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-10 03:58:38  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-10 03:58:43  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-10 03:58:48  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-10 03:58:52  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-10 03:58:56  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-10 03:59:01  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-10 03:59:05  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-10 03:59:09  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-10 03:59:14  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-10 03:59:18  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-10 03:59:22  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-10 03:59:27  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-10 03:59:31  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-10 03:59:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-10 03:59:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-10 03:59:45  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-10 03:59:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-10 03:59:53  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-10 03:59:58  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-10 04:00:02  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-10 04:00:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-10 04:00:12  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-10 04:00:16  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-10 04:00:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-10 04:00:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-10 04:00:29  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-10 04:00:34  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-10 04:00:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-10 04:00:42  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-10 04:00:47  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-10 04:00:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-10 04:00:56  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-10 04:01:00  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-10 04:01:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-10 04:01:09  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-10 04:01:13  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-10 04:01:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-10 04:01:22  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-10 04:01:26  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-10 04:01:31  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-10 04:01:35  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-10 04:01:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-10 04:01:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-10 04:01:49  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-10 04:01:53  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-10 04:01:57  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-10_04-01-58 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl?_prerender {"code":"ECONNRESET"}
2017-04-10 04:04:02  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-10 04:04:07  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-10 04:04:12  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-10 04:04:16  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-10 04:04:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-10 04:04:26  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-10 04:04:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-10 04:04:35  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-10 04:04:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-10 04:04:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-10 04:04:49  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-10 04:04:54  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-10 04:04:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-10 04:05:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-10 04:05:07  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-10 04:05:11  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-10 04:05:16  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-10 04:05:20  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-10 04:05:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-10 04:05:29  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-10 04:05:33  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-10 04:05:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-10 04:05:42  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-10 04:05:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-10 04:05:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-10 04:05:56  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-10 04:06:00  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-10 04:06:04  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-10 04:06:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-10 04:06:13  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-10 04:06:18  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-10 04:06:22  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-10 04:06:27  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-10 04:06:31  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-10 04:06:36  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-10 04:06:40  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-10 04:06:45  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-10 04:06:49  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-10 04:06:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-10 04:06:58  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-10 04:07:02  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-10 04:07:07  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-10 04:07:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-10 04:07:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-10 04:07:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-10 04:07:25  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-10 04:07:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-10 04:07:34  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-10 04:07:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-10 04:07:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-10 04:07:47  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-10 04:07:52  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-10 04:07:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-10 04:08:00  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-10 04:08:05  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-10 04:08:09  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-10 04:08:13  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-10 04:08:17  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-10 04:08:22  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-10 04:08:26  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-10 04:08:31  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-10 04:08:35  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-10 04:08:39  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-10 04:08:44  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-10 04:08:48  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-10 04:08:53  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-10 04:08:57  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-10 04:09:02  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-10 04:09:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-10 04:09:10  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-10 04:09:15  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-10 04:09:19  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-10 04:09:24  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-10 04:09:28  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-10 04:09:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-10 04:09:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-10 04:09:42  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-10 04:09:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-10 04:09:51  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-10 04:09:55  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-10 04:10:00  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-10 04:10:04  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-10 04:10:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-10 04:10:13  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-10 04:10:17  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-10 04:10:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-10 04:10:26  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-10 04:10:31  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-10 04:10:35  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-10 04:10:39  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-10 04:10:43  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-10 04:10:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-10 04:10:52  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-10 04:10:56  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-10 04:11:01  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-10 04:11:05  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-10 04:11:10  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-10 04:11:14  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-10 04:11:19  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-10 04:11:23  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-10 04:11:27  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-10 04:11:31  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-10 04:11:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-10 04:11:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-10 04:11:44  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-10 04:11:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-10 04:11:53  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-10 04:11:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-10 04:12:02  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-10 04:12:06  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-10 04:12:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-10 04:12:15  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-10 04:12:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-10 04:12:23  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-10 04:12:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-10 04:12:32  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-10 04:12:37  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-10 04:12:41  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-10 04:12:45  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-10 04:12:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-10 04:12:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-10 04:12:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-10 04:13:02  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-10 04:13:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-10 04:13:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-10 04:13:15  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-10 04:13:19  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-10 04:13:23  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-10 04:13:28  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-10 04:13:32  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-10 04:13:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-10 04:13:42  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-10 04:13:46  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-10 04:13:50  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-10 04:13:54  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-10 04:13:59  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-10 04:14:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-10 04:14:08  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-10 04:14:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-10 04:14:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-10 04:14:21  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-10 04:14:22  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-10 04:14:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-10 04:14:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-10 04:14:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-10 04:14:39  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-10 04:14:43  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-10 04:14:48  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-10 04:14:52  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-10 04:14:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-10 04:15:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-10 04:15:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-10 04:15:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-10 04:15:13  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-10 04:15:17  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-10 04:15:22  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-10 04:15:26  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-10 04:15:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-10 04:15:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-10 04:15:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-10 04:15:44  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-10 04:15:48  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-10 04:15:52  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-10 04:15:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-10 04:16:01  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-10 04:16:05  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-10 04:16:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-10 04:16:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-10 04:16:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-10 04:16:23  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-10 04:16:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-10 04:16:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-10 04:16:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-10 04:16:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-10 04:16:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-10 04:16:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-10 04:16:51  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-10 04:16:55  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-10 04:16:59  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-10 04:17:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-10 04:17:07  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-10 04:17:11  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-10 04:17:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-10 04:17:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-10 04:17:24  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-10 04:17:28  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-10 04:17:32  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-10 04:17:36  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-10 04:17:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-10 04:17:45  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-10 04:17:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-10 04:17:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-10 04:17:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-10 04:18:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-10 04:18:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-10 04:18:11  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-10 04:18:14  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-10 04:18:18  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-10 04:18:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-10 04:18:27  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-10 04:18:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-10 04:18:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-10 04:18:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-10 04:18:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 04:18:47  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 04:18:51  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 04:18:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 04:18:59  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-10 04:19:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 04:19:07  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 04:19:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-10 04:19:15  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-10 04:19:19  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-10 04:19:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-10 04:19:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-10 04:19:31  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-10 04:19:35  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-10 04:19:39  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-10 04:19:43  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-10 04:19:47  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-10 04:19:51  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-10 04:19:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-10 04:19:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-10 04:20:03  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-10 04:20:07  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-10 04:20:11  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-10 04:20:15  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-10 04:20:19  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-10 04:20:23  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-10 04:20:27  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-10 04:20:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 04:20:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 04:20:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 04:20:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 04:20:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 04:20:51  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-10 04:20:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 04:20:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 04:21:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 04:21:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 04:21:11  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-10 04:21:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 04:21:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 04:21:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 04:21:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-10 04:21:31  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-10_04-31-58 Restart Xvfb...
2017-04-10_05-01-58 Restart Xvfb...
2017-04-10_05-31-58 Restart Xvfb...
2017-04-10_06-01-58 Restart Xvfb...
2017-04-10 06:31:46 reset updateRequest
2017-04-10 06:31:47  - 14968  http://www.lymphomahub.com/
2017-04-10 06:31:51  - 14968  http://www.lymphomahub.com/
2017-04-10 06:31:52  - 14968  http://www.lymphomahub.com/about
2017-04-10 06:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-10_06-31-58 Restart Xvfb...
2017-04-10 06:31:58  - 14968  http://www.lymphomahub.com/terms
2017-04-10 06:32:02  - 14968  http://www.lymphomahub.com/undefined
2017-04-10 06:32:02  - 14968  http://www.lymphomahub.com/therapies
2017-04-10 06:32:08  - 14968  http://www.lymphomahub.com/newsletter
2017-04-10 06:32:12  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-10 06:32:15  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-10 06:32:20  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-10 06:32:24  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-10 06:32:29  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-10 06:32:33  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-10 06:32:37  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-10 06:32:42  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-10 06:32:46  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-10 06:32:51  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-10 06:32:55  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-10 06:33:00  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-10 06:33:04  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-10 06:33:08  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-10 06:33:12  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-10 06:33:16  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-10 06:33:21  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-10 06:33:25  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-10 06:33:30  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-10 06:33:34  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-10 06:33:39  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-10 06:33:43  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-10 06:33:48  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-10 06:33:51  - 14968  http://www.lymphomahub.com/therapies/alt-803
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-10 06:33:55  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-10 06:33:59  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-10 06:34:00  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-10 06:34:04  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-10 06:34:05  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-10 06:34:09  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-10 06:34:09  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-10 06:34:15  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-10 06:34:19  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-10 06:34:24  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-10 06:34:28  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-10 06:34:32  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-10 06:34:36  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-10 06:34:41  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-10 06:34:45  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-10 06:34:49  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-10 06:34:53  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-10 06:34:58  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-10 06:35:02  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-10 06:35:06  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-10 06:35:11  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-10 06:35:15  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-10 06:35:19  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-10 06:35:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-10 06:35:28  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-10 06:35:32  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-10 06:35:36  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-10 06:35:40  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-10 06:35:45  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-10 06:35:49  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-10 06:35:53  - 14968  http://www.lymphomahub.com/medical-information
2017-04-10 06:35:57  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-10 06:36:02  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-10 06:36:06  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-10 06:36:10  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-10 06:36:15  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-10 06:36:19  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-10 06:36:23  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-10 06:36:28  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-10 06:36:32  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-10 06:36:36  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-10 06:36:40  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-10 06:36:45  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-10 06:36:45  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-10 06:36:50  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-10 06:36:54  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-10 06:36:59  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-10 06:37:03  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-10 06:37:07  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-10 06:37:11  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-10 06:37:15  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-10 06:37:20  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-10 06:37:24  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-10 06:37:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-10 06:37:32  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-10 06:37:37  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-10 06:37:41  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-10 06:37:45  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-10 06:37:49  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-10 06:37:54  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-10 06:37:58  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-10 06:38:02  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-10 06:38:06  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-10 06:38:11  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-10 06:38:15  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-10 06:38:19  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-10 06:38:24  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-10 06:38:28  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-10 06:38:32  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-10 06:38:36  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-10 06:38:41  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-10 06:38:45  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-10 06:38:50  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-10 06:38:54  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-10 06:38:54  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-10 06:38:59  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-10 06:39:03  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-10 06:39:07  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-10 06:39:12  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-10 06:39:16  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-10 06:39:20  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-10 06:39:24  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-10 06:39:29  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-10 06:39:32  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-10 06:39:33  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-10 06:39:37  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-10 06:39:41  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-10 06:39:46  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-10 06:39:50  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-10 06:39:54  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-10 06:39:55  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan?_prerender {"code":"ECONNRESET"}
2017-04-10 06:42:00  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-10 06:42:04  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-10 06:42:09  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-10 06:42:13  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-10 06:42:17  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-10 06:42:22  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-10 06:42:25  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-10 06:42:29  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-10 06:42:32  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-10 06:42:36  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-10 06:42:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-10 06:42:44  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-10 06:42:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-10 06:42:53  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-10 06:42:57  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-10 06:42:57  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-10 06:43:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-10 06:43:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-10 06:43:10  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-10 06:43:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-10 06:43:18  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-10 06:43:23  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-10 06:43:26  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-10 06:43:30  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-10 06:43:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-10 06:43:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-10 06:43:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-10 06:43:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-10 06:43:48  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-10 06:43:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-10 06:43:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-10 06:44:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-10 06:44:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-10 06:44:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-10 06:44:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-10 06:44:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-10 06:44:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-10 06:44:26  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-10 06:44:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-10 06:44:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-10 06:44:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-10 06:44:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-10 06:44:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-10 06:44:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-10 06:44:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-10 06:45:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-10 06:45:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-10 06:45:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-10 06:45:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-10 06:45:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-10 06:45:24  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-10 06:45:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-10 06:45:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-10 06:45:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-10 06:45:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-10 06:45:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-10 06:45:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-10 06:45:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-10 06:45:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-10 06:46:03  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-10 06:46:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-10 06:46:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-10 06:46:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-10 06:46:20  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-10 06:46:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-10 06:46:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-10 06:46:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-10 06:46:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-10 06:46:40  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-10 06:46:45  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-10 06:46:49  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-10 06:46:53  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-10 06:46:58  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-10 06:47:02  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-10 06:47:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-10 06:47:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-10 06:47:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-10 06:47:19  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-10 06:47:23  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-10 06:47:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-10 06:47:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-10 06:47:35  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-10 06:47:39  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-10 06:47:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-10 06:47:47  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-10 06:47:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-10 06:47:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-10 06:48:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-10 06:48:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-10 06:48:09  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-10 06:48:10  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-10 06:48:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-10 06:48:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-10 06:48:24  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-10 06:48:29  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-10 06:48:33  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-10 06:48:37  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 06:48:42  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 06:48:46  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-10 06:48:50  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 06:48:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-10 06:48:59  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-10 06:49:03  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-10 06:49:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-10 06:49:12  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-10 06:49:17  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-10 06:49:21  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-10 06:49:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-10 06:49:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-10 06:49:34  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-10 06:49:39  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 06:49:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-10 06:49:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-10 06:49:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-10 06:49:57  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-10 06:50:02  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-10 06:50:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-10 06:50:11  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-10 06:50:15  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-10 06:50:20  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-10 06:50:24  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-10 06:50:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-10 06:50:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-10 06:50:38  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-10 06:50:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-10 06:50:47  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-10 06:50:51  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-10 06:50:56  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-10 06:51:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-10 06:51:05  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-10 06:51:09  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-10 06:51:14  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-10 06:51:14  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-10 06:51:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-10 06:51:23  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-10 06:51:27  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-10 06:51:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-10 06:51:37  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-10 06:51:41  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-10 06:51:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-10 06:51:50  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-10 06:51:55  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-10 06:51:59  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-10 06:52:04  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-10 06:52:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-10 06:52:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-10 06:52:17  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-10 06:52:22  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-10 06:52:26  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-10 06:52:30  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-10 06:52:35  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-10 06:52:40  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-10 06:52:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-10 06:52:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-10 06:52:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-10 06:52:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-10 06:53:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-10 06:53:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-10 06:53:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-10 06:53:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-10 06:53:18  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-10 06:53:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-10 06:53:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-10 06:53:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-10 06:53:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-10 06:53:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-10 06:53:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-10 06:53:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-10 06:53:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-10 06:53:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-10 06:53:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-10 06:53:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-10 06:54:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-10 06:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-10 06:54:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-10 06:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-10 06:54:14  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-10 06:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-10 06:54:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-10 06:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-10 06:54:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-10 06:54:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-10 06:54:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-10 06:54:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-10 06:54:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-10 06:54:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-10 06:54:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-10 06:54:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-10 06:55:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-10 06:55:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-10 06:55:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-10 06:55:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-10 06:55:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-10 06:55:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-10 06:55:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-10 06:55:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-10 06:55:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-10 06:55:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-10 06:55:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-10 06:55:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-10 06:55:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-10 06:55:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-10 06:55:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-10 06:55:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-10 06:55:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-10 06:56:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-10 06:56:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-10 06:56:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-10 06:56:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-10 06:56:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-10 06:56:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-10 06:56:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-10 06:56:29  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-10 06:56:33  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-10 06:56:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-10 06:56:42  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-10 06:56:43  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-10 06:56:47  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-10 06:56:52  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-10 06:56:56  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-10 06:57:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-10 06:57:04  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-10 06:57:09  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-10 06:57:14  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-10 06:57:18  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-10 06:57:22  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-10 06:57:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-10 06:57:31  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-10 06:57:36  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-10 06:57:40  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-10 06:57:45  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-10 06:57:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-10 06:57:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-10 06:57:58  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-10 06:58:02  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-10 06:58:06  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-10 06:58:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-10 06:58:15  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-10 06:58:20  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-10 06:58:24  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-10 06:58:29  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-10 06:58:33  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-10 06:58:37  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-10 06:58:42  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-10 06:58:46  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-10 06:58:50  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-10 06:58:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-10 06:58:59  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-10 06:59:04  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-10 06:59:08  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-10 06:59:13  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-10 06:59:17  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-10 06:59:21  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-10 06:59:26  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-10 06:59:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-10 06:59:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-10 06:59:39  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-10 06:59:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-10 06:59:48  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-10 06:59:52  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-10 06:59:57  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-10 07:00:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-10 07:00:06  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-10 07:00:10  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-10 07:00:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-10 07:00:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-10 07:00:24  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-10 07:00:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-10 07:00:36  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-10 07:00:40  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-10 07:00:45  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-10 07:00:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-10 07:00:54  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-10 07:00:59  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-10 07:01:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-10 07:01:07  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-10 07:01:12  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-10 07:01:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-10 07:01:20  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-10 07:01:25  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-10 07:01:29  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-10 07:01:34  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-10 07:01:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-10 07:01:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-10 07:01:47  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-10 07:01:51  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-10 07:01:56  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-10_07-01-58 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl?_prerender {"code":"ECONNRESET"}
2017-04-10 07:04:01  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-10 07:04:06  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-10 07:04:11  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-10 07:04:15  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-10 07:04:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-10 07:04:25  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-10 07:04:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-10 07:04:34  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-10 07:04:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-10 07:04:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-10 07:04:47  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-10 07:04:52  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-10 07:04:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-10 07:05:01  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-10 07:05:06  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-10 07:05:10  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-10 07:05:14  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-10 07:05:18  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-10 07:05:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-10 07:05:27  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-10 07:05:31  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-10 07:05:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-10 07:05:40  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-10 07:05:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-10 07:05:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-10 07:05:54  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-10 07:05:58  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-10 07:06:02  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-10 07:06:07  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-10 07:06:11  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-10 07:06:16  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-10 07:06:20  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-10 07:06:25  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-10 07:06:29  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-10 07:06:34  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-10 07:06:39  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-10 07:06:43  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-10 07:06:47  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-10 07:06:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-10 07:06:56  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-10 07:07:00  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-10 07:07:05  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-10 07:07:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-10 07:07:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-10 07:07:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-10 07:07:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-10 07:07:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-10 07:07:32  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-10 07:07:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-10 07:07:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-10 07:07:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-10 07:07:50  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-10 07:07:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-10 07:07:59  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-10 07:08:03  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-10 07:08:08  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-10 07:08:12  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-10 07:08:16  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-10 07:08:20  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-10 07:08:25  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-10 07:08:29  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-10 07:08:33  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-10 07:08:38  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-10 07:08:43  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-10 07:08:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-10 07:08:51  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-10 07:08:56  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-10 07:09:00  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-10 07:09:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-10 07:09:10  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-10 07:09:15  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-10 07:09:19  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-10 07:09:23  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-10 07:09:28  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-10 07:09:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-10 07:09:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-10 07:09:42  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-10 07:09:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-10 07:09:51  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-10 07:09:55  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-10 07:10:00  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-10 07:10:05  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-10 07:10:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-10 07:10:15  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-10 07:10:19  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-10 07:10:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-10 07:10:28  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-10 07:10:32  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-10 07:10:36  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-10 07:10:40  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-10 07:10:45  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-10 07:10:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-10 07:10:54  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-10 07:10:58  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-10 07:11:02  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-10 07:11:07  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-10 07:11:11  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-10 07:11:16  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-10 07:11:20  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-10 07:11:25  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-10 07:11:29  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-10 07:11:33  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-10 07:11:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-10 07:11:42  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-10 07:11:46  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-10 07:11:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-10 07:11:55  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-10 07:11:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-10 07:12:03  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-10 07:12:08  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-10 07:12:12  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-10 07:12:16  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-10 07:12:20  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-10 07:12:25  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-10 07:12:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-10 07:12:34  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-10 07:12:38  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-10 07:12:42  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-10 07:12:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-10 07:12:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-10 07:12:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-10 07:12:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-10 07:13:04  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-10 07:13:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-10 07:13:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-10 07:13:17  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-10 07:13:21  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-10 07:13:25  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-10 07:13:30  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-10 07:13:34  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-10 07:13:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-10 07:13:42  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-10 07:13:46  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-10 07:13:51  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-10 07:13:55  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-10 07:14:00  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-10 07:14:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-10 07:14:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-10 07:14:13  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-10 07:14:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-10 07:14:22  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-10 07:14:22  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-10 07:14:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-10 07:14:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-10 07:14:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-10 07:14:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-10 07:14:44  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-10 07:14:49  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-10 07:14:53  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-10 07:14:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-10 07:15:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-10 07:15:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-10 07:15:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-10 07:15:15  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-10 07:15:19  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-10 07:15:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-10 07:15:28  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-10 07:15:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-10 07:15:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-10 07:15:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-10 07:15:45  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-10 07:15:49  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-10 07:15:54  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-10 07:15:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-10 07:16:02  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-10 07:16:06  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-10 07:16:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-10 07:16:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-10 07:16:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-10 07:16:24  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-10 07:16:28  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-10 07:16:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-10 07:16:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-10 07:16:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-10 07:16:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-10 07:16:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-10 07:16:52  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-10 07:16:56  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-10 07:17:00  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-10 07:17:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-10 07:17:08  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-10 07:17:12  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-10 07:17:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-10 07:17:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-10 07:17:25  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-10 07:17:30  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-10 07:17:34  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-10 07:17:38  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-10 07:17:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-10 07:17:46  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-10 07:17:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-10 07:17:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-10 07:17:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-10 07:18:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-10 07:18:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-10 07:18:13  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-10 07:18:16  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-10 07:18:20  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-10 07:18:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-10 07:18:29  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-10 07:18:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-10 07:18:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-10 07:18:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-10 07:18:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 07:18:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 07:18:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 07:18:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 07:19:01  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-10 07:19:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 07:19:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 07:19:13  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-10 07:19:17  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-10 07:19:21  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-10 07:19:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-10 07:19:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-10 07:19:34  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-10 07:19:37  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-10 07:19:42  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-10 07:19:46  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-10 07:19:49  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-10 07:19:54  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-10 07:19:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-10 07:20:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-10 07:20:06  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-10 07:20:10  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-10 07:20:14  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-10 07:20:18  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-10 07:20:22  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-10 07:20:26  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-10 07:20:30  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-10 07:20:34  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 07:20:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 07:20:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 07:20:46  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 07:20:50  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 07:20:54  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-10 07:20:58  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 07:21:02  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 07:21:06  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 07:21:10  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 07:21:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-10 07:21:18  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 07:21:22  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 07:21:26  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 07:21:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-10 07:21:34  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-10_07-31-58 Restart Xvfb...
2017-04-10_08-01-58 Restart Xvfb...
2017-04-10_08-31-58 Restart Xvfb...
2017-04-10_09-01-58 Restart Xvfb...
2017-04-10 09:31:46 reset updateRequest
2017-04-10 09:31:49  - 14968  http://www.lymphomahub.com/
2017-04-10 09:31:51  - 14968  http://www.lymphomahub.com/
2017-04-10 09:31:53  - 14968  http://www.lymphomahub.com/about
2017-04-10 09:31:57  - 14968  http://www.lymphomahub.com/about
2017-04-10_09-31-58 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-10 09:33:58  - 14968  http://www.lymphomahub.com/about
2017-04-10 09:34:02  - 14968  http://www.lymphomahub.com/terms
2017-04-10 09:34:02  - 14968  http://www.lymphomahub.com/terms
2017-04-10 09:34:06  - 14968  http://www.lymphomahub.com/undefined
2017-04-10 09:34:06  - 14968  http://www.lymphomahub.com/therapies
2017-04-10 09:34:07  - 14968  http://www.lymphomahub.com/therapies
2017-04-10 09:34:17  - 14968  http://www.lymphomahub.com/newsletter
2017-04-10 09:34:18  - 14968  http://www.lymphomahub.com/newsletter
2017-04-10 09:34:21  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-10 09:34:22  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-10 09:34:26  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-10 09:34:26  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-10 09:34:31  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-10 09:34:36  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-10 09:34:40  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-10 09:34:44  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-10 09:34:49  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-10 09:34:53  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-10 09:34:58  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-10 09:35:02  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-10 09:35:06  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-10 09:35:11  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-10 09:35:15  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-10 09:35:20  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-10 09:35:24  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-10 09:35:29  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-10 09:35:33  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-10 09:35:38  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-10 09:35:42  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-10 09:35:46  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-10 09:35:51  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-10 09:35:55  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-10 09:35:59  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-10 09:36:03  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-10 09:36:07  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-10 09:36:11  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-10 09:36:16  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-10 09:36:20  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-10 09:36:24  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-10 09:36:29  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-10 09:36:33  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-10 09:36:37  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-10 09:36:41  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-10 09:36:46  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-10 09:36:50  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-10 09:36:54  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-10 09:36:59  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-10 09:37:03  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-10 09:37:07  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-10 09:37:12  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-10 09:37:16  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-10 09:37:20  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-10 09:37:25  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-10 09:37:29  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-10 09:37:34  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-10 09:37:38  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-10 09:37:42  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-10 09:37:47  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-10 09:37:51  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-10 09:37:55  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-10 09:37:59  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-10 09:38:03  - 14968  http://www.lymphomahub.com/medical-information
2017-04-10 09:38:07  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-10 09:38:11  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-10 09:38:15  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-10 09:38:20  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-10 09:38:24  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-10 09:38:28  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-10 09:38:32  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-10 09:38:37  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-10 09:38:41  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-10 09:38:46  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-10 09:38:50  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-10 09:38:55  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-10 09:38:55  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-10 09:39:00  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-10 09:39:04  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-10 09:39:08  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-10 09:39:13  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-10 09:39:17  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-10 09:39:21  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-10 09:39:25  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-10 09:39:29  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-10 09:39:34  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-10 09:39:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-10 09:39:42  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-10 09:39:46  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-10 09:39:51  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-10 09:39:55  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-10 09:39:59  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-10 09:40:04  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-10 09:40:08  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-10 09:40:12  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-10 09:40:16  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-10 09:40:21  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-10 09:40:25  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-10 09:40:30  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-10 09:40:34  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-10 09:40:38  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-10 09:40:42  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-10 09:40:47  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-10 09:40:51  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-10 09:40:55  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-10 09:40:59  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-10 09:41:03  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-10 09:41:04  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-10 09:41:08  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-10 09:41:12  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-10 09:41:17  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-10 09:41:21  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-10 09:41:26  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-10 09:41:30  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-10 09:41:34  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-10 09:41:38  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-10 09:41:42  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-10 09:41:43  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-10 09:41:47  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-10 09:41:51  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-10 09:41:55  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-10 09:41:59  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-10 09:42:04  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-10 09:42:05  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-10 09:42:09  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-10 09:42:13  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-10 09:42:17  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-10 09:42:21  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-10 09:42:26  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-10 09:42:30  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-10 09:42:34  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-10 09:42:37  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-10 09:42:41  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-10 09:42:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-10 09:42:49  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-10 09:42:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-10 09:42:58  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-10 09:43:02  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-10 09:43:02  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-10 09:43:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-10 09:43:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-10 09:43:15  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-10 09:43:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-10 09:43:24  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-10 09:43:28  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-10 09:43:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-10 09:43:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-10 09:43:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-10 09:43:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-10 09:43:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-10 09:43:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-10 09:43:55  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-10 09:43:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-10 09:44:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-10 09:44:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-10 09:44:12  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-10 09:44:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-10 09:44:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-10 09:44:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-10 09:44:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-10 09:44:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-10 09:44:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-10 09:44:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-10 09:44:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-10 09:44:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-10 09:44:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-10 09:44:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-10 09:45:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-10 09:45:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-10 09:45:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-10 09:45:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-10 09:45:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-10 09:45:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-10 09:45:30  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-10 09:45:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-10 09:45:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-10 09:45:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-10 09:45:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-10 09:45:51  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-10 09:45:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-10 09:46:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-10 09:46:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-10 09:46:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-10 09:46:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-10 09:46:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-10 09:46:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-10 09:46:26  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-10 09:46:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-10 09:46:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-10 09:46:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-10 09:46:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-10 09:46:46  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-10 09:46:51  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-10 09:46:55  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-10 09:46:59  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-10 09:47:04  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-10 09:47:09  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-10 09:47:13  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-10 09:47:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-10 09:47:21  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-10 09:47:25  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-10 09:47:29  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-10 09:47:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-10 09:47:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-10 09:47:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-10 09:47:46  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-10 09:47:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-10 09:47:54  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-10 09:47:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-10 09:48:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-10 09:48:07  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-10 09:48:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-10 09:48:16  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-10 09:48:17  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-10 09:48:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-10 09:48:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-10 09:48:31  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-10 09:48:35  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-10 09:48:40  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-10 09:48:44  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 09:48:49  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 09:48:53  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-10 09:48:58  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 09:49:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-10 09:49:07  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-10 09:49:11  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-10 09:49:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-10 09:49:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-10 09:49:24  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-10 09:49:29  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-10 09:49:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-10 09:49:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-10 09:49:42  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-10 09:49:47  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 09:49:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-10 09:49:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-10 09:50:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-10 09:50:05  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-10 09:50:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-10 09:50:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-10 09:50:18  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-10 09:50:22  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-10 09:50:27  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-10 09:50:31  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-10 09:50:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-10 09:50:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-10 09:50:45  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-10 09:50:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-10 09:50:54  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-10 09:50:58  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-10 09:51:03  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-10 09:51:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-10 09:51:12  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-10 09:51:16  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-10 09:51:21  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-10 09:51:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-10 09:51:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-10 09:51:30  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-10 09:51:34  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-10 09:51:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-10 09:51:43  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-10 09:51:48  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-10 09:51:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-10 09:51:57  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-10 09:52:02  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-10 09:52:06  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-10 09:52:11  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-10 09:52:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-10 09:52:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-10 09:52:25  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-10 09:52:29  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-10 09:52:34  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-10 09:52:38  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-10 09:52:42  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-10 09:52:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-10 09:52:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-10 09:52:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-10 09:53:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-10 09:53:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-10 09:53:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-10 09:53:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-10 09:53:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-10 09:53:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-10 09:53:25  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-10 09:53:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-10 09:53:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-10 09:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-10 09:53:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-10 09:53:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-10 09:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-10 09:53:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-10 09:53:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-10 09:53:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-10 09:54:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-10 09:54:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-10 09:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-10 09:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-10 09:54:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-10 09:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-10 09:54:23  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-10 09:54:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-10 09:54:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-10 09:54:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-10 09:54:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-10 09:54:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-10 09:54:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-10 09:54:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-10 09:54:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-10 09:54:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-10 09:55:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-10 09:55:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-10 09:55:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-10 09:55:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-10 09:55:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-10 09:55:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-10 09:55:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-10 09:55:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-10 09:55:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-10 09:55:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-10 09:55:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-10 09:55:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-10 09:55:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-10 09:55:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-10 09:55:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-10 09:55:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-10 09:56:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-10 09:56:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-10 09:56:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-10 09:56:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-10 09:56:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-10 09:56:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-10 09:56:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-10 09:56:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-10 09:56:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-10 09:56:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-10 09:56:38  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-10 09:56:43  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-10 09:56:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-10 09:56:52  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-10 09:56:53  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-10 09:56:57  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-10 09:57:01  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-10 09:57:06  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-10 09:57:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-10 09:57:15  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-10 09:57:19  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-10 09:57:24  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-10 09:57:29  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-10 09:57:34  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-10 09:57:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-10 09:57:43  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-10 09:57:47  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-10 09:57:52  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-10 09:57:56  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-10 09:58:01  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-10 09:58:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-10 09:58:11  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-10 09:58:16  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-10 09:58:20  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-10 09:58:24  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-10 09:58:29  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-10 09:58:33  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-10 09:58:38  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-10 09:58:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-10 09:58:47  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-10 09:58:52  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-10 09:58:56  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-10 09:59:00  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-10 09:59:05  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-10 09:59:09  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-10 09:59:14  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-10 09:59:18  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-10 09:59:22  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-10 09:59:27  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-10 09:59:31  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-10 09:59:35  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-10 09:59:40  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-10 09:59:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-10 09:59:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-10 09:59:53  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-10 09:59:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-10 10:00:02  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-10 10:00:09  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-10 10:00:13  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-10 10:00:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-10 10:00:22  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-10 10:00:27  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-10 10:00:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-10 10:00:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-10 10:00:41  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-10 10:00:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-10 10:00:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-10 10:00:54  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-10 10:00:59  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-10 10:01:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-10 10:01:08  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-10 10:01:12  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-10 10:01:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-10 10:01:21  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-10 10:01:26  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-10 10:01:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-10 10:01:35  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-10 10:01:39  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-10 10:01:43  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-10 10:01:48  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-10 10:01:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-10 10:01:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-10_10-01-58 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll?_prerender {"code":"ECONNRESET"}
2017-04-10 10:04:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-10 10:04:07  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-10 10:04:12  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-10 10:04:16  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-10 10:04:21  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-10 10:04:26  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-10 10:04:30  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-10 10:04:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-10 10:04:39  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-10 10:04:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-10 10:04:48  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-10 10:04:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-10 10:04:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-10 10:05:02  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-10 10:05:06  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-10 10:05:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-10 10:05:15  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-10 10:05:20  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-10 10:05:24  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-10 10:05:29  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-10 10:05:34  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-10 10:05:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-10 10:05:43  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-10 10:05:47  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-10 10:05:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-10 10:05:56  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-10 10:06:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-10 10:06:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-10 10:06:09  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-10 10:06:14  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-10 10:06:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-10 10:06:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-10 10:06:28  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-10 10:06:32  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-10 10:06:36  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-10 10:06:41  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-10 10:06:45  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-10 10:06:50  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-10 10:06:55  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-10 10:06:59  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-10 10:07:04  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-10 10:07:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-10 10:07:13  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-10 10:07:17  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-10 10:07:21  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-10 10:07:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-10 10:07:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-10 10:07:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-10 10:07:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-10 10:07:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-10 10:07:48  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-10 10:07:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-10 10:07:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-10 10:08:01  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-10 10:08:06  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-10 10:08:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-10 10:08:15  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-10 10:08:19  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-10 10:08:23  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-10 10:08:28  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-10 10:08:32  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-10 10:08:36  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-10 10:08:40  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-10 10:08:45  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-10 10:08:49  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-10 10:08:54  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-10 10:08:58  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-10 10:09:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-10 10:09:07  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-10 10:09:11  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-10 10:09:16  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-10 10:09:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-10 10:09:24  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-primary-results-from-the-pivotal-zuma-1-trial-of-kte-c19-in-refractory-aggressive-non-hodgkin-lymphoma-patients
2017-04-10 10:09:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-10 10:09:34  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-10 10:09:38  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-10 10:09:42  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-10 10:09:47  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-10 10:09:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-10 10:09:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-10 10:10:00  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-10 10:10:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-10 10:10:09  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-10 10:10:13  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-10 10:10:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-10 10:10:22  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-10 10:10:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-10 10:10:31  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-10 10:10:36  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-10 10:10:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-10 10:10:44  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-10 10:10:48  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-10 10:10:52  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-10 10:10:57  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-10 10:11:01  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-10 10:11:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-10 10:11:10  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-10 10:11:14  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-10 10:11:19  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-10 10:11:24  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-10 10:11:28  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-10 10:11:32  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-10 10:11:37  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-10 10:11:41  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-10 10:11:46  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-10 10:11:49  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-10 10:11:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-10 10:11:58  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-10 10:12:03  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-10 10:12:07  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-10 10:12:11  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-10 10:12:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-10 10:12:20  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-10 10:12:24  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-10 10:12:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-10 10:12:33  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-10 10:12:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-10 10:12:42  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-10 10:12:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-10 10:12:50  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-10 10:12:55  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-10 10:12:59  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-10 10:13:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-10 10:13:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-10 10:13:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-10 10:13:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-10 10:13:21  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-10 10:13:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-10 10:13:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-10 10:13:34  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-10 10:13:38  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-10 10:13:42  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-10 10:13:47  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-10 10:13:51  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-10 10:13:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-10 10:14:00  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-10 10:14:03  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-10 10:14:08  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-10 10:14:12  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-10 10:14:17  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-10 10:14:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-10 10:14:26  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-10 10:14:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-10 10:14:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-10 10:14:40  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-10 10:14:40  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-10 10:14:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-10 10:14:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-10 10:14:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-10 10:14:57  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-10 10:15:02  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-10 10:15:06  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-10 10:15:11  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-10 10:15:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-10 10:15:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-10 10:15:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-10 10:15:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-10 10:15:32  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-10 10:15:36  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-10 10:15:40  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-10 10:15:45  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-10 10:15:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-10 10:15:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-10 10:15:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-10 10:16:02  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-10 10:16:07  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-10 10:16:11  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-10 10:16:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-10 10:16:19  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-10 10:16:23  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-10 10:16:28  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-10 10:16:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-10 10:16:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-10 10:16:41  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-10 10:16:45  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-10 10:16:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-10 10:16:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-10 10:16:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-10 10:17:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-10 10:17:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-10 10:17:09  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-10 10:17:13  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-10 10:17:18  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-10 10:17:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-10 10:17:26  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-10 10:17:30  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-10 10:17:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-10 10:17:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-10 10:17:43  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-10 10:17:47  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-10 10:17:50  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-10 10:17:54  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-10 10:17:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-10 10:18:03  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-10 10:18:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-10 10:18:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-10 10:18:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-10 10:18:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-10 10:18:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-10 10:18:28  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-10 10:18:32  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-10 10:18:37  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-10 10:18:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-10 10:18:45  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-10 10:18:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-10 10:18:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-10 10:18:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-10 10:19:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 10:19:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 10:19:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 10:19:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 10:19:18  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-10 10:19:22  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 10:19:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 10:19:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-10 10:19:34  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-10 10:19:38  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-10 10:19:42  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-10 10:19:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-10 10:19:51  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-10 10:19:55  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-10 10:19:59  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-10 10:20:02  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-10 10:20:06  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-10 10:20:12  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-10 10:20:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-10 10:20:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-10 10:20:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-10 10:20:28  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-10 10:20:32  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-10 10:20:36  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-10 10:20:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-10 10:20:45  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-10 10:20:49  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-10 10:20:53  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 10:20:57  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 10:21:01  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 10:21:05  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 10:21:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 10:21:13  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-10 10:21:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 10:21:21  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 10:21:25  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 10:21:30  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 10:21:34  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-10 10:21:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 10:21:41  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 10:21:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 10:21:49  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-10 10:21:53  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-10_10-31-58 Restart Xvfb...
2017-04-10_11-01-58 Restart Xvfb...
2017-04-10_11-31-58 Restart Xvfb...
2017-04-10_12-01-58 Restart Xvfb...
2017-04-10 12:31:46 reset updateRequest
2017-04-10 12:31:47  - 14968  http://www.lymphomahub.com/
2017-04-10 12:31:51  - 14968  http://www.lymphomahub.com/
2017-04-10 12:31:52  - 14968  http://www.lymphomahub.com/about
2017-04-10 12:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-10_12-31-58 Restart Xvfb...
2017-04-10 12:31:58  - 14968  http://www.lymphomahub.com/terms
2017-04-10 12:32:02  - 14968  http://www.lymphomahub.com/undefined
2017-04-10 12:32:03  - 14968  http://www.lymphomahub.com/therapies
2017-04-10 12:32:09  - 14968  http://www.lymphomahub.com/newsletter
2017-04-10 12:32:12  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-10 12:32:15  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-10 12:32:19  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-10 12:32:24  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-10 12:32:28  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-10 12:32:32  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-10 12:32:36  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-10 12:32:42  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-10 12:32:46  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-10 12:32:51  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-10 12:32:55  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-10 12:32:59  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-10 12:33:03  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-10 12:33:08  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-10 12:33:12  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-10 12:33:17  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-10 12:33:21  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-10 12:33:26  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-10 12:33:30  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-10 12:33:34  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-10 12:33:39  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-10 12:33:44  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-10 12:33:49  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-10 12:33:52  - 14968  http://www.lymphomahub.com/therapies/alt-803
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-10 12:33:56  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-10 12:34:01  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-10 12:34:01  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-10 12:34:06  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-10 12:34:06  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-10 12:34:11  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-10 12:34:16  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-10 12:34:20  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-10 12:34:24  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-10 12:34:28  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-10 12:34:33  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-10 12:34:37  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-10 12:34:42  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-10 12:34:46  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-10 12:34:50  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-10 12:34:54  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-10 12:34:58  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-10 12:35:03  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-10 12:35:07  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-10 12:35:12  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-10 12:35:16  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-10 12:35:20  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-10 12:35:25  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-10 12:35:29  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-10 12:35:33  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-10 12:35:38  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-10 12:35:43  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-10 12:35:47  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-10 12:35:51  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-10 12:35:56  - 14968  http://www.lymphomahub.com/medical-information
2017-04-10 12:35:59  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-10 12:36:04  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-10 12:36:08  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-10 12:36:12  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-10 12:36:17  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-10 12:36:22  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-10 12:36:26  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-10 12:36:30  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-10 12:36:35  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-10 12:36:39  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-10 12:36:43  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-10 12:36:48  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-10 12:36:48  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-10 12:36:52  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-10 12:36:57  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-10 12:37:01  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-10 12:37:05  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-10 12:37:10  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-10 12:37:14  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-10 12:37:18  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-10 12:37:22  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-10 12:37:27  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-10 12:37:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-10 12:37:35  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-10 12:37:40  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-10 12:37:44  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-10 12:37:48  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-10 12:37:52  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-10 12:37:57  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-10 12:38:01  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-10 12:38:05  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-10 12:38:09  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-10 12:38:13  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-10 12:38:18  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-10 12:38:22  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-10 12:38:26  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-10 12:38:30  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-10 12:38:35  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-10 12:38:39  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-10 12:38:43  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-10 12:38:47  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-10 12:38:52  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-10 12:38:56  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-10 12:38:57  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-10 12:39:01  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-10 12:39:06  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-10 12:39:10  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-10 12:39:15  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-10 12:39:19  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-10 12:39:23  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-10 12:39:27  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-10 12:39:32  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-10 12:39:35  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-10 12:39:36  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-10 12:39:40  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-10 12:39:45  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-10 12:39:49  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-10 12:39:53  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-10 12:39:58  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-10 12:39:58  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-10 12:40:03  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-10 12:40:08  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-10 12:40:11  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-10 12:40:15  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-10 12:40:20  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-10 12:40:24  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-10 12:40:28  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-10 12:40:32  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-10 12:40:35  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-10 12:40:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-10 12:40:44  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-10 12:40:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-10 12:40:53  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-10 12:40:56  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-10 12:40:57  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-10 12:41:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-10 12:41:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-10 12:41:10  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-10 12:41:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-10 12:41:18  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-10 12:41:23  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-10 12:41:26  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-10 12:41:30  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-10 12:41:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-10 12:41:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-10 12:41:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-10 12:41:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-10 12:41:49  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-10 12:41:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-10 12:41:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-10 12:42:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-10 12:42:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-10 12:42:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-10 12:42:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-10 12:42:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-10 12:42:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-10 12:42:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-10 12:42:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-10 12:42:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-10 12:42:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-10 12:42:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-10 12:42:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-10 12:42:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-10 12:42:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-10 12:43:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-10 12:43:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-10 12:43:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-10 12:43:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-10 12:43:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-10 12:43:26  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-10 12:43:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-10 12:43:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-10 12:43:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-10 12:43:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-10 12:43:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-10 12:43:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-10 12:43:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-10 12:44:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-10 12:44:06  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-10 12:44:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-10 12:44:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-10 12:44:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-10 12:44:24  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-10 12:44:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-10 12:44:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-10 12:44:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-10 12:44:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-10 12:44:44  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-10 12:44:48  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-10 12:44:53  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-10 12:44:57  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-10 12:45:01  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-10 12:45:05  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-10 12:45:09  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-10 12:45:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-10 12:45:17  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-10 12:45:21  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-10 12:45:25  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-10 12:45:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-10 12:45:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-10 12:45:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-10 12:45:42  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-10 12:45:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-10 12:45:50  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-10 12:45:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-10 12:45:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-10 12:46:04  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-10 12:46:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-10 12:46:13  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-10 12:46:13  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-10 12:46:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-10 12:46:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-10 12:46:26  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-10 12:46:31  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-10 12:46:35  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-10 12:46:39  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 12:46:44  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 12:46:48  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-10 12:46:53  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 12:46:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-10 12:47:01  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-10 12:47:06  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-10 12:47:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-10 12:47:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-10 12:47:19  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-10 12:47:24  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-10 12:47:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-10 12:47:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-10 12:47:37  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-10 12:47:42  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 12:47:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-10 12:47:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-10 12:47:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-10 12:48:00  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-10 12:48:05  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-10 12:48:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-10 12:48:14  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-10 12:48:18  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-10 12:48:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-10 12:48:28  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-10 12:48:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-10 12:48:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-10 12:48:41  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-10 12:48:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-10 12:48:50  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-10 12:48:54  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-10 12:48:59  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-10 12:49:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-10 12:49:07  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-10 12:49:12  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-10 12:49:16  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-10 12:49:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-10 12:49:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-10 12:49:26  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-10 12:49:31  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-10 12:49:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-10 12:49:40  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-10 12:49:44  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-10 12:49:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-10 12:49:53  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-10 12:49:57  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-10 12:50:02  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-10 12:50:06  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-10 12:50:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-10 12:50:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-10 12:50:20  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-10 12:50:25  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-10 12:50:29  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-10 12:50:33  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-10 12:50:39  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-10 12:50:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-10 12:50:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-10 12:50:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-10 12:50:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-10 12:51:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-10 12:51:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-10 12:51:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-10 12:51:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-10 12:51:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-10 12:51:23  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-10 12:51:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-10 12:51:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-10 12:51:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-10 12:51:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-10 12:51:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-10 12:51:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-10 12:51:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-10 12:51:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-10 12:51:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-10 12:51:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-10 12:52:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-10 12:52:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-10 12:52:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-10 12:52:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-10 12:52:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-10 12:52:20  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-10 12:52:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-10 12:52:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-10 12:52:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-10 12:52:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-10 12:52:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-10 12:52:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-10 12:52:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-10 12:52:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-10 12:52:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-10 12:52:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-10 12:53:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-10 12:53:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-10 12:53:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-10 12:53:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-10 12:53:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-10 12:53:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-10 12:53:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-10 12:53:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-10 12:53:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-10 12:53:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-10 12:53:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-10 12:53:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-10 12:53:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-10 12:53:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-10 12:53:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-10 12:53:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-10 12:54:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-10 12:54:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-10 12:54:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-10 12:54:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-10 12:54:14  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-10 12:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-10 12:54:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-10 12:54:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-10 12:54:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-10 12:54:34  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-10 12:54:39  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-10 12:54:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-10 12:54:48  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-10 12:54:48  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-10 12:54:53  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-10 12:54:57  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-10 12:55:02  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-10 12:55:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-10 12:55:11  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-10 12:55:15  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-10 12:55:20  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-10 12:55:24  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-10 12:55:28  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-10 12:55:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-10 12:55:37  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-10 12:55:42  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-10 12:55:46  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-10 12:55:51  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-10 12:55:55  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-10 12:56:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-10 12:56:04  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-10 12:56:09  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-10 12:56:13  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-10 12:56:17  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-10 12:56:22  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-10 12:56:26  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-10 12:56:31  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-10 12:56:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-10 12:56:40  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-10 12:56:44  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-10 12:56:49  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-10 12:56:53  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-10 12:56:57  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-10 12:57:01  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-10 12:57:06  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-10 12:57:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-10 12:57:14  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-10 12:57:19  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-10 12:57:23  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-10 12:57:28  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-10 12:57:32  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-10 12:57:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-10 12:57:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-10 12:57:46  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-10 12:57:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-10 12:57:55  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-10 12:57:59  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-10 12:58:04  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-10 12:58:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-10 12:58:12  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-10 12:58:17  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-10 12:58:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-10 12:58:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-10 12:58:30  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-10 12:58:34  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-10 12:58:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-10 12:58:43  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-10 12:58:48  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-10 12:58:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-10 12:58:57  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-10 12:59:01  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-10 12:59:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-10 12:59:10  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-10 12:59:14  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-10 12:59:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-10 12:59:23  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-10 12:59:28  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-10 12:59:32  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-10 12:59:37  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-10 12:59:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-10 12:59:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-10 12:59:50  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-10 12:59:55  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-10 12:59:59  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-10 13:00:04  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-10 13:00:08  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-10 13:00:13  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-10 13:00:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-10 13:00:22  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-10 13:00:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-10 13:00:34  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-10 13:00:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-10 13:00:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-10 13:00:48  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-10 13:00:53  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-10 13:00:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-10 13:01:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-10 13:01:06  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-10 13:01:10  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-10 13:01:15  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-10 13:01:19  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-10 13:01:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-10 13:01:27  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-10 13:01:32  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-10 13:01:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-10 13:01:41  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-10 13:01:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-10 13:01:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-10 13:01:54  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-10_13-01-58 Restart Xvfb...
2017-04-10 13:01:59  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-10 13:02:03  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-10 13:02:08  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-10 13:02:12  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-10 13:02:17  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-10 13:02:21  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-10 13:02:26  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-10 13:02:30  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-10 13:02:35  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-10 13:02:39  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-10 13:02:43  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-10 13:02:48  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-10 13:02:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-10 13:02:57  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-10 13:03:01  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-10 13:03:05  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-10 13:03:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-10 13:03:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-10 13:03:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-10 13:03:24  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-10 13:03:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-10 13:03:33  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-10 13:03:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-10 13:03:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-10 13:03:46  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-10 13:03:51  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-10 13:03:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-10 13:03:59  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-10 13:04:04  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-10 13:04:08  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-10 13:04:13  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-10 13:04:17  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-10 13:04:21  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-10 13:04:26  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-10 13:04:30  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-10 13:04:34  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-10 13:04:39  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-10 13:04:43  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-10 13:04:48  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-10 13:04:52  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-10 13:04:57  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-10 13:05:01  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-10 13:05:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-10 13:05:11  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-primary-results-from-the-pivotal-zuma-1-trial-of-kte-c19-in-refractory-aggressive-non-hodgkin-lymphoma-patients
2017-04-10 13:05:15  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-10 13:05:20  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-10 13:05:24  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-10 13:05:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-10 13:05:33  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-10 13:05:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-10 13:05:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-10 13:05:46  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-216112-pharmacological-downregulation-of-bfl-1-by-cpi203-overcomes-abt-199-resistance-in-double-hit-lymphoma
2017-04-10 13:05:51  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-10 13:05:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-10 13:06:00  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-10 13:06:04  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-10 13:06:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-10 13:06:13  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-10 13:06:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-10 13:06:22  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-10 13:06:27  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-10 13:06:31  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-10 13:06:35  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-10 13:06:40  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-10 13:06:44  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-10 13:06:48  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-10 13:06:53  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-10 13:06:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-10 13:07:02  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-10 13:07:06  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-10 13:07:10  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-10 13:07:14  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-10 13:07:19  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-10 13:07:24  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-10 13:07:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-10 13:07:33  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-10 13:07:38  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-10 13:07:42  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-10 13:07:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-10 13:07:50  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-10 13:07:55  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-10 13:07:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-10 13:08:03  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-10 13:08:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-10 13:08:12  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-10 13:08:16  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-10 13:08:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-10 13:08:25  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-10 13:08:29  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-10 13:08:33  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-39396-two-evolutionary-models-proposed-for-development-of-drug-resistance-between-primary-and-relapsed-diffuse-large-b-cell-lymphoma
2017-04-10 13:08:38  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-10 13:08:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-10 13:08:47  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-10 13:08:52  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-10 13:08:56  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-10 13:09:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-10 13:09:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-10 13:09:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-10 13:09:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-10 13:09:17  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-10 13:09:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-10 13:09:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-10 13:09:30  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-10 13:09:35  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-10 13:09:39  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-10 13:09:43  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-10 13:09:48  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-10 13:09:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-10 13:09:56  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-10 13:10:00  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-10 13:10:05  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-10 13:10:09  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-10 13:10:14  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-10 13:10:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-10 13:10:22  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-10 13:10:27  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-10 13:10:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-10 13:10:36  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-10 13:10:37  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-10 13:10:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-10 13:10:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-10 13:10:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-10 13:10:54  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-10 13:10:59  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-10 13:11:03  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-10 13:11:08  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-10 13:11:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-10 13:11:16  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-10 13:11:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-10 13:11:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-10 13:11:29  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-10 13:11:33  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-10 13:11:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-10 13:11:42  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-10 13:11:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-10 13:11:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-10 13:11:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-10 13:11:59  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-10 13:12:03  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-10 13:12:08  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-10 13:12:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-10 13:12:16  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-10 13:12:20  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-10 13:12:25  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-10 13:12:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-10 13:12:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-10 13:12:38  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-10 13:12:42  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-10 13:12:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-10 13:12:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-10 13:12:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-10 13:12:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-10 13:13:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-10 13:13:07  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-10 13:13:11  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-10 13:13:15  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-10 13:13:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-10 13:13:23  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-10 13:13:27  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-10 13:13:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-10 13:13:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-10 13:13:40  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-10 13:13:44  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-10 13:13:47  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-10 13:13:51  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-10 13:13:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-10 13:14:00  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-10 13:14:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-10 13:14:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-10 13:14:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-10 13:14:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-10 13:14:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-10 13:14:26  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-10 13:14:30  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-10 13:14:34  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-10 13:14:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-10 13:14:42  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-10 13:14:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-10 13:14:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-10 13:14:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-10 13:14:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 13:15:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 13:15:07  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 13:15:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 13:15:15  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-10 13:15:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 13:15:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 13:15:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-10 13:15:31  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-10 13:15:36  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-10 13:15:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-10 13:15:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-10 13:15:48  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-10 13:15:52  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-10 13:15:56  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-10 13:16:00  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-10 13:16:04  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-10 13:16:08  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-10 13:16:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-10 13:16:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-10 13:16:20  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-10 13:16:24  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-10 13:16:28  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-10 13:16:32  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-10 13:16:36  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-10 13:16:41  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-10 13:16:45  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-10 13:16:49  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 13:16:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 13:16:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 13:17:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 13:17:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 13:17:08  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-10 13:17:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 13:17:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 13:17:21  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 13:17:25  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 13:17:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-10 13:17:32  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 13:17:37  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 13:17:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 13:17:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-10 13:17:48  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-10_13-31-59 Restart Xvfb...
2017-04-10_14-01-59 Restart Xvfb...
2017-04-10_14-31-59 Restart Xvfb...
2017-04-10_15-01-59 Restart Xvfb...
2017-04-10 15:31:46 reset updateRequest
2017-04-10 15:31:48  - 14968  http://www.lymphomahub.com/
2017-04-10 15:31:51  - 14968  http://www.lymphomahub.com/
2017-04-10 15:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-10 15:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-10_15-31-59 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-10 15:34:00  - 14968  http://www.lymphomahub.com/about
2017-04-10 15:34:01  - 14968  http://www.lymphomahub.com/about
2017-04-10 15:34:04  - 14968  http://www.lymphomahub.com/terms
2017-04-10 15:34:06  - 14968  http://www.lymphomahub.com/terms
2017-04-10 15:34:08  - 14968  http://www.lymphomahub.com/undefined
2017-04-10 15:34:09  - 14968  http://www.lymphomahub.com/therapies
2017-04-10 15:34:10  - 14968  http://www.lymphomahub.com/therapies
2017-04-10 15:34:19  - 14968  http://www.lymphomahub.com/newsletter
2017-04-10 15:34:21  - 14968  http://www.lymphomahub.com/newsletter
2017-04-10 15:34:23  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-10 15:34:25  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-10 15:34:27  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-10 15:34:28  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-10 15:34:32  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-10 15:34:33  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-10 15:34:36  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-10 15:34:38  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-10 15:34:41  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-10 15:34:42  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-10 15:34:46  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-10 15:34:47  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-10 15:34:51  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-10 15:34:52  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-10 15:34:57  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-10 15:35:01  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-10 15:35:06  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-10 15:35:10  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-10 15:35:14  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-10 15:35:18  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-10 15:35:23  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-10 15:35:27  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-10 15:35:31  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-10 15:35:36  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-10 15:35:40  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-10 15:35:44  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-10 15:35:49  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-10 15:35:53  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-10 15:35:57  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-10 15:36:02  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-10 15:36:05  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-10 15:36:09  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-10 15:36:13  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-10 15:36:18  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-10 15:36:22  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-10 15:36:27  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-10 15:36:31  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-10 15:36:35  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-10 15:36:39  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-10 15:36:44  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-10 15:36:48  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-10 15:36:52  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-10 15:36:56  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-10 15:37:01  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-10 15:37:05  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-10 15:37:10  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-10 15:37:14  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-10 15:37:19  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-10 15:37:23  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-10 15:37:28  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-10 15:37:32  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-10 15:37:37  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-10 15:37:41  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-10 15:37:46  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-10 15:37:50  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-10 15:37:55  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-10 15:37:59  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-10 15:38:03  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-10 15:38:08  - 14968  http://www.lymphomahub.com/medical-information
2017-04-10 15:38:12  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-10 15:38:17  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-10 15:38:21  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-10 15:38:25  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-10 15:38:30  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-10 15:38:34  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-10 15:38:38  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-10 15:38:43  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-10 15:38:47  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-10 15:38:51  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-10 15:38:55  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-10 15:38:59  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-10 15:39:00  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-10 15:39:04  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-10 15:39:09  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-10 15:39:13  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-10 15:39:17  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-10 15:39:21  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-10 15:39:26  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-10 15:39:30  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-10 15:39:35  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-10 15:39:39  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-10 15:39:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-10 15:39:48  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-10 15:39:52  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-10 15:39:56  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-10 15:40:01  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-10 15:40:05  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-10 15:40:09  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-10 15:40:14  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-10 15:40:18  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-10 15:40:22  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-10 15:40:27  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-10 15:40:31  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-10 15:40:35  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-10 15:40:39  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-10 15:40:44  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-10 15:40:48  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-10 15:40:52  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-10 15:40:56  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-10 15:41:00  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-10 15:41:06  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-10 15:41:11  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-10 15:41:11  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-10 15:41:16  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-10 15:41:20  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-10 15:41:25  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-10 15:41:29  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-10 15:41:33  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-10 15:41:38  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-10 15:41:42  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-10 15:41:46  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-10 15:41:50  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-10 15:41:50  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-10 15:41:54  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-10 15:41:59  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-10 15:42:03  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-10 15:42:07  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-10 15:42:11  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-10 15:42:12  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-10 15:42:16  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-10 15:42:20  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-10 15:42:24  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-10 15:42:29  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-10 15:42:34  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-10 15:42:38  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-10 15:42:42  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-10 15:42:46  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-10 15:42:50  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-10 15:42:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-10 15:42:58  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-10 15:43:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-10 15:43:07  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-10 15:43:11  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-10 15:43:11  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-10 15:43:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-10 15:43:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-10 15:43:24  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-10 15:43:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-10 15:43:32  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-10 15:43:36  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-10 15:43:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-10 15:43:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-10 15:43:47  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-10 15:43:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-10 15:43:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-10 15:43:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-10 15:44:03  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-10 15:44:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-10 15:44:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-10 15:44:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-10 15:44:21  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-10 15:44:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-10 15:44:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-10 15:44:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-10 15:44:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-10 15:44:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-10 15:44:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-10 15:44:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-10 15:44:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-10 15:44:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-10 15:45:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-10 15:45:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-10 15:45:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-10 15:45:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-10 15:45:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-10 15:45:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-10 15:45:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-10 15:45:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-10 15:45:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-10 15:45:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-10 15:45:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-10 15:45:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-10 15:45:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-10 15:46:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-10 15:46:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-10 15:46:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-10 15:46:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-10 15:46:21  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-10 15:46:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-10 15:46:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-10 15:46:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-10 15:46:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-10 15:46:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-10 15:46:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-10 15:46:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-10 15:46:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-10 15:46:58  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-10 15:47:02  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-10 15:47:07  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-10 15:47:12  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-10 15:47:16  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-10 15:47:20  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-10 15:47:24  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-10 15:47:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-10 15:47:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-10 15:47:37  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-10 15:47:40  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-10 15:47:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-10 15:47:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-10 15:47:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-10 15:47:57  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-10 15:48:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-10 15:48:05  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-10 15:48:10  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-10 15:48:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-10 15:48:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-10 15:48:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-10 15:48:28  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-10 15:48:29  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-10 15:48:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-10 15:48:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-10 15:48:42  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-10 15:48:46  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-10 15:48:51  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-10 15:48:55  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 15:48:59  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 15:49:04  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-10 15:49:08  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 15:49:13  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-10 15:49:17  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-10 15:49:22  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-10 15:49:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-10 15:49:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-10 15:49:35  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-10 15:49:39  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-10 15:49:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-10 15:49:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-10 15:49:53  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-10 15:49:57  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 15:50:02  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-10 15:50:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-10 15:50:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-10 15:50:15  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-10 15:50:19  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-10 15:50:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-10 15:50:28  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-10 15:50:33  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-10 15:50:37  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-10 15:50:42  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-10 15:50:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-10 15:50:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-10 15:50:55  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-10 15:51:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-10 15:51:05  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-10 15:51:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-10 15:51:15  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-10 15:51:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-10 15:51:24  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-10 15:51:28  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-10 15:51:33  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-10 15:51:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-10 15:51:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-10 15:51:42  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-10 15:51:46  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-10 15:51:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-10 15:51:55  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-10 15:52:00  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-10 15:52:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-10 15:52:08  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-10 15:52:13  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-10 15:52:17  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-10 15:52:22  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-10 15:52:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-10 15:52:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-10 15:52:35  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-10 15:52:40  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-10 15:52:44  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-10 15:52:49  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-10 15:52:53  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-10 15:52:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-10 15:53:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-10 15:53:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-10 15:53:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-10 15:53:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-10 15:53:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-10 15:53:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-10 15:53:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-10 15:53:31  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-10 15:53:36  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-10 15:53:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-10 15:53:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-10 15:53:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-10 15:53:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-10 15:53:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-10 15:53:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-10 15:54:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-10 15:54:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-10 15:54:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-10 15:54:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-10 15:54:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-10 15:54:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-10 15:54:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-10 15:54:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-10 15:54:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-10 15:54:35  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-10 15:54:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-10 15:54:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-10 15:54:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-10 15:54:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-10 15:54:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-10 15:54:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-10 15:55:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-10 15:55:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-10 15:55:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-10 15:55:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-10 15:55:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-10 15:55:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-10 15:55:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-10 15:55:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-10 15:55:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-10 15:55:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-10 15:55:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-10 15:55:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-10 15:55:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-10 15:55:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-10 15:55:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-10 15:55:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-10 15:56:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-10 15:56:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-10 15:56:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-10 15:56:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-10 15:56:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-10 15:56:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-10 15:56:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-10 15:56:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-10 15:56:31  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-10 15:56:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-10 15:56:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-10 15:56:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-10 15:56:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-10 15:56:51  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-10 15:56:56  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-10 15:57:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-10 15:57:05  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-10 15:57:06  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-10 15:57:10  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-10 15:57:15  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-10 15:57:19  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-10 15:57:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-10 15:57:28  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-10 15:57:33  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-10 15:57:37  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-10 15:57:41  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-10 15:57:46  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-10 15:57:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-10 15:57:55  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-10 15:57:59  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-10 15:58:04  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-10 15:58:08  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-10 15:58:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-10 15:58:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-10 15:58:21  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-10 15:58:26  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-10 15:58:30  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-10 15:58:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-10 15:58:40  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-10 15:58:44  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-10 15:58:48  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-10 15:58:53  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-10 15:58:57  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-10 15:59:02  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-10 15:59:06  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-10 15:59:11  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-10 15:59:15  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-10 15:59:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-10 15:59:24  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-10 15:59:28  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-10 15:59:33  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-10 15:59:37  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-10 15:59:41  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-10 15:59:46  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-10 15:59:50  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-10 15:59:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-10 15:59:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-10 16:00:04  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-10 16:00:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-10 16:00:13  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-10 16:00:17  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-10 16:00:25  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-10 16:00:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-10 16:00:34  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-10 16:00:38  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-10 16:00:43  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-10 16:00:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-10 16:00:51  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-10 16:00:56  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-10 16:01:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-10 16:01:04  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-10 16:01:09  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-10 16:01:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-10 16:01:18  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-10 16:01:23  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-10 16:01:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-10 16:01:32  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-10 16:01:37  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-10 16:01:41  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-10 16:01:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-10 16:01:50  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-10 16:01:54  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-10_16-01-59 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients?_prerender {"code":"ECONNRESET"}
2017-04-10 16:04:00  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-10 16:04:04  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-10 16:04:08  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-10 16:04:13  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-10 16:04:18  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-10 16:04:22  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-10 16:04:27  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-10 16:04:32  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-10 16:04:36  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-10 16:04:41  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-10 16:04:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-10 16:04:50  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-10 16:04:55  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-10 16:04:59  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-10 16:05:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-10 16:05:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-10 16:05:13  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-10 16:05:17  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-10 16:05:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-10 16:05:26  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-10 16:05:31  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-10 16:05:36  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-10 16:05:40  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-10 16:05:44  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-10 16:05:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-10 16:05:53  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-10 16:05:57  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-10 16:06:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-10 16:06:06  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-10 16:06:11  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-10 16:06:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-10 16:06:20  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-10 16:06:24  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-10 16:06:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-10 16:06:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-10 16:06:38  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-10 16:06:43  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-10 16:06:47  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-10 16:06:52  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-10 16:06:56  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-10 16:07:01  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-10 16:07:05  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-10 16:07:10  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-10 16:07:14  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-10 16:07:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-10 16:07:23  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-10 16:07:29  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-10 16:07:33  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-10 16:07:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-10 16:07:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-10 16:07:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-10 16:07:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-10 16:07:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-10 16:08:01  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-10 16:08:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-10 16:08:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-10 16:08:15  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-10 16:08:19  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-10 16:08:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-10 16:08:28  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-10 16:08:33  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-10 16:08:37  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-10 16:08:42  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-10 16:08:46  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-10 16:08:51  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-10 16:08:55  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-10 16:09:00  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-10 16:09:04  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-10 16:09:09  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-10 16:09:13  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-10 16:09:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-10 16:09:22  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-10 16:09:27  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-10 16:09:31  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-10 16:09:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-10 16:09:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-primary-results-from-the-pivotal-zuma-1-trial-of-kte-c19-in-refractory-aggressive-non-hodgkin-lymphoma-patients
2017-04-10 16:09:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-10 16:09:49  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-10 16:09:54  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-10 16:09:58  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-10 16:10:03  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-10 16:10:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-10 16:10:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-10 16:10:16  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-216112-pharmacological-downregulation-of-bfl-1-by-cpi203-overcomes-abt-199-resistance-in-double-hit-lymphoma
2017-04-10 16:10:20  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-10 16:10:25  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-10 16:10:29  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-10 16:10:34  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-10 16:10:38  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-10 16:10:43  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-10 16:10:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-10 16:10:52  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-10 16:10:56  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-10 16:11:00  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-10 16:11:04  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-10 16:11:09  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-10 16:11:13  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-37249-pd-l1-protein-expression-and-tumor-mutation-burden-correlates-with-hodgkin-and-diffuse-large-b-cell-lymphoma
2017-04-10 16:11:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-10 16:11:22  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-10 16:11:27  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-10 16:11:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-10 16:11:36  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-10 16:11:40  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-10 16:11:45  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-10 16:11:49  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-10 16:11:53  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-10 16:11:58  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-10 16:12:03  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-10 16:12:07  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-10 16:12:12  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-365124-preclinical-examination-of-the-effects-of-a-cd20-specific-engineered-toxin-body-mt-3724-in-mantle-cell-lymphoma
2017-04-10 16:12:16  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-36314-delivery-of-a-cd20-transferrin-receptor-vnar-bispecific-antibody-to-the-brain-for-central-nervous-system-lymphoma
2017-04-10 16:12:20  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-10 16:12:24  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-10 16:12:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-10 16:12:33  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-10 16:12:38  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-10 16:12:42  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-10 16:12:47  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-10 16:12:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-10 16:12:55  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-10 16:12:59  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-10 16:13:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-10 16:13:08  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-10 16:13:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-10 16:13:17  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-39396-two-evolutionary-models-proposed-for-development-of-drug-resistance-between-primary-and-relapsed-diffuse-large-b-cell-lymphoma
2017-04-10 16:13:21  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-10 16:13:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-10 16:13:30  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-10 16:13:34  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-10 16:13:39  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-10 16:13:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-10 16:13:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-10 16:13:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-10 16:13:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-10 16:14:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-10 16:14:04  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-10 16:14:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-10 16:14:13  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-10 16:14:17  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-10 16:14:21  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-10 16:14:26  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-10 16:14:31  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-10 16:14:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-10 16:14:39  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-10 16:14:43  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-10 16:14:47  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-10 16:14:52  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-10 16:14:56  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-10 16:15:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-10 16:15:05  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-10 16:15:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-10 16:15:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-10 16:15:20  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-10 16:15:20  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-10 16:15:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-10 16:15:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-10 16:15:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-10 16:15:38  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-10 16:15:43  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-10 16:15:47  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-10 16:15:52  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-10 16:15:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-10 16:16:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-10 16:16:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-10 16:16:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-10 16:16:13  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-10 16:16:17  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-10 16:16:22  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-10 16:16:26  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-10 16:16:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-10 16:16:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-10 16:16:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-10 16:16:44  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-10 16:16:48  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-10 16:16:53  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-10 16:16:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-10 16:17:02  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-10 16:17:06  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-10 16:17:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-10 16:17:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-10 16:17:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-10 16:17:23  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-10 16:17:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-10 16:17:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-10 16:17:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-10 16:17:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-10 16:17:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-10 16:17:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-10 16:17:52  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-10 16:17:56  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-10 16:18:00  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-10 16:18:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-10 16:18:08  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-10 16:18:12  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-10 16:18:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-10 16:18:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-10 16:18:25  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-10 16:18:29  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-10 16:18:33  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-10 16:18:37  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-10 16:18:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-10 16:18:46  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-10 16:18:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-10 16:18:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-10 16:18:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-10 16:19:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-10 16:19:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-10 16:19:12  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-10 16:19:16  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-10 16:19:20  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-10 16:19:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-10 16:19:29  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-10 16:19:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-10 16:19:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-10 16:19:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-10 16:19:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 16:19:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 16:19:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 16:19:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 16:20:02  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-10 16:20:06  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 16:20:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 16:20:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-10 16:20:18  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-10 16:20:22  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-10 16:20:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-10 16:20:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-10 16:20:34  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-10 16:20:38  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-10 16:20:43  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-10 16:20:47  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-10 16:20:51  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-10 16:20:55  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-10 16:20:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-10 16:21:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-10 16:21:07  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-10 16:21:11  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-10 16:21:15  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-10 16:21:19  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-10 16:21:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-10 16:21:27  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-10 16:21:31  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-10 16:21:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 16:21:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 16:21:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 16:21:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 16:21:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 16:21:56  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-10 16:22:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 16:22:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 16:22:08  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 16:22:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 16:22:16  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-10 16:22:20  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 16:22:24  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 16:22:28  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 16:22:32  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-10 16:22:36  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-10_16-31-59 Restart Xvfb...
2017-04-10_17-01-59 Restart Xvfb...
2017-04-10_17-31-59 Restart Xvfb...
2017-04-10_18-01-59 Restart Xvfb...
2017-04-10 18:31:46 reset updateRequest
2017-04-10 18:31:51  - 14968  http://www.lymphomahub.com/
2017-04-10 18:31:51  - 14968  http://www.lymphomahub.com/
2017-04-10 18:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-10 18:31:57  - 14968  http://www.lymphomahub.com/about
2017-04-10_18-31-59 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-10 18:34:02  - 14968  http://www.lymphomahub.com/about
2017-04-10 18:34:02  - 14968  http://www.lymphomahub.com/about
2017-04-10 18:34:09  - 14968  http://www.lymphomahub.com/terms
2017-04-10 18:34:10  - 14968  http://www.lymphomahub.com/terms
2017-04-10 18:34:13  - 14968  http://www.lymphomahub.com/undefined
2017-04-10 18:34:13  - 14968  http://www.lymphomahub.com/therapies
2017-04-10 18:34:14  - 14968  http://www.lymphomahub.com/therapies
2017-04-10 18:34:30  - 14968  http://www.lymphomahub.com/newsletter
2017-04-10 18:34:30  - 14968  http://www.lymphomahub.com/newsletter
2017-04-10 18:34:34  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-10 18:34:35  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-10 18:34:39  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-10 18:34:39  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-10 18:34:45  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-10 18:34:49  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-10 18:34:53  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-10 18:34:58  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-10 18:35:03  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-10 18:35:07  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-10 18:35:11  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-10 18:35:15  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-10 18:35:19  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-10 18:35:24  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-10 18:35:28  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-10 18:35:32  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-10 18:35:37  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-10 18:35:41  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-10 18:35:45  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-10 18:35:50  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-10 18:35:55  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-10 18:35:59  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-10 18:36:03  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-10 18:36:07  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-10 18:36:12  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-10 18:36:15  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-10 18:36:19  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-10 18:36:24  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-10 18:36:28  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-10 18:36:32  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-10 18:36:37  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-10 18:36:41  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-10 18:36:46  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-10 18:36:50  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-10 18:36:55  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-10 18:36:59  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-10 18:37:03  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-10 18:37:07  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-10 18:37:11  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-10 18:37:16  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-10 18:37:20  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-10 18:37:24  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-10 18:37:29  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-10 18:37:33  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-10 18:37:38  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-10 18:37:42  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-10 18:37:46  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-10 18:37:50  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-10 18:37:54  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-10 18:37:58  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-10 18:38:03  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-10 18:38:07  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-10 18:38:11  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-10 18:38:15  - 14968  http://www.lymphomahub.com/medical-information
2017-04-10 18:38:19  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-10 18:38:24  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-10 18:38:29  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-10 18:38:34  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-10 18:38:38  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-10 18:38:42  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-10 18:38:47  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-10 18:38:51  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-10 18:38:55  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-10 18:39:00  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-10 18:39:04  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-10 18:39:08  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-10 18:39:09  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-10 18:39:13  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-10 18:39:17  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-10 18:39:22  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-10 18:39:26  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-10 18:39:30  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-10 18:39:34  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-10 18:39:39  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-10 18:39:43  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-10 18:39:47  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-10 18:39:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-10 18:39:56  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-10 18:40:00  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-10 18:40:04  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-10 18:40:08  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-10 18:40:12  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-10 18:40:16  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-10 18:40:21  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-10 18:40:25  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-10 18:40:29  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-10 18:40:33  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-10 18:40:38  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-10 18:40:42  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-10 18:40:46  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-10 18:40:50  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-10 18:40:54  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-10 18:40:59  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-10 18:41:03  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-10 18:41:07  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-10 18:41:11  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-10 18:41:15  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-10 18:41:16  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-10 18:41:20  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-10 18:41:24  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-10 18:41:29  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-10 18:41:33  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-10 18:41:39  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-10 18:41:44  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-10 18:41:48  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-10 18:41:53  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-10 18:41:57  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-10 18:41:57  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-10 18:42:01  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-10 18:42:06  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-10 18:42:10  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-10 18:42:15  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-10 18:42:19  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-10 18:42:19  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-10 18:42:24  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-10 18:42:28  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-10 18:42:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-10 18:42:36  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-10 18:42:40  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-10 18:42:44  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-10 18:42:48  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-10 18:42:51  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-10 18:42:55  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-10 18:43:00  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-10 18:43:04  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-10 18:43:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-10 18:43:12  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-10 18:43:16  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-10 18:43:17  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-10 18:43:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-10 18:43:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-10 18:43:30  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-10 18:43:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-10 18:43:38  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-10 18:43:42  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-10 18:43:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-10 18:43:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-10 18:43:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-10 18:43:57  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-10 18:44:01  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-10 18:44:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-10 18:44:08  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-10 18:44:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-10 18:44:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-10 18:44:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-10 18:44:26  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-10 18:44:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-10 18:44:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-10 18:44:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-10 18:44:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-10 18:44:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-10 18:44:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-10 18:44:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-10 18:45:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-10 18:45:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-10 18:45:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-10 18:45:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-10 18:45:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-10 18:45:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-10 18:45:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-10 18:45:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/33/10/keyword/
2017-04-10 18:45:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-10 18:45:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-10 18:45:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-10 18:45:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-10 18:45:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-10 18:45:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-10 18:46:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-10 18:46:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-10 18:46:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-10 18:46:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-10 18:46:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-10 18:46:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-10 18:46:29  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-10 18:46:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-10 18:46:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-10 18:46:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-10 18:46:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-10 18:46:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-10 18:46:54  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-10 18:46:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-10 18:47:02  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-10 18:47:06  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-10 18:47:11  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-10 18:47:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-10 18:47:19  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-10 18:47:23  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-10 18:47:27  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-10 18:47:31  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-10 18:47:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-10 18:47:40  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-10 18:47:43  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-10 18:47:47  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-10 18:47:51  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-10 18:47:55  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-10 18:47:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-10 18:48:04  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-10 18:48:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-10 18:48:12  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-10 18:48:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-10 18:48:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-10 18:48:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-10 18:48:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-10 18:48:35  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-10 18:48:35  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-10 18:48:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-10 18:48:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-10 18:48:49  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-10 18:48:53  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-10 18:48:58  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-10 18:49:02  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 18:49:06  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 18:49:11  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-10 18:49:15  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 18:49:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-10 18:49:24  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-10 18:49:28  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-10 18:49:33  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-10 18:49:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-10 18:49:42  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-10 18:49:46  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-10 18:49:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-10 18:49:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-10 18:49:59  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-10 18:50:04  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 18:50:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-10 18:50:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-10 18:50:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-10 18:50:22  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-10 18:50:26  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-10 18:50:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-10 18:50:36  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-10 18:50:40  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-10 18:50:45  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-10 18:50:49  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-10 18:50:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-10 18:50:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-10 18:51:03  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-10 18:51:07  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-10 18:51:11  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-10 18:51:16  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-10 18:51:21  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-10 18:51:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-10 18:51:30  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-10 18:51:34  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-10 18:51:39  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-10 18:51:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-10 18:51:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-10 18:51:48  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-10 18:51:53  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-10 18:51:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-10 18:52:02  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-10 18:52:06  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-10 18:52:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-10 18:52:15  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-10 18:52:20  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-10 18:52:25  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-10 18:52:29  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-10 18:52:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-10 18:52:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-10 18:52:43  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-10 18:52:47  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-10 18:52:51  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-10 18:52:56  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-10 18:53:00  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-10 18:53:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-10 18:53:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-10 18:53:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-10 18:53:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-10 18:53:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-10 18:53:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-10 18:53:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-10 18:53:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-10 18:53:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-10 18:53:43  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-10 18:53:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-10 18:53:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-10 18:53:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-10 18:53:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-10 18:53:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-10 18:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-10 18:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-10 18:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-10 18:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-10 18:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-10 18:54:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-10 18:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-10 18:54:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-10 18:54:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-10 18:54:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-10 18:54:42  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-10 18:54:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-10 18:54:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-10 18:54:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-10 18:54:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-10 18:55:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-10 18:55:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-10 18:55:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-10 18:55:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-10 18:55:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-10 18:55:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-10 18:55:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-10 18:55:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-10 18:55:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-10 18:55:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-10 18:55:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-10 18:55:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-10 18:55:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-10 18:55:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-10 18:55:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-10 18:55:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-10 18:56:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-10 18:56:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-10 18:56:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-10 18:56:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-10 18:56:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-10 18:56:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-10 18:56:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-10 18:56:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-10 18:56:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-10 18:56:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-10 18:56:37  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-10 18:56:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-10 18:56:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-10 18:56:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-10 18:56:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-10 18:56:58  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-10 18:57:02  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-10 18:57:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-10 18:57:12  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-10 18:57:12  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-10 18:57:17  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-10 18:57:21  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-10 18:57:26  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-10 18:57:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-10 18:57:35  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-10 18:57:39  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-10 18:57:43  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-10 18:57:48  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-10 18:57:53  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-10 18:57:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-10 18:58:01  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-10 18:58:06  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-10 18:58:10  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-10 18:58:15  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-10 18:58:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-10 18:58:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-10 18:58:28  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-10 18:58:32  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-10 18:58:37  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-10 18:58:41  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-10 18:58:46  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-10 18:58:50  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-10 18:58:55  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-10 18:58:59  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-10 18:59:03  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-10 18:59:08  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-10 18:59:12  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-10 18:59:17  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-10 18:59:21  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-10 18:59:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-10 18:59:30  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-10 18:59:34  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-10 18:59:39  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-10 18:59:43  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-10 18:59:48  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-10 18:59:52  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-10 18:59:56  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-10 19:00:01  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-10 19:00:05  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-10 19:00:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-10 19:00:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-10 19:00:19  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-10 19:00:23  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-10 19:00:28  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-10 19:00:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-10 19:00:37  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-10 19:00:42  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-10 19:00:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-10 19:00:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-10 19:00:55  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-10 19:00:59  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-10 19:01:04  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-10 19:01:08  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-10 19:01:13  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-10 19:01:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-10 19:01:22  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-10 19:01:26  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-10 19:01:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-10 19:01:35  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-10 19:01:39  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-10 19:01:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-10 19:01:48  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-10 19:01:53  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-10 19:01:57  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-10_19-01-59 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients?_prerender {"code":"ECONNRESET"}
2017-04-10 19:04:02  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-10 19:04:07  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-10 19:04:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-10 19:04:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-10 19:04:20  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-10 19:04:25  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-10 19:04:29  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-10 19:04:34  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-10 19:04:38  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-10 19:04:43  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-10 19:04:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-10 19:04:52  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-10 19:04:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-10 19:05:01  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-10 19:05:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-10 19:05:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-10 19:05:15  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-10 19:05:20  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-10 19:05:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-10 19:05:29  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-10 19:05:34  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-10 19:05:39  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-10 19:05:43  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-10 19:05:47  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-10 19:05:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-10 19:05:57  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-10 19:06:01  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-10 19:06:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-10 19:06:10  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-10 19:06:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-10 19:06:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-10 19:06:24  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-10 19:06:28  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-10 19:06:32  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-10 19:06:37  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-10 19:06:41  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-10 19:06:46  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-10 19:06:51  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-10 19:06:55  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-10 19:07:00  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-10 19:07:04  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-10 19:07:10  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-10 19:07:14  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-10 19:07:18  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-10 19:07:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-10 19:07:27  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-10 19:07:32  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-10 19:07:36  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-10 19:07:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-10 19:07:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-10 19:07:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-10 19:07:54  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-10 19:07:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-10 19:08:03  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-10 19:08:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-10 19:08:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-10 19:08:16  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-10 19:08:21  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-10 19:08:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-10 19:08:30  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-10 19:08:34  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-10 19:08:39  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-10 19:08:44  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-10 19:08:47  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-10 19:08:52  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-10 19:08:56  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-10 19:09:01  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-10 19:09:05  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-10 19:09:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-10 19:09:14  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-10 19:09:19  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-10 19:09:23  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-10 19:09:27  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-10 19:09:32  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-10 19:09:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-10 19:09:41  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-primary-results-from-the-pivotal-zuma-1-trial-of-kte-c19-in-refractory-aggressive-non-hodgkin-lymphoma-patients
2017-04-10 19:09:46  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-10 19:09:51  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-10 19:09:55  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-10 19:09:59  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-10 19:10:04  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-10 19:10:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-10 19:10:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-10 19:10:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-216112-pharmacological-downregulation-of-bfl-1-by-cpi203-overcomes-abt-199-resistance-in-double-hit-lymphoma
2017-04-10 19:10:22  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-10 19:10:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-10 19:10:31  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-10 19:10:36  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-10 19:10:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-10 19:10:45  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-10 19:10:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-10 19:10:54  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-10 19:10:58  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-10 19:11:02  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-10 19:11:06  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-10 19:11:11  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-10 19:11:15  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-37249-pd-l1-protein-expression-and-tumor-mutation-burden-correlates-with-hodgkin-and-diffuse-large-b-cell-lymphoma
2017-04-10 19:11:19  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-10 19:11:24  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-10 19:11:28  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-10 19:11:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-10 19:11:37  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-10 19:11:41  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-10 19:11:45  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-10 19:11:50  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-10 19:11:54  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-313221-inhibition-of-the-integrin-v3-improves-the-effect-of-bexarotene-in-the-treatment-of-cutaneous-t-cell-lymphoma
2017-04-10 19:11:59  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-10 19:12:03  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-10 19:12:08  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-10 19:12:12  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-10 19:12:17  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-365124-preclinical-examination-of-the-effects-of-a-cd20-specific-engineered-toxin-body-mt-3724-in-mantle-cell-lymphoma
2017-04-10 19:12:21  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-36314-delivery-of-a-cd20-transferrin-receptor-vnar-bispecific-antibody-to-the-brain-for-central-nervous-system-lymphoma
2017-04-10 19:12:26  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-10 19:12:30  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-10 19:12:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-10 19:12:38  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-10 19:12:43  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-10 19:12:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-10 19:12:52  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-10 19:12:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-10 19:13:00  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-10 19:13:05  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-10 19:13:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-10 19:13:14  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-10 19:13:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-10 19:13:23  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-39396-two-evolutionary-models-proposed-for-development-of-drug-resistance-between-primary-and-relapsed-diffuse-large-b-cell-lymphoma
2017-04-10 19:13:27  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-10 19:13:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-10 19:13:36  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-10 19:13:40  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-10 19:13:44  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-10 19:13:48  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-10 19:13:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-10 19:13:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-10 19:14:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-10 19:14:06  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-10 19:14:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-10 19:14:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-10 19:14:19  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-10 19:14:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-10 19:14:28  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-10 19:14:32  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-10 19:14:37  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-10 19:14:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-10 19:14:46  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-10 19:14:50  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-10 19:14:54  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-10 19:14:58  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-10 19:15:03  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-10 19:15:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-10 19:15:12  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-10 19:15:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-10 19:15:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-10 19:15:25  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-10 19:15:26  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-10 19:15:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-10 19:15:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-10 19:15:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-10 19:15:44  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-10 19:15:49  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-10 19:15:53  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-10 19:15:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-10 19:16:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-10 19:16:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-10 19:16:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-10 19:16:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-10 19:16:18  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-10 19:16:22  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-10 19:16:27  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-10 19:16:31  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-10 19:16:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-10 19:16:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-10 19:16:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-10 19:16:49  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-10 19:16:53  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-10 19:16:58  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-10 19:17:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-10 19:17:06  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-10 19:17:10  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-10 19:17:15  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-10 19:17:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-10 19:17:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-10 19:17:28  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-10 19:17:32  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-10 19:17:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-10 19:17:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-10 19:17:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-10 19:17:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-10 19:17:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-10 19:17:57  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-10 19:18:01  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-10 19:18:05  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-10 19:18:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-10 19:18:12  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-10 19:18:17  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-10 19:18:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-10 19:18:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-10 19:18:30  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-10 19:18:34  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-10 19:18:38  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-10 19:18:42  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-10 19:18:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-10 19:18:50  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-10 19:18:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-10 19:18:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-10 19:19:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-10 19:19:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-10 19:19:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-10 19:19:17  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-10 19:19:21  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-10 19:19:25  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-10 19:19:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-10 19:19:33  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-10 19:19:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-10 19:19:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-10 19:19:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-10 19:19:50  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 19:19:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 19:19:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 19:20:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 19:20:06  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-10 19:20:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 19:20:14  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 19:20:18  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-10 19:20:22  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-10 19:20:26  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-10 19:20:30  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-10 19:20:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-10 19:20:39  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-10 19:20:43  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-10 19:20:47  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-10 19:20:51  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-10 19:20:54  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-10 19:20:59  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-10 19:21:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-10 19:21:07  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-10 19:21:11  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-10 19:21:15  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-10 19:21:19  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-10 19:21:23  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-10 19:21:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-10 19:21:31  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-10 19:21:35  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-10 19:21:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 19:21:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 19:21:48  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 19:21:52  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 19:21:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 19:22:00  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-10 19:22:04  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 19:22:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 19:22:12  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 19:22:16  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 19:22:20  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-10 19:22:24  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 19:22:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 19:22:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 19:22:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-10 19:22:39  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-10_19-31-59 Restart Xvfb...
2017-04-10_20-01-59 Restart Xvfb...
2017-04-10_20-31-59 Restart Xvfb...
2017-04-10_21-01-59 Restart Xvfb...
2017-04-10 21:31:46 reset updateRequest
2017-04-10 21:31:49  - 14968  http://www.lymphomahub.com/
2017-04-10 21:31:51  - 14968  http://www.lymphomahub.com/
2017-04-10 21:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-10 21:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-10_21-31-59 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-10 21:34:01  - 14968  http://www.lymphomahub.com/about
2017-04-10 21:34:01  - 14968  http://www.lymphomahub.com/about
2017-04-10 21:34:05  - 14968  http://www.lymphomahub.com/terms
2017-04-10 21:34:06  - 14968  http://www.lymphomahub.com/terms
2017-04-10 21:34:08  - 14968  http://www.lymphomahub.com/undefined
2017-04-10 21:34:09  - 14968  http://www.lymphomahub.com/therapies
2017-04-10 21:34:10  - 14968  http://www.lymphomahub.com/therapies
2017-04-10 21:34:22  - 14968  http://www.lymphomahub.com/newsletter
2017-04-10 21:34:24  - 14968  http://www.lymphomahub.com/newsletter
2017-04-10 21:34:26  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-10 21:34:27  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-10 21:34:30  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-10 21:34:31  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-10 21:34:35  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-10 21:34:35  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-10 21:34:40  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-10 21:34:41  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-10 21:34:45  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-10 21:34:45  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-10 21:34:50  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-10 21:34:50  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-10 21:34:55  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-10 21:34:55  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-10 21:35:00  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-10 21:35:00  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-10 21:35:06  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-10 21:35:06  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-10 21:35:11  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-10 21:35:11  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-10 21:35:16  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-10 21:35:16  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-10 21:35:22  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-10 21:35:26  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-10 21:35:30  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-10 21:35:35  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-10 21:35:39  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-10 21:35:43  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-10 21:35:48  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-10 21:35:52  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-10 21:35:56  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-10 21:36:01  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-10 21:36:05  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-10 21:36:09  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-10 21:36:13  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-10 21:36:18  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-10 21:36:22  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-10 21:36:26  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-10 21:36:31  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-10 21:36:35  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-10 21:36:40  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-10 21:36:44  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-10 21:36:48  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-10 21:36:52  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-10 21:36:57  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-10 21:37:01  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-10 21:37:05  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-10 21:37:09  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-10 21:37:14  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-10 21:37:18  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-10 21:37:22  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-10 21:37:27  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-10 21:37:32  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-10 21:37:36  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-10 21:37:40  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-10 21:37:45  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-10 21:37:50  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-10 21:37:54  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-10 21:37:59  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-10 21:38:03  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-10 21:38:07  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-10 21:38:12  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-10 21:38:16  - 14968  http://www.lymphomahub.com/medical-information
2017-04-10 21:38:20  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-10 21:38:25  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-10 21:38:29  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-10 21:38:34  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-10 21:38:38  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-10 21:38:42  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-10 21:38:47  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-10 21:38:51  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-10 21:38:56  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-10 21:39:00  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-10 21:39:05  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-10 21:39:09  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-10 21:39:10  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-10 21:39:15  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-10 21:39:19  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-10 21:39:23  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-10 21:39:28  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-10 21:39:32  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-10 21:39:36  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-10 21:39:41  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-10 21:39:45  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-10 21:39:49  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-10 21:39:54  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-10 21:39:58  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-10 21:40:02  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-10 21:40:07  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-10 21:40:11  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-10 21:40:15  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-10 21:40:20  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-10 21:40:24  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-10 21:40:28  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-10 21:40:33  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-10 21:40:37  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-10 21:40:42  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-10 21:40:46  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-10 21:40:51  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-10 21:40:55  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-10 21:40:59  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-10 21:41:03  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-10 21:41:07  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-10 21:41:12  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-10 21:41:17  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-10 21:41:22  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-10 21:41:22  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-10 21:41:27  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-10 21:41:31  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-10 21:41:35  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-10 21:41:39  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-10 21:41:44  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-10 21:41:48  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-10 21:41:53  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-10 21:41:58  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-10 21:42:01  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-10 21:42:02  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-10 21:42:06  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-10 21:42:11  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-10 21:42:15  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-10 21:42:19  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-10 21:42:24  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-10 21:42:25  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-10 21:42:29  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-10 21:42:33  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-10 21:42:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-10 21:42:41  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-10 21:42:45  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-10 21:42:49  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-10 21:42:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-10 21:42:58  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-10 21:43:01  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-10 21:43:06  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-10 21:43:10  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-10 21:43:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-10 21:43:18  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-10 21:43:22  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-10 21:43:23  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-10 21:43:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-10 21:43:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-10 21:43:35  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-10 21:43:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-10 21:43:44  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-10 21:43:48  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-10 21:43:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-10 21:43:56  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-10 21:43:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-10 21:44:03  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-10 21:44:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-10 21:44:11  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-10 21:44:14  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-10 21:44:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-10 21:44:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-10 21:44:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-10 21:44:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-10 21:44:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-10 21:44:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-10 21:44:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-10 21:44:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-10 21:44:52  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-10 21:44:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-10 21:45:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-10 21:45:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-10 21:45:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-10 21:45:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-10 21:45:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-10 21:45:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-10 21:45:28  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-10 21:45:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-10 21:45:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/33/10/keyword/
2017-04-10 21:45:40  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-10 21:45:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-10 21:45:49  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-10 21:45:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-10 21:45:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-10 21:46:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-10 21:46:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-10 21:46:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-10 21:46:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-10 21:46:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-10 21:46:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-10 21:46:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-10 21:46:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-10 21:46:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-10 21:46:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-10 21:46:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-10 21:46:51  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-10 21:46:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-10 21:46:59  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-10 21:47:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-10 21:47:10  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-10 21:47:14  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-10 21:47:18  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-10 21:47:23  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-10 21:47:27  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-10 21:47:31  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-10 21:47:35  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-10 21:47:39  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-10 21:47:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-10 21:47:48  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-10 21:47:52  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-10 21:47:55  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-10 21:47:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-10 21:48:04  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-10 21:48:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-10 21:48:12  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-10 21:48:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-10 21:48:21  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-10 21:48:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-10 21:48:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-10 21:48:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-10 21:48:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-10 21:48:43  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-10 21:48:44  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-10 21:48:49  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-10 21:48:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-10 21:48:58  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-10 21:49:03  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-10 21:49:07  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-10 21:49:11  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 21:49:16  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 21:49:20  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-10 21:49:24  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 21:49:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-10 21:49:33  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-10 21:49:37  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-10 21:49:42  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-10 21:49:47  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-10 21:49:51  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-10 21:49:56  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-10 21:50:00  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-10 21:50:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-10 21:50:09  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-10 21:50:14  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-10 21:50:18  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-10 21:50:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-10 21:50:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-10 21:50:32  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-10 21:50:36  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-10 21:50:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-10 21:50:45  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-10 21:50:50  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-10 21:50:54  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-10 21:50:58  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-10 21:51:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-10 21:51:08  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-10 21:51:12  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-10 21:51:16  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-10 21:51:21  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-10 21:51:25  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-10 21:51:30  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-10 21:51:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-10 21:51:39  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-10 21:51:43  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-10 21:51:48  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-10 21:51:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-10 21:51:52  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-10 21:51:57  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-10 21:52:01  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-10 21:52:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-10 21:52:10  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-10 21:52:15  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-10 21:52:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-10 21:52:24  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-10 21:52:29  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-10 21:52:33  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-10 21:52:37  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-10 21:52:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-10 21:52:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-10 21:52:52  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-10 21:52:56  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-10 21:53:01  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-10 21:53:05  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-10 21:53:10  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-10 21:53:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-10 21:53:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-10 21:53:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-10 21:53:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-10 21:53:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-10 21:53:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-10 21:53:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-10 21:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-10 21:53:50  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-10 21:53:55  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-10 21:53:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-10 21:54:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-10 21:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-10 21:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-10 21:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-10 21:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-10 21:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-10 21:54:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-10 21:54:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-10 21:54:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-10 21:54:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-10 21:54:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-10 21:54:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-10 21:54:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-10 21:54:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-10 21:54:52  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-10 21:54:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-10 21:55:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-10 21:55:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-10 21:55:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-10 21:55:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-10 21:55:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-10 21:55:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-10 21:55:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-10 21:55:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-10 21:55:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-10 21:55:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-10 21:55:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-10 21:55:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-10 21:55:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-10 21:55:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-10 21:55:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-10 21:55:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-10 21:55:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-10 21:56:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-10 21:56:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-10 21:56:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-10 21:56:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-10 21:56:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-10 21:56:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-10 21:56:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-10 21:56:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-10 21:56:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-10 21:56:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-10 21:56:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-10 21:56:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-10 21:56:48  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-10 21:56:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-10 21:56:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-10 21:57:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-10 21:57:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-10 21:57:09  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-10 21:57:14  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-10 21:57:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-10 21:57:23  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-10 21:57:23  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-10 21:57:28  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-10 21:57:32  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-10 21:57:37  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-10 21:57:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-10 21:57:46  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-10 21:57:51  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-10 21:57:56  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-10 21:58:01  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-10 21:58:05  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-10 21:58:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-10 21:58:14  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-10 21:58:19  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-10 21:58:24  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-10 21:58:29  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-10 21:58:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-10 21:58:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-10 21:58:42  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-10 21:58:47  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-10 21:58:52  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-10 21:58:56  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-10 21:59:01  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-10 21:59:05  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-10 21:59:09  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-10 21:59:14  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-10 21:59:19  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-10 21:59:24  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-10 21:59:28  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-10 21:59:32  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-10 21:59:37  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-10 21:59:41  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-10 21:59:46  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-10 21:59:50  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-10 21:59:55  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-10 21:59:59  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-10 22:00:03  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-10 22:00:08  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-10 22:00:13  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-10 22:00:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-10 22:00:25  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-10 22:00:29  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-10 22:00:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-10 22:00:38  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-10 22:00:43  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-10 22:00:47  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-10 22:00:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-10 22:00:56  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-10 22:01:01  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-10 22:01:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-10 22:01:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-10 22:01:14  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-10 22:01:19  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-10 22:01:23  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-10 22:01:28  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-10 22:01:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-10 22:01:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-10 22:01:41  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-10 22:01:45  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-10 22:01:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-10 22:01:54  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-10 22:01:59  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-10_22-01-59 Restart Xvfb...
2017-04-10 22:02:03  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-10 22:02:08  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-10 22:02:12  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-10 22:02:17  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-10 22:02:22  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-10 22:02:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-10 22:02:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-10 22:02:36  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-10 22:02:40  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-10 22:02:45  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-10 22:02:49  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-10 22:02:54  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-10 22:02:58  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-10 22:03:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-10 22:03:07  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-10 22:03:12  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-10 22:03:16  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-10 22:03:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-10 22:03:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-10 22:03:30  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-10 22:03:34  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-10 22:03:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-10 22:03:43  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-10 22:03:48  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-10 22:03:52  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-10 22:03:58  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-10 22:04:02  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-10 22:04:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-10 22:04:11  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-10 22:04:15  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-10 22:04:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-10 22:04:24  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-10 22:04:29  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-10 22:04:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-10 22:04:38  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-10 22:04:42  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-10 22:04:47  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-10 22:04:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-10 22:04:56  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-10 22:05:00  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-10 22:05:05  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-10 22:05:10  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-10 22:05:14  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-10 22:05:19  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-10 22:05:23  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-10 22:05:28  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-10 22:05:32  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-10 22:05:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-10 22:05:42  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-10 22:05:46  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-10 22:05:51  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-10 22:05:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-10 22:05:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-10 22:06:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-10 22:06:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-10 22:06:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-10 22:06:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-10 22:06:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-10 22:06:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-10 22:06:32  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-10 22:06:37  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-10 22:06:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-10 22:06:46  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-10 22:06:50  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-10 22:06:55  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-10 22:06:59  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-10 22:07:03  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-10 22:07:08  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-10 22:07:12  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-10 22:07:17  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-10 22:07:21  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-10 22:07:26  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-10 22:07:30  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-10 22:07:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-10 22:07:39  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-10 22:07:43  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-10 22:07:48  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-10 22:07:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-10 22:07:57  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-primary-results-from-the-pivotal-zuma-1-trial-of-kte-c19-in-refractory-aggressive-non-hodgkin-lymphoma-patients
2017-04-10 22:08:01  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-10 22:08:06  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-10 22:08:10  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-10 22:08:15  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-10 22:08:19  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-10 22:08:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-10 22:08:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-10 22:08:33  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-216112-pharmacological-downregulation-of-bfl-1-by-cpi203-overcomes-abt-199-resistance-in-double-hit-lymphoma
2017-04-10 22:08:37  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-10 22:08:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-10 22:08:46  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-10 22:08:51  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-10 22:08:55  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-10 22:09:00  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-10 22:09:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-10 22:09:09  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-10 22:09:14  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-10 22:09:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-10 22:09:22  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-10 22:09:27  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-10 22:09:31  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-37249-pd-l1-protein-expression-and-tumor-mutation-burden-correlates-with-hodgkin-and-diffuse-large-b-cell-lymphoma
2017-04-10 22:09:36  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-10 22:09:40  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-10 22:09:45  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-10 22:09:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-10 22:09:54  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-10 22:09:58  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-10 22:10:03  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-10 22:10:07  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-10 22:10:11  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-313221-inhibition-of-the-integrin-v3-improves-the-effect-of-bexarotene-in-the-treatment-of-cutaneous-t-cell-lymphoma
2017-04-10 22:10:16  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-10 22:10:20  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-10 22:10:25  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-10 22:10:29  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-10 22:10:34  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-365124-preclinical-examination-of-the-effects-of-a-cd20-specific-engineered-toxin-body-mt-3724-in-mantle-cell-lymphoma
2017-04-10 22:10:38  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-36314-delivery-of-a-cd20-transferrin-receptor-vnar-bispecific-antibody-to-the-brain-for-central-nervous-system-lymphoma
2017-04-10 22:10:43  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-10 22:10:46  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-10 22:10:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-10 22:10:55  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-10 22:10:59  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-10 22:11:04  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-10 22:11:08  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-10 22:11:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-10 22:11:17  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-10 22:11:22  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-10 22:11:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-10 22:11:30  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-10 22:11:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-10 22:11:39  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-39396-two-evolutionary-models-proposed-for-development-of-drug-resistance-between-primary-and-relapsed-diffuse-large-b-cell-lymphoma
2017-04-10 22:11:44  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-10 22:11:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-10 22:11:53  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-10 22:11:57  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-10 22:12:01  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-10 22:12:06  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-10 22:12:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-10 22:12:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-10 22:12:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-10 22:12:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-10 22:12:28  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-10 22:12:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-10 22:12:37  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-10 22:12:41  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-10 22:12:46  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-10 22:12:50  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-10 22:12:55  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-10 22:12:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-10 22:13:03  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-10 22:13:07  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-10 22:13:11  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-10 22:13:17  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-10 22:13:21  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-10 22:13:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-10 22:13:30  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-10 22:13:34  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-10 22:13:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-10 22:13:43  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-10 22:13:44  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-10 22:13:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-10 22:13:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-10 22:13:57  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-10 22:14:01  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-10 22:14:06  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-10 22:14:10  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-10 22:14:14  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-10 22:14:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-10 22:14:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-10 22:14:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-10 22:14:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-10 22:14:35  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-10 22:14:39  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-10 22:14:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-10 22:14:48  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-10 22:14:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-10 22:14:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-10 22:15:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-10 22:15:06  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-10 22:15:11  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-10 22:15:15  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-10 22:15:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-10 22:15:24  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-10 22:15:28  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-10 22:15:32  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-10 22:15:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-10 22:15:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-10 22:15:46  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-10 22:15:50  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-10 22:15:54  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-10 22:15:58  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-10 22:16:02  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-10 22:16:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-10 22:16:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-10 22:16:15  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-10 22:16:19  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-10 22:16:23  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-10 22:16:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-10 22:16:31  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-10 22:16:35  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-10 22:16:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-10 22:16:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-10 22:16:48  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-10 22:16:52  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-10 22:16:56  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-10 22:17:01  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-10 22:17:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-10 22:17:09  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-10 22:17:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-10 22:17:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-10 22:17:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-10 22:17:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-10 22:17:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-10 22:17:36  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-10 22:17:40  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-10 22:17:44  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-10 22:17:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-10 22:17:52  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-10 22:17:56  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-10 22:18:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-10 22:18:04  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-10 22:18:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 22:18:12  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 22:18:16  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 22:18:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 22:18:25  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-10 22:18:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 22:18:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-10 22:18:37  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-10 22:18:41  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-10 22:18:45  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-10 22:18:48  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-10 22:18:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-10 22:18:57  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-10 22:19:01  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-10 22:19:04  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-10 22:19:09  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-10 22:19:13  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-10 22:19:17  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-10 22:19:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-10 22:19:26  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-10 22:19:30  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-10 22:19:34  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-10 22:19:38  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-10 22:19:43  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-10 22:19:47  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-10 22:19:51  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-10 22:19:55  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-10 22:19:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 22:20:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 22:20:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 22:20:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 22:20:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-10 22:20:19  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-10 22:20:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 22:20:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 22:20:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 22:20:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 22:20:39  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-10 22:20:44  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 22:20:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 22:20:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-10 22:20:56  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-10 22:21:00  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-10_22-31-59 Restart Xvfb...
2017-04-10_23-01-59 Restart Xvfb...
2017-04-10_23-31-59 Restart Xvfb...
2017-04-11_00-01-59 Restart Xvfb...
2017-04-11 00:31:46 reset updateRequest
2017-04-11 00:31:49  - 14968  http://www.lymphomahub.com/
2017-04-11 00:31:51  - 14968  http://www.lymphomahub.com/
2017-04-11 00:31:53  - 14968  http://www.lymphomahub.com/about
2017-04-11 00:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-11_00-31-59 Restart Xvfb...
2017-04-11 00:31:59  - 14968  http://www.lymphomahub.com/terms
2017-04-11 00:32:03  - 14968  http://www.lymphomahub.com/undefined
2017-04-11 00:32:03  - 14968  http://www.lymphomahub.com/therapies
2017-04-11 00:32:09  - 14968  http://www.lymphomahub.com/newsletter
2017-04-11 00:32:13  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-11 00:32:16  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-11 00:32:20  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-11 00:32:25  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-11 00:32:30  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-11 00:32:34  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-11 00:32:38  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-11 00:32:43  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-11 00:32:47  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-11 00:32:52  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-11 00:32:56  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-11 00:33:00  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-11 00:33:04  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-11 00:33:09  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-11 00:33:13  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-11 00:33:17  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-11 00:33:21  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-11 00:33:26  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-11 00:33:30  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-11 00:33:35  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-11 00:33:39  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-11 00:33:43  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-11 00:33:48  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-11 00:33:51  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-11 00:33:55  - 14968  http://www.lymphomahub.com/therapies/regn1979
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-11 00:34:00  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-11 00:34:00  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-11 00:34:05  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-11 00:34:05  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-11 00:34:10  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-11 00:34:10  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-11 00:34:16  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-11 00:34:16  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-11 00:34:20  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-11 00:34:22  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-11 00:34:26  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-11 00:34:26  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-11 00:34:30  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-11 00:34:31  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-11 00:34:36  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-11 00:34:36  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-11 00:34:41  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-11 00:34:45  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-11 00:34:49  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-11 00:34:54  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-11 00:34:58  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-11 00:35:02  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-11 00:35:07  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-11 00:35:11  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-11 00:35:15  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-11 00:35:19  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-11 00:35:24  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-11 00:35:28  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-11 00:35:32  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-11 00:35:37  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-11 00:35:41  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-11 00:35:45  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-11 00:35:49  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-11 00:35:54  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-11 00:35:58  - 14968  http://www.lymphomahub.com/medical-information
2017-04-11 00:36:02  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-11 00:36:07  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-11 00:36:11  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-11 00:36:15  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-11 00:36:19  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-11 00:36:24  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-11 00:36:28  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-11 00:36:32  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-11 00:36:37  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-11 00:36:41  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-11 00:36:45  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-11 00:36:50  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-11 00:36:50  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-11 00:36:55  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-11 00:36:59  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-11 00:37:03  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-11 00:37:07  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-11 00:37:12  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-11 00:37:16  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-11 00:37:20  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-11 00:37:25  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-11 00:37:29  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-11 00:37:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-11 00:37:38  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-11 00:37:43  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-11 00:37:47  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-11 00:37:51  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-11 00:37:56  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-11 00:38:00  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-11 00:38:04  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-11 00:38:08  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-11 00:38:13  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-11 00:38:17  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-11 00:38:21  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-11 00:38:26  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-11 00:38:30  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-11 00:38:34  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-11 00:38:38  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-11 00:38:42  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-11 00:38:47  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-11 00:38:51  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-11 00:38:55  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-11 00:39:00  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-11 00:39:00  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-11 00:39:05  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-11 00:39:09  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-11 00:39:13  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-11 00:39:17  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-11 00:39:22  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-11 00:39:26  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-11 00:39:30  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-11 00:39:34  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-11 00:39:38  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-11 00:39:38  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-11 00:39:42  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-11 00:39:47  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-11 00:39:51  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-11 00:39:55  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-11 00:40:00  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-11 00:40:00  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-11 00:40:04  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-11 00:40:09  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-11 00:40:13  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-11 00:40:17  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-11 00:40:21  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-11 00:40:25  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-11 00:40:28  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-11 00:40:33  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-11 00:40:36  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-11 00:40:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-11 00:40:45  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-11 00:40:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-11 00:40:53  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-11 00:40:57  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-11 00:40:58  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-11 00:41:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-11 00:41:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-11 00:41:11  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-11 00:41:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-11 00:41:19  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-11 00:41:23  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-11 00:41:27  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-11 00:41:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-11 00:41:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-11 00:41:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-11 00:41:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-11 00:41:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-11 00:41:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-11 00:41:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-11 00:41:58  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-11 00:42:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-11 00:42:07  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-11 00:42:11  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-11 00:42:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-11 00:42:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-11 00:42:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-11 00:42:28  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-11 00:42:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-11 00:42:36  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-11 00:42:41  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-11 00:42:45  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-11 00:42:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-11 00:42:54  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-11 00:42:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-11 00:43:03  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-11 00:43:07  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-11 00:43:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/33/10/keyword/
2017-04-11 00:43:15  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-11 00:43:20  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-11 00:43:24  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-11 00:43:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-11 00:43:32  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-11 00:43:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-11 00:43:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-11 00:43:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-11 00:43:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-11 00:43:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-11 00:43:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-11 00:44:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-11 00:44:08  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-11 00:44:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-11 00:44:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-11 00:44:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-11 00:44:25  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-11 00:44:29  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-11 00:44:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-11 00:44:37  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-11 00:44:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-11 00:44:45  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-11 00:44:50  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-11 00:44:54  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-11 00:44:58  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-11 00:45:02  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-11 00:45:06  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-11 00:45:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-11 00:45:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-11 00:45:19  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-11 00:45:23  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-11 00:45:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-11 00:45:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-11 00:45:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-11 00:45:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-11 00:45:43  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-11 00:45:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-11 00:45:51  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-11 00:45:56  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-11 00:46:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-11 00:46:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-11 00:46:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-11 00:46:14  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-11 00:46:14  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-11 00:46:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-11 00:46:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-11 00:46:27  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-11 00:46:32  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-11 00:46:36  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-11 00:46:40  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-11 00:46:45  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-11 00:46:49  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-11 00:46:53  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-11 00:46:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-11 00:47:02  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-11 00:47:07  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-11 00:47:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-11 00:47:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-11 00:47:20  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-11 00:47:25  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-11 00:47:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-11 00:47:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-11 00:47:38  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-11 00:47:43  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-11 00:47:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-11 00:47:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-11 00:47:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-11 00:48:01  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-11 00:48:05  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-11 00:48:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-11 00:48:14  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-11 00:48:19  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-11 00:48:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-11 00:48:27  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-11 00:48:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-11 00:48:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-11 00:48:41  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-11 00:48:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-11 00:48:49  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-11 00:48:54  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-11 00:48:58  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-11 00:49:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-11 00:49:07  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-11 00:49:12  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-11 00:49:16  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-11 00:49:17  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-11 00:49:21  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-11 00:49:26  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-11 00:49:30  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-11 00:49:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-11 00:49:39  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-11 00:49:44  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-11 00:49:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-11 00:49:52  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-11 00:49:57  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-11 00:50:01  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-11 00:50:06  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-11 00:50:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-11 00:50:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-11 00:50:19  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-11 00:50:24  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-11 00:50:28  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-11 00:50:32  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-11 00:50:37  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-11 00:50:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-11 00:50:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-11 00:50:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-11 00:50:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-11 00:51:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-11 00:51:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-11 00:51:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-11 00:51:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-11 00:51:15  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-11 00:51:20  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-11 00:51:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-11 00:51:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-11 00:51:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-11 00:51:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-11 00:51:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-11 00:51:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-11 00:51:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-11 00:51:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-11 00:51:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-11 00:51:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-11 00:51:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-11 00:52:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-11 00:52:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-11 00:52:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-11 00:52:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-11 00:52:17  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-11 00:52:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-11 00:52:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-11 00:52:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-11 00:52:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-11 00:52:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-11 00:52:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-11 00:52:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-11 00:52:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-11 00:52:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-11 00:52:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-11 00:52:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-11 00:53:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-11 00:53:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-11 00:53:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-11 00:53:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-11 00:53:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-11 00:53:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-11 00:53:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-11 00:53:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-11 00:53:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-11 00:53:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-11 00:53:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-11 00:53:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-11 00:53:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-11 00:53:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-11 00:53:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-11 00:53:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-11 00:54:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-11 00:54:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-11 00:54:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-11 00:54:11  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-11 00:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-11 00:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-11 00:54:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-11 00:54:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-11 00:54:31  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-11 00:54:36  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-11 00:54:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-11 00:54:45  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-11 00:54:45  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-11 00:54:50  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-11 00:54:54  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-11 00:54:58  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-11 00:55:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-11 00:55:08  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-11 00:55:12  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-11 00:55:16  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-11 00:55:21  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-11 00:55:25  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-11 00:55:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-11 00:55:35  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-11 00:55:39  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-11 00:55:43  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-11 00:55:48  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-11 00:55:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-11 00:55:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-11 00:56:01  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-11 00:56:05  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-11 00:56:10  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-11 00:56:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-11 00:56:19  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-11 00:56:23  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-11 00:56:28  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-11 00:56:32  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-11 00:56:37  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-11 00:56:41  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-11 00:56:46  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-11 00:56:50  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-11 00:56:54  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-11 00:56:59  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-11 00:57:03  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-11 00:57:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-11 00:57:12  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-11 00:57:16  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-11 00:57:21  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-11 00:57:25  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-11 00:57:29  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-11 00:57:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-11 00:57:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-11 00:57:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-11 00:57:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-11 00:57:51  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-11 00:57:56  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-11 00:58:00  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-11 00:58:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-11 00:58:09  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-11 00:58:13  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-11 00:58:18  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-11 00:58:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-11 00:58:27  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-11 00:58:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-11 00:58:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-11 00:58:40  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-11 00:58:44  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-11 00:58:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-11 00:58:53  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-11 00:58:57  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-11 00:59:02  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-11 00:59:06  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-11 00:59:10  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-11 00:59:15  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-11 00:59:19  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-11 00:59:24  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-11 00:59:28  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-11 00:59:33  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-11 00:59:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-11 00:59:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-11 00:59:46  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-11 00:59:50  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-11 00:59:55  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-11 00:59:59  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-11 01:00:04  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-11 01:00:08  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-11 01:00:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-11 01:00:18  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-11 01:00:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-11 01:00:27  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-11 01:00:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-11 01:00:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-11 01:00:40  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-11 01:00:44  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-11 01:00:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-11 01:00:53  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-11 01:00:57  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-11 01:01:02  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-11 01:01:06  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-11 01:01:10  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-11 01:01:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-11 01:01:19  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-11 01:01:23  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-11 01:01:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-11 01:01:32  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-11 01:01:37  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-11 01:01:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-11 01:01:46  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-11 01:01:50  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-11 01:01:55  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-11 01:01:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-11_01-01-59 Restart Xvfb...
2017-04-11 01:02:04  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-11 01:02:08  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-11 01:02:13  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-11 01:02:17  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-11 01:02:22  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-11 01:02:26  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-11 01:02:31  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-11 01:02:35  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-11 01:02:40  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-11 01:02:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-11 01:02:48  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-11 01:02:53  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-11 01:02:57  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-11 01:03:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-11 01:03:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-11 01:03:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-11 01:03:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-11 01:03:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-11 01:03:25  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-11 01:03:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-11 01:03:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-11 01:03:38  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-11 01:03:43  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-11 01:03:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-11 01:03:52  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-11 01:03:56  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-11 01:04:01  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-11 01:04:05  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-11 01:04:09  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-11 01:04:14  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-11 01:04:18  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-11 01:04:23  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-11 01:04:27  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-11 01:04:33  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-11 01:04:38  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-11 01:04:42  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-11 01:04:47  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-11 01:04:51  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-11 01:04:55  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-11 01:05:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-11 01:05:04  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-primary-results-from-the-pivotal-zuma-1-trial-of-kte-c19-in-refractory-aggressive-non-hodgkin-lymphoma-patients
2017-04-11 01:05:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-11 01:05:13  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-11 01:05:18  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-11 01:05:22  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-11 01:05:26  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-11 01:05:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-11 01:05:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-11 01:05:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-216112-pharmacological-downregulation-of-bfl-1-by-cpi203-overcomes-abt-199-resistance-in-double-hit-lymphoma
2017-04-11 01:05:45  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-11 01:05:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-11 01:05:54  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-11 01:05:58  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-11 01:06:03  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-11 01:06:07  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-11 01:06:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-11 01:06:16  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-11 01:06:21  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-11 01:06:25  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-11 01:06:29  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-11 01:06:34  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-11 01:06:38  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-37249-pd-l1-protein-expression-and-tumor-mutation-burden-correlates-with-hodgkin-and-diffuse-large-b-cell-lymphoma
2017-04-11 01:06:42  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-11 01:06:47  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-11 01:06:51  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-11 01:06:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-11 01:07:00  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-11 01:07:04  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-11 01:07:09  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-11 01:07:13  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-11 01:07:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-313221-inhibition-of-the-integrin-v3-improves-the-effect-of-bexarotene-in-the-treatment-of-cutaneous-t-cell-lymphoma
2017-04-11 01:07:22  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-11 01:07:27  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-11 01:07:31  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-11 01:07:36  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-11 01:07:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-365124-preclinical-examination-of-the-effects-of-a-cd20-specific-engineered-toxin-body-mt-3724-in-mantle-cell-lymphoma
2017-04-11 01:07:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-36314-delivery-of-a-cd20-transferrin-receptor-vnar-bispecific-antibody-to-the-brain-for-central-nervous-system-lymphoma
2017-04-11 01:07:49  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-11 01:07:53  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-11 01:07:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-11 01:08:01  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-11 01:08:06  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-11 01:08:10  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-11 01:08:15  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-11 01:08:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-11 01:08:23  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-11 01:08:28  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-11 01:08:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-11 01:08:37  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-11 01:08:41  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-11 01:08:46  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-39396-two-evolutionary-models-proposed-for-development-of-drug-resistance-between-primary-and-relapsed-diffuse-large-b-cell-lymphoma
2017-04-11 01:08:50  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-11 01:08:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-11 01:08:59  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-11 01:09:04  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-11 01:09:08  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-11 01:09:12  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-11 01:09:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-11 01:09:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-11 01:09:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-11 01:09:29  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-11 01:09:33  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-11 01:09:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-11 01:09:42  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-11 01:09:47  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-11 01:09:51  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-11 01:09:55  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-11 01:09:59  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-11 01:10:03  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-11 01:10:08  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-11 01:10:12  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-11 01:10:16  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-11 01:10:21  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-11 01:10:25  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-11 01:10:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-11 01:10:34  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-11 01:10:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-11 01:10:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-11 01:10:47  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-11 01:10:48  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-11 01:10:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-11 01:10:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-11 01:11:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-11 01:11:07  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-11 01:11:11  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-11 01:11:16  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-11 01:11:20  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-11 01:11:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-11 01:11:28  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-11 01:11:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-11 01:11:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-11 01:11:41  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-11 01:11:46  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-11 01:11:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-11 01:11:54  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-11 01:11:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-11 01:12:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-11 01:12:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-11 01:12:12  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-11 01:12:16  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-11 01:12:21  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-11 01:12:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-11 01:12:29  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-11 01:12:33  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-11 01:12:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-11 01:12:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-11 01:12:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-11 01:12:51  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-11 01:12:55  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-11 01:12:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-11 01:13:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-11 01:13:07  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-11 01:13:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-11 01:13:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-11 01:13:20  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-11 01:13:24  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-11 01:13:28  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-11 01:13:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-11 01:13:36  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-11 01:13:39  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-11 01:13:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-11 01:13:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-11 01:13:52  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-11 01:13:56  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-11 01:14:00  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-11 01:14:04  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-11 01:14:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-11 01:14:13  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-11 01:14:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-11 01:14:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-11 01:14:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-11 01:14:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-11 01:14:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-11 01:14:39  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-11 01:14:43  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-11 01:14:47  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-11 01:14:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-11 01:14:55  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-11 01:14:59  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-11 01:15:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-11 01:15:07  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-11 01:15:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 01:15:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 01:15:20  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 01:15:24  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 01:15:28  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-11 01:15:32  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 01:15:36  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 01:15:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-11 01:15:44  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-11 01:15:48  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-11 01:15:52  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-11 01:15:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-11 01:16:01  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-11 01:16:05  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-11 01:16:09  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-11 01:16:13  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-11 01:16:17  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-11 01:16:21  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-11 01:16:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-11 01:16:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-11 01:16:33  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-11 01:16:37  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-11 01:16:41  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-11 01:16:45  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-11 01:16:49  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-11 01:16:53  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-11 01:16:57  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-11 01:17:01  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-11 01:17:05  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-11 01:17:09  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-11 01:17:13  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-11 01:17:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-11 01:17:21  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-11 01:17:25  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 01:17:29  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 01:17:33  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 01:17:37  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 01:17:41  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-11 01:17:45  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 01:17:49  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 01:17:53  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 01:17:57  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-11 01:18:01  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-11_01-31-59 Restart Xvfb...
2017-04-11_02-01-59 Restart Xvfb...
2017-04-11_02-31-59 Restart Xvfb...
2017-04-11_03-01-59 Restart Xvfb...
2017-04-11 03:31:46 reset updateRequest
2017-04-11 03:31:50  - 14968  http://www.lymphomahub.com/
2017-04-11 03:31:51  - 14968  http://www.lymphomahub.com/
2017-04-11 03:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-11 03:31:57  - 14968  http://www.lymphomahub.com/about
2017-04-11_03-31-59 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-11 03:34:01  - 14968  http://www.lymphomahub.com/about
2017-04-11 03:34:02  - 14968  http://www.lymphomahub.com/about
2017-04-11 03:34:05  - 14968  http://www.lymphomahub.com/terms
2017-04-11 03:34:07  - 14968  http://www.lymphomahub.com/terms
2017-04-11 03:34:09  - 14968  http://www.lymphomahub.com/undefined
2017-04-11 03:34:09  - 14968  http://www.lymphomahub.com/therapies
2017-04-11 03:34:10  - 14968  http://www.lymphomahub.com/therapies
2017-04-11 03:34:19  - 14968  http://www.lymphomahub.com/newsletter
2017-04-11 03:34:21  - 14968  http://www.lymphomahub.com/newsletter
2017-04-11 03:34:23  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-11 03:34:24  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-11 03:34:26  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-11 03:34:27  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-11 03:34:31  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-11 03:34:32  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-11 03:34:35  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-11 03:34:36  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-11 03:34:40  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-11 03:34:41  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-11 03:34:45  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-11 03:34:46  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-11 03:34:50  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-11 03:34:51  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-11 03:34:55  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-11 03:34:56  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-11 03:35:00  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-11 03:35:01  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-11 03:35:05  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-11 03:35:05  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-11 03:35:11  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-11 03:35:11  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-11 03:35:16  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-11 03:35:21  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-11 03:35:25  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-11 03:35:29  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-11 03:35:33  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-11 03:35:38  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-11 03:35:42  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-11 03:35:46  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-11 03:35:51  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-11 03:35:55  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-11 03:35:59  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-11 03:36:04  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-11 03:36:07  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-11 03:36:11  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-11 03:36:16  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-11 03:36:20  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-11 03:36:24  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-11 03:36:29  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-11 03:36:33  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-11 03:36:37  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-11 03:36:42  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-11 03:36:46  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-11 03:36:50  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-11 03:36:54  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-11 03:36:58  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-11 03:37:03  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-11 03:37:07  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-11 03:37:11  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-11 03:37:16  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-11 03:37:20  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-11 03:37:24  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-11 03:37:29  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-11 03:37:33  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-11 03:37:37  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-11 03:37:41  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-11 03:37:46  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-11 03:37:50  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-11 03:37:54  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-11 03:37:59  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-11 03:38:03  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-11 03:38:07  - 14968  http://www.lymphomahub.com/medical-information
2017-04-11 03:38:12  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-11 03:38:16  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-11 03:38:20  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-11 03:38:25  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-11 03:38:29  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-11 03:38:33  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-11 03:38:37  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-11 03:38:42  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-11 03:38:46  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-11 03:38:50  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-11 03:38:54  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-11 03:38:59  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-11 03:38:59  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-11 03:39:04  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-11 03:39:08  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-11 03:39:12  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-11 03:39:16  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-11 03:39:20  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-11 03:39:25  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-11 03:39:29  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-11 03:39:33  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-11 03:39:38  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-11 03:39:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-11 03:39:46  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-11 03:39:50  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-11 03:39:55  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-11 03:39:59  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-11 03:40:03  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-11 03:40:07  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-11 03:40:12  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-11 03:40:16  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-11 03:40:20  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-11 03:40:24  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-11 03:40:29  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-11 03:40:33  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-11 03:40:37  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-11 03:40:41  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-11 03:40:46  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-11 03:40:50  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-11 03:40:54  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-11 03:40:59  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-11 03:41:03  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-11 03:41:07  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-11 03:41:08  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-11 03:41:12  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-11 03:41:16  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-11 03:41:21  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-11 03:41:25  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-11 03:41:29  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-11 03:41:33  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-11 03:41:38  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-11 03:41:42  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-11 03:41:46  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-11 03:41:46  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-11 03:41:50  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-11 03:41:55  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-11 03:41:59  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-11 03:42:03  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-11 03:42:07  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-11 03:42:08  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-11 03:42:12  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-11 03:42:17  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-11 03:42:20  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-11 03:42:24  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-11 03:42:29  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-11 03:42:32  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-11 03:42:36  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-11 03:42:40  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-11 03:42:44  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-11 03:42:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-11 03:42:52  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-11 03:42:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-11 03:43:01  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-11 03:43:04  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-11 03:43:05  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-11 03:43:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-11 03:43:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-11 03:43:17  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-11 03:43:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-11 03:43:26  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-11 03:43:30  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-11 03:43:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-11 03:43:38  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-11 03:43:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-11 03:43:45  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-11 03:43:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-11 03:43:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-11 03:43:57  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-11 03:44:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-11 03:44:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-11 03:44:09  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-11 03:44:14  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-11 03:44:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-11 03:44:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-11 03:44:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-11 03:44:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-11 03:44:34  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-11 03:44:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-11 03:44:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-11 03:44:47  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-11 03:44:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-11 03:44:56  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-11 03:45:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-11 03:45:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-11 03:45:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-11 03:45:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-11 03:45:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/33/10/keyword/
2017-04-11 03:45:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-11 03:45:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-11 03:45:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-11 03:45:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-11 03:45:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-11 03:45:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-11 03:45:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-11 03:45:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-11 03:45:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-11 03:46:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-11 03:46:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-11 03:46:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-11 03:46:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-11 03:46:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-11 03:46:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-11 03:46:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-11 03:46:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-11 03:46:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-11 03:46:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-11 03:46:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-11 03:46:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-11 03:46:52  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-11 03:46:56  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-11 03:47:01  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-11 03:47:06  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-11 03:47:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-11 03:47:14  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-11 03:47:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-11 03:47:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-11 03:47:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-11 03:47:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-11 03:47:34  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-11 03:47:38  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-11 03:47:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-11 03:47:46  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-11 03:47:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-11 03:47:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-11 03:47:59  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-11 03:48:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-11 03:48:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-11 03:48:12  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-11 03:48:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-11 03:48:21  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-11 03:48:21  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-11 03:48:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-11 03:48:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-11 03:48:34  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-11 03:48:39  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-11 03:48:43  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-11 03:48:48  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-11 03:48:52  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-11 03:48:56  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-11 03:49:01  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-11 03:49:05  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-11 03:49:09  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-11 03:49:14  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-11 03:49:18  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-11 03:49:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-11 03:49:27  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-11 03:49:32  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-11 03:49:36  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-11 03:49:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-11 03:49:45  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-11 03:49:50  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-11 03:49:54  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-11 03:49:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-11 03:50:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-11 03:50:08  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-11 03:50:12  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-11 03:50:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-11 03:50:21  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-11 03:50:26  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-11 03:50:30  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-11 03:50:34  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-11 03:50:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-11 03:50:43  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-11 03:50:47  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-11 03:50:52  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-11 03:50:56  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-11 03:51:01  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-11 03:51:05  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-11 03:51:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-11 03:51:14  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-11 03:51:18  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-11 03:51:23  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-11 03:51:23  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-11 03:51:28  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-11 03:51:32  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-11 03:51:36  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-11 03:51:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-11 03:51:45  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-11 03:51:50  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-11 03:51:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-11 03:51:59  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-11 03:52:03  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-11 03:52:07  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-11 03:52:12  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-11 03:52:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-11 03:52:21  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-11 03:52:25  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-11 03:52:30  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-11 03:52:34  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-11 03:52:39  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-11 03:52:43  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-11 03:52:48  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-11 03:52:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-11 03:52:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-11 03:53:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-11 03:53:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-11 03:53:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-11 03:53:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-11 03:53:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-11 03:53:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-11 03:53:25  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-11 03:53:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-11 03:53:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-11 03:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-11 03:53:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-11 03:53:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-11 03:53:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-11 03:53:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-11 03:53:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-11 03:53:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-11 03:54:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-11 03:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-11 03:54:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-11 03:54:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-11 03:54:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-11 03:54:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-11 03:54:22  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-11 03:54:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-11 03:54:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-11 03:54:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-11 03:54:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-11 03:54:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-11 03:54:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-11 03:54:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-11 03:54:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-11 03:54:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-11 03:54:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-11 03:55:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-11 03:55:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-11 03:55:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-11 03:55:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-11 03:55:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-11 03:55:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-11 03:55:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-11 03:55:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-11 03:55:32  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-11 03:55:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-11 03:55:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-11 03:55:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-11 03:55:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-11 03:55:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-11 03:55:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-11 03:55:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-11 03:56:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-11 03:56:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-11 03:56:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-11 03:56:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-11 03:56:16  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-11 03:56:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-11 03:56:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-11 03:56:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-11 03:56:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-11 03:56:36  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-11 03:56:40  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-11 03:56:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-11 03:56:49  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-11 03:56:50  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-11 03:56:54  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-11 03:56:59  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-11 03:57:03  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-11 03:57:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-11 03:57:13  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-11 03:57:17  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-11 03:57:22  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-11 03:57:26  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-11 03:57:30  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-11 03:57:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-11 03:57:40  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-11 03:57:44  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-11 03:57:49  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-11 03:57:53  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-11 03:57:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-11 03:58:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-11 03:58:06  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-11 03:58:10  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-11 03:58:15  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-11 03:58:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-11 03:58:24  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-11 03:58:28  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-11 03:58:32  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-11 03:58:37  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-11 03:58:41  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-11 03:58:46  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-11 03:58:50  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-11 03:58:54  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-11 03:58:59  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-11 03:59:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-11 03:59:07  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-11 03:59:12  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-11 03:59:16  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-11 03:59:20  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-11 03:59:25  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-11 03:59:29  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-11 03:59:34  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-11 03:59:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-11 03:59:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-11 03:59:47  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-11 03:59:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-11 03:59:56  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-11 04:00:00  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-11 04:00:05  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-11 04:00:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-11 04:00:17  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-11 04:00:21  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-11 04:00:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-11 04:00:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-11 04:00:35  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-11 04:00:39  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-11 04:00:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-11 04:00:48  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-11 04:00:52  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-11 04:00:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-11 04:01:01  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-11 04:01:05  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-11 04:01:10  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-11 04:01:14  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-11 04:01:19  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-11 04:01:23  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-11 04:01:27  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-11 04:01:32  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-11 04:01:36  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-11 04:01:41  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-11 04:01:45  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-11 04:01:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-11 04:01:54  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-11 04:01:59  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-11_04-01-59 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos?_prerender {"code":"ECONNRESET"}
2017-04-11 04:04:04  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-11 04:04:08  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-11 04:04:13  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-11 04:04:17  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-11 04:04:22  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-11 04:04:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-11 04:04:31  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-11 04:04:36  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-11 04:04:40  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-11 04:04:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-11 04:04:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-11 04:04:54  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-11 04:04:58  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-11 04:05:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-11 04:05:07  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-11 04:05:12  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-11 04:05:16  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-11 04:05:21  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-11 04:05:25  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-11 04:05:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-11 04:05:33  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-11 04:05:38  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-11 04:05:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-11 04:05:47  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-11 04:05:51  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-11 04:05:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-11 04:06:00  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-11 04:06:04  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-11 04:06:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-11 04:06:14  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-11 04:06:18  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-11 04:06:23  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-11 04:06:27  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-11 04:06:32  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-11 04:06:36  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-11 04:06:41  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-11 04:06:45  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-11 04:06:49  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-11 04:06:54  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-11 04:06:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-11 04:07:03  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-11 04:07:07  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-11 04:07:11  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-11 04:07:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-11 04:07:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-11 04:07:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-11 04:07:30  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-11 04:07:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-11 04:07:39  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-11 04:07:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-11 04:07:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-11 04:07:52  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-11 04:07:57  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-11 04:08:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-11 04:08:05  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-11 04:08:10  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-11 04:08:14  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-11 04:08:18  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-11 04:08:22  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-11 04:08:27  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-11 04:08:31  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-11 04:08:35  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-11 04:08:40  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-11 04:08:45  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-11 04:08:49  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-11 04:08:53  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-11 04:08:58  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-11 04:09:02  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-11 04:09:06  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-11 04:09:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-11 04:09:15  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-primary-results-from-the-pivotal-zuma-1-trial-of-kte-c19-in-refractory-aggressive-non-hodgkin-lymphoma-patients
2017-04-11 04:09:20  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-11 04:09:25  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-11 04:09:29  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-11 04:09:33  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-11 04:09:38  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-11 04:09:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-11 04:09:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-11 04:09:51  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-216112-pharmacological-downregulation-of-bfl-1-by-cpi203-overcomes-abt-199-resistance-in-double-hit-lymphoma
2017-04-11 04:09:55  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-11 04:10:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-11 04:10:04  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-11 04:10:09  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-11 04:10:13  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-11 04:10:18  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-11 04:10:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-11 04:10:27  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-11 04:10:31  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-11 04:10:35  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-11 04:10:40  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-11 04:10:44  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-11 04:10:48  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-37249-pd-l1-protein-expression-and-tumor-mutation-burden-correlates-with-hodgkin-and-diffuse-large-b-cell-lymphoma
2017-04-11 04:10:52  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-11 04:10:58  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-11 04:11:03  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-11 04:11:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-11 04:11:11  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-11 04:11:15  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-11 04:11:20  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-11 04:11:24  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-11 04:11:29  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-313221-inhibition-of-the-integrin-v3-improves-the-effect-of-bexarotene-in-the-treatment-of-cutaneous-t-cell-lymphoma
2017-04-11 04:11:33  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-11 04:11:38  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-11 04:11:42  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-11 04:11:46  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-11 04:11:51  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-365124-preclinical-examination-of-the-effects-of-a-cd20-specific-engineered-toxin-body-mt-3724-in-mantle-cell-lymphoma
2017-04-11 04:11:55  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-36314-delivery-of-a-cd20-transferrin-receptor-vnar-bispecific-antibody-to-the-brain-for-central-nervous-system-lymphoma
2017-04-11 04:12:00  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-11 04:12:04  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-11 04:12:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-11 04:12:13  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-11 04:12:17  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-11 04:12:21  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-11 04:12:26  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-11 04:12:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-11 04:12:35  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-11 04:12:39  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-11 04:12:44  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-11 04:12:48  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-11 04:12:52  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-11 04:12:57  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-39396-two-evolutionary-models-proposed-for-development-of-drug-resistance-between-primary-and-relapsed-diffuse-large-b-cell-lymphoma
2017-04-11 04:13:01  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-11 04:13:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-11 04:13:10  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-11 04:13:14  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-11 04:13:18  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-11 04:13:22  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-11 04:13:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-11 04:13:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-11 04:13:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-11 04:13:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-11 04:13:44  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-11 04:13:48  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-11 04:13:53  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-11 04:13:57  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-11 04:14:01  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-11 04:14:05  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-11 04:14:10  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-11 04:14:14  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-11 04:14:18  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-11 04:14:22  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-11 04:14:27  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-11 04:14:31  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-11 04:14:36  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-11 04:14:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-11 04:14:45  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-11 04:14:49  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-11 04:14:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-11 04:14:58  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-11 04:14:58  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-11 04:15:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-11 04:15:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-11 04:15:12  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-11 04:15:16  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-11 04:15:21  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-11 04:15:25  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-11 04:15:30  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-11 04:15:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-11 04:15:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-11 04:15:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-11 04:15:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-11 04:15:51  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-11 04:15:55  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-11 04:15:59  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-11 04:16:04  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-11 04:16:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-11 04:16:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-11 04:16:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-11 04:16:21  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-11 04:16:26  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-11 04:16:30  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-11 04:16:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-11 04:16:39  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-11 04:16:43  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-11 04:16:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-11 04:16:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-11 04:16:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-11 04:17:00  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-11 04:17:04  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-11 04:17:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-11 04:17:12  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-11 04:17:16  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-11 04:17:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-11 04:17:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-11 04:17:29  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-11 04:17:33  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-11 04:17:37  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-11 04:17:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-11 04:17:45  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-11 04:17:49  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-11 04:17:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-11 04:17:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-11 04:18:01  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-11 04:18:05  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-11 04:18:09  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-11 04:18:13  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-11 04:18:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-11 04:18:22  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-11 04:18:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-11 04:18:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-11 04:18:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-11 04:18:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-11 04:18:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-11 04:18:48  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-11 04:18:52  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-11 04:18:56  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-11 04:19:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-11 04:19:04  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-11 04:19:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-11 04:19:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-11 04:19:17  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-11 04:19:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 04:19:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 04:19:29  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 04:19:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 04:19:37  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-11 04:19:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 04:19:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 04:19:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-11 04:19:53  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-11 04:19:57  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-11 04:20:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-11 04:20:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-11 04:20:10  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-11 04:20:14  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-11 04:20:18  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-11 04:20:22  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-11 04:20:26  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-11 04:20:30  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-11 04:20:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-11 04:20:38  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-11 04:20:42  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-11 04:20:46  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-11 04:20:50  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-11 04:20:54  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-11 04:20:58  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-11 04:21:02  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-11 04:21:06  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-11 04:21:10  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-11 04:21:14  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-11 04:21:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-11 04:21:23  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-11 04:21:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-11 04:21:31  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-11 04:21:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 04:21:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 04:21:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 04:21:46  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 04:21:51  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-11 04:21:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 04:21:59  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 04:22:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 04:22:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-11 04:22:11  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-11_04-31-59 Restart Xvfb...
2017-04-11_05-01-59 Restart Xvfb...
2017-04-11_05-31-59 Restart Xvfb...
2017-04-11_06-01-59 Restart Xvfb...
2017-04-11 06:31:46 reset updateRequest
2017-04-11 06:31:50  - 14968  http://www.lymphomahub.com/
2017-04-11 06:31:51  - 14968  http://www.lymphomahub.com/
2017-04-11 06:31:56  - 14968  http://www.lymphomahub.com/about
2017-04-11 06:31:57  - 14968  http://www.lymphomahub.com/about
2017-04-11_06-31-59 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/about?_prerender {"code":"ECONNRESET"}
2017-04-11 06:34:01  - 14968  http://www.lymphomahub.com/about
2017-04-11 06:34:02  - 14968  http://www.lymphomahub.com/about
2017-04-11 06:34:06  - 14968  http://www.lymphomahub.com/terms
2017-04-11 06:34:08  - 14968  http://www.lymphomahub.com/terms
2017-04-11 06:34:10  - 14968  http://www.lymphomahub.com/undefined
2017-04-11 06:34:11  - 14968  http://www.lymphomahub.com/therapies
2017-04-11 06:34:11  - 14968  http://www.lymphomahub.com/therapies
2017-04-11 06:34:21  - 14968  http://www.lymphomahub.com/newsletter
2017-04-11 06:34:23  - 14968  http://www.lymphomahub.com/newsletter
2017-04-11 06:34:26  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-11 06:34:27  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-11 06:34:30  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-11 06:34:31  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-11 06:34:35  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-11 06:34:36  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-11 06:34:40  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-11 06:34:41  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-11 06:34:46  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-11 06:34:50  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-11 06:34:54  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-11 06:34:59  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-11 06:35:03  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-11 06:35:08  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-11 06:35:12  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-11 06:35:17  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-11 06:35:21  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-11 06:35:26  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-11 06:35:30  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-11 06:35:34  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-11 06:35:39  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-11 06:35:43  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-11 06:35:47  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-11 06:35:52  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-11 06:35:56  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-11 06:36:00  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-11 06:36:05  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-11 06:36:09  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-11 06:36:13  - 14968  http://www.lymphomahub.com/therapies/regn1979
2017-04-11 06:36:17  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-11 06:36:21  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-11 06:36:25  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-11 06:36:30  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-11 06:36:34  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-11 06:36:38  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-11 06:36:43  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-11 06:36:47  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-11 06:36:51  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-11 06:36:55  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-11 06:37:00  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-11 06:37:04  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-11 06:37:08  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-11 06:37:13  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-11 06:37:17  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-11 06:37:21  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-11 06:37:26  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-11 06:37:30  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-11 06:37:34  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-11 06:37:38  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-11 06:37:43  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-11 06:37:47  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-11 06:37:51  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-11 06:37:55  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-11 06:38:00  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-11 06:38:04  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-11 06:38:08  - 14968  http://www.lymphomahub.com/medical-information
2017-04-11 06:38:12  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-11 06:38:16  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-11 06:38:21  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-11 06:38:25  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-11 06:38:29  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-11 06:38:33  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-11 06:38:38  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-11 06:38:42  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-11 06:38:46  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-11 06:38:51  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-11 06:38:55  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-11 06:38:59  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-11 06:39:00  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-11 06:39:04  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-11 06:39:08  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-11 06:39:13  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-11 06:39:17  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-11 06:39:21  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-11 06:39:25  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-11 06:39:29  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-11 06:39:34  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-11 06:39:38  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-11 06:39:42  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-11 06:39:47  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-11 06:39:51  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-11 06:39:55  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-11 06:40:00  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-11 06:40:04  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-11 06:40:08  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-11 06:40:13  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-11 06:40:17  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-11 06:40:21  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-11 06:40:25  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-11 06:40:29  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-11 06:40:34  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-11 06:40:38  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-11 06:40:43  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-11 06:40:47  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-11 06:40:51  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-11 06:40:55  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-11 06:41:00  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-11 06:41:04  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-11 06:41:08  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-11 06:41:08  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-11 06:41:13  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-11 06:41:17  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-11 06:41:21  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-11 06:41:25  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-11 06:41:30  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-11 06:41:34  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-11 06:41:38  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-11 06:41:42  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-11 06:41:46  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-11 06:41:46  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-11 06:41:51  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-11 06:41:55  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-11 06:41:59  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-11 06:42:03  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-11 06:42:08  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-11 06:42:08  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-11 06:42:13  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-11 06:42:17  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-11 06:42:21  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-11 06:42:25  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-11 06:42:29  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-11 06:42:33  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-11 06:42:37  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-11 06:42:41  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-11 06:42:44  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-11 06:42:49  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-11 06:42:53  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-11 06:42:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-11 06:43:02  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-11 06:43:05  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-11 06:43:06  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-11 06:43:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-11 06:43:14  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-11 06:43:19  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-11 06:43:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-11 06:43:27  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-11 06:43:31  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-11 06:43:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-11 06:43:39  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-11 06:43:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-11 06:43:46  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-11 06:43:50  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-11 06:43:53  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-11 06:43:57  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-11 06:44:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-11 06:44:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-11 06:44:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-11 06:44:14  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-11 06:44:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-11 06:44:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-11 06:44:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-11 06:44:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-11 06:44:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-11 06:44:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-11 06:44:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-11 06:44:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-11 06:44:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-11 06:44:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-11 06:45:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-11 06:45:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-11 06:45:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-11 06:45:14  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-11 06:45:19  - 14968  http://www.lymphomahub.com/medical-information/categories//page/33/10/keyword/
2017-04-11 06:45:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-11 06:45:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-11 06:45:31  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-11 06:45:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-11 06:45:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-11 06:45:44  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-11 06:45:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-11 06:45:53  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-11 06:45:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-11 06:46:02  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-11 06:46:06  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-11 06:46:10  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-11 06:46:15  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-11 06:46:18  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-11 06:46:23  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-11 06:46:27  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-11 06:46:32  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-11 06:46:35  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-11 06:46:40  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-11 06:46:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-11 06:46:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-11 06:46:52  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-11 06:46:56  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-11 06:47:00  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-11 06:47:05  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-11 06:47:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-11 06:47:13  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-11 06:47:18  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-11 06:47:21  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-11 06:47:26  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-11 06:47:30  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-11 06:47:33  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-11 06:47:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-11 06:47:42  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-11 06:47:45  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-11 06:47:50  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-11 06:47:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-11 06:47:58  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-11 06:48:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-11 06:48:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-11 06:48:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-11 06:48:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-11 06:48:20  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-11 06:48:21  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-11 06:48:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-11 06:48:30  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-11 06:48:34  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-11 06:48:39  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-11 06:48:43  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-11 06:48:48  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-11 06:48:52  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-11 06:48:57  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-11 06:49:01  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-11 06:49:06  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-11 06:49:10  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-11 06:49:14  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-11 06:49:19  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-11 06:49:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-11 06:49:28  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-11 06:49:32  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-11 06:49:37  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-11 06:49:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-11 06:49:46  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-11 06:49:51  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-11 06:49:55  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-11 06:50:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-11 06:50:04  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-11 06:50:09  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-11 06:50:13  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-11 06:50:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-11 06:50:22  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-11 06:50:27  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-11 06:50:31  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-11 06:50:36  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-11 06:50:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-11 06:50:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-11 06:50:49  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-11 06:50:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-11 06:50:58  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-11 06:51:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-11 06:51:06  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-11 06:51:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-11 06:51:15  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-11 06:51:20  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-11 06:51:24  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-11 06:51:25  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-11 06:51:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-11 06:51:33  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-11 06:51:38  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-11 06:51:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-11 06:51:47  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-11 06:51:51  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-11 06:51:55  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-11 06:52:00  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-11 06:52:04  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-11 06:52:08  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-11 06:52:13  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-11 06:52:18  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-11 06:52:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-11 06:52:27  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-11 06:52:31  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-11 06:52:36  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-11 06:52:40  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-11 06:52:45  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-11 06:52:50  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-11 06:52:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-11 06:52:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-11 06:53:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-11 06:53:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-11 06:53:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-11 06:53:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-11 06:53:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-11 06:53:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-11 06:53:27  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-11 06:53:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-11 06:53:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-11 06:53:36  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-11 06:53:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-11 06:53:43  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-11 06:53:47  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-11 06:53:50  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-11 06:53:54  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-11 06:53:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-11 06:54:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-11 06:54:05  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-11 06:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-11 06:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-11 06:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-11 06:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-11 06:54:23  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-11 06:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-11 06:54:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-11 06:54:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-11 06:54:39  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-11 06:54:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-11 06:54:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-11 06:54:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-11 06:54:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-11 06:54:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-11 06:55:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-11 06:55:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-11 06:55:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-11 06:55:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-11 06:55:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-11 06:55:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-11 06:55:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-11 06:55:26  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-11 06:55:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-11 06:55:33  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-11 06:55:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-11 06:55:40  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-11 06:55:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-11 06:55:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-11 06:55:51  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-11 06:55:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-11 06:55:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-11 06:56:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-11 06:56:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-11 06:56:09  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-11 06:56:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-11 06:56:17  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-11 06:56:21  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-11 06:56:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-11 06:56:29  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-11 06:56:32  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-11 06:56:37  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-11 06:56:42  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-11 06:56:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-11 06:56:51  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-11 06:56:51  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-11 06:56:56  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-11 06:57:00  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-11 06:57:05  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-11 06:57:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-11 06:57:13  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-11 06:57:18  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-11 06:57:22  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-11 06:57:27  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-11 06:57:31  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-11 06:57:35  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-11 06:57:40  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-11 06:57:45  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-11 06:57:49  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-11 06:57:53  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-11 06:57:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-11 06:58:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-11 06:58:07  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-11 06:58:11  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-11 06:58:15  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-11 06:58:20  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-11 06:58:24  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-11 06:58:28  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-11 06:58:33  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-11 06:58:37  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-11 06:58:41  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-11 06:58:46  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-11 06:58:50  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-11 06:58:55  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-11 06:58:59  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-11 06:59:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-11 06:59:08  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-11 06:59:12  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-11 06:59:16  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-11 06:59:21  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-11 06:59:25  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-11 06:59:29  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-11 06:59:34  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-11 06:59:38  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-11 06:59:43  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-11 06:59:47  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-11 06:59:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-11 06:59:56  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-11 07:00:00  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-11 07:00:05  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-11 07:00:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-11 07:00:14  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-11 07:00:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-11 07:00:22  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-11 07:00:26  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-11 07:00:31  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-11 07:00:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-11 07:00:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-11 07:00:44  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-11 07:00:49  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-11 07:00:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-11 07:00:57  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-11 07:01:02  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-11 07:01:06  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-11 07:01:11  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-11 07:01:15  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-11 07:01:19  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-11 07:01:24  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-11 07:01:28  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-11 07:01:33  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-11 07:01:37  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-11 07:01:42  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-11 07:01:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-11 07:01:51  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-11 07:01:55  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-11 07:01:59  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-11_07-02-00 Restart Xvfb...
2017-04-11 07:02:04  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-11 07:02:08  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-11 07:02:13  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-11 07:02:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl?_prerender {"code":"ECONNRESET"}
2017-04-11 07:04:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-11 07:04:27  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-11 07:04:31  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-11 07:04:36  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-11 07:04:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-11 07:04:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-11 07:04:49  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-11 07:04:53  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-11 07:04:57  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-11 07:05:02  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-11 07:05:06  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-11 07:05:11  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-11 07:05:15  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-11 07:05:20  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-11 07:05:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-11 07:05:29  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-11 07:05:33  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-11 07:05:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-11 07:05:42  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-11 07:05:46  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-11 07:05:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-11 07:05:55  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-11 07:06:00  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-11 07:06:05  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-11 07:06:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-11 07:06:14  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-11 07:06:18  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-11 07:06:23  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-11 07:06:27  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-11 07:06:32  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-11 07:06:36  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-11 07:06:40  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-11 07:06:45  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-11 07:06:50  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-11 07:06:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-11 07:06:58  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-11 07:07:02  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-11 07:07:08  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-11 07:07:13  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-11 07:07:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-11 07:07:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-11 07:07:26  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-11 07:07:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-11 07:07:35  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-11 07:07:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-11 07:07:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-11 07:07:50  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-11 07:07:54  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-11 07:07:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-11 07:08:03  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-11 07:08:07  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-11 07:08:12  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-11 07:08:16  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-11 07:08:20  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-11 07:08:25  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-11 07:08:29  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-11 07:08:33  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-11 07:08:38  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-11 07:08:42  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-11 07:08:46  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-11 07:08:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-11 07:08:55  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-11 07:08:59  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-11 07:09:04  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-11 07:09:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-11 07:09:13  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-primary-results-from-the-pivotal-zuma-1-trial-of-kte-c19-in-refractory-aggressive-non-hodgkin-lymphoma-patients
2017-04-11 07:09:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-11 07:09:22  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-11 07:09:27  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-11 07:09:31  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-11 07:09:36  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-11 07:09:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-11 07:09:45  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-11 07:09:49  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-216112-pharmacological-downregulation-of-bfl-1-by-cpi203-overcomes-abt-199-resistance-in-double-hit-lymphoma
2017-04-11 07:09:53  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-11 07:09:58  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-11 07:10:02  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-11 07:10:07  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-11 07:10:11  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-11 07:10:16  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-11 07:10:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-11 07:10:24  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-11 07:10:29  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-11 07:10:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-11 07:10:37  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-11 07:10:42  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-11 07:10:46  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-37249-pd-l1-protein-expression-and-tumor-mutation-burden-correlates-with-hodgkin-and-diffuse-large-b-cell-lymphoma
2017-04-11 07:10:50  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-11 07:10:55  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-11 07:10:59  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-11 07:11:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-11 07:11:08  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-11 07:11:12  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-11 07:11:17  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-11 07:11:21  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-11 07:11:26  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-313221-inhibition-of-the-integrin-v3-improves-the-effect-of-bexarotene-in-the-treatment-of-cutaneous-t-cell-lymphoma
2017-04-11 07:11:30  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-11 07:11:34  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-11 07:11:39  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-11 07:11:44  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-11 07:11:48  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-365124-preclinical-examination-of-the-effects-of-a-cd20-specific-engineered-toxin-body-mt-3724-in-mantle-cell-lymphoma
2017-04-11 07:11:52  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-36314-delivery-of-a-cd20-transferrin-receptor-vnar-bispecific-antibody-to-the-brain-for-central-nervous-system-lymphoma
2017-04-11 07:11:57  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-11 07:12:01  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-11 07:12:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-11 07:12:09  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-11 07:12:13  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-11 07:12:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-11 07:12:22  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-11 07:12:26  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-11 07:12:31  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-11 07:12:35  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-11 07:12:40  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-11 07:12:44  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-11 07:12:48  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-11 07:12:52  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-39396-two-evolutionary-models-proposed-for-development-of-drug-resistance-between-primary-and-relapsed-diffuse-large-b-cell-lymphoma
2017-04-11 07:12:57  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-11 07:13:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-11 07:13:06  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-11 07:13:10  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-11 07:13:14  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-11 07:13:18  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-11 07:13:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-11 07:13:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-11 07:13:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-11 07:13:35  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-11 07:13:39  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-11 07:13:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-11 07:13:48  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-11 07:13:52  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-11 07:13:56  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-11 07:14:01  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-11 07:14:05  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-11 07:14:09  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-11 07:14:14  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-11 07:14:18  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-11 07:14:22  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-11 07:14:26  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-11 07:14:31  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-11 07:14:36  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-11 07:14:40  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-11 07:14:44  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-11 07:14:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-11 07:14:54  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-11 07:14:54  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-11 07:14:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-11 07:15:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-11 07:15:08  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-11 07:15:11  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-11 07:15:16  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-11 07:15:20  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-11 07:15:25  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-11 07:15:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-11 07:15:33  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-11 07:15:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-11 07:15:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-11 07:15:46  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-11 07:15:50  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-11 07:15:54  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-11 07:15:59  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-11 07:16:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-11 07:16:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-11 07:16:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-11 07:16:16  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-11 07:16:20  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-11 07:16:25  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-11 07:16:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-11 07:16:34  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-11 07:16:37  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-11 07:16:42  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-11 07:16:46  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-11 07:16:50  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-11 07:16:55  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-11 07:16:59  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-11 07:17:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-11 07:17:07  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-11 07:17:10  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-11 07:17:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-11 07:17:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-11 07:17:23  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-11 07:17:27  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-11 07:17:31  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-11 07:17:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-11 07:17:39  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-11 07:17:43  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-11 07:17:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-11 07:17:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-11 07:17:56  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-11 07:18:00  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-11 07:18:04  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-11 07:18:08  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-11 07:18:12  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-11 07:18:16  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-11 07:18:20  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-11 07:18:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-11 07:18:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-11 07:18:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-11 07:18:38  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-11 07:18:42  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-11 07:18:46  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-11 07:18:50  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-11 07:18:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-11 07:18:59  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-11 07:19:03  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-11 07:19:07  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-11 07:19:11  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-11 07:19:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 07:19:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 07:19:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 07:19:27  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 07:19:31  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-11 07:19:35  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 07:19:39  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 07:19:43  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-11 07:19:47  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-11 07:19:51  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-11 07:19:55  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-11 07:19:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-11 07:20:03  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-11 07:20:07  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-11 07:20:11  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-11 07:20:15  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-11 07:20:19  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-11 07:20:23  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-11 07:20:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-11 07:20:31  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-11 07:20:35  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-11 07:20:39  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-11 07:20:43  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-11 07:20:47  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-11 07:20:51  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-11 07:20:55  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-11 07:20:59  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-11 07:21:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-11 07:21:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-11 07:21:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-11 07:21:15  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-11 07:21:19  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-11 07:21:23  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-11 07:21:27  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 07:21:31  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 07:21:35  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 07:21:39  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 07:21:43  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-11 07:21:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 07:21:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 07:21:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 07:22:00  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-11 07:22:04  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-11_07-32-00 Restart Xvfb...
2017-04-11_08-02-00 Restart Xvfb...
2017-04-11_08-32-00 Restart Xvfb...
2017-04-11_09-02-00 Restart Xvfb...
2017-04-11 09:31:46 reset updateRequest
2017-04-11 09:31:48  - 14968  http://www.lymphomahub.com/
2017-04-11 09:31:51  - 14968  http://www.lymphomahub.com/
2017-04-11 09:31:52  - 14968  http://www.lymphomahub.com/about
2017-04-11 09:31:55  - 14968  http://www.lymphomahub.com/about
2017-04-11 09:31:59  - 14968  http://www.lymphomahub.com/terms
2017-04-11_09-32-00 Restart Xvfb...
2017-04-11 09:32:00  - 14968  http://www.lymphomahub.com/terms
2017-04-11 09:32:03  - 14968  http://www.lymphomahub.com/undefined
2017-04-11 09:32:04  - 14968  http://www.lymphomahub.com/therapies
2017-04-11 09:32:10  - 14968  http://www.lymphomahub.com/newsletter
2017-04-11 09:32:13  - 14968  http://www.lymphomahub.com/cookie-policy
2017-04-11 09:32:16  - 14968  http://www.lymphomahub.com/therapies/afm13
2017-04-11 09:32:21  - 14968  http://www.lymphomahub.com/therapies/afm11
2017-04-11 09:32:25  - 14968  http://www.lymphomahub.com/therapies/ags67e
2017-04-11 09:32:29  - 14968  http://www.lymphomahub.com/therapies/cc-292
2017-04-11 09:32:33  - 14968  http://www.lymphomahub.com/therapies/cc-223
2017-04-11 09:32:38  - 14968  http://www.lymphomahub.com/therapies/onc201
2017-04-11 09:32:42  - 14968  http://www.lymphomahub.com/therapies/sd-101
2017-04-11 09:32:47  - 14968  http://www.lymphomahub.com/therapies/rp6530
2017-04-11 09:32:51  - 14968  http://www.lymphomahub.com/therapies/abt199
2017-04-11 09:32:55  - 14968  http://www.lymphomahub.com/therapies/mor208
2017-04-11 09:33:00  - 14968  http://www.lymphomahub.com/therapies/cc-122
2017-04-11 09:33:04  - 14968  http://www.lymphomahub.com/therapies/at-101
2017-04-11 09:33:10  - 14968  http://www.lymphomahub.com/therapies/bl8040
2017-04-11 09:33:15  - 14968  http://www.lymphomahub.com/therapies/bcl201
2017-04-11 09:33:20  - 14968  http://www.lymphomahub.com/therapies/azd3965
2017-04-11 09:33:24  - 14968  http://www.lymphomahub.com/therapies/imgn529
2017-04-11 09:33:29  - 14968  http://www.lymphomahub.com/therapies/azd2014
2017-04-11 09:33:33  - 14968  http://www.lymphomahub.com/therapies/mt-3724
2017-04-11 09:33:38  - 14968  http://www.lymphomahub.com/therapies/actr087
2017-04-11 09:33:42  - 14968  http://www.lymphomahub.com/therapies/epz6438
2017-04-11 09:33:46  - 14968  http://www.lymphomahub.com/therapies/kte-c19
2017-04-11 09:33:51  - 14968  http://www.lymphomahub.com/about/secretariat
2017-04-11 09:33:55  - 14968  http://www.lymphomahub.com/therapies/alt-803
2017-04-11 09:33:59  - 14968  http://www.lymphomahub.com/therapies/regn1979
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/terms?_prerender {"code":"ECONNRESET"}
2017-04-11 09:34:03  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-11 09:34:04  - 14968  http://www.lymphomahub.com/therapies/immu-114
2017-04-11 09:34:08  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-11 09:34:09  - 14968  http://www.lymphomahub.com/therapies/incb7839
2017-04-11 09:34:13  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-11 09:34:14  - 14968  http://www.lymphomahub.com/therapies/adct-301
2017-04-11 09:34:19  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-11 09:34:19  - 14968  http://www.lymphomahub.com/therapies/ixazomib
2017-04-11 09:34:25  - 14968  http://www.lymphomahub.com/therapies/avelumab
2017-04-11 09:34:29  - 14968  http://www.lymphomahub.com/therapies/bi836826
2017-04-11 09:34:34  - 14968  http://www.lymphomahub.com/therapies/medi-570
2017-04-11 09:34:38  - 14968  http://www.lymphomahub.com/therapies/ds-3201b
2017-04-11 09:34:42  - 14968  http://www.lymphomahub.com/therapies/sea-cd40
2017-04-11 09:34:47  - 14968  http://www.lymphomahub.com/therapies/adct-402
2017-04-11 09:34:51  - 14968  http://www.lymphomahub.com/therapies/acy-1215
2017-04-11 09:34:56  - 14968  http://www.lymphomahub.com/therapies/cudc-907
2017-04-11 09:35:00  - 14968  http://www.lymphomahub.com/therapies/tgr-1202
2017-04-11 09:35:04  - 14968  http://www.lymphomahub.com/therapies/axitinib
2017-04-11 09:35:09  - 14968  http://www.lymphomahub.com/therapies/imatinib
2017-04-11 09:35:13  - 14968  http://www.lymphomahub.com/therapies/edo-s101
2017-04-11 09:35:17  - 14968  http://www.lymphomahub.com/therapies/btct4465a
2017-04-11 09:35:22  - 14968  http://www.lymphomahub.com/therapies/alisertib
2017-04-11 09:35:26  - 14968  http://www.lymphomahub.com/therapies/lirilumab
2017-04-11 09:35:30  - 14968  http://www.lymphomahub.com/therapies/ibrutinib
2017-04-11 09:35:35  - 14968  http://www.lymphomahub.com/therapies/sgn-cd70a
2017-04-11 09:35:39  - 14968  http://www.lymphomahub.com/therapies/rituximab
2017-04-11 09:35:43  - 14968  http://www.lymphomahub.com/therapies/veliparib
2017-04-11 09:35:48  - 14968  http://www.lymphomahub.com/therapies/sunitinib
2017-04-11 09:35:52  - 14968  http://www.lymphomahub.com/therapies/nivolumab
2017-04-11 09:35:56  - 14968  http://www.lymphomahub.com/therapies/sirolimus
2017-04-11 09:36:01  - 14968  http://www.lymphomahub.com/medical-information
2017-04-11 09:36:05  - 14968  http://www.lymphomahub.com/therapies/selinexor
2017-04-11 09:36:09  - 14968  http://www.lymphomahub.com/therapies/abc294640
2017-04-11 09:36:14  - 14968  http://www.lymphomahub.com/therapies/sgn-cd19b
2017-04-11 09:36:18  - 14968  http://www.lymphomahub.com/therapies/tenofovir
2017-04-11 09:36:22  - 14968  http://www.lymphomahub.com/therapies/betalutin
2017-04-11 09:36:27  - 14968  http://www.lymphomahub.com/therapies/chidamide
2017-04-11 09:36:31  - 14968  http://www.lymphomahub.com/therapies/duvelisib
2017-04-11 09:36:35  - 14968  http://www.lymphomahub.com/therapies/dasatinib
2017-04-11 09:36:40  - 14968  http://www.lymphomahub.com/therapies/everolimus
2017-04-11 09:36:44  - 14968  http://www.lymphomahub.com/therapies/incb039110
2017-04-11 09:36:48  - 14968  http://www.lymphomahub.com/therapies/durvalumab
2017-04-11 09:36:53  - 14968  http://www.lymphomahub.com/therapies/romidepsin
2017-04-11 09:36:53  - 14968  http://www.lymphomahub.com/therapies/bortezomib
2017-04-11 09:36:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib
2017-04-11 09:37:02  - 14968  http://www.lymphomahub.com/therapies/tipifarnib
2017-04-11 09:37:06  - 14968  http://www.lymphomahub.com/therapies/ipilimumab
2017-04-11 09:37:11  - 14968  http://www.lymphomahub.com/therapies/crizotinib
2017-04-11 09:37:15  - 14968  http://www.lymphomahub.com/therapies/gsk2816126
2017-04-11 09:37:19  - 14968  http://www.lymphomahub.com/therapies/copanlisib
2017-04-11 09:37:24  - 14968  http://www.lymphomahub.com/therapies/buparlisib
2017-04-11 09:37:28  - 14968  http://www.lymphomahub.com/therapies/belinostat
2017-04-11 09:37:32  - 14968  http://www.lymphomahub.com/therapies/vorinostat
2017-04-11 09:37:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor
2017-04-11 09:37:41  - 14968  http://www.lymphomahub.com/therapies/ofatumumab
2017-04-11 09:37:45  - 14968  http://www.lymphomahub.com/therapies/pf-06801591
2017-04-11 09:37:49  - 14968  http://www.lymphomahub.com/therapies/tocilizumab
2017-04-11 09:37:53  - 14968  http://www.lymphomahub.com/therapies/msc2490484a
2017-04-11 09:37:58  - 14968  http://www.lymphomahub.com/therapies/carfilzomib
2017-04-11 09:38:02  - 14968  http://www.lymphomahub.com/therapies/ruxolitinib
2017-04-11 09:38:07  - 14968  http://www.lymphomahub.com/therapies/palbociclib
2017-04-11 09:38:11  - 14968  http://www.lymphomahub.com/therapies/fenretinide
2017-04-11 09:38:15  - 14968  http://www.lymphomahub.com/therapies/daratumumab
2017-04-11 09:38:19  - 14968  http://www.lymphomahub.com/therapies/pf-05082566
2017-04-11 09:38:24  - 14968  http://www.lymphomahub.com/therapies/ramucirumab
2017-04-11 09:38:29  - 14968  http://www.lymphomahub.com/therapies/tositumomab
2017-04-11 09:38:33  - 14968  http://www.lymphomahub.com/therapies/ublituximab
2017-04-11 09:38:38  - 14968  http://www.lymphomahub.com/therapies/epacadostat
2017-04-11 09:38:42  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab
2017-04-11 09:38:47  - 14968  http://www.lymphomahub.com/therapies/otlertuzumab
2017-04-11 09:38:51  - 14968  http://www.lymphomahub.com/therapies/panobinostat
2017-04-11 09:38:55  - 14968  http://www.lymphomahub.com/therapies/mocetinostat
2017-04-11 09:38:59  - 14968  http://www.lymphomahub.com/therapies/atezolizumab
2017-04-11 09:39:03  - 14968  http://www.lymphomahub.com/therapies/temsirolimus
2017-04-11 09:39:04  - 14968  http://www.lymphomahub.com/therapies/lenalidomide
2017-04-11 09:39:08  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab
2017-04-11 09:39:12  - 14968  http://www.lymphomahub.com/therapies/atl-car-cd30
2017-04-11 09:39:17  - 14968  http://www.lymphomahub.com/therapies/blinatumomab
2017-04-11 09:39:21  - 14968  http://www.lymphomahub.com/therapies/jnj-64052781
2017-04-11 09:39:25  - 14968  http://www.lymphomahub.com/therapies/entospletinib
2017-04-11 09:39:29  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab
2017-04-11 09:39:34  - 14968  http://www.lymphomahub.com/therapies/acalabrutinib
2017-04-11 09:39:38  - 14968  http://www.lymphomahub.com/about/innovation-committee
2017-04-11 09:39:41  - 14968  http://www.lymphomahub.com/mailto:info@lymphomahub.com
2017-04-11 09:39:42  - 14968  http://www.lymphomahub.com/therapies/pinatuzumab-vedotin
2017-04-11 09:39:46  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a
2017-04-11 09:39:51  - 14968  http://www.lymphomahub.com/therapies/polatuzumab-vedotin
2017-04-11 09:39:55  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b
2017-04-11 09:39:59  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin
2017-04-11 09:40:04  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox
2017-04-11 09:40:04  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan
2017-04-11 09:40:09  - 14968  http://www.lymphomahub.com/therapies/inotuzumab-ozogamicin
2017-04-11 09:40:13  - 14968  http://www.lymphomahub.com/about/secretariat/terri-heasman
2017-04-11 09:40:17  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board
2017-04-11 09:40:21  - 14968  http://www.lymphomahub.com/therapies/denintuzumab-mafodotin
2017-04-11 09:40:25  - 14968  http://www.lymphomahub.com/about/secretariat/cynthia-umukoro
2017-04-11 09:40:28  - 14968  http://www.lymphomahub.com/about/secretariat/anne-villeneuve
2017-04-11 09:40:32  - 14968  http://www.lymphomahub.com/about/executive-steering-committee
2017-04-11 09:40:36  - 14968  http://www.lymphomahub.com/about/secretariat/karl-kemp-obrien
2017-04-11 09:40:40  - 14968  http://www.lymphomahub.com/medical-information/know-your-subtype
2017-04-11 09:40:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-won-kim
2017-04-11 09:40:48  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-valentin-goede
2017-04-11 09:40:52  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl
2017-04-11 09:40:57  - 14968  http://www.lymphomahub.com/about/innovation-committee/Dr-Constantine-Tam
2017-04-11 09:41:00  - 14968  http://www.lymphomahub.com/medical-information/javascript:history.back()
2017-04-11 09:41:01  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-emmanuel-bachy
2017-04-11 09:41:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-mcl
2017-04-11 09:41:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-mzl
2017-04-11 09:41:13  - 14968  http://www.lymphomahub.com/about/innovation-committee/prof-sarit-assouline
2017-04-11 09:41:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-in-fl
2017-04-11 09:41:22  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-diagnosis-and-staging
2017-04-11 09:41:26  - 14968  http://www.lymphomahub.com/about/innovation-committee/dr-michael-dickinson
2017-04-11 09:41:30  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-ulrich-jager
2017-04-11 09:41:33  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-sonali-smith
2017-04-11 09:41:37  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-susan-obrien
2017-04-11 09:41:41  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-francesc-bosch
2017-04-11 09:41:44  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-marek-trneny
2017-04-11 09:41:48  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-peter-johnson
2017-04-11 09:41:52  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-simon-rule
2017-04-11 09:41:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/9/10/keyword/
2017-04-11 09:42:00  - 14968  http://www.lymphomahub.com/medical-information/categories//page/7/10/keyword/
2017-04-11 09:42:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/5/10/keyword/
2017-04-11 09:42:09  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-nathan-fowler
2017-04-11 09:42:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/1/10/keyword/
2017-04-11 09:42:16  - 14968  http://www.lymphomahub.com/medical-information/categories//page/6/10/keyword/
2017-04-11 09:42:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/4/10/keyword/
2017-04-11 09:42:25  - 14968  http://www.lymphomahub.com/medical-information/categories//page/8/10/keyword/
2017-04-11 09:42:29  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-irene-biasoli
2017-04-11 09:42:33  - 14968  http://www.lymphomahub.com/medical-information/categories//page/2/10/keyword/
2017-04-11 09:42:38  - 14968  http://www.lymphomahub.com/medical-information/categories//page/3/10/keyword/
2017-04-11 09:42:42  - 14968  http://www.lymphomahub.com/medical-information/categories//page/14/10/keyword/
2017-04-11 09:42:46  - 14968  http://www.lymphomahub.com/medical-information/categories//page/10/10/keyword/
2017-04-11 09:42:50  - 14968  http://www.lymphomahub.com/medical-information/categories//page/15/10/keyword/
2017-04-11 09:42:55  - 14968  http://www.lymphomahub.com/medical-information/categories//page/13/10/keyword/
2017-04-11 09:42:59  - 14968  http://www.lymphomahub.com/medical-information/categories//page/28/10/keyword/
2017-04-11 09:43:04  - 14968  http://www.lymphomahub.com/medical-information/categories//page/32/10/keyword/
2017-04-11 09:43:08  - 14968  http://www.lymphomahub.com/medical-information/categories//page/27/10/keyword/
2017-04-11 09:43:12  - 14968  http://www.lymphomahub.com/medical-information/categories//page/33/10/keyword/
2017-04-11 09:43:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/12/10/keyword/
2017-04-11 09:43:21  - 14968  http://www.lymphomahub.com/medical-information/categories//page/26/10/keyword/
2017-04-11 09:43:26  - 14968  http://www.lymphomahub.com/medical-information/categories//page/25/10/keyword/
2017-04-11 09:43:31  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/dr-astrid-pavlovsky
2017-04-11 09:43:34  - 14968  http://www.lymphomahub.com/medical-information/categories//page/18/10/keyword/
2017-04-11 09:43:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/11/10/keyword/
2017-04-11 09:43:43  - 14968  http://www.lymphomahub.com/medical-information/categories//page/21/10/keyword/
2017-04-11 09:43:48  - 14968  http://www.lymphomahub.com/medical-information/categories//page/22/10/keyword/
2017-04-11 09:43:52  - 14968  http://www.lymphomahub.com/medical-information/categories//page/23/10/keyword/
2017-04-11 09:43:57  - 14968  http://www.lymphomahub.com/medical-information/categories//page/29/10/keyword/
2017-04-11 09:44:01  - 14968  http://www.lymphomahub.com/medical-information/categories//page/24/10/keyword/
2017-04-11 09:44:05  - 14968  http://www.lymphomahub.com/medical-information/categories//page/19/10/keyword/
2017-04-11 09:44:10  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anas-younes
2017-04-11 09:44:13  - 14968  http://www.lymphomahub.com/medical-information/categories//page/30/10/keyword/
2017-04-11 09:44:17  - 14968  http://www.lymphomahub.com/medical-information/categories//page/17/10/keyword/
2017-04-11 09:44:22  - 14968  http://www.lymphomahub.com/medical-information/categories//page/20/10/keyword/
2017-04-11 09:44:27  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-andrei-shustov
2017-04-11 09:44:30  - 14968  http://www.lymphomahub.com/medical-information/categories//page/16/10/keyword/
2017-04-11 09:44:35  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-judith-trotman
2017-04-11 09:44:39  - 14968  http://www.lymphomahub.com/medical-information/categories//page/31/10/keyword/
2017-04-11 09:44:43  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-martin-dreyling
2017-04-11 09:44:47  - 14968  http://www.lymphomahub.com/medical-information/status-of-fdg-pet-as-a-biomarker
2017-04-11 09:44:51  - 14968  http://www.lymphomahub.com/medical-information/fl-international-prognostic-index
2017-04-11 09:44:56  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-gilles-salles
2017-04-11 09:45:00  - 14968  http://www.lymphomahub.com/medical-information/new-drugs-for-follicular-lymphoma
2017-04-11 09:45:04  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-michael-hallek
2017-04-11 09:45:08  - 14968  http://www.lymphomahub.com/medical-information/mcl-international-prognostic-index
2017-04-11 09:45:12  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-andreas-engert
2017-04-11 09:45:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-new-insights-on-imaging
2017-04-11 09:45:20  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-anton-hagenbeek
2017-04-11 09:45:25  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-massimo-federico
2017-04-11 09:45:28  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-stefano-luminari
2017-04-11 09:45:32  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-wm
2017-04-11 09:45:36  - 14968  http://www.lymphomahub.com/about/scientific-advisory-board/prof-grzegorz-nowakowski
2017-04-11 09:45:40  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-malt-lymphomas
2017-04-11 09:45:45  - 14968  http://www.lymphomahub.com/about/executive-steering-committee/prof-bertrand-coiffier
2017-04-11 09:45:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-r-chop-remains-the-soc
2017-04-11 09:45:53  - 14968  http://www.lymphomahub.com/medical-information/fl-metabolic-tumor-volume-hype-or-hope
2017-04-11 09:45:57  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-treatment-of-wm
2017-04-11 09:46:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-rituximab-in-mcl
2017-04-11 09:46:06  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-burkitt-lymphoma
2017-04-11 09:46:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-on-new-agents-in-fl
2017-04-11 09:46:15  - 14968  http://www.lymphomahub.com/news/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-11 09:46:15  - 14968  http://www.lymphomahub.com/medical-information/updated-nccn-guidelines-for-hl-fl-and-mcl
2017-04-11 09:46:20  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-hairy-cell-leukemia
2017-04-11 09:46:24  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-double-hit-lymphoma
2017-04-11 09:46:29  - 14968  http://www.lymphomahub.com/medical-information/eha-congress-2017-abstract-submissions-open
2017-04-11 09:46:33  - 14968  http://www.lymphomahub.com/medical-information/advanced-hl-upfront-escalated-beacopp-or-abvd
2017-04-11 09:46:38  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-treatment-strategies-and-prognostic-tools
2017-04-11 09:46:42  - 14968  http://www.lymphomahub.com/medical-information/hl-new-esmo-recommendations-for-prognostic-tools
2017-04-11 09:46:46  - 14968  http://www.lymphomahub.com/medical-information/fl-new-esmo-recommendations-for-prognostic-tools
2017-04-11 09:46:51  - 14968  http://www.lymphomahub.com/medical-information/cll-new-esmo-recommendations-for-prognostic-tools
2017-04-11 09:46:57  - 14968  http://www.lymphomahub.com/medical-information/mcl-new-esmo-recommendations-for-prognostic-tools
2017-04-11 09:47:03  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-advances-in-biology-of-mcl
2017-04-11 09:47:10  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-diagnosis-and-staging
2017-04-11 09:47:17  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-epidemiology-pathology-and-clinical-features
2017-04-11 09:47:22  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-bispecific-antibodies-bites
2017-04-11 09:47:26  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-t-cell-lymphomas
2017-04-11 09:47:30  - 14968  http://www.lymphomahub.com/medical-information/the-lymphoma-hub-will-be-at-ash-2016-2-weeks-to-go
2017-04-11 09:47:35  - 14968  http://www.lymphomahub.com/medical-information/fl-clinical-features-prognosis-and-therapy-in-fl3a
2017-04-11 09:47:39  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-immune-checkpoint-inhibitors
2017-04-11 09:47:44  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-r2-rituximab-lenalidomide
2017-04-11 09:47:49  - 14968  http://www.lymphomahub.com/medical-information/current-and-future-economic-burden-of-cll-in-the-us
2017-04-11 09:47:53  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-new-esmo-recommendations-for-prognostic-tools
2017-04-11 09:47:58  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-myc-driven-lymphoma
2017-04-11 09:48:02  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-mcl-moving-toward-a-chemotherapy-free-regimen
2017-04-11 09:48:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-dlbcl-which-drugs-can-be-combined-with-r-chop
2017-04-11 09:48:12  - 14968  http://www.lymphomahub.com/medical-information/cll-over-40-years-of-rai-cll-staging-system-celebrated
2017-04-11 09:48:17  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-immune-evasion-in-classical-hodgkin-lymphoma
2017-04-11 09:48:22  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-role-of-pembrolizumab-in-rr-ctcl-abstract-181
2017-04-11 09:48:26  - 14968  http://www.lymphomahub.com/medical-information/esh-clinical-updates-conference-on-aggressive-lymphoma
2017-04-11 09:48:31  - 14968  http://www.lymphomahub.com/medical-information/phase-ii-trial-results-of-abexinostat-in-rr-nhl-and-cll
2017-04-11 09:48:35  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-eft508-orphan-drug-designation-for-dlbcl
2017-04-11 09:48:40  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-b-cell-lymphoma-r-chop-14-or-r-chop-21
2017-04-11 09:48:44  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-car-t-cells-in-non-hodgkin-lymphoma
2017-04-11 09:48:48  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-current-and-future-treatment-of-mcl
2017-04-11 09:48:53  - 14968  http://www.lymphomahub.com/medical-information/keytrudar-pembrolizumab-given-positive-opinion-by-ema-chmp
2017-04-11 09:48:57  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mcl-current-and-novel-therapy
2017-04-11 09:49:02  - 14968  http://www.lymphomahub.com/medical-information/results-from-first-venetoclax-phase-i-human-trial-in-rr-nhl
2017-04-11 09:49:06  - 14968  http://www.lymphomahub.com/medical-information/the-fda-halts-clinical-trials-of-selinexor-in-cll-and-dlbcl
2017-04-11 09:49:10  - 14968  http://www.lymphomahub.com/medical-information/hl-does-interim-fluorodeoxyglucose-pet-have-predictive-value
2017-04-11 09:49:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-is-mrd-testing-performed-by-community-hematologists
2017-04-11 09:49:19  - 14968  http://www.lymphomahub.com/medical-information/eha-2017-abstract-submission-deadline-is-just-two-weeks-away
2017-04-11 09:49:24  - 14968  http://www.lymphomahub.com/medical-information/targeting-btk-with-ibrutinib-shown-to-be-effective-in-rr-mzl
2017-04-11 09:49:29  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Desktop/NCT00005089
2017-04-11 09:49:29  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-signaling-pathways-in-b-cell-lymphomas
2017-04-11 09:49:34  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-t-cell-lymphoma-novel-treatment-options
2017-04-11 09:49:38  - 14968  http://www.lymphomahub.com/medical-information/why-didnt-the-pfs-improvement-translate-into-an-os-improvement
2017-04-11 09:49:43  - 14968  http://www.lymphomahub.com/medical-information/mycosis-fungoides-treatment-is-based-on-a-stage-based-approach
2017-04-11 09:49:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-474-lenalidomide-maintenance-in-rr-dlbcl
2017-04-11 09:49:52  - 14968  http://www.lymphomahub.com/medical-information/nice-first-draft-guidance-rejects-funding-for-venclyxto-for-cll
2017-04-11 09:49:56  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-del-and-dhl-as-indicators-of-poor-prognosis-after-asct
2017-04-11 09:50:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-hl-checkpoint-inhibitors-are-changing-current-practice
2017-04-11 09:50:05  - 14968  http://www.lymphomahub.com/medical-information/patients-after-allohct-is-ibrutinib-an-effective-salvage-therapy
2017-04-11 09:50:09  - 14968  http://www.lymphomahub.com/medical-information/rr-indolent-b-cell-lymphoma-is-idelalisib-a-new-treatment-option
2017-04-11 09:50:14  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-5-year-update-of-the-pivotal-trial-with-brentuximab-vedotin
2017-04-11 09:50:18  - 14968  http://www.lymphomahub.com/medical-information/high-risk-dlbcl-r-hds-followed-by-asct-is-as-effective-as-r-chop14
2017-04-11 09:50:23  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-fl-highlights-on-patients-over-70-the-flash-group-results
2017-04-11 09:50:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-lymphomas-new-therapeutic-strategies
2017-04-11 09:50:32  - 14968  http://www.lymphomahub.com/medical-information/american-society-of-clinical-oncology-abstract-deadline-approaches
2017-04-11 09:50:36  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-which-is-a-better-treatment-option-abvd-or-beacopp
2017-04-11 09:50:41  - 14968  http://www.lymphomahub.com/medical-information/pd-1-expression-is-not-a-good-prognostic-marker-for-cutaneous-enktl
2017-04-11 09:50:45  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-lenalidomide-maintenance-abstract-474
2017-04-11 09:50:50  - 14968  http://www.lymphomahub.com/medical-information/cll-cll-ipi-applied-and-validated-in-an-unselected-prospective-study
2017-04-11 09:50:54  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-waldenstrom-macroglobulinemia-overview
2017-04-11 09:50:58  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/6/2/keyword//location//region/
2017-04-11 09:51:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/1/2/keyword//location//region/
2017-04-11 09:51:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/3/2/keyword//location//region/
2017-04-11 09:51:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/9/2/keyword//location//region/
2017-04-11 09:51:16  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/4/2/keyword//location//region/
2017-04-11 09:51:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/8/2/keyword//location//region/
2017-04-11 09:51:23  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/7/2/keyword//location//region/
2017-04-11 09:51:27  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-biology-of-central-nervous-system-cns-lymphoma
2017-04-11 09:51:32  - 14968  http://www.lymphomahub.com/uploads/media/pageMedicalInformation/0001/03/82f5b078cb3c5f68c48d87df1512f97e10bda80a.pdf
2017-04-11 09:51:32  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-pre-emptive-rituximab-the-mcl2-and-mcl3-studies-abstract-146
2017-04-11 09:51:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/2/2/keyword//location//region/
2017-04-11 09:51:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/5/2/keyword//location//region/
2017-04-11 09:51:45  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/39/2/keyword//location//region/
2017-04-11 09:51:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/33/2/keyword//location//region/
2017-04-11 09:51:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/36/2/keyword//location//region/
2017-04-11 09:51:56  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/35/2/keyword//location//region/
2017-04-11 09:52:00  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/21/2/keyword//location//region/
2017-04-11 09:52:03  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/26/2/keyword//location//region/
2017-04-11 09:52:07  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/52/2/keyword//location//region/
2017-04-11 09:52:11  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/40/2/keyword//location//region/
2017-04-11 09:52:14  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/24/2/keyword//location//region/
2017-04-11 09:52:18  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/51/2/keyword//location//region/
2017-04-11 09:52:22  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/13/2/keyword//location//region/
2017-04-11 09:52:25  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/43/2/keyword//location//region/
2017-04-11 09:52:29  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-induction-therapy
2017-04-11 09:52:34  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/18/2/keyword//location//region/
2017-04-11 09:52:37  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/25/2/keyword//location//region/
2017-04-11 09:52:41  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/12/2/keyword//location//region/
2017-04-11 09:52:44  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/37/2/keyword//location//region/
2017-04-11 09:52:48  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/44/2/keyword//location//region/
2017-04-11 09:52:52  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/46/2/keyword//location//region/
2017-04-11 09:52:55  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/30/2/keyword//location//region/
2017-04-11 09:52:59  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/47/2/keyword//location//region/
2017-04-11 09:53:02  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/27/2/keyword//location//region/
2017-04-11 09:53:06  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/48/2/keyword//location//region/
2017-04-11 09:53:10  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/53/2/keyword//location//region/
2017-04-11 09:53:13  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/14/2/keyword//location//region/
2017-04-11 09:53:17  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/16/2/keyword//location//region/
2017-04-11 09:53:20  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/49/2/keyword//location//region/
2017-04-11 09:53:24  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/29/2/keyword//location//region/
2017-04-11 09:53:28  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/32/2/keyword//location//region/
2017-04-11 09:53:31  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/42/2/keyword//location//region/
2017-04-11 09:53:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/17/2/keyword//location//region/
2017-04-11 09:53:38  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/20/2/keyword//location//region/
2017-04-11 09:53:42  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/50/2/keyword//location//region/
2017-04-11 09:53:46  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/19/2/keyword//location//region/
2017-04-11 09:53:49  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/45/2/keyword//location//region/
2017-04-11 09:53:53  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/15/2/keyword//location//region/
2017-04-11 09:53:57  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/38/2/keyword//location//region/
2017-04-11 09:54:01  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/23/2/keyword//location//region/
2017-04-11 09:54:04  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/22/2/keyword//location//region/
2017-04-11 09:54:08  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/34/2/keyword//location//region/
2017-04-11 09:54:12  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/54/2/keyword//location//region/
2017-04-11 09:54:15  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/28/2/keyword//location//region/
2017-04-11 09:54:19  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/11/2/keyword//location//region/
2017-04-11 09:54:22  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-copanlisib-in-rr-inhl-primary-results-of-the-chronos-1-study
2017-04-11 09:54:27  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/10/2/keyword//location//region/
2017-04-11 09:54:30  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/41/2/keyword//location//region/
2017-04-11 09:54:35  - 14968  http://www.lymphomahub.com/therapies/licenses//settings//subtype//trials/0/drug//page/31/2/keyword//location//region/
2017-04-11 09:54:38  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-fl-novel-developments-beyond-chemotherapy
2017-04-11 09:54:43  - 14968  http://www.lymphomahub.com/medical-information/health-canada-approve-obinutuzumab-plus-bendamustine-for-rr-fl-patients
2017-04-11 09:54:48  - 14968  http://www.lymphomahub.com/medical-information/rr-dlbcl-not-eligible-for-asct-is-there-a-role-for-imids-in-maintenance
2017-04-11 09:54:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-highlights-in-hl-with-a-special-focus-on-checkpoint-inhibitors
2017-04-11 09:54:57  - 14968  http://www.lymphomahub.com/medical-information/file:///C:/Users/Sushmita%20Roy%20Nawathe/Downloads/dbr160001%20(3).pdf
2017-04-11 09:54:58  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximar-approved-by-the-ema-for-use-in-cll-and-nhl
2017-04-11 09:55:02  - 14968  http://www.lymphomahub.com/medical-information/once-a-week-ofatumumab-shown-to-be-effective-and-safe-in-treatment-of-wm
2017-04-11 09:55:06  - 14968  http://www.lymphomahub.com/medical-information/rr-b-cell-and-t-cell-lymphoma-encouraging-phase-1-results-with-nivolumab
2017-04-11 09:55:11  - 14968  http://www.lymphomahub.com/medical-information/rr-ptcl-results-from-a-european-multicenter-phase-ii-mogamulizumab-trial
2017-04-11 09:55:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-tcl-pet-guided-therapy-analysis-of-the-petal-trial-abstract-185
2017-04-11 09:55:20  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-approved-by-the-ema-for-the-treatment-of-mf-ctcl
2017-04-11 09:55:24  - 14968  http://www.lymphomahub.com/medical-information/results-of-extended-treatment-with-420mg-ibrutinib-daily-in-nd-and-rr-cll
2017-04-11 09:55:29  - 14968  http://www.lymphomahub.com/medical-information/chronic-lymphocytic-leukemia-role-of-the-microenvironment-in-pathogenesis
2017-04-11 09:55:33  - 14968  http://www.lymphomahub.com/medical-information/cll-which-is-more-accurate-for-predicting-os-and-ttft-cll-ipi-or-mdacc-pi
2017-04-11 09:55:38  - 14968  http://www.lymphomahub.com/medical-information/reducing-ibrutinib-dose-shown-not-to-adversely-affect-cll-patient-outcome
2017-04-11 09:55:42  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-meta-analysis-of-pre-emptive-studies-with-rituximab-abstract-1802
2017-04-11 09:55:47  - 14968  http://www.lymphomahub.com/medical-information/fl-dlbcl-results-from-first-phase-i-study-of-new-pi3k-inhibitor-copanlisib
2017-04-11 09:55:52  - 14968  http://www.lymphomahub.com/medical-information/cll-minimal-residual-disease-is-a-prognostic-factor-for-10-year-os-and-pfs
2017-04-11 09:55:56  - 14968  http://www.lymphomahub.com/medical-information/combination-ublituximab-and-ibrutinib-in-rr-cll-patients-safe-and-effective
2017-04-11 09:56:00  - 14968  http://www.lymphomahub.com/medical-information/cll-treatment-in-elderly-new-challenges-treatment-options-and-opportunities
2017-04-11 09:56:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-eatcl-enteropathy-associated-t-cell-lymphomas
2017-04-11 09:56:09  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-lba-6-zuma-1-kte-c19-car-t-cells-show-significant-clinical-benefit
2017-04-11 09:56:13  - 14968  http://www.lymphomahub.com/medical-information/chl-biomarkers-plus-interim-pet-scan-helps-predict-patient-treatment-outcome
2017-04-11 09:56:18  - 14968  http://www.lymphomahub.com/medical-information/is-the-geltamo-ipi-more-accurate-than-nccn-ipi-or-ipi-in-patients-with-dlbcl
2017-04-11 09:56:22  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-jcar017-breakthrough-therapy-designation-in-dlbcl-nos-pmbcl-fl
2017-04-11 09:56:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-cll-moving-towards-chemotherapy-free-approaches
2017-04-11 09:56:31  - 14968  http://www.lymphomahub.com/medical-information/rl-pcnsl-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-11 09:56:36  - 14968  http://www.lymphomahub.com/medical-information/imbruvicar-ibrutinib-given-fda-accelerated-approval-in-the-treatment-of-rr-mzl
2017-04-11 09:56:40  - 14968  http://www.lymphomahub.com/medical-information/phase-ib-trial-results-using-combination-of-venetoclax-and-rituximab-in-rr-cll
2017-04-11 09:56:44  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-cll
2017-04-11 09:56:49  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-treated-with-ibrutinib-incidence-of-brittle-nails-and-hair-changes
2017-04-11 09:56:53  - 14968  http://www.lymphomahub.com/medical-information/cd19-car-t-cell-therapy-serum-il-15-levels-associated-with-nhl-patient-response
2017-04-11 09:56:57  - 14968  http://www.lymphomahub.com/medical-information/the-success-of-ibrutinib-in-treating-b-cell-malignancies-cll-mcl-wm-fl-and-dlbcl
2017-04-11 09:57:02  - 14968  http://www.lymphomahub.com/medical-information/fl-with-high-tumor-burden-a-case-report-rituximab-induced-acute-thrombocytopenia
2017-04-11 09:57:06  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-hl-fl-cll-pmbcl-prognostic-role-of-pd-l1pd-1-expression-in-b-cell-lymphomas
2017-04-11 09:57:11  - 14968  http://www.lymphomahub.com/medical-information/eha-swg-rare-lymphomas-the-role-of-the-microenvironment-in-cll-and-rare-lymphomas
2017-04-11 09:57:15  - 14968  http://www.lymphomahub.com/medical-information/response-to-challenges-in-defining-a-new-standard-of-care-in-primary-cns-lymphoma
2017-04-11 09:57:19  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tg-1101-and-tgr-1202-combination-orphan-drug-designation-for-dlbcl
2017-04-11 09:57:24  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-classification-and-diagnosis
2017-04-11 09:57:28  - 14968  http://www.lymphomahub.com/medical-information/rr-hl-promising-results-of-a-new-hdac-inhibitor-entinostat-in-phase-ii-engage-501
2017-04-11 09:57:32  - 14968  http://www.lymphomahub.com/medical-information/hodgkin-lymphoma-hd2000-update-abvd-or-beacopp-which-is-a-better-treatment-option
2017-04-11 09:57:37  - 14968  http://www.lymphomahub.com/medical-information/hif1a-mrna-overexpression-found-to-be-an-independent-prognostic-indicator-for-cll
2017-04-11 09:57:41  - 14968  http://www.lymphomahub.com/medical-information/atll-results-from-phase-ii-lenalidomide-study-appear-promising-for-recurrent-atll
2017-04-11 09:57:46  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pi3-kinase-inhibition-in-chronic-lymphocytic-leukemia
2017-04-11 09:57:50  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-small-molecule-therapy-in-chronic-lymphocytic-leukemia
2017-04-11 09:57:55  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-tazemetostat-epz-6438-fast-track-designation-for-treatment-of-dlbcl
2017-04-11 09:57:59  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-922-relapsed-nodular-lymphocyte-predominant-hodgkin-lymphoma
2017-04-11 09:58:04  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-assessment-of-response-and-mrd
2017-04-11 09:58:08  - 14968  http://www.lymphomahub.com/medical-information/venclyxtor-venetoclax-granted-ema-approval-first-approved-bcl-2-inhibitor-in-europe
2017-04-11 09:58:12  - 14968  http://www.lymphomahub.com/medical-information/btk-and-plcg2-mutations-could-potentially-identify-early-post-ibrutinib-cll-relapse
2017-04-11 09:58:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-what-are-the-treatment-options-for-ibrutinib-failing-patients-mcl-004-study
2017-04-11 09:58:21  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/fl/nd/ema/roferon-is-indicated-for-follicular-non-hodgkin-lymphoma
2017-04-11 09:58:25  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24474-the-mutational-landscape-of-chemo-refractory-burkitt-lymphoma
2017-04-11 09:58:30  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-mzl-recent-developments-in-diagnostics-and-therapeutics
2017-04-11 09:58:34  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-educational-session-hl-how-to-incorporate-novel-therapies-into-the-treatment
2017-04-11 09:58:39  - 14968  http://www.lymphomahub.com/medical-information/cll-discovery-of-a-germ-line-mutation-in-shelterin-complex-associated-with-familial-cll
2017-04-11 09:58:43  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-accelerated-approved-for-the-treatment-of-rr-chl
2017-04-11 09:58:47  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-pd-1-inhibitors-in-hodgkin-lymphoma-abstracts-7535-and-7555
2017-04-11 09:58:52  - 14968  http://www.lymphomahub.com/medical-information/clonal-heterogeneity-and-level-of-ctdna-for-ig-vdj-as-potential-prognostic-makers-in-fl
2017-04-11 09:58:56  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-keytrudar-pembrolizumab-priority-review-for-the-possible-treatment-of-chl
2017-04-11 09:59:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-will-obinutuzumab-based-induction-and-maintenance-change-clinical-practice-in-fl
2017-04-11 09:59:05  - 14968  http://www.lymphomahub.com/medical-information/results-from-the-phase-i-zuma-1-study-into-kte-c19-car-t-cell-therapy-in-refractory-dlbcl
2017-04-11 09:59:09  - 14968  http://www.lymphomahub.com/medical-information/rl-enktl-treatment-with-hdac-inhibitors-in-enktl-has-an-association-with-ebv-reactivation
2017-04-11 09:59:14  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-emzl-clarithromycin-dose-for-treating-emzl-is-1gday
2017-04-11 09:59:18  - 14968  http://www.lymphomahub.com/medical-information/refractoryrelapsed-hl-after-asct-new-data-from-the-phase-ii-trial-with-brentuximab-vedotin
2017-04-11 09:59:22  - 14968  http://www.lymphomahub.com/medical-information/hl-the-impact-of-post-treatment-severe-fatigue-on-patient-outcome-and-social-reintegration
2017-04-11 09:59:27  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-fl
2017-04-11 09:59:31  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-understanding-success-and-failure-of-car-t-cell-therapy-for-non-hodgkin-lymphoma
2017-04-11 09:59:36  - 14968  http://www.lymphomahub.com/medical-information/will-the-gallium-study-with-obinutuzumab-change-current-practice-in-first-line-fl-patients
2017-04-11 09:59:40  - 14968  http://www.lymphomahub.com/medical-information/inhl-encouraging-phase-ii-safety-and-efficacy-data-of-inotuzumab-ozogamicin-ino-in-patients
2017-04-11 09:59:45  - 14968  http://www.lymphomahub.com/medical-information/bendamustine-rituximab-as-a-front-line-therapy-in-cll-patients-a-retrospective-study-report
2017-04-11 09:59:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-mcl
2017-04-11 09:59:53  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-cll
2017-04-11 09:59:58  - 14968  http://www.lymphomahub.com/medical-information/vr-cap-improved-duration-and-quality-of-response-in-newly-diagnosed-mcl-patients-over-r-chop
2017-04-11 10:00:02  - 14968  http://www.lymphomahub.com/medical-information/anti-mal-antibody-compared-to-cd200-is-more-effective-at-distinguishing-pmbcl-from-dlbcl-nos
2017-04-11 10:00:07  - 14968  http://www.lymphomahub.com/medical-information/rituximab-biosimilar-truximatm-given-positive-opinion-by-the-ema-chmp-for-use-in-cll-and-nhl
2017-04-11 10:00:11  - 14968  http://www.lymphomahub.com/medical-information/ledagar-chlormethine-gel-given-positive-opinion-by-the-ema-chmp-for-the-treatment-of-mf-ctcl
2017-04-11 10:00:16  - 14968  http://www.lymphomahub.com/medical-information/improved-pfs-seen-in-the-g-b-arm-of-the-gadolin-study-did-not-result-in-poorer-patient-hrqol
2017-04-11 10:00:20  - 14968  http://www.lymphomahub.com/medical-information/orcharrd-study-results-ofatumumab-dhap-vs-rituximab-dhap-in-rr-dlbcl-which-is-more-effective
2017-04-11 10:00:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-470-final-results-of-phase-3-study-of-obinutuzumab-or-r-chop-in-dlbcl
2017-04-11 10:00:29  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-achieving-pr-prospective-mrd-assessment-improves-prediction-of-patient-outcomes
2017-04-11 10:00:35  - 14968  http://www.lymphomahub.com/medical-information/esmo-consensus-conference-on-malignant-lymphoma-recommendations-for-prognostic-tools-in-dlbcl
2017-04-11 10:00:39  - 14968  http://www.lymphomahub.com/medical-information/pd-1-blockade-via-pembrolizumab-may-be-an-effective-salvage-treatment-for-rr-nkt-cell-lymphoma
2017-04-11 10:00:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-183-phase-i-checkmate-039-nivolumab-plus-ipilimumab-for-rr-hl-nhl-and-mm
2017-04-11 10:00:48  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-novel-agents-and-strategies-in-relapsedrefractory-hodgkin-lymphoma
2017-04-11 10:00:52  - 14968  http://www.lymphomahub.com/medical-information/rituximab-induction-response-as-a-predictive-biomarker-in-risk-stratification-in-ptld-after-sot
2017-04-11 10:00:56  - 14968  http://www.lymphomahub.com/medical-information/chl-is-disease-bulk-by-coronal-and-transverse-computed-tomography-a-useful-prognostic-indicator
2017-04-11 10:01:01  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-473-ibrutinib-in-combination-with-lenalidomide-and-rituximab-in-rr-dlbcl
2017-04-11 10:01:05  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-cmd-003-fast-track-designation-for-treatment-of-ebv-positive-rr-lymphoma-and-ptld
2017-04-11 10:01:10  - 14968  http://www.lymphomahub.com/medical-information/nhl-fl-dlbcl-mzl-efficacy-of-maintenance-rituximab-post-r-chop-questioned-in-comdis-nhl-patients
2017-04-11 10:01:14  - 14968  http://www.lymphomahub.com/medical-information/cll-venclyxtor-venetoclax-given-positive-opinion-by-the-ema-chmp-for-use-in-the-treatment-of-cll
2017-04-11 10:01:19  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/fda/velcade-is-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma
2017-04-11 10:01:22  - 14968  http://www.lymphomahub.com/medical-information/atll-increased-risk-of-gvhd-related-mortality-with-mogamulizumab-administration-before-allo-hsct
2017-04-11 10:01:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-471-lenalidomide-maintenance-in-r-chop-treated-elderly-patients-with-dlbcl
2017-04-11 10:01:31  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-at-high-risk-of-recurrence-after-r-chop-no-improvement-in-dfs-with-enzastaurin-versus-placebo
2017-04-11 10:01:36  - 14968  http://www.lymphomahub.com/medical-information/hsct-after-pd-1-blockade-shown-to-be-effective-in-rr-lymphoma-patients-but-with-higher-risk-of-gvhd
2017-04-11 10:01:40  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-response-adapted-frontline-therapy-in-hodgkin-lymphoma-are-we-there-yet
2017-04-11 10:01:44  - 14968  http://www.lymphomahub.com/medical-information/relapsedrefractory-mcl-with-bendamustine-rituximab-measurement-of-response-and-prediction-by-fdg-pet
2017-04-11 10:01:49  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-pmlbl-r-da-epoch-or-r-chop-which-is-a-more-effective-treatment
2017-04-11 10:01:53  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-469-results-of-phase-iii-study-of-r-chop-versus-da-epoch-r-in-untreated-dlbcl
2017-04-11 10:01:58  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-11_10-02-00 Restart Xvfb...
/opt/spark/crawler.js:187
spark cant crawl : http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients?_prerender {"code":"ECONNRESET"}
2017-04-11 10:04:03  - 14968  http://www.lymphomahub.com/medical-information/rr-sllcll-with-del17p-new-treatment-option-use-of-ibrutinib-for-treating-difficult-subset-of-patients
2017-04-11 10:04:07  - 14968  http://www.lymphomahub.com/medical-information/cll-ibrutinib-monotherapy-shown-to-result-in-increased-susceptibility-of-pcp-opportunistic-infections
2017-04-11 10:04:12  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24441-recurrent-mutations-and-clinical-outcomes-in-patients-with-follicular-lymphoma
2017-04-11 10:04:16  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-extended-education-session-immunotherapeutic-approaches-to-treating-hematologic-malignancies
2017-04-11 10:04:21  - 14968  http://www.lymphomahub.com/medical-information/early-event-status-in-follicular-lymphoma-providing-simple-endpoints-for-assessing-outcomes-in-patients
2017-04-11 10:04:25  - 14968  http://www.lymphomahub.com/medical-information/high-serum-ferritin-level-is-a-simple-and-easily-accessible-prognostic-indicator-in-newly-diagnosed-ptcl
2017-04-11 10:04:29  - 14968  http://www.lymphomahub.com/medical-information/the-fda-grants-final-approval-of-abbreviated-new-drug-application-for-generic-bendamustine-hydrochloride
2017-04-11 10:04:34  - 14968  http://www.lymphomahub.com/medical-information/allogeneic-donor-cd19-specific-car-t-cells-promote-anti-lymphoma-activity-with-minimal-incidence-of-gvhd
2017-04-11 10:04:38  - 14968  http://www.lymphomahub.com/medical-information/gastric-and-ocular-malt-lymphoma-infectious-agent-directed-or-radiation-therapy-which-is-more-appropriate
2017-04-11 10:04:43  - 14968  http://www.lymphomahub.com/medical-information/addition-of-idelalisib-to-soc-for-rr-cll-results-in-improved-pfs-but-at-what-risk-phase-iii-trial-results
2017-04-11 10:04:47  - 14968  http://www.lymphomahub.com/medical-information/arzerrar-ofatumumab-given-positive-opinion-by-the-ema-chmp-for-use-in-combination-therapy-in-relapsed-cll
2017-04-11 10:04:52  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-incidence-survival-immunophenotype-and-molecular-characteristics
2017-04-11 10:04:56  - 14968  http://www.lymphomahub.com/medical-information/rare-lymphoma-enkl-has-an-improved-outcome-following-rt-devic-treatment-data-supports-new-prognostic-marker
2017-04-11 10:05:00  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-treatment-regimens-in-primary-central-nervous-system-cns-lymphoma
2017-04-11 10:05:05  - 14968  http://www.lymphomahub.com/medical-information/liquid-biopsy-cfdna-an-accurate-real-time-non-invasive-method-of-clonal-somatic-mutation-detection-in-dlbcl
2017-04-11 10:05:10  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-with-del17p-in-an-extended-phase-i-trial-with-a-p53-inhibitor-apr-246-shows-encouraging-results
2017-04-11 10:05:15  - 14968  http://www.lymphomahub.com/medical-information/a-subgroup-of-poor-risk-patients-with-dlbcl-who-achieve-cr-by-pet-ct-can-be-identified-using-nccn-ipi-and-coo
2017-04-11 10:05:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-230-maintenance-lenalidomide-improves-pfs-primary-results-of-phase-iii-continuum-trial
2017-04-11 10:05:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1110-nivolumab-monotherapy-in-rr-chl-12-month-follow-up-of-phase-2-checkmate-205-trial
2017-04-11 10:05:28  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-rituximab-maintenance-after-asct-analysis-of-the-phase-3-trial-of-the-lysagoelams-group-abstract-145
2017-04-11 10:05:33  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7501-higher-rate-of-orr-achieved-with-moga-vs-investigators-choice-for-treatment-of-rr-atl
2017-04-11 10:05:37  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-921-outcome-of-patients-with-primary-refractory-or-relapsed-peripheral-t-cell-lymphoma
2017-04-11 10:05:42  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-24485-deep-exome-sequencing-reveals-recurrent-somatic-mutations-in-classical-hodgkin-lymphoma
2017-04-11 10:05:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1105-brentuximab-vedotin-plus-nivolumab-is-active-and-well-tolerated-in-rr-chl-patients
2017-04-11 10:05:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-150-ibrutinib-plus-palbociclib-in-patients-with-previously-treated-mantle-cell-lymphoma
2017-04-11 10:05:56  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265716-pd-l1-blockade-enhances-t-cell-cytotoxicity-against-primary-mediastinal-b-cell-lymphoma
2017-04-11 10:06:00  - 14968  http://www.lymphomahub.com/medical-information/consensus-guidelines-for-classic-hairy-cell-leukemia-treatment-at-relapse-and-infection-prevention-and-treatment
2017-04-11 10:06:05  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-sakk-3510-first-analysis-of-survival-endpoints-of-rituximab-combined-with-lenalidomide-in-first-line-fl
2017-04-11 10:06:09  - 14968  http://www.lymphomahub.com/medical-information/mundesiner-forodesine-hydrochloride-approved-by-japans-mhlw-for-relapsed-or-refractory-peripheral-t-cell-lymphoma
2017-04-11 10:06:13  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-the-role-of-pet-scan-response-assessment-in-guiding-choice-of-treatment
2017-04-11 10:06:18  - 14968  http://www.lymphomahub.com/medical-information/chl-opdivor-nivolumab-given-positive-opinion-for-new-indication-by-the-ema-chmp-for-the-treatment-of-classical-hl
2017-04-11 10:06:22  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-waldenstr-m-s-macroglobulinemia--wm-
2017-04-11 10:06:26  - 14968  http://www.lymphomahub.com/medical-information/ctcl-patients-with-prior-systemicradiation-therapy-new-data-from-alcanza-a-phase-iii-trial-with-brentuximab-vedotin
2017-04-11 10:06:31  - 14968  http://www.lymphomahub.com/medical-information/diffuse-large-b-cell-lymphoma-patients-benefiting-after-receiving-a-novel-combined-treatment-everolimus-with-r-chop
2017-04-11 10:06:35  - 14968  http://www.lymphomahub.com/medical-information/ofatumumab-plus-reduced-dose-chop-minichop-after-pre-phase-vincristine-and-prednisone-improves-os-in-older-patients
2017-04-11 10:06:40  - 14968  http://www.lymphomahub.com/medical-information/elderly-nhl-and-dlbcl-patients-use-of-the-cga-comprehensive-geriatric-assessment-when-considering-treatment-options
2017-04-11 10:06:44  - 14968  http://www.lymphomahub.com/medical-information/limited-stage-dlbcl-continued-risk-of-relapse-shown-to-be-independent-of-treatment-modality-in-the-swog-s8736-study
2017-04-11 10:06:49  - 14968  http://www.lymphomahub.com/medical-information/the-fda-lifts-hold-on-clinical-trials-of-selinexor-in-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-11 10:06:53  - 14968  http://www.lymphomahub.com/medical-information/hdac-inhibitors-targeting-microrna-shown-to-reduce-btk-expression-and-potentially-relieve-ibrutinib-resistance-in-cll
2017-04-11 10:06:58  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7503-maintain-trial-first-results-rituximab-versus-observation-for-maintenance-in-patients-with-mcl
2017-04-11 10:07:02  - 14968  http://www.lymphomahub.com/medical-information/cll-patients-harboring-egr-2-mutations-represent-a-so-far-undefined-sub-group-of-cll-patients-with-a-very-poor-outcome
2017-04-11 10:07:06  - 14968  http://www.lymphomahub.com/medical-information/older-dlblc-patients-is-bendamustine-plus-rituximab-an-option-for-first-line-therapy-for-patients-ineligible-for-r-chop
2017-04-11 10:07:11  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-or-chlorambucil-in-the-first-line-treatment-of-elderly-cll-patients-phase-iii-results-from-the-origin-trial
2017-04-11 10:07:16  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470
2017-04-11 10:07:20  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-primary-results-from-the-pivotal-zuma-1-trial-of-kte-c19-in-refractory-aggressive-non-hodgkin-lymphoma-patients
2017-04-11 10:07:25  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-268615-dual-inhibition-of-bcr-and-tlr-signaling-has-therapeutic-potential-in-chronic-lymphocytic-leukemia
2017-04-11 10:07:29  - 14968  http://www.lymphomahub.com/medical-information/indolent-b-cell-and-mcl-practical-management-of-aes-induced-lenalidomide-in-monotherapy-or-in-combination-with-rituximab-r2
2017-04-11 10:07:34  - 14968  http://www.lymphomahub.com/medical-information/ghsg-hd18-addition-of-rituximab-to-beacoppescalated-does-not-improve-newly-diagnosed-advanced-aggressive-hl-patient-outcome
2017-04-11 10:07:38  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-20335-testing-the-combined-effects-of-low-dose-olaparib-plus-ibrutinib-on-mantle-cell-lymphoma-cytotoxicity
2017-04-11 10:07:42  - 14968  http://www.lymphomahub.com/medical-information/maintenance-therapy-shown-to-be-effective-in-relapsed-dlbcl-for-the-first-time-with-lenalidomide-in-asct-ineligible-patients
2017-04-11 10:07:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-educational-session-long-term-risk-of-second-malignancy-and-cardiovascular-disease-after-hodgkin-lymphoma-treatment
2017-04-11 10:07:51  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-229-lenalidomide-is-an-efficient-option-for-maintenance-treatment-interim-analysis-of-the-cllm1-study
2017-04-11 10:07:56  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-216112-pharmacological-downregulation-of-bfl-1-by-cpi203-overcomes-abt-199-resistance-in-double-hit-lymphoma
2017-04-11 10:08:00  - 14968  http://www.lymphomahub.com/medical-information/lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-combination-is-tolerable-and-effective-in-previously-untreated-inhl
2017-04-11 10:08:05  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-selected-oral-presentations-dlbcl-hd-mtx-is-a-highly-effective-prophylaxis-in-patients-with-high-risk-of-cns-relapse
2017-04-11 10:08:09  - 14968  http://www.lymphomahub.com/medical-information/danish-population-based-study-in-dlbcl-post-treatment-efs-for-24-months-is-a-potential-surrogate-end-point-for-clinical-trials
2017-04-11 10:08:13  - 14968  http://www.lymphomahub.com/medical-information/dlbcl-risk-factors-related-to-death-in-older-patients-treated-with-rituximab-based-immunochemotherapy-in-an-outpatient-setting
2017-04-11 10:08:18  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-polyfunctional-anti-cd19-car-t-cells-associated-with-clinical-activity-in-patients-with-advanced-non-hodgkin-lymphoma
2017-04-11 10:08:22  - 14968  http://www.lymphomahub.com/medical-information/rr-hodgkin-lymphoma-promising-phase-ii-results-of-a-novel-bendamustine-containing-regimen-begev-as-induction-therapy-before-asct
2017-04-11 10:08:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1108-long-term-responses-with-pembrolizumab-in-patients-with-rr-chl-results-of-phase-1b-keynote-013-study
2017-04-11 10:08:31  - 14968  http://www.lymphomahub.com/medical-information/long-term-follow-up-of-phase-2-gelcab-trial-first-line-fludarabine-cyclophosphamide-and-mitoxantrone-in-patients-with-advanced-fl
2017-04-11 10:08:36  - 14968  http://www.lymphomahub.com/therapies/alemtuzumab/campath/cll-sll/nd/fda/campath-is-indicated-as-a-single-agent-for-the-treatment-of-b-cell-chronic-lymphocytic-leukemia--b-cll--
2017-04-11 10:08:39  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7502-lenalidomide-as-maintenance-for-recurrentrefractory-cns-lymphoma-yields-promising-results-in-phase-i-study
2017-04-11 10:08:44  - 14968  http://www.lymphomahub.com/medical-information/ielsg-19-final-results-is-combination-chlorambucil-and-rituximab-more-effective-than-monotherapy-in-the-treatment-of-malt-lymphoma
2017-04-11 10:08:48  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/ema/revlimid-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
2017-04-11 10:08:52  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-37249-pd-l1-protein-expression-and-tumor-mutation-burden-correlates-with-hodgkin-and-diffuse-large-b-cell-lymphoma
2017-04-11 10:08:57  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-265110-hub4-dgn462-a-novel-cd19-targeting-antibody-drug-conjugate-shows-promising-activity-in-cd19-lymphoma-models
2017-04-11 10:09:01  - 14968  http://www.lymphomahub.com/medical-information/waldenstrom-macroglobulinemia-six-year-follow-up-of-phase-ii-trial-into-front-line-bdr-in-the-treatment-of-newly-diagnosed-patients
2017-04-11 10:09:06  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-long-term-outcomes-of-90-patients-with-chronic-lymphocytic-leukemia-who-discontinued-ibrutinib-based-regimens
2017-04-11 10:09:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-based-induction-and-maintenance-in-first-line-fl-patients-results-of-the-phase-3-gallium-study-plenary-session
2017-04-11 10:09:15  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/ema/arzerra-is-indicated-for-the-treatment-of-cll-in-patients-who-are-refractory-to-fludarabine-and-alemtuzumab
2017-04-11 10:09:19  - 14968  http://www.lymphomahub.com/medical-information/primary-mediastinal-large-b-cell-lymphoma-first-line-therapy-first-versus-third-generation-chemotherapy-and-the-addition-of-rituximab
2017-04-11 10:09:24  - 14968  http://www.lymphomahub.com/medical-information/real-world-study-median-os-after-ibrutinib-failure-is-poor-in-rr-mcl-patients-and-ibrutinib-represents-a-potential-bridge-to-allo-hct
2017-04-11 10:09:28  - 14968  http://www.lymphomahub.com/medical-information/burkitt-and-dlbcl-in-children-and-adolescents-identification-of-prognostic-factors-in-patients-treated-with-the-aieop-lnh-97-protocol
2017-04-11 10:09:32  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-313221-inhibition-of-the-integrin-v3-improves-the-effect-of-bexarotene-in-the-treatment-of-cutaneous-t-cell-lymphoma
2017-04-11 10:09:37  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-the-myc-oncogene-is-a-master-regulator-of-immune-response-myc-inactivation-presents-a-potential-curative-option-for-lymphoma
2017-04-11 10:09:41  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15522-addition-of-rp6530-a-dual-pi3k-inhibitor-accentuates-romidepsin-activity-in-non-hodgkin-lymphoma-cells-in-vitro
2017-04-11 10:09:46  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-147921-differential-expression-of-micrornas-in-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma
2017-04-11 10:09:50  - 14968  http://www.lymphomahub.com/medical-information/rituximab-bendamustine-and-low-dose-cytarabine-induction-shown-to-be-an-effective-and-safer-induction-therapy-for-elderly-mcl-patients
2017-04-11 10:09:54  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-365124-preclinical-examination-of-the-effects-of-a-cd20-specific-engineered-toxin-body-mt-3724-in-mantle-cell-lymphoma
2017-04-11 10:09:59  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-36314-delivery-of-a-cd20-transferrin-receptor-vnar-bispecific-antibody-to-the-brain-for-central-nervous-system-lymphoma
2017-04-11 10:10:03  - 14968  http://www.lymphomahub.com/therapies/belinostat/beleodaq/ptcl/r-r/fda/beleodaq-is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t--cell-lymphoma--ptcl-
2017-04-11 10:10:07  - 14968  http://www.lymphomahub.com/therapies/temsirolimus/torisel/mcl/r-r/ema/torisel-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma--mcl-
2017-04-11 10:10:11  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-106-intensive-chemotherapy-with-da-epoch-r-presents-new-frontline-treatment-option-in-patients-with-high-risk-dlbcl
2017-04-11 10:10:16  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-ct03814-204653-study-design-a-phase-i-open-label-dose-escalation-study-of-gsk3326595-in-patients-with-non-hodgkin-lymphoma
2017-04-11 10:10:20  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-170120-men1309-a-novel-anti-cd205-antibody-drug-conjugate-shows-strong-anti-tumor-activity-in-diffuse-large-b-cell-lymphoma
2017-04-11 10:10:25  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7506-no-improved-dfs-but-improved-os-and-lss-observed-with-adjuvant-everolimus-therapy-versus-placebo-for-poor-risk-dlbcl
2017-04-11 10:10:29  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl-
2017-04-11 10:10:33  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-231-idelalisib-br-significantly-improves-os-compared-to-br-alone-updated-os-results-of-phase-iii-trial-in-rr-cll-patients
2017-04-11 10:10:38  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-13589-pams-present-as-a-novel-therapeutic-strategy-for-follicular-small-cell-cleaved-lymphoma-and-diffuse-large-b-cell-lymphoma
2017-04-11 10:10:42  - 14968  http://www.lymphomahub.com/medical-information/subcutaneous-rituximab-recommended-for-approval-by-fdas-odac-in-follicular-lymphoma-diffuse-large-b-cell-lymphoma-and-chronic-lymphocytic-leukemia
2017-04-11 10:10:46  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-maintenance-therapy-is-indicated-for-the-treatment-of-follicular-lymphoma--fl--patients-responding-to-induction-therapy-
2017-04-11 10:10:51  - 14968  http://www.lymphomahub.com/medical-information/classical-hodgkin-lymphoma-the-role-of-the-microenvironment-and-possible-implications-in-clinical-practice-with-the-arrival-of-checkpoint-inhibitors
2017-04-11 10:10:55  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7505-maintenance-therapy-with-rituximab-after-fcr-induction-contributes-to-longer-median-pfs-when-treating-older-patients-with-cll
2017-04-11 10:10:59  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-39396-two-evolutionary-models-proposed-for-development-of-drug-resistance-between-primary-and-relapsed-diffuse-large-b-cell-lymphoma
2017-04-11 10:11:03  - 14968  http://www.lymphomahub.com/medical-information/inferior-outcomes-in-elderly-over-75-year-compared-to-younger-chronic-lymphocytic-leukemia-patients-real-world-findings-from-the-connect-cll-registry
2017-04-11 10:11:08  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1109-brentuximab-vedotin-and-eshap-is-a-highly-effective-combination-for-remission-induction-in-pre-apbsct-patients-with-rr-hl
2017-04-11 10:11:12  - 14968  http://www.lymphomahub.com/medical-information/ublituximab-shown-to-be-safe-and-effective-in-chronic-lymphocytic-leukemia-and-b-cell-non-hodgkin-lymphoma-patients-who-have-failed-rituximab-therapy
2017-04-11 10:11:17  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ptcl/r-r/fda/istodax-is-indicated-for-treatment-of-peripheral-t-cell-lymphoma--ptcl--in-patients-who-have-received-at-least-one-prior-therapy
2017-04-11 10:11:21  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/nd/ema/zydelig-is-indicated-in-combination-with-rituximab-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukaemia--cll-
2017-04-11 10:11:25  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7500-act-2-phase-iii-international-trial-final-results-improved-cr-with-a-chop-compared-to-chop-alone-in-elderly-patients-with-ptnhl
2017-04-11 10:11:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-233-durable-responses-with-single-agent-ibrutinib-in-treatment-naive-or-rr-cllsll-5-year-follow-up-of-phase-ibii-pcyc-1102-trial
2017-04-11 10:11:34  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-185-interim-pet-based-outcome-prediction-and-treatment-changes-in-patients-with-t-cell-lymphomas-participating-in-the-petal-trial
2017-04-11 10:11:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-472-results-from-phase-2-study-of-rituximab-bendamustine-and-cytarabine-rbac500-as-induction-therapy-in-elderly-patients-with-mcl
2017-04-11 10:11:43  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll---small-lymphocytic-lymphoma--sll--
2017-04-11 10:11:47  - 14968  http://www.lymphomahub.com/medical-information/esmo-2016-multidisciplinary-cases-session-therapy-regimens-for-treatment-of-patients-with-central-nervous-system-cns-relapses-and-secondary-cns-lymphoma
2017-04-11 10:11:51  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-education-session-chemoimmunotherapy-versus-targeted-treatment-in-chronic-lymphocytic-leukemia-when-how-long-how-much-and-in-which-combination
2017-04-11 10:11:56  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-131819-waldenstrom-macroglobulinemialymphoplasmacytic-lymphoma-genome-wide-association-study-finds-association-with-chromosomes-6-and-14
2017-04-11 10:12:00  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/r-r/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--mcl--
2017-04-11 10:12:04  - 14968  http://www.lymphomahub.com/medical-information/pi3k-blockade-with-idelalisib-or-duvelisib-enhances-aid-mediated-genomic-instability-in-normal-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-cells
2017-04-11 10:12:08  - 14968  http://www.lymphomahub.com/medical-information/nice-approves-funding-for-imbruvicar-ibrutinib-as-second-line-therapy-for-adult-cll-patients-with-del17p-tp53-mutation-or-in-whom-chemotherapy-is-unsuitable
2017-04-11 10:12:13  - 14968  http://www.lymphomahub.com/therapies/pembrolizumab/keytruda/hl/r-r/fda/keytruda-is-indicated-in-adult-and-pediatric-patients-with-refractory-chl--or-who-have-relapsed-after-3-or-more-prior-lines-of-therapy
2017-04-11 10:12:17  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7504-early-intensification-of-rituximab-plus-2-weekly-chop-showed-no-significant-improvement-to-cr-or-pfs-in-patients-with-stage-ii-iv-dlbcl
2017-04-11 10:12:21  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-315010-plcg2-c2-domain-mutations-co-occur-with-btk-and-plcg2-resistance-mutations-in-chronic-lymphocytic-leukemia-undergoing-ibrutinib-therapy
2017-04-11 10:12:26  - 14968  http://www.lymphomahub.com/therapies/romidepsin/istodax/ctcl/r-r/fda/istodax-is-indicated-for-treatment-of-cutaneous-t--cell-lymphoma--ctcl--in-patients-who-have-received-at-least-one-prior-systemic-therapy-
2017-04-11 10:12:30  - 14968  http://www.lymphomahub.com/medical-information/results-of-the-phase-ii-ncrn-cll207-trial-alemtuzumab-consolidation-of-mrd-positive-patients-after-conventional-chemotherapy-results-in-an-improvement-in-outcome
2017-04-11 10:12:34  - 14968  http://www.lymphomahub.com/medical-information/nice-draft-guidance-is-currently-minded-to-not-recommend-opdivor-nivolumab-for-relapsedrefractory-classical-hodgkin-lymphoma-unless-updated-analyses-are-provided
2017-04-11 10:12:39  - 14968  http://www.lymphomahub.com/medical-information/burkitt-lymphoma-dlbcl-and-fl-integrative-sequencing-analysis-identifies-alterations-in-microrna-and-microrna-regulated-mrna-which-contributes-to-lymphomagenesis
2017-04-11 10:12:43  - 14968  http://www.lymphomahub.com/medical-information/the-phase-iib-admire-trial-adding-mitoxantrone-to-gold-standard-fcr-as-first-line-therapy-for-cll-does-not-improve-responses-however-marginally-increases-toxicity
2017-04-11 10:12:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-234-extension-of-phase-iii-resonate-2-trial-single-agent-ibrutinib-has-substantial-efficacy-in-previously-untreated-elderly-cllsll-patients
2017-04-11 10:12:52  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-27702-bcl-2-overexpression-is-a-predictive-biomarker-for-the-combination-of-abt-199-with-chemotherapy-in-diffuse-large-b-cell-lymphoma-cell-lines
2017-04-11 10:12:56  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7508-brentuximab-vedotin-consolidation-after-abvd-treatment-increases-rates-of-pet-negative-disease-in-patients-with-non-bulky-hodgkin-lymphoma
2017-04-11 10:13:00  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-1106-brentuximab-vedotin-plus-nivolumab-is-well-tolerated-in-patients-with-rr-hl-preliminary-safety-and-response-data-of-phase-i-e4412-trial
2017-04-11 10:13:05  - 14968  http://www.lymphomahub.com/medical-information/\\appserv1\Documents\kko\Documents\1.	https:\www.ehaweb.org\congress-and-events\scientific-events\eha-swg-scientific-meeting-on-rare-lymphomas\scientific-program-2\
2017-04-11 10:13:05  - 14968  http://www.lymphomahub.com/medical-information/filo-real-world-results-ibrutinib-was-efficacious-and-demonstrated-known-safety-profile-in-very-elderly-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia
2017-04-11 10:13:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-783-phase-12-trial-finds-single-agent-ibrutinib-is-well-tolerated-in-recurrentrefractory-primary-and-secondary-central-nervous-system-lymphomas
2017-04-11 10:13:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-104-brentuximab-vedotin-plus-rchp-appears-an-effective-and-well-tolerated-frontline-therapy-in-high-intermediatehigh-risk-dlblc-expressing-cd30
2017-04-11 10:13:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/nd/ema/mabthera-is-indicated-for-the-treatment-of-previously-untreated-patients-with-stage-iii-iv-follicular-lymphoma--fl--in-combination-with-chemotherapy
2017-04-11 10:13:23  - 14968  http://www.lymphomahub.com/medical-information/aacr-2017-poster-15421-copanlisib-is-active-as-monotherapy-or-in-combination-in-mantle-cell-lymphoma-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-cell-lines
2017-04-11 10:13:27  - 14968  http://www.lymphomahub.com/medical-information/clonal-hematopoiesis-of-indeterminate-potential-at-time-of-asct-associated-with-poor-outcome-and-increased-risk-of-therapy-related-myeloid-neoplasm-in-patients-with-nhl
2017-04-11 10:13:32  - 14968  http://www.lymphomahub.com/medical-information/alemtuzumab-consolidation-therapy-at-low-doses-can-be-an-effective-option-in-chronic-lymphocytic-leukemia-patients-in-second-remission-after-fludarabine-based-treatment
2017-04-11 10:13:37  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--small-lymphocytic-lymphoma--sll--with-17p-deletion
2017-04-11 10:13:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-181-pembrolizumab-for-treatment-of-relapsedrefractory-mycosis-fungoides-and-sezary-syndrome-clinical-efficacy-in-a-citn-multicenter-phase-2-study
2017-04-11 10:13:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/nd/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia--cll-
2017-04-11 10:13:49  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-782-precis-phase-ii-trial-whole-brain-radiotherapy-compared-with-intensive-chemotherapy-and-hematopoietic-stem-cell-rescue-for-young-pcnsl-patients
2017-04-11 10:13:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-232-mutated-ighv-is-best-pre-treatment-predictor-of-achieving-mrd-negative-disease-and-subsequent-longer-pfs-in-cll-patients-receiving-first-line-fcr
2017-04-11 10:13:58  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/ema/zydelig-is-indicated-as-monotherapy-for-the-treatment-of-adult-patients-with-follicular-lymphoma--fl--that-is-refractory-to-two-prior-lines-of-treatment
2017-04-11 10:14:02  - 14968  http://www.lymphomahub.com/medical-information/evaluation-of-1450-patients-higher-absolute-monocyte-count-amc-is-poor-predictor-of-5-year-pfs-and-5-year-os-in-patients-with-nodular-sclerosis-ns-classical-hodgkin-lymphoma
2017-04-11 10:14:07  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-abstract-7507-e2408-phase-ii-trial-addition-of-bortezomib-to-bendamustine-rituximab-greatly-improves-cr-rates-in-patients-with-untreated-high-risk-follicular-lymphoma
2017-04-11 10:14:11  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-therapy-after-remission-induction-in-previously-untreated-patients-with-follicular-lymphoma
2017-04-11 10:14:15  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-186-5-point-deauville-criteria-assessed-interim-pet-more-accurately-identifies-ptcl-patients-likely-to-have-a-poorer-outcome-than-baseline-pit-and-ipi-score
2017-04-11 10:14:19  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-149-durable-remissions-with-the-vcr-cvad-regimen-for-mantle-cell-lymphoma-mcl-regardless-of-age-long-term-follow-up-of-a-wisconsin-oncology-network-won-study
2017-04-11 10:14:24  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-614-sequential-rchop-radioimmunotherapy-and-rituximab-maintenance-improves-early-outcomes-in-advanced-stage-follicular-lymphoma-5-year-outcomes-from-swog-0801
2017-04-11 10:14:28  - 14968  http://www.lymphomahub.com/medical-information/pcnsl-in-young-patients-whole-brain-radiotherapy-versus-intensive-chemotherapy-with-hematopoietic-stem-cell-rescue-an-intergroup-anocefgoelams-randomized-phase-ii-trial-abstract-782
2017-04-11 10:14:33  - 14968  http://www.lymphomahub.com/medical-information/primary-prophylaxis-with-pegfilgrastim-reduces-chemotherapy-disruptions-due-to-febrile-neutropenia-in-patients-with-indolent-non-hodgkin-lymphoma-after-bendamustine-rituximab-induction
2017-04-11 10:14:37  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma-at-high-risk-of-relapse-or-progression-as-post-auto-hsct-consolidation-
2017-04-11 10:14:41  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-148-ibrutinib-lenalidomide-rituximab-in-patients-with-relapsedrefractory-mantle-cell-lymphoma-first-results-from-the-nordic-lymphoma-group-mcl6-philemon-phase-ii-trial
2017-04-11 10:14:46  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-in-combination-with-fludarabine-and-cyclophosphamide-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll--
2017-04-11 10:14:49  - 14968  http://www.lymphomahub.com/medical-information/retrospective-analysis-of-77-patients-finds-allogeneic-stem-cell-transplantation-is-associated-with-lower-overall-survival-in-patients-with-aggressive-rather-than-indolent-non-hodgkin-lymphoma
2017-04-11 10:14:54  - 14968  http://www.lymphomahub.com/medical-information/asco-2016-poster-discussion-long-term-toxicity-and-fatigue-after-treatment-for-non-hodgkin-lymphoma-nhl-an-analysis-of-twelve-collaborative-lymphoma-study-association-lysa-trials-the-simonal-study
2017-04-11 10:14:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-617-phase-2-study-of-venetoclax-plus-rituximab-or-randomized-ven-plus-bendamustinerituximab-br-versus-br-in-patients-with-relapsedrefractory-follicular-lymphoma-interim-data
2017-04-11 10:15:03  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-184-prognostic-value-of-baseline-quantitative-pet-metrics-for-patients-with-unfavorable-early-stage-hodgkin-lymphoma-enrolled-in-the-standard-arm-of-the-eortclysafil-h10-trial
2017-04-11 10:15:07  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/ema/introna-is-indicated-for-the-treatment-of-high-tumour-burden-follicular-lymphoma-as-adjunct-to-appropriate-combination-induction-chemotherapy-such-as-a-chop-like-regimen-
2017-04-11 10:15:11  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mzl/r-r/fda/imbruvica-is-indicated-for-the-treatment-of-patients-with-marginal-zone-lymphoma--mzl--who-require-systemic-therapy-and-have-received-at-least-one-prior-anti-cd20-based-therapy-
2017-04-11 10:15:15  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-as-a-single-agent-
2017-04-11 10:15:19  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/nd/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular--cd20-positive--b-cell-non-hodgkin-s-lymphoma-in-combination-with-cvp-chemotherapy
2017-04-11 10:15:23  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/fl/r-r/ema/mabthera-monotherapy-is-indicated-for-treatment-of-patients-with-stage-iii-iv-follicular-lymphoma-who-are-chemoresistant-or-are-in-their-second-or-subsequent-relapse-after-chemotherapy-
2017-04-11 10:15:27  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-924-subsequent-malignant-neoplasms-among-children-and-adolescents-with-hodgkin-lymphoma-treated-with-response-adapted-therapy-a-report-from-the-childrens-oncology-group-study-ahod0031
2017-04-11 10:15:31  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-785-rituximab-lenalidomide-revri-in-relapse-or-refractory-primary-central-nervous-system-or-vitreo-retinal-lymphoma-results-of-a-proof-of-concept-phase-ii-study-of-the-french-loc-network
2017-04-11 10:15:36  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-small-lymphocytic-lymphoma--sll--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-11 10:15:40  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/r-r/ema/imbruvica-as-a-single-agent-or-in-combination-with-bendamustine-and-rituximab--br--is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-11 10:15:44  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-cd30--hodgkin-lymphoma--hl--at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--asct-
2017-04-11 10:15:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/r-r/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-11 10:15:58  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/ema/-90y--radiolabelled-zevalin-is-indicated-as-consolidation-for-the-tratment-of-adult-patients-with-rituximab-relapsed-or-refractory-cd20--follicular-b-cell-non-hodgkin-s-lymphoma--nhl--
2017-04-11 10:16:02  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/fl/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-follicular-b-cell-non-hodgkin-lymphoma--fl--in-patients-who-have-received-at-least-two-prior-systemic-therapies
2017-04-11 10:16:06  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-784-ibrutinib-monotherapy-in-relapse-or-refractory-primary-cns-lymphoma-and-primary-vitreo-retinal-lymphoma-interim-analysis-of-the-iloc-phase-ii-study-from-the-lysa-and-the-french-loc-network
2017-04-11 10:16:10  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-613-minimal-residual-disease-in-patients-with-follicular-lymphoma-treated-with-obinutuzumab-or-rituximab-as-first-line-induction-immunochemotherapy-and-maintenance-in-the-phase-3-gallium-study
2017-04-11 10:16:14  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/fda/arzerra--ofatumumab--is-indicated-in-combination-with-chlorambucil--for-the-treatment-of-previously-untreated-patients-with-cll-for-whom-fludarabine-based-therapy-is-considered-inappropriate-
2017-04-11 10:16:18  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-a-cd20-directed-cytolytic-monoclonal-antibody-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--refractory-to-fludarabine-and-alemtuzumab
2017-04-11 10:16:22  - 14968  http://www.lymphomahub.com/therapies/abt199/venclexta/cll-sll/r-r/fda/venclexta-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia--cll--with-17p-deletion--as-detected-by-an-fda-approved-test--who-have-received-at-least-one-prior-therapy-
2017-04-11 10:16:26  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/ema/opdivo-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct--and-treatment-with-brentuximab-vedotin-
2017-04-11 10:16:30  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-923-beacoppescalated-followed-by-radiotherapy-of-initial-bulk-or-residual-disease-in-advanced-stage-hodgkin-lymphoma-long-term-follow-up-of-the-hd9-and-hd12-trials-of-the-german-hodgkin-study-group
2017-04-11 10:16:35  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/cll-sll/nd/fda/gazyva--obinutuzumab--is-a-cd20-directed-cytolytic-antibody-and-is-indicated--in-combination-with-chlorambucil--for-the-treatment-of-patients-with-previously-untreated-chronic-lymphocytic-leukemia
2017-04-11 10:16:39  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-781-high-dose-chemotherapy-with-autologous-hematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicenter-trial-by-the-german-cooperative-pcnsl-study-group
2017-04-11 10:16:43  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-plenary-session-primary-results-of-the-randomized-phase-3-gallium-study-obinutuzumab-based-induction-and-maintenance-prolongs-progression-free-survival-pfs-in-patients-with-previously-untreated-follicular-lymphoma
2017-04-11 10:16:47  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-618-r2w-subcutaneous-bortezomib-cyclophosphamide-and-rituximab-bcr-versus-fludarabine-cyclophosphamide-and-rituximab-fcr-for-initial-therapy-of-waldenstroms-macroglobulinemia-a-randomized-phase-ii-study
2017-04-11 10:16:54  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-147-chemotherapy-free-induction-with-ibrutinib-rituximab-followed-by-shortened-cycles-of-chemo-immunotherapy-consolidation-in-young-newly-diagnosed-mantle-cell-lymphoma-patients-a-phase-ii-clinical-trial
2017-04-11 10:16:58  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-146-molecular-monitoring-and-tailored-strategy-with-pre-emptive-rituximab-treatment-for-molecular-relapse-results-from-the-nordic-mantle-cell-lymphoma-studies-mcl2-and-mcl3-with-median-follow-up-of-85-years
2017-04-11 10:17:03  - 14968  http://www.lymphomahub.com/therapies/vorinostat/zolinza/ctcl/r-r/fda/zolinza-is-indicated-for-treatment-of-cutaneous-manifestations-in-patients-with-cutaneous-t--cell-lymphoma--ctcl--who-have-progressive--persistent-or-recurrent-disease-on-or-following-two-systemic-therapies-
2017-04-11 10:17:09  - 14968  http://www.lymphomahub.com/therapies/denileukin-diftitox/ontak/ctcl/r-r/fda/ontak-is-a-cd25-directed-cytotoxin-indicated-for-the-treatment-fo-patients-with-persistent-or-recurrent-cutaneous-t-cell-lymphoma-whose-malignant-cells-express-the-cd25-component-of-the-il-2-receptor-
2017-04-11 10:17:13  - 14968  http://www.lymphomahub.com/therapies/lenalidomide/revlimid/mcl/r-r/fda/revlimid-is-a-thalidomide-analogue-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--whose-disease-has-relapsed-or-progressed-after-two-prior-therapies--one-of-which-included-bortezomib
2017-04-11 10:17:17  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-145-rituximab-maintenance-after-autologous-stem-cell-transplantation-prolongs-survival-in-younger-patients-with-mantle-cell-lymphoma-final-results-of-the-randomized-phase-3-lyma-trial-of-the-lysagoelams-group
2017-04-11 10:17:21  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/r-r/fda/arzerra--ofatumumab--is-indicated-for-extended-treatment-of-patients-who-are-in-complete-or-partial-response-after-at-least-two-lines-of-therapy-for-recurrent-or-progressive-chronic-lymphocytic-leukemia--cll-
2017-04-11 10:17:25  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/dlbcl/nd/ema/mabthera-is-indicated-for-the-treatment-of-patients-with-cd20-positive-diffuse-large-b--cell-non-hodgkin-s-lymphoma-in-combination-with-chop--cyclophosphamide--doxorubicin--vincristine--prednisolone--chemotherapy
2017-04-11 10:17:29  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-182-brentuximab-vedotin-demonstrates-significantly-superior-clinical-outcomes-in-patients-with-cd30-expressing-cutaneous-t-cell-lymphoma-versus-physicians-choice-methotrexate-or-bexarotene-the-phase-3-alcanza-study
2017-04-11 10:17:34  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/cll-sll/nd/fda/rituxan---rituximab--is-indicated--in-combination-with-fludarabine-and-cyclophosphamide--fc---for-the-treatment-of-patients-with-previously-untreated-and-previously-treated-cd20-positive-chronic-lymphocytic-leukemia
2017-04-11 10:17:41  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/wm/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 10:17:45  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/fl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 10:17:49  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/bl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 10:17:53  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 10:17:57  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyva/fl/r-r/fda/gazyva--in-combination-with-bendamustine-followed-by-gazyva-monotherapy--is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-relapsed-after--or-are-refractory-to--a-rituximab-containing-regimen
2017-04-11 10:18:01  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/mzl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 10:18:05  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy
2017-04-11 10:18:09  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/pcnsl/r-r/fda/rituxan--rituximab--is-indicated-for-the-treatment-of-patients-with-non-progressing--including-stable-disease---low-grade--cd20-positive--b-cell-non-hodgkin-lymphoma--as-a-single-agent--after-first-line-cvp-chemotherapy-
2017-04-11 10:18:13  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2b/intron-a/fl/nd/fda/intron-a-is-indicated-for-the-initial-treatment-of-clinically-aggressive-follicular-non-hodgkin-s-lymphoma-in-conjunction-with-anthracycline-containing-combination-chemotherapy-in-patients-18-years-of-age-or-older-
2017-04-11 10:18:17  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/ema/zydelig-is-indicated-in-combination-with-an-anti-cd20-monoclonal-antibody--rituximab-or-ofatumumab--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia--cll--who-have-received-at-least-one-prior-therapy
2017-04-11 10:18:21  - 14968  http://www.lymphomahub.com/therapies/rituximab/rituxan/dlbcl/nd/fda/rituxan---rituximab--is-indicated-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell--cd20-positive-non-hodgkin-s-lymphoma-in-combination-with-chop-or-other-anthracycline-based-chemotherapy-regimens
2017-04-11 10:18:25  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-616-continued-excellent-outcomes-in-previously-untreated-follicular-lymphoma-patients-after-treatment-with-chop-plus-rituximab-or-chop-plus-131-iodine-tositumomab-long-term-follow-up-of-phase-iii-randomized-study-swog-s0016
2017-04-11 10:18:32  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/ema/adcetris-is-indicated-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-cd30--hodgkin-lymphoma--hl--following-at-least-two-prior-therapies-when-asct-or-multi-agent-chemotherapy-is-not-a-treatment-option-
2017-04-11 10:18:36  - 14968  http://www.lymphomahub.com/therapies/nivolumab/opdivo/hl/r-r/fda/opdivo-is-indicated-for-the-treatment-of-patients-with-classical-hodgkin-lymphoma--chl--that-has-relapsed-or-progressed-after-autologous-hematopoietic-stem-cell-transplantation--hsct--and-post-transplantation-brentuximab-vedotin-
2017-04-11 10:18:40  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia-in-the-absence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-have-failed-both-chemoimmunotherapy-and-a-b-cell-receptor-pathway-inhibitor-
2017-04-11 10:18:44  - 14968  http://www.lymphomahub.com/therapies/ofatumumab/arzerra/cll-sll/nd/ema/arzerra-in-combination-with-chlorambucil-or-bendamustine-is-indicated-for-the-treatment-of-patients-with-chronic-lymphocytic-leukaemia--cll--who-have-not-received-prior-therapy-and-who-are-not-eligible-for-fludarabine-based-therapy
2017-04-11 10:18:48  - 14968  http://www.lymphomahub.com/therapies/abt199/venclyxto/cll-sll/r-r/ema/venclyxto-monotherapy-is-indicated-for-the-treatment-of-chronic-lymphocytic-leukemia--cll--in-the-presence-of-17p-deletion-or-tp53-mutation-in-adult-patients-who-are-unsuitable-for-or-have-failed-a-b-cell-receptor-pathway-inhibitor-
2017-04-11 10:18:52  - 14968  http://www.lymphomahub.com/therapies/interferon-alpha-2a/roferon/ctcl/r-r/ema/roferon-a-is-indicated-for-the-treatment-of-cutaneous-t--cell-lymphoma--interferon-alfa-2a--roferon-a---may-be-active-in-patients-who-have-progressive-disease-and-who-are-refractory-to--or-unsuitable-for--conventional-therapy-
2017-04-11 10:18:56  - 14968  http://www.lymphomahub.com/medical-information/ash-2016-oral-abstract-615-obinutuzumab-plus-bendamustine-followed-by-obinutuzumab-maintenance-prolongs-overall-survival-compared-with-bendamustine-alone-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-updated-results-of-the-gadolin-study
2017-04-11 10:19:00  - 14968  http://www.lymphomahub.com/therapies/rituximab/mabthera/cll-sll/r-r/ema/mabthera-in-combination-with-chemotherapy-is-indicated-for-the-treatment-of-patients-with-relapsed-refractory-cll--only-limited-data-are-available-on-efficacy-and-safety-for-patients--refractory-to-previous-mabthera-plus-chemotherapy
2017-04-11 10:19:04  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/wm/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-waldenstr-m-s-macroglobulinaemia--wm--who-have-received-at-least-one-prior-therapy--or-in-first-line-treatment-for-patients-unsuitable-for-chemo-immunotherapy-
2017-04-11 10:19:11  - 14968  http://www.lymphomahub.com/therapies/bortezomib/velcade/mcl/nd/ema/velcade-in-combination-with-rituximab--cyclophosphamide--doxorubicin-and-prednisone-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-mantle-cell-lymphoma-who-are-unsuitable-for-haematopoietic-stem-cell-transplantation
2017-04-11 10:19:15  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/cll-sll/nd/ema/gazyvaro-in-combination-with-chlorambucil-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll--and-with-comorbidities-making-them-unsuitable-for-full-dose-fludarabine-based-therapy
2017-04-11 10:19:19  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/r-r/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-relapsed-or-refractory--low-grade-or-follicular-b-cell-non-hodgkin-s-lymphoma--nhl-
2017-04-11 10:19:23  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/cll-sll/nd/ema/imbruvica-as-a-single-agent-is-indicated-for-the-treatment-of-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia--cll---imbruvica-is-indicated-for-the-treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy
2017-04-11 10:19:27  - 14968  http://www.lymphomahub.com/therapies/idelalisib/zydelig/cll-sll/r-r/fda/zydelig-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia--cll---in-combination-with-rituximab--in-patients-for-whom-rituximab-alone-would-be-considered-appropriate-therapy-due-to-other-co-morbidities
2017-04-11 10:19:34  - 14968  http://www.lymphomahub.com/therapies/ibritumomab-tiuxetan/zevalin/fl/nd/fda/zevalin-is-a-cd20-directed-radiotherapeutic-antibody-administered-as-part-of-the-zevalin-therapeutic-regimen-indicated-for-the-treatment-of-patients-with-previously-untreated-follicular-nhl-who-achieve-a-partial-or-complete-response-to-first-line-chemotherapy
2017-04-11 10:19:38  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-11 10:19:43  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-11 10:19:47  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-11 10:19:51  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-11 10:19:55  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/fda/mozobil--plerixafor-injection--is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-mobilize-hematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-patients-with-non-hodgkin-s-lymphoma--nhl-
2017-04-11 10:19:59  - 14968  http://www.lymphomahub.com/therapies/obinutuzumab/gazyvaro/fl/nd/ema/gazyvaro-in-combination-with-bendamustine-followed-by-gazyvaro-maintenance-is-indicated-for-the-treatment-of-patients-with-follicular-lymphoma--fl--who-did-not-respond-or-who-progressed-during-or-up-to-6-months-after-treatment-with-rituximab-or-a-rituximab-containing-regimen-
2017-04-11 10:20:03  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/hl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 10:20:07  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/fl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 10:20:11  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 10:20:17  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/mzl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 10:20:21  - 14968  http://www.lymphomahub.com/therapies/ibrutinib/imbruvica/mcl/nd/fda/imbruvica-is-a-kinase-inhibitor-indicated-for-the-treatment-of-patients-with-mantle-cell-lymphoma--mcl--who-have-received-at-least-one-prior-therapy--this-indication-is-based-on-overall-response-rate--an-improvement-in-survival-or-disease-related-symptoms-has-not-been-established
2017-04-11 10:20:25  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/ptcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 10:20:29  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/dlbcl/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 10:20:36  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/ema/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly
2017-04-11 10:20:40  - 14968  http://www.lymphomahub.com/therapies/plerixafor/mozobil/cll-sll/nd/fda/mozobil-is-indicated-in-combination-with-granulocyte-colony-stimulating-factor--g-csf--to-enhance-mobilisation-of-haematopoietic-stem-cells-to-the-peripheral-blood-for-collection-and-subsequent-autologous-transplantation-in-adult-patients-with-lymphoma-whose-cells-mobilise-poorly-
2017-04-11 10:20:44  - 14968  http://www.lymphomahub.com/therapies/brentuximab-vedotin/adcetris/hl/r-r/fda/adcetris-is-indicated-for-treatment-of-patients-with-classical-hodgkin-lymphoma--hl--after-failure-of-autologous-hematopoietic-stem-cell-transplantation--auto-hsct--or-after-failure-of-at-least-two-prior-multi-agent-chemotherapy-regimens-in-patients-who-are-not-auto-hsct-candidates-
2017-04-11_10-32-00 Restart Xvfb...